Something big is about to happen in cancer diagnostics.

In 2013, Dako launches new solutions for cancer diagnostics that will help move pathology forward on A Better Path™.

Visit us at booth no. 638 and find out what’s new.
THANK YOU FOR YOUR USCAP MEMBERSHIP PAYMENT.

We’re pleased that you have chosen to continue your commitment to North America’s leading pathology organization. As a member of the USCAP you have a wide array of benefits designed to keep you informed of the fast moving world of pathology. We’ve included a sampling of these benefits below; however for a full listing, please log onto our website: www.uscap.org

Membership status includes benefits like:

**Learn:** members-only educational discounts
- Online, at your convenience. Tailor your educational requirements to your schedule with our extensive list of online courses from world-class authorities.
- Or in beautiful venues throughout North America. Obtain up to 400 CME credits (of which 350 can be SAM’s). Attend our accredited educational conferences, held quarterly, in stunning locales.

**Simplify your MOC management**
Manage your MOC credits through your individual, online professional portfolio found on the USCAP website. Evaluate courses, print certificates and transmit your education credits—all in one place!

**Connect with world-class pathology professionals**
Membership connects you to the “Who’s Who” of pathology through our membership directory. Or utilize MyPath™ —The USCAP’s premiere portal to the world of pathology—which includes the National Institute of Health’s PubMed biomedical information. Research. Bookmark. Collaborate.

**Stay informed with USCAP’s leading journals**
Members receive their choice of USCAP’s leading journals, “Modern Pathology” or “Laboratory Investigation” with information designed to keep you in the vanguard of our profession.

**Advance your career**
New opportunities await at our online Career Center.

**Dual membership within the International Academy of Pathology**
Links you with colleagues through world-wide affiliated divisions.

Please don’t hesitate to contact our Membership Team at 706.733.7550, or at help@uscap.org, should you have any questions about your membership benefits. Thanks!

May 2-5, 2013
Hyatt Fisherman’s Wharf
San Francisco, CA

Diagnostic Pathology Update

July 14-19, 2013
Captain Cook Hotel
Anchorage, AK

* These activities have been approved for AMA PRA Category 1 Credit™
WELCOME to the 102nd Annual Meeting of the United States and Canadian Academy of Pathology, and to our first time in Baltimore and its waterfront Convention Center! Once again, this meeting has innumerable educational opportunities that we hope you will take full advantage of, including state-of-the-art lectures by our Nathan Kaufman “Timely Topics” lecturer, Dr. Christopher Crum, and our Maude Abbott lecturer, Dr. Victor Reuter. I also invite you to take a look at the Long Course program on Soft Tissue Tumors, and wish to thank our Long Course Directors, Drs. Christopher Fletcher and Cristina Antonescu for putting together this year’s program. I hope you will enjoy as many educational offerings as you can while you are in Baltimore, but if you have to miss some aspects of the meeting, I remind you that the USCAP offers extensive CME and SAMs accredited, online, educational offerings once the Meeting is over.

It’s been an eventful year since we last met in Vancouver. The new Executive Vice-President, Dr. Bruce Smoller, is now in full stride with the second Annual Meeting under his leadership. In the past year, he has worked to increase the role of the Council in the decision making for the USCAP, developed a plan for future succession of course directors, and expanded the role of the Nominating Committee. He also is leading the way in long term strategic planning with a detailed evaluation of the infrastructure of the USCAP, with help from both a professional business consultant and a task force of USCAP members. The growth of the USCAP, both in membership and educational offerings, has placed significantly more demands on the administrative group, so our next challenge will involve consideration of expanding to a new location to accommodate these extra needs. Finally, he is leading the way to develop a state-of-the-art website that will be easier to navigate and enhancing our online educational opportunities. His energy and enthusiasm are infectious.

The Education Committee, chaired by Dr. John Goldblum (in his final year as Chair), has once again brought us once an outstanding program. New offerings to resident/trainee members include a Saturday workshop and expanded collaboration opportunities. We really want to extend our gratitude to John for his service as Chair for 5 years, as well as his hardworking group of committee members for their efforts!

The Innovative Educational Products Development Committee, chaired by Dr. Jeff Myers, continues to examine other innovative ways to add to our educational and membership offerings. A new committee was formed, the Informatics Implementation for eEducation Subcommittee, chaired by Dr. Jeffrey Pritchard, to help implement new e-related products brought forward by the IEPC group as well as examine and improve our e-Education offerings.

Two other relatively new committees, Membership, chaired by Dr. Julia Iezzoni, in concert with the Residency Advisory Committee, chaired by Dr. Laura Collins, are continuing to review and advise on how to enhance our offerings to our younger members while encouraging life-time involvement with the USCAP. Last year’s new initiatives to expand the Housestaff Hospitality Room and the addition of a Saturday forum aimed at housestaff issues were a great success. You’ll find that we are continuing and enhancing these programs here in Baltimore.

The Finance Committee is now chaired by Dr. Jim Linder, and we are happy to report that the USCAP is in sound financial condition so that we have suitable resources to meet the upcoming challenges of the future, including a possible change in location of the main office and a new website. Our Foundation, led by Dr. Jonathan Epstein, continues to support our philanthropy as well as other fundraising efforts. You can learn more about these efforts on our website.

The USCAP is one of the most successful providers of educational opportunities for pathologists around the world, and I hope you will take advantage of all the opportunities. Enjoy your time on the Baltimore waterfront!

Linda Ferrell, MD
President, USCAP, 2012-13
Leica Biosystems
Total Digital Pathology
Scan. Manage. Analyze.

Welcome to USCAP 2013! Visit Leica Biosystems Booth #703 and see how our Total Digital Pathology Solutions can help lean workflow, automate slide analysis, and accelerate your lab.

SCAN LOCALLY, COLLABORATE GLOBALLY – Move your images, not your staff. With SlidePath cloud-based deployment and Digital Image Hub (DIH), slides can be shared quickly and easily without physical transfer of people or specimens.

WORK EFFICIENTLY – The Leica SCN400 offers high throughput, one touch walk-away batch scanning, and DIH software supports image formats from other scanners, ensuring quick and flexible support.

www.LeicaBiosystems.com

© November 2012 Leica Biosystems Inc., Buffalo Grove, IL

Gold Sponsor
2013

102nd USCAP Annual Meeting

NetworkNow! is a free networking and scheduling service that offers you a list of matched event participants based on your business profile. It allows you to:
• Search, match and connect with your peers and colleagues
• Schedule meetings before, during and after the event.
• Create personalized, printable planners.

Access networkNow! using this QR code

"The sponsor of this ad verifies that they had no input into decision making regarding selection of educational programs, content or faculty for this 2013 Annual Meeting."

© November 2013 Laboratory Corporation of America® Holdings. All rights reserved.
Baltimore, MD is a city of firsts, from the first common carrier railroad to the first metropolitan cathedral. Join Biocare Medical at booth #230 to learn how we too are a company of firsts in groundbreaking technology such as innovative markers for prostate, breast, lung & bladder tissues.

CONNECT. LEARN. ACHIEVE. (RENEW!)

IT’S NOT TOO LATE!

Renewing your membership is easy; just follow these steps:

- Log on to www.uscap.org
- Click the login link found in the top right hand corner of the website
- Select “Online Dues Payment”
- Don’t forget to select which journal you wish to receive

Or call the USCAP Membership Team (706) 733-7550 for immediate assistance.

United States & Canadian Academy of Pathology
LEADING PATHOLOGY EDUCATIONAL EXCELLENCE

Log on to www.uscap.org

DEFINIENS
Understanding Images

Booth #530

Expect More From Your Pathology
Better Data, Novel Biomarkers. Much Sooner.

Efficiently analyze any tissue specimen, fully automate workflows and explore results and data with Definiens’ leading solutions for Quantitative Digital Pathology. Visit Definiens at booth #530.

Definiens Inc., Bernhard Wicki Str. 5, 80636 Munich, Germany
Tel. 001.888.782.6883 www.definiens.com

The sponsor of this ad verifies that they had no input into decisive making regarding selection of educational programs, content or faculty for this 2013 Annual Meeting.
YOUR ANNUAL MEETING. YOUR WAY.

Get Organized!

Download the Annual Meeting’s free mobile app at the USCAP website.

2013 ANNUAL MEETING
REGISTER
- Welcome Letter
- Conference Information
- Trip Builder: Baltimore
- Exhibit Hall
- Alerts
- Social Networking
- My Show

United States & Canadian Academy of Pathology
Leading pathology educational excellence

http://www.tripbuilder.com/uscap2013apps
THANK YOU SPONSORS!
Official Sponsors of the 2013 Annual Meeting include:

PLATINUM SPONSORS

GOLD SPONSORS

SILVER SPONSORS

ADDITIONAL SPONSORS

Our sponsors verify they had no input into decision making regarding selection of educational programs, content or faculty for this 2013 Annual Meeting.

United States & Canadian Academy of Pathology
LEADING PATHOLOGY EDUCATIONAL EXCELLENCE
ONLINE LEARNING AT YOUR FINGERTIPS

2013 Diagnostic Cytopathology Course
Leading physician-pathologists discuss the changing trends in cytodiagnosis and laboratory management, addressing the resolution of diagnostic pitfalls relative to each of the major organ systems. This session provides a maximum of 16.75 CME/SAM credit hours.

You can view and participate in select sessions – as they were presented – captured as true multimedia re-creations with PowerPoint presentations.

Log in now to the eAcademy at www.uscap.org to purchase any of the available courses and obtain your CME/SAM credits!

*These activities have been approved for AMA PRA Category 1 Credit™

EDUCATION ON DEMAND
Visit www.uscap.org for more information.

This activity has been planned and implemented in accordance with the essential areas and policies of the Accreditation Council for Continuing Medical Education. The USCAP is accredited by the ACCME to provide continuing medical education for physicians.
YOUR LEARNING DOESN’T END WITH THIS MEETING.

The eAcademy is here to help.

• Earn ACCME-accredited CME and SAMs credit
• Online
• On your schedule
• Find the eAcademy @ www.uscapeacademy.org

The USCAP offers learning discounts and MOC management assistance with your membership.
Do you remember what your mentor did for you?

*This year, honor them with a contribution to the USCAP Foundation and help sustain pathology’s future.*

A mentor is one of the most influential figures in the life of an aspiring medical professional.

As we continue to make great strides in the field of pathology, we must look back and honor those leaders who paved the way for us. What better way to honor your mentor than with a gift to the United States & Canadian Academy of Pathology Foundation.

Log on to [www.uscap.org](http://www.uscap.org) and make a gift to Honor Your Mentor today.

This activity has been planned and implemented in accordance with the essential areas and policies of the Accreditation Council for Continuing Medical Education. The USCAP is accredited by the ACCME to provide continuing medical education for physicians.
Party for a Passion*

The United States & Canadian Academy of Pathology invites you to our Welcome Reception, “Party for a Passion”

All are invited!
Join friends, new and old, while sampling Baltimore’s wonderful food, drinks and entertainment.

Please join us
Tuesday, March 5, 2013
Immediately following the Maude Abbott Lecture
6:00PM – 7:30PM
Hilton Key Ballroom 1-12
in the Hilton Baltimore

*Spotlighting the USCAP Foundation.
Proceeds from your registration have benefited the USCAP Foundation.
We’re pleased that you have chosen the USCAP’s Annual Meeting to achieve your professional education and credentialing goals. Once again we offer cutting edge education, taught by the world’s leading pathology authorities. We have much to offer you — so be sure to take time to explore ALL that is the world’s largest pathology education event. Consider the information available to you this week:

61 Short Courses  
19 Specialty Conferences  
5 Special Courses  
1 Long Course  
1,825 Abstract Posters  
280 Proffered Papers  
28 Companion Society Meetings  
Countless! Resident and Fellows Events  

All of this activity results in your ability to earn up to 53.5 AMA PRA Category 1 Credit(s)™ and 48.5 SAM credit hours during your stay in Baltimore.

Add special lectures, awards, the Exhibition Hall, collaborative conversations with peers, receptions, and you have the crowning pathology event designed to enhance your career: The 102nd USCAP Annual Meeting.

Welcome!

Linda Ferrell, MD  
President, USCAP  

Bruce Smoller, MD  
Executive Vice President, USCAP
2013 INDEX OF CONTENTS

President's Message & Biographic Sketch

Tab 1 – General Information

Daily Program Outline / Meeting at a Glance .................................................. 2-8
Sessions by Topic .................................................................................. 9-18
Receptions ............................................................................................ 19
General Information ........................................................................ 20-24
Past Presidents & Secretary-Treasurers ................................................ 25
Committees & USCAP Officers ............................................................... 26-28
Business Meeting Agenda & 2012 Business Meeting Minutes .......... 29-34
Exhibitor Overview ............................................................................... 35

Tab 2 – Events of Interest for Pathologists-in-Training

Resident Workshop ................................................................................. 37
Housestaff Hospitality Room Information & Schedule .................... 38
Special & Long Courses of Interest to Pathologists-in-Training .......... 39
Pathologists-in-Training Award Information ........................................ 40
Receptions .......................................................................................... 41
Resident Advisory Committee ............................................................... 41
Participating Institutions ..................................................................... 42-43
Housestaff Fellowship Fair ................................................................. 44-45

Tab 3 – Companion Meetings

Companion Meetings Saturday ............................................................... 47-53
Companion Meetings Sunday ................................................................. 54-71
Companion Societies & Officers ............................................................. 72-75

Tab 4 – Special Courses & Specialty Conferences

Special Course Monday – A Practical Guide to Molecular Testing in Cancer ........................................................... 77-78
Special Course Monday – Introduction to Molecular Pathology for the Practicing Pathologist: Technology, Assay Interpretation, and Pitfalls .......................................................... 79-80
Special Course Monday – Careers in Investigation Pathology: The Next Generation ...................................................... 81
Special Course Tuesday – Advanced Molecular Pathology ............... 82
Special Course Tuesday – Basic Principles in Cytology .................... 83-84
Specialty Conference Sunday – Dermatopathology ....................... 85
Specialty Conference Sunday – Genitourinary Pathology ............... 85
Specialty Conference Sunday – Gynecologic Pathology .................. 86
Specialty Conference Sunday – Ophthalmic Pathology .................. 86
Specialty Conference Sunday – Pediatric Pathology ...................... 87
Specialty Conference Monday – Bone & Soft Tissue Pathology .... 87
Specialty Conference Monday – Cytopathology ............................. 88
Specialty Conference Monday – Hematopathology ....................... 88
Specialty Conference Monday – Liver Pathology ............................. 89
Specialty Conference Tuesday – Cardiovascular Pathology .......... 89
Specialty Conference Tuesday – Neuropathology ......................... 90
Specialty Conference Tuesday – Surgical Pathology .................... 90
Specialty Conference Wednesday – Breast Pathology ................. 91
Specialty Conference Wednesday – Gastrointestinal Pathology ..... 91
Specialty Conference Wednesday – Infectious Disease Pathology .... 92
Specialty Conference Wednesday – Renal Pathology ..................... 92
Specialty Conference Thursday – Gynecologic Pathology ............. 93
Specialty Conference Thursday – Head/Neck/Endocrine Pathology .................................................. 93
Specialty Conference Thursday – Pulmonary Pathology ............... 94

Tab 5 – Long & Short Courses

Long Course ....................................................................................... 95-96
Short Courses Wednesday ................................................................. 97-98
Short Courses Thursday ................................................................. 99-100
Short Courses Friday ................................................................. 101-102

Tab 6 – Special Lectures

Nathan Kaufman Timely Topics Lecture ........................................ 103
Maude Abbott Lecture ................................................................. 104

Tab 7 – Awards

Distinguished Pathologist Award Recipient .................................. 105
Harvey Goldman Master Teacher Award .................................. 106
Mostofi Award Recipient ............................................................... 107
President’s Awardee ................................................................. 108
Ramzi Cotran Young Investigator Award .................................. 109
Recognition Awards ................................................................. 110
Past Honored Lecturers and Awardees ........................................ 111-113
Index of Participants ................................................................. 114-115

Tab 8 – Proffered Papers & Posters

Proffered Papers

Monday AM ................................................................................. 117-122
Monday PM ............................................................................... 122-126
Tuesday AM ............................................................................... 126-130
Tuesday PM ........................................................................ 131-135

Poster Sessions

I – Monday AM (Stowell-Oribson, Autopsy & Surgical Pathology Award Competition) .................. 135-152
II – Monday PM ................................................................. 152-168
III – Tuesday AM .................................................................. 168-184
IV – Tuesday PM ................................................................ 185-201
V – Wednesday AM ............................................................. 202-218
VI – Wednesday PM ............................................................. 218-234
Abstract Review Board ............................................................... 235
Abstract Disclosure Information .................................................. 236-244
Abstract Author Index ................................................................. 245-272

Floor Plans for Convention Center Meeting Rooms and Exhibit Halls are located in the back of this book.
USCAP 2013 MEETING AT A GLANCE

Information in this section was current as of January 23. Please check the “Last Minute Updates” document distributed at the Registration Desk for any changes in presentation times or dates.

USCAP 2013 NEWS EMBARGO POLICY

Unless otherwise noted, all abstracts presented at USCAP are embargoed until the date and time of presentation. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The United States & Canadian Academy of Pathology reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during The United States & Canadian Academy of Pathology.

USCAP 2013 DISCLAIMER STATEMENT

The information presented at The United States & Canadian Academy of Pathology news conferences and within the Research Summaries Book represents the opinion of the presenters and authors and is not necessarily the view of The United States & Canadian Academy of Pathology. The United States & Canadian Academy of Pathology makes no representation as to the truth or warranty, accuracy, or originality of the information presented.
### Saturday, March 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Page #</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 PM – 6:00 PM</td>
<td><strong>Resident’s Workshop</strong>&lt;br&gt;Leadership, Collaboration, and Change in Health Care – A Residents Workshop for Essential Skills</td>
<td>(pp 37)</td>
<td>CC 301/302</td>
</tr>
<tr>
<td>7:00 PM – 10:00 PM</td>
<td><strong>Companion Meeting</strong>&lt;br&gt;American Association of Neuropathologists – Update on Pituitary Adenomas and Sellar Region Masses</td>
<td>(pp 47)</td>
<td>CC 317</td>
</tr>
<tr>
<td></td>
<td>American Association of Ophthalmic Oncologists and Pathologists – Advances in Intraocular Oncology and Emerging Entities</td>
<td>(pp 48)</td>
<td>CC 311</td>
</tr>
<tr>
<td></td>
<td>American College of Veterinary Pathology – Contemporary Animal Models of Human Cancer</td>
<td>(pp 48)</td>
<td>CC 313</td>
</tr>
<tr>
<td></td>
<td>Association for Pathology Informatics – Hot Topics in Pathology Informatics</td>
<td>(pp 49)</td>
<td>CC 316</td>
</tr>
<tr>
<td></td>
<td>Endocrine Pathology Society – Genomic Approaches to Problems in Endocrine Neoplasia</td>
<td>(pp 50)</td>
<td>CC 318-320</td>
</tr>
<tr>
<td></td>
<td>International Society of Urological Pathology – Current Concepts and Controversies in GU Pathology Current Concepts and Controversies in GU Pathology</td>
<td>(pp 51)</td>
<td>CC 309/310</td>
</tr>
<tr>
<td></td>
<td>Papanicolaou Society of Cytopathology in Coordination with American Society of Cytopathology – Algorithmic Approach to Pancreaticobiliary Cytology: A Step Towards Recommendations and Guidelines</td>
<td>(pp 52)</td>
<td>CC 307/308</td>
</tr>
<tr>
<td></td>
<td>Pulmonary Pathology Society – Topical Debates in Pulmonary Pathology</td>
<td>(pp 53)</td>
<td>CC 321-323</td>
</tr>
</tbody>
</table>

### Sunday, March 3

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Page #</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 AM – 12:00 PM</td>
<td><strong>Companion Meeting</strong>&lt;br&gt;Arthur Purdy Stout Society of Surgical Pathologists – Benign Mimics of Malignancy: Clues for Differential Diagnosis</td>
<td>(pp 54)</td>
<td>CC Ballroom 1/2</td>
</tr>
<tr>
<td></td>
<td>Binford-Dammin Society of Infectious Disease Pathologists – The Role of the Autopsy in Infectious Disease Diagnosis and Public Health</td>
<td>(pp 55)</td>
<td>CC 316</td>
</tr>
<tr>
<td></td>
<td>College of American Pathologists – The Application and Criticality of Specimen Asset Tracking in Anatomic Pathology and Clinical Research</td>
<td>(pp 56)</td>
<td>CC Ballroom 4</td>
</tr>
<tr>
<td></td>
<td>Hans Popper Hepatopathology Society – Update on Liver Fibrosis</td>
<td>(pp 57)</td>
<td>CC 307/308</td>
</tr>
<tr>
<td></td>
<td>Renal Pathology Society – Recent Advances in Renal Pathology</td>
<td>(pp 57)</td>
<td>CC 309/310</td>
</tr>
<tr>
<td></td>
<td>Society for Cardiovascular Pathology – Angiogenesis In Health and Disease: It's All about the Vessels</td>
<td>(pp 58)</td>
<td>CC 318-320</td>
</tr>
<tr>
<td></td>
<td>Society for Ultrastructural Pathology – Let's Get Small: Ultrastructural Evaluation of Cellular and Subcellular Specimens</td>
<td>(pp 59)</td>
<td>CC 301</td>
</tr>
<tr>
<td>1:30 PM – 3:00 PM</td>
<td><strong>Companion Meeting</strong>&lt;br&gt;Paleopathology Club – Paleopathology of Canada</td>
<td>(pp 60)</td>
<td>CC 313</td>
</tr>
<tr>
<td>1:30 PM – 5:00 PM</td>
<td><strong>Companion Meeting</strong>&lt;br&gt;American Society for Investigative Pathology – Interactive Molecular Pathology American Society of Dermatopathology and Society for Pediatric Pathology – Update on Cutaneous Melanocytic, Mesenchymal and Lymphoproliferative Lesions in Children International Society of Bone and Soft Tissue Pathology – Recent Advances in Soft Tissue and Bone Pathology International Society of Gynecological Pathologists – The Origins of Ovarian Cancer Part 2: Non-Serous Tumors</td>
<td>(pp 61)</td>
<td>CC 318-320</td>
</tr>
<tr>
<td></td>
<td>Pathology: Interesting Skeletal Tumors and Genetic Alterations of Salivary Gland Tumors</td>
<td>(pp 62)</td>
<td>CC 309/310</td>
</tr>
<tr>
<td></td>
<td>Rodger C. Haggitt Gastrointestinal Pathology Society – Multifocal and Diffuse Diseases of the GI Tract</td>
<td>(pp 63)</td>
<td>CC 307/308</td>
</tr>
<tr>
<td></td>
<td>Society for Hematopathology – Advances in Small B-Cell Neoplasms: Bringing New Discoveries into Clinical Practice</td>
<td>(pp 64)</td>
<td>CC Ballroom 4</td>
</tr>
<tr>
<td>3:30 PM – 5:00 PM</td>
<td><strong>Companion Meeting</strong>&lt;br&gt;History of Pathology Society – History of Pathology in the Arab World</td>
<td>(pp 67)</td>
<td>CC 313</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Page #</td>
<td>Location</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
<td>--------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>7:30 PM – 10:30 PM</td>
<td>Companion Meeting: American Society for Clinical Pathology in Coordination with the American Pathology; Challenges Facing the Pathologist of the Future; American Society for Cytopathology in Coordination with Papanicolaou Society of Cytopathology – Algorithmic Approach to Pancreaticobiliary Cytology: A Step Towards Recommendations and Guidelines; Results into the Surgical Pathology Report</td>
<td></td>
<td>CC 321-323</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monday, March 4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:50 AM – 1:00 PM</td>
<td>Special Course: A Practical Guide to Molecular Testing in Cancer</td>
<td></td>
<td>CC 307/308</td>
</tr>
<tr>
<td>8:00 AM – 9:30 AM</td>
<td>Proffered Papers: Section A – Genitourinary; Section B – Breast; Section C – Hematopathology; Section D – Gastrointestinal; Section E – Gynecologic &amp; Obstetrics; Section F – Dermatopathology</td>
<td></td>
<td>CC Ballroom 2</td>
</tr>
<tr>
<td>8:00 AM – 9:30 AM</td>
<td>Proffered Papers: Section G1 – Neuropathology; Section H1 – Potpourri – Autopsy, Cardiac, Education, Ophthalmic, Pediatrics, Ultrastructural</td>
<td></td>
<td>CC 307/308</td>
</tr>
<tr>
<td>8:00 AM – 4:30 PM</td>
<td>Special Course: Introduction to Molecular Pathology for the Practicing Pathologist: Technology, Assay Interpretation, and Pitfalls</td>
<td></td>
<td>CC 318-320</td>
</tr>
<tr>
<td>9:30 AM – 12:00 PM</td>
<td>Stowell-Orbison, Poster Session 1: Stowell-Orbison Award Posters: Autopsy; Stowell-Orbison Award Posters: Bone &amp; Soft Tissue; Stowell-Orbison Award Posters: Breast; Stowell-Orbison Award Posters: Cardiovascular; Stowell-Orbison Award Posters: Cytology; Stowell-Orbison Award Posters: Dermatopathology; Stowell-Orbison Award Posters: Education; Stowell-Orbison Award Posters: Endocrine; Stowell-Orbison Award Posters: Gastrointestinal; Stowell-Orbison Award Posters: Genitourinary; Stowell-Orbison Award Posters: Gynecologic &amp; Obstetrics; Stowell-Orbison Award Posters: Head &amp; Neck; Stowell-Orbison Award Posters: Hematopathology; Stowell-Orbison Award Posters: Infections; Stowell-Orbison Award Posters: Informatics; Stowell-Orbison Award Posters: Kidney; Stowell-Orbison Award Posters: Liver; Stowell-Orbison Award Posters: Neuropathology; Stowell-Orbison Award Posters: Ophthalmic; Stowell-Orbison Award Posters: Pancreas; Stowell-Orbison Award Posters: Pan-Genomic/Pan-Proteomic Approaches to Cancer; Stowell-Orbison Award Posters: Pathobiology; Stowell-Orbison Award Posters: Pediatrics; Stowell-Orbison Award Posters: Pulmonary; Stowell-Orbison Award Posters: Quality Assurance</td>
<td></td>
<td>CC Exhibit Hall A-D</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Page #</td>
<td>Location</td>
</tr>
<tr>
<td>-------------------</td>
<td>----------------------------------------------</td>
<td>---------</td>
<td>---------------------------</td>
</tr>
<tr>
<td><strong>Meeting at a Glance - Monday &amp; Tuesday</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>11:00 AM – 12:00 PM</strong></td>
<td>Proffered Papers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Section G2 – Pathobiology</td>
<td>(pp 121)</td>
<td>CC 309</td>
<td></td>
</tr>
<tr>
<td>Section H2 – Informatics</td>
<td>(pp 122)</td>
<td>CC 310</td>
<td></td>
</tr>
<tr>
<td><strong>1:00 PM – 3:00 PM</strong></td>
<td>Proffered Papers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Section A – Genitourinary</td>
<td>(pp 122)</td>
<td>CC Ballroom 2</td>
<td></td>
</tr>
<tr>
<td>Section B – Breast</td>
<td>(pp 122)</td>
<td>CC Ballroom 4</td>
<td></td>
</tr>
<tr>
<td>Section C – Hematopathology</td>
<td>(pp 123)</td>
<td>CC Ballroom 3</td>
<td></td>
</tr>
<tr>
<td>Section D – Pulmonary</td>
<td>(pp 123)</td>
<td>CC Ballroom 1</td>
<td></td>
</tr>
<tr>
<td>Section E – Liver</td>
<td>(pp 124)</td>
<td>CC 314/315</td>
<td></td>
</tr>
<tr>
<td>Section F – Head &amp; Neck</td>
<td>(pp 124)</td>
<td>CC 316/317</td>
<td></td>
</tr>
<tr>
<td>Section G – Quality Assurance</td>
<td>(pp 125)</td>
<td>CC 309</td>
<td></td>
</tr>
<tr>
<td>Section H – Endocrine</td>
<td>(pp 125)</td>
<td>CC 310</td>
<td></td>
</tr>
<tr>
<td><strong>1:00 PM – 4:30 PM</strong></td>
<td>Poster Session II</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone &amp; Soft Tissue</td>
<td>(pp 152)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>(pp 153)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Cytology</td>
<td>(pp 155)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>(pp 157)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Genitourinary</td>
<td>(pp 159)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Hematopathology</td>
<td>(pp 162)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Kidney</td>
<td>(pp 164)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Pathobiology</td>
<td>(pp 166)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Pulmonary</td>
<td>(pp 167)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td><strong>2:00 PM – 4:00 PM</strong></td>
<td>Special Course</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Careers in Investigation Pathology: The Next Generation</td>
<td>(pp 81)</td>
<td>CC 307/308</td>
<td></td>
</tr>
<tr>
<td><strong>4:30 PM – 5:30 PM</strong></td>
<td>Special Lecture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Nathan Kaufman Timely Topics Lecture</td>
<td>(pp 103)</td>
<td>CC Ballroom 1-4</td>
<td></td>
</tr>
<tr>
<td><strong>7:30 PM – 9:30 PM</strong></td>
<td>Evening Specialty Conference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone &amp; Soft Tissue Specialty Conference – The Marriage of Pathology and Genetics</td>
<td>(pp 87)</td>
<td>CC Ballroom 2</td>
<td></td>
</tr>
<tr>
<td>Cytology Specialty Conference – Lessons Learned from a Mentor</td>
<td>(pp 88)</td>
<td>CC Ballroom 1</td>
<td></td>
</tr>
<tr>
<td>Hematopathology Specialty Conference – Pediatric Hematopathology</td>
<td>(pp 88)</td>
<td>CC Ballroom 3</td>
<td></td>
</tr>
<tr>
<td>Liver Pathology Specialty Conference – Liver Pathology Cases: Taming of an Arduous Terrain</td>
<td>(pp 89)</td>
<td>CC Ballroom 4</td>
<td></td>
</tr>
<tr>
<td><strong>Tuesday, March 5</strong></td>
<td><strong>Proffered Papers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>8:00 AM – 12:00 PM</strong></td>
<td>Proffered Papers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Section A – Genitourinary</td>
<td>(pp 126)</td>
<td>CC Ballroom 2</td>
<td></td>
</tr>
<tr>
<td>Section B – Breast</td>
<td>(pp 126)</td>
<td>CC Ballroom 4</td>
<td></td>
</tr>
<tr>
<td>Section C – Hematopathology</td>
<td>(pp 127)</td>
<td>CC Ballroom 1</td>
<td></td>
</tr>
<tr>
<td>Section D – Gastrointestinal</td>
<td>(pp 128)</td>
<td>CC Ballroom 3</td>
<td></td>
</tr>
<tr>
<td>Section E – Gynecologic &amp; Obstetrics</td>
<td>(pp 128)</td>
<td>CC 314/315</td>
<td></td>
</tr>
<tr>
<td>Section F – Cytology</td>
<td>(pp 129)</td>
<td>CC 316/317</td>
<td></td>
</tr>
<tr>
<td>Section G – Bone &amp; Soft Tissue</td>
<td>(pp 129)</td>
<td>CC 309</td>
<td></td>
</tr>
<tr>
<td>Section H – Kidney</td>
<td>(pp 130)</td>
<td>CC 310</td>
<td></td>
</tr>
<tr>
<td><strong>8:00 AM – 1:00 PM</strong></td>
<td>Special Course</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Advanced Molecular Pathology</td>
<td>(pp 82)</td>
<td>CC 318-320</td>
<td></td>
</tr>
<tr>
<td><strong>8:00 AM – 5:00 PM</strong></td>
<td>Special Course</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basic Principles in Cytology</td>
<td>(pp 83)</td>
<td>CC 307/308</td>
<td></td>
</tr>
<tr>
<td><strong>9:30 AM – 12:00 PM</strong></td>
<td>Poster Session III</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>(pp 168)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Dermatopathology</td>
<td>(pp 170)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Education</td>
<td>(pp 171)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Genitourinary</td>
<td>(pp 171)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Gynecologic &amp; Obstetrics</td>
<td>(pp 174)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Head &amp; Neck</td>
<td>(pp 176)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Hematopathology</td>
<td>(pp 177)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>(pp 178)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td>(pp 179)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Ophthalmic</td>
<td>(pp 180)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Page #</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
<td>------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>1:00 PM – 2:45 PM</td>
<td>Proffered Papers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Section A – Genitourinary</td>
<td>(pp 131)</td>
<td>CC Ballroom 2</td>
<td></td>
</tr>
<tr>
<td>Section B – Gynecologic &amp; Obstetrics</td>
<td>(pp 131)</td>
<td>CC Ballroom 4</td>
<td></td>
</tr>
<tr>
<td>Section C – Cytology</td>
<td>(pp 132)</td>
<td>CC Ballroom 1</td>
<td></td>
</tr>
<tr>
<td>Section D – Pulmonary</td>
<td>(pp 132)</td>
<td>CC Ballroom 3</td>
<td></td>
</tr>
<tr>
<td>Section E – Techniques</td>
<td>(pp 133)</td>
<td>CC 314/315</td>
<td></td>
</tr>
<tr>
<td>Section F – Pancreas</td>
<td>(pp 133)</td>
<td>CC 316/317</td>
<td></td>
</tr>
<tr>
<td>Section G – Hematopathology</td>
<td>(pp 134)</td>
<td>CC 309</td>
<td></td>
</tr>
<tr>
<td>Section H1 – Pan-Genomic/Pan-Proteomic Approaches to Cancer</td>
<td>(pp 134)</td>
<td>CC 310</td>
<td></td>
</tr>
<tr>
<td>1:00 PM – 4:30 PM</td>
<td>Poster Session IV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone &amp; Soft Tissue</td>
<td>(pp 185)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>(pp 186)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Cytology</td>
<td>(pp 188)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>(pp 190)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>(pp 192)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td>(pp 193)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Genitourinary</td>
<td>(pp 194)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Gynecologic &amp; Obstetrics</td>
<td>(pp 197)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Hematopathology</td>
<td>(pp 198)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Pediatrics</td>
<td>(pp 200)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Pulmonary</td>
<td>(pp 200)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>2:05 PM – 2:50 PM</td>
<td>Proffered Papers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Section H2 – Infections</td>
<td>(pp 135)</td>
<td>CC 310</td>
<td></td>
</tr>
<tr>
<td>3:30 PM – 5:00 PM</td>
<td>Special Awards</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Distinguished Pathologist Awardee</td>
<td>(pp 105)</td>
<td>CC Ballroom 1-4</td>
<td></td>
</tr>
<tr>
<td>The Harvey Goldman Master Teacher Awardee</td>
<td>(pp 106)</td>
<td>CC Ballroom 1-4</td>
<td></td>
</tr>
<tr>
<td>The F.K. Mostofi Distinguished Service Awardee</td>
<td>(pp 107)</td>
<td>CC Ballroom 1-4</td>
<td></td>
</tr>
<tr>
<td>The President's Awardee</td>
<td>(pp 108)</td>
<td>CC Ballroom 1-4</td>
<td></td>
</tr>
<tr>
<td>The Ramzi Cotran Young Investigator Awardee</td>
<td>(pp 109)</td>
<td>CC Ballroom 1-4</td>
<td></td>
</tr>
<tr>
<td>5:00 PM – 5:50 PM</td>
<td>Special Lecture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fifty-Sixth Maude Abbott Lecture</td>
<td>(pp 104)</td>
<td>CC Ballroom 1-4</td>
<td></td>
</tr>
<tr>
<td>7:30 PM – 9:30 PM</td>
<td>Evening Specialty Conference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular Pathology Specialty Conference – Cardiac Surgical Specimen Gross</td>
<td>(pp 109)</td>
<td>CC 310</td>
<td></td>
</tr>
<tr>
<td>Neuropathology Specialty Conference – Lessons and Lessons from Peter Burger’s Notebook</td>
<td>(pp 90)</td>
<td>CC 309</td>
<td></td>
</tr>
<tr>
<td>Surgical Pathology Specialty Conference – Interesting Surgical Pathology Cases</td>
<td>(pp 90)</td>
<td>CC Ballroom 1-4</td>
<td></td>
</tr>
</tbody>
</table>

**Wednesday, March 6**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Page #</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM – 12:00 PM</td>
<td>Short Course</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short Course 04-Diagnostic Problems in Vulvar Pathology</td>
<td>(pp 97)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Short Course 05-Cases and Controversies in Inflammatory Bowel Disease</td>
<td>(pp 97)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Short Course 11-Emerging Issues in Pulmonary Pathology</td>
<td>(pp 97)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Short Course 23-Interventional Pathologists’ Role in USFNA &amp; Core Biopsy</td>
<td>(pp 97)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Short Course 25-Diagnosis of Gestational Trophoblastic Diseases in the Molecular Era</td>
<td>(pp 97)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Short Course 26-Non-Neoplastic Hematopathology:</td>
<td>(pp 97)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Short Course 56-Salivary Gland Pathology at the Intersection of Histopathologic Criteria and Clinical Relevance</td>
<td>(pp 97)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>Short Course 63-A Morphology Guide To Unwind Common Overlapping Patterns in Genitourinary Tumors</td>
<td>(pp 97)</td>
<td>CC Exhibit Hall A-D</td>
<td></td>
</tr>
<tr>
<td>8:00 AM – 5:15 PM</td>
<td>Long Course</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soft Tissue Tumors – A Modern, Integrated and Practical Approach to Diagnosis and Classification</td>
<td>(pp 95)</td>
<td>CC Ballroom 2</td>
<td></td>
</tr>
</tbody>
</table>
### Meeting at a Glance - Wednesday & Thursday

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Page #</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30 AM – 12:00 PM</td>
<td>Poster Session V</td>
<td></td>
<td>CC Exhibit Hall A-D</td>
</tr>
<tr>
<td>Autopsy</td>
<td></td>
<td>(pp 202)</td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td></td>
<td>(pp 202)</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular</td>
<td></td>
<td>(pp 204)</td>
<td></td>
</tr>
<tr>
<td>Dermatopathology</td>
<td></td>
<td>(pp 205)</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td></td>
<td>(pp 206)</td>
<td></td>
</tr>
<tr>
<td>Genitourinary</td>
<td></td>
<td>(pp 208)</td>
<td></td>
</tr>
<tr>
<td>Gynecologic &amp; Obstetrics</td>
<td></td>
<td>(pp 211)</td>
<td></td>
</tr>
<tr>
<td>Head &amp; Neck</td>
<td></td>
<td>(pp 212)</td>
<td></td>
</tr>
<tr>
<td>Hematopathology</td>
<td></td>
<td>(pp 214)</td>
<td></td>
</tr>
<tr>
<td>Infections</td>
<td></td>
<td>(pp 215)</td>
<td></td>
</tr>
<tr>
<td>Techniques</td>
<td></td>
<td>(pp 216)</td>
<td></td>
</tr>
<tr>
<td>Ultrastructural</td>
<td></td>
<td>(pp 218)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CC Exhibit Hall A-D</td>
</tr>
</tbody>
</table>

| 1:00 PM – 4:00 PM | Poster Session VI                            |        | CC Exhibit Hall A-D |
| Breast          |                                               | (pp 218)|                    |
| Endocrine       |                                               | (pp 220)|                    |
| Gastrointestinal|                                               | (pp 222)|                    |
| Liver           |                                               | (pp 224)|                    |
| Pancreas        |                                               | (pp 225)|                    |
| Genitourinary   |                                               | (pp 226)|                    |
| Gynecologic & Obstetrics |                                           | (pp 228)|                    |
| Hematopathology |                                               | (pp 229)|                    |
| Neuropathology  |                                               | (pp 231)|                    |
| Informatics     |                                               | (pp 232)|                    |
| Pulmonary       |                                               | (pp 233)|                    |
|                 |                                               |        | CC Exhibit Hall A-D |

| 1:30 PM – 5:30 PM | Short Course                                 |        | CC Exhibit Hall A-D |
| Short Course 18-Modern Approach to the Diagnosis of Neoplastic Splenic Disorders | (pp 98) |                    |
| Short Course 19-Practical Cardiovascular Pathology                            | (pp 98) |                    |
| Short Course 30-Head & Neck Lesions at the Interface of Benign and Malignant | (pp 98) |                    |
| Short Course 33-Bone Marrow Assessment of Cytopenic Patients                   | (pp 98) |                    |
| Short Course 34-Utility and Pitfalls of Immunohistochemistry in the Daily Diagnosis of Gynecologic Pathology | (pp 98) |                    |
| Short Course 38-Ten Diagnoses in Breast Pathology You Cannot Afford To Miss  | (pp 98) |                    |
| Short Course 40-Situational Awareness on the Melanocytic Battlefield          | (pp 98) |                    |
| Short Course 50-Clinically Relevant Challenges in GI Neoplasia                | (pp 98) |                    |

| 7:30 PM – 9:30 PM | Evening Specialty Conference                 |        | CC Exhibit Hall A-D |
| Breast Pathology Specialty Conference – Diagnostic Dilemmas in Breast Pathology and How To Resolve Them | (pp 91) | CC Ballroom 2       |
| Gastrointestinal Pathology Specialty Conference – Early Neoplasia of the GI Tract: Diagnostic Challenges and Clinical Implications | (pp 91) | CC Ballroom 1       |
| Infectious Disease Pathology Specialty Conference – Parasitic Infections: Typical and Atypical | (pp 92) | CC 310              |
| Renal Pathology Specialty Conference – Important Take-Home Messages for Tomorrow’s Signout | (pp 92) | CC 309              |

### Thursday, March 7

| 8:00 AM – 11:30 AM | Short Course                                 |        | CC Exhibit Hall A-D |
| Short Course 06-Common Challenging Problems in Bone and Soft Tissue Pathology  | (pp 99) |                    |
| Short Course 10-Practice of Breast Pathology in 2013 and Beyond               | (pp 99) |                    |
| Short Course 20-Dermatopathology Greatest Hits                                | (pp 99) |                    |
| Short Course 21-Practice of Gastrointestinal Issues in the Diagnosis, Staging and Reporting of Prostatic Adenocarcinoma | (pp 99) |                    |
| Short Course 31-Endocervical Glandular Lesions of the Female Genital Tract   | (pp 99) |                    |
| Short Course 37-Diagnostic Issues in Pediatric Brain Tumors – ABC’s for Sorting out the Routine and the “Zebras” | (pp 99) |                    |
| Short Course 42-Hepatocellular Neoplasms                                    | (pp 99) |                    |
| Short Course 48-Mediastinal Tumors                                           | (pp 99) |                    |
| Short Course 49-Diagnostic Hematopathology - A Roadmap for Surgical Pathologists | (pp 99) |                    |
| Short Course 52-Of Critical Value: Management and Leadership Skills for the Anatomic Pathologist | (pp 99) |                    |
| Short Course 55-Tubulointerstitial and Vascular Diseases of the Kidney       | (pp 99) |                    |
| Short Course 59-Frozen Section Diagnostic Pitfalls & Pearls in Head & Neck Pathology | (pp 99) |                    |
| Short Course 62-Algorithmic Approach to Diagnosis of Inflammatory Disorders of the Gastrointestinal Tract | (pp 99) |                    |
Meeting at a Glance - Friday

Friday, March 8

1:00 PM – 4:30 PM

**Short Course**

Short Course 07-Core Needle Biopsy of the Breast.................................................................(pp 100)

Short Course 08-The Nine Things You Need To Know about Bone Pathology Before Signing

Your Report .............................................................................................................................(pp 100)

Short Course 12-Surgical Pathology of Blood Vessels ..............................................................(pp 100)

Short Course 15-Pancreaticobiliary Cytology with Clinical, Endoscopic Ultrasound and

Histologic Correlation ............................................................................................................(pp 100)

Short Course 21-Biopsy Pathology of Gastrointestinal Neoplasia..............................................(pp 100)

Short Course 27-An Algorithmic Approach to the Diagnosis of Tumors and Tumor-Like

Lesions of the Urinary Bladder .............................................................................................(pp 100)

Short Course 35-Diagnostic Immunohistochemistry: Plagued with Potential Problems but

Pregnant with Possibilities ...................................................................................................(pp 100)

Short Course 36-Germ Cell Tumors, Sex Cord-Stromal Tumors and Other Non-Epithelial

Tumors of the Ovary ...............................................................................................................(pp 100)

Short Course 41-Pattern-Based Algorithms in Diagnostic Liver Pathology ..............................(pp 100)

Short Course 43-Impact of Personalized Medicine on the Practice of Hematopathology ..........(pp 100)

Short Course 44-Practical Placental Pathology .......................................................................(pp 100)

Short Course 47-Glomerular Diseases ....................................................................................(pp 100)

Short Course 54-A Practical Approach to Non-Neoplastic Surgical Neuropathology ..........(pp 100)

7:30 PM – 9:30 PM

**Evening Specialty Conference**

Gynecologic Pathology Specialty Conference – New Diagnoses Need New Approaches: A Glimpse

into the Near Future of GYN Pathology ..................................................................................(pp 93) CC 307/308

Head/Neck/Endocrine Pathology Specialty Conference – Challenging Diagnoses in Head and Neck,

and Endocrine Pathology ....................................................................................................(pp 93) CC 309

Pulmonary Pathology Specialty Conference – The Lung and Systemic Diseases ..................(pp 94) CC 310

8:00 AM – 11:30 AM

**Short Course**

Short Course 03-Common Dilemmas in Breast Pathology ......................................................(pp 101)

Short Course 14-The Diagnosis of Mediastinal Lesions by EBUS-FNA and EUS-FNA . ....(pp 101)

Short Course 22-Modern Prostate Needle Biopsy Interpretation ............................................(pp 101)

Short Course 24-Classification and Prognostication of Mesenchymal Tumors of the

Gastrointestinal Tract with Emphasis on Immunohistochemical and Molecular Markers ....(pp 101)

Short Course 32-How To Diagnose Clinically Relevant High Risk Gynecologic Precancerous

Lesions .....................................................................................................................................(pp 101)

Short Course 39-The Interpretation of the Medical Liver Biopsy ..............................................(pp 101)

Short Course 45-Systems Pathology: An Introduction to Omic Approaches in Modern

Personalized Pathology ..........................................................................................................(pp 101)

Short Course 46-Neuropathology After Dark: Surviving Intraoperative Frozen Section

Consultation ...............................................................................................................................(pp 101)

Short Course 51-Infectious Disease Pathology .......................................................................(pp 101)

Short Course 57-Ophthalmic Pathology: A Look through the Window to the World ..........(pp 101)

Short Course 58-Diffuse Lung Disease ...................................................................................(pp 101)

Short Course 60-Lean Quality Improvement ..........................................................................(pp 101)

Short Course 61-Transplant Pathology of Solid Organs .........................................................(pp 101)

1:00 PM – 4:30 PM

**Short Course**

Short Course 02-Proteomics for Pathologists ...........................................................................(pp 102)

Short Course 09-Integrating Morphology and Molecular Techniques in Breast Pathology ....(pp 102)

Short Course 16-Thyroid FNA: Using the Bethesda System Category Definitions and

Terminology ..............................................................................................................................(pp 102)

Short Course 17-Difficult Diagnoses in Endocrine Pathology .........(pp 102)

Short Course 28-Renal Tumors in Adults ............................................................................(pp 102)

Short Course 53-Diagnoses and Dilemmas in Pancreaticobiliary Pathology .........................(pp 102)
USCAP 2013 Sessions by Topic
The Sessions by Topic Index serves as a general guide to highlight sessions by interest area. Please also refer to the complete United States & Canadian Academy of Pathology Program, beginning on page 3.

**Autopsy Pathology**

**Monday**
- 8:00 AM – 9:30 AM Proffered Papers Section H1.............CC 310
- 9:30 AM – 12:00 PM Poster Session I, Posters 1-5..................CC Exhibit Hall A-D

**Wednesday**
- 9:30 AM – 12:00 PM Poster Session V, Posters 1-12.............CC Exhibit Hall A-D

**Bone & Soft Tissue Pathology**

**Sunday**
- 1:30 PM – 5:00 PM International Society of Bone and Soft Tissue Pathology – Recent Advances in Soft Tissue and Bone Pathology..............CC 307/308

**Monday**
- 9:30 AM – 12:00 PM Poster Session I, Posters 6-11.............CC Exhibit Hall A-D
- 1:00 PM – 4:30 PM Poster Session II, Posters 1-30.............CC Exhibit Hall A-D
- 7:30 PM – 9:30 PM Bone & Soft Tissue Pathology Specialty Conference – The Marriage of Pathology and Genetics.........................CC 314/315

**Tuesday**
- 8:00 AM – 12:00 PM Proffered Papers Section G.............CC 309
- 1:00 PM – 4:30 PM Poster Session IV, Posters 1-31.............CC Exhibit Hall A-D

**Wednesday**
- 8:00 AM – 5:30 PM The Long Course: Soft Tissue Tumors – A Modern, Integrated and Practical Approach to Diagnosis and Classification......CC Ballroom 2

**Thursday**
- 8:00 AM – 11:30 AM Short Course 06-Common Challenging Problems in Bone and Soft Tissue Pathology..................See Short Course Ticket
- 1:00 PM – 4:30 PM Short Course 08-The Nine Things You Need To Know about Bone Pathology before Signing Your Report ..................See Short Course Ticket

**Cardiovascular Pathology**

**Sunday**
- 8:30 AM – 12:00 PM Society for Cardiovascular Pathology – Angiogenesis In Health and Disease: It’s All about the Vessels..................CC 318-320

**Monday**
- 8:00 AM – 9:30 AM Proffered Papers Section H1.............CC 310
- 9:30 AM – 12:00 PM Poster Session I, Posters 46-46.............CC Exhibit Hall A-D
### Sessions by Topic

**Tuesday**
- **7:30 PM – 9:30 PM** Cardiovascular Pathology Specialty Conference
  - Cardiac Surgical Specimen Gross Examination
  - Pitfalls and Perils
  - **CC 310**

**Wednesday**
- **9:30 AM – 12:00 PM** Poster Session V, Posters 46-58
  - **CC Exhibit Hall A-D**
- **1:30 PM – 5:30 PM** Short Course 19-Practical Cardiovascular Pathology
  - See Short Course Ticket

**Thursday**
- **1:00 PM – 4:30 PM** Short Course 12-Surgical Pathology of Blood Vessels
  - See Short Course Ticket

**Cytology**

**Saturday**
- **7:00 PM – 10:00 PM** Papanicolaou Society of Cytopathology in Coordination with American Society of Cytopathology – Algorithmic Approach to Pancreaticobiliary Cytology: A Step Towards Recommendations and Guidelines
  - **CC 307/308**

**Sunday**
- **7:30 PM – 10:30 PM** American Society for Cytopathology in Coordination with Papanicolaou Society of Cytopathology – Algorithmic Approach to Pancreaticobiliary Cytology: A Step Towards Recommendations and Guidelines
  - **CC 307/308**

**Monday**
- **9:30 AM – 12:00 PM** Poster Session I, Posters 47-62
  - **CC Exhibit Hall A-D**
- **1:00 PM – 4:30 PM** Poster Session II, Posters 63-105
  - **CC Exhibit Hall A-D**
- **7:30 PM – 9:30 PM** Cytopathology Specialty Conference – Lessons Learned from a Mentor
  - **CC 316/317**

**Tuesday**
- **8:00 AM – 12:00 PM** Proffered Papers Section F
  - **CC 316/317**
- **8:00 AM – 5:00 PM** Basic Principles in Cytology
  - **CC 307/308**
- **1:00 PM – 2:45 PM** Proffered Papers Section C
  - **CC Ballroom 1**
- **1:00 PM – 4:30 PM** Poster Session IV, Posters 64-106
  - **CC Exhibit Hall A-D**

**Wednesday**
- **8:00 AM – 12:00 PM** Short Course 23-Interventional Pathologists’ Role in Ultrasound-Guided Fine Needle Aspiration (USFNA) & Core Biopsy
  - **See Short Course Ticket**

**Thursday**
- **1:00 PM – 4:30 PM** Short Course 15-Pancreaticobiliary Cytology with Clinical, Endoscopic Ultrasound and Histologic Correlation
  - **See Short Course Ticket**

**Friday**
- **8:00 AM – 11:30 AM** Short Course 14-The Diagnosis of Mediastinal Lesions by EBUS-FNA and EUS-FNA
  - **See Short Course Ticket**
- **1:00 PM – 4:30 PM** Short Course 16-Thyroid FNA: Using the Bethesda System Category Definitions and Terminology
  - **See Short Course Ticket**

### Dermatopathology

**Sunday**
- **1:30 PM – 5:00 PM** American Society of Dermatopathology and Society for Pediatric Pathology – Update on Cutaneous Melanocytic, Mesenchymal and Lymphoproliferative Lesions in Children
  - **CC Ballroom 3**
- **7:30 PM – 9:30 PM** Dermatopathology Specialty Conference – My Biggest Mistake in Dermatopathology & How I Could Have Avoided It
  - **CC Ballroom 3**

**Monday**
- **8:00 AM – 12:00 PM** Proffered Papers Section F
  - **CC 316/317**
- **9:30 AM – 12:00 PM** Poster Session I, Posters 63-72
  - **CC Exhibit Hall A-D**

**Tuesday**
- **9:30 AM – 12:00 PM** Poster Session III, Posters 34-55
  - **CC Exhibit Hall A-D**

**Wednesday**
- **9:30 AM – 12:00 PM** Poster Session V, Posters 59-80
  - **CC Exhibit Hall A-D**
- **1:30 PM – 5:30 PM** Short Course 40-Situational Awareness on the Melanocytic Battlefield
  - **See Short Course Ticket**

**Thursday**
- **8:00 AM – 11:30 AM** Short Course 20-Dermatopathology Greatest Hits
  - **See Short Course Ticket**

### Education

**Sunday**
- **7:30 PM – 9:30 PM** Housestaff Specialty Conference – Boards Preparation: How and What To Study
  - **CC 316**

**Monday**
- **8:00 AM – 9:30 AM** Proffered Papers Section H1
  - **CC 310**
- **9:30 AM – 12:00 PM** Poster Session I, Posters 73-78
  - **CC Exhibit Hall A-D**

**Tuesday**
- **9:30 AM – 12:00 PM** Poster Session III, Posters 56-62
  - **CC Exhibit Hall A-D**
Endocrine Pathology

Saturday
7:00 PM – 10:00 PM Endocrine Pathology Society – Genomic Approaches to Problems in Endocrine Neoplasia ........................................ CC 321-323

Monday
9:30 AM – 12:00 PM Poster Session I, Posters 79-86 ............................................... CC Exhibit Hall A-D
1:00 PM – 3:00 PM Proffered Papers Section H .................. CC 310

Wednesday
1:00 PM – 4:00 PM Poster Session VI, Posters 33-71 ................................................. CC Exhibit Hall A-D

Thursday
7:30 PM – 9:30 PM Head/Neck/Endocrine Pathology Specialty Conference – Challenging Diagnoses in Head and Neck, and Endocrine Pathology ........................................ CC Ballroom 2

Friday
1:00 PM – 4:30 PM Short Course 17-Difficult Diagnoses in Endocrine Pathology ........................................ See Short Course Ticket

Gastrointestinal Pathology

Sunday
1:30 PM – 5:00 PM Rodger C. Haggitt Gastrointestinal Pathology Society – Multifocal and Diffuse Diseases of the GI Tract ........................................ CC Ballroom 2

Monday
8:00 AM – 12:00 PM Proffered Papers Section D .................. CC Ballroom 1
9:30 AM – 12:00 PM Poster Session I, Posters 87-124 ................................................. CC Exhibit Hall A-D
1:00 PM – 4:30 PM Poster Session II, Posters 106-140 .................. CC Exhibit Hall A-D

Tuesday
8:00 AM – 12:00 PM Proffered Papers Section D .................. CC Ballroom 3
1:00 PM – 4:30 PM Poster Session IV, Posters 107-142 .................. CC Exhibit Hall A-D

Wednesday
8:00 AM – 12:00 PM Short Course 05-Cases and Controversies in Inflammatory Bowel Disease ........................................ See Short Course Ticket
9:30 AM – 12:00 PM Poster Session V, Posters 81-116 ................................................. CC Exhibit Hall A-D
1:00 PM – 4:00 PM Poster Session VI, Posters 72-107 .................. CC Exhibit Hall A-D
1:30 PM – 5:30 PM Short Course 50-Clinically Relevant Challenges in GI Neoplasia: The Pathologist, Surgical Oncologist Interaction ........................................ See Short Course Ticket
7:30 PM – 9:30 PM Gastrointestinal Pathology Specialty Conference – Early Neoplasia of the GI Tract: Diagnostic Challenges and Clinical Implications ........................................ CC Ballroom 2

Thursday
8:00 AM – 11:30 AM Short Course 62-Algorithmic Approach to Diagnosis of Inflammatory Disorders of the Gastrointestinal Tract .... See Short Course Ticket
1:00 PM – 4:30 PM Short Course 21-Biopsy Pathology of Gastrointestinal Neoplasia ........................................ See Short Course Ticket

Friday
8:00 AM – 11:30 AM Short Course 24-Classification and Prognostication of Mesenchymal Tumors of the Gastrointestinal Tract with Emphasis on Immunohistochemical and Molecular Markers ... See Short Course Ticket

General

Saturday
12:00 PM – 6:00 PM Leadership, Collaboration, and Change in Health Care: A Residents Workshop for Essential Skills ........................................ CC 301/302
7:00 PM – 10:00 PM American College of Veterinary Pathology – Contemporary Animal Models of Human Cancer ........................................ CC 313

Sunday
8:30 AM – 12:00 PM Arthur Purdy Stout Society of Surgical Pathologists – Benign Mimics of Malignancy: Clues for Differential Diagnosis ........................................ CC Ballroom 1/2
1:30 PM – 3:00 PM Paleopathology Club – Paleopathology of Canada ........................................ CC 313
3:30 PM – 5:00 PM History of Pathology Society – History of Pathology in the Arab World .......................... CC 313

Monday
2:00 PM – 4:00 PM Careers in Investigation Pathology: The Next Generation ........................................ CC 307/308
Sessions by Topic

**Tuesday**
- 7:30 PM – 9:30 PM Surgical Pathology Specialty Conference – Interesting Surgical Pathology Cases
  .................................................CC Exhibit Hall A-D

**Genitourinary Pathology**

**Saturday**
- 7:00 PM – 10:00 PM International Society of Urological Pathology – Current Concepts and Controversies in GU Pathology
  ...........................................................................CC 309/310

**Sunday**
- 7:30 PM – 9:30 PM Genitourinary Pathology Specialty Conference – GU Spindle Cell Lesions
  .........................................................CC Ballroom 1

**Monday**
- 8:00 AM – 12:00 PM Proffered Papers Section A
  .........................................................CC Ballroom 2
- 9:30 AM – 12:00 PM Poster Session I, Posters 125-166
  .........................................................CC Exhibit Hall A-D
- 1:00 PM – 3:00 PM Proffered Papers Section A
  .........................................................CC Ballroom 2
- 1:00 PM – 4:30 PM Poster Session II, Posters 141-187
  .........................................................CC Exhibit Hall A-D

**Tuesday**
- 8:00 AM – 12:00 PM Proffered Papers Section A
  .........................................................CC Ballroom 2
- 9:30 AM – 12:00 PM Poster Session III, Posters 63-108
  .........................................................CC Exhibit Hall A-D
- 1:00 PM – 2:45 PM Proffered Papers Section A
  .........................................................CC Ballroom 2
- 1:00 PM – 4:30 PM Poster Session IV, Posters 172-218
  .........................................................CC Exhibit Hall A-D

**Wednesday**
- 8:00 AM – 12:00 PM Short Course 63-A Morphology Guide to Unwind Common Overlapping Patterns in Genitourinary Tumors
  .........................................................See Short Course Ticket
- 9:30 AM – 12:00 PM Poster Session V, Posters 117-162
  .........................................................CC Exhibit Hall A-D
- 1:00 PM – 4:00 PM Poster Session VI, Posters 136-181
  .........................................................CC Exhibit Hall A-D

**Thursday**
- 8:00 AM – 11:30 AM Short Course 29-Practical Issues in the Diagnosis, Staging and Reporting of Prostatic Adenocarcinoma
  .........................................................See Short Course Ticket
- 1:00 PM – 4:30 PM Short Course 27-An Algorithmic Approach to the Diagnosis of Tumors and Tumor-Like Lesions of the Urinary Bladder
  .........................................................See Short Course Ticket

**Friday**
- 8:00 AM – 11:30 AM Short Course 22-Modern Prostate Needle Biopsy Interpretation
  .........................................................See Short Course Ticket
- 1:00 PM – 4:30 PM Short Course 28-Renal Tumors In Adults: A Comprehensive Contemporaneous Review
  .........................................................See Short Course Ticket

**Gynecologic Pathology**

**Sunday**
- 1:30 PM – 5:00 PM International Society of Gynecological Pathologists – The Origins of Ovarian Cancer Part 2: Non-Serous Tumors
  .........................................................CC 309/310

**Monday**
- 8:00 AM – 12:00 PM Proffered Papers Section E
  .........................................................CC 314/315
- 9:30 AM – 12:00 PM Poster Session I, Posters 167-187
  .........................................................CC Exhibit Hall A-D

**Tuesday**
- 8:00 AM – 12:00 PM Proffered Papers Section E
  .........................................................CC 314/315
- 9:30 AM – 12:00 PM Poster Session III, Posters 109-137
  .........................................................CC Exhibit Hall A-D
- 1:00 PM – 2:45 PM Proffered Papers Section B
  .........................................................CC Ballroom 4
- 1:00 PM – 4:30 PM Poster Session IV, Posters 219-247
  .........................................................CC Exhibit Hall A-D

**Wednesday**
- 8:00 AM – 12:00 PM Short Course 04-Diagnostic Problems in Vulvar Pathology
  .........................................................See Short Course Ticket
- 8:00 AM – 12:00 PM Short Course 25-Diagnosis of Gestational Trophoblastic Diseases in the Molecular Era
  .........................................................See Short Course Ticket
- 9:30 AM – 12:00 PM Poster Session V, Posters 163-191
  .........................................................CC Exhibit Hall A-D
- 1:00 PM – 4:00 PM Poster Session VI, Posters 182-209
  .........................................................CC Exhibit Hall A-D
- 1:30 PM – 5:30 PM Short Course 34-Utility and Pitfalls of Immunohistochemistry in the Daily Diagnosis of Gynecologic Pathology
  .........................................................See Short Course Ticket

**Thursday**
- 8:00 AM – 11:30 AM Short Course 31-Endocervical Glandular Lesions of the Female Genital Tract
  .........................................................See Short Course Ticket
- 1:00 PM – 4:30 PM Short Course 36-Germ Cell Tumors, Sex Cord-Stromal Tumors and Other Non-Epithelial Tumors of the Ovary
  .........................................................See Short Course Ticket
- 1:00 PM – 4:30 PM Short Course 44-Practical Placental Pathology: A Systematic Approach
  .........................................................See Short Course Ticket
- 7:30 PM – 9:30 PM Gynecologic Pathology Specialty Conference – New Diagnoses Need New Approaches: A Glimpse into the near Future of GYN
  .........................................................CC 307/308

**Friday**
- 8:00 AM – 11:30 AM Short Course 02-How To Diagnose Clinically Relevant High Risk Gynecologic Precancerous Lesions
  .........................................................See Short Course Ticket
**Sessions by Topic**

### Head & Neck Pathology

**Sunday**

1:30 PM – 5:00 PM  
North American Society of Head and Neck Pathology – Exciting Topics in Head and Neck Pathology: Interesting Skeletal Tumors and Genetic Alterations of Salivary Gland Tumors  
CC 318-320

**Monday**

9:30 AM – 12:00 PM  
Poster Session I, Posters 188-197  
CC Exhibit Hall A-D

1:00 PM – 3:00 PM  
Proffered Papers Section F  
CC 316/317

**Tuesday**

9:30 AM – 12:00 PM  
Poster Session III, Posters 138-158  
CC Exhibit Hall A-D

**Wednesday**

8:00 AM – 12:00 PM  
Short Course 56-Salivary Gland Pathology at the Intersection of Histopathologic Criteria and Clinical Relevance  
See Short Course Ticket

9:30 AM – 12:00 PM  
Poster Session V, Posters 192-213  
CC Exhibit Hall A-D

1:30 PM – 5:30 PM  
Short Course 30-Head & Neck Lesions at the Interface of Benign and Malignant  
See Short Course Ticket

**Thursday**

8:00 AM – 11:30 AM  
Short Course 59-Frozen Section Diagnostic Pitfalls & Pearls in Head & Neck Pathology  
See Short Course Ticket

7:30 PM – 9:30 PM  
Head/Neck/Endocrine Pathology Specialty Conference – Challenging Diagnoses in Head and Neck, and Endocrine Pathology  
CC 309

### Hematopathology

**Sunday**

1:30 PM – 5:00 PM  
Society for Hematopathology – Advances in Small B-Cell Neoplasms: Bringing New Discoveries into Clinical Practice  
CC Ballroom 4

**Monday**

8:00 AM – 12:00 PM  
Proffered Papers Section C  
CC Ballroom 3

9:30 AM – 12:00 PM  
Poster Session I, Posters 198-244  
CC Exhibit Hall A-D

1:00 PM – 3:00 PM  
Proffered Papers Section C  
CC Ballroom 3

1:00 PM – 4:30 PM  
Poster Session II, Posters 188-218  
CC Exhibit Hall A-D

7:30 PM – 9:30 PM  
Hematopathology Specialty Conference – Pediatric Hematopathology  
CC Ballroom 4

**Tuesday**

8:00 AM – 12:00 PM  
Proffered Papers Section C  
CC Ballroom 1

9:30 AM – 12:00 PM  
Poster Session III, Posters 159-188  
CC Exhibit Hall A-D

1:00 PM – 2:45 PM  
Proffered Papers Section G  
CC 309

1:00 PM – 4:30 PM  
Poster Session IV, Posters 248-277  
CC Exhibit Hall A-D

**Wednesday**

8:00 AM – 12:00 PM  
Short Course 26-Non-Neoplastic Hematopathology: Pitfalls in the Differential with Hematologic Malignancies  
See Short Course Ticket

9:30 AM – 12:00 PM  
Poster Session V, Posters 214-244  
CC Exhibit Hall A-D

1:00 PM – 4:00 PM  
Poster Session VI, Posters 210-238  
CC Exhibit Hall A-D

1:30 PM – 5:30 PM  
Short Course 18-Modern Approach to the Diagnosis of Neoplastic Splenic Disorders  
See Short Course Ticket

1:30 PM – 5:30 PM  
Short Course 33-Bone Marrow Assessment of Cytopenic Patients  
See Short Course Ticket

**Thursday**

8:00 AM – 11:30 AM  
Short Course 49-Diagnostic Hematopathology – A Roadmap for Surgical Pathologists  
See Short Course Ticket

1:00 PM – 4:30 PM  
Short Course 43-Impact of Personalized Medicine for the Practice of Hematopathology  
See Short Course Ticket

### Infectious Diseases Pathology

**Sunday**

8:30 AM – 12:00 PM  
Binford-Dammin Society of Infectious Disease Pathologists – The Role of the Autopsy in Infectious Disease Diagnosis and Public Health  
CC 316

**Monday**

9:30 AM – 12:00 PM  
Poster Session I, Posters 245-246  
CC Exhibit Hall A-D

**Tuesday**

2:05 PM – 2:50 PM  
Proffered Papers Section H2  
CC 310

**Wednesday**

9:30 AM – 12:00 PM  
Poster Session V, Posters 245-255  
CC Exhibit Hall A-D

7:30 PM – 9:30 PM  
Infectious Disease Pathology Specialty Conference – Parasitic Infections: Typical and Atypical  
CC 310
<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thursday</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1:00 PM – 4:30 PM</td>
<td>Short Course 35-Diagnostic Immunohistochemistry: Plagued with Potential Problems but Pregnant with Possibilities ........................................ See Short Course Ticket</td>
</tr>
<tr>
<td><strong>Friday</strong></td>
<td>8:00 AM – 11:30 AM</td>
<td>Short Course 51-Infectious Disease Pathology: A Practical Approach for General Surgical Pathologists................................. See Short Course Ticket</td>
</tr>
<tr>
<td><strong>Informatics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Saturday</strong></td>
<td>7:00 PM – 10:00 PM</td>
<td>Association for Pathology Informatics – Hot Topics in Pathology Informatics................. CC 316</td>
</tr>
<tr>
<td><strong>Monday</strong></td>
<td>9:30 AM – 12:00 PM</td>
<td>Poster Session I, Posters 247-251.............................................. CC Exhibit Hall A-D</td>
</tr>
<tr>
<td></td>
<td>11:00 AM – 12:00 PM</td>
<td>Proffered Papers Section H2................. CC 310</td>
</tr>
<tr>
<td><strong>Wednesday</strong></td>
<td>1:00 PM – 4:00 PM</td>
<td>Poster Session VI, Posters 257-278.............................................. CC Exhibit Hall A-D</td>
</tr>
<tr>
<td><strong>Kidney Pathology</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sunday</strong></td>
<td>8:30 AM – 12:00 PM</td>
<td>Renal Pathology Society – Recent Advances in Renal Pathology.......................... CC 309/310</td>
</tr>
<tr>
<td><strong>Monday</strong></td>
<td>9:30 AM – 12:00 PM</td>
<td>Poster Session I, Posters 252-255.............................................. CC Exhibit Hall A-D</td>
</tr>
<tr>
<td></td>
<td>1:00 PM – 4:30 PM</td>
<td>Poster Session II, Posters 219-259.............................................. CC Exhibit Hall A-D</td>
</tr>
<tr>
<td><strong>Tuesday</strong></td>
<td>8:00 AM – 12:00 PM</td>
<td>Proffered Papers Section H.................................................. CC 310</td>
</tr>
<tr>
<td><strong>Wednesday</strong></td>
<td>7:30 PM – 9:30 PM</td>
<td>Renal Pathology Specialty Conference – Take Home Messages for the Practicing Renal Pathologist................................. CC 309</td>
</tr>
<tr>
<td><strong>Thursday</strong></td>
<td>8:00 AM – 11:30 AM</td>
<td>Short Course 55-Tubulointerstitial and Vascular Diseases of the Kidney............................. See Short Course Ticket</td>
</tr>
<tr>
<td></td>
<td>1:00 PM – 4:30 PM</td>
<td>Short Course 47-Glomerular Diseases........................................ See Short Course Ticket</td>
</tr>
<tr>
<td><strong>Liver Pathology</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sunday</strong></td>
<td>8:30 AM – 12:00 PM</td>
<td>Hans Popper Hepatopathology Society – Update on Liver Fibrosis.......................... CC 307/308</td>
</tr>
<tr>
<td></td>
<td>7:30 PM – 9:30 PM</td>
<td>Pediatric Pathology Specialty Conference – Non-Neoplastic Liver Disease in Pediatrics: Selected Topics................................. CC 320</td>
</tr>
<tr>
<td><strong>Monday</strong></td>
<td>9:30 AM – 12:00 PM</td>
<td>Poster Session I, Posters 256-264.............................................. CC Exhibit Hall A-D</td>
</tr>
<tr>
<td></td>
<td>1:00 PM – 3:00 PM</td>
<td>Proffered Papers Section E ......................... CC 314/315</td>
</tr>
<tr>
<td></td>
<td>7:30 PM – 9:30 PM</td>
<td>Liver Pathology Specialty Conference – Liver Pathology Cases: Taming of an Arduous Terrain........................................ CC Ballroom 2</td>
</tr>
<tr>
<td><strong>Tuesday</strong></td>
<td>9:30 AM – 12:00 PM</td>
<td>Poster Session III, Posters 189-204.............................................. CC Exhibit Hall A-D</td>
</tr>
<tr>
<td></td>
<td>1:00 PM – 4:30 PM</td>
<td>Poster Session IV, Posters 143-159.............................................. CC Exhibit Hall A-D</td>
</tr>
<tr>
<td><strong>Wednesday</strong></td>
<td>1:00 PM – 4:00 PM</td>
<td>Poster Session VI, Posters 108-124.............................................. CC Exhibit Hall A-D</td>
</tr>
<tr>
<td><strong>Thursday</strong></td>
<td>8:00 AM – 11:30 AM</td>
<td>Short Course 42-Hepatocellular Neoplasms........................................ CC Exhibit Hall A-D</td>
</tr>
<tr>
<td></td>
<td>1:00 PM – 4:30 PM</td>
<td>Short Course 41-Pattern-Based Algorithms in Diagnostic Liver Pathology................................. See Short Course Ticket</td>
</tr>
<tr>
<td><strong>Friday</strong></td>
<td>8:00 AM – 11:30 AM</td>
<td>Short Course 39-The Interpretation of the Medical Liver Biopsy: What Do Clinicians Want?........................................ See Short Course Ticket</td>
</tr>
<tr>
<td></td>
<td>1:00 PM – 4:30 PM</td>
<td>Short Course 53-Diagnoses and Dilemmas in Pancreaticobiliary Pathology................................. See Short Course Ticket</td>
</tr>
<tr>
<td><strong>Molecular Pathology</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sunday</strong></td>
<td>7:30 PM – 10:30 PM</td>
<td>American Society for Clinical Pathology in Coordination with the American Pathology Foundation – Meeting the Leadership and Management Challenges Facing the Pathologist of the Future................................. CC 321-323</td>
</tr>
</tbody>
</table>
**Neuropathology**

**Saturday**
7:00 PM – 10:00 PM  American Association of Neuropathologists – Update on Pituitary Adenomas and Sellar Region Masses \(..........................\) CC 317

**Monday**
8:00 AM – 9:30 AM  Proffered Papers Section H1 \(..................\) CC 309
9:30 AM – 12:00 PM  Poster Session I, Posters 265-267 \(..........................\) CC Exhibit Hall A-D

**Tuesday**
7:30 PM – 9:30 PM  Neuropathology Specialty Conference – Lessons and Lessons from Peter Burger’s Notebook \(..........................\) CC 309

**Wednesday**
1:00 PM – 4:00 PM  Poster Session VI, Posters 239-256 \(..........................\) CC Exhibit Hall A-D

**Thursday**
8:00 AM – 11:30 AM  Short Course 37-Diagnostic Issues in Pediatric Brain Tumors – ABC’s for Sorting out the Routine and the “Zebras” \(..........................\) See Short Course Ticket
1:00 PM – 4:30 PM  Short Course 54-A Practical Approach to Non-Neoplastic Surgical Neuropathology \(..........................\) See Short Course Ticket

**Friday**
8:00 AM – 11:30 AM  Short Course 46-Neuropathology After Dark: Surviving Intraoperative Frozen Section Consultation \(..........................\) See Short Course Ticket

**Ophthalmic Pathology**

**Saturday**
7:00 PM – 10:00 PM  American Association of Ophthalmic Oncologists and Pathologists – Advances in Intraocular Oncology and Emerging Entities \(..........................\) CC 311

**Sunday**
7:30 PM – 9:30 PM  Ophthalmic Pathology Specialty Conference – Ophthalmic Pathology: A Spectrum of Interesting Cases \(..........................\) CC 313

**Monday**
8:00 AM – 9:30 AM  Proffered Papers Section H1 \(..................\) CC 310
9:30 AM – 12:00 PM  Poster Session I, Posters 268-268 \(..........................\) CC Exhibit Hall A-D

**Tuesday**
9:30 AM – 12:00 PM  Poster Session III, Posters 216-222 \(..........................\) CC Exhibit Hall A-D

**Friday**
8:00 AM – 11:30 AM  Short Course 57-Ophthalmic Pathology: A Look Through the Window to the World \(..........................\) See Short Course Ticket

**Pancreas Pathology**

**Sunday**
7:30 PM – 9:30 PM  Pediatric Pathology Specialty Conference – Non-Neoplastic Liver Disease in Pediatrics: Selected Topics \(..........................\) CC 320

**Monday**
9:30 AM – 12:00 PM  Poster Session I, Posters 269-274 \(..........................\)
.......................... CC Exhibit Hall A-D

**Tuesday**
9:30 AM – 12:00 PM  Poster Session III, Posters 205-215 \(..........................\)
.......................... CC Exhibit Hall A-D
1:00 PM – 2:45 PM  Proffered Papers Section F \(.............\) CC 316/317
1:00 PM – 4:30 PM  Poster Session IV, Posters 160-171 \(..........................\)
.......................... CC Exhibit Hall A-D

**Wednesday**
1:00 PM – 4:00 PM  Poster Session VI, Posters 125-135 \(..........................\)
.......................... CC Exhibit Hall A-D

**Thursday**
8:00 AM – 11:30 AM  Short Course 42-Hepatocellular Neoplasms: Navigating the Labyrinth of Terminology, Histological Variants and Differential Diagnosis \(..........................\) See Short Course Ticket
1:00 PM – 4:30 PM  Short Course 41-Pattern-Based Algorithms in Diagnostic Liver Pathology \(..........................\) See Short Course Ticket

**Pan-genomic/Pan-proteomic Approaches to Cancer**

**Saturday**
7:00 PM – 10:00 PM  Endocrine Pathology Society – Genomic Approaches to Problems in Endocrine Neoplasia \(..........................\) CC 321-323

**Sunday**
1:30 PM – 5:00 PM  American Society for Investigative Pathology – Interactive Molecular Pathology \(.............\) CC 321-323
7:30 PM – 10:30 PM  Association for Molecular Pathology – Integrating Advanced Sequencing and Genomic Results into the Surgical Pathology Report \(..........................\) CC 309/310
Sessions by Topic

Monday
7:50 AM – 1:00 PM A Practical Guide to Molecular Testing in Cancer .................................................. CC 307/308
8:00 AM – 4:30 PM Introduction to Molecular Pathology for the Practicing Pathologist: Technology, Assay Interpretation and Pitfalls .......... CC 318-320
9:30 AM – 12:00 PM Poster Session I, Posters 275-279 .......................................................... CC Exhibit Hall A-D

Tuesday
8:00 AM – 1:00 PM Advanced Molecular Pathology ..... CC 318-320
9:30 AM – 12:00 PM Poster Session III, Posters 223-242 .......................................................... CC Exhibit Hall A-D
1:00 PM – 2:00 PM Proffered Papers Section H1...............CC 310

Friday
8:00 AM – 11:30 AM Short Course 45-Systems Pathology: An Introduction to Omic Approaches in Modern Personalized Pathology.......................... See Short Course Ticket
1:00 PM – 4:30 PM Poster Session II, Posters 280-301 .......................................................... CC Exhibit Hall A-D

Pathobiology
Monday
9:30 AM – 12:00 PM Poster Session I, Posters 280-284 .......................................................... CC Exhibit Hall A-D
11:00 AM – 12:00 PM Proffered Papers Section G2.............CC 309
1:00 PM – 4:30 PM Poster Session II, Posters 260-279 .......................................................... CC Exhibit Hall A-D

Pediatric Pathology
Monday
8:00 AM – 9:30 AM Proffered Papers Section H1..............CC 310
9:30 AM – 12:00 PM Poster Session I, Posters 285-285 .......................................................... CC Exhibit Hall A-D

Tuesday
1:00 PM – 4:30 PM Poster Session IV, Posters 278-282 .......................................................... CC Exhibit Hall A-D

Pulmonary Pathology
Saturday
7:00 PM – 10:00 PM Pulmonary Pathology Society – Topical Debates in Pulmonary Pathology ................. CC 318-320

Monday
9:30 AM – 12:00 PM Poster Session I, Posters 286-297 .................................
1:00 PM – 3:00 PM Proffered Papers Section D............CC Ballroom 1
1:00 PM – 4:30 PM Poster Session II, Posters 280-301 .................................

Tuesday
1:00 PM – 2:45 PM Proffered Papers Section D.............CC Ballroom 3
1:00 PM – 4:30 PM Poster Session IV, Posters 283-302 .................................

Wednesday
8:00 AM – 12:00 PM Short Course 11-Emerging Issues in Pulmonary Pathology ........................ See Short Course Ticket
1:00 PM – 4:00 PM Poster Session VI, Posters 279-300 .................................

Thursday
8:00 AM – 11:30 AM Short Course 48-Mediastinal Tumors ........................
7:30 PM – 9:30 PM Pulmonary Pathology Specialty Conference – The Lung and Systemic Diseases ............CC 308

Friday
8:00 AM – 11:30 AM Short Course 58-Diffuse Lung Disease: Is it Neoplastic or Not? Or Maybe Both? .......... See Short Course Ticket

Quality Assurance
Sunday
8:30 AM – 12:00 PM College of American Pathologists – The Application and Criticality of Specimen Asset Tracking in Anatomic Pathology and Clinical Research..........................CC Ballroom 4

Monday
9:30 AM – 12:00 PM Poster Session I, Posters 298-302 .........................
1:00 PM – 3:00 PM Proffered Papers Section G.............CC 309

Tuesday
9:30 AM – 12:00 PM Poster Session III, Posters 243-303 .................................

Thursday
8:00 AM – 11:30 AM Short Course 52-Of Critical Value: Management and Leadership Skills for the Anatomic Pathologist ............... See Short Course Ticket

Friday
8:00 AM – 11:30 AM Short Course 60-Lean Quality Improvement: A Practical Approach........ See Short Course Ticket
Techniques

Monday
9:30 AM – 12:00 PM  Poster Session I, Posters 303-313
................................................. CC Exhibit Hall A-D

Tuesday
1:00 PM – 2:45 PM  Proffered Papers Section E
............................................. CC 314/315

Wednesday
9:30 AM – 12:00 PM  Poster Session V, Posters 256-299
................................................. CC Exhibit Hall A-D

Friday
8:00 AM – 11:30 AM  Short Course 61-Transplant Pathology of Solid Organs
............................................. See Short Course Ticket

Ultrastructural

Sunday
8:30 AM – 12:00 PM  Society for Ultrastructural Pathology – Let’s Get Small: Ultrastructural Evaluation of Cellular and Subcellular Specimens
............................................. CC 301

Monday
8:00 AM – 9:30 AM  Proffered Papers Section H1
............................................. CC 310
9:30 AM – 12:00 PM  Poster Session I, Posters 314-316
................................................. CC Exhibit Hall A-D

Wednesday
9:30 AM – 12:00 PM  Poster Session V, Posters 300-303
................................................. CC Exhibit Hall A-D
**RECEPTIONS**

**Please note:** For *Alumni receptions:* You are invited to attend if you are an alumnus, a guest of an alumnus, or a friend of the institution. 
*For Specialty/Companion Society Receptions:* You are invited if you are a member of this society or are considering joining the society and wish to learn more about it. *All luncheons are by invitation only*

HH=Hilton Baltimore Hotel

<table>
<thead>
<tr>
<th>Saturday, March 2(^{nd})</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ADASP Reception</td>
<td>HH Key Ballroom 8</td>
</tr>
<tr>
<td>Chinese American Pathology Association</td>
<td>HH Holiday Ballroom 6</td>
</tr>
<tr>
<td>Endocrine Society Reception</td>
<td>HH Key Ballroom 3</td>
</tr>
<tr>
<td>International Society of Urological Pathology Reception</td>
<td>HH Key Ballroom 1</td>
</tr>
<tr>
<td>Papanicolaou Society Reception</td>
<td>HH Key Ballroom 2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sunday, March 3(^{rd})</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Albany Medical College Reception</td>
<td>HH Key Ballroom 11</td>
</tr>
<tr>
<td>Arthur Purdy Stout Society Reception</td>
<td>HH Holiday Ballroom 2</td>
</tr>
<tr>
<td>ASCP Resident’s Reception</td>
<td>HH Tubman</td>
</tr>
<tr>
<td>Association of Indian Pathology Reception</td>
<td>HH Holiday Ballroom 6</td>
</tr>
<tr>
<td>Columbia University (Pres. Hosp.) Alumni Reception</td>
<td>HH Holiday Ballroom 1</td>
</tr>
<tr>
<td>GI Path Society Reception</td>
<td>HH Holiday Ballroom 4</td>
</tr>
<tr>
<td>Head &amp; Neck Reception</td>
<td>HH Poe</td>
</tr>
<tr>
<td>Iranian Pathologists Association of NA Reception</td>
<td>HH Blake</td>
</tr>
<tr>
<td>Stanford University Reception</td>
<td>HH Key Ballroom 2</td>
</tr>
<tr>
<td>University of Pittsburgh Luncheon</td>
<td>HH Key Ballroom 9</td>
</tr>
<tr>
<td>University of Washington Alumni Reception</td>
<td>HH Key Ballroom 3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Monday, March 4(^{th})</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AJ French Society Reception</td>
<td>HH Douglas</td>
</tr>
<tr>
<td>Alumni &amp; Friends of Yale Reception</td>
<td>HH Key Ballroom 7</td>
</tr>
<tr>
<td>Baylor College of Medicine Reception</td>
<td>HH Hopkins</td>
</tr>
<tr>
<td>Brigham and Women’s Reception</td>
<td>HH Key Ballroom 12</td>
</tr>
<tr>
<td>Cleveland Clinic Alumni Reception</td>
<td>HH Key Ballroom 9</td>
</tr>
<tr>
<td>Dartmouth-Hitchcock/Fletcher Allen Reception</td>
<td>HH Holiday Ballroom 2</td>
</tr>
<tr>
<td>Emory University Reception</td>
<td>HH Carroll</td>
</tr>
<tr>
<td>IAP Arab Division Reception</td>
<td>HH Stone</td>
</tr>
<tr>
<td>International Association of Chinese Pathology Reception</td>
<td>HH Tubman</td>
</tr>
<tr>
<td>Lab Medicine &amp; Path (University of Toronto) Reception</td>
<td>HH Blake</td>
</tr>
<tr>
<td>Latin American Pathology Foundation Reception</td>
<td>HH Poe</td>
</tr>
<tr>
<td>Mass General Alumni Reception</td>
<td>HH Key Ballroom 11</td>
</tr>
<tr>
<td>Mayo Alumni Reception</td>
<td>HH Key Ballroom 10</td>
</tr>
<tr>
<td>McGill University Luncheon</td>
<td>HH Key Ballroom 12</td>
</tr>
<tr>
<td>MD Anderson Reception</td>
<td>HH Key Ballroom 2</td>
</tr>
<tr>
<td>Northwestern University Reception</td>
<td>HH Paca</td>
</tr>
<tr>
<td>NYU School of Medicine Alumni Reception</td>
<td>HH Holiday Ballroom 3</td>
</tr>
<tr>
<td>The Methodist Hospital Resident Reception</td>
<td>HH Johnson</td>
</tr>
<tr>
<td>The OSU Medical Wexner Center Dept. of Pathology Reception</td>
<td>HH Holiday Ballroom 4</td>
</tr>
<tr>
<td>UCLA Alumni Reception</td>
<td>HH Tilghman</td>
</tr>
<tr>
<td>UMass Medical School Alumni Reception</td>
<td>HH Key Ballroom 4</td>
</tr>
<tr>
<td>University of Chicago Reception</td>
<td>HH Key Ballroom 3</td>
</tr>
<tr>
<td>University of PA Reception</td>
<td>HH Key Ballroom 1</td>
</tr>
<tr>
<td>University of TX Med Branch Reunion</td>
<td>HH Holiday Ballroom 1</td>
</tr>
<tr>
<td>Vanderbilt Alumni Reception</td>
<td>HH Brent</td>
</tr>
<tr>
<td>Washington University in St. Louis Reception</td>
<td>HH Key Ballroom 5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tuesday, March 5(^{th})</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Assembly of the Asia Pacific IAP</td>
<td>HH Tubman</td>
</tr>
<tr>
<td>Beth Israel Deaconess Hospital Reception</td>
<td>HH Holiday Ballroom 1</td>
</tr>
<tr>
<td>Histopathology Editorial Board Reception</td>
<td>HH Holiday Ballroom 3</td>
</tr>
<tr>
<td>Japanese Division of IAP Reception</td>
<td>HH Poe</td>
</tr>
<tr>
<td>MSKCC Alumni Reception</td>
<td>HH Holiday Ballroom 2</td>
</tr>
<tr>
<td>Subspecialty Pathology Milestones Meeting</td>
<td>HH Holiday Ballroom 2</td>
</tr>
<tr>
<td>UCSF Reception</td>
<td>HH Holiday Ballroom 4</td>
</tr>
<tr>
<td>UNC Reception</td>
<td>HH Paca</td>
</tr>
<tr>
<td>University of Maryland Reception</td>
<td>HH Holiday Ballroom 5</td>
</tr>
</tbody>
</table>
GENERAL INFORMATION

MEETING VENUE

The 2013 USCAP Annual Meeting Scientific Sessions will be held at the Baltimore Convention Center. Visit Baltimore Housing Services has been designated as the Official Housing Bureau for USCAP 2013. The headquarters hotel for this meeting is the Hilton Baltimore.

REGISTRATION CENTER

The USCAP Registration Desk will be located in the Convention Center Charles Street Lobby and will be open during the following hours:

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, March 2</td>
<td>2:00 PM – 7:00 PM</td>
</tr>
<tr>
<td>Sunday, March 3 to Thursday, March 7</td>
<td>7:00 AM – 5:00 PM</td>
</tr>
<tr>
<td>Friday, March 8</td>
<td>7:00 AM – 2:00 PM</td>
</tr>
</tbody>
</table>

ON SITE REGISTRATION FEES

<table>
<thead>
<tr>
<th></th>
<th>Member of USCAP/IAP</th>
<th>Junior Member (USCAP only)</th>
<th>Senior Non-Member</th>
<th>Non-Member Resident/Fellow</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Registration Only</td>
<td>$ 245</td>
<td>$ 95</td>
<td>$ 295</td>
<td>$ 190</td>
</tr>
<tr>
<td>General Registration and Companion Meetings</td>
<td>$ 395</td>
<td>$ 165</td>
<td>$ 445</td>
<td>$ 330</td>
</tr>
<tr>
<td>Companion Meetings Only</td>
<td>$ 180</td>
<td>$ 85</td>
<td>$ 180</td>
<td>$ 175</td>
</tr>
<tr>
<td>Residents Workshop-Leadership</td>
<td>n/a</td>
<td>$ 0</td>
<td>n/a</td>
<td>$ 0</td>
</tr>
<tr>
<td>Long Course – Soft Tissue Tumors</td>
<td>$ 295</td>
<td>$ 145</td>
<td>$ 340</td>
<td>$ 285</td>
</tr>
<tr>
<td>Short Courses per half-day</td>
<td>$ 200</td>
<td>$ 100</td>
<td>$ 230</td>
<td>$ 190</td>
</tr>
<tr>
<td>Special Courses:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Practical Guide to Molecular Testing in Cancer</td>
<td>$ 240</td>
<td>$ 120</td>
<td>$ 275</td>
<td>$ 230</td>
</tr>
<tr>
<td>Advanced Molecular Pathology</td>
<td>$ 240</td>
<td>$ 120</td>
<td>$ 275</td>
<td>$ 230</td>
</tr>
<tr>
<td>Special Courses:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basic Principles in Cytology</td>
<td>$ 315</td>
<td>$ 160</td>
<td>$ 360</td>
<td>$ 305</td>
</tr>
<tr>
<td>Intro to Molecular Pathology for the Practicing Pathologist</td>
<td>$ 315</td>
<td>$ 160</td>
<td>$ 360</td>
<td>$ 305</td>
</tr>
<tr>
<td>Special Course:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Careers in Investigative Pathology</td>
<td>$ 105</td>
<td>$ 55</td>
<td>$ 120</td>
<td>$ 95</td>
</tr>
</tbody>
</table>

General Registration Fee is required for admittance to any function at the meeting. This one fee allows you to attend all scientific abstract presentations (platforms and posters on Monday, Tuesday, and Wednesday); all the evening Specialty Conferences, the plenary lectures, exhibits, and the USCAP Welcome Reception on Tuesday evening. Additional fees are required for the Long Course, Special Courses and Short Courses. The Companion Meetings on Saturday and Sunday are available to persons who select one of the passes which includes the General Registration and Companion Meetings as well as the passes for Companion Meetings only.
USCAP CANCELLATION POLICY

Cancellations of entire registration: For cancellations received on or before January 25, 2013, a $50 administrative charge will be due. After January 25, 2013, full cancellations will be assessed an administrative charge of 25% of the total registration fee.

For individual course cancellations: An administrative charge of $25 will be made in order to process the refund.

We are aware that occasionally it is necessary to make changes to courses selected. However, after 2 course changes, it will be necessary to charge the $25 administrative charge for any additional changes.

There will be no refunds for cancellations after the start of the meeting – March 2, 2013.

BADGE/TICKET REPLACEMENT CHARGE

In the event of a lost name badge or tickets, there will be a $25 replacement fee for reprints. Name badges are required for admittance into course sessions and the exhibit hall.

POSTER SESSIONS

<table>
<thead>
<tr>
<th>Session</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Session I</td>
<td>Monday, March 4</td>
<td>9:30 AM – 12:00 PM</td>
</tr>
<tr>
<td>Session II</td>
<td>Monday, March 4</td>
<td>1:00 PM – 4:30 PM</td>
</tr>
<tr>
<td>Session III</td>
<td>Tuesday, March 5</td>
<td>9:30 AM – 12:00 PM</td>
</tr>
<tr>
<td>Session IV</td>
<td>Tuesday, March 5</td>
<td>1:00 PM – 4:30 PM</td>
</tr>
<tr>
<td>Session V</td>
<td>Wednesday, March 6</td>
<td>9:30 AM – 12:00 PM</td>
</tr>
<tr>
<td>Session VI</td>
<td>Wednesday, March 6</td>
<td>1:00 PM – 4:30 PM</td>
</tr>
</tbody>
</table>

Those responsible for presentation of a poster should be at these sessions during the coffee breaks in order to expand on the material and to answer questions.

Monday AM Break 9:30 – 11:00            Tuesday AM Break 9:30 – 11:00            Wednesday AM Break 9:30 – 11:00
PM Break 3:00 – 4:30                  PM Break 2:45 – 4:00                   PM Break 2:30 – 4:00

CERTIFICATE OF CME/SAM CREDIT OR PARTICIPATION

Accreditation Statement
The United States & Canadian Academy of Pathology (USCAP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement
The USCAP designates this live activity for a maximum of 53.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

International Physicians
The American Medical Association has determined that physicians not licensed in the U.S. who participate in this CME activity are eligible for AMA PRA Category 1 Credit(s)™.
Health Professionals
Health Professional participants (including residents and fellows-in-training) may claim hours to receive a Certificate of Participation for an activity designated for **AMA PRA Category 1 Credit(s)™**.

CME Credits
Certificates of continuing medical education **AMA PRA Category 1 Credit(s)™** will be issued through the USCAP. CME credits will only be awarded after completion of an online evaluation form.

Self-Assessment Module Credits
The USCAP is approved by the American Board of Pathology to offer Self-Assessment Module (SAM) credits for the purpose of meeting the American Board of Pathology (ABP) requirements for Maintenance of Certification (MOC). Registrants must take and pass the post-test in order to claim SAM credit(s).

The number of SAM credits has increased again this year. There will be more than 314 SAM credits offered during this year's meeting. Since many of these offerings are presented in overlapping time slots, an individual may earn a maximum of 48.5 SAM credit hours during the Annual Meeting.

Session Types for which **AMA PRA Category 1 Credit(s)™** are offered:

- Scientific Abstract Presentations: 8.75 credits (total available)
- Specialty Conferences: 2.0 credits each
- Kaufman Timely Topics Lecture: 1.0 credit
- Maude Abbott Lecture: 1.0 credit
- Long Course: 5.0 credits
- Short Courses: 3.0 credits each
- Molecular Special Courses: 4.5 credits each
- Intro Molecular Special Course: 6.25 credits
- Basic Cytopathology Special Course: 6.0 credits
- Careers Special Course: 2.0 credits
- Companion Society Meetings: 3.0 credits each

The USCAP also jointly sponsors the programs of the following Companion Societies whose programs have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the USCAP and these societies.

Companion Symposia, which are offering SAM credits at this meeting, are indicated by an asterisk (*):
- American Association of Neuropathologists *
- American Association of Ophthalmic Oncologists and Pathologists *
- American College of Veterinary Pathology
- American Society for Clinical Pathology
- American Society of Cytotechnology *
- American Society of Dermatopathology Joint Session with Society for Pediatric Pathology *
- American Society for Investigative Pathology *
- Arthur Purdy Stout Society of Surgical Pathologists *
- Association for Molecular Pathology *
- Binford-Dammin Society of Infectious Disease Pathologists *
- Association for Pathology Informatics *
- College of American Pathologists
- Endocrine Pathology Society *
- Hans Popper Hepatopathology Society *
- History of Pathology Society
- International Society of Bone and Soft Tissue Pathology *
- International Society of Breast Pathology *
- International Society of Gynecological Pathologists *
INTERNET CAFÉ
A bank of computers will be available in the Convention Center Charles Street Lobby second floor, at the top of the escalator. Please limit your use to 15 minutes so everyone will have an opportunity to use these.

SPEAKER PREVIEW ROOM
Only electronic/LCD projection will be utilized for all presentations. Specific details regarding AV requirements were sent to all presenters prior to the meeting. Computers as well as projection equipment will be available in the Speaker-Preview Room, Convention Center 324, beginning Friday, March 1 (3:00 – 6:00 PM), Saturday through Thursday (7:00 AM – 6:00 PM) and Friday (7:00 AM – 1:00 PM) so that individuals presenting papers, as well as faculty, may have the opportunity to review their materials and familiarize themselves with the projection equipment that will be used.

POSTER PICKUP AND POSTER VIEWING STATION
Poster Pick-up Location: Call4Posters® and iPosters™ Booth #436 in the Convention Center Exhibit Halls A-D. The hours are Monday and Tuesday 7:00 AM – 5:00 PM and Wednesday, 7:00 AM – 4:00 PM. Posters which were created or submitted for printing and shipping using Learner's Digest International Call4Posters, may be picked up at their booth. All poster presenters have the option of submitting (free of charge) their posters electronically and having them posted on the USCAP website through iPosters where they will be available for viewing after the meeting. Please visit the iPosters booth for details.

SECRETARIAT
The United States & Canadian Academy of Pathology
3643 Walton Way Extension
Augusta, GA 30909
(706)733-7550 phone (706)733-8033 fax
help@uscap.org email / www.uscap.org website

Bruce R. Smoller, MD – Executive Vice President — bruce@uscap.org
Kerry Crockett, MBA, CAE, CMP – Executive Director — kerry@uscap.org
Annette Dixon – Educational Program Coordinator — annette@uscap.org
Kia Gray, MPH – Director of Education — kia@uscap.org
Victoria Hann, CFRE – Director, USCAP Foundation — victoria@uscap.org
Carolyn Lane – Director of Membership Services — carolyn@uscap.org
Jeff Monks – Director of Business Development and Marketing — jeff@uscap.org
Teresa Powers – Membership Services Coordinator — teresa@uscap.org
Brenden Taylor, MS – Associate Editor, eAcademy — brenden@uscap.org
Janice Wallace – Educational Program Assistant — janice@uscap.org
Stacie Wells – Membership Services Assistant – stacie@uscap.org
Nancy West – Assistant Meeting Planner — nancy@uscap.org
USCAP TV at the 2013 Annual Meeting

The United States & Canadian Academy of Pathology (USCAP) is once again partnering with the international film and broadcasting company, WebsEdge, to bring USCAP-TV to this year’s Annual Meeting, March 2-8, 2013.

USCAP-TV will be an onsite conference television channel featuring a new episode daily, screened around the venue, as well as on a dedicated television channel in selected guest hotel rooms.

This venture serves to raise the visibility of the hard work of leaders in key areas of pathology and to provide an opportunity to learn about ongoing innovation and scientific breakthroughs that are making a difference.

Each daily program has two features: “Thought Leadership” and “Conference News.” Thought Leadership pieces are five-minute sponsored film segments highlighting programs, case studies and best practices from the field of pathology. Conference News is a daily program of conference highlights, featuring “behind the scenes” interviews, coverage of conference events, and reactions to the day from attending delegates.
United States & Canadian Academy of Pathology
(United States-Canadian Division of the International Academy of Pathology)

PAST PRESIDENTS

1907-08 James Carroll  1970-71 T.C. Jones
1908-10 W. G. MacCallum  1971-72 William Christopherson
1910-13 A. S. Warthin  1972-73 F.K. Mostofi
1913-15 R. M. Pearce  1973-74 Nathan Kaufman
1915-16 A. S. Warthin  1974-75 Richard E. Palmer
1916-20 O. Klotz  1975-76 Murray R. Abell
1921-22 James Ewing  1977-78 Benjamin F. Trump
1922-24 F. B. Mallory  1978-79 Jack P. Strong
1924-29 James F. Coupal  1979-80 William Hartmann
1929-32 H. E. Robertson  1980-81 Kenneth M. Earle
1932-33 George R. Callender  1981-82 Leland D. Stoddard
1933-34 Victor Jacobsen  1982-83 Bernard M. Wagner
1936-38 V. H. Cornell  1984-85 David M. Robertson
1938-39 Carl V. Weller  1985-86 Robert McCluskey
1939-40 James E. Ash  1986-87 John Yardley
1940-41 Tracy B. Mallory  1987-88 Robert Leader
1941-42 William H. Fieldman  1988-89 Ronald S. Weinstein
1942-47 Samuel R. Haythom  1989-90 Cecilia Fenoglio-Preiser
1947-48 Ralph D. Lillie  1990-91 David F. Hardwick
1948-49 Everett L. Bishop  1991-92 Costan W. Berard
1949-50 James E. Ash  1992-93 Peter A. Ward
1950-51 G. Lyman Duff  1993-94 Ramzi S. Cotran
1951-52 Granville A. Bennett  1994-95 Hector Battifora
1953-54 Averill A. Liebow  1996-97 Richard Kempson
1954-55 Harold L. Stewart  1997-98 Sharon Weiss
1956-57 Edward B. Smith  1999-00 Harvey Goldman
1957-58 William O. Russell  2000-01 Deborah Powell
1958-59 Chapman H. Binford  2001-02 Ronald DeLellis
1959-60 Robert E. Stowell  2002-03 Louis P. Dehner
1960-61 F.W. Wiglesworth  2003-04 Virginia A. LiVolsi
1961-62 Benjamin Castleman  2004-05 Ricardo V. Lloyd
1962-63 John B. Hazard  2005-06 Sylvia L. Asa
1963-64 J. Lowell Orbison  2006-07 Henry D. Appelman
1964-65 David E. Smith  2007-08 Christopher P. Crum
1966-67 A. James French  2009-10 Richard J. Zarbo
1968-69 Joshua L. Edwards  2011-12 Gregory N. Fuller
1969-70 Edward A. Gall

Past Secretary-Treasurers

1907-40 Maude Abbott  1970-79 Leland D. Stoddard
1940-49 James E. Ash  1979-91 Nathan Kaufman
1951-52 Harold Stewart  1999-2011 Fred G. Silva
1952-70 F. K. Mostofi  2011-Present Bruce R. Smoller
2012 – 2013
UNITED STATES & CANADIAN ACADEMY OF PATHOLOGY

Council
Linda D. Ferrell, President
Jeffrey L. Myers, President-Elect
Celeste Powers, Vice President
Bruce R. Smoller, Secretary-Treasurer and Executive Vice-President
Gregory Fuller, Past-President

Adam Bagg (‘14)                     Wendy Frankel (‘15)                     Christina Isaacs (‘13)
Kathleen R. Cho (‘13)                Joel Greenson (‘14)                     Esther Oliva (‘14)
Christopher Fletcher (‘13)           Jennifer Hunt (‘15)                      John Sinard (‘15)

Journal Editors

Editor of Laboratory Investigation
Gene P. Siegal, Robert W. Hardy & Brian P. Rubin {Term 1/1/09 – 12/31/13; 1/1/14-12/31/18}
Catherine Ketcham, Managing Editor

Editor of Modern Pathology
John Eble & Harvey M. Cramer {Term 7/1/05 – 6/30/15}
Catherine Ketcham, Managing Editor

Committees

Education Committee {4 Year Terms}
John R. Goldblum, Chair (‘13)
Jesse K. McKenney, Short Course Coordinator (‘15)
Jeffrey Prichard, Chair, Informatics Implementation for e-Education (‘16)
Jason Hornick Abstract Review Subcommittee Chair (‘16)
Brad Quade, Director, CME Subcommittee (‘16)

N. Volkan Adsay (‘13)                     Tarik Elsheikh (‘13)                  Marisa R. Nucci (‘15)
Steven D. Billings (‘15)                   Jason Hornick (‘14)                   Carol Reynolds (‘13)
Edi Brogi (‘16)                           Laura Lamps (‘13)                     Marie E. Robert (‘13)
Kiril Trpkov (‘15)                        Alexander Lazar (‘15)                 Ilan Weinreb (‘14)
Laura Collins (‘16)                       Megan Lim (‘16)                      Robert A. Soslow (‘16)
Sanja Dacic (‘15)

Ashley Mathews-Cimino (‘13) [Housestaff Representative]
Kristie L. White (‘13) [Housestaff Representative]
Kathleen R. Cho (‘13) [Council Liaison]
Christopher Fletcher (‘13) [Council Liaison]
Bruce R. Smoller [Ex-Officio]
Kia Gray [USCAP Staff]
Informatics Implementation for e-Education Subcommittee
Jeffrey Prichard, Chair ('16)  Victor Brodsky  Michael Riben
Shree Sharma  Robert Stapp  Myra Wilkerson
John Sinard ('15) [Council Liaison]  Kia Gray [USCAP Staff]

CME Sub-Committee
Brad Quade, Chair ('16)  Michele Bloomer  Sarah Calkins [Resident Member]
Murat Gokden  Christina Isacson  Adam Bagg ('14) [Council Liaison]
Kia Gray [USCAP Staff]

Stowell-Orbison Award Committee
Amy Chadburn, Chair ('13)  Soheila Korourian ('15)  Hannes Vogel ('14)
Omar Hameed ('16)  Megan Lim ('16)  Ilan Weinreb ('14)

Subcommittee for Unique Live Course Offerings
Marissa Nucci ('15) Chair  Sanja Dacic ('15)  John A. Hart ('16)
Daniel A. Arber ('14)  Megan Lim ('16)  Ilan Weinreb ('14)
Steve Billings ('15)

Finance Committee {4 Year Terms}
James Linder, Chair ('16)  Jeffrey Saffitz ('14)  Bruce Smoller [Ex-Officio]
Julia Dahl ('15)  Allan Tucker ('15)  Linda Ferrell [Ex-Officio]
Mahul Amin ('16)  Joel Greenson ('14) [Council Liaison]  Kerry M. Crockett [USCAP Staff]

Innovative Educational Products Committee
Jeffrey L. Myers, Chair  Rish K. Pai  Bruce Smoller
Sylvia L. Asa  Mary Richardson  Matthew J. Wasco
Tarik Elsheikh  David F. Schaeffer  Darren T. Wheeler
John Goldblum  Shree G. Sharma  Kerry M. Crockett [USCAP Staff]
Christina Isacson  John Sinard  Jeff Monks [USCAP Staff]
Kia Gray [USCAP Staff]

Membership Committee {3 Year Terms}
Julia Iezzoni, Chair ('15)  Lawrence Browne ('14)  Brian T. Pavlovitz ('14)
Oyedele Adeyi ('15)  Leona A. Doyle ('14)  Celeste N. Powers ('14)
Amy L. Adams ('14)  Suntrea T. G. Hammer ('14)  Carolyn Lane [USCAP Staff]
Diana Bell ('15)  Oleksandr Kryvenko ('14)

Resident Advisory Committee
Laura C. Collins, Subcommittee Chair  Jennifer Kaplan
Marwan Yared, Subcommittee-Vice Chair  Scott Kilpatrick
Melissa Austin  Trent Marburger
Benjamin Coulter  Barbara McKenna
Christopher Crum  Elizabeth Morgan
Nora Frisch  Jason Pimental
Ryan Gill  Suzanne Z. Powell
Rondell Graham  Christine Van Beek
Ian Hagemann  Kristie White
Carolyn Lane [USCAP Staff]

Nominating Committee – 2012-2013
Gregory Fuller, Chair  Stuart Schnitt  Richard Zarbo
Allan Tucker ('13)  Julia Bridge ('14)

Publications Committee {4 Year Terms}
Murray Resnick, Chair ('16)  Cesar Moran ('15)  Bruce R. Smoller [Ex-Officio]
Pedram Argani ('15)  Marc Rosenblum ('13)  Linda Ferrell [Ex-Officio]
Gregory Lauwers ('16)  Tony Yachnis ('14)  Jennifer Hunt ('15) [Council Liaison]
Awards Committees

**Castleman Award Committee** {3 Year Terms}
- Adam Bagg, Chair ('13)
- Cristina Antonescu ('14)
- Stephen Black-Schaffer ('15)
- Julia Bridge ('13)
- Bill Faquin ('15)
- Jennifer Hunt ('14)
- Matt van de Rijn ('14)
- Linda Ferrell, [Ex-Officio]
- David N. Louis, [Ex-Officio]

**Goldman Award Committee** – 2012-2013
- John Goldblum, Chair
- Jeffrey Myers
- Victor E. Reuter
- Jeffrey Saffitz
- Stuart J. Schnitt
- Bruce R. Smoller

**Vogel Award Committee** {2 Year Terms}
- Alexander Lazar, Chair ('14)
- Rex Bentley ('13)
- Cynthia Guy ('14)
- Ilan Weinreb ('13)
- Gene Siegal, [Ex-Officio]
- Bruce R. Smoller, [Ex-Officio]
- John Eble, [Ex-Officio]

**Young Investigator Award Committee** {2 Year Terms}
- Kathleen Cho, Chair ('13)
- Kojo Elenitoba-Johnson ('14)
- Christopher Fletcher ('13)
- Esther Oliva ('14)
- Rhonda Yantiss ('14)
- Bruce R. Smoller [Ex-Officio]

Representation

**American Medical Association**
- Jack P. Strong, Delegate
- Bruce R. Smoller, Alternate Delegate
- Allan Tucker (Pathology Section Representative)
- Nicole Riddle (Pathology Section and Young Physicians Section Representative)

**American Registry of Pathology**
- Ronald DeLellis

**Biological Stain Commission**
- Paul Swanson

**Intersociety Committee on Pathology Information**
- Margaret M. Grimes

**Intersociety Pathology Council**
- Bruce R. Smoller and Linda Ferrell

**Program Directors Section of Association of Pathology Chairs (PRODS)**
- Suzanne Powell

**Foundation Board**
- Jonathan Epstein
- Henry Appelman
- Kenneth Bloom
- Cheryl Coffin
- Tarik Elsheikh
- Allen Gown
- Victoria Hann [USCAP Staff]
- David Hardwick
- James Linder
- Celeste Powers
- Jeffrey Ross
- Richard Zarbo
- Kari Hooper
# 2013 USCAP Business Meeting Agenda

**Tuesday, March 5, 2013**

**3:30 PM**

**Ballroom 1-4; Baltimore Convention Center**

**3:30 PM  Order of Business**

<table>
<thead>
<tr>
<th></th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Call to Order</td>
</tr>
<tr>
<td>2.</td>
<td>Introduction</td>
</tr>
<tr>
<td>3.</td>
<td>Minutes of the 2012 Business Meeting</td>
</tr>
<tr>
<td></td>
<td>(Published in the 2013 Program Book)</td>
</tr>
<tr>
<td>4.</td>
<td>Report of the President</td>
</tr>
<tr>
<td></td>
<td>a) General Information</td>
</tr>
<tr>
<td></td>
<td>b) Recognition of Dignitaries attending the Meeting and Announcement of USCAP Recognition Awards (See Program Book for complete list)</td>
</tr>
<tr>
<td>5.</td>
<td>Report of the Executive VP</td>
</tr>
<tr>
<td>6.</td>
<td>Report of the Education Committee</td>
</tr>
<tr>
<td>7.</td>
<td>Report of the Finance Committee</td>
</tr>
<tr>
<td>8.</td>
<td>Innovative Educational Product Committee</td>
</tr>
<tr>
<td>9.</td>
<td>Report of the Membership Committee</td>
</tr>
<tr>
<td>10.</td>
<td>Report of the Foundation</td>
</tr>
<tr>
<td>11.</td>
<td>Report of the Publications Committee</td>
</tr>
<tr>
<td>12.</td>
<td>Report of the Nominating Committee</td>
</tr>
<tr>
<td>13.</td>
<td>Election of Officers</td>
</tr>
<tr>
<td>14.</td>
<td>Installation of the President to take office April 1, 2013</td>
</tr>
<tr>
<td>15.</td>
<td>Presentation of the President's Medal to the Past-President</td>
</tr>
<tr>
<td>16.</td>
<td>IAP Report</td>
</tr>
<tr>
<td></td>
<td>2012 IAP Congress – Cape Town, SA</td>
</tr>
<tr>
<td></td>
<td>Future Congresses</td>
</tr>
<tr>
<td></td>
<td>a) Bangkok, Thailand, 2014</td>
</tr>
<tr>
<td></td>
<td>b) Cologne, Germany, 2016</td>
</tr>
<tr>
<td>17.</td>
<td>Other Business:</td>
</tr>
<tr>
<td>18.</td>
<td>Adjournment of Business Meeting</td>
</tr>
</tbody>
</table>
I. Call to Order

Dr. Gregory N. Fuller called the meeting to order at 3:30 PM.

III. Minutes of the 2011 Business Meeting

Minutes of the previous business meeting held in San Antonio, TX were approved as published in the 2012 Program Book.

IV. Report of the President – Dr. Gregory N. Fuller

A. General Information – This is the largest meeting of the USCAP in its 101 years of existence with over 4,400 attendees, and the largest number of submitted and presented scientific abstracts.

B. Recognition Awards – Dr. Fuller recognized a number of dignitaries, which were in attendance at the meeting. Their names are listed in the Program Book.

V. Report of the Secretary-Treasurer/Executive Vice-President – Dr. Bruce R. Smoller

Dr. Smoller presented a graph of new membership applications over each year. This year was a little bit of a tail off, but it was basically pretty flat. He expects to do more traveling and hopes the Junior Membership numbers will increase.

Junior Membership continues to rise while the Emeritus Membership may be flattening a little bit which is a good sign for the future that our Junior Membership is increasing. Sustaining Members are pretty flat in the last few years.

The composition of the USCAP is made up of 9% of members coming from neither the US or Canada, 8% come from Canada and 83% from the US.


The current annual meeting number of registrants is 4,480, which makes this the biggest meeting ever (by 200+ attendees). This number includes 1838 members, 998 members in training, 689 non-members, and 408 members of the IAP. This is the highest number of junior registrants we've ever had. There are 63 countries represented which equates to 26.4% of the attendees as of 2/23/12.

There are 5,364 Short Course registrants and 7,056 Companion Society registrants, which are both the highest ever. This number equates to the number of registrants times the number of courses they attended.

Scientific abstracts are not only the biggest number ever, but if you look at both the number submitted and the number presented, they are huge. The increase in abstracts submitted in 2012 compared to 2011 was 405 or 15.1%.

Stowell-Orbison abstracts submitted were 522, which is by far the biggest number we've ever had. This is an increase of 32% over last year.

There were over 150 academic centers that submitted abstracts and over 100 academic centers had accepted abstracts.

1679 or 54% of the 3083 abstracts submitted had a trainee listed as the first author.

Abstracts presented per category look pretty much the same as last year. No great trends were seen.

Dr. Smoller discussed other courses beyond the annual meeting (Diagnostic Cytopathology, Practical Pathology Seminars and Diagnostic Pathology Update). All 3 courses in their last run had increases over previous years.

The website had over 6,950,000 page views and more than 20,000 unique visitors per month (defined as different computers) from at least 163 separate countries.

Current CME/SAM opportunities on our website through the eAcademy include: 58 APECS cases which continues to grow; Short Courses continue to be added as they expire including 11 new courses added this year for a total of 28; 4 Special Courses from the 2011 Annual Meeting were added along with the entire Practical Pathology Seminars course.

Our website links to 29 other divisions of the IAP plus 2 links to the IAP Central. Other links include: 28 Companion Societies, 27 other Pathology Societies/Institutions, 13 other Pathology/Lab websites, other meetings/educational opportunities, our academic journals (Modern Pathology and Laboratory Investigation) and Pathology jobs/Career Center.
USCAP initiatives we’re currently working on include resident directed activities, which are a big thing to increase our membership among junior pathologists. Things included in this year’s meeting are: full day seminar on Saturday, cocktail party with Ambassadors and USCAP Leadership (Council Members and Executive Committee), Specialty Conference on Sunday afternoon, Monday and Tuesday breakfast and lunch round-table discussions on issues of importance to our residents, re-energized Ambassador Program, residents participation in most USCAP committees, newly designed “Resident Portal” on the website and the Fellowship Fair.

The Education Committee has been expanded to include several new subcommittees designed to: streamline the abstract review process and selection process to come up with a faster and more knowledgeable selection process; develop and maintain new eAcademy offerings; develop, evaluate and terminate current and future non-standard educational offerings.

The newly appointed Stowell-Orbison Committee oversees the selection of winners of these prestigious awards.

The nominating committee has undergone a great expansion in its role to standardize and make transparent the selection of new candidates for all committees and other leadership positions.

A plan was developed for the succession of directorships for other USCAP courses (Diagnostic Cytopathology, Practical Pathology Seminars, Diagnostic Pathology Update, and other courses not yet developed). This plan has been used by two of our current courses (Diagnostic Cytopathology and Practical Pathology Seminars).

The Innovative Educational Products Committee chaired by Jeff Myers will talk about MyPath. They meet on a regular basis with plans for ongoing initiatives that will hopefully continue far into the future.

The USCAP, IAP, and the Hong Kong Division will co-sponsor a meeting in January 2013. We are excited about this new collaborative initiative.

Looking forward, we’re hoping to redesign and update the website to improve the ease of use and ability to search, increased infrastructural support for e-offerings to enable the marked increase in the scope of our offerings.

A MOC board review exam for residents is on the table and new versions of MyPath are already in development with many new features.

Humanitarian Initiatives – Friends of Africa program generated over $100,000 in order to send African Pathologists to the IAP meeting to be held in Cape Town, South Africa in October.

Discussions are underway to develop a weeklong “school” to rotate through different countries within the West African division of the IAP.

USCAP Infrastructure – Dr. Smoller stated that the most sticking item for him when he took his position was the disparity between what you see here at this meeting and what you see when you go to Augusta. A total of 10.5 FTEs including himself put on this meeting and all of our other offerings.

Richard Matthews, CPA joined the team in October, and we’ll need to undergo further expansion in order to continue with our diversification and growth.

VI. Report of the Finance Committee – Dr. Peter M. Banks

Dr. Banks reported once again that the Academy’s finances are very strong and getting stronger. At the end of last fiscal year which ended June 30, 2011, the invested savings of the Academy had a very high performance. In fact that portion vested in equities outperformed the broader indices, so we are doing very well in that respect.

Just a reminder of where the money comes from for the Academy (Revenue Sources) – educational events which are at the very heart of our mission and accounts for the vast predominance of our income in particular the annual meeting; There is a positive trend towards increasing vendor support in relation to the exhibits at this meeting; membership dues are an important part (though not the biggest part of our revenue); both journals (Modern Pathology and Laboratory Investigation) continue to significantly contribute to our source of revenue.

Opportunities are always available to think of your Academy as well as other worthwhile organizations as a beneficiary of your largess. These would include Sustaining the Academy, Friends of Africa, and The Silva Fund.

Dr. Banks is completing his four year term as Chair of Finance and is succeeded very ably by Dr. James Linder. Dr. Banks stated that it has been a privilege for him to serve in this capacity.

VII. Report of the Foundation – Dr. Celeste N. Powers

Dr. Powers displayed a current list of Foundation Board Members: Chair – Jonathan Epstein, Chair-Elect – Celeste Powers, Henry Appelman, David Hardwick, Kari Hooper, Kenneth Bloom, James Linder, Cheryl Coffin, Tarik Elsheikh, Jeffrey Ross, Allen Gown, Richard Zarbo, and the USCAP Staff – Bruce Smoller, Kerry Crockett, and Victoria Hann.

Ralph Hruban was a charter member and Co-Chair of the Foundation Committee who resigned in 2011. Dr. Powers took a moment to thank him and express her appreciation of his contributions during his tenure with the Foundation.

Dr. Keri Hooper is our first and only resident member and we look forward to working with her in the coming years. She represents a voice for the resident constituents of the USCAP.

Looking at the financials, we can see that the Foundation Corpus (restricted) is doing very well and increased by $8,447 due to investment dividends and interest. The unrestricted funds did very nicely with $164,474. This represents donations particularly in response to sustaining the Academy and The Fred Silva Fund.
With the temporary restricted funds we show a diminution of $75,298. Much of this is due to reallocation of some assets and this is also the fund where the monetary awards come from.

Moving forward, 4 working Committees have been established to diversify the Foundation’s methods of fund raising which includes: Annual Gifts Task Force – Tarik Elsheikh, Chair; Major Gifts and Special Friends – Jeffrey Ross, Chair; Corporate and Foundation Giving – Kenneth Bloom, Chair; and Planned Giving and Endowment – Chair TBD. Throughout the year we will be pulling from the membership to add new ideas and fresh voices to these 4 major areas.

The Friends of Africa fund raised $112,975 which includes $50,000 match from the USCAP. The primary function of this is to fund the Sub-Saharan Pathologists to the IAP Meeting in 2012 in Cape Town.

VIII. Report of the Education Committee – Dr. John R. Goldblum

Dr. Goldblum presented a slide of the members of the Education Committee. He has served as Chair for the last four years. He recognized members who put in a great deal of effort and shared particular aspects of the committee: Jesse McKenney – Short Course Coordinator; Jeffrey Prichard – Chair, eAcademy Sub-Committee; and Tarik Tihan – Chair, CME Subcommittee.

There are 22 individuals including Housestaff who put in a tremendous amount of effort and time to organize this meeting as well as other educational offerings.

Dr. Goldblum thanked the three members whose terms ended in 2012 for their efforts: Robert Hasserjian, Celina Kleer and Jim Zhai.

Events of the 2012 Meeting include: 60 Short Courses, 26 Companion Society Symposia, 19 Evening Specialty Conferences, 2 Plenary Lectures, 2,176 accepted scientific abstracts, 3 Special Courses on Molecular topics, SAMs offered for 4 of the 6 Special Courses, 3 Special Courses for Junior Faculty and Housestaff, New Resident’s Workshop, and 1 Long Course with SAMs offered. The Education Committee is largely responsible for these courses and it requires a tremendous amount of effort and Dr. Goldblum again thanked the individuals on the committee for their service.

The number of Short Course proposals continues to increase. There were 67 proposals submitted and we could only accept 18. There is tremendous competition to have the honor of teaching at this Annual Meeting.

We had over 3,000 abstracts submitted and the acceptance rate overall is 71%. The acceptance rate of the Stowell-Orbison abstracts is 61%, so the old myth that it’s easier to get a Stowell-Orbison abstract submitted is in fact completely wrong.

Dr. Smoller talked earlier about the events at the Annual Meeting that are especially for Housestaff. We’ve made a great effort over the past few years to increase the specific offering for Housestaff. Dr. Goldblum emphasized the Saturday offering put on by Drs. Farver and colleagues. It was an all-day Resident’s Workshop, and he personally learned a lot about leadership and mentoring. It was a fantastic course.

Courses offered outside the annual meeting include Practical Pathology Seminars which will be offered next May in Boston, MA. This course has grown over the past few years. It’s essentially taking the best from this annual meeting and putting it into a 3 ½ day course.

Diagnostic Pathology Update is a week long course occurring this year in Bar Harbor, Maine. It’s a superb course that covers all aspects of surgical pathology.

Dr. Smoller also mentioned the e-Academy (Virtual Lifelong Learning and Self-Assessment). CME/SAMs are available on the eAcademy website including APECS cases and eLibrary courses containing more than 65 hours of content. New this year is the addition of the Diagnostic Cytopathology 2012 and Diagnostic Pathology 2012 recordings.

IX. Report of the Publications Committee – Dr. Ronald DeLellis

Dr. DeLellis is pleased to tell us that it has been a most successful year for both journals. We began our association with Nature in 2004, and it has been a remarkable partnership both for the Academy and for Nature Publishing. Nature is the leading publisher of medical articles and scientific articles with an impact factor of more than 30. Each journal offers 4 full pages of color. The quality of the images and graphics as you know is really superb in both of the journals.

Laboratory Investigation is under the editorship of Gene Siegal and has been for the past 4 years. His editorial group includes 2 Senior Associate Editors, a group of 13 Associate Editors including members from Asia and Europe. Dr. Catherine Ketcham serves as the Managing Editor of this journal.

Dr. Siegal has initiated a number of special features for the journal including summaries of articles and a page which lists all of the articles in that month’s issue of Modern Pathology as well.

Laboratory Investigation is among the top 2 journals devoted to general experimental pathology.

Modern Pathology has been under the editorship of Dr. John Eble for a number of years, and the impact factor is 4.176 which is quite excellent given the competition. This represents a significant increase from the impact factor of 3.75 that was the impact factor 5 years ago. This is one of the leading journals devoted to general diagnostic anatomic and surgical pathology.

USCAP Journals Data: Submissions for both journals continue to be strong with 533 for Laboratory Investigation and 722 for Modern Pathology. Acceptance rates are 28% for Laboratory Investigation and 22% for Modern Pathology which is where we want to be to keep our journals competitive and on top. Advanced online publication occurs within 29 days for Laboratory Investigation and 29.6 days for
Modern Pathology. Print copies of the articles appear within 91.6 days for Laboratory Investigation and 103.7 days for Modern Pathology. The number of webpage visits for Laboratory Investigation is 529,000 and for Modern Pathology there were 1,274,600. Corresponding full text PDF views are also quite high with 247,424 for Laboratory Investigation and 417,282 for Modern Pathology. PubMed link outs for Laboratory Investigation was 102,686 and for Modern Pathology it was 168,377. Each journal is doing a splendid job of putting our publications before the medical public.

This concluded Dr. DeLellis’ presentation and his tenure as the Chair of the Publications Committee.

X. Report of Membership Committee – Dr. Linda Ferrell

Dr. Ferrell said that it was an honor to present the first Membership Committee Report. This newly formed committee was recommended by a 2010 Task Force. There is a Membership Committee and a Sub-Committee called the Residency Advisory Committee which is chaired by Dr. Laura Collins. The priority goal mandates set forward for these committees is to recruit and retain young pathologists in the USCAP.

The priority goals include improving offerings for young members. The action to date is a new website addition “Residents Designed for You”. This includes an introductory PowerPoint slide show on how to navigate the Annual Meeting and a listing of trainee oriented events. The new Saturday course was established for trainees with a focus on their topics of interest.

There is a new Saturday reception for Trainees, Ambassadors, Council, and the USCAP leadership following the course.

An expanded breakfast/lunch hospitality suite offering special topic round table discussions pertinent to trainees needs was also been implemented.

Another goal is to reorganize and re-energize the Ambassador Program.

There was a special Ambassador gathering in 2012 to discuss the program and look at the roles of ambassadors. A goal was set to transform the Ambassador Program into a more active tool to attract young members to long term USCAP membership.

Future additional directions include input into the USCAP website including additions and changes for both trainees and all members. The focus is on educational needs and opportunities.

The committee will also work with the USCAP marketing staff.

Dr. Ferrell thanked all of the committee members and staff for their work on this new committee and their endeavors.

XI. Report of the Nominating Committee – Dr. Stuart J. Schnitt

Dr. Schnitt presented the report on proceedings on the Nominating Committee this year. By electronic vote of the Academy Membership, 3 members of the Academy were elected to serve on the USCAP Council. They are Wendy Frankel, Jennifer Hunt and John Sinard.

XII. Report of Innovative Educational Products Committee – Dr. Jeffrey Myers

Dr. Myers reported that the committee began this journey 2 years ago when it first met as a task force at the 2010 Annual Meeting. In 2011, MyPath was just an idea. Committee Members include: Sylvia Asa, Kerry Crockett, Tarik Elsheikh, John Goldblum, Victoria Hann, Christina Isaacson, Mary Richardson, David Schaeffer, John Sinard, Bruce Smoller, Candace Spradley, Matthew Wasco, and Richard Zarbo. All of these individuals were responsible for getting us this far in collaboration with our managing partners from Inovo, an innovation consulting company.

The committee brought its 1st product to this meeting and 847 people have logged into this beta product. Beta doesn’t mean it’s broken; it’s a fully functional product. It’s not yet fully formed. MyPath is from the Academy, but it belongs to you. You have an opportunity to make it better. The vendor partners have committed to a regular cadence of product enhancement cycles. The feedback tab on each page in MyPath is for you to help us get it right. It is meant to meet the wants, needs and desires of the pathology community worldwide. It is brought to you in a fully functional, but incomplete form. The product cycles will be delivered in 30-90 day increments. MyPath is a benefit of membership in the Academy and available to all attendees registered for this meeting for 30 days.

Dr. Myers thanked David Hardwick who led the strategic planning effort that launched the committee. He also thanked Dr. Fred Silva and then President Richard Zarbo who were strongly supportive of thinking differently about how we create the future of education while maintaining the operational excellence for which the Academy is well known. He thanked succeeding leadership, succeeding President Stuart Schnitt and Greg Fuller and their Executive Committees for recognizing that innovation must happen differently and the new EVP Bruce Smoller for his strong support for a process that is unlike anything that has confronted the Academy in the past. MyPath is the first but not only product. The committee went back to work Saturday to imagine what’s next, and Dr. Myers will be very excited to bring something new to you a year from now.

XIII. Election of Officers – Dr. Stuart J. Schnitt

The USCAP Executive Committee and Council have approved the nomination of Celeste Powers for Vice-President and Jeffrey Myers for President Elect.
There being no nominations from the floor, it was moved to close nominations and officers were declared elected.

**XIV. Installation of the President to take office April 1, 2012 – Dr. Gregory N. Fuller**

The new President of the USCAP officially takes office on April 1, 2012 and the new President is Linda Ferrell.

**XV. Presentation of the President’s Medal to the Past-President – Dr. Gregory N. Fuller**

Dr. Fuller presented the Past Presidents Medal to the Past President Dr. Stuart Schnitt.

**XVI. Future IAP Congresses – Dr. David F. Hardwick and Dr. Martin J. Hale**

Dr. Hardwick reported that the IAP is flourishing in an unusually positive way worldwide.

The upcoming XXIX Congress of the IAP Cape Town, South Africa will be on September 30 – October 5, 2012.

The XXX Congress of the IAP will be in Bangkok, Thailand October 5 – 10, 2014. (Please note that the dates have changed from September 21 – 26, 2014).

The XXXI Congress of the IAP and the 28th Congress of the European Society of Pathology (jointly sponsored by the ESP and the German Division of the IAP) will be held in Cologne, Germany, September 24 – 30, 2016.

Dr. Hale invited everyone to attend the next meeting of the IAP in Cape Town on September 30 – October 5, 2012. Scientific programs include: A wide selection of symposia covering all organ systems included in the general registration fee; 2 slide seminars (included in general registration) 1) AMR slide club 2) AIPNA Slide Seminar; 56 slide seminars/Short Courses and Long Courses.

He encouraged everyone to register now for early rates.

There are a wide range of excellent hotels for all budgets, and can be booked now for discounted rates.

Bursaries are being made available through the Education Committee of the IAP (see Congress website for details).

**XVII. Other Business and Adjournment – Dr. Gregory N. Fuller**

Dr. Fuller asked if there was any other business to conduct. There was no other business. A motion to adjourn the meeting was called for, and the meeting was adjourned at 4:25.
Now that you are chock-full of new knowledge, here’s a great opportunity to apply it to current technology. We’ve assembled over 120 vendors in our Exhibition Hall this year. From software to services to equipment you have a one-stop shop of experts awaiting the opportunity to explain how their company can support your professional development.

Stop by – and please remember to thank our exhibitors – their support is an integral component to our annual meeting.

Schedule a Meeting with our new mobile app

Thanks to our mobile app you can now find every vendor and their location within the Exhibition Hall. If you’re pressed for time – or want to be assured of quality time with one of our vendors – utilize the app Network Now to schedule a time to speak with the vendor. Go to: http://s36.a2zinc.net/clients/herlitz/uscap2013nm/public/nz_Login.aspx

**Exhibition Hall Schedule (same hours as the posters sessions)**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, March 4</td>
<td>9:30 AM – 4:30 PM</td>
</tr>
<tr>
<td>Tuesday, March 5</td>
<td>9:30 AM – 4:30 PM</td>
</tr>
<tr>
<td>Wednesday, March 6</td>
<td>9:00 AM – 4:00 PM</td>
</tr>
</tbody>
</table>

**Exhibit Hall Location**

CC Exhibit Halls A – D – Exhibit Floor
One place for everything.

MyPath™ is the definitive starting point for pathologists with a world of information and connections. And now, we're introducing a seamless relationship with PubMed, allowing you to view their content using our remarkable features. When we created MyPath, our promise was to keep making it better and more powerful. Thanks to you, we continue to fulfill that promise every day. Visit MyPath™ to sign up, search, interact, organize, and start contributing today.

To learn more:
Visit mypath.uscap.org

Download the MyPath app
Available on the iPad App Store

The sponsor of this ad verifies that they had no input into decision making regarding selection of educational programs, content or faculty for this 2013 Annual Meeting.
RESIDENTS & FELLOWS

GREETINGS RESIDENTS AND FELLOWS!

We are especially glad that you have chosen to participate in the 102nd USCAP Annual Meeting.

There are an incredible number of opportunities available to you. On the education front, I hope that you are one of the many that have registered for the sold out Resident Workshop, “Leadership, Collaboration & Change in Healthcare: A Resident’s Workshop in Essential Skills”. If you hurry, the Special Course, “Careers in Investigative Pathology: The Next Generation”, and the Housestaff Specialty Conference, “Boards Preparation: How and What to Study”, still have a few seats left. All of these sessions are led by world-class instructors, so don’t miss them! Speaking of world-class, be sure to attend the Maude Abbott and Nathan Kaufman Timely Topics Lectures — you won’t find more timely information anywhere!

Looking for a Fellowship? Visit the Fellowship Fair where 39 organizations are offering fellowships this year. To help you organize your search we’ve created charts of the institutions and their fellowship offerings; both are found later in this chapter.

Collaboration opportunities abound at our two Residents Receptions, while the Housestaff Hospitality Room is a great place to grab breakfast, lunch or a snack. Of course the USCAP Reception, “Party for a Passion”, is THE place to meet all of the meeting’s attendees, while the Business Meeting and Awards Ceremony will clue you in on the USCAP’s annual initiatives and the individuals who are leading our profession.

Now that you are chock-full of new knowledge, apply it to current technology by chatting with the Exhibitors in the Exhibition Hall. From software to services to equipment, you have a one-stop shop of experts awaiting the opportunity to explain how their company can support your professional development.

Finally, make sure that you review our annual presentation of Posters and Proffered Papers. You’ll find a wealth of cutting edge information generated by your peers.

So, welcome! There’s a world of activities awaiting you at the 2013 USCAP Annual Meeting.

Sincerely,

Dr. Laura C. Collins
Resident Advisory Committee Chair
Beth Israel Deaconess Medical Center

PS — Be sure to keep an eye out for Insider tips. You’ll find special italicized notations in bold under selected topics throughout this section of the Program Book.
EVENTS OF INTEREST FOR PATHOLOGISTS-IN-TRAINING

Resident Workshop
LEADERSHIP, COLLABORATION, AND CHANGE IN HEALTH CARE: A RESIDENTS WORKSHOP FOR ESSENTIAL SKILLS
Date: Saturday, March 2
Time: 12:00 PM – 6:00 PM
Where: CC 301/302

Course Directors: Carol F. Farver, MD, Cleveland Clinic, Cleveland, OH
Phyllis C. Huettner, MD, Washington University Medical Center, St Louis, MO
James K. Stoller, MD, MS, Cleveland Clinic, Cleveland, OH

Course Description:
The delivery of health care in today’s world is increasingly complex. Historically, medical training has centered exclusively on developing clinical and research competence in the medical sciences. However, as healthcare is being delivered more and more by integrated teams and organizations, medical education must teach physicians core competencies of working in and leading healthcare organizations. This workshop is designed to educate residents in leadership, collaboration and communication in healthcare organizations. The course syllabus and bibliography are developed from studies specific to the health care industry that focus on the role of leadership and the functioning of teams within healthcare organizations. The workshop will serve as an introduction to these concepts and an extensive bibliography for further reading will be provided.

The curriculum will provide an opportunity for residents to undertake a guided exploration of the areas of study below, and upon completion of this course, participants should be able to:

- Use emotional intelligence
- Define the characteristics of effective leaders in health care.
- Discuss the importance of mentoring and time management in career success.
- Understand the characteristics and importance of effective teams in health care.
- Administer basic theories on how to change and improve organizations.
- Develop basic tools to manage conflict.

12:00 PM Leadership, Collaboration and Health Care: The Tools Physicians Need To Lead
Carol F. Farver, MD, Cleveland Clinic, Cleveland, OH
James K. Stoller, MD, MS, Cleveland Clinic, Cleveland, OH

Upon completion of this presentation, participants should be able to:

- Define emotional intelligence and the evidence for its importance in leadership.
- Discuss the important physician competencies needed to lead healthcare organizations.
- Define the models of organizational change.
- Review examples of change management in health care organizations.

1:15 PM The New Physician Leader: Basic Survival Skills
Phyllis C. Huettner, MD, Washington University Medical Center, St Louis, MO

Upon completion of this presentation, participants should be able to:

- Define models of time management.
- Define effective tools to improve one’s own time management.
- Summarize the basic elements of a mentoring network and its importance in career success.

2:45 PM Break

3:00 PM Building an Effective Health Care Team
James K. Stoller, MD, MS, Cleveland Clinic, Cleveland, OH

Upon completion of this presentation, participants should be able to:

- Review the importance of teams in health care.
- Define characteristics of effective health care teams.
- Summarize and reflect on one’s own role in a team.

4:45 PM Identifying and Resolving Conflict: Effective Tools for Tomorrow’s Leaders
Carol F. Farver, MD, Cleveland Clinic, Cleveland, OH
Phyllis C. Huettner, MD, Washington University Medical Center, St Louis, MO

Upon completion of this presentation, participants should be able to:

- Review the types of conflict.
- Complete a standard inventory on how one handles conflict.
- List tools for conflict resolution.
- Discuss case scenarios of conflict that residents experience.

5:45 PM Wrap-Up and Evaluations

Insider’s Tip: There’s a Residents’ Reception following this conference – but you must attend the conference to obtain entry. Held in CC 303, the Reception runs from 6:00 – 7:30 PM.
Housestaff Specialty Conference

BOARDS PREPARATION: HOW AND WHAT TO STUDY
Date: Sunday, March 3
Time: 7:30 PM – 9:30 PM
Where: CC316

Join Moderators Drs. Ann Folkins, Stanford Medical University and Barbara McKenna, University of Michigan Hospital, as they speak with Drs. Rebecca Johnson, the American Board of Pathology and Mika Fujiwara, Stanford University Medical Center, about tips for this crucial exam.

HOUSESTAFF HOSPITALITY ROOM
Date: Monday, March 4 – Tuesday, March 5
Time: 7:00 AM – 3:00 PM
Where: CC 301-303

Continental breakfast (7:00 – 8:00 AM) and a light buffet lunch (12:00 – 1:00 PM.) for Housestaff only will be available on a first-come, first-served basis (food will not be replenished). Coffee and soft drinks, as well as assorted snacks, will be available throughout the day. This is a great opportunity to meet renowned pathologists and talk with them on a one to one basis. Take this opportunity to chat informally about career choices or other pathology-related issues.

Our Residency Advisory Committee and Membership Committee have recommended that we give you the opportunity for a more focused experience during the breakfast and lunch hours listed below. Therefore, we will have topic-related round-table discussions available to cover topics relating to pathology training issues to include Boards and MOC; preparing for success in academic practice; preparing for success in private practice; sub-specialty practice/fellowship advice.

The room will only be staffed by distinguished pathologists at the times listed below, but will remain open all day if you want a quiet place to relax and re-group.

A RED DOT on your name tag will identify you as a Housestaff participant and you must show your name tag to be admitted to this room.

SCHEDULE FOR HOSPITALITY ROOM

Monday, March 4th
Breakfast – 7:00 – 8:00 AM:
Drs. Laura Collins, Ryan Gill, Steven Swerdlow, W. Lawrence Browne, Oyedele Adeyi, Paul Wakely

Lunch – 12:00 – 1:00 PM:
Drs. Wendy Frankel, Christopher Crum, Fred Silva, Oleksandr Kryvenko, Mark Wick, Perkins Mukunyadzi, Ann Folkins

Tuesday, March 5th
Breakfast – 7:00 – 8:00 AM:
Drs. Pei Hui, Suzanne Powell, Ricardo Lloyd, Perkins Mukunyadzi, John Hicks, Richard Zaino, Elizabeth Morgan

Lunch – 12:00 – 1:00 PM:
Drs. Linda Ferrell, Rondell Graham, Adam Bagg, W. Lawrence Browne, Eric Hsi, John Sinard, Celeste Powers

Others will drop by from time to time.

Insiders’ Tip: A great place to meet other Fellows as well as USCAP leaders while grabbing breakfast, lunch or a mid day snack.
Special Course
CAREERS IN INVESTIGATIVE PATHOLOGY: GET PUBLISHED
Date: Monday, March 4
Time: 2:00 – 4:00 PM
Where: CC 307/308

The advent of next generation genomic technologies has ushered in tremendous opportunities to reclassify disease. With unparalleled insights into disease manifestations in cells and tissues, pathologists are uniquely well-suited to lead this effort. There are, however, some barriers to entry into this new and exciting arena. With a focus on practical tips and concepts for non-specialists, this course is designed to lower these barriers. This course is aimed at pathologists with no specialized training in genomics or bioinformatics. After an overview of how to incorporate these technologies into your career, you will learn specific strategies to use massive data sets to enhance your research.

Short Courses
When: Wednesday, March 6 – Friday, March 8

There are 61 short courses offered this year. Investigate a wide scope of subspecialty areas with in-depth instruction. Each course targets specific questions in pathology, reviews diagnostic challenges and details practical reviews and approaches.

Insider’s Tip: These courses are very high yield sessions for pathologists-in-training!

The Long Course
SOFT TISSUE TUMORS – A MODERN, INTEGRATED AND PRACTICAL APPROACH TO DIAGNOSIS AND CLASSIFICATION
When: Wednesday, March 6
Time: 8:00 AM – 5:30 PM
Where: CC Ballroom 2

There have been huge advances in our understanding of soft tissue tumors since the last USCAP Long Course on this topic in 1994 – including clinicopathologic characterization of many new entities, major revisions of the classification, introduction of many new immunohistochemical reagents of daily utility and, most especially, recognition of the molecular genetic basis of many of these lesions, bringing not only pathogenetic insights but also a range of valuable new diagnostic tools. This year’s lecture topics seek to address this broad spectrum of new information, focusing on areas of direct practical relevance to general surgical pathologists. The topics to be discussed and the learning objectives for each lecture are listed below.

Fellowship Fair
Date: Sunday, March 3
Time: 5:30 – 7:30 PM
Where: CC 314/315/317

Looking for a fellowship? Here’s an opportunity to speak with representatives of 39 leading institutions about fellowships ranging from Anatomic Pathology to Virology!

Insiders Tip: Be sure to check out the Fellowship posters as you enter. They will enable you to quickly find the location of the institution or type of fellowship that you seek.
AWARDS
FOR PATHOLOGISTS-IN-TRAINING

Awards Ceremony
PATHOLOGISTS-IN-TRAINING AWARDS
When: Tuesday, March 5
Time: 3:30 – 5:00 PM
Where: CC Ballroom 1-4

The Awards for pathologists-in-training will be announced, as well as the USCAP Leadership Awards, during the Business Meeting and Awards Ceremony.

THE STOWELL ORBINSON AWARDS

The Stowell-Orbison Awards were inaugurated to recognize scientific achievement by young pathologists while in training. The selections will be made by members of the Stowell-Orbison Award Committee. The Association of Directors of Anatomic and Surgical Pathology and the USCAP jointly offer an award for the best scientific poster based on autopsy material and in general surgical pathology. The selection will be made by a panel of members of the ADASP. Posters eligible for these Awards will be on display on Monday morning. The awards will be presented during the Business Meeting on Tuesday, March 5.

AUTOPSY AND SURGICAL PATHOLOGY AWARDS

The Association of Directors of Anatomic and Surgical Pathology and the United States and Canadian Academy of Pathology co-sponsor two additional awards of $500 each to a pathologist-in-training for the best posters on a morphology-based surgical pathology study and on autopsy material, respectively, presented as part of the Stowell-Orbison Competition. Applicants may win either of these awards alone, or they may win it in addition to a Stowell-Orbison Award. Eligibility is the same as for the Stowell-Orbison abstracts. Applicants can only submit one paper per person, and the first author must be a pathologist-in-training. Posters for this competition will be judged by a panel of members of the ADASP.

BENJAMIN CASTLEMAN AWARD

The Benjamin Castleman Award is presented to a pathologist or a pathologist-in-training who has not yet reached the age of 40, for an outstanding paper published in English. The subject may be on any topic in pathology based on human material. This award is administered by the Massachusetts General Hospital and the United States and Canadian Academy of Pathology and financed by a fund established by former students, residents, and colleagues at the Massachusetts General Hospital in recognition of Dr. Castleman’s valued contributions to human anatomic pathology. The award will be presented at the Business Meeting on Tuesday, March 5.

F. STEPHEN VOGEL AWARD

The F. Stephen Vogel Award was established by contributions to a fund created by his family and friends. It is awarded for an outstanding paper by a resident or fellow published in one of the Academy journals, Modern Pathology or Laboratory Investigation, during the preceding calendar year. The Awardee must: 1) be a member, in good standing of the United States and Canadian Academy of Pathology for at least a year prior to receiving the award; 2) possess an M.D. or equivalent degree; and 3) be a pathology resident or fellow in an accredited training program at the time of the paper’s acceptance for publication. Applicants should be the first author or must document a significant contribution to the paper. For papers with multiple authorship, only one author is eligible. The award will be presented at the Business Meeting on Tuesday, March 5.

Insiders’ tip: The awards ceremony takes place during the second half of the Business Meeting. You do not have to sit through the business portion and may enter the meeting at any time!
RECEPTIONS

Resident’s Reception:
Date: Saturday, March 2
Time: 6:00 – 7:30 PM
Where: CC 303

You won’t want to miss this!

Here’s a great way to meet the USCAP Ambassadors, Councilors, Speakers and other conference VIP’s. Be sure to attend this event to rub elbows with pathology leaders from around the globe.

Insiders’ tip: You must attend the Resident’s Workshop beforehand for entry to the reception.

New! Our Second Resident’s Reception:
Date: Monday, March 4, 2013
Time: 5:30 – 6:30 PM
Where: Housestaff Hospitality Room, CC 301-303

New this year, the USCAP created this second reception to assure that our pathologists-in-training have the opportunity to meet the USCAP Councilors and Ambassadors in a convivial setting.

The USCAP Reception, “Party for a Passion”, honoring the USCAP Foundation
Date: Tuesday, March 5
Time: 6:00 – 7:30 PM
Where: Hilton Hotel, Key Ballroom 1-12

Insiders Tip: All of the conference attendees will be here. Don’t miss this!

RESIDENT ADVISORY COMMITTEE

Laura C. Collins, Subcommittee Chair
Marwan Yared, Subcommittee-Vice Chair
Melissa Austin
Benjamin Coulter
Christopher Crum
Nora Frisch
Ryan Gill
Rondell Graham
Ian Hagemann

Jennifer Kaplan
Scott Kilpatrick
Trent Marburger
Barbara McKenna
Elizabeth Morgan
Jason Pimental
Suzanne Z. Powell
Christine Van Beek
Kristie White
Carolyn Lane [USCAP Staff]
<table>
<thead>
<tr>
<th>Table</th>
<th>Institution</th>
<th>Fellowships</th>
<th>Hematopathology</th>
<th>Molecular Pathology</th>
<th>Neuropathology</th>
<th>Pediatrics</th>
<th>Surgical Path</th>
</tr>
</thead>
<tbody>
<tr>
<td>37</td>
<td>Baylor College of Medicine</td>
<td>Blood Banking/Transfusion Medicine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cytopathology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dermatopathology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>33</td>
<td>Cleveland Clinic Foundation</td>
<td>Blood Banking/Transfusion Medicine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bone &amp; Soft Tissue</td>
<td></td>
<td></td>
<td>Microbiology</td>
<td>Surgical Path</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Breast</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cardiovascular</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cytopathology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Hospital of the University of Pennsylvania</td>
<td></td>
<td>Surgical Path</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Johns Hopkins Medical Institutions</td>
<td>Blood Banking/Transfusion Medicine</td>
<td></td>
<td></td>
<td>Neuropathology</td>
<td>Renal Pathology</td>
<td>Surgical Path</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chemical Pathology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cytopathology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dermatopathology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Massachusetts General Hospital</td>
<td>Blood Banking/Transfusion Medicine</td>
<td></td>
<td></td>
<td>Microbiology</td>
<td>Molecular Pathology</td>
<td>Neuropathology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bone &amp; Soft Tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Breast</td>
<td></td>
<td></td>
<td>Microbiology</td>
<td>Neuropathology</td>
<td>Pulmonary</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cardiovascular</td>
<td></td>
<td></td>
<td>Microbiology</td>
<td>Neuropathology</td>
<td>Pulmonary</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cytopathology</td>
<td></td>
<td></td>
<td>Microbiology</td>
<td>Neuropathology</td>
<td>Pulmonary</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dermatopathology</td>
<td></td>
<td></td>
<td>Microbiology</td>
<td>Neuropathology</td>
<td>Pulmonary</td>
</tr>
<tr>
<td>7</td>
<td>Mayo Clinic</td>
<td>Bone &amp; Soft Tissue</td>
<td></td>
<td></td>
<td>Pulmonary</td>
<td>Surgical Path</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Breast</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cardiovascular</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cytopathology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Memorial Sloan-Kettering Cancer Center</td>
<td>Blood Banking/Transfusion Medicine</td>
<td></td>
<td></td>
<td>Hematopathology</td>
<td>Molecular Pathology</td>
<td>Surgical Path</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bone &amp; Soft Tissue</td>
<td></td>
<td></td>
<td>Hematopathology</td>
<td>Molecular Pathology</td>
<td>Surgical Path</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Breast</td>
<td></td>
<td></td>
<td>Hematopathology</td>
<td>Molecular Pathology</td>
<td>Surgical Path</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cancer Biomarker</td>
<td></td>
<td></td>
<td>Hematopathology</td>
<td>Molecular Pathology</td>
<td>Surgical Path</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cytopathology</td>
<td></td>
<td></td>
<td>Hematopathology</td>
<td>Molecular Pathology</td>
<td>Surgical Path</td>
</tr>
<tr>
<td>1</td>
<td>NephroPath</td>
<td></td>
<td>Renal Pathology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>New York Presbyterian Hospital - Cornell Medical Center</td>
<td>Blood Banking/Transfusion Medicine</td>
<td></td>
<td></td>
<td>Molecular Pathology</td>
<td>Molecular Pathology</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cytopathology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dermatopathology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>New York University Langone Medical Center</td>
<td>Cytopathology</td>
<td></td>
<td></td>
<td>Orthopedic Pathology</td>
<td>Urologic</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Northwestern University Feinberg School of Medicine</td>
<td>Blood Banking/Transfusion Medicine</td>
<td></td>
<td></td>
<td>Pediatric Pathology</td>
<td>Surgical Path</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bone &amp; Soft Tissue</td>
<td></td>
<td></td>
<td>Pediatric Pathology</td>
<td>Surgical Path</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Breast</td>
<td></td>
<td></td>
<td>Pediatric Pathology</td>
<td>Surgical Path</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cytopathology</td>
<td></td>
<td></td>
<td>Pediatric Pathology</td>
<td>Surgical Path</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dermatopathology</td>
<td></td>
<td></td>
<td>Pediatric Pathology</td>
<td>Surgical Path</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Endocrine</td>
<td></td>
<td></td>
<td>Pediatric Pathology</td>
<td>Surgical Path</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Forensic</td>
<td></td>
<td></td>
<td>Pediatric Pathology</td>
<td>Surgical Path</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Genetics</td>
<td></td>
<td></td>
<td>Pediatric Pathology</td>
<td>Surgical Path</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>PathologyOutlines.com, Inc.</td>
<td>Blood Banking/Transfusion Medicine</td>
<td></td>
<td></td>
<td>Neuropathology</td>
<td>Ophthalmology</td>
<td>Pediatric Pathology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bone &amp; Soft Tissue</td>
<td></td>
<td></td>
<td>Neuropathology</td>
<td>Ophthalmology</td>
<td>Pediatric Pathology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Breast</td>
<td></td>
<td></td>
<td>Neuropathology</td>
<td>Ophthalmology</td>
<td>Pediatric Pathology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cardiovascular</td>
<td></td>
<td></td>
<td>Neuropathology</td>
<td>Ophthalmology</td>
<td>Pediatric Pathology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cytopathology</td>
<td></td>
<td></td>
<td>Neuropathology</td>
<td>Ophthalmology</td>
<td>Pediatric Pathology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dermatopathology</td>
<td></td>
<td></td>
<td>Neuropathology</td>
<td>Ophthalmology</td>
<td>Pediatric Pathology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Endocrine</td>
<td></td>
<td></td>
<td>Neuropathology</td>
<td>Ophthalmology</td>
<td>Pediatric Pathology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Forensic</td>
<td></td>
<td></td>
<td>Neuropathology</td>
<td>Ophthalmology</td>
<td>Pediatric Pathology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Genetics</td>
<td></td>
<td></td>
<td>Neuropathology</td>
<td>Ophthalmology</td>
<td>Pediatric Pathology</td>
</tr>
<tr>
<td>24</td>
<td>Roswell Park Cancer Institute</td>
<td>Cytopathology</td>
<td>Surgical Path</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>The Methodist Hospital</td>
<td>Blood Banking/Transfusion Medicine</td>
<td></td>
<td></td>
<td>Hematopathology</td>
<td>Ophthalmology</td>
<td>Surgical Path</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Chemistry</td>
<td></td>
<td></td>
<td>Hematopathology</td>
<td>Ophthalmology</td>
<td>Surgical Path</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cytopathology</td>
<td></td>
<td></td>
<td>Hematopathology</td>
<td>Ophthalmology</td>
<td>Surgical Path</td>
</tr>
</tbody>
</table>
## PARTICIPATING INSTITUTIONS (Continued)

<table>
<thead>
<tr>
<th>Table</th>
<th>Institution</th>
<th>Fellowships</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>The Ohio State University</td>
<td>Blood Banking/Transfusion Medicine, Cytopathology, Dermatopathology, GI &amp; Liver, Hematopathology</td>
</tr>
<tr>
<td>32</td>
<td>UMDNJ Robert Wood Johnson Medical School</td>
<td>Hematopathology</td>
</tr>
<tr>
<td>30</td>
<td>University of Alabama at Birmingham</td>
<td>Blood Banking/Transfusion Medicine, Cytopathology, Dermatopathology, GI &amp; Liver, Hematopathology, Surgical Path</td>
</tr>
<tr>
<td>23</td>
<td>University of Arkansas Medical School</td>
<td>Blood Banking/Transfusion Medicine, Cytopathology, Dermatopathology, GI &amp; Liver, Gynecologic, Hematopathology, Surgical Path</td>
</tr>
<tr>
<td>13</td>
<td>University of California, San Francisco</td>
<td>Blood Banking/Transfusion Medicine, Cytopathology, Dermatopathology, GI &amp; Liver, Gynecologic, Hematopathology, Molecular Pathology, Neuropathology, Surgical Path</td>
</tr>
<tr>
<td>18</td>
<td>University of Massachusetts Memorial Med Center</td>
<td>Cytopathology, Dermatopathology, Hematopathology, Surgical Path</td>
</tr>
<tr>
<td>29</td>
<td>University of Michigan</td>
<td>Blood Banking/Transfusion Medicine, Breast, Cytopathology, Dermatopathology, GI &amp; Liver, Gynecologic, Hematopathology, Informatics, Molecular Pathology, Neuropathology, Pulmonary, Surgical Path</td>
</tr>
<tr>
<td>40</td>
<td>University of Nebraska Medical Center</td>
<td>Hematopathology, Surgical Path</td>
</tr>
<tr>
<td>11</td>
<td>University of Pittsburgh</td>
<td>Blood Banking/Transfusion Medicine, Bone &amp; Soft Tissue, Breast, Cytopathology, Dermatopathology, Genitourinary Pathology, GI &amp; Liver, Gynecologic, Head &amp; Neck, Hematopathology, Immunopathology/Transplant, Informatics, Molecular Pathology, Neuropathology, Pediatric Pathology, Surgical Path, Thoracic Path</td>
</tr>
<tr>
<td>4</td>
<td>University of Texas Medical Branch Surgical Pathology Division</td>
<td>Cytopathology, Dermatopathology, Surgical Path</td>
</tr>
<tr>
<td>38</td>
<td>University of Texas Southwestern Medical Center</td>
<td>Blood Banking/Transfusion Medicine, Breast, Clinical Chemistry, Clinical Cytogenetics, Cytopathology, Dermatopathology, GI &amp; Liver, Gynecologic, Head &amp; Neck, Hematopathology, Molecular Pathology, Neuropathology, Pediatric Pathology, Surgical Path, Perinatal &amp; Developmental, Pulmonary, Renal Pathology</td>
</tr>
<tr>
<td>35</td>
<td>University of Toronto</td>
<td>Bone &amp; Soft Tissue, Breast, Cytopathology, Dermatopathology, Endocrine, Environmental, Forensic, Genitourinary Pathology, GI &amp; Liver, Gynecologic, Head &amp; Neck, Hematopathology, Microbiology, Neuropathology, Pediatric Pathology, Perinatal &amp; Developmental, Pulmonary, Renal Pathology</td>
</tr>
<tr>
<td>17</td>
<td>University of Utah Health Sciences Center</td>
<td>Biochemistry, Clinical Chemistry, Clinical Cytogenetics, Cytopathology, Genetics, GI &amp; Liver, Hematopathology, Immunopathology/Transplant, Microbiology, Molecular Pathology, Pediatric Pathology, Surgical Path</td>
</tr>
<tr>
<td>22</td>
<td>University of Virginia Health System</td>
<td>Blood Banking/Transfusion Medicine, Clinical Chemistry, Cytopathology, Dermatopathology, GI &amp; Liver, Gynecologic, Hematopathology, Neurupathology</td>
</tr>
<tr>
<td>10</td>
<td>University of Washington</td>
<td>Bone &amp; Soft Tissue, Breast, Cytopathology, Dermatopathology, GI &amp; Liver, Gynecologic, Hematopathology, Molecular Pathology, Neuropathology, Pediatric Pathology, Surgical Path</td>
</tr>
<tr>
<td>36</td>
<td>USCAP</td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>Vanderbilt University Medical Center</td>
<td>Anatomic Pathology, Blood Banking/Transfusion Medicine, Clinical Chemistry, Cytopathology, GI &amp; Liver, Hematopathology, Microbiology, Molecular Pathology, Neuropathology, Pediatric Pathology, Renal Pathology</td>
</tr>
<tr>
<td>6</td>
<td>Virginia Commonwealth University</td>
<td>Forensic, Hematopathology, Molecular Pathology, Neuropathology, Surgical Path</td>
</tr>
<tr>
<td>19</td>
<td>Washington University in St. Louis</td>
<td>Blood Banking/Transfusion Medicine, Cytopathology, Dermatopathology, GI &amp; Liver, Hematopathology, Molecular Pathology, Neuropathology, Pediatric Pathology, Surgical Path</td>
</tr>
<tr>
<td>34</td>
<td>Yale University School of Medicine</td>
<td>Blood Banking/Transfusion Medicine, Breast, Cytopathology, Endocrine, Genitourinary Pathology, GI &amp; Liver, Gynecologic, Head &amp; Neck, Hematopathology, Microbiology, Molecular Pathology, Renal Pathology</td>
</tr>
<tr>
<td>Fellowship</td>
<td>Institution (Table)</td>
<td></td>
</tr>
<tr>
<td>----------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Anatomic Pathology</strong></td>
<td>Vanderbilt University Medical Center (31)</td>
<td></td>
</tr>
</tbody>
</table>
| Blood Banking/Transfusion Medicine | Baylor College of Medicine (37)  
Cedars-Sinai Medical Center (9)  
Cleveland Clinic Foundation (33)  
Johns Hopkins Medical Institutions (26)  
Massachusetts General Hospital (5)  
M.D. Anderson Cancer Center (21)  
PathologyOutlines.com, Inc. (25)  
The Methodist Hospital (5)  
The Ohio State University (2)  
University of Alabama at Birmingham (30)  
University of Arkansas Medical School (23)  
University of California, San Francisco (13)  
University of Michigan (29)  
University of Pittsburgh (11)  
University of Texas Southwestern Medical Center (38)  
University of Virginia Health System (22)  
Vanderbilt University Medical Center (31)  
Washington University in St. Louis (19)  
Yale University School of Medicine (34) |
| Biochemistry                     | University of Utah Health Services Center (17)                                     |
| Bone & Soft Tissue               | Cleveland Clinic Foundation (33)  
Massachusetts General Hospital (5)  
Mayo Clinic (7)  
M.D. Anderson Cancer Center (21)  
PathologyOutlines.com, Inc. (25)  
University of Pittsburgh (11)  
University of Toronto (35)  
University of Washington (10) |
| Breast                           | Brown University Warren Alpert Medical School (15)  
Massachusetts General Hospital (3)  
Mayo Clinic (7)  
M.D. Anderson Cancer Center (21)  
Memorial Sloan-Kettering Cancer Center (16)  
New York Presbyterian Hospital - Cornell Medical Center (14)  
Northwestern University Feinberg School of Medicine (8)  
University of Alabama at Birmingham (30)  
University of Arkansas Medical School (23)  
University of California, San Francisco (13)  
University of Michigan (29)  
University of Pittsburgh (11)  
University of Texas Southwestern Medical Center (38)  
University of Toronto (35)  
University of Washington (10)  
Yale University School of Medicine (34) |
| Cardiovascular                   | Cleveland Clinic Foundation (33)  
Massachusetts General Hospital (5)  
Mayo Clinic (7)  
M.D. Anderson Cancer Center (21)  
PathologyOutlines.com, Inc. (25)  
University of Pittsburgh (11)  
University of Toronto (35)  
Yale University School of Medicine (34) |
| Cancer Biomarker                 | M.D. Anderson Cancer Center (21)                                                   |
| Chemical Pathology               | Johns Hopkins Medical Institutions (26)                                            |
| Clinical Chemistry               | The Methodist Hospital (5)  
University of Texas Southwestern Medical Center (38)  
University of Virginia Health System (22)  
Vanderbilt University Medical Center (31) |
| Clinical Cytogenetics            | University of Texas Southwestern Medical Center (38)  
University of Utah Health Sciences Center (17)  
University of Virginia Health System (22)  
Vanderbilt University Medical Center (31)  
Washington University in St. Louis (19)  
Yale University School of Medicine (34) |
| Cytopathology                    | Baylor College of Medicine (37)  
Cleveland Clinic Foundation (33)  
Johns Hopkins Medical Institutions (26)  
Massachusetts General Hospital (5)  
Mayo Clinic (7)  
M.D. Anderson Cancer Center (21)  
Memorial Sloan-Kettering Cancer Center (16)  
New York Presbyterian Hospital - Cornell Medical Center (14)  
NYU Langone Medical Center (12)  
North Shore-LIJ Health System (39)  
Northwestern University Feinberg School of Medicine (8)  
University of Michigan (29)  
Oregon Health & Sciences University (27)  
PathologyOutlines.com, Inc. (25)  
Roswell Park Cancer Institute (24)  
The Methodist Hospital (5)  
The Ohio State University (2)  
University of Alabama at Birmingham (30)  
University of Arkansas Medical School (23)  
University of California, San Francisco (13)  
University of Massachusetts Memorial Med Center (18)  
University of Pittsburgh (11)  
University of Texas Medical Branch Surgical Pathology Division (4)  
University of Texas Southwestern Medical Center (38)  
University of Toronto (35)  
University of Utah Health Sciences Center (17)  
University of Virginia Health System (22)  
Vanderbilt University Medical Center (31)  
Washington University in St. Louis (19)  
Yale University School of Medicine (34) |
| Dermatopathology                 | Baylor College of Medicine (37)  
Cleveland Clinic Foundation (33)  
Johns Hopkins Medical Institutions (26)  
Massachusetts General Hospital (5)  
M.D. Anderson Cancer Center (21)  
Memorial Sloan-Kettering Cancer Center (16)  
New York Presbyterian Hospital - Cornell Medical Center (14)  
PathologyOutlines.com, Inc. (25)  
The Ohio State University (2)  
University of Arkansas Medical School (23)  
University of Michigan (29)  
University of Pittsburgh (11)  
University of Texas Medical Branch Surgical Pathology Division (4)  
University of Texas Southwestern Medical Center (38)  
University of Toronto (35)  
University of Virginia Health System (22)  
Vanderbilt University Medical Center (31)  
Washington University in St. Louis (19)  
Yale University School of Medicine (34) |
| Endocrine                        | PathologyOutlines.com, Inc. (25)  
University of Toronto (35)  
Yale University School of Medicine (34) |
| Environmental                    | University of Toronto (35)  
University of Virginia Commonwealth University (2)  |
| Forensic                         | PathologyOutlines.com, Inc. (25)  
University of Toronto (35)  
Yale University School of Medicine (34) |
| Genetics                         | University of Utah Health Sciences Center (17)  
PathologyOutlines.com, Inc. (25)  
University of Virginia Health System (22)  
Vanderbilt University Medical Center (31)  
Washington University in St. Louis (19)  
Yale University School of Medicine (34) |
| Genitourinary Pathology          | Cedar-Sinai Medical Center (9)  
Cleveland Clinic Foundation (33)  
Johns Hopkins Medical Institutions (26)  
Massachusetts General Hospital (5)  
M.D. Anderson Cancer Center (21)  
Memorial Sloan-Kettering Cancer Center (16)  
Memorial Sloan-Kettering Cancer Center (16)  
New York Presbyterian Hospital - Cornell Medical Center (14)  
Northwestern University Feinberg School of Medicine (8)  
PathologyOutlines.com, Inc. (25)  
University of Michigan (29)  
University of Pittsburgh (11)  
Yale University School of Medicine (34) |
| GI & Liver                       | Brown University Warren Alpert Medical School (15)  
Cedars-Sinai Medical Center (9)  
Cleveland Clinic Foundation (33)  
Johns Hopkins Medical Institutions (26)  
Massachusetts General Hospital (5)  
Mayo Clinic (7)  
M.D. Anderson Cancer Center (21)  
Memorial Sloan-Kettering Cancer Center (16)  
New York Presbyterian Hospital - Cornell Medical Center (14)  
Northwestern University Feinberg School of Medicine (8)  
PathologyOutlines.com, Inc. (25)  
The Ohio State University (2)  
University of Arkansas Medical School (23)  
University of California, San Francisco (13)  
University of Michigan (29)  
University of Pittsburgh (11)  
University of Texas Southwestern Medical Center (38)  
University of Toronto (35)  
University of Utah Health Sciences Center (17)  
University of Washington (10)  
Yale University School of Medicine (34) |
| Gynecologic                      | Brown University Warren Alpert Medical School (15)  
Johns Hopkins Medical Institutions (26)  
Massachusetts General Hospital (5)  
M.D. Anderson Cancer Center (21)  
Memorial Sloan-Kettering Cancer Center (16)  
New York University Langone Medical Center (12)  
PathologyOutlines.com, Inc. (25)  
University of Pittsburgh (11)  
University of Michigan (29)  
University of Toronto (35)  
University of California, San Francisco (13)  
University of Virginia Health System (22)  
University of Washington (10)  
Yale University School of Medicine (34) |
<table>
<thead>
<tr>
<th>Fellowship</th>
<th>Institution (Table)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Head &amp; Neck</td>
<td>Massachusetts General Hospital (3)</td>
</tr>
<tr>
<td></td>
<td>M.D. Anderson Cancer Center (21)</td>
</tr>
<tr>
<td></td>
<td>PathologyOutlines.com, Inc. (25)</td>
</tr>
<tr>
<td></td>
<td>University of Pittsburgh (11)</td>
</tr>
<tr>
<td></td>
<td>University of Toronto (35)</td>
</tr>
<tr>
<td></td>
<td>Yale University School of Medicine (24)</td>
</tr>
<tr>
<td>Hematopathology</td>
<td>Baylor College of Medicine (37)</td>
</tr>
<tr>
<td></td>
<td>Cedars-Sinai Medical Center (9)</td>
</tr>
<tr>
<td></td>
<td>Cleveland Clinic Foundation (33)</td>
</tr>
<tr>
<td></td>
<td>Johns Hopkins Medical Institutions (26)</td>
</tr>
<tr>
<td></td>
<td>Massachusetts General Hospital (3)</td>
</tr>
<tr>
<td></td>
<td>Mayo Clinic (7)</td>
</tr>
<tr>
<td></td>
<td>M.D. Anderson Cancer Center (21)</td>
</tr>
<tr>
<td></td>
<td>Memorial Sloan-Kettering Cancer Center (16)</td>
</tr>
<tr>
<td></td>
<td>New York Presbyterian Hospital - Cornell Medical Center (14)</td>
</tr>
<tr>
<td></td>
<td>NYU Langone Medical Center (12)</td>
</tr>
<tr>
<td></td>
<td>North Shore-LIJ Health System (39)</td>
</tr>
<tr>
<td></td>
<td>Northwestern University Feinberg School of Medicine (8)</td>
</tr>
<tr>
<td></td>
<td>Oregon Health &amp; Sciences University (27)</td>
</tr>
<tr>
<td></td>
<td>PathologyOutlines.com, Inc. (25)</td>
</tr>
<tr>
<td></td>
<td>The Methodist Hospital (5)</td>
</tr>
<tr>
<td></td>
<td>The Ohio State University (2)</td>
</tr>
<tr>
<td></td>
<td>UMDNJ Robert Wood Johnson Medical School (32)</td>
</tr>
<tr>
<td></td>
<td>University of Alabama at Birmingham (30)</td>
</tr>
<tr>
<td></td>
<td>University of Arkansas Medical School (25)</td>
</tr>
<tr>
<td></td>
<td>University of California, San Francisco (13)</td>
</tr>
<tr>
<td></td>
<td>University of Massachusetts Memorial Med Center (18)</td>
</tr>
<tr>
<td></td>
<td>University of Michigan (29)</td>
</tr>
<tr>
<td></td>
<td>University of Nebraska Medical Center (40)</td>
</tr>
<tr>
<td></td>
<td>University of Pittsburgh (11)</td>
</tr>
<tr>
<td>Immunopathology/Transplant</td>
<td>PathologyOutlines.com, Inc. (25)</td>
</tr>
<tr>
<td></td>
<td>University of Pittsburgh (11)</td>
</tr>
<tr>
<td></td>
<td>University of Utah Health Sciences Center (17)</td>
</tr>
<tr>
<td>Informatics</td>
<td>Massachusetts General Hospital (3)</td>
</tr>
<tr>
<td></td>
<td>University of Michigan (29)</td>
</tr>
<tr>
<td></td>
<td>University of Pittsburgh (11)</td>
</tr>
<tr>
<td>Laboratory Medicine</td>
<td>Memorial Sloan-Kettering Cancer Center (16)</td>
</tr>
<tr>
<td></td>
<td>PathologyOutlines.com, Inc. (25)</td>
</tr>
<tr>
<td>Microbiology</td>
<td>Cleveland Clinic Foundation (33)</td>
</tr>
<tr>
<td></td>
<td>Johns Hopkins Medical Institutions (26)</td>
</tr>
<tr>
<td></td>
<td>Massachusetts General Hospital (3)</td>
</tr>
<tr>
<td></td>
<td>Mayo Clinic (7)</td>
</tr>
<tr>
<td></td>
<td>M.D. Anderson Cancer Center (21)</td>
</tr>
<tr>
<td></td>
<td>Memorial Sloan-Kettering Cancer Center (16)</td>
</tr>
<tr>
<td></td>
<td>New York Presbyterian Hospital - Cornell Medical Center (14)</td>
</tr>
<tr>
<td></td>
<td>Oregon Health &amp; Sciences University (27)</td>
</tr>
<tr>
<td></td>
<td>PathologyOutlines.com, Inc. (25)</td>
</tr>
<tr>
<td></td>
<td>University of Texas Western Medical Center (38)</td>
</tr>
<tr>
<td></td>
<td>Vanderbilt University Medical Center (31)</td>
</tr>
<tr>
<td></td>
<td>Yale University School of Medicine (34)</td>
</tr>
<tr>
<td>Molecular Pathology</td>
<td>Baylor College of Medicine (37)</td>
</tr>
<tr>
<td></td>
<td>Cedars-Sinai Medical Center (9)</td>
</tr>
<tr>
<td></td>
<td>Massachusetts General Hospital (3)</td>
</tr>
<tr>
<td></td>
<td>Mayo Clinic (7)</td>
</tr>
<tr>
<td></td>
<td>M.D. Anderson Cancer Center (21)</td>
</tr>
<tr>
<td></td>
<td>Memorial Sloan-Kettering Cancer Center (16)</td>
</tr>
<tr>
<td></td>
<td>New York Presbyterian Hospital - Cornell Medical Center (14)</td>
</tr>
<tr>
<td></td>
<td>NYU Langone Medical Center (12)</td>
</tr>
<tr>
<td></td>
<td>Northwestern University Feinberg School of Medicine (8)</td>
</tr>
<tr>
<td></td>
<td>Oregon Health &amp; Sciences University (27)</td>
</tr>
<tr>
<td></td>
<td>PathologyOutlines.com, Inc. (25)</td>
</tr>
<tr>
<td></td>
<td>University of Alabama at Birmingham (30)</td>
</tr>
<tr>
<td></td>
<td>University of Arkansas Medical School (25)</td>
</tr>
<tr>
<td></td>
<td>University of California, San Francisco (13)</td>
</tr>
<tr>
<td></td>
<td>University of Colorado, Denver School of Medicine (15)</td>
</tr>
<tr>
<td></td>
<td>University of Connecticut Health Center (14)</td>
</tr>
<tr>
<td></td>
<td>University of Nebraska Medical Center (40)</td>
</tr>
<tr>
<td></td>
<td>University of Pittsburgh (11)</td>
</tr>
<tr>
<td></td>
<td>University of Washington (10)</td>
</tr>
<tr>
<td></td>
<td>Vanderbilt University Medical Center (31)</td>
</tr>
<tr>
<td></td>
<td>Virginia Commonwealth University (6)</td>
</tr>
<tr>
<td></td>
<td>Washington University in St. Louis (19)</td>
</tr>
<tr>
<td></td>
<td>Yale University School of Medicine (34)</td>
</tr>
<tr>
<td>Multidisciplinary</td>
<td>M.D. Anderson Cancer Center (21)</td>
</tr>
<tr>
<td>Subspecialty Pathology</td>
<td>PathologyOutlines.com, Inc. (25)</td>
</tr>
<tr>
<td>Neuroradiology</td>
<td>PathologyOutlines.com, Inc. (25)</td>
</tr>
<tr>
<td></td>
<td>The Methodist Hospital (5)</td>
</tr>
<tr>
<td>Orthopedic Pathology</td>
<td>NYU Langone Medical Center (12)</td>
</tr>
<tr>
<td>Pulmonary Pathology</td>
<td>Baylor College of Medicine (37)</td>
</tr>
<tr>
<td></td>
<td>Brown University Warren Alpert Medical School (15)</td>
</tr>
<tr>
<td></td>
<td>Children's Mercy Hospital and Clinics (28)</td>
</tr>
<tr>
<td></td>
<td>North Shore-LIJ Health System (39)</td>
</tr>
<tr>
<td></td>
<td>Northwestern University Feinberg School of Medicine (8)</td>
</tr>
<tr>
<td></td>
<td>University of Pittsburgh (11)</td>
</tr>
<tr>
<td></td>
<td>University of Southwestern Medical Center (38)</td>
</tr>
<tr>
<td></td>
<td>University of Virginia Health System (22)</td>
</tr>
<tr>
<td>Perinatal &amp; Developmental</td>
<td>Brown University Warren Alpert Medical School (15)</td>
</tr>
<tr>
<td></td>
<td>PathologyOutlines.com, Inc. (25)</td>
</tr>
<tr>
<td></td>
<td>University of Minnesota (19)</td>
</tr>
<tr>
<td></td>
<td>University of Nebraska Medical Center (40)</td>
</tr>
<tr>
<td></td>
<td>University of Pittsburgh (11)</td>
</tr>
<tr>
<td>Pulmonary Pathology</td>
<td>Massachusetts General Hospital (3)</td>
</tr>
<tr>
<td></td>
<td>Mayo Clinic (7)</td>
</tr>
<tr>
<td>Renal Pathology</td>
<td>Cedars-Sinai Medical Center (9)</td>
</tr>
<tr>
<td></td>
<td>Johns Hopkins Medical Institutions (26)</td>
</tr>
<tr>
<td></td>
<td>Massachusetts General Hospital (3)</td>
</tr>
<tr>
<td>Research</td>
<td>PathologyOutlines.com, Inc. (25)</td>
</tr>
<tr>
<td>Surgical Path</td>
<td>Brown University Warren Alpert Medical School (15)</td>
</tr>
<tr>
<td></td>
<td>Children's Mercy Hospital and Clinics (28)</td>
</tr>
<tr>
<td></td>
<td>North Shore-LIJ Health System (39)</td>
</tr>
<tr>
<td></td>
<td>Northwestern University Feinberg School of Medicine (8)</td>
</tr>
<tr>
<td></td>
<td>Oregon Health &amp; Sciences University (27)</td>
</tr>
<tr>
<td></td>
<td>PathologyOutlines.com, Inc. (25)</td>
</tr>
<tr>
<td></td>
<td>Roswell Park Cancer Institute (24)</td>
</tr>
<tr>
<td></td>
<td>The Methodist Hospital (5)</td>
</tr>
<tr>
<td></td>
<td>University of Alabama at Birmingham (30)</td>
</tr>
<tr>
<td></td>
<td>University of Arkansas Medical School (25)</td>
</tr>
<tr>
<td></td>
<td>University of California, San Francisco (13)</td>
</tr>
<tr>
<td></td>
<td>University of Massachusetts Memorial Med Center (18)</td>
</tr>
<tr>
<td></td>
<td>University of Michigan (29)</td>
</tr>
<tr>
<td></td>
<td>University of Nebraska Medical Center (40)</td>
</tr>
<tr>
<td></td>
<td>University of Pittsburgh (11)</td>
</tr>
<tr>
<td>Thoracic Path</td>
<td>M.D. Anderson Cancer Center (21)</td>
</tr>
<tr>
<td>Urologic</td>
<td>NYU Langone Medical Center (12)</td>
</tr>
<tr>
<td>Virology</td>
<td>PathologyOutlines.com, Inc. (25)</td>
</tr>
</tbody>
</table>
DIAGNOSTIC PATHOLOGY
July 14-19, 2013
Captain Cook Hotel
Anchorage, AK

Cutting Edge Education
Dynamic Speakers
One Great Location

United States & Canadian Academy of Pathology
LEADING PATHOLOGY EDUCATIONAL EXCELLENCE

Log on to learn more at www.uscap.org
Welcome to the members of the 28 Companion Societies Composed of national societies, associations, and “Clubs” in the sub disciplines of pathology. We’re honored that you have chosen to participate alongside the 102nd USCAP Annual Meeting.

Once you’ve completed your societies’ meetings don’t forget to take advantage of the many courses, lectures, receptions, and the Exhibition Hall, as well as the Proffered Paper and Poster Sessions that the USCAP Annual Meeting offers.

Haven’t registered for a particular event? No problem! Just visit our registration desk located in the Charles Street Lobby of the Baltimore Convention Center.

Having trouble keeping up with all of the events? Utilize our Annual Meeting App to keep you on schedule. Download it at: www.tripbuilder.com/uscap2013apps.

All right Doctors, there’s lots to do… and time to talk about all of the activities at the USCAP Reception, “Party for a Passion”, on Tuesday, March 5 from 6:00 to 7:30 PM in the Hilton’s Key Ballroom 1-12

Special Note
Companion Meeting handouts available at www.USCAP.org
COMPANION MEETING

American Association of Neuropathologists

Update on Pituitary Adenomas and Sellar Region Masses

Saturday, March 2, 2013
7:00 PM – 10:00 PM
CC 317

Moderator: Bette K. Kleinschmidt-Demasters, University of Colorado Health Sciences Center, Aurora, CO

7:00 PM Introduction – Bette K. Kleinschmidt-Demasters, University of Colorado Health Sciences Center, Aurora, CO

7:10 PM Diagnostic Controversies in Pituitary Tumor Pathology – Maria Beatriz Lopes, MD, PhD, University of Virginia Health Science Center, Charlottesville, VA

8:10 PM What's New in Inflammatory Pituitary Lesions, Pituicytomas, Spindle Cell Oncocytomas, and Craniopharyngiomas – Bette K. Kleinschmidt-Demasters, University of Colorado Health Sciences Center, Aurora, CO

9:00 PM Oddball Lesions of the Sellar Region – Peter C. Burger, MD, The Johns Hopkins Hospital, Baltimore, MD

The topic was chosen by the Educational Committee of the SCVP because pituitary region masses, especially adenomas, are common neoplasms seen by both surgical pathologists and neuropathologists, and yet, to our knowledge, have never been the focus of previous symposia or review courses given either by USCAP or the AANP.

The recent publication of the College of American Pathologists (CAP) pituitary checklist in the Archives of Pathology and Laboratory Medicine included suggested standards for best-practice in pituitary adenoma diagnosis. This checklist proposed use of several special histochemical and immunohistochemical stains that require some experience in interpretation. The checklist recommended use of the term “atypical” pituitary adenoma for those cases with strong nuclear TP53 immunostaining or elevated MIB-1 rate. Our first speaker, a member of the CAP pituitary checklist panel, and one of the leading experts on pituitary adenomas in the AANP, will discuss these issues. A 20-minute time for discussion of these newly published recommendations is included in the program.

New insights into the biology of craniopharyngiomas and new publications on rare pituicytomas and spindle cell oncocytomas will be discussed by our second speaker. The latter two entities were only recently codified in 2007 WHO and additional case studies and series have been published since then and will form the basis for the updates provided.

Finally, Dr. Peter Burger will share from his extensive surgical pathology files his personal experience with a series of unusual sellar region masses; this portion of the symposium will be highly educational for even the most experienced surgical pathologists and neuropathologists in the audience.

Thus, the companion society program will be highly practical, relevant to daily diagnostic practice, and cover pituitary adenomas as well as the less common, to highly unique, sellar region masses.
COMPANION MEETING
American Association of Ophthalmic Oncologists and Pathologists
Advances in Intraocular Oncology and Emerging Entities
Saturday, March 2, 2013
7:00 PM – 10:00 PM
CC 311

Moderator: Charles Eberhart, MD, PhD, The Johns Hopkins University/Medicine, Baltimore, MD

7:00 AM    Introduction – Charles Eberhart, MD, PhD, The Johns Hopkins University/Medicine, Baltimore, MD

7:10 PM    Diagnosis and Staging of Retinoblastoma – Patricia Chevez-Barrios, MD, The Methodist Hospital, Houston, TX

7:55 PM    Diagnosis and Staging of Uveal Melanoma – Amy Lin, MD, University of Illinois, Chicago, IL

8:40 PM    Classification of Melanocytic Conjunctival Lesions and Emerging Eyelid Entities – Charles Eberhart, MD, PhD, Johns Hopkins University/Medicine, Baltimore, MD

9:20 PM    Diagnosis of Ciliary Body and Iris Tumors – Ralph Eagle, MD, Wills Eye Institute, Philadelphia, PA

The topics were determined by the USCAP-AAOOP Companion Committee (Hans Grossniklaus, J. Douglas Cameron, and Patricia Chevez-Barrios) and the moderator Charles Eberhart. Presentations on these topics were chosen because they represent areas in which ophthalmic pathology practice is changing, and for which an update on diagnostic and reporting practices fulfills a need in our field. The objective of the program is to alert ophthalmic and general pathologists to the current guidelines on the diagnosis and staging of intraocular tumors.

COMPANION MEETING
American College of Veterinary Pathology
Contemporary Animal Models of Human Cancer
Saturday, March 2, 2013
7:00 PM – 10:00 PM
CC 313

Moderator: John M. Cullen, VMD, PhD, North Carolina State University, Raleigh, NC

7:00 PM    Animal Models of Cancer – David E. Malarkey, DVM, PhD, National Institute of Environmental Health Sciences, Triangle Park, NC

7:45 PM    Zebrafish Models for Human Cancer – Heather Shive, DVM, PhD, National Cancer Institute/NIH, Bethesda, MD

8:30 PM    Developing a Relevant Mouse Model of Prostate Cancer: Searching for the Holy Grail – Philip L. Martin, MS, DVM, Center for Advanced Preclinical Research, Frederick, MD

The topic was chosen by the moderator of the session because there is a considerable overlap in interest in veterinary pathologists and medical pathologists regarding the pathogenesis of cancer in general and in several clinically important varieties of cancer such as ovarian and prostatic cancer. The presentations will discuss contemporary animal models of ovarian cancer in fish and prostatic cancer in rodents in addition to a broader overview of animal models of neoplasia. The information provided should be of interest to researchers involved in the pathogenesis and therapeutic interventions of various types of cancer. Pathologist with an interest in comparative pathology will learn about the areas of greatest utility for each of the models and current limitations to available animal models.
COMPANION MEETING

Association for Pathology Informatics

Hot Topics in Pathology Informatics

Saturday, March 2, 2013
7:00 PM – 10:00 PM
CC 316

Moderator: J. Mark Tuthill, MD, Henry Ford Hospital, Detroit, MI

7:00 PM Introduction – J. Mark Tuthill, MD, Henry Ford Hospital, Detroit, MI

7:05 PM Robust Identification of the Patient: Biometrics – Ulysses Balis, MD, University of Michigan, Ann Arbor, MI

7:30 PM Digital Imaging: Rules and Regulations for Research and Clinical Practice – Stephen M. Hewitt, MD, PhD, National Cancer Institute, Bethesda, MD

7:40 PM The Modern LIS – John Gilbertson, MD, Massachusetts General Hospital, Boston, MA

8:10 PM Electronic Document Management – J. Mark Tuthill, MD, Henry Ford Hospital, Detroit, MI

8:30 PM Synoptic Reporting – Anil V. Parwani, MD, PhD, University of Pittsburgh, Pittsburgh, PA

8:40 PM Teleconsultation – Liron Pantanowitz, MD, University of Pittsburgh, Pittsburgh, PA

9:00 PM Clinical Informatics of Genomics – Lynn Bry, Brigham & Women’s Hospital, Boston, MA

9:30 PM Informatics Training and Education: API Overview – J. Mark Tuthill, MD, Henry Ford Hospital, Detroit, MI, Liron Pantanowitz, MD, University of Pittsburgh, Pittsburgh, PA

2013 will mark the second time that the Association of Pathology Informatics (API) will present a companion conference at USCAP. The topic “Hot Topics in Pathology Informatics” was chosen by API Program Committee and Training and Education Committee in conjunction with the API’s Governing Council because Pathology Informatics is being increasingly appreciated as a critical area of pathology practice. The goal of the symposium is to present a range of pathology informatics topics in the context of the clinical practice of anatomic, clinical and molecular pathology so that attendees can understand and apply these approaches in their practices. Once again, part of the session will be dedicated to pathology informatics training including approaches to residency training in informatics, fellowship opportunities and the potential for ACGME certification of clinical informatics as sub-specialty.
COMPANION MEETING
Endocrine Pathology Society

Genomic Approaches to Problems in Endocrine Neoplasia
Saturday, March 2, 2013
7:00 PM – 10:00 PM
CC 321-323

Moderator: Thomas Giordano, MD, PhD, University/Michigan Hospitals, Ann Arbor, MI

7:00 PM Genomic Approaches to Problems in Pancreatic Endocrine Neoplasia – Ralph H. Hruban, MD, The Johns Hopkins University, Baltimore, MD

7:45 PM Genomic Approaches to Problems in Pituitary Neoplasia – Sylvia L. Asa, MD, University of Toronto, Toronto, ON, Canada

8:30 PM Genomic Approaches to Problems in Thyroid Neoplasia – Ronald A. Ghossein, MD, Memorial Sloan-Kettering Cancer Center, New York, NY

9:15 PM Genomic Approaches to Problems in Adenocortical Neoplasia – Thomas Giordano, MD, PhD, University/Michigan Hospitals, Ann Arbor, MI

Much genomic work is being performed to address problems in oncologic pathology, including tumors of the endocrine system. Endocrine tumors are sometimes diagnostically difficult and prognostication of these tumors is lacking. Genomic data offers to improve diagnosis and refine prognostic assessment of endocrine tumors. This companion meeting will focus on how genomic data can be applied to diagnostic and prognostic problems to advance the care of patients with endocrine neoplasia.

The details of this session were assembled in collaboration with a group of established endocrine pathologists, most former Presidents of the Endocrine Pathology Society. All agreed that a genomic session, if focused on problems in endocrine pathology, would be appropriate. This group included Ric Lloyd, Vania Nose, Ronald Ghossein, Sylvia Asa, and myself.

The purpose of this session will be to highlight how genomic data can be applied to problems in endocrine neoplasia and thereby improve the diagnostic and prognostic evaluation of these tumors.
COMPANION MEETING

International Society of Urological Pathology

Current Concepts and Controversies in GU Pathology

Saturday, March 2, 2013
7:00 PM – 10:00 PM
CC 309/310

Moderators: Cristina Magi-Galluzzi, MD, PhD, Cleveland Clinic, Cleveland, OH
Kiril Trpkov, MD, University of Calgary and Calgary Laboratory Services, Calgary, AB, Canada

7:00 PM  Introduction and President’s Remarks – Rodolfo Montironi, MD, Polytechnic University of the Marche Region School of Medicine, Ancona, Italy

7:20 PM  New and Old Hereditary Forms of Renal Cell Carcinoma (RCC) You Don’t Want To Miss – Maria J. Merino, MD, National Cancer Institute, Bethesda, MD

7:55 PM  Intraductal Carcinoma of the Prostate – The Whole Story – Ming Zhou, MD, PhD, New York University Langone Medical Center Tisch Hospital, New York, NY

8:30 PM  Controversies in Immunohistochemistry in Renal Cell Cancers – Satish K. Tickoo, MD, Memorial Sloan-Kettering Cancer Center, New York, NY

9:05 PM  Controversies and Hot Topics in Urological Pathology: A Dialogue with the Experts – Rodolfo Montironi, MD, Polytechnic University of the Marche Region School of Medicine, Ancona, Italy
Peter A. Humphrey, MD, Washington University, St Louis, MO
Mahul B. Amin, MD, Cedars-Sinai Medical Center, Los Angeles, CA
Jonathan I. Epstein, MD, The Johns Hopkins Hospital, Baltimore, MD

The topics for the symposium were determined by the President in consultation with the Executive Committee and the Annual Meeting Program Committee representing the general membership. The selection of topics takes into consideration previous companion meeting presentations, the needs of our society members and the general audience and the recent advances in the field of genitourinary pathology.

The program for the ISUP companion meeting 2013 is entitled “CURRENT CONCEPTS AND CONTROVERSIES IN GENITOURINARY PATHOLOGY.” The aim is to cover some novel concepts in genitourinary pathology, with a focus on important and practical organ-specific topics and issues. We hope that the program will offer an update on some current diagnostic challenges and relevant topics in genitourinary pathology. This will allow for improved accuracy in diagnosis and prognosis of organ-specific genitourinary cancers and will provide directions to improve the current genitourinary cancer pathology practice. Separate lectures will cover the topics of new and old hereditary forms of renal cell carcinoma (Dr. Maria Merino), intraductal carcinoma of the prostate (Dr. Ming Zhou) and the controversial issues regarding the immunohistochemistry in renal cell cancers (Dr. Satish Tickoo). A novelty in the program is the inclusion of a session entitled “Controversies and Hot Topics in Urological Pathology: A dialogue with the experts.” This is intended to be an interactive session with participation of two genitourinary pathology experts (Drs. Jonathan I. Epstein and Mahul Amin) and the session rapporteurs will be Dr Rodolfo Montironi and Peter Humphrey.
COMPANION MEETING

Papanicolaou Society of Cytopathology in Coordination with American Society of Cytopathology

Algorithmic Approach to Pancreaticobiliary Cytology: A Step towards Recommendations and Guidelines

Saturday, March 2, 2013
7:00 PM – 10:00 PM
CC 307/308

Moderator: Matthew A. Zarka, MD, Mayo Clinic Arizona, Scottsdale, AZ

7:00 PM Introduction – Matthew A. Zarka, MD, Mayo Clinic Arizona, Scottsdale, AZ

7:15 PM Indications and Techniques for Cytologic Sampling of Pancreatic and Bile Duct Lesions – William R. Brugge, Massachusetts General Hospital, Harvard Medical School, Boston, MA

7:45 PM Cystic Lesions of the Pancreas: Diagnostic Criteria with Emphasis on Pitfalls – Barbara Centeno, MD, University of South Florida, Tampa, FL

8:15 PM Solid Ductal Pancreatic Neoplasms: Diagnostic Criteria with Emphasis on Pitfalls – Syed Ali, MD, The Johns Hopkins Hospital, Baltimore, MD

8:45 PM Pancreatic Pathology: There's an APP for That – Ralph H. Hruban, MD, The Johns Hopkins University, Baltimore, MD

The PSC and ASC solicited topics of interest from their membership at the annual business meetings. Several potential topics were discussed at the Executive Board meeting and the topic for the 2013 session was chosen in agreement with the chairs of the scientific program committees. Improving the current practice of pancreaticobiliary cytology is of high interest to PSC & ASC membership and is currently cited as an important topic in cytopathology and pancreaticobiliary pathology. The PSC & ASC membership are focused on the dissemination of best practices to improve quality of pancreaticobiliary cytology specimens and small biopsies, classification and explore the role of various ancillary techniques that may prove beneficial to the cytopathologist and surgical pathologist.

Our needs assessment process was based on the evaluation of the current literature and the feedback provided by audience participating in person and online (NCI pancreaticobiliary cytology guidelines website).
COMPANION MEETING

Pulmonary Pathology Society

Topical Debates in Pulmonary Pathology

Saturday, March 2, 2013
7:00 PM – 10:00 PM
CC 318-320

Moderators:
Philip T. Cagle, MD, *The Methodist Hospital, Houston, TX*
Mary B. Beasley, MD, *Mt. Sinai Medical Center, New York, NY*

7:00 PM  
**Introduction** – Mary B. Beasley, MD, *Mt. Sinai Medical Center, New York, NY* and Philip T. Cagle, MD, *The Methodist Hospital, Houston, TX*

7:05 PM  
The IASLC/ERS/ATS Adenocarcinoma Classification: Case 1-The New Classification Helped – Keith M. Kerr, MBChB, *Aberdeen University School of Medicine, Aberdeen, Aberdeen, Scotland*

7:10 PM  
The IASLC/ERS/ATS Adenocarcinoma Classification: Case 2-I Struggles with the New Classification – Andre L. Moreira, MD, PhD, *Memorial Sloan Kettering Cancer Center, New York, NY*

7:15 PM  
The IASLC/ERS/ATS Adenocarcinoma Classification: Case 3-The New Classification Helped – Lucian Radu Chirieac, MD, *Brigham & Women’s Hospital, Boston, MA*

7:20 PM  
The IASLC/ERS/ATS Adenocarcinoma Classification: Case 4-I Struggled with the New Classification – Yasushi Yatabe, MD, PhD, *Aichi Cancer Center Hospital, Nagoya, Aichi, Japan*

7:30 PM  
The IASLC/ERS/ATS Adenocarcinoma Classification: Rationale and Strengths – William D. Travis, MD, *Memorial Sloan Kettering Cancer Center, New York, NY*

7:55 PM  
The IASLC/ERS/ATS Adenocarcinoma Classification: Issues Still To Be Resolved – Alain Borczuk, MD, *Columbia University Medical Center, New York, NY*

9:00 PM  
When Is “NSIP” an Appropriate Final Diagnosis in Current Practice? – Jeffrey L. Myers, MD, *University of Michigan, Ann Arbor, MI*

These are two issues which are of interest to those working in Pulmonary Pathology.

The new proposals for Classification of Pulmonary Adenocarcinomas have provided new approaches and nomenclature for diagnosis of this common malignant disease, not only for those diagnosing surgically resected tumours, but also for those pathologists who sign out a range of small diagnostic samples. The new classification also assists in correlation with radiologic findings in this disease and emphasizes the importance of molecular pathology as part of the full, complete diagnosis of lung adenocarcinoma.

Non-specific Interstitial Pneumonia (NSIP) is both a pathological and a clinical/radiological diagnosis, as part of the idiopathic interstitial pneumonia (IIP) classification. As a ‘non-specific’ appellation, there is the risk of designation as a ‘waste basket’ diagnosis. Emerging data suggest some cases of NSIP may reflect, and be identifiable as, other IIPs or more specific diseases.

Pathologists have issues with the diagnosis of some cases of these conditions: Adenocarcinomas have diverse morphological, clinical, molecular and therapeutic aspects. Diagnosis of NSIP is a less common clinical problem but remains an important issue in IIP classification.

The programme aims to highlight and discuss some of the diagnostic issues which been addressed, resolved, created or remain unanswered, by the current classification criteria for these two conditions.
COMPANION MEETING

Arthur Purdy Stout Society of Surgical Pathologists

Benign Mimics of Malignancy: Clues for Differential Diagnosis

Sunday, March 3, 2013
8:30 AM – 12:00 PM
CC Ballroom 1/2

Moderators:
Vania Nosé, MD, PhD, University of Miami Miller School of Medicine, Miami, FL
Jason L. Hornick, MD, PhD, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA

8:30 AM Introduction – Christopher D.M. Fletcher, MD, FRCPath, Brigham & Women’s Hospital, Boston, MA and Vania Nosé, MD, PhD, University of Miami Miller School of Medicine, Miami, FL and Jason L. Hornick, MD, PhD, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA

8:35 AM President’s Award – Christopher D.M. Fletcher, MD, FRCPath, Brigham & Women’s Hospital, Boston, MA

8:45 AM Benign Mimics of Malignancy in Gastrointestinal Pathology – Gregory Y. Lauwers, MD, Massachusetts General Hospital, Boston, MA

9:10 AM Benign Mimics of Malignancy in Genitourinary Pathology – Cristina Magi-Galluzzi, MD, PhD, Cleveland Clinic, Cleveland, OH

9:35 AM Benign Mimics of Malignancy in Head and Neck Pathology – Bruce M. Wenig, MD, Beth Israel Medical Center, New York, NY

10:40 AM Benign Mimics of Malignancy in Pulmonary Pathology – Jeffrey L. Myers, MD, University of Michigan, Ann Arbor, MI

11:05 AM Benign Mimics of Malignancy in Dermatopathology – Jennifer McNiff, MD, Yale University School of Medicine, New Haven, CT

11:30 AM Benign Mimics of Malignancy in Breast Pathology – Stuart J. Schnitt, MD, Beth Israel Deaconess Medical Center, Boston, MA

The topic was chosen by the President, the Officers, the Committee members, and the Co-Chairs of the Program Committee of the Arthur Purdy Stout Society because of the recognition that surgical pathologists are often confronted with benign mimics of malignant neoplasms in many different organ systems in daily practice. These lesions pose particularly difficult challenges for differential diagnosis and not uncommonly lead to misdiagnosis. This symposium will examine some of the more common benign mimics of malignancy in various organ systems, focusing on histologic clues for differential diagnosis, with the goals of helping practicing surgical pathologists better recognize these histologic mimics and providing approaches to arrive at the correct diagnosis.
COMPANION MEETING
Binford-Dammin Society of Infectious Disease Pathologists

*The Role of the Autopsy in Infectious Disease Diagnosis and Public Health*

Sunday, March 3, 2013
8:30 AM – 12:00 PM
CC 316

**Moderators:**
Vicki J. Schnadig, MD, *University of Texas Medical Branch, Galveston, TX*
Corinne L. Fligner, MD, *University of Washington, Seattle, WA*

**8:30 AM**
*Optimizing Recovery of Microorganisms at Autopsy during Epidemiologic Investigations* – Jeannette Guarner, MD, *Emory University, Decatur, GA*

**9:15 AM**
*The Problem of Mortality Statistics in Resource Poor Settings: The Upsurge of the Verbal Autopsy* – Drucilla Roberts, MD, *Massachusetts General Hospital, Boston, MA*

**10:30 AM**

**11:15 AM**
*Cytology as a Diagnostic Modality in the Autopsy Suite: It’s Not Just for the Warm and Breathing Anymore* – Vicki J. Schnadig, MD, *University of Texas Medical Branch, Galveston, TX*

Topics determined by the Education Committee members, Drs. Schnadig, Montone and Moreira.

The above topic was chosen this year because there is a growing, erroneous, belief that the autopsy is an obsolete modality in the age of high resolution imaging and high tech laboratory testing. In fact, the autopsy remains an important tool for understanding the pathology, pathogenesis and epidemiology of infectious diseases. The conference objectives are to: 1. Inform members of the audience as to the necessity and utility of the conventional autopsy for the study of infectious disease; 2. To provide information regarding use of ancillary diagnostic modalities such as the “verbal” autopsy and use of cytologic techniques in the autopsy suite; 3. Demonstrate the utility of the autopsy for gathering of public health information.
COMPANION MEETING

College of American Pathologists

The Application and Criticality of Specimen Asset Tracking in Anatomic Pathology and Clinical Research

Sunday, March 3, 2013
8:30 AM – 12:00 PM
CC Ballroom 4

Moderator: Saul M. Suster, MD, Medical College of Wisconsin, Milwaukee, WI

8:30 AM Introduction – Saul M. Suster, MD, Medical College of Wisconsin, Milwaukee, WI

8:45 AM Tracking as Part of an AP Program – Why Do It – Liron Pantanowitz, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

9:15 AM Histology Asset Tracking – John Sinard, MD, PhD, Yale University School of Medicine, New Haven, CT

10:15 AM Approaching Specimen Tracking in Translational Research Core Laboratories – Alexander C. Mackinnon, MD, PhD, Medical College of Wisconsin, Milwaukee, WI

10:45 AM Application of Specimen Tracking Systems in Biorepositories – Eduardo V. Zambrano, MD, Medical College of Wisconsin, Milwaukee, WI

The Curriculum Committee of the College of American Pathologists considers the list of past offerings, the current and evolving state of anatomic pathology, needs of the USCAP audience, and expert opinion in selecting the topic for the 2013 CAP Companion Society education program.

With external demands to improve turnaround times, decrease costs, reduce errors and improve patient care (from lost or mislabeled slides/blocks), pathologists are looking at barcode-based asset tracking solutions to automate histology. Selecting and implementing such a system is neither trivial nor inexpensive and pathologists need to understand the implications. There are significant workflow issues from the gross room, into histology, and implications for special testing. Nonetheless, a successful implementation can yield definite advantages. Vendors offer “out of the box” solutions to resolve all these issues, either as stand-alone products or integrated into existing LIS.

Translational research labs have unique and challenging demands for managing patient specimens when compared to traditional AP/CP pathology labs. Clearly defining the translational research lab’s workflow and client needs is essential to developing efficient protocols and tools for tracking patient samples. In addition, solutions for managing patient specimens in a translational research lab frequently need to be customized and lab-developed. Banking human tissues in a manner that is compliant with federal and local health information privacy regulations, but which can be accurately and efficiently linked with the individual's medical information stored in clinical data warehouses is essential to the research mission of medical academic institutions.

The intent of the symposium is to discuss practical issues in selecting, budgeting, implementing, and maintaining an asset tracking solution for the AP lab and offer tips to help pathologists uncover secondary costs and “hidden” practices which may affect the success of your implementation. In addition, this session will describe faculty’s experience with customized commercial LIS software and solutions in order to safely and effectively manage patient specimens in a translational research core lab and in an academic biorepository unit.
COMPANION MEETING
Hans Popper Hepatopathology Society
Update on Liver Fibrosis
Sunday, March 3, 2013
8:30 AM – 12:00 PM
CC 307/308

Moderator: Matthew M. Yeh, MD, PhD, University of Washington Medical Center, Seattle, WA

8:30 AM Liver Fibrosis: Spanning the Translational Spectrum – Alastair Burt, BSc, MD, University Adelaide, Australia
9:15 AM Quantitative MR Imaging Biomarkers of Hepatic Fibrosis – Scott Reeder, University of Wisconsin, Madison, WI
10:30 AM Assessment of Fibrosis in Liver Biopsy: Progression and Regression – Pierre Bedossa, University of Paris-Diderot, Paris, France
11:15 AM Clinical Evaluation and Future Perspectives of Fibrosis in Chronic Liver Disease – Jay Hoofnagle, NIDDK, National Institutes of Health, Bethesda, MD

The first half of the symposium will address the topics of the pathogenesis of liver fibrosis and imaging evaluation of liver fibrosis. The discussion of the pathogenesis of liver fibrosis will focus on updating pathologists on the current understanding of the mechanisms of progression of hepatic fibrosis from a liver pathologist. The second talk will focus on the recently developed imaging modalities in assessing hepatic fibrosis from a radiologist. The second half of the symposium will focus on the update of the pathology and staging schemes of liver fibrosis from a liver pathologist, and clinical evaluation of fibrosis and the future perspectives in this field from a hepatologist.

The objective of the symposium is to bring pathologists up-to-date on the new development in these critical areas of hepatic pathology.

COMPANION MEETING
Renal Pathology Society
Recent Advances in Renal Pathology
Sunday, March 3, 2013
8:30 AM – 12:00 PM
CC 309/310

Moderators: Luan Dinh Truong, MD, The Methodist Hospital, Houston, TX
Lois J. Arend, MD, PhD, The Johns Hopkins Hospital, Baltimore, MD

8:30 AM Atypical Hemolytic Uremic Syndrome (aHUS): 2013 State of the Art – Richard Smith, University of Iowa, Iowa City, IA
9:15 AM Recent Insights into C3 Glomerulopathies and MPGN – Terence Cook, FRCPath, Imperial College, London, UK
10:30 AM Mass Spectrometry and its Role in Renal Pathology – Sanjeev Sethi, MD, PhD, Mayo Clinic, Rochester, MN
11:15 AM Viral Nephropathies: An Update for the Renal Pathologist – Parmjeet Randhawa, MD, University of Pittsburgh, Pittsburgh, PA

The topic of this symposium is Recent Advances in Renal Pathology. This topic is selected by the Program Committee of the Renal Pathology Society with input from the members of the Society. There are several recent advances in renal pathology. These advances not only provide novel insights into the pathogenesis of renal diseases but also serve as foundation for new venues for clinical and renal biopsy diagnosis of these diseases. This symposium focuses on four of these advances, i.e. atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, mass spectrometry in the diagnosis of renal diseases, and viral nephropathy. This symposium will provide a concise but complete review of the current understanding of these topics including the new findings and at the same time emphasizes the practical applications of these findings in renal biopsy interpretation.
COMPANION MEETING

Society for Cardiovascular Pathology

Angiogenesis In Health and Disease: It's All about the Vessels

Sunday, March 3, 2013
8:30 AM – 12:00 PM
CC 318-320

Moderators:
Richard N. Mitchell, MD, PhD, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
Barbara Sampson, MD, PhD, Office of Chief Medical Examiner, New York, NY

8:30 AM Angiogenesis in Disease – Patricia D’Amore, Schepens Eye Research Institute, Harvard Medical School, Boston, MA
9:00 AM Angiogenesis in Ischemic Heart Disease – Pavan Atluri, MD, University of Pennsylvania School of Medicine, Philadelphia, PA
9:30 AM Angiogenesis in Malignancy – William Stetler-Stevenson, MD, National Institutes of Health, Bethesda, MD
11:00 AM Understanding Vascular Endothelium: A Pilgrim’s Progress – Michael A. Gimbrone, Jr, MD, Brigham & Women’s Hospital, Boston, MA

Endothelial cell biology and vessel proliferation are increasingly recognized as important fundamental players in both normal physiology and pathologic processes. Neovascularization in physiologic hyperplasia and wound healing is the flip side of the coin to the angiogenesis occurring in diabetic retinopathy and malignancy. Understanding and regulating vessel growth and maturation thus has far-reaching implications for treating conditions as divergent as pre-eclampsia, ischemic heart disease, and cancer.

The Education Committee of the SCVP has therefore selected this topic because clinicians and pathologists alike need to understand the mechanisms and pathophysiologic processes that drive angiogenesis. This is not only to evaluate vascular adequacy—when blood supply is limiting, but also to regulate vascular proliferation—when vessel growth is problematic. Recent advances in therapeutic intervention—both blocking and promoting neovascularization—offer exciting clinical opportunities, and make the discussion considerably more than simply academic. The session will be capped by Dr. Michael Gimbrone, the recipient of the SCVP Distinguished Achievement Award speaking on the fundamental biology of the endothelial cell, and his observations from a lifetime spent pioneering insights on this “simple vessel lining.”

The objectives of the symposium are to present organizing principles for understanding the physiologic and pathologic angiogenesis, and to highlight new developments and innovations in both augmenting and limiting the neovascular process. In addition, there will be a portion of the session devoted to short presentations by a selected subset of young investigators who have submitted heart- and vessel-oriented posters to USCAP. This will provide an important opportunity to develop and build fellowship amongst junior and senior members of the USCAP with an interest in cardiovascular pathology. Moreover the brief presentations will allow a more fair and nuanced judging of posters being considered for award of the SCVP Young Investigator prize, with excellent feed-back from an increased number of cardiovascular pathologists at the meeting.
COMPANION MEETING

Society for Ultrastructural Pathology

Let's Get Small: Ultrastructural Evaluation of Cellular and Subcellular Specimens

Sunday, March 3, 2013
8:30 AM – 12:00 PM
CC 301

Moderators: David N. Howell, MD, PhD, Duke University Medical Center, Durham, NC
Victor L. Roggli, MD, Duke University Medical Center, Durham, NC

8:30 AM The Role of Electron Microscopy in the Analysis of Cytologic Specimens – Elba A. Turbat-Herrera, MD, Louisiana State University Health Sciences Center, Shreveport, LA

9:15 AM It’s a Small, Small World: Electron Microscopy of Minute and Unusual Specimens – Sara E. Miller, PhD, Duke University Medical Center, Durham, NC

10:30 AM Diagnostic Platelet Electron Microscopy: Everyone into the Storage Pool – Evelyn L. Lockhart, Duke University Medical Center, Durham, NC

11:00 AM Ultrastructural Evaluation of Peripheral Blood and Fibroblast Cultures in Diagnosis of Metabolic Storage Disorders – John Hicks, MD, Texas Children’s Hospital, Houston, TX

11:30 AM Cytopathology of Asbestos: Associated Diseases – Frank Schneider, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

The topic for this Companion Meeting was determined by the Executive Committee of the Society for Ultrastructural Pathology.

The topic of diagnostic electron microscopy of small and unusual specimens represents an area of keen current interest and importance in the ultrastructural pathology community, particularly given the steady increase in the use of cytopathology as a diagnostic tool.

This Companion Meeting will provide both theoretical and practical information on the application of ultrastructural examination to a wide variety of diagnostic specimens (see below). It will be of utility both to practicing ultrastructural pathologists and to other pathologists wishing to learn more about the capabilities of diagnostic electron microscopy.

Participants will receive a comprehensive review of the utility of electron microscopy in the analysis of cytopathology specimens (aspiration and exfoliative), cell lines cultured from patients, body cavity fluids, formed elements of the blood, and other unusual specimens (e.g., tissue retrieved from histologic sections). The special topic of X-ray microprobe analysis of pulmonary cytologic specimens from patients with asbestos-related diseases will also be covered. For pathologists currently practicing diagnostic ultrastructural pathology, the session will provide information that can be applied directly to their diagnostic work. For others, it will reveal situations in which referral of specimens to a diagnostic EM laboratory would be of value.
COMPANION MEETING
Paleopathology Club
Paleopathology of Canada
Sunday, March 3, 2013
1:30 PM – 3:00 PM
CC 313

Moderators: Pedro L. Fernandez, MD, PhD, Hospital Clinico de Barcelona, Barcelona, Spain
             Enrique Gerszten, MD, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA

1:30 PM   Controversies in Egyptian Paleopathology – Miguel A. Sanchez, MD, Englewood Hospital, Englewood, NJ and Mount Sinai School of Medicine, New York, NY

2:00 PM   Endoscopy in Paleopathology – Agustin Franco De Castro, Hospital Clinic, University of Barcelona, Barcelona, Spain

2:30 PM   Paleopathology of Royal Mummies in Spain – Pedro L. Fernandez, MD, PhD, Hospital Clinico de Barcelona, Barcelona, Spain

The topics were suggested by members of the Club at the last Symposium. This Symposium’s objective is to identify diseases in the antiquity of different regions of the globe.
COMPANION MEETING
American Society for Investigative Pathology
Interactive Molecular Pathology
Sunday, March 3, 2013
1:30 PM – 5:00 PM
CC 321-323

Moderators:
Karen L. Kaul, MD, PhD, Northwestern Hospital, Evanston, IL
Dani S. Zander, MD, Milton S. Hershey Medical Center, Penn State College, Hershey, PA

1:30 PM Introduction – Mark E. Sobel, MD, PhD, American Society for Investigative Pathology, Bethesda, MD
1:35 PM Overview of Small Group Cases – Dani S. Zander, MD, Milton S. Hershey Medical Center, Penn State College, Hershey, PA
1:50 PM Bladder Cancer – Kevin C. Halling, MD, PhD, Mayo Clinic, Rochester, MN
2:00 PM Colon Cancer – Antonia Sepulveda, MD, PhD, University of Pennsylvania, Philadelphia, PA
2:10 PM Gliomas – Arie Perry, MD, University of California San Francisco, San Francisco, CA
2:20 PM Infectious Disease – Randall Olsen, MD, PhD, The Methodist Hospital, Houston, TX
2:30 PM Hematopathology – Y. Lynn Wang, MD, PhD, Weill Cornell Medical College, New York, NY
2:40 PM Lung Cancer – Neal Ian Lindeman, MD, Brigham & Women’s Hospital, Boston, MA
2:50 PM Thyroid Cancer
Jennifer Laudadio, MD, Wake Forest University, Winston-Salem, NC
Jennifer L. Hunt, MD, University of Arkansas for Medical Sciences, Little Rock, AR

3:30 PM Overview of Small Group Cases – Karen L. Kaul, MD, PhD, Evanston Northwestern Hospital, Evanston, IL
3:35 PM Bladder Cancer – Kevin C. Halling, MD, PhD, Mayo Clinic, Rochester, MN
3:45 PM Colon Cancer – Antonia Sepulveda, MD, PhD, University of Pennsylvania, Philadelphia, PA
3:55 PM Gliomas – Arie Perry, MD, University of California San Francisco, San Francisco, CA
4:05 PM Infectious Disease – Randall Olsen, MD, PhD, The Methodist Hospital, Houston, TX
4:15 PM Hematopathology – Y. Lynn Wang, Weill Cornell Medical College, New York, NY
4:25 PM Lung Cancer – Neal Ian Lindeman, MD, Brigham & Women’s Hospital, Boston, MA
4:35 PM Thyroid Cancer
Jennifer Laudadio, MD, Wake Forest University, Winston-Salem, NC
Jennifer L. Hunt, MD, University of Arkansas for Medical Sciences, Little Rock, AR

The topic was determined by the ASIP Education Committee in collaboration with the ASIP Task Force on Scientific Events and Special Programs. Molecular pathology evaluation is becoming increasingly integrated into the practice of anatomic pathology but many practitioners have not been exposed to interactive case studies and therefore lack a full appreciation for the value added by molecular diagnostics. The integration of molecular and genomic pathology into anatomic pathology practice is most conspicuous in oncology, where definition of molecular pathways important for specific tumors has enabled development of drugs to target these pathways, and companion tests to predict which tumors are likely to respond to these targeted agents. Use of molecular testing can also benefit the anatomic pathologist by enhancing accurate pathologic interpretation of samples and confirming the presence of infectious agents. This session will offer an experiential, case-based opportunity to understand and interpret the results of molecular pathology tests in a small group, interactive format. Each small group will be led by an experienced molecular pathologist. Multiple cases requiring a spectrum of types of molecular tests will be used as the medium for participants to choose methods of evaluation appropriate for the clinical scenarios, interpret test results, recognize potential pitfalls, and learn about costs, quality assurance and proficiency testing needs. By the end of this session, participants will have personally constructed interpretative reports for a variety of important molecular pathology tests, and gain knowledge valuable for providing a relevant clinical consultation.
COMPANION MEETING

American Society of Dermatopathology and Society for Pediatric Pathology

Update on Cutaneous Melanocytic, Mesenchymal and Lymphoproliferative Lesions in Children

Sunday, March 3, 2013
1:30 PM – 5:00 PM
CC Ballroom 3

Moderators:
Victor G. Prieto, MD, UT MD Anderson Cancer Center, Houston, TX
Jennifer O. Black, MD, Vanderbilt University, Nashville, TN

1:30 PM Melanocytic Lesions in Children: Clinico-Pathologic Features – Victor G. Prieto, MD, UT MD Anderson Cancer Center, Houston, TX

2:00 PM Melanocytic Lesions in Children: New Genetic Techniques – David E. Elder, MB ChB, FRCPA, Hospital/University of Pennsylvania, Philadelphia, PA

2:30 PM Melanocytic Lesions in Children: Application of Mass Spectrometry to the Diagnosis – Rossitza Lazova, Yale University, New Haven, CT

3:00 PM Three Interactive Case Presentations with Application of Principles Discussed in Lectures
Victor G. Prieto, MD, UT MD Anderson Cancer Center, Houston, TX
David E. Elder, MB ChB, FRCPA, Hospital/University of Pennsylvania, Philadelphia, PA
Rossitza Lazova, Yale University, New Haven, CT

4:00 PM Cutaneous Mesenchymal Lesions in Children – Cheryl Coffin, MD, Vanderbilt University, Nashville, TN

4:30 PM Cutaneous Lymphoproliferative Disorders in Children – John Kim K. Choi, MD, PhD, St. Jude Children’s Research Hospital, Memphis, TN

Childhood cutaneous lesions can be challenging, particularly melanocytic lesions. Most melanocytic lesions in children are benign nevi, with which the average pathologist is comfortable, but not all nevi are straightforward. Some of the nevi of special sites, Spitz nevi, and congenital nevi with proliferative nodules to name a few, can pose great diagnostic difficulty. These lesions can display worrisome features that can be difficult to distinguish from melanoma. Making the diagnosis of melanoma in a child can be challenging, and has important consequences related to treatment, including surgical management, and the lifelong burden imparted by a diagnosis of malignancy. Childhood melanocytic lesions can be difficult for both pediatric pathologists, who typically see few melanomas, and dermatopathologists, whose practice are often dominated by adult lesions.

Cutaneous mesenchymal and lymphoproliferative lesions can also be diagnostically challenging, each with unique features that mimic other disease processes, including melanocytic lesions. Moreover, exposure to cutaneous mesenchymal and lymphoproliferative lesions in children is limited in both pediatric pathology and dermatopathology training programs, and few practices see a large enough concentration of these lesions, for the individual pediatric pathologist or dermatopathologist to be fully comfortable when encountering a challenging lesion.

The goal of this symposium is to provide an update on the diagnosis of cutaneous melanocytic lesions in children, including the use of genetic studies and mass spectrometry, and on the diagnostic features and differential diagnostic considerations of selected mesenchymal and lymphoproliferative lesions in children. This symposium aims to improve the diagnostic abilities of the pediatric pathologist and dermatopathologist who are confronted with these challenging cutaneous lesions, and thereby to contribute to timely and appropriate clinical patient management.

At the conclusion of the symposium, participant will be able to understand and apply to their practice (a) histopathologic criteria for pediatric melanocytic lesions, including use of sentinel lymph node biopsy, (b) use of genetic studies and mass spectrometry in analysis of pediatric melanocytic lesions, (c) histopathologic criteria for pediatric cutaneous mesenchymal tumors, including ancillary studies and (d) histopathologic criteria for pediatric cutaneous lymphoproliferative processes, including ancillary studies.
COMPANION MEETING

International Society of Bone and Soft Tissue Pathology

Recent Advances in Soft Tissue and Bone Pathology

Sunday, March 3, 2013
1:30 PM – 5:00 PM
CC 307/308

Moderator: Shinichiro Ushigome, MD, Keihin Medical Laboratory, Kawasaki, Japan and Ji Kei University School of Medicine, Tokyo, Japan

1:30 PM Mesenchymal Stem Cells in Sarcomagenesis – Pancras C.W. Hogendoorn, MD, Leiden University Medical Center, Leiden, Netherlands

2:00 PM Immunohistochemistry in Mesenchymal Tumours – An Update – Yoshinao Oda, Kyushu University, Fukuoka, Japan

2:30 PM Fibrosarcoma – Where Do We Stand Now? – Andrew L. Folpe, MD, Mayo Clinic, Rochester, MN

3:30 PM Vascular Tumours of Soft Tissue – What’s New? – Cristina R. Antonescu, MD, Memorial Sloan-Kettering Cancer Center, New York, NY

4:00 PM Malignant Peripheral Nerve Sheath Tumours – An Update – G. Petur Nielsen, MD, Massachusetts General Hospital, Boston, MA

4:30 PM Paediatric Small Round Cell Sarcoma – An Update – David M. Parham, MD, Oklahoma University, Oklahoma City, OK

The theme and content of the meeting were chosen and approved by the Society’s officers, taking into account the need to pick a novel theme of both utility and interest to general surgical pathologists as well as subspecialists interested in soft tissue and bone tumors. Better prediction of clinical behavior as well as testing which enhances treatment selection are increasingly important for the preferred multidisciplinary approach to the care of patients with malignant mesenchymal tumors. The relative value of the contributions from morphology, immunohistochemistry and molecular genetics continue to evolve and new data regarding the role of mesenchymal stem cells are emerging.

COMPANION MEETING

International Society of Gynecological Pathologists

The Origins of Ovarian Cancer Part 2: Non-Serous Tumors

Sunday, March 3, 2013
1:30 PM – 5:00 PM
CC 309/310

Moderators: C. Simon Herrington, MD, PhD, University of Dundee, Dundee, Scotland, UK
Xavier Matias-Guiu, MD, Hospital University of Lleida, Lleida, Spain

1:30 PM Clear Cell Carcinoma of the Ovary – 1e-Ming Shih, MD, PhD, Johns Hopkins Hospital, Baltimore, MD

2:00 PM Endometrioid Carcinoma of the Ovary – Xavier Matias-Guiu, MD, Hospital University of Lleida, Lleida, Spain

2:30 PM Mucinous Ovarian Tumors – Russell S. Vang, MD, The Johns Hopkins University, Baltimore, MD

3:30 PM Developments in the International Society of Gynecological Pathologists – C. Simon Herrington, MD, PhD, University of Dundee, Dundee, Scotland, UK

3:40 PM Identifying Novel Molecular Abnormalities in Ovarian Tumors – David G. Huntsman, MD, British Columbia Cancer Agency, Vancouver, BC, Canada

4:10 PM Clinical Implications of Our Developing Understanding of the Molecular Pathology of Ovarian Tumors – Carol Aghajanian, Memorial Sloan Kettering Cancer Center, New York, NY

The topic was chosen following discussion by the executive committee of the Society. There have been considerable recent advances in our understanding of the origins of ovarian carcinoma. In particular, most mucinous ovarian tumors are not recognized to be metastatic, and specific molecular abnormalities have been identified in different morphologic sub-types of carcinoma. This symposium will bring delegates up to date through discussion of recent clinic-pathologic and molecular data on non-serous ovarian tumors and their implications for clinical and pathologic practice. This follows on from the symposium on serous ovarian tumors presented at USCAP 2012 in Vancouver, Canada.
COMPANION MEETING

North American Society of Head and Neck Pathology

Exciting Topics in Head and Neck Pathology: Interesting Skeletal Tumors and Genetic Alterations of Salivary Gland Tumors

Sunday, March 3, 2013
1:30 PM – 5:00 PM
CC 318-320

Moderator: Peter B. Illei, MD, The Johns Hopkins Hospital, Baltimore, MD

1:30 PM Introduction and Tribute to Dr. Andrew Huvos. Dr. Andrew (“Andy”) Huvos: A Retrospective – Diane L. Carlson, MD, Cleveland Clinic Florida, Weston, FL

1:40 PM Fibro-Osseous Lesions of the Head and Neck Region – Edward F. McCarthy, MD, The Johns Hopkins Hospital, Baltimore, MD

2:10 PM The Importance of Diagnosing NUT Midline Carcinoma – Christopher A. French, MD, Brigham and Women’s Hospital, Boston, MA

2:40 PM Molecular Pathogenesis of Adenoid Cystic Carcinoma – Christopher Moskaluk, MD, PhD, University of Virginia Health System, Charlottesville, VA

3:30 PM Molecular Heterogeneity in Mucoepidermoid Carcinoma: Conceptual and Practical Implications – Adel K. El-Naggar, MD, MD Anderson Cancer Center, Houston, TX

4:00 PM What EWSR1-ATF1 Has Taught Us About Hyalinizing Clear Cell Carcinoma – Ilan Weinreb, MD, University Health Network, Toronto, ON, Canada

4:30 PM Unmasking MASC: Mammary Analogue Secretory Carcinoma of the Salivary Glands – Justin Bishop, MD, The Johns Hopkins Hospital, Baltimore, MD

The selection of topics for this Companion Meeting was gathered from the input of the executive committee and several senior members of the North American Society of Head and Neck Pathology, all of whom have served in leadership or speaking roles for the society in the past. The topics were selected by the speakers in order to highlight recent development in the areas of surgical and cytopathology in head and neck, and how to avoid pitfalls that even experts in the field may make. The objectives of this meeting are aimed to help the attendees stay current in diagnostic criteria in important head and neck lesions.

NASHNP endorses this program and its delivery of critical information to those who review head and neck pathology.
COMPANION MEETING
Rodger C. Haggitt Gastrointestinal Pathology Society

**Multifocal and Diffuse Diseases of the GI Tract**

Sunday, March 3, 2013
1:30 PM – 5:00 PM
CC Ballroom 2

**Moderator:** Galen Cortina, MD, PhD, UCLA Medical Center, David Geffen School of Medicine, Los Angeles, CA

1:30 PM **Hypertrophic Gastropathies** – Mary Kay Washington, MD, PhD, Vanderbilt University Medical Center, Nashville, TN

2:00 PM **From the Obvious to the Sublime: Multiple/Diffuse GI Mesenchymal Tumors** – Sarah M. Dry, MD, UCLA Medical Center, David Geffen School of Medicine, Los Angeles, CA

2:30 PM **Granulomatous Diseases** – Mary P. Bronner, MD, University of Utah, Salt Lake City, UT

3:30 PM **Increasingly Recognized Diseases of the Ampulla, Extrahepatic Bile Ducts and Gallbladder** – Deepti Dhall, MD, Cedars Sinai Medical Center, Los Angeles, CA

4:00 PM **Rodger C. Haggitt Memorial Lecture: GI Endoscopic Imaging-HD, EUS, and Microscopy** – Marcia Canto, The Johns Hopkins Hospital, Baltimore, MD

Members of the Rodger C. Haggitt Gastrointestinal Pathology Society Education Committee selected this topic in order to highlight the added value of imaging to microscopic diagnosis. Good surgical pathology diagnoses begin with good gross descriptions. But in the days of biopsies, the organ(s) involved are seen by radiologists and endoscopists in most cases. Endoscopists sometimes serve both roles. Since the microscopic image of focal histopathology may be identical to multifocal or diffuse disease, the best diagnosis for the patient may be dependent on the information provided by radiology or endoscopy. The selected pathology lectures will demonstrate how a more sophisticated pathophysiological interpretation can result from the gross input by a radiologist or endoscopist. The Memorial lecture is designed for the same effect, from the point of view of advanced endoscopy.
COMPANION MEETING

Society for Hematopathology

Advances in Small B-Cell Neoplasms: Bringing New Discoveries into Clinical Practice

Sunday, March 3, 2013
1:30 PM – 5:00 PM
CC Ballroom 4

Moderators: James R. Cook, MD, PhD, Cleveland Clinic, Cleveland, OH
Leticia Quintanilla-Fend, MD, Institute of Pathology, Comprehensive Cancer Center, Tuebingen, Germany

1:30 PM Introduction – James R. Cook, MD, PhD, Cleveland Clinic, Cleveland, OH and Leticia Quintanilla-Fend, MD, Institute of Pathology, Comprehensive Cancer Center, Tuebingen, Germany

1:35 PM Overview of Molecular Biology and Small B-Cell Neoplasm Classification – Carlo Croce, Ohio State University, Columbus, OH

2:05 PM Mutations in Small B-Cell Neoplasms – Laura Pasqualucci, MD, Columbia University, New York, NY

2:35 PM Follicular Lymphoma – Andreas Rosenwald, MD, Wuerzburg, Germany

3:30 PM Splenic Leukemia/Lymphomas – Miguel Angel Piris Pinilla, MD, Hospital Marques de Valdecilla, Santander, Cantabria, Spain

3:55 PM Mantle Cell Lymphoma – Elias Campo, MD, Hospital Clinic, Barcelona, Spain

4:20 PM CLL/Monoclonal B-Cell Lymphocytosis – Paolo Ghia, Universita ’Vita-Salute San Raffaele, Milan, Italy

The symposium theme is selected by the President with input from the Executive Committee of the Society for Hematopathology based on input from the membership of the Society. Moderators are selected by the President with suggestions from the Executive Committee. Speakers are selected by the moderators in consultation with the President.

The topic is chosen based on input from the membership of the Society and upon review of prior symposium topics by the Executive Committee. The topic of small B-cell neoplasms was selected as this topic includes entities frequently encountered in routine clinical practice, and has not been addressed by a companion meeting symposium in more than 10 years.

Small B-cell neoplasms represent some of the most commonly encountered lymphoproliferative disorders in routine surgical pathology practice. Data emerging in recent years have provided new insights into the diagnosis, classification, and prognostic assessment of these neoplasms. The symposium will provide a detailed update on small B-cell neoplasms for Society members and general surgical pathologists who encounter hematopathology cases in their routine practice.
COMPANION MEETING

History of Pathology Society

History of Pathology in the Arab World

Sunday, March 3, 2013
3:30 PM – 5:00 PM
CC 313

Moderator: Kristin Henry, MD, Imperial College, London, UK

3:30 PM The Influence of Arabic-Islamic Civilization on Modern Medicine and Pathology – Samir S. Amr, MD, King Fahad Specialist Hospital, Dammam, Saudi Arabia

4:00 PM History of Pathology in Lebanon, and the Historical Influence of the American University of Beirut on Pathology in the Middle East – Ghazi S. Zaatar, MD, American University/Beirut, Lebanon

4:20 PM History of Pathology Teaching and Services in Egypt Since the 19th Century – Salwa I. El Haddad, Ain Shams University, Cairo, Egypt

4:40 PM History of Pathology Education and Services in Jordan – Ismail Matalka, DR, Jordan University of Science and Technology, Irbid, Jordan

This session on “History of Pathology in the Arab World” was chosen by the Secretary of the Society (Dr Allan Tucker) and the current President of the Society (Dr Samir Amr) to give those pathologists who are interested in the history of pathology an idea about the development and evolution of pathology education and services in some Arab countries. Also, one lecture shall be dedicated to the influence of the Arabic civilization on the modern medical knowledge including pathological concepts advanced by ancient scholars like Avicenna, Rhazes and Albucasis.

The session shall give a historical perspective to the evolution of pathology, old and recent, in one area of the world which is the focus of much attention on historical, political, religious, and cultural levels.
COMPANION MEETING

American Society for Clinical Pathology in Coordination with the American Pathology Foundation

Meeting the Leadership and Management Challenges Facing the Pathologist of the Future

Sunday, March 3, 2013
7:30 PM – 10:30 PM
CC 321-323

Moderator: Ronald L. Weiss, MD, University of Utah, Salt Lake City, UT

7:30 PM Introduction – Ronald L. Weiss, MD, University of Utah, Salt Lake City, UT

7:35 PM The ACGME Milestones: Shaping the Future Pathology Workforce – C. Bruce Alexander, MD, University of Alabama, Birmingham, AL

8:10 PM The Leadership Role for Pathology in the Health Care System/OR the Integrated Delivery System – James M. Crawford, MD, PhD, Hofstra North Shore-LIJ School of Medicine, Lake Success, NY

8:50 PM The Pathologist at the Center of the Diagnostic Management Team – Robert D. Hoffman, MD, PhD, Vanderbilt University Medical Center, Nashville, TN

9:30 PM Reality Check: How Well Are Pathologists Prepared for the Real World – Samuel K. Caughron, MD, MAWD Pathology Group PA, North Kansas City, MO

Results of a survey of the Pathology Program Directors (PRODs) were presented during a 2009 PRODs workshop and concluded that there was extreme variability in the teaching of laboratory management to residents as a result of a lack of faculty time; a lack of resident interest; and a lack of faculty interest. As a result of the workshop, a Laboratory Management Curriculum Development Workgroup was formed and the laboratory curriculum was published in 2011 in the American Journal of Clinical Pathology.

Additionally, a set of 27 Milestones for pathology residency training has been drafted by a Pathology Milestones Workgroup of the ACGME. These Milestones not only shape residency training but also impact the future of the pathology workforce.

Finally, expectations for the new pathologist in practice have been outlined (Horowitz, RE, APC 2012 Annual Meeting) and include: communication skills, interpersonal skills, practice management, professional skills, leadership and teaching skills and laboratory direction. The experience of the pathologist in these areas varies with and within practice settings and there is a recognition that management training needs to be individualized both in content and timing.

The educational needs for this program are related to knowledge and competence. These needs underlie several professional practice gaps of pathologists in training and newly in practice and include: lack of sufficient training and effective strategies for training in laboratory management; variability of experience in competencies related to areas such as administration and management, coding, billing, legal, regulatory and communication and interpersonal skills; exposure to laboratory activity during residency training may not be sufficient to effectively direct lab operations or provide consultative advice. The educational needs related to the outlined professional practice gaps include understanding the leadership role for pathology in the health care system/integrated delivery system and at the center of the disease management team as well as the competencies required in residency training that will shape the future of the pathology workforce.

As a result of this program, pathologist learners should be able to (1) describe opportunities they have to play in leadership roles in their institution, their practice, or their educational setting and the influence they have on the future of health care; (2) define the leadership and management skills required to be successful, whether in a community or academic setting; and (3) respond to the upcoming Pathology Milestones for measuring performance in such areas as leadership skills, health care team interactions, consultation, and laboratory management.
COMPANION MEETING

American Society for Cytopathology in Coordination with Papanicolaou Society of Cytopathology

Algorithmic Approach to Pancreaticobiliary Cytology: A Step towards Recommendations and Guidelines

Sunday, March 3, 2013
7:30 PM – 10:30 PM
CC 307/308

Moderator: Zubair W. Baloch, MD, Hospital of the University of Pennsylvania, Philadelphia, PA

7:30 PM Introduction of Program and Panelists – Zubair W. Baloch, MD, Hospital of the University of Pennsylvania, Philadelphia, PA

7:40 PM Use and Abuse of On-Site Evaluation of EUS-Guided FNA Specimens of Pancreas – Nirag C. Jhala, MD, Hospital of the University of Pennsylvania, Philadelphia, PA

8:00 PM Cytomorphology of Bile Duct Lesions: Diagnostic Criteria with Emphasis on Pitfalls – Lester J. Layfield, MD, University of Utah School of Medicine, Salt Lake City, UT

8:25 PM Utilization of Ancillary Studies in Pancreaticobiliary Cytology Specimens – Anirban Maitra, MBBS, The Johns Hopkins University/Medicine, Baltimore, MD

8:50 PM The Aftermath of Cytologic Interpretation: Follow-Up and Treatment Options – Daniel F. Kurtycz, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI

9:15 PM Session Summary & Recommendations – Martha Bishop Pitman, MD, Massachusetts General Hospital, Boston, MA

The ASC and PSC solicited topics of interest from their membership at the annual business meetings. Several potential topics were discussed at the Executive Board meeting and the topic for the 2013 session was chosen in agreement with the chairs of the scientific program committees. Improving the current practice of pancreaticobiliary cytology is of high interest to ASC & PSC membership and is currently cited as an important topic in cytopathology and pancreaticobiliary pathology. The ASC & PSC membership are focused on the dissemination of best practices to improve quality of pancreaticobiliary cytology specimens and small biopsies, classification and explore the role of various ancillary techniques that may prove beneficial to the cytopathologist.

Our needs assessment process was based on the evaluation of the current literature and the feedback provided by audience participating in person and online (NCI pancreaticobiliary cytology guidelines website).

- Evidence that the purpose or objectives of the activity were communicated to the learner. The purpose and objectives of the program are as follows:
- Provide a cytopathologic approach to the on-site evaluation, examination and diagnosis of EUS-guided pancreas FNA and biliary brush specimens.
- Highlight the role of molecular techniques as an aid to cytopathologic diagnosis of EUS-guided pancreas FNA and biliary brush specimens.
- Describe the role of the pathologist in the management of pancreaticobiliary lesions.
- Discuss known “best-practices” and means of implementation.
- Provide and illustrate various common and uncommon pancreaticobiliary lesions and diagnostic pitfalls.

Evaluations through the USCAP are required in order to obtain CME credit. We also will evaluate effectiveness by monitoring attendance and tracking the scope and breadth of questions and the evaluations of each speaker.

The American Society of Cytopathology is very excited about the 2013 program, one that we are confident is in keeping with the quality expected of Companion Societies, and one that we feel will appeal to a broad spectrum of pathologists in all practice settings.
COMPANION MEETING

Association for Molecular Pathology

*Integrating Advanced Sequencing and Genomic Results into the Surgical Pathology Report*

Sunday, March 3, 2013
7:30 PM – 10:30 PM
CC 309/310

Moderators:

- Dan Jones, MD, PhD, *Nichols Institute, Quest Diagnostics, Chantilly, VA*
- Ronald Przygodzki, MD, *Veterans Affairs, Washington, DC*

7:30 PM  **Introduction** – Ronald Przygodzki, MD, *Veterans Affairs, Washington, DC*

7:40 PM  **Integrating FISH and Genomic Array into the Diagnostic Workup of Melanoma** – Julie Reimann, MD, PhD, *Virginia Mason Medical Center, Newton, MA*

8:05 PM  **The Bone Marrow Comprehensive Report: Advances in Molecular and Cytogenetic Risk Stratification in AML and MDS** – Daniel A. Arber, MD, *Stanford University, Stanford, CA*

8:30 PM  **HNPCC and the Molecular Cross Roads in CRC: Providing Guidance on Follow-Up Testing in MSI Tumors and Molecular Testing for Targeted Therapies** – Antonia Sepulveda, MD, PhD, *Columbia University Medical Center, New York, NY*

8:55 PM  **Approaches to Reporting Next Generation Sequencing Results for Solid Tumors** – Federico A. Monzon, MD, *The Methodist Hospital, Houston, TX*

9:20 PM  **How To Pull It All Together: Workflow and Report Design Considerations in Personalized Medicine** – Dan Jones, MD, PhD, *Nichols Institute, Quest Diagnostics, Chantilly, VA*

The topic was chosen by the AMP senior co-moderator, Dan Jones, who was selected by the AMP Program Committee and Membership Affairs Committee in 2012, and approved by the AMP Executive Committee. The proposal was reviewed during that process.

The molecular diagnostic topics presented at various national pathology meetings over the last several years, including USCAP, CAP and ASCP, were reviewed to look for gaps and opportunities for timely content in Molecular Pathology. The need for a session on guidance on adding molecular and genomic data into an integrated surgical pathology report was identified. The symposium is focused on how to effectively incorporate molecular and genomic data into the surgical pathology report, covering melanoma, hematopathology, genitor-urinary, and next generation sequencing reporting for solid tumors.
COMPANION MEETING

International Society of Breast Pathology

Practice of Breast Pathology in the Era of Targeted Therapy

Sunday, March 3, 2013
7:30 PM - 10:30 PM
CC Ballroom 2

Moderators: Ayseguł Sahin, MD, The University of Texas MD Anderson Cancer Center, Houston, TX
              Gelareh Farshid, MBBS, MD, SA Pathology, BreastScreen SA & Adelaide University, Adelaide, South Australia, Australia

7:30 PM  Introduction and President’s Remarks – Ann D. Thor, MD, University of Colorado Denver, Aurora, CO

7:35 PM  Trainee Awards in Breast Pathology – Puay Hoon Tan, FRCPA, Singapore, Singapore

7:45 PM  Breast Cancer Diagnosis in the Molecular Era-Morphology Matters
          Jean F. Simpson, MD, Vanderbilt University Medical Center, Franklin, TN
          Melinda E. Sanders, MD, Vanderbilt University, Nashville, TN

8:20 PM  Clinical Implementation of Molecular Testing for Targeted Therapy of Breast Cancer – Antonio Wolff, The Johns Hopkins Hospital, Baltimore, MD

8:50 PM  Critical Questions Regarding Biomarkers of Breast Cancer – Allen M. Gown, MD, PhenoPath Laboratories, PLLC, Seattle, WA

The topics for the symposium were determined by the Executive Committee members of International Society of Breast Pathology after soliciting input from membership. Our needs assessment process was based on the evaluation of the current literature and feedback provided by audience participating in our prior companion symposiums.

The purpose of the companion meeting is to inform the audience most recent advances in practice of breast pathology and integration of recent developments in clinical practice. In each presentation there will be a discussion of recent scientific developments related to different aspects of breast pathology practice.

The current program will cover integration of morphology and biomarker evaluation in breast pathology practice.
COMPANION SOCIETIES AND OFFICERS

**American Association of Neuropathologists**
Raymond Sobel, President
John M. Lee, Vice-President
Charles White, President Elect
Elizabeth J. Cochran, Vice President Elect
C. Harker Rhodes, Secretary/Treasurer

**American Association of Ophthalmic Oncologists and Pathologists**
Deepak P. Edward, President
David Wilson, Past President
Hans Grossniklaus, President Elect
Patricia Chevez Barrios, Secretary/Treasurer
USCAP – AAOP Committee Members – J. Douglas Cameron, Patricia Cheves-Barrios Hans Grossniklaus

**American Society for Clinical Pathology**
C. Bruce Alexander, President
Joel M. Shilling, President-Elect
Steven H. Kroft, Vice President
Kenneth Emancipator, Treasurer
William G. Finn, Secretary
John E. Tomaszewski, Immediate Past President

**American Society of Cytopathology**
Nancy A. Young, President
Hormoz Ehya, Past President
Lydia Howell, President-Elect
Edmund Cibas, Secretary/Treasurer

**American Society of Dermatopathology**
Zsolt B. Argenyi, President
Jennifer M. McNiff, President-Elect
Mark A. Hurt, Secretary-Treasurer
Earl J. Glusac, Immediate Past-President

**American Society for Investigative Pathology**
Martha B. Furie, President
Charles A. Parkos, Past-President
Elizabeth R. Unger, President-Elect
James M. Musser, Vice President
William B. Coleman, Secretary-Treasurer
Asma Nusrat, Program Committee Chair
Mark E. Sobel, Executive Officer

**Arthur Purdy Stout Society of Surgical Pathologists**
Christopher D.M. Fletcher, President
John Goldblum, Past President
Elizabeth Anne Montgomery, President-Elect
Barry R. DeYoung, Secretary
Peter A. Humphrey, Treasurer
Association for Molecular Pathology
Iris Schrijver, President
Timothy O’Leary, Past-President
Stanley Cohen, Secretary-Treasurer
Daniel H. Farkas, Program Committee Chair

Binford-Dammin Society of Infectious Disease Pathologists
Mike Wilson, President
Ann Nelson, Past President
Daniel Zander, President-Elect
Jeannette Guarner, Secretary/Treasurer

College of American Pathologists
Stephen N. Bauer, President
Stanley J. Robboy, President-Elect
Gene N. Herbek, Secretary-Treasurer

Endocrine Pathology Society
George Kontogeorgos, President
Ronald Ghossein, Past President
Thomas Giordano, Secretary / Treasurer

Rodger C. Haggitt Gastrointestinal Pathology Society
Alyssa Krasinskas, President
Sanjay Kakar, President Elect
Barbara McKenna, Past President
Rhonda Yantiss, Vice President
Mathew Yeh, Training Committee Chair
Rhonda Yantiss & Galen Cortina, Chair Education Committee
Hala El-Zimaity, Secretary/Treasurer

Hans Popper Hematopathology Society
David E. Kleiner, President
Matthew Yeh, Vice President
Kay M. Washington, Past President
Elizabeth Brunt, Secretary-Treasurer

History of Pathology Society
Mark R. Wick, President
J. Allan Tucker, Secretary/Treasurer

International Society of Bone & Soft Tissue Pathology
Shinichiro Ushigome, President
Christopher D.M. Fletcher, Past-President
John S.J. Brooks, Secretary
Andrea T. Deyrup, Treasurer

International Society of Breast Pathology
Ann Thor, President
Aysegul Sahin, Past-President
Timothy W. Jacobs, Secretary
Elizabeth Wiley, Treasurer
International Society of Gynecological Pathologists
C. Simon Herrington, President
Richard Zaino, President-Elect
Wilson Glenn McCluggage, Secretary
Teri A. Longacre, Treasurer
Elvio G. Silva, Past-President

International Society of Urological Pathology
Rodolfo Montironi, President
Peter Humphrey, President-Elect
John Srigley, Past-President
Lars Egevad, Secretary
Ming Zhou, Treasurer

North American Society of Head and Neck Pathology
Bruce M. Wenig, President
Manju Prasad, Vice President / President Elect
Mary S. Richardson, Secretary
Nasser Said Al-Naief, Treasurer
Samir K. El-Mofty, Past President

Paleopathology Club
Enrique Gerszten, Program Co-Chairman
Pedro L. Fernandez, Program Co-Chairman

Papanicolaou Society of Cytopathology
Lester Layfield, President
Zubair Baloch, President-Elect
Martha Bishop Pitman, Past President
David Chhieng, Secretary
Eric Suba, Treasurer
Members at Large: Britt-Marie Ljung, Philip Viehl, Tarik Elsheikh Andrew Field, Matt Zarka, Daniel Kurtycz

Pulmonary Pathology Society
Donald Guinee, President
Philip Cagle, Past President
Elisabeth Brambilla, Vice President
Timothy Allen, Secretary
Kevin Leslie, Treasurer
Sanja Dacic, Program Committee Chair

Renal Pathology Society
Guillermo Herrera, President
Volker Nickelet, Vice President
Harsharan Singh, Secretary
Neeraja Kambham, Treasurer

Society for Cardiovascular Pathology
John P. Veinot, President
Richard Mitchell, Vice-President, President-Elect
Sylvio Litovsky, Treasurer
Barbara A. Sampson, Secretary
Michael Fishbein, Past-President
Robert Mitchell, Programming Chair
Society for Hematopathology
Jonathan W. Said, President
Marsha C. Kinney, Vice President/President-Elect
Sherrie L. Perkins, Secretary/Treasurer
LoAnn C. Peterson, Past President

Society for Ultrastructural Pathology
David N. Howell, President
Guillermo A. Herrera, Past-President
Victor L. Roggli, President-Elect
Eric Wartchow, Secretary
J. Allan Tucker, Treasurer
Josep Lloreta-Trull, Councillor for Europe
Susan Brammah, Councillor for Australasia
Sara E. Miller, Councillor for America
Gary Mierau, Historian

Society for Pediatric Pathology
Kathleen Patterson, President
Linda Margraf, President-Elect
Jeffrey Goldstein, Past-President
Sara Vargas, Secretary-Treasurer

American College of Veterinary Pathology
Derek Moiser, President
Claire B. Andreasen, President-Elect
Michael J. Topper, Secretary-Treasurer

Association for Pathology Informatics
Ronald S. Weinstein, President
Raymond D. Aller, President-Elect
Myra L. Wilkerson, Past-President
Anand S. Dighe, Vice President
Philip J. Boyer, Secretary-Treasurer
REGISTER NOW AND SAVE!

Join us in the beautiful City by the Bay for updated, pragmatic, problem-solving information for practicing anatomic pathologists. The seminars will focus on the resolution of diagnostic pitfalls in an array of five difficult areas of surgical pathology:

Prostatic Adenocarcinoma  Pancreaticobiliary Pathology  Extranodal Lymphomas  Gastrointestinal Pathology  Non-Epithelial Tumors of the Ovary

Earn 15 AMA PRA Category 1 Credits™ and 15 SAMs credits

PRACTICAL PATHOLOGY SEMINARS

May 2-5, 2013  
Hyatt Fisherman’s Wharf  
San Francisco, CA

United States & Canadian Academy of Pathology  
LEADING PATHOLOGY EDUCATIONAL EXCELLENCE

Log on to learn more at www.uscap.org
The USCAP is pleased to present 19 Specialty Conferences and 5 Special Courses this year enabling you to earn up to 22.5 *AMA PRA Category 1 Credits™*.

The **Specialty Conferences** are scheduled in the evenings and utilize a case presentation format wherein highly experienced faculty discuss current diagnostic problems and methodologies.

The **Special Courses** are didactic courses that are structured to provide pathologists with in-depth knowledge of advanced scientific techniques and methodologies.

Regardless of which you choose to attend, you’ll find our faculty and their experience, are stellar! So, go find a star, and expand your universe of pathology knowledge.

**SPECIAL NOTE**
Prior to this Annual Meeting, images and case histories for the Specialty Conferences are posted on the USCAP website (www.uscap.org) so they may be reviewed in advance. **Handouts for all Specialty Conferences** will be available on the website the morning after the conference. Printed copies of the handouts will not be available at the meeting.
SPECIAL COURSE
A Practical Guide to Molecular Testing in Cancer
Monday, March 4, 2013
7:50 AM – 1:00 PM
CC 307/308

Course Director:  Julia A. Bridge, MD, University of Nebraska Medical Center, Omaha, NE

Course Description:
Accumulating discoveries of the biological mechanisms that control cell growth and differentiation, and developments in the clinical management of cancer, continue to expand the role of molecular technology in diagnostic surgical pathology. In this course, the fundamental principles of molecular pathology in cancer and their application to laboratory medicine will be emphasized in a format designed to be practical and straightforward. Specifically, this course is aimed at providing pathologists with a foundation in the practice of oncologic molecular pathology to include: nomenclature, commonly used techniques and their specimen requirements, assay selection and indications, diagnostic and prognostic utility, test turn-around-times, and quality assurance issues. Select cases may be presented to illustrate use in routine practice and serve as useful paradigms. Moreover, specific areas will be highlighted in which major advances can be expected and to which the key principles learned can be applied.

Upon completion of this course, participants should be able to:
• Summarize the central genetic principles of oncologic molecular tests commonly used in the practice of pathology
• Identify tests available in oncologic molecular pathology as well as their application and interpretation in screening, diagnosis, monitoring, and treatment of cancer.

7:50 AM  Introduction
Julia A. Bridge, MD, University of Nebraska Medical Center, Omaha, NE

8:00 AM  Clinical Cytogenetic and Molecular Genetic Testing of Bone and Soft Tissue Tumors
Julia A. Bridge, MD, University of Nebraska Medical Center, Omaha, NE
Upon completion of this presentation, participants should be able to:
• Review sample requirements and handling for RT-PCR, FISH, and cytogenetic analysis as they pertain to evaluating mesenchymal neoplasms.
• Describe the advantages and limitations of genetic approaches commonly used in the classification of mesenchymal neoplasms to include conventional karyotyping, FISH and RT-PCR.
• Recognize the diagnostic, prognostic, and therapeutic value of molecular markers in mesenchymal neoplasia.

8:40 AM  Molecular Testing in the Management of Patients with Breast Cancer: Current Status and Future Directions
Stuart J. Schnitt, MD, Beth Israel Deaconess Medical Center, Boston, MA
Upon completion of this presentation, participants should be able to:
• Provide an overview of the molecular classification of breast cancer and its clinical implications.
• Review the uses and limitations of currently available molecular prognostic tests for patients with breast cancer.
• Describe the emerging role of genome sequencing in the management of patients with breast cancer.

9:10 AM  Molecular Markers for Targeted Lung Cancer Therapy
A. John Iafrate, MD, PhD, Massachusetts General Hospital, Boston, MA
Upon completion of this presentation, participants should be able to:
• Understand the current genetic landscape of lung tumors.
• Understand the role of genetic testing in guiding targeted therapies in lung cancer.
• Appreciate the importance of advanced technologies in the future of pathologic assessment of tumors.

9:40 AM  Clinical Applications of Recent Molecular Advances in Urologic Malignancies: No Longer Chasing a “Mirage”
George J. Netto, MD, Johns Hopkins University, Baltimore, MD
Upon completion of this presentation, participants should be able to:
• Review salient “translationally” pertinent advances in our understanding of the molecular pathogenesis of Selected Urologic Malignancies.
• Recognize Upcoming Novel Diagnostic and Prognostic markers and potential targets of Therapy in Selected Urologic Malignancies.

10:10 AM  Break

10:40 AM  Molecular Diagnostics of Leukemias and Lymphomas: The Impact of Recent Molecular Advances on the Surgical Pathology Diagnosis of Hematopoietic Neoplasms
Dan Jones, MD, PhD, Quest Diagnostics, Nicholas Institute, Chantilly, VA
Upon completion of this presentation, participants should be able to:
• Evaluate the benefits of PCR, FISH, mutation and array profiling testing in the workup of lymphomas and tissue-based leukemic infiltrates of various types.
• Understand the impact of recent molecular advances on the routine diagnostics of these neoplasms.
11:20 AM  GIST and Melanoma: The KIT Connection and So Much More
Alexander Lazar, MD, PhD, University of Texas, M.D. Anderson Cancer Center, Houston, TX
Upon completion of this presentation, participants should be able to:
• Understand the techniques and results of molecular testing for gastrointestinal stromal tumor (GIST) and melanoma.
• Realize the association between histologic and molecular features in GIST and melanoma.
• Appreciate the emerging role of molecular diagnostics in patient management for GIST and melanoma.

11:50 AM  Colorectal Cancer: Molecular Testing for the Surgical Pathologist
Kevin C. Halling, MD, PhD, Mayo Clinic, Rochester, MN
Upon completion of this presentation, participants should be able to:
• Discuss how MSI and DNA mismatch repair IHC testing and germline DNA mismatch repair gene sequencing are used to identify, diagnose, and manage patients with HNPCC.
• Explain how microsatellite instability testing can be used to assess stage II and III CRC patients’ prognosis and response to 5FU treatment.
• Describe how KRAS and BRAF testing can be used to predict response to anti-EGFR therapies for patients with metastatic colorectal cancer (CRC).

12:20 PM  Molecular Diagnostics of Thyroid Cancer
Yuri E. Nikiforov, MD, PhD, University of Pittsburgh, UPMC Presbyterian, Pittsburgh, PA
Upon completion of this presentation, participants should be able to:
• Provide a summary of the most common molecular alterations in thyroid tumors and their histopathologic correlations.
• Discuss specimen requirements and techniques for molecular testing of thyroid surgical resections and fine needle aspiration (FNA) samples.
• Discuss the diagnostic and prognostic application of specific molecular markers in thyroid cancer.

12:50 PM  Question Period and Concluding Remarks
SPECIAL COURSE

Introduction to Molecular Pathology for the Practicing Pathologist: Technology, Assay Interpretation, and Pitfalls
Monday, March 4, 2013
8:00 AM - 4:30 PM
CC 318-320

Course Director: Jennifer L. Hunt, MD, University of Arkansas for Medical Sciences, Little Rock, AR

Course Description:
It is becoming more and more important to go beyond morphology in the pathologic assessment of tumors, with incorporation of molecular testing into our diagnostic algorithms. While much of this testing may be performed in molecular pathology laboratories, surgical pathologists need to be comfortable with their understanding of the technology associated with these tests in order to select adjunctive tests, incorporate molecular results into their interpretive reports, and to lead clinicopathologic correlation. Molecular pathology is a rapidly evolving specialty, with novel technologies and new complex testing being introduced all the time. However, basic technologies, including polymerase chain reaction, in situ hybridization, sequencing, and others, underpin most molecular anatomic pathology tests today. This course will provide an overview to these fundamental molecular technologies at an introductory level. The faculty will use both didactic lectures and case presentations to illustrate the techniques, discuss the interpretation of the results, and highlight some of the pitfalls of the molecular testing. A selection of standard technology, specialized techniques, and emerging assays will be introduced. The course is designed specifically for the practicing pathologist or trainee who wants to gain comfort with currently available molecular anatomic pathology techniques and result interpretation.

Upon completion of this course, participants should be able to:
• Identify diagnostic surgical pathology cases that might benefit from additional molecular testing.
• Select the optimal technology, based on the type of tissue samples available.
• Interpret some common molecular test results.
• Recognize potential pitfalls in molecular testing for commonly applied tests.
• Illustrate the basic techniques that underpin commonly available molecular anatomic pathology assays.
• Outline specialized techniques and potential emerging technologies for molecular anatomic pathology testing.

8:00 AM Introduction to Basic Molecular Pathology Techniques: Fixation, Microdissection, and Polymerase Chain Reaction-Based Assays
Jennifer L. Hunt, MD, University of Arkansas for Medical Sciences, Little Rock, AR
Upon completion of this presentation, participants should be able to:
• Recognize the effects of fixation on nucleic acids and will be able to select assays that are appropriate to the tissue material available.
• Describe the phases of a standard polymerase chain reaction.

9:15 AM Loss of Heterozygosity and Microsatellite Instability in Tumors: Mechanisms, Testing, and Clinical Implications
Wade S. Samowitz, MD, University of Utah Health Sciences Center, Salt Lake City, UT
Upon completion of this presentation, participants should be able to:
• Define and explain the biologic mechanism behind loss of heterozygosity and microsatellite instability.
• Describe the clinical utility and methods of testing for these molecular alterations.

10:00 AM Break: Poster Viewing

10:45 AM Applications of Tissue Genotyping in the Routine Practice of Surgical Pathology
Pei Hui, MD, PhD, Yale University School of Medicine, New Haven, CT
Upon completion of this presentation, participants should be able to:
• Comprehend the basic technical aspects of short tandem repeat (STR) genotyping analysis using conventional tissue specimens.
• Describe clinical diagnostic applications of STR genotyping for in surgical pathology.

11:30 AM Questions and Answers

11:45 AM Lunch

12:45 PM Copy Number Detection by Chromosomal Microarray Analysis
Long Phi Le, MD, PhD, Massachusetts General Hospital, Boston, MA
Upon completion of this presentation, participants should be able to:
• Describe the role of copy number variation in genetics and disease.
• Characterize the methodology, utility and limitation of chromosomal microarray analysis.

1:30 PM Introduction to In Situ Hybridization Technology, Interpretation, and Pitfalls
Long Phi Le, MD, PhD, Massachusetts General Hospital, Boston, MA
Upon completion of this presentation, participants should be able to:
• Select the appropriate approach for translocation testing in clinical testing.
• Describe the pitfalls in interpretation and scoring of FISH based testing.
2:00 PM  HPV Detection: Testing Methodologies and Their Clinical Utility
Jennifer Laudadio, MD, University of Arkansas for Medical Sciences, Little Rock, AR
Upon completion of this presentation, participants should be able to:
• Explain the role of Human Papillomavirus in oncogenesis.
• Describe the clinical indications, appropriate sample types and available methods for HPV detection.

2:30 PM  Principles and Applications of Real-Time Quantitative PCR
Janina A. Longtine, MD, Mount Sinai Medical Center, New York, NY
Upon completion of this presentation, participants should be able to:
• Explain the basic chemistry of real-time quantitative PCR and distinguish it from end-point PCR.
• Illustrate a clinical application of real-time quantitative PCR.

3:00 PM  Break

3:30 PM  Sequencing To Detect Oncogene Mutations in Clinical Anatomic Pathology Applications
Jennifer L. Hunt, MD, University of Arkansas for Medical Sciences, Little Rock, AR
Upon completion of this presentation, participants should be able to:
• Identify the best approach for detecting oncogene mutations in tumor samples
• Recognize the pitfalls in common approaches for oncogene detection technology.

4:00 PM  Review and Summary

4:15 PM  Questions and Answers Session
SPECIAL COURSE
Careers in Investigation Pathology: The Next Generation
Monday, March 4, 2013
2:00 PM - 4:00 PM
CC 307/308

Course Directors: Massimo F. Loda, MD, Dana Farber Cancer Center and Brigham and Women's Hospital, Harvard University School of Medicine, Boston, MA
David M. Berman, PhD, Queen's Cancer Research Institute, Queen's University, Kingston, ON, Canada

Course Description:
The advent of next generation genomic technologies has ushered in tremendous opportunities to reclassify disease. With unparalleled insights into disease manifestations in cells and tissues, pathologists are uniquely well-suited to lead this effort. There are, however, some barriers to entry into this new and exciting arena. With a focus on practical tips and concepts for non-specialists, this course is designed to lower these barriers. This course is aimed at pathologists with no specialized training in genomics or bioinformatics. After an overview of how to incorporate these technologies into your career, you will learn specific strategies to use massive data sets to enhance your research.

2:00 PM Introduction
Massimo F. Loda, MD, Dana Farber Cancer Center and Brigham and Women's Hospital, Harvard University School of Medicine, Boston, MA
David M. Berman, PhD, Queen's Cancer Research Institute, Queen's University, Kingston, ON, Canada

2:10 PM How To Integrate Complex Data Sets into a Career in Investigative Pathology
David G. Huntsman, MD, University of British Columbia, Vancouver, BC, Canada
Upon completion of this presentation, participants should be able to:
• Identify ways to impact patient care using next generation technologies.
• Understand new ways of classifying disease on the basis of genomic properties.
• Understand how to operate as an investigative pathologist within a genomics-oriented team.

2:30 PM In Silico Experiments: How To Use Other People's Data To Do Your Own Experiments
Daniel J. Brat, MD, PhD, Emory University School of Medicine, Atlanta, GA
Upon completion of this presentation, participants should be able to:
• Appreciate the vast array of genomic data available online.
• Learn to use online data to generate and test hypotheses.

2:50 PM From the Archives: Platforms for High Dimensional Analysis of Formalin-Fixed Paraffin Embedded (FFPE) Tissues
Edward Stack, PhD, Dana Farber Cancer Institute, Harvard School of Public Health, Boston, MA
Upon completion of this presentation, participants should be able to:
• Become familiar with platforms for profiling protein and nucleic acids from FFPE tissue.
• Understand how analytes in FFPE are affected by pre-analytic variation.
• Compare and contrast costs, risks, and benefits of different profiling strategies.
• Distinguish between well-established and emergent technologies for profiling FFPE.

3:10 PM Making Sense of Complex Datasets: What the Pathologist Needs To Know
John Quackenbush, PhD, Harvard School of Public Health, Boston, MA
Upon completion of this presentation, participants should be able to:
• Learn basic statistical concepts as they pertain to massive data sets.
• Understand conceptual frameworks used to analyze genomic data (e.g. geneset enrichment analysis)
• Become familiar with user-friendly resources for genomic analysis.
• Identify ways that non-specialists can make sense of genomic data.

3:30 PM Questions and Answers / Moderated Panel Discussion
SPECIAL COURSE
Advanced Molecular Pathology
Tuesday, March 5, 2013
8:00 AM - 1:00 PM
CC 318-320

Course Director: Frederic G. Barr, MD, PhD, National Cancer Institute, Bethesda, MD

Course Description:
This special course will provide an in-depth consideration of recent advances in molecular biology and genetics that are enhancing the understanding of the pathogenesis of human cancer and other diseases, and impacting on the practice of diagnostic pathology. Topics will be chosen to highlight specific advances in the molecular and cell biology related to disease pathogenesis, with considerations of molecular mechanisms, genetic and cellular signaling pathways, and various methodologic approaches. The program is designed as an update for both practicing pathologists and primary investigators on these specific topics as well as general trends in the field of molecular pathology. In addition to presenting a basic scientific foundation on each topic, these lectures will provide practical information concerning how this information can be applied in diagnostic and therapeutic settings. Therefore, an important overall emphasis of this course will be translational issues that link basic discoveries with the practice of pathology.

8:00 AM Introduction
Frederic G. Barr, MD, PhD, National Cancer Institute, Bethesda, MD

8:10 AM The Molecular Pathology of Acute Leukemia
James R. Downing, MD, St. Jude Children’s Hospital, Memphis, TN
• Review the genetic lesions that underlie acute lymphoblastic leukemia.
• Review the genetic lesions that underlie acute myeloid leukemia.
• Highlight the new insights that have emerged from cancer genome sequencing projects.
• Highlight how next-generation sequencing approaches will impact clinical practice in the coming years.

8:55 AM The Hypoxia Inducible Factor Pathway: Molecular Biology and Role in Disease Pathogenesis
Frank S. Lee, MD, PhD, University of Pennsylvania, Philadelphia, PA
• Understand how oxygen is sensed by cells via the Hypoxia Inducible Factor pathway.
• Appreciate how dysregulation of this pathway can lead to diseases that include cancer and polycythemia.
• Discuss how analysis of this pathway may have relevance to the practice of pathology in the future.

9:40 AM Biomarker Development from High Throughput Studies
Matt van de Rijn, MD, PhD, Stanford University Medical Center, Stanford, CA
• Describe the development of several clinically relevant diagnostic and prognostic markers developed from high-throughput studies.
• Show the development of several therapeutic targets identified through expression profiling.
• Describe the use of paraffin embedded specimens as a source of DNA and RNA for high throughput analyses.

10:25 AM Break

10:45 AM Applications of Next Generation Sequencing in Molecular Oncology
Christopher L. Corless, MD, PhD, Oregon Health & Science University, Portland, OR
• Review examples of how massively parallel sequencing (next gen sequencing) is impacting clinical tumor genotyping.
• Be familiar with the platforms being used for next gen sequencing.
• Describe general approaches to library preparations for next gen sequencing.
• Understand the challenges in sequencing data analysis, assay validation, and results reporting.

11:30 AM The Evolving Role of Gene Fusions In Cancer Molecular Pathology
Frederic G. Barr, MD, PhD, National Cancer Institute, Bethesda, MD
• Summarize how recurrent chromosomal translocations and other chromosomal alterations generate fusion products in cancer.
• Compare and contrast the various methodologies by which these fusion products can be detected.
• Describe the neoplastic categories in which fusion products have been detected and the significance of these findings, including therapeutic implications.

12:15 PM Pancreatic Cancer 2013: Advances and Challenges
Anirban Maitra, MBBS, Johns Hopkins University School of Medicine, Baltimore, MD
• Understand the challenges associated with diagnosis and current treatment standards for pancreatic cancer.
• Learn about the advances made with sequencing of the pancreatic cancer genome and that of its precursor lesions.
• Understand the unique role that will be played by the community as they integrate histology with genomics based approaches in the diagnosis and therapeutic stratification of pancreatic neoplasia.

1:00 PM Concluding Remarks
SPECIAL COURSE
Basic Principles in Cytology
Tuesday, March 5, 2013
8:00 AM - 5:00 PM
CC 307/308

Course Director: Tarik M. Elsheikh, MD, Cleveland Clinic Foundation, Cleveland, OH

Course Description:
Cytology has grown to play a major role in tumor diagnosis. Surgical pathologists who may have had limited or no specialized training in cytology, are increasingly asked to render more definitive diagnoses based on small cytological samples, and/or provide immediate interpretations for radiology-guided FNA’s.

This special course emphasizes the essentials and basics of diagnostic cytology, and is intended for surgical pathologists who wish to be introduced or re-introduced to the discipline of cytology, or those who are interested in a “refresher” in general basic cytology. This course is also ideal for residents in training, and those preparing for boards or in-service exams. The faculty is made up of experts in the field, who will cover the most commonly encountered specimen types, including gynecologic, exfoliative, and FNA cytology. They will present detailed diagnostic criteria, adequacy requirements, differential diagnosis, and histopathologic correlation. Potential pitfalls, as well as the value of ancillary studies, including immunohistochemistry and molecular testing, will be discussed when relevant. There will be an ample opportunity for questions and audience participation. This course may also serve as an introduction to other cytology workshops or courses, which often tend to be of an advanced level, and more geared towards pathologists with strong cytology background.

The goals of this special course are for the participants to become less intimidated by cytologic samples, and more confidently diagnose commonly encountered lesions, and recognize potential limitations and pitfalls. All registrants will receive a detailed text syllabus, in addition to the PowerPoint lectures and images.

Upon completion of this course, participants should be able to:
• Review essentials and basics of diagnostic cytology, including gynecologic, exfoliative, and FNA cytology.
• Review detailed diagnostic criteria, adequacy requirements, and histologic correlation for different organ systems and specimen types, including normal cytology and more commonly encountered lesions.
• Recognize potential limitations, common pitfalls and differential diagnostic considerations.
• Appreciate the value of ancillary studies, including immunohistochemistry and molecular testing in the diagnostic workup.

8:00 AM Introduction
Tarik M. Elsheikh, MD, Cleveland Clinic Foundation, Cleveland, OH

8:20 AM Cervical Cytology
Fadi W. Abdul-Karim, MD, Cleveland Clinic, Cleveland, OH

Upon completion of this presentation, participants should be able to:
• Review the Bethesda System 2001: Adequacy and reporting of Pap test results.
• Recognize the commonly encountered infectious organisms, reactive changes, and contaminants.
• Recognize the cytologic criteria for squamous and glandular cell abnormalities, main mimickers and histopathologic correlates.
• Describe the utility of HPV testing in and ASCCP patient management guidelines.

9:10 AM Urine Cytology 101
Eva M. Wojcik, MD, Loyola University Medical Center, Maywood, IL

Upon completion of this presentation, participants should be able to:
• Present cellular and non-cellular components of normal urine specimens.
• Recognize the pitfalls and limitations of routine urine cytology.
• Explain the limitation of cytology/histology correlation.

9:45 AM Questions and Answers / Break

10:15 AM Effusion Cytology: A Practical Approach
Walid E. Khalbuss, MD, PhD, University of Pittsburgh Medical Center (UPMC)-Shadyside, Pittsburgh, PA

Upon completion of this presentation, participants should be able to:
• Differentiate reactive mesothelial cells from neoplastic cells in serous effusion specimens.
• Analyze and illustrate common potential diagnostic pitfalls, with a focus on a practical approach to making accurate diagnoses in fluid cytology
• Learn the appropriate use of ancillary studies including immunocytochemistry and other ancillary studies in the diagnostic workup of challenging cases in fluid cytology.
Thyroid Cytology: Another Look
Ritu Nayar, MD, Northwestern University Feinberg School/Medicine, Chicago, IL
Upon completion of this presentation, participants should be able to:
• Discuss and illustrate the basic concepts in thyroid cytomorphology.
• Generate a cytologic differential diagnosis with histologic correlation of commonly encountered thyroid lesions.
• Recognize the overlapping architectural and cytologic features of benign and malignant thyroid lesions.

Liver FNA – Basics and Beyond
Gladwyn Leiman, MD, University of Vermont, Burlington, VT
Upon completion of this presentation, participants should be able to:
• Identify all components of benign and reactive liver aspirates.
• Discuss indications and contra-indications to FNA.
• Diagnose common benign liver findings.
• Identify the features of common liver lesions, benign, and malignant.
• Recognize important less common liver tumors.
• Apply appropriate immunochemistry for diagnosis.

Questions and Answers / Lunch Break

Basic Principles of Pancreatic Aspiration Cytology
Barbara Centeno, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Upon completion of this presentation, participants should be able to:
• Recognize normal pancreatic acinar and ductal cells and contaminants from the stomach and duodenum, and distinguish these from lesional tissue.
• Recognize ductal adenocarcinoma and its variants and distinguish it from benign and reactive processes.
• Classify the criteria for the common nonductal neoplasms of the pancreas.
• Implement a practical approach to the cytological assessment of pancreatic cysts.

Lymph Node Cytopathology: A Practical Architectural Pattern Approach
Matthew A. Zarka, MD, Mayo Clinic Scottsdale, Scottsdale, AZ
Upon completion of this presentation, participants should be able to:
• Recognize the cytologic features of a benign lymph node including infectious and reactive conditions.
• Recognize and subclassify lymphoproliferative disorders, utilizing cytomorphologic patterns and ancillary techniques.
• Know the architectural patterns of metastatic lesions and common mimickers of lymphoproliferative disorders.

Questions and Answers / Break

Respiratory Cytopathology
Michael R. Henry, MD, Mayo Clinic, Rochester, MN
Upon completion of this presentation, participants should be able to:
• Recognize the types of respiratory cytology specimens and their normal constituents.
• Review the basic cytomorphologic criteria for common infectious processes and neoplasms seen in respiratory specimens.
• Discuss the pitfalls and mimics associated with primary lung malignancies.
• Review the utility of immunohistochemistry in the diagnosis and subclassification of non-small cell lung carcinoma.

Ancillary Testing, IHC and Molecular
Fernando Schmitt, MD, PhD, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal
Upon completion of this presentation, participants should be able to:
• Review the main principles and applications of ancillary techniques on cytological material.
• Recognize the advantages and disadvantages of the different pre-analytical variables for the application of ancillary techniques on cytology.
• Recognize the importance of immunocytochemistry and molecular techniques as adjuncts to morphology to achieve a precise diagnosis.
• Recognize the importance of immunocytochemistry and molecular techniques as adjuncts to morphology to study therapeutic targets.
• Discuss the different applications of ancillary techniques in primary and metastatic tumors sampled by fine-needle aspiration cytology.

Questions and Answers
EVENING SPECIALTY CONFERENCE

Dermatopathology Specialty Conference

My Biggest Mistake in Dermatopathology & How I Could Have Avoided It

Sunday, March 3, 2013
7:30 PM - 9:30 PM
CC Ballroom 3

Moderator: Mark Robert Wick, MD, University of Virginia Health System, Charlottesville, VA
Panelists: Lyn McDivitt Duncan, MD, Massachusetts General Hospital and Harvard Medical School, Boston, MA
David E. Elder, MB ChB, FRCPA, University of Pennsylvania, Philadelphia, PA
Bruce R. Smoller, MD, USCAP and Georgia Health Sciences University, Augusta, GA
Janis M. Taube, MD, The Johns Hopkins Hospital, Baltimore, MD

Please Note -
Prior to this Annual Meeting, slides and case histories for each of the Specialty Conferences will be posted on the USCAP website (www.uscap.org) so they may be reviewed in advance. In most instances there is a virtual slide for each case to be discussed.

Handouts for all Specialty Conferences will be available on the website the morning after the conference. Printed copies of the handout will not be available at the meeting.

EVENING SPECIALTY CONFERENCE

Genitourinary Pathology Specialty Conference

GU Spindle Cell Lesions

Sunday, March 3, 2013
7:30 PM - 9:30 PM
CC Ballroom 4

Moderators: John R. Srigley, MD, The Credit Valley Hospital, Mississauga, ON, Canada
Panelists: Michelle Hirsch, MD, PhD, Brigham & Women’s Hospital, Boston, MA
David Grignon, MD, Indiana University Health, Indianapolis, IN
Kiril Trpkov, MD, University of Calgary and Calgary Laboratory Services, Calgary, AB, Canada
Daniel M. Berney, FRCPat, Queen Mary, University of London, St. Bartholomew’s Hospital, London, United Kingdom

Please Note –
Prior to this Annual Meeting, slides and case histories for each of the Specialty Conferences will be posted on the USCAP website (www.uscap.org) so they may be reviewed in advance. In most instances there is a virtual slide for each case to be discussed.

Handouts for all Specialty Conferences will be available on the website the morning after the conference. Printed copies of the handout will not be available at the meeting.
EVENING SPECIALTY CONFERENCE

Housestaff Specialty Conference

*Boards Preparation: How and What To Study*

Sunday, March 3, 2013
7:30 PM - 9:30 PM
CC 316

**Moderators:**
Ann K. Folkins, MD, *Stanford University Medical Center, Stanford, CA*
Barbara McKenna, MD, *University of Michigan Hospital, Ann Arbor, MI*

**Panelists:**
Rebecca L. Johnson, MD, *The American Board of Pathology, Tampa, FL*
Mika Fujiwara, MD, *Stanford University Medical Center, Stanford, CA*

---

EVENING SPECIALTY CONFERENCE

Ophthalmic Pathology Specialty Conference

*Ophthalmic Pathology: A Spectrum of Interesting Cases*

Sunday, March 3, 2013
7:30 PM - 9:30 PM
CC 320

**Moderator:**
Thomas J. Cummings, MD, *Duke University Medical Center, Durham, NC*

**Panelists:**
Charleen Chu, MD, PhD, *University of Pittsburgh, Pittsburgh, PA*
Lynn Schoenfield, MD, *Cleveland Clinic, Cleveland, OH*
Neena M. Mirani, MD, *UMDNJ/University Hospital, Newark, NJ*
Alexandre N. Odashiro, MD, *McGill University, Montreal, QC, Canada*
Charles Eberhart, MD, PhD, *Johns Hopkins University/Medicine, Baltimore, MD*

**Please Note -**
Prior to this Annual Meeting, slides and case histories for each of the Specialty Conferences will be posted on the USCAP website (www.uscap.org) so they may be reviewed in advance. In most instances there is a virtual slide for each case to be discussed.

**Handouts for all Specialty Conferences will be available on the website the morning after the conference. Printed copies of the handout will not be available at the meeting.**
EVENING SPECIALTY CONFERENCE

Pediatric Pathology Specialty Conference

Non-Neoplastic Liver Disease in Pediatrics: Selected Topics

Sunday, March 3, 2013
7:30 PM - 9:30 PM
CC 309-310

Moderator: John Hicks, MD, Texas Children’s Hospital, Houston, TX

Panelists: Kevin E. Bove, MD, Cincinnati Children’s Hospital, Cincinnati, OH
Milton J. Finegold, MD, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX
Sarangarajan Ranganathan, MD, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA
Pierre Russo, MD, Children’s Hospital of Philadelphia, Philadelphia, PA

Please Note -
Prior to this Annual Meeting, slides and case histories for each of the Specialty Conferences will be posted on the USCAP website (www.uscap.org) so they may be reviewed in advance. In most instances there is a virtual slide for each case to be discussed.

Handouts for all Specialty Conferences will be available on the website the morning after the conference. Printed copies of the handout will not be available at the meeting.

---

EVENING SPECIALTY CONFERENCE

Bone & Soft Tissue Pathology Specialty Conference

The Marriage of Pathology and Genetics

Monday, March 4, 2013
7:30 PM - 9:30 PM
CC Ballroom 2

Moderator: Angelo P. Dei Tos, MD, General Hospital of Treviso, Treviso, Italy

Panelists: Jason L. Hornick, MD, PhD, Brigham & Women's Hospital, Boston, MA
Carrie Y. Inwards, MD, Mayo Clinic, Rochester, MN
Brian P. Rubin, MD, PhD, Cleveland Clinic, Cleveland, OH
Judith V.M.G. Bovee, MD, PhD, Leiden University Medical Center, Leiden, Netherlands
Julia A. Bridge, MD, University of Nebraska Medical Center, Omaha, NE

Please Note -
Prior to this Annual Meeting, slides and case histories for each of the Specialty Conferences will be posted on the USCAP website (www.uscap.org) so they may be reviewed in advance. In most instances there is a virtual slide for each case to be discussed.

Handouts for all Specialty Conferences will be available on the website the morning after the conference. Printed copies of the handout will not be available at the meeting.
EVENING SPECIALTY CONFERENCE
Cytopathology Specialty Conference

 Lessons Learned from a Mentor

Monday, March 4, 2013
7:30 PM - 9:30 PM
CC Ballroom 1

**Moderator:** Paul E. Wakely, Jr, MD, *The Ohio State University Medical Center, Columbus, OH*

**Panelists:**
- Susan J. Maygarden, MD, *University of North Carolina Chapel Hill, Chapel Hill, NC*
- Diane D. Davey, MD, *University of Central Florida College of Medicine, Orlando, FL*
- Tarik M. Elsheikh, MD, *Cleveland Clinic Foundation, Cleveland, OH*
- Zubair W. Baloch, MD, *University of Pennsylvania Medical Center, Philadelphia, PA*

**Please Note -**
Prior to this Annual Meeting, slides and case histories for each of the Specialty Conferences will be posted on the USCAP website (www.uscap.org) so they may be reviewed in advance. In most instances there is a virtual slide for each case to be discussed.

**Handouts for all Specialty Conferences will be available on the website the morning after the conference. Printed copies of the handout will not be available at the meeting.**

---

EVENING SPECIALTY CONFERENCE
Hematopathology Specialty Conference

*Pediatric Hematopathology*

Monday, March 4, 2013
7:30 PM - 9:30 PM
CC Ballroom 4

**Moderator:** Eric D. Hsi, MD, *Cleveland Clinic Foundation, Cleveland, OH*

**Panelists:**
- Robert Hasserjian, MD, *Massachusetts General Hospital, Boston, MA*
- Michele E. Paessler, DO, *Children’s Hospital of Philadelphia, PA*
- John Kim K. Choi, MD, PhD, *St. Jude Children’s Research Hospital, Memphis, TN*
- M. Kathryn Foucar, MD, *University of New Mexico, Albuquerque, NM*

**Please Note -**
Prior to this Annual Meeting, slides and case histories for each of the Specialty Conferences will be posted on the USCAP website (www.uscap.org) so they may be reviewed in advance. In most instances there is a virtual slide for each case to be discussed.

**Handouts for all Specialty Conferences will be available on the website the morning after the conference. Printed copies of the handout will not be available at the meeting.**
EVENING SPECIALTY CONFERENCE

Liver Pathology Specialty Conference

Liver Pathology Cases: Taming of an Arduous Terrain

Monday, March 4, 2013
7:30 PM - 9:30 PM
CC Ballroom 4

Moderator: Sanjay Kakar, MD, VA and University of California San Francisco, San Francisco, CA

Panelists: Rish K. Pai, MD, PhD, Cleveland Clinic Foundation, Cleveland, OH
Grace Kim, MD, University of California San Francisco, San Francisco, CA
Henry D. Appelman, MD, University of Michigan Medical Center, Ann Arbor, MI
Michael S. Torbenson, MD, The Johns Hopkins Hospital, Baltimore, MD

Please Note -
Prior to this Annual Meeting, slides and case histories for each of the Specialty Conferences will be posted on the USCAP website (www.uscap.org) so they may be reviewed in advance. In most instances there is a virtual slide for each case to be discussed.

Handouts for all Specialty Conferences will be available on the website the morning after the conference. Printed copies of the handout will not be available at the meeting.

EVENING SPECIALTY CONFERENCE

Cardiovascular Pathology Specialty Conference

Cardiac Surgical Specimen Gross Examination and Processing – Pitfalls and Perils

Tuesday, March 5, 2013
7:30 PM - 9:30 PM
CC 310

Moderator: John P. Veinot, MD, Ottawa Hospital, Ottawa, ON, Canada

Panelists: Gayle Winters, MD, Brigham & Women’s Hospital, Boston, MA
James R. Stone, MD, PhD, Massachusetts General Hospital, Boston, MA
Dylan V. Miller, MD, Intermountain Central Laboratory, Salt Lake City, UT
Gaetano Thiene, MD, University of Padua/Medical School, Padova, Italy

Please Note -
Prior to this Annual Meeting, slides and case histories for each of the Specialty Conferences will be posted on the USCAP website (www.uscap.org) so they may be reviewed in advance. In most instances there is a virtual slide for each case to be discussed.

Handouts for all Specialty Conferences will be available on the website the morning after the conference. Printed copies of the handout will not be available at the meeting.
EVENING SPECIALTY CONFERENCE

Neuropathology Specialty Conference

Lessons and Lesions from Peter Burger’s Notebook

Tuesday, March 5, 2013

7:30 PM - 9:30 PM

CC 309

Moderator: Daniel J. Brat, MD, PhD, Emory University School of Medicine, Atlanta, GA

Panelists: Ty Abel, MD, PhD, Vanderbilt University Medical Center, Nashville, TN
          Charles Eberhart, MD, PhD, The Johns Hopkins Hospital, Baltimore, MD
          Tarik Tihan, MD, University of California San Francisco, San Francisco, CA
          Gregory N. Fuller, MD, PhD, MD Anderson Cancer Center, Houston, TX
          Peter C. Burger, MD, The Johns Hopkins Hospital, Baltimore, MD

Please Note -
Prior to this Annual Meeting, slides and case histories for each of the Specialty Conferences will be posted on the USCAP website (www.uscap.org) so they may be reviewed in advance. In most instances there is a virtual slide for each case to be discussed.

Handouts for all Specialty Conferences will be available on the website the morning after the conference. Printed copies of the handout will not be available at the meeting.

EVENING SPECIALTY CONFERENCE

Surgical Pathology Specialty Conference

Interesting Surgical Pathology Cases

Tuesday, March 5, 2013

7:30 PM - 9:30 PM

CC Ballroom 1-4

Moderator: Pedram Argani, MD, The Johns Hopkins Hospital, Baltimore, MD

Panelists: David S. Klimstra, MD, Memorial Sloan Kettering Cancer Center, New York, NY
          Stuart J. Schnitt, MD, Beth Israel Deaconess Medical Center, Boston, MA
          Kathleen T. Montone, MD, Hospital of the University of Pennsylvania, Philadelphia, PA
          Victor E. Reuter, MD, Memorial Sloan-Kettering Cancer Center, New York, NY
          Christopher D.M. Fletcher, MD, FRCPath, Brigham & Women’s Hospital, Boston, MA

Please Note -
Prior to this Annual Meeting, slides and case histories for each of the Specialty Conferences will be posted on the USCAP website (www.uscap.org) so they may be reviewed in advance. In most instances there is a virtual slide for each case to be discussed.

Handouts for all Specialty Conferences will be available on the website the morning after the conference. Printed copies of the handout will not be available at the meeting.
EVENING SPECIALTY CONFERENCE

Breast Pathology Specialty Conference

*Diagnostic Dilemmas in Breast Pathology and How To Resolve Them*

Wednesday, March 6, 2013
7:30 PM - 9:30 PM
CC Ballroom 2

**Moderator:** Laura C. Collins, MBBS, *Beth Israel Deaconess Medical Center, Boston, MA*

**Panelists:**
- Donald L. Weaver, MD, *University of Vermont, Burlington, VT*
- Celina G. Kleer, MD, *University of Michigan Medical School, Ann Arbor, MI*
- Daniel Visscher, MD, *Mayo Clinic, Rochester, MN*
- Erinn P. Downs-Kelly, DO, *Cleveland Clinic, Cleveland, OH*
- Fattaneh A. Tavassoli, MD, *Yale University School of Medicine, New Haven, CT*

**Please Note -**
Prior to this Annual Meeting, slides and case histories for each of the Specialty Conferences will be posted on the USCAP website (www.uscap.org) so they may be reviewed in advance. In most instances there is a virtual slide for each case to be discussed.

Handouts for all Specialty Conferences will be available on the website the morning after the conference. Printed copies of the handout will not be available at the meeting.

---

EVENING SPECIALTY CONFERENCE

Gastrointestinal Pathology Specialty Conference

*Early Neoplasia of the GI Tract: Diagnostic Challenges and Clinical Implications*

Wednesday, March 6, 2013
7:30 PM - 9:30 PM
CC Ballroom 1

**Moderator:** Gregory Y. Lauwers, MD, *Massachusetts General Hospital, Boston, MA*

**Panelists:**
- Michael Vieth, MD, *Institut fur Pathologie, Klinikum Bayreuth, Germany*
- Elizabeth A. Montgomery, MD, *The Johns Hopkins University, Baltimore, MD*
- Fatima Carneiro, MD, PhD, *University of Porto, Portugal*
- Christophe Rosty, *University of Queensland, Australia*
- Kieran Sheahan, MBCh, *St. Vincent Hospital, Dublin, Ireland*

**Please Note -**
Prior to this Annual Meeting, slides and case histories for each of the Specialty Conferences will be posted on the USCAP website (www.uscap.org) so they may be reviewed in advance. In most instances there is a virtual slide for each case to be discussed.

Handouts for all Specialty Conferences will be available on the website the morning after the conference. Printed copies of the handout will not be available at the meeting.
EVENING SPECIALTY CONFERENCE

Infectious Disease Pathology Specialty Conference

Parasitic Infections: Typical and Atypical

Wednesday, March 6, 2013
7:30 PM - 9:30 PM
CC 310

Moderator: Danny A. Milner, MD, MSc, Brigham Women’s Hospital and Harvard Medical School, Boston, MA

Panelists: Bobbi S. Pritt, MD, Mayo Clinic, Rochester, MN
Dhanpat Jain, MD, Yale University School of Medicine, New Haven, CT
S. David Hudnall, MD, Yale University School of Medicine, New Haven, CT
Wun-Ju Shieh, MD, MPH, PhD, Centers for Disease Control and Prevention, Atlanta, GA
Danny A. Milner, MD, MSc, Brigham Women’s Hospital and Harvard Medical School, Boston, MA

Please Note -
Prior to this Annual Meeting, slides and case histories for each of the Specialty Conferences will be posted on the USCAP website (www.uscap.org) so they may be reviewed in advance. In most instances there is a virtual slide for each case to be discussed.

Handouts for all Specialty Conferences will be available on the website the morning after the conference. Printed copies of the handout will not be available at the meeting.

------------------------------------------------------------------------------------------------------------------
EVENING SPECIALTY CONFERENCE

Renal Pathology Specialty Conference

Important Take-Home Messages for Tomorrow's Signout

Wednesday, March 6, 2013
7:30 PM - 9:30 PM
CC 309

Moderator: Fred G. Silva, MD, NephroPath Inc, The University of Arkansas Medical Center, Little Rock, AR

Panelists: Agnes B. Fogo, MD, Vanderbilt University Medical Center, Nashville, TN
Vivette D. D’Agati, MD, Columbia University P&S, New York, NY
Arthur H. Cohen, MD, Cedars-Sinai Medical Center, Los Angeles, CA
Robert Colvin, MD, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Christopher Larsen, MD, NephroPath, Little Rock, AR

Please Note -
Prior to this Annual Meeting, slides and case histories for each of the Specialty Conferences will be posted on the USCAP website (www.uscap.org) so they may be reviewed in advance. In most instances there is a virtual slide for each case to be discussed.

Handouts for all Specialty Conferences will be available on the website the morning after the conference. Printed copies of the handout will not be available at the meeting.
EVENING SPECIALTY CONFERENCE
Gynecologic Pathology Specialty Conference

New Diagnoses Need New Approaches: A Glimpse into the Near Future of GYN Pathology

Thursday, March 7, 2013
7:30 PM - 9:30 PM
CC 307/308

Moderator: Richard J. Zaino, MD, M S Hershey Medical Center, Hershey, PA

Panelists: Christina S. Kong, MD, Stanford University School of Medicine, Stanford, CA
Anna Yemelyanova, MD, The Johns Hopkins University, Baltimore, MD
Michael H. Roh, MD, PhD, University of Michigan Medical School, Ann Arbor, MI
Joseph T. Rabban, MD, University of California San Francisco, San Francisco, CA

Please Note -
Prior to this Annual Meeting, slides and case histories for each of the Specialty Conferences will be posted on the USCAP website (www.uscap.org) so they may be reviewed in advance. In most instances there is a virtual slide for each case to be discussed.

Handouts for all Specialty Conferences will be available on the website the morning after the conference. Printed copies of the handout will not be available at the meeting.

EVENING SPECIALTY CONFERENCE
Head/Neck/Endocrine Pathology Specialty Conference

Challenging Diagnoses in Head and Neck, and Endocrine Pathology

Thursday, March 7, 2013
7:30 PM - 9:30 PM
CC 309

Moderator: Bruce M. Wenig, MD, Beth Israel Medical Center, New York, NY

Panelists: William C. Faquin, MD, PhD, Massachusetts General Hospital, Boston, MA
Edward B. Stelow, MD, University of Virginia Health System, Charlottesville, VA
Virginia A. LiVolsi, MD, University of Pennsylvania, Philadelphia, PA
William H. Westra, MD, The Johns Hopkins Hospital, Boston, MA

Please Note -
Prior to this Annual Meeting, slides and case histories for each of the Specialty Conferences will be posted on the USCAP website (www.uscap.org) so they may be reviewed in advance. In most instances there is a virtual slide for each case to be discussed.

Handouts for all Specialty Conferences will be available on the website the morning after the conference. Printed copies of the handout will not be available at the meeting.
EVENING SPECIALTY CONFERENCE

Pulmonary Pathology Specialty Conference

The Lung and Systemic Diseases

Thursday, March 7, 2013
7:30 PM - 9:30 PM
CC 310

Moderator:  Thomas V. Colby, MD, Mayo Clinic Arizona, Scottsdale, AZ

Panelists:  Henry D. Tazelaar, MD, Mayo Clinic Arizona, Scottsdale, AZ
Mari Mino-Kenudson, MD, Massachusetts General Hospital, Boston, MA
Alain Borczuk, MD, Columbia University Medical Center, New York, NY
Teri J. Franks, MD, Joint Center for Pathology, Silver Springs, MD
Kevin O. Leslie, MD, Mayo Clinic Arizona, Scottsdale, AZ

Please Note -
Prior to this Annual Meeting, slides and case histories for each of the Specialty Conferences will be posted on the USCAP website (www.uscap.org) so they may be reviewed in advance. In most instances there is a virtual slide for each case to be discussed.

Handouts for all Specialty Conferences will be available on the website the morning after the conference. Printed copies of the handout will not be available at the meeting.
Too many great presentations to take in?

Relax. Purchase these courses, as presented at the Annual Meeting, online.

Short Course 02: Proteomics for Pathologists
Short Course 16: Thyroid FNA: Using the Bethesda System
Short Course 17: Difficult Diagnoses in Endocrine Pathology
Short Course 21: Biopsy Pathology/GI Neoplasia
Short Course 22: Modern Prostate Needle Biopsy Interpretation
Short Course 51: Infectious Disease Pathology
Short Course 54: Non-neoplastic Surgical Neuropathology
Short Course 57: Ophthalmic Pathology
Short Course 58: Diffuse Lung Disease
Short Course 60: Lean Quality Improvement
Short Course 61: Transplant Pathology of Solid Organs
Long Course: Soft Tissue Tumors
Special Course: A Practical Guide to Molecular Testing in Cancer (2013)
Special Course: Advanced Molecular Pathology (2013)
Special Course: Basic Principles in Cytology (2013)

Enjoy these courses on your schedule. Go to www.uscap.org and click on the eAcademy.
You’ll feel better in the morning.

These courses will appear online within 30 days after the Annual Meeting

THE SYMPTOM
Doctor wants to be in two places at one time

THE DIAGNOSIS
Stress due to too many Annual Meeting activities

THE CURE
The eAcademy found at www.USCAP.org

THE eAcADeMY
ONLINE LEARNING AT YOUR FINGERTIPS

UNITED STATES & CANADIAN ACADEMY OF PATHOLOGY
LEADING PATHOLOGY EDUCATIONAL EXCELLENCE

3643 Walton Way Extension | Augusta, GA 30909 | (706) 733-7550 | www.uscap.org
HERE’S THE LONG AND THE SHORT OF IT: THERE ARE 61 SHORT COURSES AND 1 LONG COURSE AVAILABLE THIS WEEK. ALL OFFER THE OPPORTUNITY TO ADD TO YOUR MOC CREDITS.

The topic of the Long Course this year is Soft Tissue Tumors — A Modern, Integrated and Practical Approach to Diagnosis and Classification. Led by Course Directors Drs. Christopher Fletcher and Cristina Antonescu, the long course provides an in-depth review in biology and disease and bridges them with the practical needs of hospital-based pathologists.

Our 61 Short Courses are a series of half-day events conducted by educators, selected and rotated, to present “state-of-the-art” concepts on timely aspects of the many sub-disciplines of pathology. The objectives of these courses are: to update basic science information and concepts, to provide an understanding of current techniques and procedures that relate to pathology, and foremost, to broaden the professional competency of attendees.

Short Courses are three hours each in duration and are presented on Wednesday, Thursday and Friday, in the morning and the afternoon.

Wednesday courses are scheduled from 8:00 AM – 12:00 PM and from 1:30 – 5:30 PM. 
*An hour break is included in each session to allow for poster viewing.*

Thursday and Friday courses are scheduled from 8:00 – 11:30 AM and from 1:00 – 4:30 PM. 
*A half hour break is included in each session.*

Both Long and Short Courses may be used as Self-Assessment Module (SAM) credits toward satisfying the American Board of Pathology requirements for SAM Maintenance of Certification (MOC). Successful completion of a post-test is required to earn SAM credits.

In keeping with the Short Course rotation policy, certain courses will not be offered after the 2013 meeting. This information is noted in the Program Book’s Short Course Daily Schedules. Courses which are new for 2013 are also identified.

**SPECIAL NOTE**
Some Short Courses have virtual slides or digital images and case histories for advance study. These study sets are available online. Registrants have received an email instructing them on how to access the online materials from the USCAP web site. After the meeting, all registrants will be sent an email containing instructions on how to access their short course materials on the USCAP web site to view or keep for their future reference.
There have been huge advances in our understanding of soft tissue tumors since the last USCAP Long Course on this topic in 1995 – including clinicopathologic characterization of many new entities, major revisions of the classification, introduction of many new immunohistochemical reagents of daily utility and, most especially, recognition of the molecular genetic basis of many of these lesions, bringing not only pathogenetic insights but also a range of valuable new diagnostic tools. This year’s lecture topics seek to address this broad spectrum of new information, focusing on areas of direct practical relevance to general surgical pathologists. The topics to be discussed and the learning objectives for each lecture are listed below.

8:00 AM  Introduction
Christopher D.M. Fletcher, MD, FRCPath, Brigham & Women’s Hospital and Harvard Medical School, Boston, MA
Cristina R. Antonescu, MD, Memorial Sloan-Kettering Cancer Center, New York, NY

8:05 PM  Gastrointestinal Stromal Tumors – What Do We Know Now?
Christopher L. Corless, MD, PhD, Oregon Health & Science University, Portland, OR

Upon completion of this presentation, participants should be able to:
• Describe the key morphologic and immunohistochemical features of GISTs.
• Understand the molecular subclassification of GISTs and its relevance to the use of tyrosine kinase inhibitor therapies.
• Identify mechanisms of resistance to tyrosine kinase inhibitor therapies.

8:40 AM  Smooth Muscle Tumors of Soft Tissue and Non-Uterine Viscera – Biology and Prognosis
Markku M. Miettinen, MD, National Cancer Institute/NIH, Bethesda, MD

Upon completion of this presentation, participants should be able to:
• Describe the histologic features of peripheral and visceral, non-uterine smooth muscle tumors.
• Describe the immunophenotype of smooth muscle tumors.
• Describe the differential diagnosis of smooth muscle tumors.

9:15 AM  Questions and Discussions

9:20 AM  Coffee Break and Poster Viewing

11:00 AM  Malignant Vascular Tumors – An Update
Cristina R. Antonescu, MD, Memorial Sloan-Kettering Cancer Center, New York, NY

Upon completion of this presentation, participants should be able to:
• Provide an update on the latest classification of malignant vascular tumors and the recent genetic discoveries.
• Discuss the differential diagnosis of epithelioid vascular neoplasms and the use of molecular markers in challenging cases.
• Describe the heterogeneity of angiosarcomas, morphologic and genetic spectrum, based on their anatomic location and prior history of radiation.

11:35 AM  An Approach to Pleomorphic Sarcomas: Can We Subclassify and Does It Even Matter
John R. Goldblum, MD, Cleveland Clinic, Lerner College of Medicine, Cleveland, OH

Upon completion of this presentation, participants should be able to:
• Describe the differential diagnosis of a pleomorphic (“MFH-like”) malignant neoplasm.
• Discuss the clinical significance of distinguishing among these pleomorphic sarcomas.
• Discuss the utility of ancillary techniques in the workup of a pleomorphic malignant neoplasm, including distinguishing among the various pleomorphic sarcomas.

12:10 PM  Questions and Discussions

12:15 PM  Lunch

1:30 PM  Novel Uses of Immunohistochemistry in the Diagnosis and Classification of Soft Tissue Tumors
Jason L. Hornick, MD, PhD, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA

Upon completion of this presentation, participants should be able to:
• Discuss the limitations of conventional diagnostic markers for soft tissue tumors.
• Describe the recently developed immunohistochemical markers for soft tissue tumors.
• Explain the application of novel markers in differential diagnosis of soft tissue tumors.
2:05 PM  The Differential Diagnosis of Epithelioid Soft Tissue Tumors
Andrew L. Folpe, MD, Mayo Clinic, Rochester, MN

Upon completion of this presentation, participants should be able to:
• Generate a comprehensive differential diagnosis for epithelioid soft tissue tumors, including both common and less-common entities.
• Apply appropriate ancillary immunohistochemical and molecular tests for this differential diagnosis.
• Appreciate the impact of advances in molecular pathology to the correct classification of epithelioid soft tissue tumors.

2:40 PM  Questions and Discussions

2:45 PM  Coffee Break and Poster Viewing

4:00 PM  The Role of Cytogenetics and Molecular Diagnostics in the Diagnosis of Soft Tissue Tumors
Julia A. Bridge, MD, University of Nebraska Medical Center, Omaha, NE

Upon completion of this presentation, participants should be able to:
• Describe the role of molecular markers in the diagnostic classification and management of soft tissue tumors.
• Recognize the advantages and limitations of molecular approaches commonly used in the classification of mesenchymal neoplasms.
• Apply clinicohistopathologic and molecular criteria for selecting appropriate and cost-effective testing for the workup of soft tissue tumors.

4:35 PM  Recently Characterized Soft Tissue Tumors Which Bring Biologic Insight
Christopher D.M. Fletcher, MD, FRCPath, Brigham & Women’s Hospital and Harvard Medical School, Boston, MA

Upon completion of this presentation, participants should be able to:
• Recognize a variety of recently characterized soft tissue tumors.
• Summarize the role of cytogenetics and molecular genetics in helping to define ‘entities’ and in influencing classification schemes.
• Describe how accurate diagnosis of newer ‘entities’ may influence treatment selection

5:10 PM  Questions and Closing Remarks
Christopher D.M. Fletcher, MD, FRCPath, Brigham & Women’s Hospital and Harvard Medical School, Boston, MA
Cristina R. Antonescu, MD, Memorial Sloan-Kettering Cancer Center, New York, NY
A coffee break is scheduled for 9:30 – 10:30 AM to allow time for viewing posters.

* indicates this is a new course
++ indicates this is an ending course

04 Diagnostic Problems in Vulvar Pathology*
Mai P. Hoang, MD, Massachusetts General Hospital, Boston, MA
Maria Angelica Selim, MD, Duke University Medical Center, Durham, NC

05 Cases and Controversies in Inflammatory Bowel Disease*
Scott R. Owens, MD, University of Michigan, Ann Arbor, MI
Leslie B. Aldrich, MD, University of Michigan, Ann Arbor, MI

11 Emerging Issues in Pulmonary Pathology*
Mary Beth Beasley, MD, Mount Sinai Medical Center, New York, NY
Sanja Dacic, MD, PhD, University of Pittsburgh, Pittsburgh, PA

23 Interventional Pathologists' Role in USFNA & Core Biopsy*
David K. Lieu MD, MBA, FNA Medical Group, Alhambra, CA
Mai Gu, MD, PhD, University of California, Irvine, CA

25 Diagnosis of Gestational Trophoblastic Diseases in the Molecular Era*
Brigitte M. Ronnett, MD, Johns Hopkins Hospital, Baltimore, MD
Pei Hui, MD, PhD, Yale University School of Medicine, New Haven, CT

26 Non-Neoplastic Hematopathology*
Robert P. Hasserjian, MD, Massachusetts General Hospital, Boston, MA
Laurence de Leval, MD, PhD, University of Lausanne, Lausanne, Switzerland
Judith Ferry, MD, Massachusetts General Hospital, Boston, MA

56 Salivary Gland Pathology at the Intersection of Histopathologic Criteria and Clinical Relevance*
Bruce M. Wenig, MD, Beth Israel Medical Center and St. Luke's Roosevelt Hospitals, New York, NY
Joaquin J. Garcia, MD, Mayo Clinic, Rochester, MN
Kerry D. Olsen, MD, Mayo Clinic, Rochester, MN

63 A Morphology Guide To Unwind Common Overlapping Patterns in Genitourinary Tumors*
Gladell P. Paner, MD, University of Chicago, Chicago, IL
Rafael E. Jimenez, MD, Mayo Clinic, Rochester, MN
A coffee break is scheduled for 3:00 – 4:00 PM to allow time for viewing posters.

* indicates this is a new course
++ indicates this is an ending course

18 Modern Approach to the Diagnosis of Neoplastic Splenic Disorders*
Daniel A. Arber, MD, Stanford University, Stanford, CA
Attilio Orazi, MD, FRCPath, Weill Medical College/Cornell University, New York, NY

19 Practical Cardiovascular Pathology*
William D. Edwards, MD, Mayo Clinic, Rochester, MN
Joseph J. Maleszewski, MD, Mayo Clinic, Rochester, MN

30 Head & Neck Lesions at the Interface of Benign and Malignant*
Jennifer L. Hunt, MD, University of Arkansas for Medical Sciences, Little Rock, AR
Ilan Weinreb, MD, University Health Network, Toronto, ON, Canada
Bayardo Perez-Ordonez, MD, University Health Network, Toronto, ON, Canada

33 Bone Marrow Assessment of Cytopenic Patients*
Sa A. Wang, MD, University of Texas MD Anderson Cancer Center, Houston, TX
Robert P. Hasserjian, MD, Massachusetts General Hospital, Boston, MA

34 Utility and Pitfalls of Immunohistochemistry in the Daily Diagnosis of Gynecologic Pathology*
Carmen Tornos, MD, Stony Brook University Medical Center, Stony Brook, NY
Esther Oliva, MD, Massachusetts General Hospital, Boston, MA

38 Ten Diagnoses in Breast Pathology You Cannot Afford to Miss*
Geza Acs, MD, PhD, Moffitt Cancer Center, Tampa, FL
Gelareh Farshid, MBBS, MD, SA Pathology, BreastScreen SA, Adelaide, South Australia
Thomas J. Lawton, MD, Seattle Breast Pathology Consultants, Seattle, WA

40 Situational Awareness on the Melanocytic Battlefield*
May P. Chan, MD, University of Michigan, Ann Arbor, MI
Steven R. Tahan, MD, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
Alireza Sepehr, MD, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

50 Clinically Relevant Challenges in GI Neoplasia*
Wendy L. Frankel, MD, Ohio State University, Columbus, OH
Kisha Mitchell, MD, Yale University School of Medicine, New Haven, CT
Mark Bloomston, MD, Ohio State University Medical Center, Columbus, OH
SHORT COURSES – THURSDAY MORNING
Thursday, March 7, 2013
8:00 – 11:30 AM

Room locations are printed on the Short Course Ticket

A coffee break is scheduled for 9:30 – 10:30 AM to allow time for viewing posters.

* indicates this is a new course
++ indicates this is an ending course

06 Common Challenging Problems in Bone and Soft Tissue Pathology*
Andrew L. Folpe, MD, Mayo Clinic, Rochester, MN
Andrew E. Horvai, MD, PhD, University of California, San Francisco, CA

10 Practice of Breast Pathology in 2013 and Beyond
Aysegul A. Sahin, MD, MD The University of Texas MD Anderson Cancer Center, Houston, TX
Lavinia P. Middleton, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

20 Dermatopathology Greatest Hits
May P. Chan, MD, University of Michigan, Ann Arbor, MI
Rajiv M. Patel, MD, University of Michigan, Ann Arbor, MI
Alexandra Hristov, MD, University of Michigan, Ann Arbor, MI

29 Practical Issues in the Diagnosis, Staging and Reporting of Prostatic Adenocarcinoma++
Lawrence D. True, MD, University of Washington, Seattle, WA
Jesse K. McKenney, MD, Cleveland Clinic, Cleveland, OH

31 Endocervical Glandular Lesions of the Female Genital Tract
Teri A. Longacre, MD, Stanford University School of Medicine, Stanford, CA
Christina S. Kong, MD, Stanford University School of Medicine, Stanford, CA
Kristen A. Atkins, MD, University of Virginia, Charlottesville, VA

37 Diagnostic Issues in Pediatric Brain Tumors – ABC’s for Sorting Out the Routine and the “Zebras”*
Christine E. Fuller, MD, Virginia Commonwealth University, Richmond, VA
Adekunle M. Adesina, MD, PhD, Baylor College of Medicine, Texas Children's Hospital, Houston, TX

42 Hepatocellular Neoplasms*
Sanjay Kakar, MD, University of California San Francisco, San Francisco, CA
Michael S. Torbenson, MD, The Johns Hopkins Hospital, Baltimore, MD

48 Mediastinal Tumors
Saul M. Suster, MD, The Medical College of Wisconsin, Milwaukee, WI
Cesar A. Moran, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

49 Diagnostic Hematopathology – A Roadmap for Surgical Pathologists++
Steven H. Swerdlow, MD, University of Pittsburgh School of Medicine, Pittsburgh, PA
Marsha C. Kinney, MD, University of Texas Health Science Center, San Antonio, TX
James R. Cook, MD, PhD, Cleveland Clinic, Cleveland, OH

52 Of Critical Value: Management and Leadership Skills for the Anatomic Pathologist
Michael L. Talbert, MD, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Lewis A. Hassell, MD, University of Oklahoma Health Sciences Center, Oklahoma City, OK

55 Tubulointerstitial and Vascular Diseases of the Kidney
Samih H. Nasr, MD, Mayo Clinic, Rochester, MN
Christopher Larsen, MD, NephroPath, Little Rock, AR
Patrick D. Walker, MD, NephroPath, Little Rock, AR

59 Frozen Section Diagnostic Pitfalls & Pearls in Head & Neck Pathology*
Qihui (Jim) Zhai, MD, Mayo Clinic, Jacksonville, FL
Yash J. Patil, MD, University of Cincinnati, Cincinnati, OH

62 Algorithmic Approach to Diagnosis of Inflammatory Disorders of the Gastrointestinal Tract*
Gregory Y. Lauwers, MD, Massachusetts General Hospital, Boston, MA
Amitabh Srivastava, MBBS, Brigham and Women's Hospital, Boston, MA
Robert D. Odze, MD, Brigham & Women's Hospital, Boston, MA
SHORT COURSES – THURSDAY AFTERNOON
Thursday, March 7, 2013
1:00 – 4:30 PM

Room locations are printed on the Short Course Ticket

A coffee break is scheduled for 3:00 – 4:00 PM to allow time for viewing posters.

* indicates this is a new course
++ indicates this is an ending course

07 Core Needle Biopsy of the Breast
Laura C. Collins, MBBS, Beth Israel Deaconess Medical Center, Boston, MA
Edi Brogi, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY

08 The Nine Things You Need to Know about Bone Pathology Before Signing Your Report*
Michael J. Klein, MD, The Hospital for Special Surgery, New York, NY
Meera R. Hameed, MD, Memorial Sloan-Kettering Cancer Center, New York, NY

12 Surgical Pathology of Blood Vessels
J. Charles Jennette, MD, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC

15 Pancreaticobiliary Cytology with Clinical, Endoscopic Ultrasound and Histologic Correlation
Tyler M. Berzin, MD, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
Helen H. Wang, MD, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

21 Biopsy Pathology of Gastrointestinal Neoplasia**
Thomas P. Plesec, MD, Cleveland Clinic Foundation, Cleveland, OH
John R. Goldblum, MD, Cleveland Clinic Foundation, Cleveland, OH
Ana E. Bennett, MD, Cleveland Clinic Foundation, Cleveland, OH

27 An Algorithmic Approach to the Diagnosis of Tumors and Tumor-Like Lesions of the Urinary Bladder
Donna E. Hansel, MD, PhD, The Cleveland Clinic, Cleveland, OH
Mahul B. Amin, MD, Cedars-Sinai Medical Center, Los Angeles, CA

35 Diagnostic Immunohistochemistry: Plagued with Potential Problems but Pregnant with Possibilities
Allen M. Gown, MD, PhenoPath Laboratories, Seattle, WA

36 Germ Cell Tumors, Sex Cord-Stromal Tumors and Other Non-Epithelial Tumors of the Ovary**
Charles Zaloudek, MD, University of California San Francisco, San Francisco, CA
Joseph T. Rabban, MD, University of California San Francisco, San Francisco, CA
Glenn W. McCluggage, FRCPath, The Royal Hospitals, Belfast, United Kingdom

41 Pattern-Based Algorithms in Diagnostic Liver Pathology
Romil Saxena, MD, Indiana University School of Medicine, Indianapolis, IN
Neil D. Theise, MD, Beth Israel Medical Center, New York, NY

43 Impact of Personalized Medicine on the Practice of Hematopathology*
Megan S. Lim, MD, PhD, University of Michigan, Ann Arbor, MI
Adam Bagg, MD, University of Pennsylvania, Philadelphia, PA
Kojo S. J. Elentob-Johnson, MD, University of Michigan, Ann Arbor, MI

44 Practical Placental Pathology**
Cynthia G. Kaplan, MD, State University of New York at Stony Brook, Stony Brook, NY
Rebecca N. Baergen, MD, New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY

47 Glomerular Diseases
Mark Haas, MD, PhD, Cedars-Sinai Medical Center, Los Angeles, CA
Anthony Chang, MD, University of Chicago Medical Center, Chicago, IL

54 A Practical Approach to Non-Neoplastic Surgical Neuropathology**
Richard A. Prayson, MD, Cleveland Clinic Foundation, Cleveland, OH
Bette K. Kleinschmidt-Demasters, MD, University of Colorado at Denver and Health Sciences Center, Aurora, CO
SHORT COURSES – FRIDAY MORNING

Friday, March 8, 2013
8:00 – 11:30 AM

A coffee break is scheduled for 9:30 – 10:30 AM to allow time for viewing posters.

* indicates this is a new course
++ indicates this is an ending course

03 Common Dilemmas in Breast Pathology
Ian O. Ellis, MBBS, FRCPath, Nottingham City Hospital, Nottingham, UK
Sunil S. Badve, MD, FRCPath, Indiana University, Indianapolis, IN
Jorge S. Reis-Filho, MD, PhD, FRCPath, The Breakthrough Breast Cancer Research Centre, London, UK

14 The Diagnosis of Mediastinal Lesions by EBUS-FNA and EUS-FNA
Sara E. Monaco, MD, University of Pittsburgh Medical Center, Pittsburgh, PA
Walid E. Khalbuss, MD, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA

22 Modern Prostate Needle Biopsy Interpretation++
Peter A. Humphrey, MD, PhD, Washington University Medical Center, St Louis, MO
Samson W. Fine, MD, Memorial Sloan Kettering Cancer Center, New York, NY

24 Classification and Prognostication of Mesenchymal Tumors of the Gastrointestinal Tract with Emphasis on Immunohistochemical and Molecular Markers
Brian P. Rubin, MD, PhD, Cleveland Clinic, Cleveland, OH
Jason L. Hornick, MD, PhD, Brigham & Women’s Hospital, Boston, MA

32 How To Diagnose Clinically Relevant High Risk Gynecologic Precancerous Lesions
George L. Mutter, MD, Harvard Medical School and Brigham & Women’s Hospital, Boston, MA
Marisa R. Nucci, MD, Harvard Medical School and Brigham & Women’s Hospital, Boston, MA

39 The Interpretation of the Medical Liver Biopsy
Rish K. Pai, MD, PhD, Cleveland Clinic Foundation, Cleveland, OH
David S. Barnes, MD, Cleveland Clinic Foundation, Cleveland, OH
Lisa M. Yerian, MD, Cleveland Clinic Foundation, Cleveland, OH

45 Systems Pathology: An Introduction to Omic Approaches in Modern Personalized Pathology
Michael H. Roehrl, MD, PhD, Boston Medical Center, Chestnut Hill, MA
Sylvia L. Asa, MD, University Health Network, Toronto, ON, Canada
Massimo F. Loda, MD, Dana Farber Cancer Institute, Boston, MA

46 Neuropathology After Dark: Surviving Intraoperative Frozen Section Consultation
Gregory N. Fuller, MD, PhD, MD Anderson Cancer Center, Houston, TX
Christine E. Fuller, MD, Virginia Commonwealth University, Richmond, VA

51 Infectious Disease Pathology++
Danny A. Milner, MD, Brigham & Women’s Hospital, Boston, MA
Laura W. Lamps, MD, University of Arkansas for Medical Sciences, Little Rock, AR

57 Ophthalmic Pathology++
Michele M. Bloomer, MD, University of California San Francisco, San Francisco, CA
Patricia Chevez-Barrios, MD, The Methodist Hospital, Houston, TX
Thomas J. Cummings, MD, Duke University Medical Center, Durham, NC

58 Diffuse Lung Disease++
Henry D. Tazelaar, MD, Mayo Clinic, Scottsdale, AZ,
Marie Christine Aubry, MD, Mayo Clinic, Rochester, MN

60 Lean Quality Improvement++
Maxwell L. Smith, MD, Mayo Clinic, Scottsdale, AZ
Stephen S. Raab, MD, Eastern Health, Denver, CO

61 Transplant Pathology of Solid Organs++
Rene P. Michel, MD, McGill University, Montreal, QC, Canada
Chantal Bernard, MD, McGill University, Montreal, QC, Canada
SHORT COURSES – FRIDAY AFTERNOON
Friday, March 8, 2013
1:00 – 4:30 PM

Room locations are printed on the Short Course Ticket

A coffee break is scheduled for 3:00 – 4:00 PM to allow time for viewing posters.

* indicates this is a new course
++ indicates this is an ending course

02 Proteomics for Pathologists++
Megan S. Lim, MD, PhD, University of Michigan, Ann Arbor, MI
Kojo S. J. Elenitoba-Johnson, MD, University of Michigan, Ann Arbor, MI
Ahmet Dogan, MD, PhD, Mayo Clinic, Rochester, MN

09 Integrating Morphology and Molecular Techniques in Breast Pathology++
Stuart J. Schnitt, MD, Beth Israel Deaconess Medical Center, Boston, MA
Jennifer L. Hunt, MD, University of Arkansas for Medical Sciences, Little Rock, AR

16 Thyroid FNA: Using the Bethesda System Category Definitions and Terminology++
Edmund S. Cibas, MD, Brigham & Women’s Hospital and Harvard Medical School, Boston, MA
William C. Faquin, MD, PhD, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Edward B. Stelow, MD, University of Virginia Health System, Charlottesville, VA

17 Difficult Diagnoses in Endocrine Pathology++
Richardo V. Lloyd, MD, PhD, University of Wisconsin School of Medicine & Public Health, Madison, WI
Lori A. Erickson, MD, Mayo Clinic, Rochester, MN

28 Renal Tumors in Adults
Priya Rao, MD, The University of Texas MD Anderson Cancer Center, Houston, TX
Pheroze Tamboli, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX

53 Diagnoses and Dilemmas in Pancreaticobiliary Pathology++
Alyssa M. Krasinskas, MD, University of Pittsburgh Medical Center, Pittsburgh, PA
Susan C. Abraham, MD, The University of Texas-MD Anderson Cancer Center, Houston, TX
INVEST
SUSTAIN
ADVANCE

A Tradition of Giving…
Leaving a Legacy of
Excellence in Pathology

The role of the USCAP Foundation is to support the mission of the USCAP through fundraising focused on education and research that will benefit the field of pathology and ultimately the patients we serve.

www.uscap.org

United States & Canadian Academy of Pathology Foundation
WOW, ARE WE EXCITED ABOUT THESE TWO GREAT LECTURES AND THEIR PRESENTERS!

The first lecture, the *Nathan Kaufman Timely Topics Lecture*, is a plenary lecture concerning a major area of scientific interest and concern to pathologists.

This year, we welcome Dr. Christopher P. Crum, Division Chief, Women’s and Perinatal Pathology at Brigham and Women’s Hospital, a teaching hospital of Harvard Medical School. Dr. Crum is a world authority on the pathology of the female genital tract. His presentation is entitled *Through the Glass Darkly: Highways and Byways to Gynecologic Cancer*.

**Date:** Monday, March 4  
**Time:** 4:30 – 5:30 PM  
**Location:** CC Ballroom 1-4

The second lecture, the *Maude Abbott Lecture* is a prestigious, scholarly, scientific lecture presented by a recognized person in contemporary pathology who has contributed to the advancement of pathology in the areas of teaching, research or practice. This lectureship was established in memory of Maude Abbott, a founding member and the initial secretary of the Academy for 33 years.

This year’s speaker is Dr. Victor E. Reuter the Vice Chairman of the Department of Pathology at the Memorial Sloan-Kettering Cancer Center. His specialty is genitourinary pathology and the title of his presentation is *Grawitz Tumor: Clearly an Evolutionary Tale*.

**Date:** Tuesday, March 5  
**Time:** 5:00 – 5:50 PM  
**Location:** CC Ballroom 1-4

You won’t want to miss either of these lecturers, so be sure to schedule both on your Annual Meeting App. Not utilizing the Meeting App? It’s the easiest way to organize your meeting schedule! Download it now at: [www.tripbuilder.com/uscap2013apps](http://www.tripbuilder.com/uscap2013apps).
Dr. Christopher P. Crum was born in Newport News, Virginia and received his undergraduate and medical school education at the University of Virginia. Following a medical internship at Medical University of South Carolina, he returned to University of Virginia for his pathology residency. In 1979 he accepted a gynecologic pathology fellowship with Ralph Richart (known for the CIN classification) at Columbia Presbyterian Hospital in New York. He developed expertise in clinical colposcopy and supervised the clinic at Columbia from 1981 to 1987, at which point he began to study the pathology of genital human papillomaviruses. In 1983 he collaborated with Richart and Lutz Gissman in Harold zur Hausen’s lab in publishing the first detailed account of the histology of HPV 16 infections in the cervix, joining others in revolutionizing the concept of cervical cancer pathogenesis. Inspired by the impact of this investigation, Dr. Crum joined Saul Silverstein’s lab at Columbia in order to develop skills in molecular biology. This collaboration resulted in series of papers describing the molecular pathology of HPV in the cervix. Crum received a Physician Scientist Award in 1987 returned to University of Virginia where he accepted a joint appointment in Pathology, Microbiology and Obstetrics and Gynecology.

In 1990 he was recruited by Ramzi Cotran to succeed Shirley Driscoll as Director of Women’s and Perinatal Pathology at Brigham and Women’s Hospital, a teaching hospital of Harvard Medical School. BWH’s Women’s and Perinatal division is one of the largest subspecialty units of its type in the United States with a tradition dating back to the Boston Hospital for Women. In collaboration with George Mutter at BWH, Crum described monoclonal early precursors to HPV negative vulvar cancers, promoting the concept that early genetic changes could occur in the absence of both HPV and morphologic atypia. Later reports from these authors corroborated other works implicating mutations in p53 with the HPV-negative vulvar precursor pathway. In 1998 Crum initiated what would become a longstanding collaboration with Frank McKeon at Harvard Medical School. They were the first to map p63 expression in the female genital tract. A proposed model, in which reserve cells of the cervix and endometrium could be manufactured in the adult, came directly from this work. When McKeon’s group linked residual embryonic cells in the esophageal squamo-columnar junction to Barrett’s metaplasia in 2011, Crum, McKeon, Wa Xian, and Michael Herfs, discovered a similar embryonic population in the cervix and proposed these cells as the origin of cervical cancer. A series of papers followed proposing the mechanism by which cancer prone Mullerian cells persist, are infected by HPV, and undergo trans-differentiation to form a multiplicity of precursor types seen with HPV infection. The implications are profound: that site of origin has an enormous influence on cancer risk in the cervix might explain the disproportionate risk of cervical versus vaginal cancer, why some low grade precursors progress while others do not, and why ablation of the squamo columnar junction has been so successful in preventing recurrences.

In 2005 Crum diverted from studying the cervix to pursue a hypothesis proposed earlier by Piek and others that the fallopian tube was responsible for some ovarian cancers. He developed a protocol for detailed histologic evaluation of the fimbria (SEE-FIM) in women with BRCA1 mutations, identified serous tubal intraepithelial carcinomas (STICs) in their distal fallopian tubes, and established this region as the source of a significant percentage of pelvic serous cancers, both in women with and without genetic (BRCA) risk factors. These findings have initiated a paradigm shift in ovarian cancer research and have been corroborated in numerous studies by Crum and others. In 2007, Crum worked with Yonghee Lee, a visiting fellow from Korea, and collaborators at the Dana Farber Cancer Institute, to isolate a putative precursor to serous cancer in the tube, termed the p53 signature, and confirmed its relationship to malignancy. Crum’s group then described a serous carcinogenic sequence in the tube in which these latent precursors could evolve into malignancies. This powerful link between the fallopian tube and serous carcinogenesis has not gone unnoticed by authorities on ovarian cancer prevention, leading to new research initiatives from the NIH and Department of Defense as well as proposals to explore opportunistic salpingectomy as an ovarian cancer preventive.

Crum and colleagues McKeon and Xian have recently pursued the hypothesis that specialized cells exist in the oviduct that give rise to serous cancer. Towards this end they have discovered unique proliferations in the tube termed secretory cell outgrowths (SCOUTs). They believe SCOUTs, like p53 signatures, are emblematic of the expansion potential of resident precursor stem cells. Dovetailing this work with cell culture and recognizing the potential parallels between the unique tissue interfaces in the fimbria and cervix, they are narrowing the search for a putative cell of origin. This work will be discussed in the 2013 Nathan Kaufman Timely Topics Lecture.

Dr. Crum has published more than 300 articles and three books, including a major textbook, Diagnostic Gynecologic and Obstetric Pathology. He is a world authority on the pathology of the female genital tract. He has trained innumerable residents and fellows and has lectured widely over the past 30 years, embracing interactive and novel visual formats to enhance learning. Crum’s philosophy is that meaningful discoveries in the field must always be validated from multiple perspectives. The microscope remains a critical tool because a minute biologic event visible only “through the glass” might hold the key to cancer discovery and prevention. Crum is quick to note that the opportunity to make such discoveries exists today and every day and that the future will become the past in short order. As a famous movie star once said, “time starts now!”
Dr. Victor E. Reuter was born in Mayaguez, Puerto Rico and attended the University of Puerto Rico, obtaining his BS in Biology. He received his MD from the University National Pedro Henriquez Ureña, Santo Domingo, Dominican Republic. After a flexible internship in Danbury Hospital (Danbury, Connecticut) he served as a Resident in Anatomic and Clinical Pathology at Thomas Jefferson University Hospital/Philadelphia. In 1983-1984 Victor served as a Clinical Fellow (American Cancer Society Fellow in Anatomic Pathology) at Memorial Sloan-Kettering Cancer Center (MSKCC), NYC, NY. He was selected as Chief Fellow in the Department of Pathology there to serve the following year and has remained at that great institution ever since.

He has risen through the ranks in the Department of Pathology at Memorial Hospital becoming Attending Pathologist and Member in the late 1990’s. Dr. Reuter has served in a great many prominent positions at MSKCC including Chairman of the Pathology Tissue Research Utilization Committee, President of the Memorial Sloan-Kettering Cancer Center Alumni Society, Director of the Immunohistochemistry Research Core Laboratory and Genitourinary Pathology Research Laboratory, and President of the MSKCC Medical Staff from 2001-2003. In 2000 he became Acting Chief of the Surgical Pathology Service as MSKCC and now serves as Vice Chairman of the Department of Pathology (since 2005). He is a Professor of Pathology at the Weill Medical College of Cornell University. He serves as the Leader of the Genitourinary Pathology Team at Memorial as well as Director of the Genitourinary Pathology Subspecialty Fellowship that has existed uninterrupted at his institution since 1991. Dr. Reuter has received multiple Pathology Fellows Education Awards.

Dr. Reuter is an internationally renowned and respected anatomic pathologist, with subspecialty expertise in genitourinary pathology. His contributions to literature span the entire spectrum of urologic tumors. He serves, or has served, on many Editorial Boards including Modern Pathology, The American Journal of Surgical Pathology, Journal of Urologic Pathology, Urologic Oncology, Journal of Clinical Oncology, Molecular Pathology, Annals of Diagnostic Pathology and Advances in Anatomic Pathology. Dr. Reuter has over 420 peer-reviewed journal publications and has authored over 24 book chapters. Dr. Reuter is a very sought-after expert and lecturer in the field of GU Pathology, participating in over 70 regional/national/international meetings in the last 12 years, and more than 70 invited Lectures/Lectureships throughout the world in the last 12 years. He served on the Scientific Advisory Board of the AFIP. He presently serves as Co-Director of the Pathology Core of the NIH/NCI sponsored SPORE in Prostate Cancer at MSKCC. He is Chairman of the Oversight Committee of the Pathology Research Core of his institution’s NIH/NCI sponsored Cancer Center Support Grant. He is a Committee Member for the American Urological Association, PGC-Follow-up for Renal Malignancies, and Co-Chair of the NCI Kidney Cancer Clinical Trials Task Force. His Institution has served as a major contributor to the NIH sponsored Cancer Genome Atlas and Dr. Reuter serves on the data analysis group for both bladder and kidney carcinoma.

Dr. Reuter has served the United States and Canadian Academy of Pathology in many capacities. From 1998 to 2003, Dr. Reuter was President of the Education Committee. He subsequently served on Council and the Executive Committee. Dr. Reuter was President of the USCAP from 2008 to 2009. In 2007 he was the recipient of the F.K. Mostofi Distinguished Service award. He is presently Vice President for North America of the International Academy of Pathology.
102nd
USCAP
ANNUAL
MEETING
Better pathology starts here.

Your learning doesn’t end with this meeting.

Clinical and translational research
Hundreds of original papers
Monthly subscriptions
Print or Online

Your USCAP membership includes a free journal subscription

United States & Canadian Academy of Pathology
LEADING PATHOLOGY EDUCATIONAL EXCELLENCE

www.uscap.org
AWARDS

ABOUT THIS SECTION

Every year we take great delight in recognizing our colleagues who have distinguished themselves through their work in pathology. From new doctors achieving a first time award like the Ramzi Cotran Young Investigator Award or a Master Teacher celebrating their years of achievement, please join us on Tuesday, March 5 in the Convention Center’s Ballrooms 1 thru 4 — immediately following the Business Meeting — as we recognize their contributions to our profession and the world of medicine.
Dr. Krishnan Unni was born and raised in Kerala, India. He received his medical degree at the All India Institute of Medical Sciences in 1962. He then came to the United States and continued his training at Memorial Hospital in Worcester, MA, after which he did a fellowship in pathology at Mayo Graduate School in Rochester, MN. Following his training in 1970, he returned to India. By 1973, he had returned to Rochester, MN and joined the staff at Mayo Clinic. He trained extensively under Dr. David Dahlin and after Dr. Dahlin’s retirement, continued to build on the collection of bone tumors started by his mentor. He became a Professor of both Pathology and Orthopedics. After more than 30 years, he retired from Mayo Clinic at the end of 2006. He is currently working at the Medical College of Wisconsin in Milwaukee, WI.

Mayo Graduate School/University of Minnesota
Pathology – Examining Member
New Delhi, India
House Job – Surgery 1964-1965
Memorial Hospital, Massachusetts 1965-1967
Mayo Clinic – Consultant in Pathology 1974-2006
Mayo Medical School – Instructor in Pathology 1974-1978
Mayo Medical School – Assistant Professor of Pathology 1978-1981
Mayo Medical School – Associate Professor of Pathology 1981-1987
Mayo Medical School – Professor of Pathology 1987-2006
Mayo Clinic – Consultant in Orthopedics 1991-2006
Mayo Medical School – Professor of Orthopedics 1992-2006
Mayo Medical School – Professor Emeritus of Orthopedics 2007 – Present
Mayo Medical School – Professor Emeritus of Orthopedics 2007 – Present
Medical College of Wisconsin – Consultant in Pathology

THE HARVEY GOLDMAN MASTER TEACHER Awardee

The Harvey-Goldman Distinguished Teaching and Mentoring Award was established in 2011 as a tribute to honor a dedicated, long-standing educator and mentor, Dr. Harvey Goldman, in order to recognize his seminal contributions to the USCAP post-graduate educational and mentoring activities.

2013

Sharon K. Weiss, MD

Award Presentation at Business Meeting

3:30 – 5:00 PM – Tuesday, March 5, 2013
CC Ballroom 1-4

A native of Lynn, Massachusetts, Dr. Weiss earned her BA from Wellesley College and her MD from the Johns Hopkins School of Medicine. Following housestaff training at the Johns Hopkins Hospital and a brief tenure on the faculty, she joined the staff of the Armed Forces Institute of Pathology (AFIP), eventually becoming the Chair of the Department of Soft Tissue Pathology. During those 13 formative years at the AFIP, she co-authored with Franz Enzinger the now iconic textbook, *Soft Tissue Tumors*, soon to be issued in its 6th edition with co-authors, Drs. John Goldblum and Andrew Folpe. Subsequent academic appointments included the A. J. French Professor and Director of Anatomic Pathology at the University of Michigan and Professor and Vice Chair of Pathology at Emory University. She currently divides her time at Emory between Department of Pathology and the School of Medicine where she is the Associate Dean for Faculty Affairs.

Over her career she has published extensively and lectured widely on all aspects of soft tissue tumors. She has given generously of her time in many key leadership positions including Chair of the World Health Organization Committee for the Classification of Soft Tissue Tumors, President of International Society of Bone and Soft Tissue Tumors, and most recently Trustee and Vice President of the American Board of Pathology for which she also chairs the Maintenance of Certification Committee. Her honors include: Phi Beta Kappa, Alpha Omega Alpha, Alumnae Achievement Award (Wellesley College), and the Society of Scholars (Johns Hopkins University).

As a former President of the USCAP, her career has been emblematic of her devotion to our organization, especially its educational programs. She has served on the Education Committee, Council, and editorial board of *Modern Pathology* and directed several courses including a short course with Dr. Franz Enzinger, the 1995 Long Course “Soft Tissue Tumors” with Dr. Jack Brooks, “Diagnostic Pathology” with Dr. Richard Kempson, and a Special Course, “Navigating the Academic Waters,” with Dr. Peter Jensen. One of her most impressive magisterial accomplishments, however, was the 2001 Maude Abbott Lecture, for which she received a standing ovation. Dr. Weiss’s educational impact has also been affirmed by the countless residents and fellows she has trained over the past three decades. Many, especially her soft tissue fellows, hold important positions and have received prestigious honors in their own right.

Says Dr. Weiss, “Harvey was a brilliant pathologist, teacher, and friend who was endowed with kindness and great wit. To receive this award in his name is a singular honor.”
John Reid Goldblum was born and raised in Pittsburgh, Pennsylvania, before moving to the University of Michigan in Ann Arbor, Michigan, where he received his B.S. and medical degree and then pursued an anatomic pathology residency and surgical pathology fellowship at the University of Michigan. Having been strongly influenced by Drs. Henry Appelman and Sharon Weiss, he focused his training in the areas of gastrointestinal and soft tissue pathology and joined the Department of Anatomic Pathology at the Cleveland Clinic in 1993, where he has been ever since.

In 2002, Dr. Goldblum became Chairman of the Department of Anatomic Pathology. At that time, there were fewer than 16 staff members, but the department has grown to over 40 anatomic pathologists that handle over 115,000 surgical pathology specimens and over 80,000 cytology specimens. Under Dr. Goldblum’s guidance, the department transformed to a completely subspecialized department in 2004. Aside from continuing to develop his own expertise in GI and soft tissue pathology, Dr. Goldblum has focused his professional efforts on developing the subspecialty model and mentoring junior faculty to successful academic careers.

He has co-authored over 270 publications, mostly in the areas of GI and soft tissue pathology and was asked by his mentor, Dr. Sharon Weiss, to co-author Enzinger and Weiss’s Soft Tissue Tumors, 4th and 5th editions. With Drs. Andrew Folpe and Sharon Weiss, he recently completed the 6th edition of this textbook, which will be published in 2014. In addition, he has served as co-editor with Dr. Robert Odze on two editions of the textbook ‘Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas,’ and he and Dr. Odze recently finished editing the 3rd edition of this textbook, which will be published in 2014. He also serves as the Series Editor of the highly successful Foundations in Diagnostic Pathology series, a compilation of books covering virtually all areas of surgical pathology, now in their 2nd edition. More recently, he has served as Series Editor for a new series of surgical pathology books entitled “Surgical Pathology Clinics,” which provide up-to-date summaries on cutting-edge topics in surgical pathology. He has been an active member of the editorial boards for a number of pathology journals, including the American Journal of Surgical Pathology, Human Pathology and has served as President of the Gastrointestinal Pathology Society and Arthur Purdy Strout Society of Surgical Pathologists.

Dr. Goldblum is also a renowned educator and has served as faculty for many years at the ASCP, including a presentation of the ASCP Anatomic Pathology Seminar at the 2009 annual meeting and serving as faculty for the CAP, being the recipient of the 2012 CAP Excellence in Teaching Award. However, Dr. Goldblum would consider his most important contributions to the area of pathology education to be his involvement with the USCAP.

Dr. Goldblum has been a member of the Education Committee for 14 consecutive years, serving as a member, short course coordinator and chair, for which he finished his sixth year at this annual meeting. He has had the privilege to learn from his prior Education Committee chairs, Dr. Jeffrey Myers and Dr. Victor Reuter, worked closely with many members of the USCAP team, including Kerry Crockett and with the two Executive Vice Presidents to which he has served, Dr. Fred Silva and Dr. Bruce Smoller. Dr. Goldblum has provided four separate USCAP short courses, has been moderator and presenter at both the GI and soft tissue Evening Specialty Conferences, served as faculty for two separate long courses (GI and soft tissue), directed the highly successful USCAP Practical Pathology Seminars course since its inception, and served as Diagnostic Pathology faculty for eight consecutive years, teaching both GI and soft tissue pathology. He has been an active member for the Academy’s long-term strategic planning initiative and has served as a member of the Innovative Education Products Committee since its inception.

On a personal note, Dr. Goldblum is an avid work-out fanatic, loves Bruce Springsteen (69 concerts) and prides himself on knowing completely useless movie and television trivia. Given that “The Wire” is his favorite show of all-time, he is particularly pleased to be in Baltimore for the annual meeting. Of course, Dr. Goldblum’s most important achievement has been his marriage to his wife of 22 years, Asmita, and successfully raising four fantastic children, Andrew (21), Ryan (19), Janavi (15) and Raedan (12). He wishes to thank all of them for their incredible support and patience in pursuing his professional goals, which include his service to the USCAP.
Jean was born in Oklahoma City, very near to where her future husband, Fred, had been born a couple of years earlier, but they did not meet until 1969 when Fred was a sophomore at The University of Oklahoma Medical School. Jean was working for The Massachusetts Life Insurance Company and living with her sister who was a physical therapy student, also at OU. Being bored one night (and maybe for other reasons also), she went with her sister to the Medical School Library. Fred was there, studying for – of all things – a Pathology test!! Having a great eye, he spotted Jean there and asked a mutual friend to introduce them. When the library closed, the mutual friend, the sister, Fred and Jean went out to get a beer. The rest is history. Fred passed the Pathology test and he passed the “Jean test”. They celebrated their 40th wedding anniversary last year.

Jean is the third of nine children. She grew up in Bartlesville, Oklahoma. She was a student at Ursuline Academy (a Catholic boarding school in Paola, Kansas) for three out of her four years of High School. She graduated from St. Gregory’s Junior College in Shawnee, Oklahoma with an Associates Degree in Arts and Sciences in 1969. Later she earned a certificate for computer programming and computer operating. She remembers handling computer discs that were about the size of a tire!

After marrying Fred and moving to New York City, Jean worked as a medical receptionist then a medical secretary at The Columbia-Presbyterian Medical Center. In 1981, now living in Dallas where Fred was Chief of Surgical Pathology, their daughter, Lindsay, was born. When Lindsay was one and a half years old, she began attending St. Alcuin Montessori School and Jean became an active parent volunteer. Volunteering has been her chief occupation since that time.

The first time she volunteered at the USCAP was in the mid 1980’s. Fred was the Course Director for the USCAP’s new Diagnostic Pathology course, which was holding its first meeting at Dartmouth. Jean was recruited by JoAnn Johnson to help put 2x2’s into plastic sleeves – part of the course material for the participants. Thus, when Fred became the Executive Vice-President of the USCAP in 1999 and Jean gave up her volunteer job as cafeteria lady at Lindsay’s high school because Lindsay had graduated and gone off to college, it was almost a given that she would look for something else to do to help out at the Academy. She was shown all the archival photographs and other historical memorabilia that had been collected at the home office in Augusta, Georgia and stored in boxes and cupboards. No one had the time to organize it. Jean did! She found it very interesting and enjoyed sorting through it, labeling and dating everything, and putting the photographs into albums. This activity lead to an even bigger project, “The Hall of Presidents” for both the IAP and the USCAP. With a huge amount of help from Fred and from many Pathology Departments around the world, photographs, academic records and career achievements were gathered for each of the presidents of the IAP and the USCAP since its beginnings in 1906 by Maude Abbott. Abstract-sized posters were made by Laura McKie from the graphics department at The Medical College of Georgia. She commented that this was the most interesting project she had ever worked on. Jean definitely agreed! The Hall of Presidents was completed in time for its first display at the 100th meeting of the IAP in Montreal in 2006. Since then it has been shown at several other USCAP meetings, including its 100th meeting in San Antonio in 2011. Like many other things these days, The Hall of Presidents is now in the process of being digitalized. (See the USCAP Website.)

For many years between 1999 and 2011 Jean enjoyed being the unofficial photographer at the various receptions and events held at the USCAP meetings. She took thousands of “party pics” which were put up on the website (with permission, of course). “May I take your picture for the website?”

Besides volunteering at the USCAP office, Jean was also active in her church. She became involved with Child Enrichment, Inc., a child advocacy center for abused, abandoned and neglected children in Augusta, Georgia. Visiting and playing with the children who were living in their shelter was one of her most rewarding activities. After the shelter was closed by the state, Jean was instrumental in converting their unused space into a Children’s Clothes Closet. Working with Child Enrichment, Inc. and with other volunteers from her Church, she collected donations of clothing, shoes, toiletries and other items. A system was set up so that any foster parent in a three county area could request clothing for their foster children (some who came into the foster system with nothing but what they were wearing). From a very small beginning, this Clothes Closet continues to grow. It had an inventory of over 25,000 items when she stepped down as its manager in 2010, and it has become an important and much welcomed service for foster parents and others who are in need. It now benefits hundreds of children each year. In appreciation of her dedication and service, Jean received the Volunteer of the Year Award from Child Enrichment in 2009.

Besides her volunteer work, Jean enjoys reading, walking, gardening, Words With Friends and talking with her friends and family. She is continuing all of these activities in Little Rock, Arkansas where she and Fred moved when he stepped down as EVP of the USCAP in 2011.
Dr. Celina G. Kleer is the Harold A. Oberman Collegiate Professor of Pathology at the University of Michigan Medical School. She received her medical degree from the University of Buenos Aires School of Medicine in Buenos Aires, Argentina in 1993, at the age of 22. During medical school Dr. Kleer worked in the Histology Department as an instructor, and in the laboratory of Dr. Pellegrino de Iraldi, a scientist at the University of Buenos Aires. After graduating from medical school, Dr. Kleer came to the US with the goal of making important contributions to medicine. She began her residency in Anatomic and Clinical Pathology at the Mayo Clinic in Rochester, Minnesota in 1994, and completed her training in anatomic and clinical pathology at the University of Michigan School of Medicine in 1999.

During residency, Dr. Kleer was fortunate to train with distinguished pathologists who became instrumental in guiding her career. These included Drs. Harold Oberman and Henry Appelman, who not only taught her surgical pathology but showed her the joy of teaching, loyalty, and ethics. During the last year of training, Dr. Kleer served as a surgical pathology fellow with special emphasis in breast pathology, under the mentorship of Dr. Oberman. As a resident, Dr. Kleer received numerous awards including the M.R. Abell House Officer Award and the Arthur Purdy Stout Fellowship. The latter enabled her to spend three months in the laboratory of Dr. Maria Merino at the National Cancer Institute, who sparked her interest in cancer biology. Her passion for understanding how cancer begins and progresses was enhanced by her further training in the laboratory of Dr. Sofia Merajver at the University of Michigan Cancer Center. In Dr. Merajver’s lab, Dr. Kleer investigated the molecular biology of inflammatory breast cancer, the most lethal form of locally advanced breast cancer. After finishing residency, Dr. Kleer went on to join the Department of Pathology at the University of Michigan as an Assistant Professor in July 1999. She was promoted to Associate Professor with tenure in 2005 and, more recently to full Professor, in 2011. In 2007 she had the privilege of being endowed with the Harold A. Oberman Collegiate Professorship of Pathology.

Dr. Kleer is a physician scientist. She is an active academic surgical pathologist and the Principal Investigator of an R01 funded laboratory that studies breast cancer. Her scientific career is dedicated towards a better understanding of the fundamental mechanisms enabling cancer cells to invade and metastasize, and the discovery of novel biomarkers for this malignancy. Her work bridges clinical and basic science research. She has authored or co-authored 111 peer-reviewed publications largely in the field of breast cancer.

One major contribution of Dr. Kleer’s research efforts has centered on the discovery that epigenetic regulators of cellular transcriptional memory are directly linked to malignant transformation of the breast epithelium. A series of publications from her laboratory has delineated the functional consequences and the underlying mechanisms of EZH2 overexpression and downregulation in breast cancer. Dr. Kleer’s laboratory has found that EZH2 protein expression can predict survival in patients with breast cancer. In recent years, her laboratory has developed the only mouse model of EZH2 overexpression targeted to the mammary gland, and has made the seminal observation that EZH2 controls the intracellular localization and function of the tumor suppressor BRCA1 in triple negative breast cancer. Her laboratory has discovered that EZH2 regulates breast cancer stem cells through a new mechanism of action. Dr. Kleer’s work has paved the way for the potential utility of EZH2 as a biomarker of increased breast cancer risk, and for the development of targeted therapies based on EZH2. Indeed, the latter are now becoming available for clinical use.

Another major contribution of Dr. Kleer’s research program has been the study of the molecular determinants of inflammatory and metastatic breast cancer through the characterization of a tumor suppressor gene, CCN6 (also called WISP3). This work has led to the discovery that CCN6 is an important regulator of epithelial cell polarity in the breast and functions to maintain normal acinar organization with normal E-cadherin localization and function. Upon CCN6 loss there is disruption of normal tissue architecture, and increased cell motility and tissue invasion through mechanisms which involve the epithelial-to-mesenchymal transition transition transcription factors Snail1 and ZEB1. Dr. Kleer’s work has established CCN6 as a novel tumor suppressor gene, which may lead to improvement in the treatment of women with inflammatory and metastatic breast cancer. Dr. Kleer’s contributions to advance breast cancer research were recognized by being invited to join the Tumor Progression and Metastasis Study Section of the National Institutes of Health for a four year term.

In addition to her devotion to research, Dr. Kleer is a dedicated breast pathologist at the University of Michigan Medical School, where she has been the Director of the Breast Pathology Service since 2002. She strives to provide the best possible patient care, signing out in-house as well as consultation cases from the US and abroad. She enjoys working as a team member at the University of Michigan Breast Oncology Program alongside fabulous clinicians including surgical, medical, and radiation oncologists. Dr. Kleer mentors pathology residents and fellows, medical students as well as post-doctoral fellows, graduate and undergraduate students. One of her major contributions to education has been the initiation of a Breast Pathology Subspecialty Training at the University of Michigan in 2002. She has been a member of the United States & Canadian Academy of Pathology Education Committee (2008-2012) and has been a moderator of breast pathology platform sessions for several years. Dr. Kleer has been a member of the editorial board of the American Journal of Pathology since 2009, an Associate Editor of BMC Cancer since 2010, and is a Section Editor of Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms. She has been invited as a Visiting Professor nationally and internationally to lecture on both clinical breast pathology and her breast cancer research work. Dr. Kleer’s goal is to improve the lives of women with breast cancer through clinical and research work, and by inspiring young trainees to pursue a career in academic surgical pathology.

Dr. Kleer is married to Eduardo, and they have two children, Gabriel and Sophia. She is honored to be presented with the 2013 Ramzi Cotran Young Investigator Award.
RECOGNITION AWARDS – 2013

By action of Council, a Recognition Award was established to acknowledge services of individuals who have completed elective or appointive positions. The following individuals are to be honored for terms of service ending in 2012.

**PRESIDENT**
Gregory N. Fuller

**COUNCIL**
Frederic G. Barr  
John N. Eble  
Laura W. Lamps

**EDUCATION COMMITTEE**
Tarik Tihan, Director, CME Subcommittee  
Robert Hasserjian  
Celina Kleer  
Qihui (Jim) Zhai

**LONG COURSE DIRECTORS**
Steven H. Swerdlow  
Elias Campo

**SPECIALTY CONFERENCE MODERATORS**
Jagdish Butany  
Adam Bagg  
Jennifer Hunt  
Suzanne Powell  
Jeanette Guarner  
Kenneth Batts  
David Parham  
Mark Haas  
Henry Appleman

**SHORT COURSE FACULTY**

Daniel A. Arber  
Sylvia L. Asa  
Zubar W. Baloch  
Mary Beth Beasley  
Andrew M. Bellizzi  
Steven D. Billings  
Thomas Brenn  
Russell R. Broaddus  
Jagdish Butany  
Christopher P. Crum  
Sanja Dacic  
Laila Dahmoush  
Andrea T. Deyrup  
William D. Edwards  
Wendy L. Frankel  
Michael Gilcrease  
John R. Goldblum  
Jeffrey C. Goldsmith  
Stanley R. Hamilton  
Eric D. Hsi  
Rana S. Hoda  
Syed A. Hoda  
Jason Hornick  
Serge Jothy  
Joseph Khoury

Scott E. Kilpatrick  
Alexander Lazar  
Virginia A. LiVolsi  
L. Jeffrey Medeiros  
Dylan Miller  
Elizabeth A. Montgomery  
Robert M. Najarian  
Yaso Natkunam  
Dennis P. O’Malley  
Attilio Orazi  
David Parham  
Victor G. Prieto  
Jon A. Reed  
Robert Robinson  
Andrew E. Rosenberg  
J. Jordi Rowe  
Alan L. Schiller  
Christopher R. Shea  
John Sinard  
John P. Veinot  
Steven D. Vincent  
Ximing J. Yang  
George M. Yousef  
Qihui (Jim) Zhai
## Past United States & Canadian Academy of Pathology Award Recipients

### Maude Abbott Lecturers

<table>
<thead>
<tr>
<th>Year</th>
<th>Lecturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>1958</td>
<td>E. Uehlinger</td>
</tr>
<tr>
<td>1959</td>
<td>Charles V. Harrison</td>
</tr>
<tr>
<td>1960</td>
<td>John N.P. Davies</td>
</tr>
<tr>
<td>1961</td>
<td>Niels Dungal</td>
</tr>
<tr>
<td>1962</td>
<td>Isaac Costero</td>
</tr>
<tr>
<td>1963</td>
<td>M. El Gazayerli</td>
</tr>
<tr>
<td>1964</td>
<td>V. Ramalingaswami</td>
</tr>
<tr>
<td>1965</td>
<td>James F. Murray</td>
</tr>
<tr>
<td>1966</td>
<td>Nils Ringertz</td>
</tr>
<tr>
<td>1967</td>
<td>Henry Ungar</td>
</tr>
<tr>
<td>1968</td>
<td>Herwig Hamperl</td>
</tr>
<tr>
<td>1969</td>
<td>Tomizo Yoshida</td>
</tr>
<tr>
<td>1970</td>
<td>Pelayo Correa</td>
</tr>
<tr>
<td>1971</td>
<td>Harold L. Stewart</td>
</tr>
<tr>
<td>1972</td>
<td>Benjamin Castleman</td>
</tr>
<tr>
<td>1973</td>
<td>Chapman H. Binford</td>
</tr>
<tr>
<td>1974</td>
<td>Edward A. Gall</td>
</tr>
<tr>
<td>1975</td>
<td>John Higginson</td>
</tr>
<tr>
<td>1976</td>
<td>Vincent J. McGovern</td>
</tr>
<tr>
<td>1977</td>
<td>Michael S.R. Hutt</td>
</tr>
<tr>
<td>1978</td>
<td>Erkki A. Saxen</td>
</tr>
<tr>
<td>1979</td>
<td>F.K. Mostofi</td>
</tr>
<tr>
<td>1980</td>
<td>Walter Sandritter</td>
</tr>
<tr>
<td>1981</td>
<td>Lauren V. Ackerman</td>
</tr>
<tr>
<td>1982</td>
<td>Raffaele Lattes</td>
</tr>
<tr>
<td>1983</td>
<td>Robert H. Heptinstall</td>
</tr>
<tr>
<td>1984</td>
<td>William Christopherson</td>
</tr>
<tr>
<td>1985</td>
<td>Kenneth M. Brinkhous</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year</th>
<th>Lecturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>1986</td>
<td>Paul E. Lacy</td>
</tr>
<tr>
<td>1987</td>
<td>Emmanuel Farber</td>
</tr>
<tr>
<td>1988</td>
<td>Marilyn G. Farquhar</td>
</tr>
<tr>
<td>1989</td>
<td>Leopold G. Koss</td>
</tr>
<tr>
<td>1990</td>
<td>Emanuel Rubin</td>
</tr>
<tr>
<td>1991</td>
<td>Guido Majno</td>
</tr>
<tr>
<td>1992</td>
<td>Robert E. Scully</td>
</tr>
<tr>
<td>1993</td>
<td>Ronald F. Dorfman</td>
</tr>
<tr>
<td>1994</td>
<td>Morris Karnovsky</td>
</tr>
<tr>
<td>1995</td>
<td>Juan Rosai</td>
</tr>
<tr>
<td>1996</td>
<td>Ramzi S. Cotran</td>
</tr>
<tr>
<td>1997</td>
<td>Charles S. Hirsch</td>
</tr>
<tr>
<td>1998</td>
<td>Louis P. Dehner</td>
</tr>
<tr>
<td>1999</td>
<td>Richard Kempson</td>
</tr>
<tr>
<td>2000</td>
<td>Rodger Haggitt</td>
</tr>
<tr>
<td>2001</td>
<td>Sharon Weiss</td>
</tr>
<tr>
<td>2002</td>
<td>Peter Isaacson</td>
</tr>
<tr>
<td>2003</td>
<td>James R. Downing</td>
</tr>
<tr>
<td>2004</td>
<td>J. Aiden Carney</td>
</tr>
<tr>
<td>2005</td>
<td>David L. Page</td>
</tr>
<tr>
<td>2006</td>
<td>Anna-Luise Katzenstein</td>
</tr>
<tr>
<td>2007</td>
<td>Virginia A. LiVolsi</td>
</tr>
<tr>
<td>2008</td>
<td>Christopher D.M. Fletcher</td>
</tr>
<tr>
<td>2009</td>
<td>Michael Gimbrone</td>
</tr>
<tr>
<td>2010</td>
<td>Henry Appelman</td>
</tr>
<tr>
<td>2011</td>
<td>Elaine S. Jaffe</td>
</tr>
<tr>
<td>2012</td>
<td>Robert J. Kurman</td>
</tr>
<tr>
<td>2013</td>
<td>Victor E. Reuter</td>
</tr>
</tbody>
</table>

### Nathan Kaufman Timely Topics Lecturers

<table>
<thead>
<tr>
<th>Year</th>
<th>Lecturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>1983</td>
<td>Edwin Ewing &amp; Thomas Spira</td>
</tr>
<tr>
<td>1984</td>
<td>Arthur Upton &amp; Robert Squire</td>
</tr>
<tr>
<td>1985</td>
<td>Robert Leader</td>
</tr>
<tr>
<td>1986</td>
<td>James W. Curran</td>
</tr>
<tr>
<td>1987</td>
<td>Ronald Weinstein</td>
</tr>
<tr>
<td>1988</td>
<td>Cecilia Fenoglio-Preiser</td>
</tr>
<tr>
<td>1989</td>
<td>Jay A. Levy</td>
</tr>
<tr>
<td>1990</td>
<td>Philip Leder</td>
</tr>
<tr>
<td>1991</td>
<td>Stanley Cohen</td>
</tr>
<tr>
<td>1992</td>
<td>W. French Anderson</td>
</tr>
<tr>
<td>1993</td>
<td>Judah Folkman</td>
</tr>
<tr>
<td>1994</td>
<td>Francis Collins</td>
</tr>
<tr>
<td>1995</td>
<td>Eric J. Stanbridge</td>
</tr>
<tr>
<td>1996</td>
<td>Anthony Epstein</td>
</tr>
<tr>
<td>1997</td>
<td>Raymond L. White</td>
</tr>
<tr>
<td>1998</td>
<td>David Korn</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year</th>
<th>Lecturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>Anthony S. Fauci</td>
</tr>
<tr>
<td>2000</td>
<td>Peter M. Howley</td>
</tr>
<tr>
<td>2001</td>
<td>James Madara</td>
</tr>
<tr>
<td>2002</td>
<td>Lance Liotta</td>
</tr>
<tr>
<td>2003</td>
<td>Irving L. Weissman</td>
</tr>
<tr>
<td>2004</td>
<td>David H. Walker</td>
</tr>
<tr>
<td>2005</td>
<td>Phillip Sharp</td>
</tr>
<tr>
<td>2006</td>
<td>Tyler Jacks</td>
</tr>
<tr>
<td>2007</td>
<td>Steven L. Kunkel</td>
</tr>
<tr>
<td>2008</td>
<td>Frank McKeon</td>
</tr>
<tr>
<td>2009</td>
<td>Todd Golub</td>
</tr>
<tr>
<td>2010</td>
<td>Anthony Atala</td>
</tr>
<tr>
<td>2011</td>
<td>Guillermo J. Tearney</td>
</tr>
<tr>
<td>2012</td>
<td>Bogdan A. Czerniak</td>
</tr>
<tr>
<td>2013</td>
<td>Christopher P. Crum</td>
</tr>
</tbody>
</table>
## Ramzi Cotran Young Investigator Award

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1996</td>
<td>James R. Downing</td>
</tr>
<tr>
<td>1997</td>
<td>Christopher D.M. Fletcher</td>
</tr>
<tr>
<td>1998</td>
<td>Cheryl L. Willman</td>
</tr>
<tr>
<td>1999</td>
<td>Lawrence Weiss</td>
</tr>
<tr>
<td>2000</td>
<td>Mary Sunday</td>
</tr>
<tr>
<td>2001</td>
<td>Ralph Hruban</td>
</tr>
<tr>
<td>2002</td>
<td>Frederic G. Barr</td>
</tr>
<tr>
<td>2003</td>
<td>Julia A. Bridge</td>
</tr>
<tr>
<td>2004</td>
<td>Mark A. Rubin</td>
</tr>
<tr>
<td>2005</td>
<td>Marc Ladanyi</td>
</tr>
<tr>
<td>2006</td>
<td>Kojo S.J. Elenitoba-Johnson</td>
</tr>
<tr>
<td>2007</td>
<td>Arul M. Chinnaiyan</td>
</tr>
<tr>
<td>2008</td>
<td>Anirban Maitra</td>
</tr>
<tr>
<td>2009</td>
<td>Christine Iacobuzio-Donahue</td>
</tr>
<tr>
<td>2010</td>
<td>Jorge S. Reis-Filho</td>
</tr>
<tr>
<td>2011</td>
<td>Shuji Ogino</td>
</tr>
<tr>
<td>2012</td>
<td>Christina Antonescu</td>
</tr>
<tr>
<td>2013</td>
<td>Celina Kleer</td>
</tr>
</tbody>
</table>

## F.K. Mostofi Distinguished Service Award

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1977</td>
<td>Harold L. Stewart</td>
</tr>
<tr>
<td>1978</td>
<td>Chapman H. Binford</td>
</tr>
<tr>
<td>1979</td>
<td>Robert E. Stowell</td>
</tr>
<tr>
<td>1980</td>
<td>Joshua L. Edwards</td>
</tr>
<tr>
<td>1981</td>
<td>Benjamin Castlemaker</td>
</tr>
<tr>
<td>1982</td>
<td>Jack M. Layton</td>
</tr>
<tr>
<td>1983</td>
<td>Richard E. Palmer</td>
</tr>
<tr>
<td>1984</td>
<td>Murray R. Abell</td>
</tr>
<tr>
<td>1985</td>
<td>Robert H. More</td>
</tr>
<tr>
<td>1986</td>
<td>Leland D. Stoddard</td>
</tr>
<tr>
<td>1987</td>
<td>F. Stephen Vogel</td>
</tr>
<tr>
<td>1988</td>
<td>Jack P. Strong</td>
</tr>
<tr>
<td>1989</td>
<td>Benjamin F. Trump</td>
</tr>
<tr>
<td>1990</td>
<td>Nathan Kaufman</td>
</tr>
<tr>
<td>1991</td>
<td>Kamal G. Ishak</td>
</tr>
<tr>
<td>1992</td>
<td>Kenneth Earle</td>
</tr>
<tr>
<td>1993</td>
<td>Bernard M. Wagner</td>
</tr>
<tr>
<td>1994</td>
<td>David Hardwick</td>
</tr>
<tr>
<td>1995</td>
<td>Harvey Goldman</td>
</tr>
<tr>
<td>1996</td>
<td>Emanuel Rubin</td>
</tr>
<tr>
<td>1997</td>
<td>Cecilia M. Fenoglio-Preiser</td>
</tr>
<tr>
<td>1998</td>
<td>Costan W. Berard</td>
</tr>
<tr>
<td>1999</td>
<td>William A. Gardner</td>
</tr>
<tr>
<td>2000</td>
<td>Fred G. Silva</td>
</tr>
<tr>
<td>2001</td>
<td>Virginia LiVolisi</td>
</tr>
<tr>
<td>2002</td>
<td>Robert Pascal</td>
</tr>
<tr>
<td>2003</td>
<td>Elaine S. Jaffe</td>
</tr>
<tr>
<td>2004</td>
<td>Donald A. Antonioli</td>
</tr>
<tr>
<td>2005</td>
<td>Ronald A. DeLellis</td>
</tr>
<tr>
<td>2006</td>
<td>Richard J. Zarbo</td>
</tr>
<tr>
<td>2007</td>
<td>Victor E. Reuter</td>
</tr>
<tr>
<td>2008</td>
<td>Richard Fraser</td>
</tr>
<tr>
<td>2009</td>
<td>Jeffrey L. Myers</td>
</tr>
<tr>
<td>2010</td>
<td>John Eble</td>
</tr>
<tr>
<td>2010</td>
<td>James Crawford</td>
</tr>
<tr>
<td>2011</td>
<td>Sylvia L. Asa</td>
</tr>
<tr>
<td>2012</td>
<td>Celeste N. Powers</td>
</tr>
<tr>
<td>2013</td>
<td>John R. Goldblum</td>
</tr>
</tbody>
</table>

## Distinguished Pathologist Award

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1988</td>
<td>Hans Popper</td>
</tr>
<tr>
<td>1989</td>
<td>Earl P. Benditt</td>
</tr>
<tr>
<td>1990</td>
<td>Arthur T. Hertig</td>
</tr>
<tr>
<td>1991</td>
<td>Stanley L. Robbins</td>
</tr>
<tr>
<td>1992</td>
<td>Emmanuel Farber</td>
</tr>
<tr>
<td>1993</td>
<td>Wallace H. Clark</td>
</tr>
<tr>
<td>1994</td>
<td>Franz Enzinger</td>
</tr>
<tr>
<td>1995</td>
<td>Henry Rappaport</td>
</tr>
<tr>
<td>1996</td>
<td>Raffaele Lattes</td>
</tr>
<tr>
<td>1997</td>
<td>Elson B. Helwig</td>
</tr>
<tr>
<td>1998</td>
<td>Robert E. Scully</td>
</tr>
<tr>
<td>1999</td>
<td>David C. Dahlin</td>
</tr>
<tr>
<td>2000</td>
<td>John H. Yardley</td>
</tr>
<tr>
<td>2001</td>
<td>Margaret Billingham</td>
</tr>
<tr>
<td>2001</td>
<td>Leopold Koss</td>
</tr>
<tr>
<td>2002</td>
<td>Robert Heptinstall</td>
</tr>
<tr>
<td>2003</td>
<td>William Hartmann</td>
</tr>
<tr>
<td>2004</td>
<td>Daria Haust</td>
</tr>
<tr>
<td>2004</td>
<td>Kalman Kovacs</td>
</tr>
<tr>
<td>2005</td>
<td>J. Bruce Beckwith</td>
</tr>
<tr>
<td>2005</td>
<td>Robert D. Collins</td>
</tr>
<tr>
<td>2006</td>
<td>Harvey Goldman</td>
</tr>
<tr>
<td>2007</td>
<td>Peter Burger</td>
</tr>
<tr>
<td>2008</td>
<td>Nathan Kaufman</td>
</tr>
<tr>
<td>2008</td>
<td>Bernard M. Wagner</td>
</tr>
<tr>
<td>2009</td>
<td>Louis P. Dehner</td>
</tr>
<tr>
<td>2010</td>
<td>Juan Rosai</td>
</tr>
<tr>
<td>2011</td>
<td>Stephen S. Sternberg</td>
</tr>
<tr>
<td>2012</td>
<td>Steven G. Silverberg</td>
</tr>
<tr>
<td>2013</td>
<td>K. Krishnan Unni</td>
</tr>
</tbody>
</table>

## President’s Award

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>Ramzi Cotran</td>
</tr>
<tr>
<td>2002</td>
<td>Ruth Kirschstein &amp; Alan Rabin</td>
</tr>
<tr>
<td>2003</td>
<td>Kamal G. Ishak</td>
</tr>
<tr>
<td>2004</td>
<td>David F. Hardwick</td>
</tr>
<tr>
<td>2005</td>
<td>Andrew G. Huvos</td>
</tr>
<tr>
<td>2006</td>
<td>USCAP Staff</td>
</tr>
<tr>
<td>2007</td>
<td>James P. Crimmins</td>
</tr>
<tr>
<td>2008</td>
<td>Jack Perry Strong</td>
</tr>
<tr>
<td>2009</td>
<td>JoAnn Q. Johnson</td>
</tr>
<tr>
<td>2010</td>
<td>Jeffrey L. Myers</td>
</tr>
<tr>
<td>2011</td>
<td>Fred G. Silva</td>
</tr>
<tr>
<td>2012</td>
<td>Robin Cooke</td>
</tr>
<tr>
<td>2013</td>
<td>Jean Silva</td>
</tr>
</tbody>
</table>
F. Stephen Vogel Award

2001 Pei Hui
2002 Ilene B. Bayer-Garner
2003 Dinesh Rakheja
2004 Robert Pu
2005 Dylan V. Miller
2006 Rohit Bhargava
2007 Donna E. Hansel
2008 Jeremy Wallentine
2009 Samantha L. Butler
2010 Ibrahim Batal
2011 José Gaal
2012 Elizabeth Demicco

Benjamin Castleman Award

1981 Roger Warnke
1982 William E. Beschorner
1983 Renato V. Iozzo
1984 George F. Murphy
1985 Ann D. Thor
1986 Lawrence M. Weiss
1987 James T. Kurnick
1988 John Anastasi
1989 Stephen Chalmer Peiper
1990 Ivan Stamenkovic
1991 Peter A. Humphrey
1992 Giorgio Ingrahami
1993 Timothy J. McDonnell
1994 Cheryl L. Willman
1995 Marc Ladanyi
1996 Frederic G. Barr
1997 Sarah S. Frankel
1998 Jeffrey K. Taubenberger
1999 Irina Lubensky
2000 Daniel J. Brat
2001 Todd Kroll
2002 David G. Huntsman
2003 Jerome T. O’Connell
2004 Anirban Maitra
2005 Andrew P. Weng
2006 Arul M. Chinnaiyan
2007 Adebowale Joel Adeniran
2008 Laurence de Leval
2009 Kirsten D. Mertz
2010 Adeboye Osunkoya
2011 Anthony Gill
2012 Daniel A. Winer

The Harvey Goldman Master Teacher Award

2011 Donald Antonioli
2011 Henry Appleman
2012 Virginia LiVolsi
2013 Sharon W. Weiss
Your next job is a click away at USCAP.org

JOB SEEKERS
Whether you’re looking for a new job, or ready to take the next step in your career, we’ll help you find the opportunity that’s right for you.

EMPLOYERS
Target your recruiting and reach qualified candidates quickly and easily. Simply complete our online registration form and start posting jobs today!

United States & Canadian Academy of Pathology
Leading Pathology Educational Excellence

www.uscap.org > career center
HERE’S A GREAT OPPORTUNITY TO REVIEW THE RESEARCH COMPLETED BY OVER 2100 OF YOUR COLLEAGUES. THIS YEAR’S 1800+ POSTERS AND NEARLY 300 PROFFERED PAPERS OFFER A CORNUCOPIA OF ALL THINGS PATHOLOGY.

View the Posters — and meet their presenters — Monday through Wednesday. You’ll find each conveniently located in the Exhibition Hall, so be sure to allow yourself plenty of time to take in both posters and exhibitor information at the world’s largest pathology meeting.

The Exhibit Hall offers over 100 vendors of pathology products, services and support. Here’s the place to see the latest technology and discuss its application. Is there a particular vendor that you must speak with? Utilize our new Exhibitor App, “Network Now”. This app enables you to schedule exhibitor meetings before, during and after the show, search for products, create a personalized, printable show floor plan and more!

Download the Exhibitor app, “Network Now” at:
http://s36.a2zinc.net/clients/herlitz/uscap2013nn/public/nz_Login.aspx

When the meetings, posters, and exhibitors all wrap up for the year, don’t forget that you may also continue to view uploaded posters through iPosters, on line, at www.uscap.org.
PROFFERED PAPERS
Monday, March 4, 2013
8:00 AM – 12:00 PM
CC Ballroom 2
Section A – Genitourinary
Chaired by: Andrew Evans and Liang Cheng

8:00 Mucinous Tubular and Spindle Cell Carcinoma of the Kidney Is Genomically Distinct from Papillary Renal Cell Carcinoma
(CC Huang, C Magi-Galluzzi, K Smith, M Zhou
New York University Langone Medical Center, New York, NY; Cleveland Clinic, Cleveland, OH)

8:15 Collecting Duct Carcinoma of Kidney: Molecular Heterogeneity Revealed by Targeted Deep Sequencing
(Y-B Chen, A Gopalan, H Al-Ahmadie, SW Fine, H Won, AR Brannon, MF Berger, VE Reuter, SK Tickoo
Memorial Sloan-Kettering Cancer Center, New York, NY)

8:30 The Role of GATA3 in the Differential Diagnosis of Upper Tract Urothelial and Collecting Duct Carcinomas
(N Gonzalez-Roibon, A Chaux, R Sharma, ME Allaf, GJ Netto
Johns Hopkins Hospital, Baltimore, MD)

8:45 Are Cysts the Precancerous Lesion in HLRCC? The Morphologic Spectrum of Premalignant Lesions and Associated Molecular Changes in Hereditary Renal Cell Carcinoma: Their Clinical Significance
(A Ghosh, MJ Merino, MW Linehan
Laboratory of Pathology, National Cancer Institute/Bethesda, MD)

9:00 Role of Percutaneous Needle Core Biopsy in Diagnosis and Clinical Management of Renal Mass: Experience of a Single Institution
(R Hu, C Montemayor-Garcia, K Das
University of Wisconsin, Madison, WI)

9:15 Regional Chromosome 9 Targeted Capture and Sequencing Detects Papillary 2 Renal Cell Carcinoma
(W LaFramboise, P Petrosko, M Lyons, M Belsky, M Beech, C Sciulli, M Bastacky, G Meredith, S Bastacky, A Parwani, R Dhir
University of Pittsburgh, Pittsburgh, PA; Life Technologies, Inc., Carlsbad, CA)

11:00 Mutations of 3p21 Epigenetic Regulators in Clear Cell Renal Cell Carcinoma: Sequencing and Clinicopathologic Analysis of 188 Cases
(H Huang, AA Hakimi, I Ostrovnya, HA Al-Ahmadie, A Gopalan, SW Fine, JJ Hsieh, VE Reuter, SK Tickoo, Y-B Chen
Memorial Sloan-Kettering Cancer Center, New York, NY)

11:15 Metastases to the Kidney: A Clinicopathologic Study of Forty One Cases with an Emphasis on Deceptive Features
(AJ Wu, LP Kunju, J Reynolds, S Tomlins, R Mehra, C Przybycin
University of Michigan, Ann Arbor, MI; Cleveland Clinic, Cleveland, OH)

11:30 Significance Analysis of Prognostic Signatures Applied to Prostate Cancer
(L Montaser, AH Beck
Beth Israel Deaconess Medical Center, Boston, MA)

PROFFERED PAPERS
Monday, March 4, 2013
8:00 AM – 12:00 PM
CC Ballroom 4
Section B – Breast
Chaired by: Anna Marie Mulligan and Melinda Sanders

8:00 Evaluation of Breast Pathologies Using Multi-Photon Microscopy
(Y Sheykin, YK Tao, OO Ahsen, D Shen, D Schmolze, N Johnson, JG Fujimoto, JL Connolly
Beth Israel Deaconess Medical Center, Boston, MA; Massachusetts Institute of Technology, Cambridge, MA)

8:15 Should Sentinel Lymph Node (SLN) Biopsy Be Performed in Microinvasive Breast Carcinomas (MIC)?
(A Nayak, SE Frost, CS Nagi, LJ Bleiweiss, SJ Affer
Mount Sinai School of Medicine, New York, NY)

8:30 An Interobserver Concordance Study Reporting Estrogen Receptor (ER) in Invasive Breast Tumors Reveals a High Prevalence (4.9%) of Discordant Positive Versus Negative Results, Despite Excellent Overall Concordance
(ES Reisenbichler, A Ly, SC Lester, JE Brock
Brigham and Women's Hospital, Boston, MA)

8:45 Negative Estrogen Receptor and HER2 Assays at Core Biopsy of Invasive Cancers Should Be Confirmed in the Surgical Specimens
(D Jaggessarsingh, J Catalano, M Akram, E Brogi, M Murray
Memorial Sloan-Kettering Cancer Center, New York, NY)

9:00 Pogesterone Receptor (PgR) Protein but Not mRNA Is Associated with Better Outcome in Tamoxifen Treated Breast Cancer Patients
(KA Schalper, K Li, E Zarrrella, DL Rimm
Yale University, New Haven, CT)

9:15 Intratumoral Heterogeneity of HER2 in Invasive Breast Carcinoma: How Much Testing Is Enough?
(GC Bethune, MC Chang
Mount Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada)
11:00 Characterisation of the Genetic Heterogeneity of Invasive Breast Cancers with Heterogeneous HER2 Overexpression and Gene Amplification (234)
CKY Ng, A Gauthier, PM Wilkerson, MB Lambros, L Arnoud, M Lacroix-Triki, P Penault-Llorca, MC Baranzelli, X Sastre-Garau, CJ Lord, M Zvelebil, C Mitsiopoulou, A Ashworth, R Natrajan, B Weigelt, O Delattre, P Cotta, JS Reis-Filho, A Vincent-Salomon
Memorial Sloan-Kettering Cancer Center, New York, NY; Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; Centre Georges Frêllec, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Oscar Lambret, Lille, France

11:15 Analytical Variables That Affect the Prognostic Utility of Ki67 in Invasive Breast Cancer (304)
Y Wu, B Li, G Pond, AM Mulligan, MN Levine, T Whelan, A Bane
McMaster University, Hamilton, ON, Canada; University of Toronto, Toronto, ON, Canada

11:30 To Count or Not To Count? Scoring Ki67 in Breast Cancers According to International Working Group Recommendations (98)
KH Adamson, EQ Konnick, SM Dintzis, MH Rendi, HM Linden, KH Allison
University of Washington, Seattle, WA

11:45 Immunohistochemical Evaluation of GATA-3 Expression in ER-Negative Breast Carcinomas (216)
H Liu, J Shi, J Prichard, Y Gong, F Lin
Geisinger Medical Center, Danville, PA; University of Texas MD Anderson Cancer Center, Houston, TX

PROFFERED PAPERS
Monday, March 4, 2013
8:00 AM – 12:00 PM
CC Ballroom 3
Section C – Hematopathology
Chair by: Megan Lim and Richard Burack

8:00 Chronic Lymphocytic Leukemia (CLL) with a High Number of Losses in 13q Is Associated with Different Biological Features (1497)
Comprehensive Cancer Center Research-USAL, Salamanca, Spain; Hospital Universitario Infanta Leonor, Madrid, Spain; IECSCYL, Salamanca, Spain; Hospital Clinico Universitario, Salamanca, Spain

8:15 Chronic Lymphocytic Leukemia (CLL) with Clonal B-Cell Counts of 5–10x10^9/L Behaves Clinically Similar to Monoclonal B Cell Lymphocytosis (MBL) (1368)
AD Earhart, TT Nguyen, JL Frater, A Hassan, F Kreisel
Washington University School of Medicine, Saint Louis, MO

8:30 Plasma Cell Differentiation in CLL/SLL Tissue Sections Is Associated with Monoclonal Serum Free Light Chain and Better Clinical Outcome but Are Unrelated to MYD-88 Mutations (1444)
D Martinez, P Castillo, A Martinez-Trillos, C Sole, E Gine, A Lopez-Guillermo, E Campo, A Martinez
Hospital Clinic, Barcelona, Spain

8:45 Pyrosequencing for MYD88 L265P Mutation Discriminates between Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma (1401)
G Insuasti-Beltrán, S Wenceslao, H Kang, JM Gale, DR Czachlewski
University of New Mexico, Albuquerque, NM; TriCore Reference Laboratories, Albuquerque, NM

9:00 Follicular Large Cleaved Cell Lymphoma Is a Distinctive Morphological and Clinical Variant of Follicular Lymphoma (1369)
RA El Behery, JA Laurini, DD Weisenburger, LM Smith, BJ Dave, WC Chan, K Fu, TC Greiner, P Aoun
University of Nebraska Medical Center, Omaha, NE

9:15 Algorithm for Paraffin-Based Subclassification of B-Cell Lymphoproliferative Disorders in Bone Marrow (1467)
MO Nakashima, DW Warden, SL Ondrejka, J Lin, I Durkin, J Bodo, ED Hsi
Cleveland Clinic, Cleveland, OH

11:00 IgG4-Positive Plasma Cell Myeloma: New Insights into the Pathogenesis of IgG4-Related Disease (1373)
JT Geyer, DS Jayabalan, RN Pearse, R Niesvizky, SA Ely Weil Cornell Medical College, New York, NY

11:15 The Detection of Genomic Abnormalities and Prognostic Stratification in Plasma Cell Myeloma Using Array-Based Karyotyping Post Plasma Cell Enrichment (1387)
L Hartmann, CF Stephenson, KR Johnson, DB Chapman, DA Wells, MR Loken, B Tirtorahardjo, SR Gunn, LC Lim, ME de Baca, BK Zehentner
Hematologics, Inc., Seattle, WA; Combimatrix Inc, Irvine, CA; PLUS Diagnostics, Irvine, CA

11:30 MYC Protein Expression Is Detected in Majority of Multiple Myeloma but Not in Monoclonal Gammopathy of Undetermined Significance (MGUS) (1535)
R Xiao, K Dresser, B Woda, H Yu
University of Massachusetts Medical School, Worcester, MA

11:45 C-Myc Expression Correlates with Plasmablastic Morphology (1319)
SC Acree, RK Brynes, E Thornborrow, IN Siddiqi
LAC+USC Medical Center, Los Angeles, CA; University of California, San Francisco, CA
PROFFERED PAPERS
Monday, March 4, 2013
8:00 AM – 12:00 PM
CC Ballroom 1

Section D – Gastrointestinal
Chaired by: Jason Hornick and Sarah Dry

8:00 Hereditary Predisposition to LINE-1 Hypomethylated Colorectal Cancer: Potential Clinical Utility of Tumor LINE-1 Methylation Test for Familial Cancer Risk Assessment (698)
R Nishihara, C Fuchs, S Ogino
Dana-Farber Cancer Institute, Boston, MA; Brigham and Women’s Hospital, Boston, MA

8:15 Clinicopathologic Features of Synchronous Colorectal Carcinoma: A Distinct Subset Arising from Multiple Sessile Serrated Adenomas and Associated with High-Levels of Microsatellite Instability and Favorable Prognosis (645)
H Hu, DT Chang, MN Nikiforova, S-F Kuan, RK Pai
University of Pittsburgh, Pittsburgh, PA; Stanford University, Stanford, CA

8:30 Endometrial Carcinomas with DNA Mismatch Repair Abnormalities: Analysis of 75 Cases (1167)
A Bruegl, B Djordjevic, B Fellman, D Urbauer, R Luthra, R Broaddus
MD Anderson Cancer Center, Houston, TX; Medical University of Vienna, Vienna, Austria; Centre Léon-Bérard, Lyon, France

8:45 Screening by Young Age and Family History of Colon Cancer Misses the Majority of Endometrial Cancer Patients with Lynch Syndrome (1112)
A Brueng, B Djordjevic, B Fellman, D Urbauer, R Luthra, R Broaddus
MD Anderson Cancer Center, Houston, TX; University of Ottawa, Ottawa, ON, Canada

9:00 Analysis of Columnar Lined Esophagus Reveals Less Frequent Mutations in Non-Goblet Cell Metaplasia Than Intestinal Metaplasia (604)
S Bandia, JH Peters, D Ruff, S-M Chen, C-Y Li, K Song, K Thoms, VR Little, T Watson, N Chapurin, A Pennathur, JD Luketich, D Peterson, A Dalak, L Lin, A Bass, DG Beer, TE Godfrey, Z Zhou
URMC, Rochester, NY; University of Pittsburgh, Pittsburgh, PA; Life Technologies, Foster City, CA; Dana Farber Cancer Center, Boston, MA; University of Michigan, Ann Arbor, MI

9:15 Debatable Deposits: An Inter-Observer Variability Study of Lymph Nodes and Pericolic Tumor Deposits in Colorectal Adenocarcinoma (722)
JB Rock, MK Washington, V Adsay, J Greenson, E Montgomery, M Robert, R Yantiss, A Lehman, WL Frankel
Ohio State University, Columbus, OH; Vanderbilt University, Nashville, TN; Emory University, Atlanta, GA; University of Michigan, Ann Arbor, MI; Johns Hopkins University, Baltimore, MD; Yale University, New Haven, CT; Weill Cornell Medical College, New York, NY

11:00 Tumor Budding Is a Predictor of Nodal Metastasis and Tumor Recurrence in T1 Esophageal Adenocarcinoma (700)
JA Nowak, A Agoston, Y Zheng, R Bueno, RD Odze, A Srivastava
Brigham and Women’s Hospital, Boston, MA

11:15 Pseudoadenomatous Transformation of Tubal Gut Mucosa Secondary to Metastasis, Including a Unique Cytokeratin 7 Positive Type Not Previously Described (587)
C Adackapara, R Odze
Brigham and Women’s Hospital, Boston, MA

11:30 Multicenter Validation Study of Pathologic Response and Tumor Thickness at the Tumor–Normal Liver Interface as Independent Predictors of Disease-Free Survival after Preoperative Chemotherapy and Surgery for Colorectal Liver Metastases (591)
Baylor College of Medicine, Houston, TX; Ambroise Paré Hospital, Paris, France; University of Texas MD Anderson Cancer Center, Houston, TX; Medical University of Vienna, Vienna, Austria; Centre Léon-Bérard, Lyon, France

11:45 Esophageal Intestinal Metaplasia (Barrett’s Esophagus) Accompanies Most Esophageal and Gastroesophageal Junction Adenocarcinomas – A Single Institution Experience (736)
GV Shah, EA Montgomery
Johns Hopkins Medical Institutions, Baltimore, MD

PROFFERED PAPERS
Monday, March 4, 2013
8:00 AM – 12:00 PM
CC 314/315

Section E – Gynecologic & Obstetrics
Chaired by: Oluwole Fadare and Vinita Parkash

8:00 Screening by Young Age and Family History of Colon Cancer Misses the Majority of Endometrial Cancer Patients with Lynch Syndrome (1112)
A Bruegl, B Djordjevic, B Fellman, D Urbauer, R Luthra, R Broaddus
MD Anderson Cancer Center, Houston, TX; University of Ottawa, Ottawa, ON, Canada

8:15 Body Mass Index Associations Including Mismatch Repair Protein Expression in 1061 Endometrial Carcinomas (1173)
AS Joehlin-Price, CM Perrino, JA Stephens, DE Cohn, AA Suarez
Ohio State University Wexner Medical Center, Columbus, OH

8:30 Endometrial Carcinomas with DNA Mismatch Repair Abnormalities: Analysis of 75 Cases (1167)
YR Hussein, K Garg, R Soslow, D DeLair
Memorial Sloan-Kettering Cancer Center, New York, NY; UCSF, San Francisco, CA

8:45 Molecular Characterization of Undifferentiated Carcinomas That Are Associated with Low-Grade Endometrioid Carcinoma (1181)
E Kuhn, A Bahadirli-Talbott, A Ayhan, M Debelayk, J Eshleman, C Zhao, I-M Shih
Johns Hopkins Medical Institutions, Baltimore, MD; Seihei Mikatahara General Hospital, Hamamatsu, Japan; Magee-Womens Hospital, Pittsburgh, PA
Correlation and Prognostic Significance of Mismatch Repair (MMR) Protein and ARID1A Gene Expression in Endometrial Carcinomas (ECs) (1097)
G Allo, S Kalloger, A Pollett, M Bernardini, B Clarke
University of Toronto, Toronto, Canada; Toronto General Hospital, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Princess Margaret Hospital, Toronto, Canada; University of British Columbia, Vancouver, Canada

Endometrial Carcinoma with Mucinous Differentiation and Kras G12D Mutation Is Associated with Lymph Node Metastasis and Vaginal Recurrence (1246)
J Xiong, M He, C Jackson, V Breese, CJ Sung, MM Steinhoff, MR Quddus, T Tejadaberges, WD Lawrence
Women & Infants Hospital, Providence, RI; Rhode Island Hospital, Providence, RI; Alpert Medical School of Brown University, Providence, RI

Improving the Value of the Endometrial Biopsy: Molecular Diagnostics for Predicting Tumor Histotype and Stage (1129)
B Djordjevic, S-S Xie, R Broadus
University of Ottawa, Ottawa, ON, Canada; MD Anderson Cancer Center, Houston, TX

Histotype-Genotype Correlation in 36 High-Grade Endometrial Carcinomas (1160)
LN Hoang, MK McConney, M Koebel, G Han, M Rozabsahan, B Davidson, J Irving, R Ali, S Leung, E Oliva, MR Nucci, RA Soslow, OG Huntsman, CB Gilks, C-H Lee
University of British Columbia, Vancouver, Canada; University of Calgary, Calgary, Canada; University of Toronto, Toronto, Canada; Norwegian Radium Hospital, Oslo, Norway; Massachusetts General Hospital, Boston, MA; Brigham and Women’s Hospital, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY

Risk Factors for Recurrence in Sites Other Than Vagina in Patients with Low Grade Endometrial Adenocarcinoma. A Multi-Institutional Study (1227)
AA Roma, DA Barbuto, E Euscher, R Ali-Fehmi, B Djordjevic, JA Bennett, E Frauenhoffer, SR Hong, J Kim, D Montiel, E Moschiano, A Malpica, E Silva
Cleveland Clinic, Cleveland, OH; Cedars Sinai, Los Angeles, CA

Characteristics of Hydatidiform Moles: Analysis of p57 Expression and Molecular Genotyping Data (1107)
N Banet, C DeScipio, BM Ronnett
Johns Hopkins University, Baltimore, MD

Proffered Papers
Monday, March 4, 2013
8:00 AM – 12:00 PM
CC 316/317
Section F – Dermatopathology
Chaired by: Victor Prieto and Alireza Sepehr

Benign Mast Cell Hyperplasia and Atypical Mast Cell Infiltrate (Mastocytosis of Undetermined Significance) in Penile Lichen Planus (491)
S Regauer, C Beham-Schmid
Medical School Graz, Graz, Austria

A Retrospective Histologic and Histochemical Evaluation of Cutaneous Calciphylaxis (482)
M Mochel, R Arakaki, G Wang, D Kroshinsky, M Hoang
Massachusetts General Hospital, Boston, MA

Expanding the Spectrum of DNA Mismatch Repair Protein Deficiency in Cutaneous Sebaceous Neoplasia (473)
CJ Jessup, M Redston, E Brodell, JDR Reimann
Miraca Life Sciences Research Institute, Newton, MA; Tufts University Medical Center, Boston, MA

CD34-Positive Superficial Myxofibrosarcoma: A Potential Diagnostic Pitfall (500)
SC Smith, A Poznanski, D Fullen, L Ma, RM Patel
University of Michigan, Ann Arbor, MI; Miraca Life Sciences, Glen Burnie, MD

MYC Amplification and Overexpression in Primary Cutaneous Angiosarcoma (AS): A Fluorescence In-Situ Hybridization (FISH) and Immunohistochemical (IHC) Study of 39 Cases (499)
W Shon, SM Jenkins, WR Sukov, AL Folpe
Mayo Clinic, Rochester, MN

Development and Validation of a Chromogenic RNA In Situ Hybridization Assay for Diagnosis of Atypical Melanocytic Nevi and Malignant Melanoma (477)
CL Kauffman, D Stout, X Wu, D Alexandrescu, Y Luo, X-J Ma, P Shitabata
Georgetown Dermpath, Washington, DC; Advanced Cell Diagnostics, Hayward, CA; Dermatopathology Institute, Torrance, CA

Discrimination of Benign Versus Malignant Melanocytic Skin Neoplasms by MALDI Imaging Mass Spectrometry (MALDI IMS) (496)
A Sepehr, E Seeley, A Harris, S Tahan, R Caprioli
Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA; Vanderbilt University, Nashville, TN

Morphogenesis and Fibrogenesis Pathways for the Distinction of Slerosing Melanocytic Nevus and Desmoplastic Malignant Melanoma (454)
A Blanes, L Pozo, SJ Diaz-Cano
University of Malaga School of Medicine, Malaga, Spain; Homerton University Hospital, London, United Kingdom; King’s College Hospital, London, United Kingdom

Immunodetection of Phosphohistone H3 (PHH3) as a Surrogate of Mitotic Figure Count and Clinical Outcome in Cutaneous Melanoma (508)
MT Tetzlaff, JL Curry, DL Stockman, D Ivan, W-L Wang, KM Valencia, R Bassett, CA Torres-Cabala, VG Prieto
University of Texas MD Anderson Cancer Center, Houston, TX

Prognostic Factors in Mycosis Fungoides with Large Cell Transformation (490)
MP Pulitzer, PL Myskowski, S Horwitz, S Dusza, C Querfeld, B Connolly, J Li, R Murali
Memorial Sloan-Kettering Cancer Center, New York, NY
PROFFERED PAPERS
Monday, March 4, 2013
8:00 AM – 9:30 AM
CC 309
Section G1 – Neuropathology
Chaired by: Charles Eberhardt and Arie Perry
8:00 Canonical TGF-Beta Pathway Activity Is a Predictor of SHH-Driven Medulloblastoma Survival (1723)
D Aref, CJ Moffatt, S Agnihotri, A Dubuc, MD Taylor, A Perry, C Eberhardt, S Cruol
University of Toronto, Toronto, ON, Canada; Hospital for Sick Children, Toronto, ON, Canada; UCSF, San Francisco, CA; Johns Hopkins University, Baltimore, MD
8:15 Altered Telomeres with Loss of ATRX Protein Are Frequently Seen in High-Grade Pediatric Gliomas (1722)
University of California San Francisco, San Francisco, CA; St. Jude Children’s Research Hospital, Memphis, TN; University of Pennsylvania Health System, Philadelphia, PA
8:30 Uncommon Focal/Regional Heterozygous or Homozygous Deletion of SMARCBl (hSNF5/INI1) Locus in Two Atypical Teratoid/Rhabdoid Tumors (1740)
JEG Peterson, V Mehta, CA Mohila, AM Adesina
Methodist Hospital, Houston, TX; Texas Children’s Hospital, Baylor College of Medicine, Houston, TX
8:45 Cerebrovascular A-beta Amyloid in Surgical Specimens: Clinicopathological Correlates (1734)
C Giannini, JM Morris, GG Hunder, JE Parisi, TD Christianson, RD Brown, C Salvarani
Mayo Clinic, Rochester, MN; Arcispedale S. Maria Nuova, Reggio Emilia, Italy
9:00 Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Mutations in NF1, RFl and TP53 and Enriched in the Mesenchymal Transcriptional Class (1277)
D Brut, C Rutledge, J Kong, D Gutman, L Cooper, C Appin, C Chisolm, Y Park, L Scarpace, T Mikkelson, C Moreno, J Saltz
Emory University School of Medicine, Atlanta, GA; Henry Ford Hospital, Detroit, MI
9:15 Somatostatin Receptor 2A: A Novel Immunohistochemical Marker of Meningioma (1725)
CE Bacchi, PL Kandalaft, HC Hwang, LC Goldstein, LL Lopes, LM Bacchi, AM Gown
PhenoPath Laboratories, Seattle, WA; Consultoria em Patologia, Botucatu, SP, Brazil
9:45 Landscape of L1 Retrotransposon Expression in Human Carcinomas (1855)
N Rodic, R Sharma, KH Burns
Johns Hopkins Hospital, Baltimore, MD

PROFFERED PAPERS
Monday, March 4, 2013
8:00 AM – 9:30 AM
CC 310
Section H1 – Pathobiology
Chaired by: Barbara Crain and Marc Halushka
8:00 Minimally Invasive Autopsy Employing Post-Mortem CT and Targeted Coronary Angiography: Evaluation of Its Application to a Routine Coronial Service (12)
ISD Roberts, ZC Trall
John Radcliffe Hospital, Oxford, United Kingdom; Churchill Hospital, Oxford, United Kingdom
8:15 Intercalated Disc Ultrastructural Abnormalities Precede Histopathologic Changes in Desmoglein2 Transgenic Mice and Are Associated with Conduction Slowing and Inducible Arrhythmias (326)
S Rizzo, EM Lodder, AO Verkerk, RW Wolswinkel, L Beekman, K Pilichou, C Basso, CA Remme, G Thiene, CR Bezzina
University of Padua, Padua, Italy; Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
8:30 Improved Pathology Resident Performance in Critical Value Communication Using Simulation Based Communication Training (520)
S Dintzis, M Rodic, R Sharma, KH Burns
University of Washington Medical Center, Seattle, WA
8:45 Uveal Melanoma Metastases: Clinico-Pathologic and Mutational Analysis of 21 Cases (1756)
JM Mosquera, A Stoner, L Zhang, K Kitabayashi, C-L Chen, YS Sung, M Edelman, MA Rubin, CR Antonescu
Weill Medical College of Cornell University, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY; North Shore LIJ Health System, Flushing, NY
9:00 Recurrent NCOA2 Gene Rearrangements in Congenital/Infantile Spindle Cell Rhabdomyosarcoma (1866)
JM Mosquera, A Stoner, L Zhang, K Kitabayashi, C-L Chen, YS Sung, M Edelman, MA Rubin, CR Antonescu
Weill Medical College of Cornell University, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY; North Shore LIJ Health System, Flushing, NY

11:00 EZH2 Expands Breast Stem Cells by Activating Notch, Acting To Accelerate the Onset of Breast Cancer (1840)
ME Gonzalez, X Li, HM Moore, ML DuPrie, KA Toy, CG Kleer
University of Michigan, Ann Arbor, MI
11:15 Medulloblastoma Expresses CD1d and Can Be Targeted for Immunotherapy with NKT Cells (1859)
L Song, D Liu, L Metelitsa
University of Texas Health Center at Houston, Houston, TX; Texas Children’s Cancer Center, Houston, TX
11:30 TGR5-Mediated NADPH Oxidase NOX5-S Expression Contributes to Bile Acid-Induced DNA Damage in Barrett’s Esophageal Adenocarcinoma Cells (1845)
D Li, M Renick, J Wands, W Cao
Rhode Island Hospital and the Alpert Medical School of Brown University, Providence, RI
11:45 Landscape of L1 Retrotransposon Expression in Human Carcinomas (1855)
N Rodic, R Sharma, KH Burns
Johns Hopkins Hospital, Baltimore, MD
9:15 Avoiding Pitfalls in Ultrastructural Evaluation of Peripheral Blood Leukocyte Buffy Coats for Metabolic Inclusion Disease (2100)
J Hicks, E Wartchow, G Mierau
Baylor College of Medicine & Texas Children’s Hospital, Houston, TX; Children’s Hospital Colorado, Aurora, CO

PROFFERED PAPERS
Monday, March 4, 2013
11:00 AM – 12:00 PM
CC 310
Section H2 – Informatics
Chaired by: Liron Pantanowitz and Anil Parwani

11:00 Lymph Node Metastasis Status in Primary Breast Carcinoma Can Be Predicted Via Image Analysis of Tumor Histology (1599)
MD Zarella, MA Reza, Y Gong, DE Breen, FU Garcia
Drexel University College of Medicine, Philadelphia, PA; Drexel University, Philadelphia, PA

11:15 Conversion of Traditional Immunohistochemistry into Virtual Multicolor Stains Using Feature Extraction and Pixel-Conversion Algorithms (1589)
A-SK Meyer, P Moller, JK Lennerz
Ulm University, Ulm, Germany

11:30 Open-Source Three-Dimensional Digital Pathology: Application to Serially Sectioned Renal Needle Core Biopsies (1597)
A Ward, S Rosen, C Law, B Faulkner-Jones
Beth Israel Deaconess Medical Center, Boston, MA; Kitware Inc., Clifton Park, NY

11:45 Optical Coherence Tomography (OCT) for Intra-Operative Style Interpretation of Endometrium (1572)
IC Cucoranu, JL Fine
UPMC, Pittsburgh, PA

PROFFERED PAPERS
Monday, March 4, 2013
1:00 PM – 3:00 PM
CC Ballroom 4
Section B – Breast
Chaired by: Ashley Cimino-Mathews and Omar Hameed

1:00 Incidental High Risk Lesions in Reduction Mammaplasty Specimens: Analysis of 2351 Cases from Large Women’s Health Centers (142)
MM Desouki, O Fadare, C Zhao
Vanderbilt University School of Medicine, Nashville, TN; Magee-Womens Hospital, Pittsburgh, PA

1:15 Incidence of Carcinoma and Atypia in Breast Reduction Mammoplasty Specimens (126)
R Canas Marques, MF Lerwill
Instituto Portugues de Oncologia de Lisboa Francisco Gentil, EPE, Lisboa, Portugal; Massachusetts General Hospital, Boston, MA

D Danneman, L Drevin, P Stattin, L Egevad
Karolinska Institutet, Stockholm, Sweden; Uppsala University Hospital, Uppsala, Sweden; Memorial Sloan-Kettering Cancer Center, New York, NY

1:45 PSA Screening and Deaths from Prostate Cancer after Diagnosis; a Population Based Analysis (1061)
MS Wahlert, AL Haynes, Jr., S Dahlbeck, W de Riese
Texas Tech University Health Sciences Center, Lubbock, TX; Texas Tech University, Lubbock, TX

2:00 Prostate Carcinomas Arising in Lynch Syndrome Patients Frequently Show Concordant Mismatch Repair Deficiency (1014)
C Rosty, MD Walsh, M Clendenning, JP Young, N Lindor, JL Hopper, MA Jenkins, DD Buchanan
Queensland Institute of Medical Research, Brisbane, Australia; University of Queensland, Brisbane, Australia; Envio Pathology, Brisbane, Australia; Sullivan Nicolaides Pathology, Brisbane, Australia; Mayo Clinic, Scottsdale, AZ; University of Melbourne, Melbourne, Australia

2:15 PINDCIS: Clinical Significance of Borderline Lesions between High Grade Prostatic Intraepithelial Neoplasms and Intraductal Carcinoma of the Prostate (IDC-P) on Needle Biopsy (893)
JS Han, S Lee, JI Epstein, TL Lotan
Johns Hopkins Medical Institutions, Baltimore, MD

2:30 Extraprostatic Extension on Prostate Needle Biopsy: Uncommon Finding with Important Implications (862)
SM Falzarano, K Streator Smith, C Magi-Galluzzi
Cleveland Clinic, Cleveland, OH

2:45 Validation of a Gleason Score 7 Weighted Based on Proportion of Gleason 4 Component (Quantitative Gleason Score) as Predictor of Biochemical Recurrence after Radical Prostatectomy (848)
F-M Deng, P Pe Benito, N Donin, A Rosenkrantz, M Zhou, H Lepor, S Taneja, J Melamed
NYU Langone Medical Center, New York, NY

122
1:45 MRI-Guided Breast Core Biopsies: Pathologic Features of Newly Diagnosed Malignancies (262)
ES Reisenbichler, SC Lester
Brigham and Women’s Hospital, Boston, MA

1:45 Prognostic Impact of Tumor Microenvironment on Diffuse Large B-Cell Lymphoma Treated with R-CHOP (1375)
JC Gomez-Gelvez, M Salama, C Cogan, M Leavitt, K Inamdar
Henry Ford Hospital, Detroit, MI; University of Utah, Salt Lake City, UT

2:00 Secretory and Cystic Hypersecretory Changes at Breast Core Needle Biopsy: Clinical, Radiologic and Pathologic Findings in 67 Cases (162)
L Galman, J Catalano, A Cordero, M Akram, E Brogi
Memorial Sloan-Kettering Cancer Center, New York, NY

2:00 Plasmablastic Lymphoma (PBL): Molecular Characterization by miRNA Expression Profiling (1414)
R Kolhe, A Rojiani, A Jillela, V Kota
Georgia Health Sciences University, Augusta, GA

2:15 Pleomorphic Lobular Carcinoma In Situ of the Breast: Clinico-pathologic Review of 57 Cases and a Proposed New Histopathologic Classification (193)
TKhoury, R Karabakhstian, L Yan, S Syric, S Liu, MM Desouki
Roswell Park Cancer Institute, Buffalo, NY; University of Kentucky, Lexington, KY; Vanderbilt University, Nashville, TN

2:15 Expression of the Immunosuppressive Molecules PD-L1 and Galectin-1 by EBV+ Lymphoproliferative Disorders: Novel Candidates for Targeted Immunotherapy (1351)
BJ Chen, J Ouyang, ML Xu, H Yu, CDM Fletcher, H Sun, MA Shipp, SJ Rodig
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; DFCI, Boston, MA; Yale School of Medicine, New Haven, CT; UMass Memorial Hospital, Worcester, MA

2:30 Does the Extent of Atypical Hyperplasia in a Benign Breast Biopsy Influence the Magnitude of Breast Cancer Risk? An Update from the Nurses’ Health Studies (133)
LC Collins, SA Aroner, RM Tamimi, JL Connolly, GA Colditz, SJ Schnitt
Beth Israel Deaconess Medical Center, Boston, MA; Channing Laboratory, Brigham and Women’s Hospital, Boston, MA; Washington University, St. Louis, MO

2:30 Promoter Hypermethylation of BANK1 Supports a Tumor Suppressor Role in Hodgkin Lymphomas (1537)
J Yan, T Zhang, K Nie, S Prakash, DM Knowles, A Orazi, W Tam
Weill Cornell Medical College, New York, NY

2:45 The Presence of Extensive Retraction Clefts in Invasive Breast Carcinomas Correlates with Lymphatic Invasion and Nodal Metastasis and Predicts Poor Outcome – A Prospective Validation Study of 2702 Consecutive Cases (97)
G Acs, N Khakpour, J Kilik, MC Lee, C Laroniga
Moffitt Cancer Center, Tampa, FL; Women’s Pathology Consultants, Ruffolo Hooper & Associates, Tampa, FL

2:45 Cyclin D1 Expression in LP Cells of Nodular Lymphocyte Predominant Hodgkin’s Lymphoma (1357)
BB Cho, RD LeGallo, TA Goldin, NS Aguilera
University of Virginia Health System, Charlottesville, VA

---

**PROFFERED PAPERS**

**Monday, March 4, 2013**

**1:00 PM – 3:00 PM**

**CC Ballroom 3**

**Section C – Hematopathology**

**Chaired by: Eric Hsi and Scott Rodig**

**1:00** MYC/BCL2 Protein Co-Expression Defines a Unique Subset of Aggressive B-Cell Lymphomas and Contributes to the Inferior Prognosis of Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-ChOP Consortium Program Study (1392)
S Hu, A Tzankov, C Visco, A Orazi, G Bhagat, ED Hsi, M Ponzoni, MA Piris, MB Moller, LJ Medeiros, KH Young
University of Texas MD Anderson Cancer Center, Houston, TX

**1:00** EGFR Exon 20 Mutations: Molecular Spectrum, Incidence and Clinicopathologic Characteristics (1906)
Y-C Liu, K Nafa, JE Chaft, N Rekhtman, B Reva, MF Zakowski, MG Kris, M Ladanyi, ME Arcila
Memorial Sloan-Kettering Cancer Center, New York, NY

**1:15** Clinical, Pathological and Molecular Predictive Factors for the Development of Brain Metastasis in Patients with Lung Adenocarcinoma (1930)
K Raparia, C Villa, M Mehta, P Cagle
Northwestern University, Chicago, IL; Methodist Hospital, Houston, TX

**1:15** NNX2.8 Expression in TTF-1 Negative and KRAS-Mutant Pulmonary Mucinous Adenocarcinoma Supports the Concept of a Biologically Distinct Category of Lung Adenocarcinoma (1944)
J Suh, S Krauter, L Chiriboga, H Pass
NYU Langone Medical Center, New York, NY

**1:30** CD30-Expression Defines a Novel Subset of Diffuse Large B-Cell Lymphoma with Superior Clinical Outcome: A Report from the International DLBCL Rituximab-ChOP Consortium Program Study (1393)
S Hu, A Tzankov, C Visco, A Orazi, G Bhagat, EE Hsi, M Ponzoni, MA Piris, MB Moller, LJ Medeiros, KH Young
University of Texas MD Anderson Cancer Center, Houston, TX

**1:30** Diagnostic Value of Immunohistochemistry for the Detection of the BRAFV600E Mutation in Primary Lung Adenocarcinoma Caucasian Patients (1891)
Pasteur Hospital, Nice, France; Central Hospital, Nancy, France; Haut-Lévêque Hospital, Pessac, France; Institute for Pathology, University of Heidelberg, Heidelberg, Germany; Ambroise Paré Hospital, Boulogne, France

**1:45** Prognostic Impact of Tumor Microenvironment on Diffuse Large B-Cell Lymphoma Treated with R-CHOP (1375)
JC Gomez-Gelvez, M Salama, C Cogan, M Leavitt, K Inamdar
Henry Ford Hospital, Detroit, MI; University of Utah, Salt Lake City, UT

---

**PROFFERED PAPERS**

**Monday, March 4, 2013**

**1:00 PM – 3:00 PM**

**CC Ballroom 1**

**Section D – Pulmonary**

**Chaired by: Andre Moreira and Peter Illei**

**1:00** MYC/BCL2 Protein Co-Expression Defines a Unique Subset of Aggressive B-Cell Lymphomas and Contributes to the Inferior Prognosis of Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-ChOP Consortium Program Study (1392)
S Hu, A Tzankov, C Visco, A Orazi, G Bhagat, ED Hsi, M Ponzoni, MA Piris, MB Moller, LJ Medeiros, KH Young
University of Texas MD Anderson Cancer Center, Houston, TX

---

**1:15** Clinical, Pathological and Molecular Predictive Factors for the Development of Brain Metastasis in Patients with Lung Adenocarcinoma (1930)
K Raparia, C Villa, M Mehta, P Cagle
Northwestern University, Chicago, IL; Methodist Hospital, Houston, TX

---

**1:30** CD30-Expression Defines a Novel Subset of Diffuse Large B-Cell Lymphoma with Superior Clinical Outcome: A Report from the International DLBCL Rituximab-ChOP Consortium Program Study (1393)
S Hu, A Tzankov, C Visco, A Orazi, G Bhagat, EE Hsi, M Ponzoni, MA Piris, MB Moller, LJ Medeiros, KH Young
University of Texas MD Anderson Cancer Center, Houston, TX

---

**1:45** Diagnostic Value of Immunohistochemistry for the Detection of the BRAFV600E Mutation in Primary Lung Adenocarcinoma Caucasian Patients (1891)
Pasteur Hospital, Nice, France; Central Hospital, Nancy, France; Haut-Lévêque Hospital, Pessac, France; Institute for Pathology, University of Heidelberg, Heidelberg, Germany; Ambroise Paré Hospital, Boulogne, France
PROFFERED PAPERS
Monday, March 4, 2013
1:00 PM – 3:00 PM
CC 314/315
Section E – Liver
Chaired by: Maria Westerhoff and Sanjay Kakar

1:00 Sinusoidal Portal Hypertension in Non-Cirrhotic Patients: Description of a Post-Transplant Cohort with Conflicting Clinical/Radiologic Features and Highlight of Deficiencies in the Current Fibrosis Staging Systems (1695)

H Li-Chang, S Hafezi-Bakhtiari, OA Adeyi
University Health Network, University of Toronto, Toronto, ON, Canada

1:15 Fibrosing Cholestatic Hepatitis C Versus Biliary Obstruction: Distinguishing Histopathologic Features (1706)

M Salomao, JH Lefkowitch, EC Verna, RK Moreira
Columbia University, New York, NY; Mayo Clinic, Rochester, MN

1:30 Standardized Histological Evaluation of Primary Sclerosing Cholangitis (PSC): Relationship of Histological Features to Laboratory Findings and Outcome (1690)

DE Kleiner, EM Brunt, KD Lindor, JA Talwalkar
National Cancer Institute, Bethesda, MD; Washington University, St. Louis, MO; Arizona State University, Phoenix, AZ; Mayo Clinic, Rochester, MN

1:45 Clinicopathological Characteristics of Serum Amyloid A-Positive Hepatocellular Neoplasms Arising in Advanced Alcoholic Liver Disease (1708)

M Sasaki, N Yoneda, Y Sato, O Matsui, Y Nakamura
Kanazawa University Graduate School of Medicine, Kanazawa, Japan

2:00 Pathological Features and Prognosis of Combined Hepatocellular and Cholangiocarcinoma by World Health Organization Classification (1658)

S Aishima, Y Kubo, Y Tanaka, Y Oda
Kyushu University, Fukuoka, Japan

PROFFERED PAPERS
Monday, March 4, 2013
1:00 PM – 3:00 PM
CC 316/317
Section F – Head & Neck
Chaired by: Diane Kowalski and Rebecca Chernock

1:00 Most Non-Parotid “Acinic Cell Carcinomas” Represent Mammary Analogue Secretory Carcinomas (1271)

JA Bishop, R Yonescu, D Batista, WH Westra
Johns Hopkins Hospital, Baltimore, MD

1:15 Solitary Fibrous Tumor of the Head and Neck: Institutional Experience of Two Referral Centers (1309)

SC Smith, M Elkins, RM Patel, DR Lucas, RR Seethala, JB McHugh
University of Michigan, Ann Arbor, MI; University of Pittsburgh, Pittsburgh, PA

1:30 Well-Differentiated Squamous Cell Carcinoma with Verrucous Features – A Variant of Verrucous Carcinoma with Extremely Favorable Prognosis (1298)

KR Patel, S Muller, R Chernock, S El-Mofy, JS Lewis, Jr.
Washington University in St Louis, St Louis, MO; Emory University School of Medicine, Atlanta, GA

1:45 PD1-Infiltrating T Cells: A Good Prognostic Biomarker in HPV Associated Head and Neck Cancer (1265)

INSERM U970 PARCC, Paris, France; Hôpital Européen G Pompidou, Paris, France

2:00 CRTC1/3-MAML2 Fusions Are Not Seen in Metaplastic Warthin Tumors and Metaplastic Pleomorphic Adenomas of Salivary Glands (1308)

A Skalova, T Vanecek, L Hauer, M Michal
Charles University, Faculty of Medicine, Pilsen, Czech Republic; Biopptic Laboratory, Pilsen, Czech Republic
2:15 Salivary Duct Carcinoma: Actionable Somatic Mutations Identified by Massively Parallel Sequencing (1280)
S Dogan, N Katabi, R Yelensky, K Wang, P Stephens, MF Berger
Memorial Sloan-Kettering Cancer Center, New York, NY;
Foundation Medicine Inc., Cambridge, MA

2:30 Do Small Oncocytic Follicular Carcinoma/Hurthle Cell Carcinoma Exist? An Institutional Experience (104)
T Samulski, B Shuting, V LiVolsi, K Montone, Z Baloch
Hospital of the University of Pennsylvania, Philadelphia, PA;
New York University Medical Center, New York, NY

2:45 BRAF Mutation Analysis in Primary Mucosal Melanoma of the Head and Neck – A Multi-Institutional Analysis of 66 Cases (1263)
E Aquino, BY Wang, G Chen, L Wu, H Liu, Q Yao, M Gu
University of California Irvine Medical Center, Orange, CA;
Beth Israel Medical Center, Albert Einstein College of Medicine,
New York, NY; Wenzhou Medical College, Wenzhou, Zhejiang, China;
Tongren Hospital, Capital Medical University, Beijing, China

**PROFFERED PAPERS**
**Monday, March 4, 2013**
**1:00 PM – 3:00 PM**
**CC 309**

**Section G – Quality Assurance**

Chaired by: Raouf Nakhlé and Frederick Meier

1:00 Influence of External Factors on Frozen Section Performance (2033)
JA Wisell, SB Sams
University of Colorado School of Medicine, Aurora, CO

1:15 Validation of Whole Slide Scanning for Use in Real-Time Clinical Frozen Section Consultation (1965)
SH Bradshaw, E Belanger, M Lamba, KT Mai, SJ Robertson, H Sekhon
Ottawa Hospital, Ottawa, ON, Canada

1:30 Quality Improvement in Pathology through Real-Time Labeling (2022)
R Stapp, M Haghighi, R Brown, M Czechowski, B Mahar, R Zarbo, M Tuthill
Henry Ford Hospital, Detroit, MI

1:45 Improving Quality and Completeness of Cancer Pathology Reporting: Results of a Large Scale 8 Year Canadian Project (2021)
J Srigley, D Diveris, T McGowan, J Brierley, M Yurcan, J Irish, R McLeod, J Ross, R Rossi, T Yardley, R Schill, M King, J Hart, D Wilson-Li, C Sawka
Cancer Care Ontario, Toronto, ON, Canada; McMaster University, Hamilton, ON, Canada; Grand River Hospital, Kitchener, ON, Canada; Credit Valley Hospital, Mississauga, ON, Canada; University Health Network, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; University Health Network & Mt Sinai Hospital, Toronto, ON, Canada

2:00 Focused Professional Peer Review for Anatomic Pathology Faculty: A Pilot Study (1999)
JM Newell, RJ Zaino
Penn State Hershey, Hershey, PA

CJ Eillermeier, J Fava, A Amin
Rhode Island Hospital, Providence, RI

2:30 Effectiveness of Pathology Resident Communication Simulation Based Education on Clinical Practice (1990)
S Mehri, A Wingerson, J Struijk, D Luff, S Raab, S Dintzis
University of Washington Medical Center, Seattle, WA

2:45 Predictive Molecular Markers in Lung Cancer – 80% Decrease in Diagnosis to Treatment Decision Times by Streamlining EGFR and ALK Testing Protocols (1967)
M Cankovic, L Whiteley, S Michalowski, CH Stone, RJ Zarbo, DA Chitale
Henry Ford Hospital, Detroit, MI

**PROFFERED PAPERS**
**Monday, March 4, 2013**
**1:00 PM – 3:00 PM**
**CC 310**

**Section H – Endocrine**

Chaired by: Lester Thompson and Justine Barletta

1:00 Immunohistochemical (IHC) Detection of Mutated BrafV600E along the Spectrum of Thyroid Carcinoma (TC) Progression (549)
R Ghossein, J Ricarte-Filho, J Knauf, M Rivera, J Fagin
Memorial Sloan-Kettering Cancer Center, New York, NY

1:15 Usefulness of Immunohistochemistry for the Detection of BRAFV600E Mutation in Papillary Thyroid Carcinoma. Comparison with Three Molecular Biology Methods (Dideoxy Sequencing, Pyrosequencing and SNaPshot) (555)
S Lassalle, M Ilie, V Hofman, C Bonnetaud, O Bordonne, A Lamy, J-C Sabourin, J Haudebourg, C Butori, I Peyrottes, J-L Sadoul, A Bozec, J Santini, P Hofman
Pasteur Hospital, Nice, France; CHU de Rouen, Rouen, France;
Antoine Lacassagne Centre, Nice, France; Archet Hospital, Nice, France

1:30 PAX8/PPARγ Rearrangements of Thyroid Tumors: Assessment of Distribution Frequency, Histopathological Features and Cytological-Histopathological Correlations (583)
H Yang, M Armstrong, S Carty, P Ohori, Y Nikiforov
University of Pittsburgh, Pittsburgh, PA

1:45 Subcapsular Sclerosing Variant (SSV) of Papillary Thyroid Microcarcinoma (PTMC): Clinicopathologic and Molecular Features (579)
RK Virk, CL Theoharis, P Hui, M Prasad
Yale School of Medicine, New Haven, CT

2:00 Pediatric Thyroid Carcinomas of Follicular Cell Origin: A Clinico-Pathologic Study of 42 Cases (535)
S Balachandar, M Rivera, M LaQuaglia, RM Tuttle, C Sklar, R Ghossein
Memorial Sloan-Kettering Cancer Center, New York, NY

2:15 Circulating Tumor Cells as Diagnostic Marker of Adrenocortical Carcinoma: Preliminary Results of a Single Center Study (570)
C Scatena, P Pinzani, F Salvianti, M Poglierani, M Luconi, M Mannelli, G Nesi
University of Florence, Florence, Italy
2:30 Development of a Multi-Gene qPCR Assay for Adrenocortical Tumor Diagnosis and Prognosis (577)
SA Tomlins, M Vinco, R Kuick, TJ Giordano
University of Michigan, Ann Arbor, MI

2:45 Molecular Alterations in Partially-Encapsulated/Well-Circumscribed Follicular Variant of Papillary Thyroid Carcinoma (551)
BE Howitt, LM Sholl, JA Barletta
Brigham and Women’s Hospital, Boston, MA

PROFFERED PAPERS
Tuesday, March 5, 2013
8:00 AM – 12:00 PM
CC Ballroom 2
Section A – Genitourinary
Chaired by: Peter Humphrey and Gladell Paner

8:00 Renal Oncocytic Tumors with Hybrid Features Occurring in a Sporadic Setting: A Clinicopathologic Study of 22 Cases (806)
D Atherton, K Sircar, P Tamboli, P Rao
MD Anderson Cancer Center, Houston, TX

8:15 Pathologic Findings in Needle Core Biopsies of Renal Tumors Treated with Ablation Therapy (918)
RE Jimenez, CM Lohse, TD Atwell, GD Schmit, AN Kurup, JC Cheville
Mayo Clinic, Rochester, MN

8:30 Aggressive Variants of Chromophobe Renal Cell Carcinoma: Importance of Recognition and Grading (794)
M Alimchandani, C Neira de Paz, S Williams, K Lara-Otero, WM Linehan, MJ Merino
National Institutes of Health, Bethesda, MD

8:45 Testicular Embryonal Carcinoma: A Morphologic Study of 168 Cases Including Newly Described Patterns (922)
C-S Kao, NJ Rush, TM Ulbright, MT Idrees
Indiana University School of Medicine, Indianapolis, IN

9:00 Testicular Fibrothecoma: A Report of 16 Cases (1087)
M Zhang, C-S Kao, TM Ulbright, JI Epstein
Johns Hopkins Hospital, Baltimore, MD; Indiana University School of Medicine, Indianapolis, IN

9:15 Prostatic Biopsy and Transurethral Resections for Primary Bladder Urothelial Carcinoma: Challenges and Ambiguities in Pathologic Reporting (998)
CM Perrino, EJ Fichtenbaum, KS Pohar, DL Zynger
Ohio State University Medical Center, Columbus, OH

11:00 Two Major Pathways of Penile Carcinogenesis: HPV-Induced Penile Cancers Overexpress p16^{ink4a}, HPV-Negative Cancers Associated with Dermatoses Express p53, but Lack p16^{ink4a} Overexpression (963)
S Mannweiler, S Sygula, E Winter, S Regauer
Medical University of Graz, Graz, Austria

11:15 ERG Immunohistochemistry in Prostatic Small Cell Carcinoma: Comparison to Fluorescence In Situ Hybridization (1027)
LJ Schelling, S Zhang, S Williamson, J Yao, M Wang, J Huang, R Montironi, A Lopez, AO Osunksy, G MacLenan, L Cheng
Indiana University School of Medicine, Indianapolis, IN; University of California at Los Angeles, Los Angeles, CA; Polytechnic University of the Marche Region, United Hospitals, Ancona, Italy; Cordoba University, Cordoba, Spain; Emory University, Atlanta, GA; Case Western Reserve University, Cleveland, OH

11:30 ERG-Immunopositivity in Prostatic Adenocarcinoma Is Unrelated to Aggressive Local Tumor Characteristics or to Biochemical Recurrence: A Study of 454 Cases (834)
M Chevarie-Davis, S Chevalier, E Scarlata, A Dragomir, S Tanguay, W Kassouf, A Aprikian, F Brimo
McGill University, Montreal, QC, Canada

11:45 Adenocarcinoma of the Prostate with Aberrant Expression of p63 (p63-PCa): A Radical Prostatectomy (RP) Study (879)
GA Giannico, HM Ross, TL Lotan, JI Epstein
Vanderbilt Medical Center, Nashville, TN; Johns Hopkins Hospital, Baltimore, MD

PROFFERED PAPERS
Tuesday, March 5, 2013
8:00 AM – 12:00 PM
CC Ballroom 4
Section B – Breast
Chaired by: Jorge Reis-Filho and Yunn-Yi Chen

8:00 Columnar Cell Hyperplasia with Atypia Is Biologically Similar to Ductal Carcinoma In Situ, Not Columnar Cell Hyperplasia (271)
S Sanati, C Allred
Washington University in St Louis, School of Medicine, St Louis, MO

8:15 Host Inflammation and Breast Cancer Molecular Subtypes: Results from a TCGA Sub-Analysis (99)
Cancer Genome Atlas (TCGA) Breast Cancer Expert Pathology Committee, Bethesda, MD

8:30 Fuzzy Logic Selection as a New Reliable Tool To Identify Gene Signatures in Breast Cancer – The INNODIAG Study (204)
Institut Claudius Regaud, Toulouse, France; CNRS, LAAS, Toulouse, France; INSA/CNRS/INRA - UMR5504/792, Toulouse, France

8:45 Presence of Lobular Features Predicts Enrichment for PI3K Pathway Mutations among No Special Type Breast Cancers (200)
MG Kuba, GM Jennifer, JM Balko, IA Mayer, V Abramson, J Meszoely, W Fao, Z Su, D Lai, DR LaFrance, CL Vnencak-Jones, CL Arteaga, ME Sanders
Vanderbilt University, Nashville, TN
9:00 A High Number of Chromosomal Breakpoints Identifies Poor Prognosis N0 Luminal HER2 Negative Early Invasive Breast Carcinomas Better Than Proliferation (298)
A Vincent-Salomon, V Benhamo, E Gravier, Y De Rycke, O Mariann, F Reyal, P Cottu, A Fourquet, X Saxtre, O Delattre Institut Curie, Paris, France; INSERM U830, Paris, France

9:15 Mucinous Carcinoma of the Breast, One or Two Diseases? MiRNAs and Molecular Profiling of Invasive and In Situ Mucinous Carcinoma (297)
L Viciouso, A Li, A Matilla, K Lara, MJ Merino NCI, Bethesda, MD; Hospital Clinico, Malaga, Spain

11:00 Wnt Signalling Pathway Activation Plays Important Role in the Oncogenesis of TNBC and Is Associated with Poor Survival Outcome (184)
J Iqbal, AA Thike, SS Ahmed, PH Tan Singapore General Hospital, Singapore, Singapore

11:15 Relapsed Classic E-Cadherin (CDH1) Mutated Invasive Lobular Breast Cancer (ILC) Features IHC/FISH Negative HER2 (ERBB2) Gene Mutations Sensitive to Anti-HER2 Targeted Therapies: A Next Generation Sequencing (NGS) Study (265)
JS Ross, C Sheehan, A Boguniewicz, G Otto, S Downing, J Curran, G Palmer, S Ali, R Yelesky, D Lipson, V Miller, P Stephens Albany Medical College, Albany, NY; Foundation Medicine Inc., Cambridge, MA

11:30 Prediction of Response to the Anti-EGFR Antibody Panitumumab Combined with Standard Neoadjuvant Chemotherapy in Triple Negative Breast Cancer (TNBC): The Immune and IGFR Pathways (254)
F Penault-Llorca, C Ablial, M-M Dauplat, M Privat, N Uhrhammer, A Desrichard, Y Bidet, N Radosevic-Robin, A Cayre, C Aube, F Kwiatkowski, Y-J Bignon, P Chollet, J-M Nabholtz Centre Jean Perrin and EA 4677 ERTICa University of Auvergne, Clermont-Ferrand, France

11:45 FISH MYC Amplification and MYC Protein Expression in Atypical Vascular Lesions, Mammary Angiosarcomas and Angiosarcomas of Other Sites (169)
PS Ginter, TY MacDonald, TM D’Alfonso, RA Kaplan, JM Mosquera, MA Rubin, SJ Shin Weill Cornell Medical College, New York, NY

8:00 Cytopenia Prior to AML Diagnosis Predicts Aggressive Behavior Even in the Absence of Antecedent MDS: Another Diagnostic Criterion for AML with Myelodysplasia-Related Changes? (1395)
A Huck, A Fathi, R Hasserjian Massachusetts General Hospital, Boston, MA

8:15 A Detailed Flow Cytometry Analysis of the Immune System in Non-Leukemic Cells of Acute Myeloid Leukemia Demonstrates the Prognostic Significance of Lymphocyte Subsets (1479)
RS Ohgami, M Alcasid, L Ren, JR Gotlib, DA Arber Stanford, Stanford, CA

8:30 Complex Karyotype but Not Blast Percentage Is Associated with Poor Survival in Acute Myeloid Leukemia and Myelodysplastic Syndrome with Inv(3)(q21q26.2)(t(3;3)(q21a;26.2)); a Bone Marrow Pathology Group Study (1498)
IJ Rogers, JW Vardiman, J Anastasi, G Raca, NM Savage, AM Cherry, D Arber, E Moore, JJD Morrissette, A Bagg, Y-C Liu, S Mathew, A Orazi, P Lin, SA Wang, CE Bueso-Ramos, K Foucar, RP Hasserjian, ED Hsi
Cleveland Clinic, Cleveland, OH; University of Chicago, Chicago, IL; Stanford University, Stanford, CA; University of Pennsylvania, Philadelphia, PA; Weill Medical College of Cornell University, New York, NY; MD Anderson Cancer Center, Houston, TX; University of New Mexico, Albuquerque, NM; Massachusetts General Hospital, Boston, MA

8:45 Day 14 Bone Marrow Cellularity Is Superior to CD34 Immunohistochemistry in Predicting Complete Remission in De Novo AML but Not in Secondary/Therapy-Related AML (1551)
G Zheng, A Dezern, KW Pratz, JE Karp, C Gocke Johns Hopkins Hospital, Baltimore, MD

9:00 CD34+HLA-DR- Is Most Commonly Seen in Children with Acute Megakaryoblastic Leukemia in Addition to Acute Promyelocytic Leukemia: A Potential Diagnostic Pitfall (1423)
K Lee, A McGranahan, TT Winkler, X Liang Children’s Hospital Colorado, Aurora, CO; University of Colorado Denver School of Medicine, Aurora, CO

9:15 Clinicopathologic and Molecular Genetic Features of De Novo Myeloid Sarcoma (1527)
XI Wang, K Patel, P Lin, Z Zuo, CE Bueso-Ramos, L Raja, JL Medeiros, CC Yin
University of Texas MD Anderson Cancer Center, Houston, TX

11:00 RAS Mutation Is a Poor Prognostic Factor in Patients with Chronic Myelomonocytic Leukemia (1544)
L Zhang, TN Aladily, Z Chakhachiro, H Yoo, X Xu, M Routhbort, SA Wang, R Luthra, R Miranda, LJ Medeiros, C Bueso-Ramos, JD Khoury
MD Anderson Cancer Center, Houston, TX

11:15 Atypical Chronic Myeloid Leukemia Versus Myelodysplastic/ Myeloproliferative Neoplasm-Unclassifiable (1405)
JM Jaso, B Fu, LJ Medeiros, SA Wang
University of Texas MD Anderson Cancer Center, Houston, TX

11:30 Post-Polyclymic Myelofibrosis: A Case Series Evaluating Incidence of Accelerated Phase, Dysmegakaryopoiesis, and Cytogenetic Abnormalities (1477)
RC Ochs, B Bashe, S Mathew, DM Knowles, A Orazi
Weill Cornell Medical College, New York, NY; Weill Cornell Medical College in Qatar, Doha, Qatar

11:45 Blastic Plasmacytoid Dendritic Cell Neoplasm in Bone Marrow, a Clinicopathological Description of 14 Cases (1325)
KM Alayed, JD Khoury, AF Alshaikh, TN Aladily, S Konoplev, LJ Medeiros
University of Texas MD Anderson Cancer Center, Houston, TX; King Saud University, Riyadh, Saudi Arabia
Section D – Gastrointestinal

Chaired by: Reetesh Pai and Maria Westerhoff

8:00 Lymphocytic Esophagitis Is Associated with CD4+ T-Cell-Predominance and Esophageal Dymotility (777)
Y. Yue, SL Gabbard, RI Rothstein, X Liu, A Suriawinata, M Lisovsky
Dartmouth-Hitchcock Medical Center, Lebanon, NH

8:15 Systemic Mastocytosis of the Gastrointestinal Tract: Clinical Pathologic Analysis of 21 Cases (622)
LA Doyle, MJ Hamilton, C Akin, MC Castells, JL Hornick
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

8:30 Like Eosinophilic Esophagitis, Reflux Esophagitis with Moderate to Abundant Eosinophils Is a Type 2 Immune Response with IgE-Staining Mast Cells (613)
P. Clayton, LA Vinson, KA Peterson
University of Utah, Salt Lake City, UT

8:45 Immunohistochemistry Improves the Detection of Adenovirus, but Not Cytomegalovirus, in Gastrointestinal Biopsies from Hematopoietic Stem Cell Transplant Recipients (770)
SR Weidner, J Jessurun, RK Yantiss, NC Panarelli
Weill Cornell Medical College, New York, NY

9:00 Cytomegalovirus (CMV) Infection in Inflammatory Bowel Disease: Role, Prevalence, Predictive Features, and Outcomes (659)
AJones, TC Smyrk, DH Bruining
Mayo Clinic, Rochester, MN

9:15 Clinical Outcome after the Diagnosis of Indefinite for Dysplasia in Patients with Idiopathic Inflammatory Bowel Disease (676)
KK Lai, Y Wang, H Xie, B Shen, JR Goldblum, BL Lewis, X Liu
Cleveland Clinic, Cleveland, OH; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

9:30 Classification and Significance of Serrated Colorectal Polyps in Inflammatory Bowel Disease (668)
HM Ko, N Harpaz, AD Polydorides
Mount Sinai School of Medicine, New York, NY

11:00 The Cervical Squamocolumnar Junction Is Not the Same as the “Transformation Zone”: Evidence for Two Related but Divergent Populations with Different Cancer Risks (1157)
M Herfs, SO Vargas, B Howitt, Y Yamamoto, MR Nucci, J Hornick, FD McKeon, W Xian, CP Crum
Brigham and Women’s Hospital, Boston, MA; University of Liege, Liege, Belgium; Children’s Hospital, Boston, MA; A-STAR, Singapore, Singapore

11:15 Squamocolumnar Junction-Specific Markers Define Biologically and Clinically Distinct Subsets of Low-Grade Cervical Intraepithelial Neoplasia (1158)
M Herfs, B Howitt, C Parra Herran, MR Nucci, S Feldman, FD McKeon, W Xian, CP Crum
Brigham and Women’s Hospital, Boston, MA; University of Liege, Liege, Belgium; A-STAR, Singapore, Singapore

11:30 Expression of p16 in Low-Grade Squamous Intraepithelial Lesions (LSIL/CIN 1): Correlation of Immunohistochemical Staining Patterns with Analysis of Human Papillomavirus (HPV) Types (1249)
A Yemelyanova, BM Ronnett, JD Seidman, A Ogurtsova, PE Gravitt
Johns Hopkins University, Baltimore, MD

11:45 V600E BRAF Mutation in Vulvovaginal Melanoma Is Rare: A Study of Anti-Human BRAF V600E Monoclonal Antibody in 24 Cases (1222)
M Raimeni, A Malpica, R Luthra, MT Deavers, ED Euscher
University of Texas MD Anderson Cancer Center, Houston, TX

12:00 Extrapulmonary Adenocarcinoma: A Clinicopathologic Study of 24 Cases (1142)
NC Fernandez, E Euscher, A Malpica
University of Texas MD Anderson Cancer Center, Houston, TX

12:15 Uterine Smooth Muscle Tumors with Features Suggesting Hereditary Leiomyomatosis and Renal Carcinoma (HLRCC) Syndrome: Detailed Morphologic Analysis and Correlation with 2SC Immunochemistry (1224)
C Reyes, Y Karamurzin, N Frizzell, K Garg, Y-B Chen, RA Saslow
Memorial Sloan-Kettering Cancer Center, New York, NY; University of South Carolina, Columbia, SC
Endometrial Stromal Sarcomas with Sex Cord Differentiation Are Associated with PHF1 Rearrangement (1125)
E D’Angelo, RH Ali, I Espinosa, C-H Lee, DG Huntsman, CB Gilks, J Prat
Hospital de la Santa Creu i Sant Pau, Institute of Biomedical Research (IIB Sant Pau), Autonomous University of Barcelona, Barcelona, Spain; University of British Columbia, Vancouver, BC, Canada; Centre for Translational and Applied Genomics (CTAG), British Columbia Cancer Agency, Vancouver, BC, Canada

Targeted Development of a Specific Biomarker of Endometrial Stromal Cell Differentiation Using Bioinformatics: The IFITM-1 Model (1218)
C Parra-Herran, L Yuan, MR Nucci, BJ Quade
Brigham and Women’s Hospital, Boston, MA

**PROFFERED PAPERS**
Tuesday, March 5, 2013
8:00 AM – 12:00 PM
CC 316/317

Section F – Cytopathology

**Chaired by: Dina Mody and RoseMary Tambouret**

8:00 Implementation of the Bethesda System for Reporting Thyroid Cytopathology: Observations from the 2011 Thyroid Supplemental Questionnaire of the College of American Pathologists (338)
M Auger, R Nayar, WE Khalbass, GA Barkan, C Benedict, R Tambouret, MR Schwartz, L Howell, R Sowers, A Hartley, N Thomas, AT Moriarty
McGill University and McGill University Health Center, Montreal, PQ, Canada; Northwestern University and Northwestern Memorial Hospital, Chicago, IL; University of Pittsburgh Medical Center, Pittsburgh, PA; Loyola University and Loyola University Medical Center Bedside Test, Maywood, IL; DCL Pathology, LLC, Indianapolis, IN; Harvard University and Massachusetts General Hospital, Boston, MA; Methodist Hospital Physician Organization, Houston, TX; University of California and University of California Davis School of Medicine, Sacramento, CA; College of American Pathologists, Northfield, IL; AmeriPath Indiana, Indianapolis, IN

8:15 Variable Impact of Qualifying Language on Clinical Management of Atypical Thyroid Fine Needle Aspirates (435)
M Vivero, AA Renshaw, KF Jeffrey
Brigham and Women’s Hospital, Boston, MA; Baptist Hospital, Miami, FL

8:30 Ultrasound Guided Fine Needle Aspiration (US-FNA) of Thyroid Nodules by a Cytopathologist at the University of Toledo Medical Center. Lessons from a Northwest Ohio Hospital (336)
SKC Arudra, SL Molnar, LE De Las Casas
University of Toledo Medical Center, Toledo, OH

8:45 Cervical Cytopathology of Stratified Mucin-Producing Intraepithelial Lesions (404)
Z Nagymanyoki, T Yang, X Qian
Brigham and Women’s Hospital, Boston, MA; Harvard Vanguard Medical Associates, Boston, MA

9:00 Vaginal Cytopathology and HPV Co-Testing Is Preferred for Follow-Up of Women with Invasive Cervical Cancer Treated by Hysterectomy (450)
C Zhao, Z Li, S Barron, W Hong, A Karunamurthy
University of Pittsburgh Medical Center, Pittsburgh, PA; Conemaugh Memorial Medical Center, Johnstown, PA

9:15 The Clinical Utility of HPV DNA, mRNA and p16INK4A/Ki-67 as Triage Tools for Low Grade Cervical Lesions LSIL and ASCUS (440)
C White, L Pilkington, H Keegan, S O’Toole, C Spillane, L Sharp, R O’Kelly, G Flannelly, JJ O’Leary, CM Martin
Trinity College Dublin, Dublin, Ireland; Coombe Women and Infants University Hospital, Dublin, Ireland; National Cancer Registry, Cork, Ireland; National Maternity Hospital, Dublin, Ireland

11:00 Cytopathology for the Diagnosis and Surveillance of Upper Urothelial Tract Carcinoma – A Single Cancer Center Experience (358)
J Dhillon, PE Spiess, WJ Sexton, JM Pow-Sang, BA Centeno
Moffitt Cancer Center, Tampa, FL

11:15 Correlation of FISH with Atypical Urine Cytology and Its Progression to Malignancy (429)
JM Ubago, EM Wojcik, GA Barkan
Loyola University Medical Center, Maywood, IL; Northwestern Memorial Hospital, Chicago, IL

11:30 The Combination of ProEx C and uCyt Tests Improve Detection of Urothelial Carcinoma in Atypical Urine Samples (434)
ME Vergara-Lluri, E Hu, M Levin, J Rao, SK Apple, NA Moatamed
David Geffen School of Medicine at UCLA, Los Angeles, CA

11:45 FNA Evaluation of Axillary Lymph Nodes for Breast Cancer Strongly Correlates with Surgical Pathology (367)
A Fung, PN Staats
University of Maryland Medical Center, Baltimore, MD
8:15  R132C IDH1 Mutations Are Found in Spindle Cell Hemangiomas and Not in Other Vascular Tumors or Malformations  (52)
KC Kurek, TC Pansuriya, MAJH van Ruler, B van den Akker, V Luks, SLJ Verbeke, HP Kozakewich, R Sciot, D Lev, AJ Lazar, CDM Fletcher, JVMG Bovee
Boston Children’s Hospital, Boston, MA; Leiden University Medical Center, Leiden, Netherlands; University of Leuven, Leuven, Belgium; MD Anderson Cancer Center, Houston, TX; Brigham and Women’s Hospital, Boston, MA

8:30  A Novel Superficial CD34-Positive Fibroblastic Sarcoma  (25)
JM Carter, SW Weiss, K Linos, DJ DiCaudo, AL Folpe
Mayo Clinic, Rochester, MN; Emory University, Atlanta, GA

8:45  Identification of Novel PAX3-MAML3 Fusion Gene in Low Grade Sinonasal Sarcoma with Neural and Myogenic Features by Transcriptome Analysis  (85)
X Wang, RP Graham, JE Lewis, JT Lewis, MR Erickson-Johnson, M Yaszemski, Y Asmann, J Jen, A Maran, ML Lonzo, AM Oliveira
Mayo Clinic, Rochester, MN

9:00  Prognosis of Retroperitoneal Sarcomas Owing to Their Histologic Subtypes: A Large Multicentre Retrospective Analysis From the French Sarcoma Group  (81)
M Toulmonde, A Neuville, P Terrier, D Ranchere-Vince, V Brouste, A Italiano, J-M Coindre
Institut Bergonié, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre Léon Bérard, Lyon, France

9:15  Myxochondroid Fibrous Pseudotumor: A Distinctive, Previously Undescribed Pseudoneoplasm of the Foot with a Predilection for Adolescent Males  (74)
W Shon, AL Folpe
Mayo Clinic, Rochester, MN

11:00  Evaluation of GNAS Mutations in Fibrous Dysplasia and Its Malignant Mimics, Including the Novel Finding of GNAS Mutation in Parosteal Osteosarcoma  (26)
JM Carter, L Jin, BR Evers, CY Inwards, AM Oliveira, KJ Fritchie
Mayo Clinic, Rochester, MN

11:15  SATB2 Is a Novel Marker of Osteoblastic Differentiation in Bone and Soft Tissue Tumors  (33)
JR Conner, JL Hornick
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

11:30  Changing Prognostic Factors in Osteosarcoma: Analysis of 381 Cases from Two Institutions  (89)
D Xing, SA Qasem, K Owusu, K Zhang, GP Siegal, S Wei
University of Alabama at Birmingham, Birmingham, AL; Wake Forest University, Winston-Salem, NC

11:45  Differential MicroRNA Expression in Low-Grade and High-Grade Cartilaginous Tumors  (86)
K Wani, M Deavers, K Aldape, A Lazar, W-L Wang
University of Texas MD Anderson Cancer Center, Houston, TX

PROFFERED PAPERS
Tuesday, March 5, 2013
8:00  APOL1 Risk Variants in Collapsing Lupus Glomerulopathy  (1628)
C Larsen, M Beggs, M Saeed, P Walker
Nephropath, Little Rock, AR; University of Arkansas for Medical Sciences, Little Rock, AR

8:15  A High-Risk Variant of the Apol1 Gene Correlates with Increased Interstitial Fibrosis and Tubular Atrophy among African Americans with Arterionephrosclerosis  (1620)
H Fatima, LP Peterson, H Yang, AB Fogo
University of Alabama at Birmingham, Birmingham, AL; Vanderbilt University Medical Center, Nashville, TN

8:30  Histopathologic Spectrum of Renal Biopsies in Patients with Inflammatory Bowel Disease  (1603)
JM Ambruzs, PD Walker, CP Larsen
Nephropath, Little Rock, AR; University of Arkansas for Medical Sciences, Little Rock, AR

8:45  A Proposed Pathologic Classification System for ANCA-Associated Glomerulonephritis Is Not Effective in Patients with Estimated Glomerular Filtration Rate of <15 at Presentation  (1621)
AH Gasim, T Lee, AS Wilkman, RJ Falk, PH Nachman, JC Jennette
UNC School of Medicine, Chapel Hill, NC

9:00  Kidney Disease in Obese Patients: A 12 Year Renal Biopsy Study  (1642)
SP Salvatore, SV Seshan
Weill Cornell Medical College, New York, NY

9:15  Plasminogen Activator Inhibitor-1 (PAI-1) Affects Parietal Epithelial Cell (PECs) Transition  (1637)
G Ren, M Khusheim, H Yang, AB Fogo
Vanderbilt University, Nashville, TN

11:00  Curcumin Enhances Mesangial Repair by Stem Cells in Light Chain-Mediated Glomerular Injury  (1649)
J Teng, EA Turbat-herrera, GA Herrera
Louisiana State University Health Science Center, Shreveport, LA

11:15  M2 Macrophages in Early Lesions of Crescentic Glomerulonephritis  (1655)
L Zhao, A Chang, S Meehan
University of Chicago, Chicago, IL

11:30  Long Term Kidney Graft Injury in Highly Sensitized Recipients  (1607)
N Carter-Monroe, ED Kraus, AA Zachary, LC Racusen, LJ Arend, RA Montgomery, SM Bagnasco
Johns Hopkins University School of Medicine, Baltimore, MD

11:45  Phospholipase A2 Receptor Staining (PLA2R) Is Very Rare in De Novo Membranous Glomerulopathy in the Renal Transplant  (1627)
CP Larsen, PD Walker
Nephropath, Little Rock, AR; University of Arkansas for Medical Sciences, Little Rock, AR
PROFFERED PAPERS
Tuesday, March 5, 2013
1:00 PM – 2:45 PM
CC Ballroom 2
Section A – Genitourinary
Chaired by: Mahul Amin and Ming Zhou

1:00 Metastatic Chemotherapy Resistant Urothelial Carcinoma (UC): Next Generation Sequencing (NGS) Reveals a Diverse Spectrum of Genomic Alterations (GA) and Targets of Therapy (1013)
Albany Medical Center, Albany, NY; Foundation Medicine Inc., Cambridge, MA

1:15 Pseudocarcinomatous Urothelial Hyperplasia (PCUH) of the Bladder: Clinical Findings and Follow-Up of 70 Patients (944)
ON Kryvenko, JI Epstein
Johns Hopkins Hospital, Baltimore, MD

1:30 Identification of Succinate Dehydrogenase-Deficient Bladder Paragangliomas (966)
EF Mason, PM Sadow, AJ Wagner, SP Remillard, TA Flood, EC Belanger, JL Hornick, JA Barletta
Brigham and Women’s Hospital, Boston, MA; Massachusetts General Hospital, Boston, MA; Dana Farber Cancer Institute, Boston, MA; Ottawa Hospital, Ottawa, ON, Canada

1:45 Effect of New AJCC pT4 Exclusion of Intraurethral Prostatic Stromal Invasion (IPSI) in Bladder Cancer: Stage in Bladder Proper Remains Predictive of Mortality in Non-pT4 Categories with IPSI (839)
JA Cohn, AR Patel, R Miocinovic, JB Taxy, GD Steinberg, DE Hansel, GP Paner
University of Chicago, Chicago, IL; Cleveland Clinic, Cleveland, OH

2:00 Recurrent Novel and Potentially Targetable Genetic Alterations in High Grade, Invasive Urothelial Carcinoma of the Bladder (788)
HA Al-Ahmadie, G Iyer, R Mehra, Y Chen, A Gopalan, SW Fine, SK Tickoo, BH Bochner, DF Bajorin, VE Reuter, MF Berger, DB Solit
Memorial Sloan-Kettering Cancer Center, New York, NY

2:15 Preoperative Immunohistochemical Biomarker Panel Predicts Upstaging at Radical Cystectomy: A Prospective Study (1035)
SF Shariat, BD Robinson, CE Matrai, A Bagrodia, V Rachakonda, E Xylinas, P Kapur, Al Sagalowsky, Y Lotan
Weill Cornell Medical College, New York, NY; UT Southwestern Medical Center, Dallas, TX

2:30 E-Cadherin (CDH1) Is Frequently Mutated in Urothelial Carcinoma with Signet-Ring Cell and Plasmacytoid Morphology (789)
HA Al-Ahmadie, G Iyer, R Mehra, Y Chen, A Gopalan, SW Fine, SK Tickoo, MF Berger, DF Bajorin, G Dalbagni, DB Solit, VE Reuter
Memorial Sloan-Kettering Cancer Center, New York, NY
PROFFERED PAPERS
Tuesday, March 5, 2013
1:00 PM – 2:45 PM
CC Ballroom 1
Section C – Cytopathology
Chaired by: David Chhieng and Bin Yang

1:00 Fine Needle Aspiration Is a Valid Tissue Source for EGFR and KRAS Molecular Testing in Lung Cancer: A Comparison Study with Core Needle Biopsy (421)
J Stewart, M Guo
University of Texas MD Anderson Cancer Center, Houston, TX

1:15 Common and Rare EGFR Mutations. The Challenge of Their Cytological Detection (415)
ED Rossi, R Gerhard, L Cirnes, JC Machado, FC Schmitt
Catholic University of Sacred Heart, Rome, Italy; IPATIMUP-Institute of Pathology and Immunology of Porto University, Porto, Portugal; Medical Faculty of the University of Porto, Porto, Portugal

1:30 The Utilization of Stained Cytologic Direct Smears for ALK Rearrangement Testing of Lung Adenocarcinoma (345)
BL Betz, CA Dixon, HC Weigelin, SM Knoepp, MH Roh
University of Michigan Health System, Ann Arbor, MI; St. Joseph Mercy Health System, Ann Arbor, MI

1:45 Alcohol and Formalin-Fixed Cytology Specimens Offer an Effective Alternative to Formalin-Fixed Tissue for ALK Break-Apart FISH Testing in Lung Adenocarcinoma (414)
F Rosenblum, J Garver, EF Cosar, L Hutchinson, EM Kurian
University of Massachusetts Medical Helathcare System, Worcester, MA

2:00 Predictive Value of Pre-Operative Thyroid FNA BRAF Mutation Testing for Risk of Lymph Node Thyroid Carcinoma Metastases: A Single Institution Experience of 498 Cases (430)
B Ustun, A Adeniran, G Cat, S Roman, J A Sosa, E Holt, DC Chhieng, CGA Theoharis
Yale University School of Medicine, New Haven, CT

2:15 Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS FNA) of Cystic Pancreatic Lesions: What Is the Value of Molecular and Chemical Analysis of Cyst Fluid in Diagnostic and Nondiagnostic Samples? (396)
W Li, S Nguyen, N Haddad, T Cermak, M Sidaway
MedStar Georgetown University Hospital, Washington, DC

2:30 A Superior Technique for Cell Block Preparation for Fine Needle Aspiration (340)
R Balassanian, J Ono, GD Wool, J Olejnik-Nave, MM Mah, BJ Sweeney, B-M Ljung, MB Pitman
University of California San Francisco, San Francisco, CA; Laboratory Medicine Consultants, Las Vegas, NV; Massachusetts General Hospital, Boston, MA

PROFFERED PAPERS
Tuesday, March 5, 2013
1:00 PM – 2:45 PM
CC Ballroom 3
Section D – Pulmonary
Chaired by: Sanjay Mukhopadhyay and Anja Roden

1:00 Intrapulmonary Mesothelioma Simulating Interstitial Lung Disease: A Distinctive Variant of Mesothelioma. Report of 5 Cases and Review of the Literature (1902)
BT Larsen, JRH Klein, H Hornychova, R Nati, S Thirumala, KO Leslie, TV Colby, HD Tazelaar
Mayo Clinic, Rochester, MN; University of Manitoba, Winnipeg, MB, Canada; Charles University Prague, Hradec Kralove, Czech Republic; Texas Tech University Health Science Center, Lubbock, TX; AmeriPath, Lubbock, TX; Mayo Clinic, Scottsdale, AZ

1:15 Targeted Cancer Genome Sequencing in Thymic Epithelial Tumors (1916)
AL Moreira, M Robert, W Helen, H James, RJ Gregory, L Marc, BF Michael
Memorial Sloan-Kettering Cancer Center, New York, NY

1:30 An Intratumoral B-Cell Immune Response Determines Favorable Prognosis for Early Stage Lung Cancer and Can Be Assessed by Different Immunoscores (1938)
J Sanz, S Hernandez, F Hernandez, JLG Larriba, J Puente, M Ferrer, B Perez Villamil, JL Subiza
Hospital Clinico San Carlos, Madrid, Spain

1:45 Neoplasms in Lung Explants: A Retrospective Review of 311 Consecutive Orthotopic Lung Transplants (1928)
J Poling, PB Illei
Johns Hopkins Medical Institutions, Baltimore, MD

2:00 Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in Common Variable Immunodeficiency (CVID) – Histological and Immunohistochemical Analysis of 12 Cases of a Rare Entity (1929)
N Rao, N Chase, JM Routes, AC Mackinnon
Medical College of Wisconsin, Milwaukee, WI

2:15 Pulmonary Cystic Lung Disease in Birt-Hogg-Dube Syndrome: Can Histology Discriminate from Bullous Emphysema? (1881)
A Fabre, R Borie, MP Debray, B Crestani, C Danel
St Vincent’s University Hospital, Dublin, Ireland; Hospital Bichat-Claude Bernard, APHP, HUPNVS, Paris, France

2:30 Hypersensitivity Pneumonia: Where Do Granulomas and Giant Cells Live? (1878)
MC Castonguay, JH Ryu, ES Yi, HD Tazelaar
Dalhousie University, Halifax, NS, Canada; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ
PROFFERED PAPERS
Tuesday, March 5, 2013
1:00 PM – 2:45 PM
CC 314/315
Section E – Techniques
Chaired by: Kenneth Aldape and Stephen Schmechel

1:00 Quantitative Assessment of Mutant Allele Burden in Solid
Tumors by Semiconductor Based Multi-Gene Next Generation
Sequencing (2081)
BP Portier, R Luthra, R Singh, M Routhert, B Handal, N Reddy,
BA Barkoh, Z Zuo, LJ Medeiros, K Aldape, KP Patel
MD Anderson, Houston, TX

1:15 Label-Free High-Resolution Infrared Spectroscopic Imaging for
Breast Tissue Histopathology (2092)
MJ Walsh, S Biswas, A Kajdacsy-Balla, R Bhargava
University of Illinois at Urbana-Champaign, Urbana, IL;
University of Illinois at Chicago, Chicago, IL

1:30 Single Cell Manipulation Technology-Towards “Ink-Jet”
Printing of Cancer Arrays (2070)
V McEneaney, H Keegan, M Gallagher, C Martin, O Sheils, J
Schondube, A Gross, P Kolay, J O’Leary
Trinity College Dublin, Dublin, Leinster, Ireland; IMTEK,
Freiburg, Germany

1:45 Mutational Load Quantification Technique as an Aid to the
Histopathologic Evaluation of Barrett’s Esophagus (2039)
WW Bivin, Jr., S Patel, JF Silverman, B Corcoran, E Ellsworth,
S Jackson, S Finkelstein
Allegheny General Hospital, Pittsburgh, PA; RedPath Integrated
Pathology, Inc., Pittsburgh, PA

2:00 Validation of Prognostic Biomarkers on Prostate Tissue
Microarrays (2059)
AD Johnson, AE Rizzardi, LO Marston, JS Koopmeiners, GJ
Metzger, CL Forster, RI Vogel, JB McCarthy, EA Turley, JR
Tiffany, Z Ronat, CA Warlick, SC Schmechel
University of Minnesota, Minneapolis, MN; NCI-Designated
Cancer Center, San Diego, CA; University of Western Ontario,
London, ON, Canada

2:15 Metabolites and Histology on Exactly the Same Biopsy Tissue
(2089)
DA Troyer, JR Shuster, R Lance
Eastern Virginia Medical School, Norfolk, VA; Biomarker
Factory, Durham, NC

2:30 Detection of Her2/Neu Overexpression in Gastric
Adenocarcinomas Using the Novel RNAScope Method (2085)
AD Singh, Y Luo, H Wang, X-J Ma, PB Illei
University of Pittsburgh, Pittsburgh, PA; Advanced Cell
Diagnostics, Inc, Hayward, CA; Johns Hopkins University,
Baltimore, MD

PROFFERED PAPERS
Tuesday, March 5, 2013
1:00 PM – 2:45 PM
CC 316/317
Section F – Pancreas
Chaired by: Wendy Frankel and Olca Basturk

1:00 Epigenetic and Genetic Changes of APC Gene in Acinar Cell
Carcinoma of the Pancreas (1777)
S La Rosa, D Furlan, N Sahman, M Stefanoili, MG Tibiletti,
B Bernasconi, V Adsay, S Asioli, S Casnedi, A Marando, K
Notohara, A Vanoli, L Zhang, F Sessa, C Capella
Ospedale di Circolo, Varese, Italy; University of Insubria,
Varese, Italy; Emory University, Atlanta, GA; University of
Turin, Turin, Italy; Hospital De Hautepierre, Strasbourg, France;
Kurashiki Central Hospital, Kurashiki, Japan; University of
Pavia, Pavia, Italy; Mayo Clinic, Rochester, MN

1:15 Is Investing Additional Time on Mitotic Counts in
Neuroendocrine Neoplasm Clinically Relevant? (1791)
M Shahid, LR Zakerberg, V Deshpande
Massachusetts General Hospital, Boston, MA

1:30 Increased (>20%) Ki67 Proliferation Index in Morphologically
Well Differentiated Pancreatic Neuroendocrine Tumors
(PanNETs) Correlates with Decreased Overall Survival (1761)
O Basturk, Z Yang, LH Tang, R Hruban, C McCull, V Adsay, A
Krasinskas, K-T Jang, A Bellizzi, C Shi, DS Klimstra
Memorial Sloan-Kettering Cancer Center, New York, NY; Penn
State Hershey MC, Hershey, PA; Johns Hopkins University,
Baltimore, MD; Emory University, Atlanta, GA; University of
Pittsburgh, Pittsburgh, PA; Samsung MC, Seoul, Korea;
Brigham and Women’s Hospital, Boston, MA; Vanderbilt
University, Nashville, TN

1:45 Analysis of KRAS Mutations in 518 Aspirated Pancreatic
Cyst Fluid Samples: KRAS Is Highly Specific for Intraductal
Mucinous Neoplasms but Fails To Detect Mucinous
Cystic Neoplasms (1795)
AD Singh, A Khalid, KE Fasanella, KM McGrath, HJ Zeh, NP
Ohori, KE Schoedel, S Navina, MN Nikiforova, RK Pai
UPMC Presbyterian Hospital, Pittsburgh, PA

2:00 Carcinogenetic Progression of Pancreatic Mucinous Cystic
Neoplasm Is of Aggressive Pancreatobiliary Lineage (1772)
K-T Jang, YL Choi, C Hill, E Stelow, DM Walters, O Basturk, P
Bagci, G Zamboni, D Klimstra, RH Hruban, V Adsay
SMC, Seoul, Korea; Emory University, Atlanta, GA; UVA,
Charlottesville, VA; Memorial Sloan-Kettering Cancer Center,
New York, NY; UV, Verona, Italy; Johns Hopkins University,
Baltimore, MD

2:15 Characterization of Putative Precursor Lesions of Familial
Pancreatic Cancer (1776)
B Konukiewitz, AM Schlitter, S Berchtold, S Haneder, P Langer,
D Bartsch, G Kluppel, I Esposito
Technical University of Munich, Munich, Germany; University
of Gießen and Marburg, Marburg, Germany

2:30 Growth Patterns of High-Grade Gallbladder Dysplasia:
Clinicopathologic Associations and Diagnostic Implications in
an Analysis of 318 Cases (1759)
P Bagci, B Saka, I Erbarut, N Dursun, O Basturk, JC Roa, OT
Escalona, H Losada, K-T Jang, SY Kong, AB Farris, V Adsay
Emory University, Atlanta, GA; Memorial Sloan-Kettering
Cancer Center, New York, NY; PU, Santiago, Chile; Frontera
University, Temuco, Chile; SMC, Seoul, Korea
PROFFERED PAPERS
Tuesday, March 5, 2013
1:00 PM – 2:45 PM
CC 309
Section G – Hematopathology
Chaired by: Dan Jones and David Dorfman

1:00 Novel Fusion Transcripts Identified in Angioimmunoblastic T Cell Lymphoma (1383)
S Guo, C Kucuk, J Iqbal, J Rohr, C Bi, C Wang, I Staudt, T McKeithan, WC Chan
University of Nebraska Medical Center, Omaha, NE; National Cancer Institute, NIH, Bethesda, MD

1:15 Defective Immune Homeostasis Mechanisms in Celiac Disease, in Its Progression to Refractory Celiac Disease and Transformation to Enteropathy-Associated T-Cell Lymphoma (1347)
J Carreras Esteban, YY Kituchi, T Kikuchi, S Hayashi, J Itoh, G Ronconador; R Hamoudi, WJ Howat, NM Tsuji, N Nakamura
Tokai University, School of Medicine, Isehara, Kanagawa, Japan; National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki, Japan; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; UCL-Cancer Institute, London, United Kingdom; CRUK CRI, Cambridge, Cambridgeshire, United Kingdom; CNIO, Madrid, Spain

1:30 Clinicopathologic Features of Anaplastic Large Cell Lymphoma (ALCL), ALK- and CD30+ Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL, nos): A Study from the North America T-Cell Lymphoma Consortium (1438)
WR Macon, MJ Maurer, J Said, SJ Rodig, RD Gascoyne, DM Dorfman, S Omdrejka, A Dogan, ED Hsi
Mayo Clinic, Rochester, MN; UCLA, Los Angeles, CA; Brigham and Women’s Hospital, Boston, MA; BCCA, Vancouver, Canada; Cleveland Clinic, Cleveland, OH

1:45 MicroRNA Expression Profiling Identifies Molecular Diagnostic Signatures for Anaplastic Large Cell Lymphoma (ALCL), ALK- and CD30+ Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL, nos): A Study from the North America T-Cell Lymphoma Consortium (1432)
C Liu, J Iqbal, J Teruya-Feldstein, Y Shen, MJ Dabrowska, K Dybklaer, MS Lim, R Piva, A Barreca, E Pellegrino, E Spaccarotella, CM Lachel, C Kucuk, C-S Jiang, X Hu, S Bhagvati, TC Greiner, DD Weisenburger, DM Dorfman, S Omdrejka, A Dogan, ED Hsi
Mayo Clinic, Rochester, MN; UCLA, Los Angeles, CA; Brigham and Women’s Hospital, Boston, MA; BCCA, Vancouver, Canada; Cleveland Clinic, Cleveland, OH;

2:00 Assessment of Tissue and Subcellular Distribution of miRNA Expressed Differentially between ALK + and ALK- Anaplastic Large Cell Lymphoma (1451)
M Mehrotra, R Luthra, R Singh, R Sargent, J Medeiros, KP Patel
MD Anderson Cancer Center, Houston, TX

2:15 Micrornas Could Be Implicated in Progression of Mycosis Fungoides (1441)
Fundacion Jimenez Diaz, Madrid, Spain; IFIMAV, Santander, Spain; Fundación Investigación Biomédica, Hospital Universitario, Puerta de Hierro-Majadahonda, Madrid, Spain; CNIO, Madrid, Spain; Hospital de Torrejón, Madrid, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Marques de Valdecilla, Santander, Spain

2:30 The Pathologist’s Approach to T-Cell Large Granular Lymphocytic Leukemia Diagnosis: A Multicenter Comparative Study by the Bone Marrow Pathology Group (1470)
JL Neff, X Fan, R Ohgami, Y Wu, SM Choi, RL King, DJ Tagliente, A Bagg, A Orazi, DA Arber, SA Wang, WG Morice II Mayo Clinic, Rochester, MN; Stanford School of Medicine, Stanford, CA; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Weill Cornell Medical College, New York, NY; MD Anderson Cancer Center, Houston, TX

PROFFERED PAPERS
Tuesday, March 5, 2013
1:00 PM – 2:00 PM
CC 310
Section H1 – Pan-Genomic/Pan-Proteomic Approaches to Cancer
Chaired by: Scott Tomlins and Marc Ladanyi

1:00 Profile: Results from Multiplexed Mass Spectrometric Genotyping of 2178 Cancer Patients (1816)
NI Lindeman, LE MacConaill, E Garcia, FC Kuo, JA Longtine, WC Hahn, PW Kantoff, BJ Rollins
Harvard Medical School, Boston, MA; Brigham and Women’s Hospital, Boston, MA; Mt. Sinai Hospital, New York City, NY; Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA

1:15 Expression Profiling and Molecular Classification of Colorectal Cancer: Meta-Analysis of 8 Independent mRNA Expression Datasets across the Globe (1830)
L Waldron, G Parmigiani, C Fuchs, C Hutterhouser, S Ogino Dana-Farber Cancer Institute, Boston, MA; Harvard School of Public Health, Boston, MA; Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

1:30 Use of Targeted Deep Sequencing To Analyze the Genomic Similarities of Concurrent Acute Myeloid Leukemia in the Peripheral Blood and Bone Marrow (1813)
JM Kleo, DH Spencer, C Miller, T Lamprecht, RS Fulton, L Ding, RK Wilson, TJ Ley
Washington University School of Medicine, St Louis, MO; Washington University, St Louis, MO

1:45 Whole Genome Analyses of Pancreatic Acinar Cell Carcinomas (1833)
LD Wood, Y Xiao, R Yonescu, JA Offerhaus, DS Klimstra, A Maitra, N Papadopoulos, KW Kinzler, B Vogelstein, RH Hruban Johns Hopkins University, Baltimore, MD; University Medical Center Utrecht, Utrecht, Netherlands; Memorial Sloan-Kettering Cancer Center, New York, NY
PROFFERED PAPERS
Tuesday, March 5, 2013
2:05 PM – 2:50 PM
CC 310
Section H2 – Infections
Chaired by: Laura Lamps and Dan Milner

2:05 Helicobacter pylori 23S rRNA Gene Sequencing for the Identification of Mutations Associated with Clarithromycin Resistance in FFPE Samples (1559)
M Mitui, SK Khokhar, NK Leos, CD Doern, JY Park
Children’s Medical Center, Dallas, TX; UT Southwestern Medical Center, Dallas, TX

2:20 Infectious Diseases Are Frequently Associated with Adult Hemophagocytic Lymphohistiocytosis in a Large Series of Cases (1565)
FN Rosado, AS Kim, EB Rinker, NM Spradlin, KK Reichard
Mayo Clinic, Rochester, MN; Vanderbilt University Medical Center, Nashville, TN

2:35 The Utility of Frozen Section in the Detection of Invasive Fungal Species in Combat-Related Injury (1555)
K Downing, D Tribble, J Wells
Walter Reed National Military Medical Center, Bethesda, MD; Uniformed Services University of the Health Sciences, Bethesda, MD

POSTER SESSION I
Monday, March 4, 2013
9:30 AM – 12:00 PM
CC Exhibit Hall A-D

Stowell-Orbison/Surgical Pathology/Autopsy Award Posters
Poster numbers to the left of the abstract title correspond to the board number where the poster will be displayed. The number in parentheses after the title is the abstract number in the Abstract Book. These posters will be on display this morning only.

AUTOPSY

1 Hospital Autopsy Quality Control and Assurance: The London Health Sciences Centre Experience (5)
R Jacques, M Shkrum
London Health Sciences Centre (University of Western Ontario), London, ON, Canada

2 Characterization of Enteric Vasculopathy in Patients with Left Ventricular Assist Device (LVAD) Therapy: A Retrospective Analysis (6)
A Kanagasabapathy, LP Dehner
Washington University School of Medicine, St Louis, MO

3 The Direct and Contributory Role of Alcohol to Mortality Rates (14)
CM Ryan, SF Crowther
Tallaght Hospital, Dublin, Ireland

4 Predictors of Toxicology Results in Sudden Unexpected Death Cases Released by the Medical Examiner to the Hospital (16)
OC Ukpo, LP Dehner
Washington University, Saint Louis, MO

5 Epidemiology of Endocarditis: A 22-Year Autopsy Review (18)
Y Zhou, SR Wilkinson, MD Cain, SD Reilley
University of Alabama Birmingham, Birmingham, AL

BONE & SOFT TISSUE

6 BRAF Mutation in “Sarcomas”: A Possible Method To Detect Melanomas (30)
NA Cipriani, PJ McLaughlin, DR Borger, GP Nielsen
Massachusetts General Hospital, Boston, MA

7 Perivascular Stem Cells Induce Bone formation and Vasculogenesis in Ectopic and Bone Injury Models (42)
AW James, G Chung, G Asatrian, O Velasco, A Pan, A Nguyen, P Liang, D Stoker, K Ting, B Peault, C Soo
University of California, Los Angeles, CA

8 Utility of Sox-10 To Distinguish MPNST from Synovial Sarcoma with a Focus on Intraneural Synovial Sarcoma (45)
Y Kang, M Pekmezci, B Scheithauer, A Ersen, A Folpe, A Horvai
UCSF, San Francisco, CA; Mayo Clinic, Rochester, MN

9 Prognostic Features of Myxofibrosarcoma: A Clinicopathologic Study Assessing the Impact of FNCLCC Grading System (73)
W Shon, MM Wozl, SM Jenkins, KJ Fritchie
Mayo Clinic, Rochester, MN
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Differential Expression of miR-138 in Malignant Peripheral Nerve Sheath Tumors and Desmoplastic Melanomas (79)</td>
<td>SK Tian, P Koty, O Sangueza, JS Gouffon, S Qasem</td>
<td>Wake Forest School of Medicine, Winston-Salem, NC; Affymetrix, Santa Clara, CA</td>
</tr>
<tr>
<td>11</td>
<td>Sensitivity and Specificity of USP6 Gene Break-Apart Assay and Protein Expression in Nodular Fasciitis (90)</td>
<td>Y Xu, G De la Roza, J Tull, S Zhang</td>
<td>SUNY Upstate Medical University, Syracuse, NY</td>
</tr>
<tr>
<td></td>
<td>BREAST</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>The Expression of Cytokeratin 19 in Breast Carcinoma and Its Association with Hormone Receptor Status (95)</td>
<td>NA Aardsma, JV Groth, SV Prabhu, EL Wiley</td>
<td>University of Illinois Hospital &amp; Health Sciences System, Chicago, IL</td>
</tr>
<tr>
<td>13</td>
<td>Histology of Breast Cancer in Patients with Lynch Syndrome (104)</td>
<td>BAqil, B Arun, N Sneige, AM Gutierrez-Barrera, D Rosen, S Abrahams, E Resekova, Y Wu, CT Albarracin</td>
<td>Baylor College of Medicine, Houston, TX; MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>14</td>
<td>High Mobility Group A1 (HMGA1) Proteins Associate with ER-Negativity and High Nuclear Grade in Breast Cancer in a Cohort of Asian Women (106)</td>
<td>RJ Asch, A Cinino-Mathews, L Coppe, A Meeker, YK Bae, LMS Resar</td>
<td>Johns Hopkins University School of Medicine, Baltimore, MD; Johns Hopkins University School of Medicine, Baltimore, Korea; Yeungnam University College of Medicine, Daegu, Korea</td>
</tr>
<tr>
<td>15</td>
<td>Mutational and Clonal Intratumoral Heterogeneity of Breast Cancer (109)</td>
<td>S Avril, LN Harris, H Hofler, HL Gilmore</td>
<td>Technische Universität München, Munich, Germany; Case Western Reserve University and University Hospitals Seidman Cancer Center, Cleveland, OH; Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH</td>
</tr>
<tr>
<td>16</td>
<td>Diagnostic Uncertainty of Fibroepithelial Lesions on Core Biopsy Results in Increased Likelihood of Excision and Final Diagnosis of Phyllodes Tumor (128)</td>
<td>SJT Chen, JC Pang, L Zhao, JM Jorns</td>
<td>University of Michigan, Ann Arbor, MI</td>
</tr>
<tr>
<td>17</td>
<td>HER2 Status in Breast Cancer as Determined by Three ASCO/CAP Recognized Reporting Techniques Reveals Testing Discordance, and Emphasizes the Utility of Co-Testing with FISH and IHC (132)</td>
<td>MR Clay, EA Gilbert, CD Bangs, A Cherry, KC Jensen</td>
<td>Stanford Hospital and Clinics, Stanford, CA; Veterans Hospital, Palo Alto, CA</td>
</tr>
<tr>
<td>18</td>
<td>GATA3 Expression in Different Subtypes of Invasive Breast Carcinoma and Comparison with GCDFP15 and Mammaglobin (140)</td>
<td>G Defiereos, U Krishnamurti, JF Silverman</td>
<td>Allegheny General Hospital, Pittsburgh, PA</td>
</tr>
<tr>
<td>19</td>
<td>Evaluation of HER2 IHC Staining Using the Ventana Image Analysis System, Correlation with HER2 FISH Amplification (141)</td>
<td>JA Dennis, R Parsa, D Chau, Y Peng, S Sahoo, YV Fang, VR Sarode</td>
<td>UT Southwestern, Dallas, TX</td>
</tr>
<tr>
<td>20</td>
<td>Metastatic Tumor Volume and Extranodal Tumor Extension: Clinical Significance in Patients with Stage II Breast Cancer (145)</td>
<td>E Drinka, A McBride, P Allen, T Buchholz, A Sahin</td>
<td>MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>21</td>
<td>Significance of GRB7 Protein Expression Level in Breast Cancer (148)</td>
<td>BD Ellsworth, D Dabbs, R Bhargava</td>
<td>University of Pittsburgh Medical Center, Magee-Womens Hospital, Pittsburgh, PA</td>
</tr>
<tr>
<td>22</td>
<td>Mucinous Carcinoma of the Breast: A Clinico-Pathological Assessment Based on the Percentage of Mucinous Component (149)</td>
<td>Z Eslami, G Omeroglu, A Omeroglu</td>
<td>McGill University Health Center, Montreal, QC, Canada</td>
</tr>
<tr>
<td>23</td>
<td>Low Estrogen Receptor Positive Breast Cancer: Is This a Distinct Group? (172)</td>
<td>NC Gloyeske, DJ Dabbs, A Mallon, R Bhargava</td>
<td>Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA</td>
</tr>
<tr>
<td>24</td>
<td>Basal-Like Breast Cancer Is Associated with Both an Enhanced Cytotoxic and Regulatory T-Cell Response (189)</td>
<td>E Kalife, S Lu, S Mangray, R Tavares, L Noble, M Resnick, E Yakirevich</td>
<td>Warren Alpert Medical School of Brown University, Providence, RI</td>
</tr>
<tr>
<td>25</td>
<td>Phenotypes of Breast Cancers Heterogeneous for HER2 Gene Amplification: Looking for Biologically Relevant Thresholds (196)</td>
<td>MR Kilgore, JS Kranzeler, SM Dintzis, RA Schmidt, PE Swanson, MH Rendi, HM Linden, KH Allison</td>
<td>University of Washington, Seattle, WA</td>
</tr>
<tr>
<td>26</td>
<td>Correlation of Sentinel Lymph Node Metastases with Breast Tumor Grade, Harbor-UCLA Medical Center Experience: A Pathologic Cases Series with Evaluation of Tumor Size and Her2 and ER Overexpression (209)</td>
<td>J Lee, S French, R Venegas</td>
<td>Harbor-UCLA Medical Center, Torrance, CA</td>
</tr>
<tr>
<td>27</td>
<td>Analysis of Gene Mutations in Subtypes of Metaplastic Carcinoma of the Breast (211)</td>
<td>X Li, L Huo, SL Moulder, MZ Gilcrease</td>
<td>University of Texas MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>28</td>
<td>Comparison of Margin Status of Separate Cavity Margins and Lumpectomy Margins in Breast Conserving Surgery (212)</td>
<td>Y Li, I Hughes, R Omman, W Roquiz, X Duan, A Szpoderska, C Perez, C Godellas, C Ersahin</td>
<td>Loyola University Medical Center, Maywood, IL</td>
</tr>
<tr>
<td>Board Number</td>
<td>Title</td>
<td>Authors</td>
<td>Institution</td>
</tr>
<tr>
<td>-------------</td>
<td>-----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>29</td>
<td>Correlation of Papillary Neoplasms Diagnosed on Core Needle Biopsy That Underwent Re-Excision at Danbury Hospital between 2009-2011 (214)</td>
<td>L Lippincott, R Vidhun</td>
<td>Danbury Hospital, Danbury, CT</td>
</tr>
<tr>
<td>30</td>
<td>Claudin Expression in Triple Negative and ER-Positive Breast Carcinoma (224)</td>
<td>MA Malik, C Cohen, A Adams, J Wang, GM Oprea</td>
<td>Emory University Hospital, Atlanta, GA</td>
</tr>
<tr>
<td>31</td>
<td>Correlative Analysis of Immunohistochemical and OncotypeDX® Derived PCR Data in Breast Cancer (227)</td>
<td>Z McCroskey, G Venkataraman, P Robinson, S Lo, A Szpaderska, X Duan, C Ersahin</td>
<td>Loyola University Medical Center, Maywood, IL</td>
</tr>
<tr>
<td>32</td>
<td>Are Breast Cancer Metastases Enriched for Stem Cells? (235)</td>
<td>DN Nguyen, A Subhawong, CG Kleer, P Argani, A Cimino-Mathews</td>
<td>Johns Hopkins Hospital, Baltimore, MD; University of Michigan, Ann Arbor, MI</td>
</tr>
<tr>
<td>33</td>
<td>The Breast Cancer Epithelial-Stromal Interactome (242)</td>
<td>E-Y Oh, NM Knoblauch, AH Beck</td>
<td>Beth Israel Deaconess Medical Center &amp; Harvard Medical School, Boston, MA</td>
</tr>
<tr>
<td>34</td>
<td>NIK- and IKK2-Binding Protein: A Novel Marker of Breast Cancer (248)</td>
<td>S Parajuli, H Wang, W Hu, X Zhang</td>
<td>Temple University Hospital, Philadelphia, PA; Temple University School of Medicine, Philadelphia, PA</td>
</tr>
<tr>
<td>35</td>
<td>Immunoexpression of Complete Response (pCR) in HER2 Positive Breast Carcinoma Patients Treated with Neoadjuvant Trastuzumab-Based Therapy (260)</td>
<td>BP Portier, Z Wang, E Minca, GT Budd, C Lanigan, L Morrison, RR Tubbs</td>
<td>Cleveland Clinic, Cleveland, OH; Ventana Medical Systems, Inc., Tucson, AZ</td>
</tr>
<tr>
<td>36</td>
<td>Prognostic Significance of Fibroblast Growth Factor Receptor 1 (FGFR-1) Overexpression in Invasive Mammary Carcinoma (BRCA) (261)</td>
<td>MJ Presta, RN Al-Rohil, CB Sheehan, CE Sheehan, AB Boguniewicz, JS Ross</td>
<td>Albany Medical College, Albany, NY</td>
</tr>
<tr>
<td>37</td>
<td>Characteristics of Breast Cancer in Patients with PTEN Hamartoma Tumour Syndrome (274)</td>
<td>AP Sciallis, A Nassar, LA Boardman, VS Chandan, SS Shah</td>
<td>Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>38</td>
<td>Molecular MicroRNA Signatures of Breast Cancer with Brain Metastasis (275)</td>
<td>S Sethi, A Ahmad, R Ali-Fehmi, S Mittal, W Chen, FH Sarkar</td>
<td>Wayne State University School of Medicine, Detroit, MI</td>
</tr>
<tr>
<td>39</td>
<td>Breast Cancer with Brain Metastases: Risk Factors and Survival (277)</td>
<td>Q Shen, NK Ibrahim, KD Aldape, A Sahin</td>
<td>University of Texas MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>40</td>
<td>Computational Image Analysis To Identify a Morphological Signature of Claudin-Low Breast Cancer (281)</td>
<td>K Singh, L Collins, N Knoblauch, M Hefit, A Beck</td>
<td>Beth Israel Deaconess Medical Center, Boston, MA</td>
</tr>
<tr>
<td>41</td>
<td>Hormone Receptor Expression in HER2+ Breast Cancer and Relationship to Ki67 and p53 Expression (284)</td>
<td>D Smith, D Xiang, A Christie, G John, Y Peng, S Sahoo, Y Fang, V Sarode</td>
<td>UT Southwestern Medical Center, Dallas, TX</td>
</tr>
<tr>
<td>42</td>
<td>P16 Expression and Its Correlation with Ki67 in Triple-Negative Breast Carcinoma (285)</td>
<td>JZ Sugianto, V Sarode, S Sahoo, Y Fang, D Oliver, Y Peng</td>
<td>University of Texas Southwestern Medical Center, Dallas, TX</td>
</tr>
<tr>
<td>43</td>
<td>Borderline Ductal Epithelial Lesions: Interobserver Reproducibility in 43 Cases with Original Diagnosis of Atypical Ductal Hyperplasia Bordering on Ductal Carcinoma In-Situ (291)</td>
<td>G Tozhikian, E Brogi, J Catalano, S Patil, KJ Van Zee, M Kadivar, CE Vallejo, YH Wen</td>
<td>Memorial Sloan-Kettering Cancer Center, New York, NY; Rasool-Akram Hospital, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran</td>
</tr>
<tr>
<td>44</td>
<td>Computational Discovery of Breast Cancer Morphologic Subtypes and Their Molecular Underpinnings (305)</td>
<td>Y Xia, M Hefit, N Knoblauch, AH Beck</td>
<td>Beth Israel Deaconess Medical Center, Boston, MA</td>
</tr>
<tr>
<td>45</td>
<td>Mesothelin, a Targetable Surface Protein, Is Highly Expressed in Breast Carcinomas in African American Women (306)</td>
<td>R Xian, T Julia, Z Amy, R Vonderheide, C June, Z Paul</td>
<td>Hospital of the University of Pennsylvania, Philadelphia, PA</td>
</tr>
<tr>
<td>46</td>
<td>Loss of PRKAR1A Expression in Carney Complex-Associated Versus Nonsyndromic Cardiac Myxomas: Immunohistochemical and Molecular Analysis of 112 Cases (321)</td>
<td>BT Larsen, MC Castonguay, NS Kip, BR Kipp, JJ Malezewski</td>
<td>Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>47</td>
<td>Prognostic Significance of Fibroblast Growth Factor Receptor 1 (FGFR-1) Overexpression in Invasive Mammary Carcinoma (BRCA) (261)</td>
<td>MJ Presta, RN Al-Rohil, CB Sheehan, CE Sheehan, AB Boguniewicz, JS Ross</td>
<td>Albany Medical College, Albany, NY</td>
</tr>
<tr>
<td>48</td>
<td>Characteristics of Breast Cancer in Patients with PTEN Hamartoma Tumour Syndrome (274)</td>
<td>AP Sciallis, A Nassar, LA Boardman, VS Chandan, SS Shah</td>
<td>Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>49</td>
<td>Molecular MicroRNA Signatures of Breast Cancer with Brain Metastasis (275)</td>
<td>S Sethi, A Ahmad, R Ali-Fehmi, S Mittal, W Chen, FH Sarkar</td>
<td>Wayne State University School of Medicine, Detroit, MI</td>
</tr>
<tr>
<td>50</td>
<td>Breast Cancer with Brain Metastases: Risk Factors and Survival (277)</td>
<td>Q Shen, NK Ibrahim, KD Aldape, A Sahin</td>
<td>University of Texas MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>51</td>
<td>Computational Image Analysis To Identify a Morphological Signature of Claudin-Low Breast Cancer (281)</td>
<td>K Singh, L Collins, N Knoblauch, M Hefit, A Beck</td>
<td>Beth Israel Deaconess Medical Center, Boston, MA</td>
</tr>
<tr>
<td>52</td>
<td>Hormone Receptor Expression in HER2+ Breast Cancer and Relationship to Ki67 and p53 Expression (284)</td>
<td>D Smith, D Xiang, A Christie, G John, Y Peng, S Sahoo, Y Fang, V Sarode</td>
<td>UT Southwestern Medical Center, Dallas, TX</td>
</tr>
<tr>
<td>53</td>
<td>P16 Expression and Its Correlation with Ki67 in Triple-Negative Breast Carcinoma (285)</td>
<td>JZ Sugianto, V Sarode, S Sahoo, Y Fang, D Oliver, Y Peng</td>
<td>University of Texas Southwestern Medical Center, Dallas, TX</td>
</tr>
<tr>
<td>54</td>
<td>Borderline Ductal Epithelial Lesions: Interobserver Reproducibility in 43 Cases with Original Diagnosis of Atypical Ductal Hyperplasia Bordering on Ductal Carcinoma In-Situ (291)</td>
<td>G Tozhikian, E Brogi, J Catalano, S Patil, KJ Van Zee, M Kadivar, CE Vallejo, YH Wen</td>
<td>Memorial Sloan-Kettering Cancer Center, New York, NY; Rasool-Akram Hospital, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran</td>
</tr>
<tr>
<td>55</td>
<td>Computational Discovery of Breast Cancer Morphologic Subtypes and Their Molecular Underpinnings (305)</td>
<td>Y Xia, M Hefit, N Knoblauch, AH Beck</td>
<td>Beth Israel Deaconess Medical Center, Boston, MA</td>
</tr>
<tr>
<td>56</td>
<td>Mesothelin, a Targetable Surface Protein, Is Highly Expressed in Breast Carcinomas in African American Women (306)</td>
<td>R Xian, T Julia, Z Amy, R Vonderheide, C June, Z Paul</td>
<td>Hospital of the University of Pennsylvania, Philadelphia, PA</td>
</tr>
<tr>
<td>57</td>
<td>Loss of PRKAR1A Expression in Carney Complex-Associated Versus Nonsyndromic Cardiac Myxomas: Immunohistochemical and Molecular Analysis of 112 Cases (321)</td>
<td>BT Larsen, MC Castonguay, NS Kip, BR Kipp, JJ Malezewski</td>
<td>Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>58</td>
<td>Prognostic Significance of Fibroblast Growth Factor Receptor 1 (FGFR-1) Overexpression in Invasive Mammary Carcinoma (BRCA) (261)</td>
<td>MJ Presta, RN Al-Rohil, CB Sheehan, CE Sheehan, AB Boguniewicz, JS Ross</td>
<td>Albany Medical College, Albany, NY</td>
</tr>
<tr>
<td>59</td>
<td>Characteristics of Breast Cancer in Patients with PTEN Hamartoma Tumour Syndrome (274)</td>
<td>AP Sciallis, A Nassar, LA Boardman, VS Chandan, SS Shah</td>
<td>Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>60</td>
<td>Molecular MicroRNA Signatures of Breast Cancer with Brain Metastasis (275)</td>
<td>S Sethi, A Ahmad, R Ali-Fehmi, S Mittal, W Chen, FH Sarkar</td>
<td>Wayne State University School of Medicine, Detroit, MI</td>
</tr>
<tr>
<td>61</td>
<td>Breast Cancer with Brain Metastases: Risk Factors and Survival (277)</td>
<td>Q Shen, NK Ibrahim, KD Aldape, A Sahin</td>
<td>University of Texas MD Anderson Cancer Center, Houston, TX</td>
</tr>
</tbody>
</table>
50  Utility of Axillary Lymph Node Fine-Needle-Aspiration in Management of Patients with Breast Cancer  (372)
B Graber, J McLeod, K Kort, DM Masrani, KK Khurana
SUNY Upstate Medical University, Syracuse, NY

51  Telepathology Assisted Immediate Assessment of EBUS-FNA Has Equivalent Accuracy to Cytopathologist On-Site Examination  (378)
JB Hudson, BA Murray, AC Chen, BT Collins, JF Wang
Washington University School of Medicine, Saint Louis, MO; Barnes-Jewish Hospital, Saint Louis, MO

52  Utility of Thyroglobulin Rinse Levels as an Adjunct to FNA of Neck Nodules in the Evaluation of Metastatic Papillary Thyroid Carcinoma  (382)
JA Jackson, MW Riben, BC Handy, NP Caraway
MD Anderson Cancer Center, Houston, TX

53  Lubricant-Related High Unsatisfactory Rate with ThinPrep – Can the Cellularity Be Improved?  (387)
T Kalinicheva, S Masineni, M Zulfiqar, H Guan, S Bandyopadhyay, P Tranchida, D Shi, S Madan, T Giorgadze, I Dhillon, M Luemmann, J Thompson, O Hassan, V Shidham
Wayne State University School of Medicine and Detroit Medical Center, Detroit, MI

54  Targeted Next-Generation Sequencing from Fine Needle Aspirates  (388)
HE Karnes, EJ Duncavage, CT Bernadt
Washington University in St Louis, St. Louis, MO

55  Renal Cell Carcinoma with Rhabdoid Features: Cytologic Features on Fine Needle Aspiration Biopsy  (390)
LY Khor, CG Przybycin, S Gmitro, C Magi-Galluzzi, JP Reynolds
Cleveland Clinic, Cleveland, OH

56  Human Papilloma Virus Testing and p16 Immunohistochemistry as Ancillary/Reflex Tests in ASC-H Cervical-Vaginal Cytology  (399)
SN Masineni, M Zulfiqar, T Kalinicheva, T Giorgadze, S Bandyopadhyay, H Guan, P Tranchida, D Shi, S Madan, VB Shidham
Wayne State University School of Medicine and Detroit Medical Center, Detroit, MI

57  Discordant Pap Tests (HPV Positive Cytology Negative Cotests): A Follow-Up Study of 334 Patients  (406)
OO Oshilaja, JP Reynolds, A Goyal
Cleveland Clinic Foundation, Cleveland, OH

58  The Pittsburgh Cervical Cancer Screening Model Indicates That Patient History Significantly Impacts Future Cervical Cancer Risk in Patients with Current Negative HPV Results  (411)
EF Rodriguez, A Onisko, RM Austin
University of Pittsburgh, Pittsburgh, PA; School of Information Sciences, University of Pittsburgh, Pittsburgh, PA; Magee-Womens Hospital of University of Pittsburgh, Pittsburgh, PA

59  Cytologic Diagnosis and Classification of Indolent B-Cell Lymphomas: Results of a 3-Year Institutional Review with Implications for Reporting  (418)
J Schwock, H-M Ko, G da Cunha Santos, SL Boerner, WR Geddie
University of Toronto, Toronto, ON, Canada

60  Utility of Islet 1, PAX8, CDX2 and TTF1 in Fine Needle Aspiration Workup of Metastatic Neuroendocrine Tumors  (432)
C Velosa, J Nunez, J Silverman
Allegheny General Hospital, Pittsburgh, PA

61  Evaluating Diagnostic Concordance of 3-D Virtual Gynecologic Imaging vs. Light Microscopy: Follow-Up Study  (439)
WR Wedel, AJ Horn, M Mukherjee, J Bridge, M McGaughey, A Donnelly, E Lyden, J Meza, SJ Radio
University of Nebraska Medical Center, Omaha, NE

62  Non-16/18 HR-HPV Genotypes Are Superior to HPV 16/18 for Predicting High-Grade Intraepithelial Lesions in LEEP Resections  (451)
H Zhou, D Mody, M Schwartz, Y Ge
Methodist Hospital, Houston, TX

DERMATOPATHOLOGY

63  Whole Exome Sequence Analysis of Merkel Cell Carcinoma  (459)
PJ Cimino, Jr., EJ Duncavage
Washington University School of Medicine, St. Louis, MO

64  Clinicopathologic Features of Cutaneous Perineurioma and Perineurial Cell-Rich Tumors  (462)
MD Cykowski, I Shendrik, CM Magro, JV Pitha, AN Crowson
University of Oklahoma Health Sciences Center, Oklahoma City, OK; Regional Medical Laboratories, Tulsa, OK; Weill Cornell Medical College, New York City, NY

65  Low Frequency of Cytogenetic Abnormality, BRAF and NRAS Mutations in Borderline Melanocytic Tumors Arising in Deep Penetrating Nevi  (470)
R Guo, S Li, C Magro, AN Crowson
University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of Oklahoma and Regional Medical Laboratory, St. John Medical Center, Tulsa, OK; Weill Medical College of Cornell University, New York, NY

66  Wnt and Hedgehog Signaling Pathway Activation in Cutaneous Fibrosing Disorders: A Tissue Microarray Study  (479)
K Linskey, J Kay, LM Duncavan, RM Nazzaro
Massachusetts General Hospital, Boston, MA; UMass Memorial Medical Center, Worcester, MA

67  Differential Stathmin 1 Immunoreactivity in Spitz Nevi and Melanoma  (483)
J Moore, E Hyjek, T Krausz
University of Chicago Medicine, Chicago, IL

68  Histopathologic Features Most Suggestive of Prodromal/ Urticarial Bullous Pemphigoid  (501)
VS Snyder, CL Kinonen, BC Gleason, AB Thomas, TL Cibull
NorthShore University HealthSystem, Evanston, IL; Diagnostic Pathology Medical Group, Sacramento, CA

69  Cell Rich Toxic Epidermal Necrolysis (TEN): A Novel Histological Variant with Prognostic Implications  (502)
JJ Speiser, V Mehta, KA Hutchens
Loyola University Medical Center, Maywood, IL
70 Keratoacanthoma: A Molecularly Distinct Entity from Squamous Cell Carcinoma (504)
A Su, S Ra, X Li, R Kulkarni, S Binder
UCLA Medical Center, Los Angeles, CA; San Diego Pathologists Medical Group, San Diego, CA

71 Next Generation Sequencing (NGS) Reveals Pathway Activations and New Routes to Targeted Therapies in Metastatic Cutaneous Melanoma (MM) (507)
A Tarasen, JA Carlson, CE Sheehan, G Otto, G Palmer, R Yelensky, D Lipson, A Donahue, K Iwaniak, J Buell, S Downing, J Curran, V Miller, P Stephens, JS Ross
Albany Medical College, Albany, NY; Foundation Medicine Inc., Cambridge, MA

72 SOX10: A Useful Marker for Identifying Metastatic Melanoma in Sentinel Lymph Nodes (513)
BC Willis, J Wang, C Cohen
Emory University, Atlanta, GA

EDUCATION

73 Knowledge Retention and Learning Benefits from Utilization of a Web-Based Learning Module Methodology for Pathology Training (518)
BM Chung, JH James, JV Groth, J Lee, S Sontag, G Chejfec, EL Wiley
University of Illinois Hospital & Health Sciences System, Chicago, IL; Edward Hines, Jr. Veterans Association Hospital, Hines, IL.

74 A Retrospective Analysis of Consultation Activities in Clinical Pathology: Implications for Transformation and Resident Training (521)
CA Garcia, RL Schmidt, J Panlener, BR Jackson, ER Ashwood, JW Hussong
University of Utah, Salt Lake City, UT

75 Facilitating Multi-Disciplinary Expertise on Esophageal Dysplasia Via a Sharable Content Object Reference Model (SCORM) Course (523)
JH James, J Lee, S Sontag, G Chejfec, EL Wiley
University of Illinois H&HSS, Chicago, IL; Edward Hines, Jr. Veterans Affairs Hospital, Chicago, IL

76 The Integration of Pathology in Medical Education; a Global Perspective (524)
MK Mirza, SD Stern, I Morgan, H Dong, B Cooper, R Sherer, AN Husain
University of Chicago Medicine, Chicago, IL

77 Effectiveness of Training in Gross Image Disease Recognition and Technical Skills Using Simulation Based Medical Education (SBME) (527)
A Simmonds, S Rath, S Mehrni, SM Dintzis, SS Raab
Eastern Health and Memorial University, St. John’s, NL, Canada; University of Washington, Seattle, WA

78 Emergency Frozen Section: Development of a Standardized Teaching Module for Residents (528)
NE Sunderland, MD Hyrcza, CB Gilks
University of British Columbia, Vancouver, BC, Canada; Vancouver General Hospital, Vancouver, BC, Canada

ENDOCRINE

79 Cytoplasmic OCT4 Staining Is a Sensitive and Specific Marker of Neuroendocrine Differentiation (532)
RE Alexander, DJ Grignon, L Cheng, MT Idrees
Indiana University School of Medicine, Indianapolis, IN

80 Clinical Characteristics of Cribriform-Morular Variant of Papillary Thyroid Carcinoma (533)
M Alikhan, M Hosseini, J Taxy
University of Chicago, Chicago, IL

81 Sunitinib Targets in Pheochromocytomas and Paragangliomas (539)
C Cassol, D Winer, W Liu, M Guo, S Asa
University of Toronto, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada; Ontario Cancer Institute, Toronto, ON, Canada

82 Claudin Proteins Are Differentially Expressed in Gastrointestinal and Pulmonary Neuroendocrine Tumors (543)
R Clubbala, J Li, S Lu, M Shamit, M Renee, N Lelia, R Murray, Y Evgeny
Rhode Island Hospita/Warren Alpert Medical School of Brown University, Providence, RI

83 BRAF V600E Mutations in Thyroid Carcinomas: Is There a Role for BRAF Immunohistochemistry? (547)
KE Fisher, L Ehsani, SG Neill, SA Caltharp, MT Siddiqui, C Cohen
Emory University School of Medicine, Atlanta, GA

84 PHH3, Ki-67 and Mitotic Count Correlation in Adrenal Cortical Carcinoma (556)
RR Lastra, SR Master, MD Feldman, T Baradet, A Ziobor, Z Bing
Hospital of the University of Pennsylvania, Philadelphia, PA

85 MicroRNA Are Differentially Expressed in Appendiceal Versus Ileal Neuroendocrine Tumors (559)
S Lu, K Cleveland, S Mangray, A Brodsky, M Resnick, E Yakirevich
Warren Alpert Medical School of Brown University, Providence, RI

86 Differential Expression of the Epithelial-Mesenchymal Transition Regulator ZEB1 in Thyroid Carcinomas (562)
C Montemayor-Garcia, H Hardin, D Buehler, H Chen, RV Lloyd
University of Wisconsin School of Medicine and Public Health, Madison, WI

GASTROINTESTINAL

87 BRAF V600E Immunohistochemical Stain in Colorectal Carcinomas (589)
K Affolter, S Page, S Tripp, M Bronner, W Samowitz
University of Utah Health Sciences Center, Salt Lake City, UT; ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT

88 Utility of pHH3 Immunohistochemistry in Risk Stratification of Gastrointestinal Stromal Tumors: An Inter-Observer Variability Study (596)
A Alkhasawneh, L Vila Duckworth, X Lu, T George, J Reith, T Zuluaga Tora
University of Florida, Gainesville, FL
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Board Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>89</td>
<td>Intratumoral CD8+ Cells Are Strongly and Inversely Correlated with Mitotic Index and Estimated Recurrence-Free Survival in Treatment-Naive Gastric GISTs (640)</td>
</tr>
<tr>
<td></td>
<td>JF Hechiman, MJ Donovan, RB McBride, X Ding, A Chen, L Peters, D Chiang, N Harpaz</td>
</tr>
<tr>
<td></td>
<td>Mount Sinai School of Medicine, New York, NY</td>
</tr>
<tr>
<td>90</td>
<td>An Institution-Wide Screening Program for Hereditary Non-Polyposis Colorectal Cancer Identified Microsatellite Instability in Patients Who Would Not Have Been Tested Using the Revised Bethesda Guidelines (655)</td>
</tr>
<tr>
<td></td>
<td>JL Jerz, H Takei, H Hendrickson, RJ Olsen, MR Schwartz</td>
</tr>
<tr>
<td></td>
<td>Methodist Hospital, Houston, TX</td>
</tr>
<tr>
<td>91</td>
<td>MLH1 Hypermethylation and BRAF Mutation Testing in Colorectal Cancer Patients with Mismatch Repair Defect (658)</td>
</tr>
<tr>
<td></td>
<td>M Jin, M C lendenning, H Hampel, WL Frankel</td>
</tr>
<tr>
<td></td>
<td>Ohio State University Wexner Medical Center, Columbus, OH; Queensland Institute of Medical Research, Herston, Queensland, Australia</td>
</tr>
<tr>
<td>92</td>
<td>Lymphocytic Gastritis: A Distinct Nosologic Entity or a Histopathologic Expression of Other Conditions? (663)</td>
</tr>
<tr>
<td></td>
<td>M Kherad Pezhoush, A Cockburn, R Genta</td>
</tr>
<tr>
<td></td>
<td>Miraca Life Sciences Research Institute, Irving, TX; University of Texas Southwestern Medical Center, Dallas, TX</td>
</tr>
<tr>
<td>93</td>
<td>Loss of RKIP Expression in Colorectal Cancer Is Associated with Activation of the NF-kB Signaling Pathway and Epithelial-Mesenchymal Transition (669)</td>
</tr>
<tr>
<td></td>
<td>VH Koelzer, H Dawson, E Karamitopoulou, A Lugli, I Zlobec</td>
</tr>
<tr>
<td></td>
<td>University of Bern, Bern, Switzerland</td>
</tr>
<tr>
<td>94</td>
<td>The Effects of Proton Pump Inhibitors on the Oxyntic Mucosa Can Only Be Reliably Assessed in the Absence of Helicobacter Infection (673)</td>
</tr>
<tr>
<td></td>
<td>KR Kumar, R Iqbal, E Coss, C Park, B Cryer, RM Genta</td>
</tr>
<tr>
<td></td>
<td>UT Southwestern Medical School, Dallas, TX; Dallas VAMC, Dallas, TX; Dallas VA Medical Center, Dallas, TX; Miraca Life Sciences Research Institute, Irving, TX</td>
</tr>
<tr>
<td>95</td>
<td>Histopathologic Parameters of Gastrointestinal and Pancreatic Neuroendocrine Tumors/Carcinomas Can Predict Their Clinical Behavior (679)</td>
</tr>
<tr>
<td></td>
<td>I Lamabzi, S Jakate, R Jain, L Cheng, P Gattuso</td>
</tr>
<tr>
<td></td>
<td>Rush University Medical Center, Chicago, IL</td>
</tr>
<tr>
<td>96</td>
<td>Nuclear FOX M1 and Phosphorylated β-Catenin S552 Expressions Are Observed in Barrett Dysplasia and Adenocarcinoma (681)</td>
</tr>
<tr>
<td></td>
<td>G Lee, MM Kiefer, D Posca, B Rea, L Zak, D Massi, W Blosky, B Bryant, R Abraham, L Li, J Goldstein, TA Berrett, P Raychaudhuri, G Gazman</td>
</tr>
<tr>
<td></td>
<td>University of Illinois, Chicago, IL; Northwestern University, Chicago, IL; Stowers Institute, Kansas City, MO</td>
</tr>
<tr>
<td>97</td>
<td>Expression Microarray Analysis Identifies Novel Epithelial Derived Differentially Expressed Protein Markers in Eosinophilic Esophagitis (691)</td>
</tr>
<tr>
<td></td>
<td>A Matoso, VA Mukkada, S Lu, R Monahan, K Cleveland, L Noble, S Mangray, MB Resnick</td>
</tr>
<tr>
<td></td>
<td>Rhode Island Hospital, Providence, RI</td>
</tr>
<tr>
<td>98</td>
<td>Should Mesenteric Tumor Deposits Be Included in Staging of Small Intestine Neuroendocrine Tumors? (630)</td>
</tr>
<tr>
<td></td>
<td>RS Gonzalez, EH Liu, MK Washington, C Shi</td>
</tr>
<tr>
<td></td>
<td>Vanderbilt University Medical Center, Nashville, TN</td>
</tr>
<tr>
<td>99</td>
<td>Should Mesenteric Tumor Deposits Be Included in Staging of Small Intestine Neuroendocrine Tumors? (630)</td>
</tr>
<tr>
<td></td>
<td>RS Gonzalez, EH Liu, MK Washington, C Shi</td>
</tr>
<tr>
<td></td>
<td>Vanderbilt University Medical Center, Nashville, TN</td>
</tr>
<tr>
<td>100</td>
<td>Intestinal Features Can Distinguish Non-Celiac Causes of Villous Atrophy from Those of Celiac Disease (599)</td>
</tr>
<tr>
<td></td>
<td>SJ Almashat, K Pallav, D Leffler, CP Kelly, JD Goldsmith, RM Najarian</td>
</tr>
<tr>
<td></td>
<td>Beth Israel Deaconess Medical Center &amp; Harvard Medical School, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; University of Mississippi Medical Center, Jackson, MS</td>
</tr>
<tr>
<td>101</td>
<td>Active Ulcerative Colitis (610)</td>
</tr>
<tr>
<td></td>
<td>AJ Carterson, S Rosen, RM Najarian</td>
</tr>
<tr>
<td></td>
<td>Beth Israel Deaconess Medical Center &amp; Harvard Medical School, Boston, MA</td>
</tr>
<tr>
<td>102</td>
<td>Napsin-A Expression in Esophageal and Gastric Adenocarcinoma Affected by Choice of Primary Antibody (617)</td>
</tr>
<tr>
<td></td>
<td>MW Cruise, EA Montgomery, JM Davison, RK Pai, AD Singhi</td>
</tr>
<tr>
<td></td>
<td>Johns Hopkins University, Baltimore, MD; University of Pittsburgh Medical Center, Pittsburgh, PA</td>
</tr>
<tr>
<td>103</td>
<td>Intratumoral Budding (ITB) in Pre-Operative Biopsies: A Strong Indicator of Lymph Node Positivity in Colon and Rectal Cancer Patients (618)</td>
</tr>
<tr>
<td></td>
<td>H Davison, M Haedrich, V Koelzer, D Inderbitzin, M Borner, I Zlobec, A Lugli</td>
</tr>
<tr>
<td></td>
<td>Institute of Pathology, University of Bern, Bern, Switzerland; Inselspital, Bern University Hospital, Bern, Switzerland; Centre Hospital Biel, Biel, Switzerland</td>
</tr>
<tr>
<td>104</td>
<td>Hedgehog Pathway Proteins Giroma-Associated Oncogene-1 (GLI-1) and Smoothened (Smo) Expression in Colorectal Cancer (CRC) (623)</td>
</tr>
<tr>
<td></td>
<td>O Elkadi, D Middleton, M Barrett, DM Jones, CE Sheehan, JS Ross</td>
</tr>
<tr>
<td></td>
<td>Albany Medical College, Albany, NY</td>
</tr>
<tr>
<td>105</td>
<td>Expression Microarray Analysis Identifies Novel Epithelial Derived Differentially Expressed Protein Markers in Eosinophilic Esophagitis (691)</td>
</tr>
<tr>
<td></td>
<td>A Matoso, VA Mukkada, S Lu, R Monahan, K Cleveland, L Noble, S Mangray, MB Resnick</td>
</tr>
<tr>
<td></td>
<td>Rhode Island Hospital, Providence, RI</td>
</tr>
<tr>
<td>Board Number</td>
<td>Title</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>107</td>
<td>RT-PCR Increases Sensitivity To Detect Cytomegalovirus in Paraffin-Embedded, Formalin-Fixed Tissue of Gastrointestinal Biopsies (692)</td>
</tr>
<tr>
<td>108</td>
<td>Indefinite for Dysplasia in Inflammatory Bowel Disease: Subtypes and Clinical Outcomes (704)</td>
</tr>
<tr>
<td>109</td>
<td>New Nodal Classification Discriminates Better Survival Time Than That of the 7th AJCC Cancer Staging in Patients with Small Intestinal Adenocarcinoma (SIAC): An Analysis with the SEER Database (707)</td>
</tr>
<tr>
<td>110</td>
<td>Duodenal Intraepithelial Lymphocytosis with Normal Villous Architecture: An Association with Inflammatory Bowel Disease? (711)</td>
</tr>
<tr>
<td>111</td>
<td>The PI3K/mTOR Pathway in Gallbladder Carcinoma (715)</td>
</tr>
<tr>
<td>113</td>
<td>Lichenoid Esophagitis; Clinical Overlap with Established Esophageal Lichen Planus (729)</td>
</tr>
<tr>
<td>114</td>
<td>MicroRNAs as Regulators of Colorectal Cancer Hepatic Metastasis (733)</td>
</tr>
<tr>
<td>115</td>
<td>Counting Colonic Mast Cells Is Not Diagnostically Useful in Patients with Chronic Diarrhea of Unknown Etiology (735)</td>
</tr>
<tr>
<td>116</td>
<td>Isolated Ileitis May Be a Manifestation of Crohn’s Disease, but Only in Symptomatic Patients: A Multi-Institution Study of 131 Cases (738)</td>
</tr>
</tbody>
</table>

**GENITOURINARY**

"More Cocktails, More Cancer"; Do Pathologists Who Use Immunohistochemistry More Frequently on Prostate Biopsies, Diagnose Prostate Cancer More Frequently? (788)
SAI Diffalha, W Roquiz, GA Barkan, EM Wojcik, MM Picken, SE Pambuccian
Loyola University Chicago, Maywood, IL

Proviral Integration Site Moloney Murine Leukemia Virus (PIM) Expression in Urothelial Carcinoma (791)
DJ Albertson, JJ Bearss, DJ Bearss, S Tripp, T Liu
University of Utah, Salt Lake City, UT; Huntsman Cancer Institute, Salt Lake City, UT; ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT; Brigham Young University, Provo, UT
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>University/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>127</td>
<td>Sub-Classification of Extracapsular Extension in Prostate Cancer (PCA): Does It Matter? Prognostic Significance from a Study of 675 Patients at a Large Academic Institution</td>
<td>University of Pittsburgh Medical Center, Pittsburgh, PA</td>
</tr>
<tr>
<td>128</td>
<td>Influence of Histologic Criteria and Confounding Factors (CFs) in Staging Equivocal Cases for Microscopic Perivesical Tissue Invasion (MPVI or pT3a): An Interobserver Study among Expert GU Pathologists</td>
<td>University of Pittsburgh Medical Center, Pittsburgh, PA; University of Pittsburgh Medical Center, Pittsburgh, PA</td>
</tr>
<tr>
<td>129</td>
<td>Differentially Expressed MicroRNA in Urothelial Carcinoma, Adenocarcinoma, and Squamous Cell Carcinoma of the Urinary Bladder</td>
<td>University of Chicago, Chicago, IL; Emory University, Atlanta, GA; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University, Indianapolis, IN; Johns Hopkins Hospital, Baltimore, MD; Cleveland Clinic, Cleveland, OH; Mayo Clinic, Rochester, MN; Polytechnic University of the Marche Region, Ancona, Italy; Massachusetts General Hospital, Boston, MA; MD Anderson Cancer Center, Houston, TX; Memorial Sloan-Kettering Cancer Center, New York, NY; Methodist Hospital, Houston, TX; McMaster University, Hamilton, ON, Canada; Nagoya Daini Red Cross Hospital, Nagoya, Japan; University of Rochester, Rochester, NY</td>
</tr>
<tr>
<td>130</td>
<td>The Morphological and Immunohistochemical Spectrum of Papillary Renal Cell Carcinoma (PRCC): A Study of 132 Type 1, Type 2 and ‘Mixed’ Tumors</td>
<td>University of Chicago, Chicago, IL; Emory University, Atlanta, GA; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University, Indianapolis, IN; Johns Hopkins Hospital, Baltimore, MD; Cleveland Clinic, Cleveland, OH; Mayo Clinic, Rochester, MN; Polytechnic University of the Marche Region, Ancona, Italy; Massachusetts General Hospital, Boston, MA; MD Anderson Cancer Center, Houston, TX; Memorial Sloan-Kettering Cancer Center, New York, NY; Methodist Hospital, Houston, TX; McMaster University, Hamilton, ON, Canada; Nagoya Daini Red Cross Hospital, Nagoya, Japan; University of Rochester, Rochester, NY</td>
</tr>
<tr>
<td>131</td>
<td>Urachal Adenocarcinoma: Is Associated with Microsatellite Instability and KRAS Mutations</td>
<td>University of Chicago, Chicago, IL; Emory University, Atlanta, GA; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University, Indianapolis, IN; Johns Hopkins Hospital, Baltimore, MD; Cleveland Clinic, Cleveland, OH; Mayo Clinic, Rochester, MN; Polytechnic University of the Marche Region, Ancona, Italy; Massachusetts General Hospital, Boston, MA; MD Anderson Cancer Center, Houston, TX; Memorial Sloan-Kettering Cancer Center, New York, NY; Methodist Hospital, Houston, TX; McMaster University, Hamilton, ON, Canada; Nagoya Daini Red Cross Hospital, Nagoya, Japan; University of Rochester, Rochester, NY</td>
</tr>
<tr>
<td>132</td>
<td>Saccrococcygeal Teratomas: Clinico-Pathological Characteristics and Isochromosome 12p Status (887)</td>
<td>Loyola University Medical Center, Maywood, IL; Ann &amp; Robert H Lurie Children’s Hospital, Chicago, IL</td>
</tr>
<tr>
<td>133</td>
<td>Microsatellite Instability in Urothelial Carcinoma of the Upper Urinary Tract</td>
<td>University of Pittsburgh Medical Center, Pittsburgh, PA</td>
</tr>
<tr>
<td>134</td>
<td>Differentiating Chromophobe Renal Cell Carcinoma from Oncocytomas: Utility of a Novel Immunomarker, Amylase 1A</td>
<td>University of Pittsburgh Medical Center, Pittsburgh, PA</td>
</tr>
<tr>
<td>135</td>
<td>Cell Type-Specific Biomarkers To Predict the Risk of Prostate Cancer in Men with Increased PSA but Negative Biopsies</td>
<td>University of Pittsburgh Medical Center, Pittsburgh, PA; University of Pittsburgh Medical Center, Pittsburgh, PA</td>
</tr>
<tr>
<td>136</td>
<td>Histone 1.5: A Novel Prostatic Cancer Marker Superior to AMACR: An Immunohistochemical Study</td>
<td>University of Pittsburgh Medical Center, Pittsburgh, PA; University of Pittsburgh Medical Center, Pittsburgh, PA</td>
</tr>
<tr>
<td>137</td>
<td>Utility of Whole-Genome SNP Microarrays in Renal Tumors: Diagnostic Implications</td>
<td>University of Pittsburgh Medical Center, Pittsburgh, PA; University of Pittsburgh Medical Center, Pittsburgh, PA</td>
</tr>
<tr>
<td>138</td>
<td>Bladder Carcinoma Lymphadenectomy: How Extensive Should Nodal Dissection Be for Adequate Staging?</td>
<td>Loyola University Medical Center, Maywood, IL; Ann &amp; Robert H Lurie Children’s Hospital, Chicago, IL</td>
</tr>
<tr>
<td>139</td>
<td>Morphological and Immunohistochemical Findings in a Large Series of Sex Cord-Stromal Tumors</td>
<td>Loyola University Medical Center, Maywood, IL; Ann &amp; Robert H Lurie Children’s Hospital, Chicago, IL</td>
</tr>
<tr>
<td>140</td>
<td>ERG Immunohistochemistry Combined with CK5/6 and AMACR in Prostate Needle Biopsy Evaluation</td>
<td>Loyola University Medical Center, Maywood, IL; Ann &amp; Robert H Lurie Children’s Hospital, Chicago, IL</td>
</tr>
<tr>
<td>141</td>
<td>Thoc1 Protein as a Novel Prognostic Marker for Prostate Cancer</td>
<td>Loyola University Medical Center, Maywood, IL; Ann &amp; Robert H Lurie Children’s Hospital, Chicago, IL</td>
</tr>
<tr>
<td>142</td>
<td>Evaluation of Pathologic Predictors of Metastasis in Renal Cell Carcinoma – Emphasis on the Renal Sinus Microscopic Involvement</td>
<td>Loyola University Medical Center, Maywood, IL; Ann &amp; Robert H Lurie Children’s Hospital, Chicago, IL</td>
</tr>
<tr>
<td>143</td>
<td>Intraepithelial Neoplasia and HPV Status in Penile Intraepithelial Lesions</td>
<td>Loyola University Medical Center, Maywood, IL; Ann &amp; Robert H Lurie Children’s Hospital, Chicago, IL</td>
</tr>
<tr>
<td>144</td>
<td>Oncocytic Papillary Renal Cell Carcinomas Should Be Classified Separately from Type 1 and Type 2 Tumors</td>
<td>Loyola University Medical Center, Maywood, IL; Ann &amp; Robert H Lurie Children’s Hospital, Chicago, IL</td>
</tr>
<tr>
<td>145</td>
<td>MicroRNA (miRNA) Profiling of Clear Cell Papillary Renal Cell Carcinoma (CCP)</td>
<td>Loyola University Medical Center, Maywood, IL; Ann &amp; Robert H Lurie Children’s Hospital, Chicago, IL</td>
</tr>
<tr>
<td>146</td>
<td>Lymph Node Staging in Bladder Cancer – Is Pathologic Evaluation of Microscopic Lymph Nodes Necessary for Adequate Staging?</td>
<td>Loyola University Medical Center, Maywood, IL; Ann &amp; Robert H Lurie Children’s Hospital, Chicago, IL</td>
</tr>
<tr>
<td>Board Number</td>
<td>Presentation Title</td>
<td>Authors and Institutions</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>165</td>
<td>Tissue PCA3 Evaluation in Prostate Cancer by In-Situ Hybridization (1067)</td>
<td>J Warrick, N Palanisamy, A Young, J Siddiqui, A Wu, R Mehra, S Carskadon, J Wei, A Chinnaiyan, S Tomlins, LP Kanju University of Michigan, Ann Arbor, MI</td>
</tr>
<tr>
<td>166</td>
<td>Clear Cell Papillary Renal Cell Carcinoma-Like Tumors in Patients with Von Hippel-Lindau Disease Are Unrelated to Sporadic Clear Cell Papillary Renal Cell Carcinoma (1076)</td>
<td>SR Williamson, S Zhang, JN Eble, DJ Grignon, G Martignoni, M Brunelli, S Gobbo, LA Baldridge, L Cheng Indiana University, Indianapolis, IN; University of Verona, Verona, Italy</td>
</tr>
<tr>
<td></td>
<td><strong>GYNECOLOGIC &amp; OBSTETRICS</strong></td>
<td></td>
</tr>
<tr>
<td>167</td>
<td>Mitotically Active Microglandular Hyperplasia of the Cervix: Absence of K-Ras Mutation and Implications for Differential Diagnosis (1095)</td>
<td>R Abi-Raad, A Alomari, P Hui, N Buza Yale University School of Medicine, New Haven, CT</td>
</tr>
<tr>
<td>168</td>
<td>Comparative Prognostic Value of Histology, p16, p53, HPV PCR and HPV mRNA and DNA Chromogenic In-Situ Hybridization (CISH) in Vulvar Squamous Cell Carcinomas (VSCC) (1098)</td>
<td>G Allo, ML Yap, J Cuartero, H Mackay, M Milosevic, J Murphy, X-J Ma, S Kamel-Reid, J Weinreb, D Ghazarian, M Pintile, B Clarke University of Toronto, Toronto, Canada; Princess Margaret and Toronto General Hospitals, Toronto, Canada; Advanced Cell Diagnostics, Hayward, CA</td>
</tr>
<tr>
<td>169</td>
<td>Correlation of K-Ras Mutation with Histological Subtypes of Endometrial Mucinous Lesions: Implications for Biological Progression and Molecular Diagnosis (1099)</td>
<td>A Alomari, R Abi-Raad, N Buza, P Hui Yale University School of Medicine, New Haven, CT</td>
</tr>
<tr>
<td>170</td>
<td>Fallopian Tube Intraluminal Tumor Spread from Non-Invasive Precursor Lesions: A Novel Metastatic Route in Early Pelvic Carcinogenesis (1110)</td>
<td>JG Bijron, CA Seldenrijk, RP Zweemer, RJ Verheijen, PJ van Diest University Medical Center Utrecht, Utrecht, Netherlands; Saint Antonius Hospital, Nieuwegein, Netherlands</td>
</tr>
<tr>
<td>171</td>
<td>mTOR Over-Expression in Recurrent Low Grade Endometrioid Adenocarcinomas (1114)</td>
<td>R Buell-Guthrod, S Chen, P-L Liew, MR Quddus, JJ Ou, C Zhang, WD Lawrence, CJ Sung Women and Infants Hospital of Rhode Island, Warren Alpert Medical School of Brown University, Providence, RI; Taipei Medical University, Taipei, Taiwan</td>
</tr>
<tr>
<td></td>
<td>Differential Expression of Heart and Neural Crest Derivatives Expressed Transcript (HAND) 2 in Progestrone Treated Endometrium (1117)</td>
<td>A Cavallo, R Buell-Guthrod, A Montag, N Lee, K Gwin University of Chicago, Chicago, IL</td>
</tr>
<tr>
<td>172</td>
<td>Evaluation of Wilm’s Tumor-1 (WT-1) Immunohistochemistry in Synchronous Primary Adenocarcinomas of the Endometrium and Ovary (1126)</td>
<td>TM Deal, JR Ross, MG Conner University of Alabama at Birmingham, Birmingham, AL</td>
</tr>
<tr>
<td></td>
<td><strong>Analysis of EPCAM Expression in Lynch Syndrome Associated Neoplasia (1128)</strong></td>
<td>MA DiMaio, S Kwok, TA Longacre Stanford University Medical Center, Stanford, CA</td>
</tr>
<tr>
<td>175</td>
<td>Incidental Gynecologic Malignancies in Morcellated Hysterectomies (1132)</td>
<td>S Ehdaivand, RA Simon, CJ Sung, MM Steinhoff, WD Lawrence, MR Quddus Warren Alpert Medical School of Brown University, Providence, RI; Women and Infants Hospital, Providence, RI</td>
</tr>
<tr>
<td>176</td>
<td>Myxoid Smooth Tumors of the Uterus: Can Histology Predict Behavior? (1154)</td>
<td>M4 Gurney, A Malpica, ED Euscher University of Texas MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td></td>
<td>Can We Successfully Subtype High Grade Endometrial Carcinomas: The Role of Morphology and Immunohistochemistry Revisited (1159)</td>
<td>C Himmetoglu Ussalki, A Usbutilun, D Bulbul, Z Isikdogan, N Haberal, O Ozen, G Guler Tezel Hacettepe University, Ankara, Turkey; Etlik Zübyeyde Hanim Women’s Health Education and Research Hospital, Ankara, Turkey; Baskent University, Ankara, Turkey</td>
</tr>
<tr>
<td>178</td>
<td>Frequent CCNE1 Amplification in Uterine Serous Carcinoma and Endometrial Intraepithelial Carcinoma (1183)</td>
<td>E Kuhn, A Bahadrit-Tabbott, I-M Shih Johns Hopkins Medical Institutions, Baltimore, MD</td>
</tr>
<tr>
<td>179</td>
<td>P16 Immunoreactivity in CIN1 Predicts Malignant Progression to High-Grade Dysplasia (1184)</td>
<td>MS Landau, Y Zhao, B Yang Cleveland Clinic Foundation, Cleveland, OH; Peking University People’s Hospital, Peking, China</td>
</tr>
<tr>
<td>180</td>
<td>Uterine Leiomyomatoma with Bizarre Nuclei: Expression of p53 and P16(^{\text{ink4}}) Is Common; However, Mutations of TP53 Are Rare and May Be Associated with Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (1197)</td>
<td>L Liu, C LaGrange, X Liu, Y Zhang, H Zhang, D Huang, TC Greiner, J Bridge, SM Lele University of Nebraska Medical Center, Omaha, NE</td>
</tr>
<tr>
<td>181</td>
<td>DNA Double Strand Break Repair Protein Expression Is Significantly Reduced in Tubal Secretory Cell Outgrowths (1213)</td>
<td>R Ovings, A Cole, C Quick University of Arkansas for Medical Sciences, Little Rock, AR</td>
</tr>
<tr>
<td>182</td>
<td>Histopathologic Changes in Progestrone-Treated Endometrial Hyperplasia and Carcinoma (1214)</td>
<td>LY Pan, AK Folkins, TA Longacre Stanford University, Stanford, CA</td>
</tr>
<tr>
<td>183</td>
<td>Complement Deposition in the Decidual Vasculature of Placentas (1223)</td>
<td>S Ravishankar, J Hankra, L Wolgast Montefiore Medical Center, Bronx, NY</td>
</tr>
<tr>
<td>184</td>
<td>MEDI12 Mutations in Uterine and Extraterine Smooth Muscle Tumors (1234)</td>
<td>K Schwete, J Pfeifer, E Duncavage Washington University in St Louis, St Louis, MO</td>
</tr>
</tbody>
</table>
HEMATOPATHOLOGY

195 The Absence of Human Papillomavirus E6/E7 mRNA Transcripts in Squamous Cell Carcinomas of the Oral Tongue: HPV Is Not a Relevant Agent in Squamous Cell Carcinomas of the Oral Tongue Including Those That Are Non-Tobacco Related (1301)
JS Poling, R Li, X-J Ma, Y Luo, S Bui, WM Koch, WH Westra
Johns Hopkins Hospital, Baltimore, MD; Advanced Cell Diagnostics, Hayward, CA

196 Comprehensive Genomic Profiling of Relapsed and Metastatic Adenoid Cystic Carcinomas (ACC) by Next Generation Sequencing (NGS) Reveals New Routes to Targeted Therapies (1302)
Albany Medical College, Albany, NY; Foundation Medicine Inc., Cambridge, MA

197 The Indoleamine 2,3-Dioxygenase (IDO) Pathway Is Constitutively Activated in HPV-Mediated Oropharyngeal Carcinoma (1316)
J Xu, T Isayeva, M Saag, M Brandwein-Gensler
University of Alabama at Birmingham, Birmingham, AL

HEMATOPATHOLOGY

198 Plasma Cell (Zoon’s) Balanitis Is Another Inflammatory Disorder That Can Be Rich in IgG4+ Plasma Cells (1321)
N Aggarwal, AV Parwani, J Ho, SH Swerdlow
University of Pittsburgh, Pittsburgh, PA

199 Utility of Multiplex Mutation Analysis in the Diagnosis of Chronic Myelomonocytic Leukemia (1327)
DC Ang, T Kovacsovics, J Dunlap, N Leeborg, M Loriaux, G Fan
Oregon Health & Science University, Portland, OR

200 Bel-2 Maturation Pattern in T-Cells Distinguishes Thymic Neoplasm/Hyperplasia, T-Lymphoblastic Lymphoma and Reactive Lymph Nodes (1332)
J Baqai, M Smith, J Huang
William Beaumont Hospital, Royal Oak, MI

201 Factor XIII Subunit A Immunohistochemical Expression Is Associated with an Inferior Outcome in Acute Promyelocytic Leukemia (1333)
AN Berg, C Roth, MA Rollins-Raval
University of Pittsburgh Medical Center, Pittsburgh, PA

202 Secondary Myelofibrosis in Children: A Single Institutional Experience of 219 Patients (1334)
D Berger, AM Sheehan, L Venkateswaran
Baylor College of Medicine, Houston, TX; Baylor College of Medicine & Texas Children’s Hospital, Houston, TX

203 An Academic Center’s Experience with Lymphoma Diagnosis: Rate of Revision and Impact on Patient Care (1340)
JM Bowen, AM Perry, L Smith, K Klinetobe, M Bast, JM Vose, K Fu, TC Greiner, W-C Chan, DD Weisenburger, P Aoun
University of Nebraska Medical Center, Omaha, NE
223 MYC Immunohistochemistry Correlates with MYC Gene Rearrangement Status in Pediatric Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma (1454)
BY Merritt, DH Lopez-Terrada, SJ Simko, AM Sheehan, VS Hernandez, AM Major, CV Curry
Baylor College of Medicine & Texas Children’s Hospital, Houston, TX

224 Detection of IGK and IGH Gene Rearrangements in Non-Hodgkin Lymphomas by BIOMED-2 PCR Primers (1469)
A Nazarullah, M Maldonado, Y Wang, K Vadlamudi, M Kinney, W Furmaga, H Fan
University of Texas Health Science Center at San Antonio, San Antonio, TX

225 Local Cell Death and Not Hemophagocytosis Is the Morphological Hallmark of Hemophagocytic Lymphohistiocytosis: A Study of 17 Cases (1472)
Q Nguyen, P Bhargava, G Pihan
Beth Israel Deaconess Medical Center, Boston, MA

226 Implications of Using the Revised International Prognostic Scoring System (IPSS-R) for Patients with Therapy-Related Neoplasms (1480)
CY Ok, Z Zuo, G Garcia-Manero, LJ Medeiros, SA Wang
University of Texas MD Anderson Cancer Center, Houston, TX

227 MYD88 (L265P) Somatic Mutation: Utility in the Differential Diagnosis of Bone Marrow Involvement by B-Cell Lymphoproliferative Disorders (1481)
SL Ondrejka, J Lin, DW Warden, L Durkin, JR Cook, ED Hsi
Cleveland Clinic, Cleveland, OH

228 Molecular Studies in Early Detection of Minimal Residual Disease (MRD) of B Lymphoblastic Leukemia (B-ALL) Status Post Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct) Correlated with Risk of Relapse (1483)
P Pantazopoulos, L Zhang, K Benson, D Qin, L Moscinski, P Horna
University of South Florida, Tampa, FL; Moffitt Cancer Center, Tampa, FL

229 Constitutive Activation of the mTORC2 and NF-kappaB Pathways and High Expression of SIRT1, COX-2 and FASN in T-Cell Lymphomas with Therapeutic Implications (1489)
AE Quesada, RE Brown, A Rios, ND Nguyen
University of Texas at Houston, Houston, TX

230 Langerhans Cell Histioctyosis (LCH) Is Characterized by a Distinct Cytoplasmic HLA-DR Staining Pattern Consistent with a Trafficking Pathway Defect (1494)
L Redd, M Schmelz, L Rimsha
University of Arizona, Tucson, AZ

231 FLT3 Inhibitor (Fl) Therapy: Morphologic and Phenotypic Findings (1500)
E Rostlund, J Altman, O Frankfurt, A Chadburn
Northwestern University Feinberg School of Medicine, Chicago, IL

232 Tumor-Associated Inflammatory Cells in Post-Transplant, Relapsed Classical Hodgkin Lymphoma May Be Recruited by Hodgkin/Reed-Sternberg Cells (1505)
MA Samols, LA Morsberger, ML Thiess, D Batista, MJ Borowitz, CD Gocke, RF Ambinder, AS Duffield
Johns Hopkins Hospital, Baltimore, MD

233 The Clonal Myeloid Disorder Associated with Isolated del(20q) Is Frequently Subtle, Unclassifiable and May Be Associated with Prior Cytotoxic Chemotherapy (1512)
C Singh, M Dolan, M Berger, T Singleton, K Naemi, RW McKenna
University of Minnesota, Minneapolis, MN

234 Terminal Deoxynucleotidyl Transferase (TdT) Flow Cytometric (FC) Expression in Acute Myeloid Leukemia (AML) Is Associated with CD34 Positivity, Lack of NPM1 Mutation, and Adverse Cytogenetic Risk Stratification (1513)
RL Singhal, N Aggarwal, SP Ten Eyck, M Boyiadzis, CG Roth, DM Djokic
University of Pittsburgh School of Medicine, Pittsburgh, PA

235 Abnormal Marrow Cellularity at Day 100 after Allogeneic Marrow Transplantation Impacts Overall Survival (OS) but Not Event-Free Survival (EFS) (1516)
P Sojitra, P Gandhi, AR Kini, MM Velankar, S Smith, PJ Stiff, GV Venkataraman
Loyola University Medical Center, Maywood, IL

236 Chronic Lymphoproliferative Disorder of Natural Killer Cells (CLPD-NK): A Singular Entity Resembling T-Cell Large Granular Lymphocytic Leukemia (T-LGL) or a Heterogeneous Group of Conditions? (1519)
DJ Tagliente, RL King, J Neff, GS Nowakowski, MT Howard, WG Morice II
Mayo Clinic, Rochester, MN; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

237 Is Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) a Lymphoma of Mantle Zone B-Cells? (1522)
B Tandon, SH Swerdlow, RP Hasserjian, SE Gibson
University of Pittsburgh School of Medicine, Pittsburgh, PA; Massachusetts General Hospital, Boston, MA

238 IRF4 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasms (1524)
CM van Slambrouck, E Hyjek, S Gurbuxani
University of Chicago, Chicago, IL

239 Ferritin H Is a Novel Marker of Tumor-Associated Macrophages and Its Expression Is Associated with Tumor Grade (1526)
W Wang, FM Torii, SV Torii, MW Beaty
Wake Forest Baptist Health, Winston Salem, NC; University of Connecticut Health Center, Farmington, CT

240 A New Entity?: Distinctive Immunophenotype in Non-Down Syndrome Pediatric Acute Megakaryoblastic Leukemia (1529)
L Wang, B Levenson, NJ Karandikar, J Emmons
UTSW Medical Center, Dallas, TX

241 Hepatosplenic α/β T-Cell Lymphoma with Polarized, Highly Motile Cytotoxic T Cells (1530)
R Willim, GA Pihan
Beth Israel Deaconess Medical Center, Boston, MA
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Clinical and Pathologic Features of Mast Cell Diseases in Patients with Unexplained Epidemic Allergic Symptoms (1532)</th>
<th>Mayo Clinic, Rochester, MN</th>
</tr>
</thead>
<tbody>
<tr>
<td>242</td>
<td>Immunophenotypic Transformation in CLL/SLL Patients (1534)</td>
<td>X Wu, A Kishitgargi, N Lamanna, M Arcila, J Feldstein Memorial Sloan-Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>243</td>
<td>Survival Analysis of 77 Cases of Acute Erythroleukemia in a Single Institution (1546)</td>
<td>X Zhang, A List, R Komrokji, JE Lancet, L Moscinski, L Zhang H. Lee Moffitt Cancer Center &amp; Research Institute, Tampa, FL</td>
</tr>
<tr>
<td>244</td>
<td>The Etiology of EBV-Negative Post-Transplantation Lymphoproliferative Disorder Remains Unclear (1554)</td>
<td>SL Cook, NS Aguilera, GC Ballock, Z Meridan, H Bonatti, HP Cattrho University of Virginia, Charlottesville, VA; University of Pittsburgh, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Vanderbilt University, Nashville, TN</td>
</tr>
<tr>
<td>245</td>
<td>Evaluation of the Becton Dickinson Phoenix Yeast Panel and the RapID Yeast Plus System in the Identification of Yeast and Yeast-Like Organisms (1561)</td>
<td>ML Oros, S Parajuli, R Deleon-Gonsalves, R Potula, AL Truant Temple University Hospital, Philadelphia, PA</td>
</tr>
<tr>
<td>246</td>
<td>Denervated Renal Graft Explants Have Extensive Damage of the Juxtaglomerular Apparatus and Neural Network (1609)</td>
<td>CD Cendrowski, W Li, MT Rooney, PL Zhang William Beaumont Hospital, Royal Oak, MI</td>
</tr>
<tr>
<td>252</td>
<td>Toward a Working Definition of C3 Glomerulopathy by Immunofluorescence (1623)</td>
<td>J Hou, GS Markowitz, LC Herlitz, MB Stokes, VD D’Agati Columbia University, College of Physicians and Surgeons, New York, NY</td>
</tr>
<tr>
<td>253</td>
<td>The Diagnostic Utility of Ki-67 Staining in Acute Renal Tubular Injury (1654)</td>
<td>CX Zhao, X Gu, SM Bonsib Louisiana State University Health Science Center, Shreveport, LA; Nephropath, Little Rock, AR</td>
</tr>
<tr>
<td>255</td>
<td>Detailed Histological Assessment of Primary Sclerosing Cholangitis: Confirmation Utilizing Significance Analysis of Microarray (SAM) and Hierarchical Clustering Analysis (HCA) (1665)</td>
<td>G Carrasco, TD Schiano, M Raoufi, SC Ward, SN Thung, M Fiel Mount Sinai School of Medicine, New York, NY; Henry Ford Hospital, Detroit, MI</td>
</tr>
<tr>
<td>257</td>
<td>Detailed Histological Assessment of Primary Sclerosing Cholangitis: Confirmation Utilizing Significance Analysis of Microarray (SAM) and Hierarchical Clustering Analysis (HCA) (1665)</td>
<td>G Carrasco, TD Schiano, M Raoufi, SC Ward, SN Thung, M Fiel Mount Sinai School of Medicine, New York, NY; Henry Ford Hospital, Detroit, MI</td>
</tr>
<tr>
<td>258</td>
<td>Hepatocellular Adenomas in a Large Community Population 2000-2010: Reclassification Per Current WHO Classification and Long-Term Follow-Up (1676)</td>
<td>G Genrich, N Shafizadeh, L Ferrell, S Kakar University of California San Francisco, San Francisco, CA; Southern California Permanente Medical Group, Woodland Hills, CA</td>
</tr>
<tr>
<td>259</td>
<td>Isolated Extrahepatic IgG4-Related Sclerosing Cholangitis Mimicking Cholangiocarcinoma (1679)</td>
<td>RP Graham, TC Smyrk, ST Chari, L Zhang Mayo Clinic, Rochester, MN</td>
</tr>
</tbody>
</table>
149

Board Number

260 A Novel Fibrosis Staging System for Cardiogenic Liver Disease and Relationship with Clinical, Biochemical, and Heart Physiologic Parameters: Development of a Common Language for Liver Transplant Decisions (1680)
MA Grilliot, J Rojas, EF Clayton, EE Furth
University of Pennsylvania, Philadelphia, PA

261 Sinusoidal Obstruction Syndrome Injury in Liver Biopsies after Hematopoietic Cell Transplantation (1697)
C Ma, EM Brant
Washington University in St Louis, Saint Louis, MO

262 TTF-1 and Napsin-A Are Expressed in a Subset of Cholangiocarcinomas Arising from the Gallbladder and Hepatic Ducts: Continued Caveats for Utilization of Immunohistochemistry Panels (1713)
LF Surrey, R Frank, PJ Zhang, EE Furth
Hospital of the University of Pennsylvania, Philadelphia, PA

263 Liver Transplant Biopsies (LTx) with Sinusoidal Dilatation, Congestion and/or Hemorrhage (SDC/H): A Retrospective Review and Prospective Follow Up in 60 of 665 Liver Transplant Patients in a Tertiary Care Transplant Center (1714)
V Swamy, V Shah
Henry Ford Hospital, Detroit, MI

264 Histopathological Features of Hepatic Venous Outflow Obstruction in Transplant Liver Biopsies (1717)
W Xiong, PE Swanson, MM Yeh
University of Washington, Seattle, WA

NEUROPATHOLOGY

265 Protein Arginine Methyltransferase 5 Is Highly Expressed in Glioblastoma and Important for the Growth of Glioma Cells (1737)
R Li, X Zhao, D Zhou, Q Ding, PH King, GY Gillespie, LB Nabors, X Han
University of Alabama at Birmingham, Birmingham, AL

266 Enhancer of Zeste Homologue 2 (EZH2) Expression Is Associated with Cell Proliferation in Medulloblastoma (1743)
M Shi, J Qiu, TW Smith, DL Kilpatrick, W Wang
UMass Memorial Medical Center, Worcester, MA; Roswell Park Cancer Institute, Buffalo, NY; UMass Medical School, Worcester, MA

267 Spectrum of Non-Synonymous Mutations in Cancer Identified by Clinical Targeted Next-Generation Sequencing (1801)
IS Hagemann, H Al-Kateh, CE Cottrell, C Lockwood, TT Nguyen, D Spencer, A Bredemeyer, R Head, S Shrivastava, R Nagarajan, K Seibert, EJ Duncavage, S Kulkarni, JD Pfeifer
Washington University, St. Louis, MO

268 Phosphoproteomic Analysis Identifies Deregulated Expression of Acting Signaling Networks in T Cell Lymphomas (1820)
C Murga-Zamalloa, D Rolland, Y Jeon, V Basrur, K Elenitoba-Johnson, M Lim
University of Michigan, Ann Arbor, MI

269 Spectrum of of Non-Synonymous Mutations in Cancer Identified by Clinical Targeted Next-Generation Sequencing (1810)
IS Hagemann, H Al-Kateh, CE Cottrell, C Lockwood, TT Nguyen, D Spencer, A Bredemeyer, R Head, S Shrivastava, R Nagarajan, K Seibert, EJ Duncavage, S Kulkarni, JD Pfeifer
Washington University, St. Louis, MO

267 INDELs in Cancer Detected by Targeted Clinical Next Generation Sequencing (1823)
J Sehn, D Spencer, H Abel, E Duncavage
Washington University in St Louis, St. Louis, MO

268 Integrative Genomic Profiling To Identify Drivers of Breast Cancer-Associated Inflammation (1824)
Cancer Genome Atlas (TCGA) Breast Cancer Expert Pathology Committee, Bethesda, MD

269 Mesothelin Expression in Pancreatic Mucinous Cysts (1766)
R Frank, NA Ahmad, P Shah, AR Sepulveda, NC Jhala
Hospital of the University of Pennsylvania, Philadelphia, PA; Columbia University, New York, NY

270 Intestinal Markers Are Expressed in Pancreatic Well-Differentiated Neuroendocrine Tumors and Associated with Sclerosing Variant (1774)
JS Johnson, C Shi
Vanderbilt University Medical Center, Nashville, TN

271 Extracellular DNA Contributes to Pancreatic Cancer Invasion and Metastasis (1792)
J Shi, F Wen, A Shen, A Choi
University of Michigan, Ann Arbor, MI; University of Arizona, Tucson, AZ

272 SMAD4 Expression in Mucin-Producing Cystic Neoplasms of the Pancreas and Associated Carcinomas (1797)
KM Stashek, JJ Mezeh, KK Roggin, AM Bellizzi
University of Iowa Hospitals and Clinics, Iowa City, IA; University of Chicago Medicine, Chicago, IL

273 Metastasis Suppressors KISS-1, RKIP and GPR54 Are Expressed in Pancreatic Neuroendocrine Tumors and Their Expression Is Altered in Metastases (1798)
BJ Swanson, LA Shirley, M Bloomston, W Frankel
Ohio State University Wexner Medical Center, Columbus, OH

274 INDELs in Cancer Detected by Targeted Clinical Next Generation Sequencing (1823)
J Sehn, D Spencer, H Abel, E Duncavage
Washington University in St Louis, St. Louis, MO

275 Spectrum of of Non-Synonymous Mutations in Cancer Identified by Clinical Targeted Next-Generation Sequencing (1810)
IS Hagemann, H Al-Kateh, CE Cottrell, C Lockwood, TT Nguyen, D Spencer, A Bredemeyer, R Head, S Shrivastava, R Nagarajan, K Seibert, EJ Duncavage, S Kulkarni, JD Pfeifer
Washington University, St. Louis, MO

276 Phosphoproteomic Analysis Identifies Deregulated Expression of Acting Signaling Networks in T Cell Lymphomas (1820)
C Murga-Zamalloa, D Rolland, Y Jeon, V Basrur, K Elenitoba-Johnson, M Lim
University of Michigan, Ann Arbor, MI

277 INDELs in Cancer Detected by Targeted Clinical Next Generation Sequencing (1823)
J Sehn, D Spencer, H Abel, E Duncavage
Washington University in St Louis, St. Louis, MO

278 Integrative Genomic Profiling To Identify Drivers of Breast Cancer-Associated Inflammation (1824)
Cancer Genome Atlas (TCGA) Breast Cancer Expert Pathology Committee, Bethesda, MD
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>279</td>
<td>Genetic Heterogeneity of Gleason Score 7 Prostate Cancer: A Pilot Study of the Canadian Prostate Cancer Genome Network (CPC-GENE)</td>
<td>D Trudel, M Fraser, ER Lalonde, A Meng, A Brown, T Chong, A Zia, M Sam, PH Hennings-Yeomans, F Yousif, R Denroche, J Johns, L Timms, N Buchner, R de Borja, NJ Harding, MA Chan-Seng-Yue, J Wang, G Zafarana, MHW Starman, M Pintilie, N Fleischer, S Volk, L Mathewson, C Collins, TJ Hudson, LD Stein, T Beck, JD McPherson, T van der Kwast, PC Boutros, RG Bristow</td>
<td>University of Toronto, Toronto, Canada; University of British Columbia, Vancouver, Canada</td>
</tr>
<tr>
<td>280</td>
<td>Mechanism of Ceramide-Induced Activation of Protein Phosphatase 2A (PP2A)</td>
<td>KK Narra, S4 Summers</td>
<td>University of Utah, Salt Lake City, UT; Duke-NUS Graduate Medical School, Singapore, Singapore</td>
</tr>
<tr>
<td>281</td>
<td>Association between Methylenetetrahydrofolate Reductase (MTHFR) Gene Variants and Hyperhomocysteinemia in United States Veterans</td>
<td>MM Pessarakli, RT Phan</td>
<td>Keck School of Medicine of USC, Los Angeles, CA; Veterans Affairs of Greater Los Angeles Healthcare System, Los Angeles, CA; David Geffen School of Medicine of UCLA, Los Angeles, CA</td>
</tr>
<tr>
<td>282</td>
<td>SIX1 Expression in Human Fetal Tissues</td>
<td>R Rong, L-P Wang, E Ruckdeschel, Z Bing</td>
<td>University of Pennsylvania, Philadelphia, PA; Upstate Medical University, Syracuse, NY</td>
</tr>
<tr>
<td>283</td>
<td>Non-Destructive Microfluidic Cell-Based Assay for Determining Cell Deformability as a Function of Epithelial-to-Mesenchymal Transition</td>
<td>P Tavassoli, L Wang, S Park, H Ma, P Black</td>
<td>University of British Columbia, Vancouver, BC, Canada</td>
</tr>
<tr>
<td>284</td>
<td>Loss of Heterozygosity (LOH) at 17p13 and 22q13 Is Associated with Metastasis and Shared by Breast and Thyroid Carcinomas</td>
<td>B Zhu, SD Finkelstein, JF Silverman, SM Rohan, X Lin</td>
<td>Northwestern University, Chicago, IL; RedPath Integrated Pathology, Inc., Chicago, IL; Allegheny General Hospital, Chicago, IL</td>
</tr>
<tr>
<td>285</td>
<td>Pediatric Anaplastic Ependymoma: Morphoproteomics and Biomedical Analytics Identify Hypoxia Pathway Signaling and Provide Targeted Therapeutic Options</td>
<td>AQ Al-Ibraheemi, MF McGuire, RE Brown</td>
<td>UT Health-Medical School, Houston, TX</td>
</tr>
<tr>
<td>286</td>
<td>Pulmonary Interstitial Emphysema in Adults: A Potential Diagnostic Pitfall</td>
<td>SM Barcia, KD Jones</td>
<td>University of California San Francisco, San Francisco, CA</td>
</tr>
<tr>
<td>287</td>
<td>Hydrophilic Polymer Embolus (HPE) Vasculopathy of the Lung</td>
<td>JM Choi, RI Mehta, AP Burke, RI Mehta</td>
<td>University of Maryland Medical Center, Baltimore, MD; State University of New York Upstate Medical University, Syracuse, NY</td>
</tr>
<tr>
<td>288</td>
<td>Pulmonary Large Cell Carcinoma Is Clinicopathologically and Molecularly Similar to Solid Subtype Adenocarcinoma</td>
<td>DH Hwang, AS Perry, LM Sholl</td>
<td>Brigham and Women’s Hospital, Boston, MA; Banner MD Anderson Cancer Center, Gilbert, AZ</td>
</tr>
<tr>
<td>289</td>
<td>Correlation of EGFR Immunohistochemistry and Molecular Analysis in Lung Adenocarcinoma</td>
<td>E Jeffrey, G Tesha, C Cynthia</td>
<td>Emory University, Atlanta, GA</td>
</tr>
<tr>
<td>290</td>
<td>Mechanism of Ceramide-Induced Activation of Protein Phosphatase 2A (PP2A)</td>
<td>KK Narra, S4 Summers</td>
<td>University of Utah, Salt Lake City, UT; Duke-NUS Graduate Medical School, Singapore, Singapore</td>
</tr>
<tr>
<td>291</td>
<td>Correlation of Cytomorphology and Molecular Findings in EGFR, KRAS, and ALK-Positive Lung Carcinomas</td>
<td>Z Li, S Dacic, L Pantanowicz, W Khalbass, M Nikiforova, SE Monaco</td>
<td>University of Pittsburgh Medical Center, Pittsburgh, PA</td>
</tr>
<tr>
<td>292</td>
<td>Neurotrophic Tyrosine Kinase Receptor Type 1 and 2 (NTRKA and NTRKBI) Expression in Non Small Cell Lungs Cancers (NSCLC)</td>
<td>K Laziuk, A Tarasen, CE Sheehan, JS Ross</td>
<td>Albany Medical College, Albany, NY</td>
</tr>
<tr>
<td>293</td>
<td>Adult Pulmonary Interstitial Emphysema: A Clinically and Pathologically Underdiagnosed Entity with Distinct Clinopathologic Features</td>
<td>AP Matynia, ML Wallander, S Tripp, WL Akerley, MB Cohen</td>
<td>University of Utah, Salt Lake City, UT; ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT</td>
</tr>
<tr>
<td>294</td>
<td>The Role of Immunohistochemical Analysis in the Evaluation of EML4-ALK Rearrangement Status in Lung Cancer</td>
<td>HC Sullivan, MT Siddiqui, J Wang, C Cohen</td>
<td>Emory University, Atlanta, GA</td>
</tr>
<tr>
<td>295</td>
<td>WHO Histologic Classification Is an Independent Predictor of Prognosis in Lung Neuroendocrine (NE) Tumors but Ki-67 Proliferation Rate Is Not</td>
<td>AQ Al-Ibraheemi, MF McGuire, RE Brown</td>
<td>University of California San Francisco, San Francisco, CA</td>
</tr>
<tr>
<td>296</td>
<td>Application of the IASLC/ATS/ERS Classification of Lung Adenocarcinomas and Implications for Tumor Grading</td>
<td>L Xu, T Huebner, F Tavora, A Burke</td>
<td>University of Maryland Medical Center, Baltimore, MD; Messejana Heart and Lung Hospital, Fortaleza, CE, Brazil</td>
</tr>
</tbody>
</table>
Board Number

297 The Histopathology of End Stage Pulmonary Sarcoidosis: Comparison of 11 Explanted Lungs with Usual Interstitial Pneumonia (1960)
C Zhang, K Chan, H Annes, J Myers, L Schmidt
University of Michigan, Ann Arbor, MI

QUALITY ASSURANCE

298 Inter- and Intra-Observer Agreement in Diagnosing Dysplasia in Barrett’s Esophagus: Comparison of Routine Glass Slide vs. Digital Image Examination (1966)
SH Bradshaw, D Driman, MP Dupre, VG Falck, R Kirsch, A Meliti, B Nguyen, D Owen, A Rahentulla, RH Riddell, H Sapp, G Soucy, C Streutker, EC Marginean
TOH, Ottawa, ON, Canada; St Luc, Montreal, QC, Canada; St. Michael’s, Toronto, ON, Canada; LHSC, London, ON, Canada; Mount Sinai, Toronto, ON, Canada; CLS, Calgary, AB, Canada; SHR, Saskatoon, SK, Canada; VGH, Vancouver, BC, Canada; BCCA, Vancouver, BC, Canada; QEI HSC, Halifax, NS, Canada

299 Diagnosing Ambiguous Melanocytic Tumors in a Tertiary Referral Center: The Contribution of Fluorescence In Situ Hybridization (FISH) to Conventional Histopathologic and Immunophenotypic Analyses (1991)
TL Milless, CL Jonathan, T-CA Carlos, W Wei-Lien, MS Michael, I Doina, PG Victor, TT Michael
UT MD Anderson Cancer Center, Houston, TX

300 Dissecting Errors in the Histology Laboratory (2004)
SM Pyatibrat, JD Goldsmith, SS Raab, YB Kushner
Beth Israel Deaconess Medical Center, Boston, MA; Eastern Health Authority, St-John’s, Newfoundland, Canada

301 Characterization of EWSR1 Break Apart FISH in Non-EWSR1 Related Samples: Avoiding the False Positive Pitfall (2010)
N.Sadri, PJ Zhang
University of Pennsylvania, Philadelphia, PA

302 The Diagnostic Black Box: Successful Integration and Performance Validation of Pathologists Using New Lung Non-Small Cell Carcinoma Classification Recommendations (2023)
ME Stevenson, P Murugan, LA Hassell
University of Oklahoma Health Sciences Center, Oklahoma City, OK

TECHNIQUES

303 Image-Guided Coring for Large-Scale Projects in Molecular Oncologic Pathology (2038)
GM Baker, L Montaser, N Knobauch, S Christensen, A Hazra, R Tamimi, LC Collins, AH Beck
Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA; Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

304 BRAF Mutations in Metastatic Malignant Melanoma: Comparison of Molecular Analysis and Immunohistochemical Expression (2049)
L Ehsani, C Cohen, KE Fisher, MT Siddiqui
Emory University Hospital, Atlanta, GA

Board Number

305 Immunohistochemistry for Novel Markers in Squamous Cell Carcinoma: Glypican-3 Is Expressed across Anatomic Sites, PAX8 Is Limited in Distribution, and p40 Is Extremely Sensitive (2050)
MP Gailey, AM Bellizzi
University of Iowa Hospitals and Clinics, Iowa City, IA

306 The Ventana INFORM HER2 Dual In Situ Hybridization (DISH) DNA Probe Cocktail Assay Versus Fluorescence In Situ Hybridization (FISH): Focused Study of Immunohistochemical 2+ Cases (2051)
FF Gao, DJ Dabbs, R Bhargava
Mage-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA

307 Reduction of Sequence Artifact in Formalin Fixed Paraffin Embedded Tissue Using Uracil DNA Glycosylase: A Comparative PCR High Resolution Melting Curve Analysis (2053)
JA Halfacre, JM Gale, MA Vasef
University of New Mexico, Albuquerque, NM; TriCore Reference Laboratories, Albuquerque, NM

308 Retrospective Review of Emergent Frozen Sections at a Large Teaching Hospital (2057)
MD Hyrcza, NE Sunderland, CB Gilks
University of British Columbia, Vancouver, BC, Canada; Vancouver General Hospital, Vancouver, BC, Canada

309 Assessment of BRAF V600E Mutation Status by Immunohistochemistry in Lung and Ovarian Carcinomas (2060)
OE Kabiawu-Ajise, JT Feldstein, R Soslow, D Levine, M Ladanyi, ME Arcila
Memorial Sloan-Kettering Cancer Center, New York, NY

310 Comparison of Breast Cancer Proliferation Rates between Core Biopsy and Surgical Excision Using Visual Mitotic Count and Automated Analysis of MIB-1 and PPH3 (2069)
R McCormick, C Cohen, M Schoen, J Wang, A Adams
Emory University, Atlanta, GA

311 Tissue Identity Testing of Cancer by Short Tandem Repeat Polymorphism: Pitfalls of Interpretation in the Presence of Microsatellite Instability (2073)
MA Much, N Buza, P Hui
Yale University School of Medicine, New Haven, CT

312 Optimum Number of H&E Levels in the Workup of Bronchial Biopsies (2076)
J Nunez, JF Silverman, U Krishnamurti
Allegheny General Hospital, Pittsburgh, PA

313 Intraoperative Pathologic Consultation by Telepathology: An Accuracy Study of 104 Analysis Performed by the Eastern Quebec Telepathology Network (2079)
E Perron, B Tetu
CHUQ-Hotel-Dieu de Quebec, Quebec, QC, Canada; Centre Hospitalier de Baie-Comeau, Baie-Comeau, QC, Canada; Faculty of Medicine, Université Laval, Quebec, QC, Canada
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>314</td>
<td>Neuroendocrine Tumors of Cervix – Clinical, Morphologic, Immunophenotypic, and Electron Microscopic Features in Two Cases (2098)</td>
<td>B Assylbekova, S Billah, S Kolodziej, M Bhattacharjee University of Texas Medical School at Houston, Houston, TX</td>
</tr>
<tr>
<td>316</td>
<td>Ultrastructural Findings in Adrenal Cortical Adenomas Clinically Mimicking Pheochromocytoma: A Comparison with Other Adrenal Tumors and Tissue Preparation Techniques (2105)</td>
<td>CM Perrino, DN Prall, EP Calomeni, T Nadosdy, DL Zynger Ohio State University Medical Center, Columbus, OH</td>
</tr>
<tr>
<td>317</td>
<td>Epigenetic Study for Expression of MUC4 in Low Grade Fibromyxoid Sarcoma (59)</td>
<td>A Matsuyama, R Shibuya, F Kubota, M Nakamoto, M Hisaoka University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan</td>
</tr>
<tr>
<td>318</td>
<td>Peripheral Hemangioblastoma: Clinicopathologic &amp; Immunohistochemical Analysis of 21 Cases (37)</td>
<td>LA Doyle, CDM Fletcher Brigham and Women’s Hospital, Harvard Medical School, Boston, MA</td>
</tr>
<tr>
<td>319</td>
<td>ALK Expression in Angiomatoid Fibrous Histiocytoma (AFH): A Potential Diagnostic Pitfall (28)</td>
<td>CL Cheah, C Lanigan, G Batliuchko, BP Rubin, SD Billings, JL Hornick, RR Tubbs, JR Goldblum Cleveland Clinic, Cleveland, OH; Brigham and Women’s Hospital, Boston, MA</td>
</tr>
<tr>
<td>320</td>
<td>Angiomatoid Fibrous Histiocytoma: Clinicopathological and Molecular Characterization with Emphasis on Variant Histomorphology (46)</td>
<td>Y-C Kao, J Lan, H-C Tai, C-F Li, H-Y Huang Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan; Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Changhua Christian Hospital, Changhua, Taiwan; Chi-Mei Medical Center, Tainan, Taiwan; Southern Taiwan University of Science and Technology, Tainan, Taiwan; National Health Research Institutes, Tainan, Taiwan</td>
</tr>
<tr>
<td>321</td>
<td>Histological Analysis of Vascular Involvement Suggests an Invasion-Independent Metastatic Mechanism in Alveolar Soft Part Sarcoma (70)</td>
<td>N Setsu, A Yoshida, H Chuman, H Tsuda National Cancer Center Hospital, Tokyo, Japan</td>
</tr>
<tr>
<td>322</td>
<td>PHF1 Rearrangements in Ossifying Fibromyxoid Tumors (OFMT), with Emphasis on the Malignant Variant (40)</td>
<td>RP Graham, SW Weiss, J Goldblum, S Billings, S Dotlic, AL Folpe Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, OH; University Hospital Center, Zagreb, Croatia; Emory University, Atlanta, GA</td>
</tr>
<tr>
<td>323</td>
<td>Clinicopathological Spectrum of 14 Myoepithelial Tumors, Primarily Involving Soft Tissues, Including Immunohistochemical Profile and EWSR1 Rearrangement in a Subset of Cases (65)</td>
<td>S Rekhi, M Sable, NA Jambhekar Tata Memorial Hospital, Mumbai, Maharashtra, India</td>
</tr>
<tr>
<td>324</td>
<td>Common Homozygous SMARCB1 Deletions in Both Proximal and Distal Types of Epithelioid Sarcoma (ES) – Can Be Reliably Detected by FISH in Archival Material (55)</td>
<td>F Le Loarer, L Zhang, J-M Coindre, CR Antonescu Memorial Sloan-Kettering Cancer Center, New York, NY; Institute Bergonic Cancer Center, Bordeaux, France</td>
</tr>
<tr>
<td>325</td>
<td>ERG and FLI1, an Ets Family Transcription Factor and Vascular Marker, Expression in Epithelioid Sarcoma: A Potential Diagnostic Pitfall (76)</td>
<td>DL Stockman, AJ Lazar, JL Hornick, W-L Wang University of Texas MD Anderson Cancer Center, Houston, TX; Brigham and Women’s Hospital, Boston, MA</td>
</tr>
</tbody>
</table>
14 Loss of INI1 Expression in Extraskeletal Myxoid Chondrosarcoma (75)
DL Stockman, JL Hornick, W-L Wang, AJ Lazar
University of Texas MD Anderson Cancer Center, Houston, TX; Brigham and Women’s Hospital, Boston, MA
15 Akt-mTOR Pathway Activation Analysis in Re-Classified Pediatric SMARCB1/INI1-Deficient Tumor (49)
K Kohashi, M Endo, N Setsu, Y Takahashi, Y Yamada, H Yamamoto, Y Oda
Kyushu University, Fukuoka, Japan
16 Do Meningeal Hemangiopericytoma and Mesenchymal Chondrosarcoma Belong to the Same Biologic Spectrum? A Study of HEY1-NCOA2 Fusion (38)
K Fritchie, L Jin, AL Ruano, AM Oliveira, BP Rubin
Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, OH
17 HEY1-NCOA2 Fusion Transcript Detection Is a Valuable Diagnostic Adjunct in the Diagnosis of Mesenchymal Chondrosarcoma (64)
A Niblett, G Bartle, F Puls
Royal Orthopaedic Hospital, Birmingham, West Midlands, United Kingdom
18 Suppressed Expression of Caveolin-1 Characterizes Solitary Fibrous Tumors: Comparison with Other Mesenchymal Tumors and Malignant Mesotheliomas (62)
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan
19 MicroRNA Expression Profiling Identifies Potential Prognostic Indicators in Primary Solitary Fibrous Tumors (36)
EG Demicco, K Wani, AJ Lazar, AD Kenneth, W-L Wang
Mount Sinai Medical Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX
20 Radiation Induced Sarcomas Occurring in Desmoid-Type Fibromatosis Are Not Derived from the Primary Tumour (32)
A-M Cleton-Jansen, PM Wijers-Koster, CM Coffin, BP Rubin, JVMG Bovee
LUMC, Leiden, Netherlands; Vanderbilt University, Nashville, TN; Taussig Cancer Center and Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH
21 Fibromatosis of the Breast: Complication of Previous Radiation and Surgery (93)
Y Zhang, S Libson, E Avisar, M Jorda, C Gomez, AE Rosenburg
University of Miami/Jackson Memorial Hospital, Miami, FL
22 Massive Localized Lymphedema: A Clinicopathologic Study of 35 Patients with an Enrichment for Multiplicity (53)
H Kurt, CA Arnold, OH Iwenofu
Ohio State University, Columbus, OH
23 Myofibromas with Atypical Features: Expanding the Morphologic Spectrum of a Benign Entity (58)
K Linos, JM Carter, AL Folpe, SW Weiss, MA Edgar
Emory University, Atlanta, GA; Mayo Clinic, Rochester, MN
24 Sclerosing Paratesticular Rhabdomyoma: A Morphologically Distinct Variant (43)
VY Jo, CDM Fletcher
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
25 Pleomorphic Fibrosarcoma of Skin and Soft Tissues. Clinicopathologic, Immunohistochemical, and Ultrastructural Analysis of 145 Cases (60)
T Mentzel, C Otto, D Katenkamp
Dermatopathology Bodensee, Friedrichshafen, Germany; University of Freiburg, Freiburg, Germany; University of Jena, Germany
26 A Contemporary Reassessment of Myxofibrosarcoma (MFS) (68)
AL Ruano, SD Billings, JR Goldblum, JL Hornick, BP Rubin
Cleveland Clinic Foundation, Cleveland, OH; Brigham and Women’s Hospital, Boston, MA
27 Recurrent Amplification at 11q13.5-14.1 Targets PAK1 as a Tumor-Promoting Oncogene in Primary Myxofibrosarcomas (57)
C-F Li, J Lan, H-C Tai, T-J Chen, H-Y Huang
Chi-Mei Medical Center, Tainan, Taiwan; Southern Taiwan University of Science and Technology, Tainan, Taiwan; Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan; Changhua Christian Hospital, Changhua, Taiwan
28 Immunohistochemical Analysis of Expression of RB1, CDK4, CHMP2B, cPLA2G4A and HSP90 in Myxofibrosarcoma and Myxoid Liposarcoma (84)
University Pittsburgh of Medical Center, Pittsburgh, PA; University Pittsburgh of Medical Center, Shadyside Hospital, Pittsburgh, PA
29 NY-ESO-1 Is a Sensitive and Specific Marker for Myxoid and Round Cell Liposarcomas among Other Mesenchymal Myxoid Neoplasms (41)
JA Hemminger, AE Toland, OH Iwenofu
Wexner Medical Center at the Ohio State University, Columbus, OH
30 Myxoid Liposarcoma with Heterologous Components: Dedifferentiation or Metaplasia? A FISH and CGH-Array Documented Case Report (87)
N Weingartner, A Neville, F Chibon, V Litique, L Foessel, A Di Marco, L Marcellin, J-P Gnasass
Hopitaux Universitaires de Strasbourg, Strasbourg, France; Institut Bergonié, Bordeaux, France; Centre Paul Strauss, Strasbourg, France
31 BREAST
Microvessel Density and Distribution in MRI-Detected Benign Breast Lesions (119)
JS Bond, RM diFlorio-Alexander, VA Memoli, WA Wells, JD Marotti
Dartmouth-Hitchcock Medical Center, Lebanon, NH
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>32</td>
<td>Non-Mass Like Enhancement (NMLE) in Breast Magnetic Resonance Imaging: A Proposal of Pathological-Radiological Correlation (191)</td>
<td>S Kandel, P Kumar, Q Liu, S Liu, T Khoury</td>
<td>Roswell Park Cancer Institute, Buffalo, NY</td>
</tr>
<tr>
<td>33</td>
<td>Correlation between MRI Findings and Gross and Microscopic Pathology in Total Mastectomy Cases: A Review of 109 Cases (233)</td>
<td>KG Neill, J Liu, B Cliff, B O'Hea, M Singh, C Tornos</td>
<td>Stony Brook University Hospital, Stony Brook, NY</td>
</tr>
<tr>
<td>34</td>
<td>MRI-Guided Needle Core Biopsies of Breast: Diagnostic Yield in 193 Cases (170)</td>
<td>PS Ginter, AJ Winant, SA Hoda</td>
<td>Weill Cornell Medical College, New York, NY</td>
</tr>
<tr>
<td>35</td>
<td>Differences in Tumor Grade of Invasive Breast Carcinomas in Core Biopsy and Excision: An Analysis of 142 Cases (251)</td>
<td>CD Patel, DM Pandya, J Liu, C Bernstein, C Tornos</td>
<td>Stony Brook University Medical Center, Stony Brook, NY</td>
</tr>
<tr>
<td>36</td>
<td>Follow-Up of Breast Papillary Lesion on Needle Core Biopsy: Experience in African-American Population (301)</td>
<td>H Wang, C D’Cruz, A Mahmoud, P Tsang</td>
<td>Newark Beth Israel Medical Center, Newark, NJ</td>
</tr>
<tr>
<td>37</td>
<td>Invasive Ductal Carcinoma with Lobular Features Can Be Diagnosed on Breast Core Biopsies and May Be Important To Distinguish from Pure Invasive Ductal Carcinomas (105)</td>
<td>D Arps, C Kleer, J Pang</td>
<td>University of Michigan, Ann Arbor, MI</td>
</tr>
<tr>
<td>38</td>
<td>Collagen XIα1. A New Marker for Breast Carcinoma Malignancy in Core Needle Biopsies (158)</td>
<td>J Freire, S Dominguez, S Pereda, A De Juan, A Vega, L Simon, J Gomez</td>
<td>Hospital Universitario Marqués de Valdecilla, Santander, Spain; Oncomatrix, Bilbao, Spain</td>
</tr>
<tr>
<td>39</td>
<td>Radiological and Pathological Extent of Columnar Cell Changes with Atypia (CCC-A) Diagnosed on Core Needle Biopsy (CNB) Correlates with Carcinoma Upgrade on Surgical Excision (SE) (221)</td>
<td>F-I Lu, D Girı</td>
<td>Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Memorial Sloan-Kettering Cancer Centre, New York, NY</td>
</tr>
<tr>
<td>40</td>
<td>Atypical Apocrine Adenosis of the Breast on Core Biopsy (186)</td>
<td>S Jaffer, S Frost, A Nayak, C Nagi, LJ Bleiweiss</td>
<td>Mount Sinai Medical Center, New York, NY</td>
</tr>
<tr>
<td>41</td>
<td>Findings on Excision Following a Core Needle Biopsy Diagnosis of Lobular Neoplasia: A Single Institution Experience (219)</td>
<td>A Lott Limbach, A Collie, E Downs-Kelly</td>
<td>Cleveland Clinic, Cleveland, OH</td>
</tr>
<tr>
<td>42</td>
<td>Histological Features Differentiating Cellular Fibroadenoma from Benign Phyllodes Tumor on Core Needle Biopsies (310)</td>
<td>S Yasir, RG Gamez, DW Visscher, A Nassar</td>
<td>Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>43</td>
<td>The Diagnosis of Phyllodes Tumour amongst Participants of Mammographic Screening (156)</td>
<td>G Farshid</td>
<td>BreastScreen SA, Wayville, South Australia, Australia</td>
</tr>
<tr>
<td>44</td>
<td>Phyllodes Tumors: Histologic Features in Relation to Clinical Follow-Up (257)</td>
<td>MR Phillips, Y Omidvar, SK Apple</td>
<td>UCLA, Los Angeles, CA</td>
</tr>
<tr>
<td>45</td>
<td>Fibroadenomatous Lesions in Pediatric Age Group (153)</td>
<td>S Faiz, V Tudor, G-P Yasim, S Badve</td>
<td>Indiana University School of Medicine, Indianapolis, IN</td>
</tr>
<tr>
<td>46</td>
<td>Phyllodes Tumor in Young Women – Focus on Tubular Adenomatous Tumors with Propensity for Phyllodes like Recurrences (278)</td>
<td>T Shet, B Ramnani, S Sethi</td>
<td>Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India</td>
</tr>
<tr>
<td>47</td>
<td>Clinico-Pathological Features of Fibroadenoma Occurring in a Cohort of Young African-American Patients: Single Institution Experience (113)</td>
<td>S Bandyopadhyay, B Alosk, M Bowles, M Cote, D Shi, N Salem, MH Kim, D Visscher, R Ali-Fehmi</td>
<td>Wayne State University, Detroit, MI; Karmanos Cancer Institute, Detroit, MI; Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>49</td>
<td>Stromal Cells in Phyllodes Tumors of Breast Exhibit Stem Cell Marker Expression (317)</td>
<td>Y Zhang, E Chung, KA Toy, LJ Pierce, CG Kleer</td>
<td>UC Davis Medical Center, Sacramento, CA; University of Michigan, Ann Arbor, MI</td>
</tr>
<tr>
<td>50</td>
<td>Multifocal Flat Epithelial Atypia: Possible Precursor of Breast Carcinoma (103)</td>
<td>MS Amin, M Hassan, SJ Robertson, S Islam</td>
<td>University of Ottawa, Ottawa, ON, Canada</td>
</tr>
<tr>
<td>51</td>
<td>The Definitive Microscopic Characterization and Long Term Follow Up of Patients with Collagenous Spherulosis. A Benign Breast Disease Cohort Study (208)</td>
<td>MD Laudenschlager, DW Visscher, R Vierkant, M Frost</td>
<td>Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>52</td>
<td>Detailed Characterization of Ductal Carcinoma In Situ Associated with a Mass on Imaging (223)</td>
<td>A Mahajan, LZ Blanco, Jr., LC Wang, EB Mendelson, KP Siziopikou, ME Sullivan</td>
<td>Northwestern University, Chicago, IL</td>
</tr>
<tr>
<td>53</td>
<td>The OncoType DX® Ductal Carcinoma In Situ (DCIS) Score™ Assay and Quantitative Gene Expression for ER, PR, and HER2: Experience with 1,071 Patients (289)</td>
<td>V Tan, H Bailey, AC Tsiatis, J Anderson, J Liu, SM Butler, FL Baehner, C Millward</td>
<td>Genomic Health, Inc., Redwood City, CA; University of California, San Francisco, CA</td>
</tr>
<tr>
<td>Board Number</td>
<td>Title</td>
<td>Authors</td>
<td>Institution(s)</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>54</td>
<td>Predicting 5-Year Recurrence of Ductal Carcinoma In Situ (DCIS) Following Initial Breast Conserving Surgery and Radiation Therapy (1586)</td>
<td>CP Kragel, S Wei</td>
<td>University of Alabama at Birmingham, Birmingham, AL</td>
</tr>
<tr>
<td>55</td>
<td>Pathological Appraisal of Low Nuclear Grade Ductal Carcinoma In Situ of the Breast (288)</td>
<td>PH Tan, AA Thike, JS-L Wong, GH Ho, S Thilagaratnam</td>
<td>Singapore General Hospital, Singapore, Singapore; National Cancer Centre, Singapore, Singapore; Health Promotion Board, Singapore, Singapore</td>
</tr>
<tr>
<td>56</td>
<td>HER2 Expression in DCIS Is Highly Associated with DCIS Associated Lymphocytes (179)</td>
<td>J Hatem, R Batiste, K Lee, B Czerniecki, P Zhang</td>
<td>University of Pennsylvania, Philadelphia, PA</td>
</tr>
<tr>
<td>57</td>
<td>Hormonal and Her-2 Receptor Status in DCIS and Concurrent Invasive Carcinoma (247)</td>
<td>DM Pandya, CD Patel, S Zee, J Liu, C Tornos</td>
<td>Stony Brook University Medical Center, Stony Brook, NY</td>
</tr>
<tr>
<td>58</td>
<td>Different Biomarkers May Play Critical Roles in Cancer Progression of Different Subgroups of Breast Carcinomas (316)</td>
<td>Z Zhang, J Wang, P Tang</td>
<td>University of Rochester Medical Center, Rochester, NY; RTI Health Solutions, Research Triangle Park, NC</td>
</tr>
<tr>
<td>59</td>
<td>Recurrence in Ductal Carcinoma In Situ (DCIS): A Clinicopathological Study (253)</td>
<td>F Penault-Llorca, L Tixier, A Cyre, F Kwiatkowski, G Leboudec, N Radosevic-Robin, C Abrial, F Mishellany, M-M Dauplat</td>
<td>Centre Jean Perrin and EA 4677 ERTICa University of Auvergne, Clermont-Ferrand, France; Centre Jean Perrin, Clermont-Ferrand, France</td>
</tr>
<tr>
<td>60</td>
<td>CCN Expression in Ductal Proliferations; a Preliminary Study (269)</td>
<td>O Saglam, G Toruner, KG Haines</td>
<td>Yale University, New Haven, CT; UMDNJ, New Jersey Medical School, Newark, PA</td>
</tr>
<tr>
<td>61</td>
<td>Clinicopathological Significance of CADM4 Expression in Invasive Ductal Carcinoma of the Breast (280)</td>
<td>J Sim, H Han, SS Paik</td>
<td>College of Medicine, Hanyang University, Seoul, Republic of Korea</td>
</tr>
<tr>
<td>62</td>
<td>Decreased Expression Levels of Phosphorylated Ser239-Vasodilator-Stimulated Phosphoprotein Indicate Progression from In-Situ to Invasive Breast Carcinomas (134)</td>
<td>PC Otzia, A Bombonati, M Ali, JP Palazzo, R Birhe, G Pitari</td>
<td>Thomas Jefferson University Hospital, Philadelphia, PA</td>
</tr>
<tr>
<td>63</td>
<td>Comparison of ER, PR and HER2 Expression between Breast Carcinoma Fine Needle Aspiration Samples and Corresponding Surgical Pathology Specimens – A Large Retrospective Study (437)</td>
<td>P Vohra, M Serrano, YY Chen, B-M Ljung</td>
<td>University of California, San Francisco, CA; San Rafael Medical Center, San Rafael, CA</td>
</tr>
<tr>
<td>64</td>
<td>Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) Cytology: Review of High-Volume Institutional Experience with a Focus on Diagnostic Accuracy and EGFR/KRAS Molecular Testing (428)</td>
<td>LC Tong, MA Friedlander, A Asmat, DJ Finley, AL Moretra, N Rekhtman</td>
<td>Memorial Sloan-Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>65</td>
<td>Rapid On-Site Cytologic Evaluation (ROSE) of Endoscopic Ultrasound-Guided Fine Needle Aspirations (EUS-FNAs): A Tale of Two Institutions (346)</td>
<td>KJ Brister, K Rao, V Paul, M Jonathan, W Helen</td>
<td>Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth-Hitchcock Medical Center, Lebanon, NH</td>
</tr>
<tr>
<td>66</td>
<td>Characterization of the Atypical Diagnostic Category in Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) of the Pancreas: A Ten Year Experience (401)</td>
<td>M Moore, J Stewart III, K Das</td>
<td>University of Wisconsin School of Medicine and Public Health, Madison, WI</td>
</tr>
<tr>
<td>67</td>
<td>Histoplasmosis: Have EUS and EBUS FNA Changed the Cytologic Face of the Disease? (368)</td>
<td>MP Gailey, CS Jensen</td>
<td>University of Iowa Hospitals and Clinics, Iowa City, IA</td>
</tr>
<tr>
<td>68</td>
<td>Endobronchial Ultrasound-Guided Fine-Needle Aspiration Cytology, a More Efficacious Diagnostic Modality to EBUS-Core Needle Biopsy – The Washington University Experience (339)</td>
<td>C Baidoo, JF Wang, R Sarkar</td>
<td>Washington University in St Louis, St. Louis, MO; Barnes-Jewish Hospital, St. Louis, MO</td>
</tr>
<tr>
<td>69</td>
<td>Comparative Study for Diagnosis of Gastrointestinal Submucosal Lesions (GISML) Using Standard EUS-Fine Needle Aspiration (FNA) Versus EUS-Fine Needle Biopsy (FNB) (385)</td>
<td>P Jimenez, A-SA Monder, M Alberola, MC Dinares, C Iglesias, J Dot, A Benages, S Ramon-y-Cajal, N Tallada</td>
<td>Vall Hebron Hospital, Barcelona, Spain</td>
</tr>
<tr>
<td>70</td>
<td>Intra-Abdominal Neuroendocrine Tumor Diagnosed by Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA): A Retrospective Study from an Academic Tertiary Center (333)</td>
<td>R Albade, G Soucy, AV Sahai, SC Paquin, G Gariepy</td>
<td>Centre Hospitalier Universitaire de Montréal, Montréal, QC, Canada</td>
</tr>
<tr>
<td>71</td>
<td>Claudin-4 Immunohistochemistry Is Highly Effective in Distinguishing Adenocarcinoma from Malignant Mesothelioma in Effusion Cytology (386)</td>
<td>VY Jo, ES Cibas, GS Pinkas</td>
<td>Brigham and Women’s Hospital, Harvard Medical School, Boston, MA</td>
</tr>
<tr>
<td>72</td>
<td>Carbonic Anhydrase IX (CAIX) Expression Does Not Discriminate between Benign and Malignant Effusions (335)</td>
<td>V Ananthanarayanan, M Tretiakova, AN Husain, T Krausz, T Antic</td>
<td>University of Chicago, Chicago, IL</td>
</tr>
</tbody>
</table>
73 When Should We Send a Cellular Lymphoid Effusion for Lymphoma Work-Up (349)
M Chaump, D Stachurski, G Yu
Rhode Island Hospital, Providence, RI; Warren Alpert Medical School, Providence, RI

74 The Utility of GLUT-1, CD146 and KOC Immunostains in Distinguishing Malignant Mesothelioma and Reactive Mesothelial Cells from Pleural Effusion (356)
H Deng, J Shi, F Lin
Geisinger Medical Center, Danville, PA; Geisinger Wyoming Valley, Wilkes-Barre, PA

75 Evaluation of Myeloid Leukemic Effusions in Cytopathology (412)
MA Rollins-Raval, SE Monaco, WE Khalbuss, L Pantanowitz
University of Pittsburgh Medical Center, Pittsburgh, PA

76 Epstein-Barr Virus (EBV)-Associated Pleural Effusions: Clinical Features, Cytomorphologic Characteristics, and Flow Cytometric Immunophenotyping (422)
H Takei, D Mody
Methodist Hospital, Houston, TX

77 Touch Preparations of Core Biopsies. Impact on Target Therapy Selection Eligibility (427)
LC Tong, D Rudomina, M Friedlander, O Lin
Memorial Sloan-Kettering Cancer Center, New York, NY

78 Ongoing Physician Performance Evaluation (OPPE) for Clinicians Performing Endoscopic Ultrasound (EUS) and Endobronchial Ultrasound (EBUS) Guided FNAs (337)
B Arville, J Speiser, W Cannon, E Wojcik
Loyola University Medical Center, Maywood, IL

79 Comparing Two Platforms of Detection for High Risk Human Papillomavirus in Both SurePath and ThinPrep Gynecologic Specimens (393)
A Levi, P Hui, K Dutch, K Schofield, DC Chhieng
Yale University, New Haven, CT

80 Pathologic Description of Pap Smears & Biopsies in Gastric Type/Minimal Deviation Endocervical Adenocarcinomas (402)
E Morency, T Kiyokawa, CS Sigel, KJ Park
Memorial Sloan-Kettering Cancer Center, New York, NY; Chiba University, Chiba, Japan

81 Digital Holographic Microscopy: Screening Tool for Cervix Cancer. Preliminary Study (343)
N Benzerdjeh, C Garbar, P Camparo, HP Sevestre
CHU Picardie, Amiens, France; Institut Jean Godinot, Reims, France; Centre de Pathologie, Amiens, France

82 Cost Paradox in Cervical Cancer Screening in South India: Expensive HPV Is a Better Screening Test Than Less Expensive Techniques: Comparison of VIA, Cytology and HPV Testing (357)
R Dewar, R Khadapkar, S Jeyapandi, A Khan, BR Das
Beth Israel Deaconess Medical Center, Boston, MA; SRL Limited, Mumbai, Maharashtra, India; Hindu Mission Hospital, Thrissur, Thrissur, India

83 Follow-Up Outcomes of a Large Cohort of Low-Risk Women with ASC-US Imaged Liquid-Based Cytology and Negative HPV Test Results (370)
C Gilbert, R Freij, A Karanamurthy, Z Li, C Zhao
University Hospitals Case Medical Center, Cleveland, OH; Magee-Womens Hospital UPMC, Pittsburgh, PA

84 Anal Cytologic Testing as a Screening Test – An Institutional Experience (449)
P Zhao, A Goyal
Cleveland Clinic Foundation, Cleveland, OH

85 Diagnostic Utility of MIB-1 and p53 in Separating Metastatic carcinoma of Gynecologic Origin from Benign Epithelial Lesions in Pelvic Washing Cytology Specimens (407)
S Patel, J Nunez, A Mohanty, JF Silverman, Y Liu
Allegheny General Hospital, Pittsburgh, PA

86 Evidence That Judicious Use of a Cellient™ Cell Block and p16/Ki67 Immunohistochemistry (IHC) in Pap Tests Improves the Prediction of Biopsy Findings of CIN2 or Worse (444)
W Xing, A Fischer, AY Hou, Z Jiang
University of Massachusetts Medical School, Worcester, MA; Brandeis University, Waltham, MA

87 The Value of Levels and p16 Immunostains in the Follow-Up of HPV Positive-Biopsy Negative Cervical Lesions (405)
A Nunez, J Roberson, A Wrenn III, J Eltoom
University of Alabama at Birmingham, Birmingham, AL

88 TelePAPology vs. Liquid-Based Cervical Cytology: A Comparative Study Evaluating p16 Immunohistochemistry and HPV Testing by Hybrid Capture-2 and In Situ Hybridization (408)
T Pham, C Winters, M Davis, F Fan, O Tawfik
Kansas University Medical Center, Kansas City, KS

89 Does Cytological Examination of Ovarian Cyst Fluids Obtained during Oophorectomy Add Useful Information? (369)
C Garady, SL Boerner
University Health Network, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada

90 Clinical Significance of High Risk Human Papillomavirus (hrHPV) DNA Testing in Women with a Cytological Diagnosis of Atypical Glandular Cells (359)
AB Domfeh, A Levi, K Schofield, D Chhieng
Yale University, New Haven, CT

91 Validation of Cervista HPV16/18 Assay in Anal Swab Specimens (447)
H Zhang, A Khanna, J Feng, S Patel, G Staerkel, M Guo
University of Texas MD Anderson Cancer Center, Houston, TX

92 Is There a Role for High Risk HPV Testing in the Triage of Patients with ASC-H? (394)
AW Levi, A Domfeh, K Schofield, M Harigopal, D Chhieng
Yale University, New Haven, CT
93 Squamous Intraepithelial Lesion of Intermediate Grade: Cytologic-Histologic Correlation and Comparison of Positive Predictive Values (424)

P Tauchi-Nishi, C Gima, N Win, J Kaneshiro, T Namiki, M Hiraoka
University of Hawaii/Hawaii Pathologists Laboratory, Honolulu, HI; University of Hawaii, Honolulu, HI

94 Gynecologic Malignancies Are Commonly Encountered on Fine Needle Aspiration of Supraclavicular Lymph Nodes (363)

DJ Fix, PN Staats
University of Maryland Medical Center, Baltimore, MD; University of Maryland School of Medicine, Baltimore, MD

95 Histologic Follow-Up for Atypical Endocervical Cells (383)

BL Janssen, MJ Thrall
Methodist Hospital, Houston, TX

96 Implantable Port System Cytology for Ovarian Cancer To Evaluate Chemotherapy Response (423)

S Tate, K Nishikimi, N Yamamoto, T Uehara, H Ushki, A Mitsuhashi, M Shozu
Chiba University Hospital, Chiba, Japan

97 Cytologic Features of Atypical Cervical Cytology Samples with and without TERC Copy Number Changes (417)

M Sanidad, M Abawi, J Kelly, D Jones, Y Hijazi
Quest Diagnostics Nichols Institute, Chantilly, VA

98 Touch Preps of Core Needle Biopsies from Renal Masses: 5 Years Retrospective Review and Interpretation Pitfalls (348)

SJ Carroll, E Hubbard, S Van Meter, L Nodit
University of Tennessee Medical Center Knoxville, Knoxville, TN


SM Barcia, SM Nobles, ZL Tabatabai
University of California San Francisco, San Francisco, CA

100 p40 (ANp63): A Highly Sensitive and Specific Immunohistochemical (IHC) Marker for Diagnosing Pulmonary Squamous Cell Carcinomas (SQCC) in Fine Needle Aspirates (436)

AP Vogt, C Cohen, MT Siddiqui
Emory University School of Medicine, Atlanta, GA

101 Cytomorphology of Non-Small Cell Lung Carcinoma (NSCLC) with Anaplastic Lymphoma Kinase (ALK) Gene Rearrangement (426)

AD Toll, P Illei, Z Maleki
Johns Hopkins, Baltimore, MD

102 The Role of p40 Immunostain in the Cytological Differential Diagnosis of Squamous Cell Carcinoma and Adenocarcinoma of the Lung (351)

X Chen, Y Bao, R Wong, K Politi, L Jiao, S Gettinger, R Homer, D Chhieng, G Cai
Yale School of Medicine, New Haven, CT

103 A Feasibility Study Comparing Single Pathologist Review, Consensus Review, and FISH for Diagnosis in Endometrial Brush Cytology (389)

SE Kerr, EG Barr Fritcher, TN Kroneman, A Nassar, M Rivera, DR Salomao, GL Keeney, MR Henry, AC Clayton, BR Kipp
Mayo Clinic, Rochester, MN

104 Cellient™ Automated Cell Block System Is Useful in the Differential Diagnosis of Atypical Glandular Cells in Pap Tests (443)

W Xing, AY Hou, A Fischer, Z Jiang
University of Massachusetts Medical School, Worcester, MA; Brandeis University, Waltham, MA

105 GATA3 Expression in Cytology Samples of Metastatic Breast Versus Gynecological Carcinoma and Comparison with GCDFP15 and Mammaglobin (355)

G Defereos, U Krishnamurtti, JF Silverman
Allegheny General Hospital, Pittsburgh, PA

106 Gastroesophageal Junction (GEJ) – Definition and Histopathologic Features – Eastern View (665)

A Kim, J-Y Kim, N Shin, W-Y Park, D-Y Park
Pusan National University Hospital, Busan, Korea

107 The Optimal Number of Biopsy Fragments To Establish a Diagnosis of Eosinophilic Esophagitis (696)

JA Nielsen, DJ Lager, M Levin, CA Roberts
ProPath, Dallas, TX

108 Distal Esophageal Squamous Papilloma Association with Eosinophilic Esophagitis and Gastroesophageal Reflux Disease: A Single Institution Large Cohort Study (687)

AA Lo, VL Kung, H Li, W Zhang, MS Rao, N Gonsalves, I Hirano, G-Y Yang
Northwestern University, Chicago, IL

109 P53 and Racemase Immunohistochemistry in the Evaluation of Glandular Atypia Versus Low Grade Dysplasia/Indefinite for Dysplasia in a Large Cohort of Patients with Barrett Esophagus (712)

R Petras, J Jeung, T Ly, W Katzin
AmeriPath Institute of Gastrointestinal Pathology and Digestive Disease, Cleveland, OH

110 Necrotizing Sialometaplasia-Like Change of the Esophageal Submucosal Glands Is Associated with Barrett’s Esophagus (609)

DR Braxton, DC Nickleach, Y Liu, AB Farris
Emory University School of Medicine, Atlanta, GA; Winship Cancer Institute of Emory University, Atlanta, GA

111 Prevalence and Characteristics of Lymphocytic Esophagitis in Barrett’s Esophagus (629)

KL Golden, C Sanchez, D Cowan, B Reid, P Blount, R Odze, A Srivastava
Brigham and Women’s Hospital, Boston, MA; Fred Hutchinson Cancer Center and University of Washington, Seattle, WA
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>112</td>
<td>Correlation of Mutational Change with Histological Disease Progression in Barrett’s Esophagus (619)</td>
<td>G Deftereos, C Narick, JF Silverman, LL Freed, EMG Ellsworth, SA Jackson, SD Finkelstein Allegheny General Hospital, Pittsburgh, PA; RedPath Integrated Pathology, Inc., Pittsburgh, PA</td>
</tr>
<tr>
<td>113</td>
<td>Does Barrett’s Carcinoma Always Arise from Intestinal Metaplasia? Detailed Histologic Examination of EMR Specimens (594)</td>
<td>J Aida, T Arai, M Vieth, C Ell, A May, H Neuhaus, K Takubo Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan; Dr. Horst Schmidt Clinic, Wiesbaden, Germany; Evangelisches Krankenhaus, Dusseldorf, Germany</td>
</tr>
<tr>
<td>114</td>
<td>Importance of Stromal Desmoplasia in Staging Early Esophageal Adenocarcinoma on Endoscopic Mucosal Resection Specimens (757)</td>
<td>M Tripathi, A Grin, C Streuker St. Michael’s Hospital, Toronto, ON, Canada</td>
</tr>
<tr>
<td>115</td>
<td>Neoadjuvant Radiotherapy in Esophageal Adenocarcinoma Is Associated with a Dense IgG4 Plasma Cell Response (598)</td>
<td>D Allen, S Lu, L Noble, J Fanton, MB Resnick, E Yakirevich Rhode Island Hospital and the Alpert Medical School of Brown University, Providence, RI</td>
</tr>
<tr>
<td>116</td>
<td>Clinicopathologic Predictors of Long Term and Disease-Free Survival in Esophageal Adenocarcinomas with Complete Pathologic Response to Neoadjuvant Chemoradiation (592)</td>
<td>AT Agoston, Y Zheng, R Bueno, GY Lanuvers, RD Ozde, A Srivastava Brigham and Women’s Hospital, Boston, MA; Massachusetts General Hospital, Boston, MA</td>
</tr>
<tr>
<td>117</td>
<td>Histologic Features Predicting High Risk of Submucosal Invasion in Mucosal Biopsies of Esophageal Adenocarcinoma (626)</td>
<td>B Fu, T Foxwell, H Hu, AM Krasinskas, KS Nason, JM Davison University of Pittsburgh School of Medicine, Pittsburgh, PA</td>
</tr>
<tr>
<td>118</td>
<td>ALK Status in Esophageal Adenocarcinoma and Squamous Carcinoma Studied by DNA Microarray, FISH and Immunohistochemistry (784)</td>
<td>Z Zhou, S Bandla, J Ye, L Li, T Godfrey, N Wang University of Rochester Medical Center, Rochester, NY</td>
</tr>
<tr>
<td>119</td>
<td>Interstitial Cells of Cajal in Gastrointestinal Leiomyoma (621)</td>
<td>A Deshpande, V Deshpande, MJ O’Brien Boston Medical Center, Boston, MA; Massachusetts General Hospital, Boston, MA</td>
</tr>
<tr>
<td>120</td>
<td>Granular Cell Tumors of the Gastrointestinal Tract: Clinicopathologic Associations in a Large Series (606)</td>
<td>B Bhattacharya, S Samaha Miraca Life Sciences Research Institute, Phoenix, AZ</td>
</tr>
<tr>
<td>121</td>
<td>BRAF V600E Mutation Analysis Simplifies the Testing Algorithm for Lynch Syndrome (657)</td>
<td>M Jin, H Hampel, X Zhou, L Schuemann, MM Yearsley, WL Frankel Ohio State University, Columbus, OH</td>
</tr>
<tr>
<td>122</td>
<td>Immunohistochemistry Using a BRAF V600E Mutation-Specific Monoclonal Antibody Is Not a Useful Surrogate for Genotyping in Colorectal Adenocarcinoma (586)</td>
<td>CA Adackapara, LM Sholl, JA Barletta, JL Hornick Brigham and Women’s Hospital, Harvard Medical School, Boston, MA</td>
</tr>
<tr>
<td>123</td>
<td>Assessment of BRAF V600E Mutation-Specific Antibody (VE1) in Colorectal Cancers (671)</td>
<td>S-F Kuan, RR Pai, S Navina, MN Nikiforova, KL Cressman University of Pittsburgh, Pittsburgh, PA</td>
</tr>
<tr>
<td>124</td>
<td>Clinicopathologic and Molecular Features of CDX2-/CK20-/MSI+ Colorectal Cancer (666)</td>
<td>HJ Kim, Y-Y Rhee, JM Bae, N-Y Cho, GH Kang Seoul National University College of Medicine, Seoul, Republic of Korea; SMG-SNU Boramae Medical Center, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea</td>
</tr>
<tr>
<td>125</td>
<td>Loss of Expression of ARID1A and BRG1 in Colorectal Cancer Occurs Infrequently and Is Associated with BRAF Mutation and Microsatellite Instability (608)</td>
<td>JR Bledsoe, M Kamioneck, DE Shvetz, M Mino-Kenudson Massachusetts General Hospital, Boston, MA</td>
</tr>
<tr>
<td>126</td>
<td>Immunohistochemical Detection of the BRAF V600E Mutant Protein in Colorectal Adenocarcinoma (762)</td>
<td>E Vakianti, Y Zhou, DS Kimstra, J Shia Memorial Sloan-Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>127</td>
<td>ARID1A in Colorectal Carcinoma: Loss of Expression Is Associated with DNA Mismatch Repair Protein Deficiency (780)</td>
<td>J Ye, Y Zhou, D DeLair, R Soslow, J Shia Memorial Sloan-Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>128</td>
<td>HER2 Protein Overexpression and Gene Amplification in Colorectal Adenocarcinomas (747)</td>
<td>Y Sun, L Zhou, D Cao Peking University Cancer Hospital, Beijing, China</td>
</tr>
<tr>
<td>129</td>
<td>PIK3CA Activating Mutation in Colorectal Carcinoma: A Stratified Analysis in a Prospective Cohort (725)</td>
<td>C Rosty, JP Young, MD Walsh, M Cledenning, MA Jenkins, AK Win, MC Southey, S Parry, JL Hopper, GG Giles, E Williamson, DR English, DD Buchanan Queensland Institute of Medical Research, Brisbane, Australia; University of Queensland, Brisbane, Australia; Envoi Pathology, Brisbane, Australia; Sullivan Nicolaides Pathology, Brisbane, Australia; University of Melbourne, Melbourne, Australia; Middlemore Hospital, Auckland, New Zealand; Cancer Council Victoria, Melbourne, Australia</td>
</tr>
<tr>
<td>130</td>
<td>Correlation of the C&gt;T SNP (rs16906252) with MGMT Promoter Hypermethylation, KRAS Mutation Status and Clinicopathologic Features in Colorectal Cancer (635)</td>
<td>CE Hagen, JA Lefferts, GJ Tsongalis, JJ Tafe Dartmouth-Hitchcock Medical Center, Lebanon, NH</td>
</tr>
<tr>
<td>131</td>
<td>SATB2 Double-Staining: Significant Improvement in Specificity for Colonic Adenocarcinoma (721)</td>
<td>J Rock, R Roth, A Lehman, W Marsh, WL Frankel Ohio State University Wexner Medical Center, Columbus, OH</td>
</tr>
</tbody>
</table>
Using Next Generation DNA Sequencing (NGS) To Select Phosphorylation of EGFR in Colorectal Cancer (607)

Prevalence of Different Polyp Types in MSI and MSS Age and Classification of Colorectal Cancer Based on DNA Methylation Routine Genotyping of Tubal Gut Adenocarcinomas Yields LINE-1 Hypomethylation and Patient Prognosis in 1253 Colorectal Cancers (702)

Classification of Colorectal Cancer Based on DNA Methylation Array Analysis (694)

Prevalence of Different Polyp Types in MSI and MSS Age and Gender Matched Cohorts of Colorectal Cancer Resections (627)

Phosphorylation of EGFR in Colorectal Cancer (607)

Using Next Generation DNA Sequencing (NGS) To Select Targeted Therapies and Predict Resistance to Standard Therapies in Colorectal Cancer (CRC) (737)

CDKN1A, 1B, TP53 mRNA and miR-34a, 192, 215, 221 Expression of Crypts and Stroma in Human Colorectal Cancer (701)

KRAS Codon 12, 13, 61 and 146 Mutations in 1267 Colorectal Cancers: Clinicopathological, Molecular, and Survival Analyses (685)

Variation of ERG Oncoprotein Expression in Prostate Cancer Patients of Different Ethnicities (999)

RNAseq Analysis of Formalin Fixed Paraffin Embedded Radical Prostatectomy Specimens Identifies Predictors of Biochemical Recurrence in Prostate Cancer (976)

MicroRNA Signature Distinguishes Early from Late Biochemical Failure in Prostate Cancer (1062)

Intraductal Carcinoma of the Prostate: An Institutional Clinicopathologic Review with Follow Up (1030)

The Increased Frequency of ERG Oncoprotein Expression in High Grade Prostate Cancer in Caucasian American Compared to African American Men (866)

The The Increased Frequency of ERG Oncoprotein Expression in Prostate Cancer (966)


Y Imamura, C Fuchs, S Ogino Dana-Farber Cancer Institute, Boston, MA; Brigham and Women’s Hospital, Boston, MA

LINE-1 Hypomethylation and Patient Prognosis in 1253 Colorectal Cancers (702)

S Ogino, Y Imamura, C Fuchs Brigham and Women’s Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA

Routine Genotyping of Tubal Gut Adenocarcinomas Yields Novel Molecular Insights (745)

M Stachler, N Lindeman, R Odze, A Srivastava Brigham and Women’s Hospital, Boston, MA

Classification of Colorectal Cancer Based on DNA Methylation Array Analysis (694)

M Milewski, D Leahy, J Conroy, T Magalhaes, S Ennis, A Maguire, H Mulcahy, J Hyland, D O’Donoghue, K Sheahan University College Dublin, Dublin, Ireland; St. Vincent’s University Hospital, Dublin, Ireland

Prevalence of Different Polyp Types in MSI and MSS Age and Gender Matched Cohorts of Colorectal Cancer Resections (627)

D Gibbons, CH Ng, R Geragthy, E Rinehart, J Hyland, RP O’Connell, D Winter, H Mulcahy, G Doherty, D O’Donoghue, F David, S Kieran St. Vincent’s University Hospital, Dublin, Ireland; Brigham and Women’s Hospital, Boston, MA

Phosphorylation of EGFR in Colorectal Cancer (607)

JR Bledsoe, DE Shvetz, M Mino-Kenudson Massachusetts General Hospital, Boston, MA

Using Next Generation DNA Sequencing (NGS) To Select Targeted Therapies and Predict Resistance to Standard Therapies in Colorectal Cancer (CRC) (737)

CE Sheehan, A Parker, M Jarosz, S Downing, R Yelensky, D Lipson, G Otto, A Donahue, S Balasubramanian, P Stephens, G Palmer, M Cronin, JS Ross Albany Medical College, Albany, NY; Foundation Medicine Inc., Cambridge, MA

CDKN1A, 1B, TP53 mRNA and miR-34a, 192, 215, 221 Expression of Crypts and Stroma in Human Colorectal Cancer (701)

H Nozaka, A Mayama, T Miura, H Takami, K Takahashi, Y Konishi, Y Mue, M Suzuki, N Uesugi, K Ishida, T Sugai Hiroaki University, Hiroaki-shi, Aomori, Japan; Iwate Medical University, Morioka-shi, Iwate, Japan

KRAS Codon 12, 13, 61 and 146 Mutations in 1267 Colorectal Cancers: Clinicopathological, Molecular, and Survival Analyses (685)

X Liu, Y Imamura, S Ogino Dana-Farber Cancer Institute, Boston, MA; Brigham and Women’s Hospital, Boston, MA

Recurrent Chromosomal Aberrations in Stressed Strial Tumors of the Prostate Detected by Array Comparative Genomic Hybridization (991)

C-C Pan, JI Epstein Taipei Veterans General Hospital, Taipei, Taiwan; Johns Hopkins Medical Institutions, Baltimore, MD

Intraductal Carcinoma of the Prostate: An Institutional Clinicopathologic Review with Follow Up (1030)

TM Schneider, AO Osunkoya Emory University School of Medicine, Atlanta, GA

Presence of Intraductal Carcinoma of the Prostate Is a Significant Prognostic Parameter for Prostate Cancer (1055)

T Tsuchi, K Kimura, M Kato, R Ishida, N Sassa, R Hattori, M Gotoh Nagoya Daini Red Cross Hospital, Nagoya, Japan; Nagoya Medical Center, Nagoya, Japan; Nagoya University Hospital, Nagoya, Japan; Nagoya First Red Cross Hospital, Nagoya, Japan

The Increased Frequency of ERG Oncoprotein Expression in Prostate Cancer Patients of Different Ethnicities (999)

G Petrovics, M Williams, S Rawal, P Rosen, D Pfister, T Inoue, T Segawa, O Ogawa, M Colombo, Y Chen, D Young, A Dobi, DG McLeod, S Srivastava, J Sesterhenn Center for Prostate Disease Research, Bethesda, MD; Walter Reed National Military Medical Center, Bethesda, MD; Joint Pathology Center, Silver Spring, MD

Variation of ERG Oncoprotein Expression in Prostate Cancer
Somatic Copy Number Alterations by Whole Exome Sequencing Reveals YWHAZ and PTK2 as Potential Therapeutic Targets in Castration Resistant Prostate Cancer (1017)
K Ruenanur, R Menon, M Deng, F Kunze, D Bohm, W Vogel, V Schebelle, F Fend, G Kristiansen, N Wernert, N Oberbeckmann, S Biskup, M Rubin, Z Shalikhbrahim, S Perner
Institute of Pathology, University Hospital of Bonn, Bonn, Germany; University Hospital of Tuebingen, Tuebingen, Germany; CeGaT GmbH, Tuebingen, Germany; Weill Cornell Medical College of Cornell University, New York, NY; Institute of Pathology, University Hospital of Tuebingen, Tuebingen, Germany

Comparison of Biochemical Recurrence Free Survival between Pelvic Lymph Node Metastasis and Periprostatic Lymph Node Metastasis of Prostate Cancer: A Case-Control Study (882)
N Gonzalez-Roibon, JS Han, S Lee, R Sharma, Z Feng, S Arslanokz, N Smith, PM Pierrozio, E Humphreys, TL Deweese, AW Partin, TJ Bivalacqua, M Han, BT Trock, GJ Netto
Johns Hopkins Hospital, Baltimore, MD; Hacettepe University School of Medicine, Ankara, Turkey

Characterizing the Dominant/Index Lesion in Prostate Cancer: Implications for Grading and Staging (869)
SW Fine, K Kanao, K Udo, HA Al-Ahmadi, Y-B Chen, A Gopalan, SK Tickoo, VE Reuter
Memorial Sloan-Kettering Cancer Center, New York, NY

Lineage Relationships of Gleason Patterns in Gleason Score 7 Prostate Cancer (835)
JC Cheville, IV Krovitin, SJ Murphy, SH Johnson, S Zarei, F Kosari, W Sukow, EJ Parkila Castellar, RJ Karnes, G Vasmazis
Mayo Clinic, Rochester, MN

Chronic Inflammation on Initial Benign Prostate Biopsy Is a Negative Predictor of Subsequent Cancer Detection (1088)
C Zhao, S Venigalla, H Miyamoto
University of Rochester, Rochester, New York

Expression of Phospholipase A2 Correlates with the Progression and Metastasis of Prostate Cancer (889)
FJ Hairston, R Reddy, Z He, JR Levin, X Zhou
University of Mississippi Medical Center, Jackson, MS

Characteristics of Prostatic Adenocarcinoma in a Contemporary Australian Radical Prostatectomy Series from a Community without Population-Based PSA Screening (1019)
H Samaratunga, J Yaxley, J Perry-Keene, M Adamson, B Delahun
Aquesta Pathology, Brisbane, Queensland, Australia; Royal Brisbane Hospital, Brisbane, Queensland, Australia; Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand

Targeted Seminal Vesicles Biopsies: Incidence and Clinicopathological Findings (1069)
KE Watts, C Magi-Galluzzi
Cleveland Clinic, Cleveland, OH

Prostate Cancer Multifocality and Heterogeneity: Implications for Gleason Grading, Tumor Volume Measurement and Tissue Sampling for Research (904)
CC Huang, M Kong, Q Ren, F-M Deng, J Melamed, M Zhou
New York University Langone Medical Center, New York, NY

Frequency and Clinicopathologic Features of Dominant Anterior Prostatic Carcinomas (984)
J Mygatt, J Rosner, J Barton, J Sesterhenn, Y Chen, J Cullen, S Srivastava, D McLeod, S Brassell
USUHS, Bethesda, MD; Walter Reed National Military Medical Center, Bethesda, MD; Joint Pathology Center, Silver Spring, MD; Center for Prostate Disease Research, Rockville, MD

Dataset for Reporting of Prostate Carcinoma in Radical Prostatectomy Specimens: Recommendations from the International Collaboration on Cancer Reporting (ICCR) (930)
JG Kench, B Delahun, DF Griffith, PA Humphrey, T McGowan, K Trepkov, M Varna, TM Wheeler, JR Srigley
Royal Prince Alfred Hospital, Sydney, NSW, Australia; Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand; University Hospital of Wales, Cardiff, United Kingdom; Washington University School of Medicine, St Louis, MO; Carlo Fidani Peel Regional Cancer Centre, Mississauga, ON, Canada; University of Calgary, Calgary Laboratory Services, Calgary, AB, Canada; Baylor College of Medicine, Houston, TX; McMaster University, Hamilton, ON, Canada

Assessing the Extent of Biopsy Core Involvement by Prostate Cancer and Its Impact on the Selection of Patients for Active Surveillance: Is “Eyeballing” Accurate Enough? (961)
O Mahamud, TH van der Kwast, MR Downes, AJ Evans
University Health Network, Toronto, ON, Canada

Collagenous Micronodules in Prostate Cancer Revisited: Are They Solely Associated with Gleason Pattern 3 Adenocarcinomas? (936)
M Kim, MK Divatia, JY Ro
College of Medicine, Yeungnam University, Daegu, Korea; Genomic Medicine, Methodist Hospital, Houston, TX

High Expression and Diagnostic Utility of Internexin alpha in Clear Cell Sarcoma of the Kidney: Comparative Proteomics Analysis and Immunohistochemical Study (1048)
Y Tanaka, A Katayama, T Inoue, H Iwafuchi, H Kishimoto, M Nakayama, N Nagahara, H Orimo, M Hamazaki, M Tanaka, M Yoshida, R Ijiri, N Kitagawa, M Shinkai, H Kigasawa
Kanagawa Children’s Medical Center, Yokohama, Kanagawa, Japan; Niin Medical School, Bunkyo-ku, Tokyo, Japan; Osaka City General Hospital, Miyakojima-ku, Osaka, Japan; Shizuoka Children’s Hospital, Shizuoka, Japan; Saitama Children’s Medical Center, Saitama, Japan; Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi, Osaka, Japan

The Impact of Routine Frozen Section Analysis (FSA) during Partial Nephrectomy (PN) on Surgical Margin (SM) Status and Long-Term Outcomes: A Clinicopathological Study of 433 Cases (1058)
S Venigalla, G Wu, H Miyamoto
University of Rochester, Rochester, NY
Cystic Partially Regressed Clear Cell Renal Cell Carcinoma: Clinical and Morphologic Distinction from Multilocular Cystic Renal Cell Carcinoma (1075)
SR Williamson, GT MacLennan, A Lopez-Beltran, R Montironi, PH Tan, G Martignoni, DJ Grignon, JN Eble, L Cheng
Indiana University, Indianapolis, IN; Case Western Reserve University, Cleveland, OH; Cordoba University, Cordoba, Spain; Polytechnic University of the Marche Region, Ancona, Italy; Singapore General Hospital, Singapore, Singapore; University of Verona, Verona, Italy

Genomic Profiles Suggest Renal Oncocytic Tumors Are Intermediate between Oncocytoma and Eosinophilic Chromophobe Renal Cell Carcinoma, but More Closely Related to the Former (1091)
M Zhou, K Smith, C Magi-Galluzzi
New York University, New York, NY; Cleveland Clinic, Cleveland, OH

Spectrum of Renal Pathology in Patients with Congenital Renal Anomalies – A Case Series from a Tertiary Cancer Center (849)
J Dhillon, SK Mohanty, T Kim, WJ Sexton, PE Spiess
Moffitt Cancer Center, Tampa, FL

SNP Microarray Analysis Assists with Diagnosis of Renal Epithelial Tumors (892)
HH Hamilton, AM McDermott, MT Smith, DJ Wolff
Medical University of South Carolina, Charleston, SC

Intraepithelial Spread of Prostate Carcinoma in Cases of Seminal Vesicle Invasion (Stage pT3b). Retrospective Analysis of Non-Recognized Pattern of Tumor Spread in Seminal Vesicle (1001)
S Pina-Oviedo, A Kristiansen, L Egevad, M Divatia, SS Shen, JY Ro
Methodist Hospital, Houston, TX; Karolinska University Hospital, Stockholm, Sweden

Renal Percutaneous Needle Core Biopsy Verse Fine Needle Aspiration, or Both? (957)
C Liu, A Heimann, W Waltzer, J Liu
Stony Brook University Medical Center, Stony Brook, NY

Gata3 Expression in Paragangliomas: A Pitfall That Could Lead to Misdiagnosis of Urothelial Carcinoma (1041)
JS So, JI Epstein
Johns Hopkins Medical Institutions, Baltimore, MD

Comparative Study of Chromosomal Imbalances, Histological and Clinical Features in a Series of 86 Clear Cell Renal Cell Carcinomas (845)
CHU Pontchaillou, Rennes, France; Faculty of Medicine, Rennes, France

Comparative Immunohistochemical Profiles of Papillary Renal Cell Carcinoma Subtypes (795)
A Alomari, H Kluger, K Haines, D Singh, ML Prasad, AJ Adeniran
Yale School of Medicine, New Haven, CT

Papillary Renal Cell Carcinoma: Clinicopathologic Study of 144 Cases with Emphasis on Subtyping (796)
A Alomari, H Kluger, K Haines, D Singh, AJ Adeniran
Yale School of Medicine, New Haven, CT

Localized Amyloidosis of the Urinary Bladder: New Pathological Features Revealed by Mass Spectrometry-Based Proteomics (972)
OM Mereuta, A D’Souza, JA Vrana, JD Theis, PS Quint, A Dispenzieri, KL Grogg, A Dogan
Mayo Clinic, Rochester, MN; University of Torino, Torino, Italy

TGF-beta Induced Epithelial-Mesenchymal Transition Promotes Bladder Cancer-Cell Migration in a Nonmuscle Myosin IIb Dependant Manner (886)
S Gupta, H Jyoti, A Shoskes, TT Egelhoff, DE Hansel
Cleveland Clinic Foundation, Cleveland, OH; University of Denver, Denver, CO

GCN2 (EIF2AK4) Is a Critical Regulator of Bladder Cancer Cell Viability in Response to Arginine Deprivation Therapy (885)
S Gupta, M Mir, J Bomalaski, K Singh, J Harwalkar, P Carver, A Almasan, DE Hansel
Cleveland Clinic Foundation, Cleveland, OH; Polaris Group, San Diego, CA; Memorial Sloan-Kettering Cancer Center, New York, NY
162 Novel Markers of Squamous Differentiation in the Urinary Bladder (903)
W Huang, SR Williamson, Q Rao, A Lopez-Beltran, R Montironi, JN Ehle, DJ Grignon, MT Idrees, X-J Zhou, S Zhang, LA Baldridge, NM Hahn, MO Koch, L Cheng
Indiana University School of Medicine, Indianapolis, IN; Nanjing Medical University Affiliated Nanjing Hospital (Nanjing First Hospital), Nanjing, China; Nanjing University School of Medicine, Nanjing, China; Cordoba University, Cordoba, Spain; Polytechnic University of the Marche Region, United Hospitals, Ancona, Italy

181 Cancer Stem Cells (CSC) Responses and Toll-Like Receptors (TLRs) and p53 Signaling Pathway: Effects of Bacillus Calmette-Guerin (BCG) and P-MAPA Immunotherapies in Non-Muscle Invasive Bladder Cancer (NMIBC) (867)
WJ Favaro, A Billis, FRF Seiva, IS Nunes, N Duran
University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil; Farmabrasilis, Campinas, Sao Paulo, Brazil; Universidade Federal do ABC, Santo Andre, Sao Paulo, Brazil

182 Low Grade Urothelial Carcinoma with Focal High Grade Component of the Urinary Bladder: Pathological Outcomes in Follow-Up Biopsies (850)
Y Ding, O Yaskiv, T Chan, F-M Deng, J Melamed, M Zhou
New York University Langone Medical Center, New York, NY; North Shore Long Island Jewish Health System, Lake Success, NY

183 DeltaNp63 Is a Protective Marker of Progression in HGT1 Bladder Cancer (823)
M Castillo-Martin, JM Gaya Sopena, N Gladoun, O Karni-Schmidt, C Gonzalez, F Algaba, J Palou Redorta, C Cordorn-Cardo
Mount Sinai School of Medicine, Mount Sinai Medical Center, New York, NY; Fundacio Puigvert, Barcelona, Spain

184 Long Term Follow-Up of Efficacy of Multicolor Fluorescence In Situ Hybridization (UroVysion) in Detecting Non-Muscle-Invasive Urothelial Neoplasias (950)
B Leng, SM Dobin, K Walker, A Rao
Scott & White Healthcare, Temple, TX

185 Carcinomas with Similar Morphology and Immunohistochemical Profile: Does GATA3 Make a Difference? (803)
T Antic, L Zhao, A Husain, K Gwin, MK Mirza, M Lingen, M Tretiakova
University of Chicago, Chicago, IL

186 Epithelioid Trophoblastic Tumor of the Testis: The Widening Spectrum of Primary Testicular Trophoblastic Neoplasia (911)
MT Idrees, TM Ulbright
Indiana University School of Medicine, Indianapolis, IN

187 Paratesticular Dedifferentiated Liposarcoma (DDL): A Clinicopathologic Study and Analysis of MDM-2 Expression in 29 Cases (943)
ON Kryvenko, JI Epstein
Weinberg 2242, Baltimore, MD

HEMATOPATHOLOGY

188 CD79B Mutation in Diffuse Large B-Cell Lymphoma (1409)
Y Kim, H Ju, D-H Kim, Y-H Ko
Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea; Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, Republic of Korea

189 Majority of the Primary Central Nervous System Large B-Cell Lymphomas Show Activated B-Cell Immunophenotype with a High Proliferation Rate and a Low Incidence of Epstein Barr Virus (1514)
D Slova, L Goodell, D Weissmann, G Salaru, R Rhodes, S Bhagavathi
UMDNJ - RWJMS, New Brunswick, NJ

190 Population-Based Heterogeneity in Prevalence, Age Distribution, and Latency Patterns of EBV-Positive Diffuse Large B-Cell Lymphoma (1400)
CM Inouye, Y Xie, L Ji, S Groshen, A Bulbul, A Tulpule, IN Siddiqi
LAC+USC Medical Center, Los Angeles, CA; University of Southern California, Los Angeles, CA

191 Epstein-Barr Virus Status and Latency State of Lymphoproliferative Disorders in Inflammatory Bowel Disease Patients Treated with Immunomodulators (1466)
MO Nakashima, AM Gruber, A Atreja, ED Hsi
Cleveland Clinic, Cleveland, OH

192 CD4-Positive Diffuse Large B-Cell Lymphoma: An Aggressive Clinical Variant (1397)
MO Hussaini, TT Nguyen, FH Kreisel, A Hassan, J Frater
Washington University, St. Louis, MO

193 SRPK1 and SRPK2: Potential Diagnostic Marker for Diffuse Large B-Cell Lymphoma (1457)
P Minoo, X-D Fu, H-Y Wang
University of California San Diego, San Diego, CA

194 Immunohistochemical and Genetic Evaluation of Cyclin D1 Positive Diffuse Large B-Cell Lymphomas in a Large Series (1380)
KE Grimm, R Agrawal, L Weiss, DP O’Malley
Clariant Inc./GE Healthcare, Aliso Viejo, CA

195 Nucleolar C-Terminal Expression of POTE G and H in Non-Hodgkin Lymphomas (1402)
N Ishaq, SC Chekuri, JE Fleming, Z He, J Lam, X Zhou
University of Mississippi, Jackson, MS

196 ERBB2 Overexpression Correlates with Non-Germinatal Center Subtype of Diffuse Large B-Cell Lymphoma (1366)
OV Danilova, AV Danilov, P Kaur
Dartmouth-Hitchcock Medical Center, Lebanon, NH; Geisel School of Medicine at Dartmouth, Hanover, NH; Norris Cotton Cancer Center, Lebanon, NH

197 The Differential Expression of Bruton’s Tyrosine Kinase in Diffuse Large B Cell Lymphoma and Hodgkin Lymphoma (1459)
Z Mo, C Chen, R Alsabeh, F Chung, S Alkan
Cedars-Sinai Medical Center, Los Angeles, CA
198 Immunohistochemical and Genetic Evaluation of De Novo CD5+ Diffuse Large B-Cell Lymphomas in a Large Series (1323)
R Agrawal, KE Grimm, L Weiss, DP O’Malley
Clariant Inc./GE Healthcare, Aliso Viejo, CA

199 Cell of Origin Subtype Determined by Immunohistochemistry and MYC and BCL2 Dual Expression in DLBCL as Potential Prognostic Indicators (1360)
AMB Collie, BT Hill, ED Hsi
Cleveland Clinic, Cleveland, OH

200 Double Hit Lymphomas: Immunohistochemical, In Situ Hybridization and Molecular Study (1336)
S Bhagavathi, H Avi, L Goodell, K David, R Strair, G Salaru, D Weissman, D Slova, N Ahuja, P Munshi, E Sadimin, N Johnson, J Bertino
UMDNJ-RWJMS, New Brunswick, NJ; UMDNJ-RWJMS & CINJ, New Brunswick, NJ

201 MYC IHC and MYC FISH Are Complementary Diagnostic Tests in the Routine Evaluation of Diffuse Large B-Cell Lymphoma (1412)
M Kluk, H Sun, H Yu, P Dal Cin, GS Pinkus, S Rodrig
Brigham and Women’s Hospital, Boston, MA; UMass Memorial Medical Center, Worcester, MA

202 Immunohistochemical and Genetic Evaluation of MYC Translocation Positive Aggressive B Cell Lymphomas (1379)
KE Grimm, R Agrawal, L Weiss, DP O'Malley
Clariant Inc./GE Healthcare, Aliso Viejo, CA

203 Quantitative Digital Image Analysis of MYC Immunohistochemistry in High Grade B Cell Lymphomas (1536)
Y Xie, C Inouye, L Ji, S Groshen, D Reddi, E Wang, D O'Malley, I Siddiqi
LAC+USC, LA, CA; Duke University, Durham, NC; Clariant/GE, Aliso Viejo, CA

204 Prognostic Impact of Myc/Bcl6 Co-Rearrangement and MYC/BCL6 Co-Expression in De Novo Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program Study (1394)
S Hu, A Tzankov, C Visco, O Orazi, G Bhagat, ED Hsi, M Ponzoni, MA Piris, MB Moller, LJ Medeiros, FH Kreisel
University of Texas MD Anderson Cancer Center, Houston, TX

205 Correlation of C-MYC Protein and the Presence of C-MYC Rearrangement in High Grade B-Cell Lymphoma (1460)
Z Mo, C Chen, S Alkan, R Alsaheb
Cedars-Sinai Medical Center, Los Angeles, CA

206 CD30 Expression in Diffuse Large B Cell Lymphomas (1439)
S Malhotra, OV Danilova, AV Danilov, P Kaur, NB Levy
Geisel School of Medicine at Dartmouth, Hanover, NH; Dartmouth-Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, NH

207 Bob1 and Oct2 Expression in Lineage Determination of B-Cell Lymphomas Negative for Conventional B-Cell Markers (1540)
L Yin, J Xu, M Li, V Reddy, Q Zhou, H Liu, P Chu, Q Zhang, Q Huang, Z Gao, H-Y Wang, X Liang, Z Pan
University of Colorado Medical Center, Aurora, CO; UAB, Birmingham, AL; Peking University HSC, Beijing, China; Zagreb University School of Medicine, Jiaxing, Zhejiang, China; Guangzhou Medical College, Guangzhou, Guangdong, China; City of Hope, Duarte, CA; University of New Mexico, Albuquerque, NM; University of California San Diego, La Jolla, CA

208 Strong BOB1 and OCT2 Expression Is Useful for Confirming B-Cell Lineage in PEL and Other Neoplasms with Plasmacytic/Plasmablastic Differentiation (1353)
CK Chen, Z Mo, E Moschiao, M Schmidt, S Alkan
Cedars-Sinai Medical Center, Los Angeles, CA

209 CD200 Expression in Post-Transplant Lymphoproliferative Disorders Correlates with an Increased Frequency of FoxP3(+) Regulatory T-Cells (1525)
J Vaughan, AC Mackinnon, AM Harrington, SH Korf, H Otecanu
MCW, Milwaukee, WI

210 Highly Expressed SIRT-1 in Hodgkin Lymphoma and the Therapeutic Implications (1488)
AE Quesada, CE Jabicuga, RE Brown, A Rios, ND Nguyen
University of Texas at Houston, Houston, TX; University of Vermont, Burlington, VT

211 EBV Is Infrequently Expressed in the LP Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) in Both Children and Adults (1473)
A Nicolae, AR Huppmann, GW Slack, JA Ferry, NL Harris, S Pittafuluga, ES Jaffe, RP Hassierian
National Cancer Institute, Bethesda, MD; BC Cancer Agency, Vancouver, Canada; Massachusetts General Hospital, Boston, MA

212 Analysis of Aberrant Antigenic Expression in Classical Hodgkin Lymphomas and Their Potential Role as Prognostic Factors (1471)
TT Nguyen, JL Frater, J Klein, L Chen, KV Foyil, NL Bartlett, FH Kreisel
Washington University, St. Louis, MO; Molecular Pathology Laboratory Network, Inc., Maryville, TN

213 CD200 Is a Valuable Diagnostic Tool To Differentiate Mediastinal Large B-Cell Lymphoma from Diffuse Large B-Cell Lymphoma (1386)
A Hariharan, J Gomez-Gelvez, KV Imamdar
Henry Ford Hospital, Detroit, MI

214 CD103 Immunoreactivity in Paraffin Sections of a Broad Spectrum of T-Cell Lymphomas (1462)
EA Morgan, C Carey, A Shahsafaei, DM Dorfman, SJ Rodig, GS Pinkus
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
A Panel of Follicular Helper T-Cell (T<sub>FH</sub>) Immunophenotypic Markers Identifies and Differentiates T<sub>FH</sub>-Derived Neoplasms from Other T-Cell Neoplasms (1486)
O Pozdnyakova, A Shahsafaei, G Freeman, D Dorfman
Brigham and Women’s Hospital, Boston, MA; Dana Farber Cancer Institute, Boston, MA

Peripheral T-Cell Lymphomas with Cytotoxic Phenotype in Patients with Nodal SLL/CLL (1341)
DF Boyer, NI Lindeman, NL Harris, JA Ferry
Massachusetts General Hospital, Boston, MA; Brigham and Women’s Hospital, Boston, MA

Increase in B/T-Cell Size Ratio Predicts Superior Survival in Peripheral T-Cell Lymphomas with Large B-Cells (1521)
LHC Tan, S-Y Tan, T Tang, S-T Lim, DCL Tan, L-C Lim, GLS Kam, Y-C Linn, T-P Loh, M Tao, ESC Koay
Singapore General Hospital, Singapore, Singapore; National Cancer Centre, Singapore, Singapore; National University Hospital, Singapore, Singapore; National University of Singapore, Singapore, Singapore

Diagnostic Clues That Differentiate Angioimmunoblastic T Cell Lymphoma from “T Zone Dysplasia”, a Type of Atypical Interfollicular Hyperplasia (1458)
T Miyata, N Asano, S Nakamura
Nagoya University Hospital, Nagoya, Japan

T-bet+ Lymphocytes and IgG4+ Plasma Cells Correlate with Poor Clinical Outcome in Plasma Cell Rich Acute Cellular Renal Transplant Rejection (1638)
G Rizzuto, T Nguyen, K-Y Jen, G Szabo, A Webber, Z Laszik
University of California, San Francisco, CA

Transplant Glomerulopathy, Pathogenesis and Evolution (1632)
N Nelles, S Dilioglou, M Afrouzian, L Gaber, R Barrios, L Truong
Methodist Hospital, Houston, TX; University of Texas Medical Branch, Galveston, TX

Histopathological Response Patterns Following Treatment of Acute Renal Allograft Rejection (1616)
MK Divatia, S Dhingra, S Patel, J Devis, LD Truong, R Barrios, RJ Knight, AO Gaber, L Gaber
Methodist Hospital, Houston, TX

Utility of Immunofluorescence and Electron Microscopy in Renal Transplant Biopsies (1622)
G Giannico, A Langone, AB Fogo
Vanderbilt University Medical Center, Nashville, TN

Adenovirus Nephritis in Renal and Other Solid Organ Transplant Recipients (1630)
V Mehta, K Mudalair, PC Chou, MM Picken
Loyola University Medical Center, Maywood, IL.; Ann & Robert H Lurie Children’s Hospital of Chicago, Chicago, IL

Positive SV-40 Staining in Cases of Early PVAN without Nuclear Inclusions (1608)
NL Carter-Monroe, SM Bagnasco, ED Kraus, LC Racusen, RA Montgomery, LJ Arend
Johns Hopkins University, Baltimore, MD

Urinary Polyomavirus-Haufen Shedding in Mouse and Man: A Proof-of-Concept Study for a Non-Invasive Urine Biomarker for Polyomavirus Nephropathy (1633)
V Nickelet, B Brylawski, H Singh, L Rivier
University of North Carolina at Chapel Hill, Chapel Hill, NC

Pylonephritis in Renal Allografts – Biopsy or Cultures? (1606)
A Bracewell, U Nori, J-M Balada, T Nadasy, A Satoskar
Ohio State University Wexner Medical Center, Columbus, OH

Differential Expression of C4d and IgG4 Immunohistochemical Markers in Lupus and Non-Lupus Membranous Glomerulonephritis (1644)
UN Sheikh, S Farooq, PJ Kowalski, H Qu
St. John Hospital & Medical Center, Detroit, MI; Good Samaritan Hospital, Cincinnati, OH

Phospholipase A2 Receptor Staining Is Not a Sensitive Indicator of Idiopathic Membranous Glomerulopathy in Children (1613)
LN Cossey, PD Walker, CP Larsen
Nephropath, Little Rock, AR; University of Arkansas for Medical Sciences, Little Rock, AR

The Significance of Immunohistochemical Detection of IgG<sub>4</sub> in Membranous Nephropathy (1612)
M Coronel, JL Farber, P McCabe
Thomas Jefferson University Hospital, Philadelphia, PA

Renal Involvement by Hematopoietic Neoplasms (1645)
M Shulderg, DS Brink, G Chen
Saint Louis University School of Medicine, St. Louis, MO

Atypical Lymphocytic Infiltrates of the Kidney: Benign or Malignant? (1605)
KL Boils, JM Ambruzs, LN Cossey, AA Harris, PD Walker, NC Messias
Nephropath, Little Rock, AR

AA Amyloidosis in a Patient with Common Variable Immunodeficiency Disease: Report of a Case (1641)
RM Saleeh, J Karmachandani, S Jothy, H Ghaffar
University of Toronto, Toronto, ON, Canada; Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, ON, Canada

Renal ALECT2 Amyloidosis: A Clinicopathologic Study of 17 Patients (1640)
SM Said, S Sethi, LD Cornell, ME Fidler, A Dogan, SH Nasr
Mayo Clinic, Rochester, MN

Leukemia and Lymphoma-Associated Crescentic Glomerulonephritis (1604)
MLZ Bissonnette, A Chang, S Meehan
University of Chicago, Chicago, IL

Correlation of Urine Red Cell Morphology and Renal Biopsy Findings (1624)
D Hull, DG Bostwick
Bostwick Laboratories, Inc., Glen Allen, VA
Board Number
236 Expression of CD71 in Mesangial Cells of IgA Nephropathy and Proliferative Parietal Epithelial Cells of Immune Complex Crescentic Glomerulonephritis (1629)
W Li, P Zhang
William Beaumont Hospital, Royal Oak, MI

237 Prognostic Value of Endocapillary Proliferation in IgA Nephropathy Patients with Minimal Immunosuppression (1610)
A Chakera, C MacEwen, SS Bellur, L Chompuk, D Lunn, ISD Roberts
Sir Charles Gairdner Hospital, Nedlands, Australia; Churchill Hospital, Oxford, United Kingdom; John Radcliffe Hospital, Oxford, United Kingdom; University of Oxford, Oxford, United Kingdom

238 IgA Deposition in Diabetic Nephropathy (1615)
LN Cossey, N Messias, PD Walker, FG Silva
Nephropath, Little Rock, AR; University of Arkansas for Medical Sciences, Little Rock, AR

239 Diabetic Nephropathy with an Atypical Clinical Course: A Potentially Treatable, Second Disease Is Commonly Found on Renal Biopsy (1650)
PD Walker, LN Cossey, JM Ambruzs, FS Silva
Nephropath, Little Rock, AR; University of Arkansas for Medical Sciences, Little Rock, AR

240 Diabetic Nephropathy and Fibrillary Glomerulopathy: An Unusual and Problematic Double Glomerulopathy (1602)
JM Ambruzs, CP Larsen, FG Silva, PD Walker
Nephropath, Little Rock, AR; University of Arkansas for Medical Sciences, Little Rock, AR

241 Acute Proliferative Glomerulonephritis in Diabetic Nephropathy (1614)
LN Cossey, N Messias, PD Walker, FG Silva
Nephropath, Little Rock, AR; University of Arkansas for Medical Sciences, Little Rock, AR

242 Correlation of Histological and Clinical Parameters in Patients with Renal Biopsy Diagnosis of Diabetic Nephropathy (1631)
M Much, G Moeckel
Yale University School of Medicine, New Haven, CT

243 Hyaline Arteriolosclerosis in Glomerular Afferent and Efferent Arterioles: Are the Deposits Hard or Soft, Stationary or Mobile? (1646)
LC Stout, Jr., J Ross
University of Texas Medical Branch, Galveston, TX; Methodist Hospital, Houston, TX

244 Diverse Renal Lesions in Obesity: Clinical and Pathologic Findings (1643)
SP Salvatore, SV Seshan
Weill Cornell Medical College, New York, NY

245 Non-Nephrotic Range Proteinuria in Asymptomatic Children (1652)
S Wu, G Ragsdale, A Chaudhuri, N Kambham
Stanford University, Stanford, CA; Stanford Hospital and Lucille Packard Children's Hospital, Stanford, CA

Board Number
246 Pediatric C1Q Nephropathy Stains for Sox9 and Belongs to Focal-Segmental Glomerulosclerosis (FSGS) (1653)
X Zeng, PL Zhang
Wayne State University, Detroit, MI; William Beaumont Hospital, Royal Oak, MI

247 Ultrastructural Changes in 5/6 Nephrectomy Rats Correlate with the Progression of Ablative Nephropathy (1634)
A Ozcan, K Ware, Q Zahida, EP Calomeni, T Nadasy, AA Satoskar; G Nadasy, B Rovin, LA Hebert, SV Brodsky, Gulhane Military Medical Academy, School of Medicine, Ankara, Turkey; Ohio State University, Columbus, OH

248 Renal Cortical Necrosis Is the Most Common Histopathological Finding in Obstetric Acute Kidney Injury in a Developing Country (1625)
A Kurien, N Gopalakrishnan, A Raychowdhury, G Abraham
Madras Medical Mission, Chennai, Tamil Nadu, India; Madras Medical College, Chennai, Tamil Nadu, India; Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India

249 Podocyte Involving in Glomerular Basement Membrane: Clinicopathological Study of 31 Cases (1648)
T Suzuki, T Yoshimoto, N Fukushima
Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan

250 Podocyturia (PCU) and Biopsy (Bx) Podocyte (PC) Globotriaosylceramide (GL-3) Accumulation Correlate with Proteinuria in Patients with Fabry Disease (FD) (1636)
C Ponchiardi, B Fall, R Scott, S Uhrich, M Mauer, C Whitley, J Pippin, S Shankland, J Jefferson, B Najafian
University of Washington, Seattle, WA; University of Minnesota, Minneapolis, MN

251 The Subcapsular Blue Strip Width: A New Marker for Evaluating the Residual Potential Nephrogenesis in the Newborn Kidney (1617)
G Faa, D Fanni, C Gerosa, M Fraschini, S Nemolato, G Ottobell, J Messana, T Cabras, G Monga, P Van Eyken, M Castagnola, V Fanos
University of Cagliari, Cagliari, Italy; University of Novara, Novara, Italy; K.U. Leuven, Leuven, Belgium; Catholic University of Rome, Roma, Italy

252 Methylmalonic Acidemia: A Megamitochondrial Disorder Affecting the Kidney (1600)
N Aljinovic, LA Teot, ZK Zsengeller, M Korson, CP Venditti, GT Berry, S Rosen
Beth Israel Deaconess Medical Center, Boston, MA; Children's Hospital Boston, Boston, MA; Tufts University, Boston, MA; NIH, Bethesda, MD

253 Medullary Injury in the Human Renal Biopsy: Fibrosis Assessment (1619)
AB Farris, D Lawson, C Cohen, S Rosen
Emory University, Atlanta, GA; Harvard University/Beth Israel Deaconess Medical Center, Boston, MA
Board Number 254
Comparison of Staining Methods for Scoring Renal Fibrosis (1626)
C Larsen, C Boils, A Harris, F Silva, P Walker, N Messias
Nephropath, Little Rock, AR; University of Arkansas for Medical Sciences, Little Rock, AR

Board Number 255
Fibroblast-Specific PAI-1 Depletion Increases Macrophages but Not Kidney Fibrosis after Unilateral Ureteral Obstruction (1635)
LS Peterson, AM Khan, H Yang, AB Fogo
Vanderbilt University Medical Center, Nashville, TN; Chicago Medical School at Rosalind Franklin University of Medicine and Science, Chicago, IL

Board Number 256
Injured Proximal Tubular Epithelium Can Dedifferentiate into Vimentin Positive Cells in Human Kidneys (1651)
L Williams, MT Rooney, X Zeng, W Li, PL Zhang
William Beaumont Health System, Royal Oak, MI; Bostwick Laboratories, Inc., Orlando, FL

Board Number 257
Immunohistochemical Markers Indicate Transdifferentiation of Tubular Epithelial Cells into Histiocytic Cells in the Presence of Monoclonal Casts/Crystals and Myoglobin (1639)
M Ryan, J Hemminger, G Nadasy, X Ao, C Hofmeister, E Calomeni, A Satoskar, S Brodsky, T Nadasy
Ohio State University Wexner Medical Center, Columbus, OH

Board Number 258
Medullary Injury in the Human Renal Biopsy: Assessment of Epithelial Mass (1618)
AB Farris, D Lawson, C Cohen, S Rosen
Emory University, Atlanta, GA; Harvard University/Beth Israel Deaconess Medical Center, Boston, MA

Board Number 259
Incidental Epithelial Neoplasms Identified in Medical Renal Biopsies (1601)
JM Ambruzs, SM Bonsib, PD Walker, N Messias
Nephropath, Little Rock, AR; University of Arkansas for Medical Sciences, Little Rock, AR

PATHOBIOLOGY

Board Number 260
Specific Hemosiderin Deposition in the Spleen of TSOD Mice – A Unique Spontaneous Model Showing Obesity, Diabetes, Hyperlipidemia, and Steatohepatitis (1852)
T Nishida, K Tsuneyama, K Nomoto, S Hayashi, S Miwa, T Nakajima, Y Nakanishi, J Imura
University of Toyama, Toyama, Japan

Board Number 261
Gingko biloba: A Potential Therapy for Lung Inflammation in Smokers (1854)
P Rastogi, J Marentette, J McHowat
St. Louis University - School of Medicine, St. Louis, MO

Board Number 262
Common MicroRNA Biomarkers To Characterize Inflammatory Bowel Disease (1847)
J Lin, Z Zhao, NC Welker, Y Liu, X Zhang, J Zhang, Y Li, H-J Lee, MP Bronner
Indiana University School of Medicine, Indianapolis, IN; University of Utah, Salt Lake City, UT; Albany Medical Center, Albany, NY

Board Number 263
Frequent Loss of PTEN and NM23H1 in Melanomas Harboring a BRAF V600E Mutation-Implications for Targeted Therapy (1858)
AN Snow, MM Milhem, AD Bossler, D Ma
University of Iowa Hospitals and Clinics, Iowa City, IA

Board Number 264
Nuclear Expression of PTEN in Endometrial Carcinoma (1838)
B Djordjevic, R Broadus
University of Ottawa, Ottawa, ON, Canada; MD Anderson Cancer Center, Houston, TX

Board Number 265
Concordance for ERG and PTEN in Matched Primary and Metastatic Prostate Cancer: Further Evidence That PTEN Loss Occurs Subsequent to ERG Gene Fusion in Prostate Cancer (1841)
B Gumuskaya, B Gurel, JL Hicks, TL Lotan, A De Marzo
Johns Hopkins Medical Institutions, Baltimore, MD

Board Number 266
Clinical Utility of ERG Immunohistochemistry as a Vascular Marker with Assessment of Lymphovascular Invasion (1844)
S Kim, HK Park, HY Jung, SD Lim, WY Kim, HS Han, TS Hwang, WS Kim
Konkuk University Medical Center, Seoul, Republic of Korea

Board Number 267
General Grading System of Malignancies: High Grade Neoplasms Express Stem Cell-Like Phenotype (1850)
J Moorhead, J Gonzalez, A Blanes, SJ Diaz-Cano
King’s College Hospital, London, England, United Kingdom; University of Malaga School of Medicine, Malaga, Spain

Board Number 268
eMET Mutations, Co-Mutations, and Survival Outcome (1861)
M Zenali, Z Liu, Z Zuo, R Broadus
University of Vermont, Burlington, VT; University of Texas MD Anderson Cancer Center, Houston, TX

Board Number 269
Detection of PML/RARA Fusion Protein in APL Using Proximity Ligation Assay as an Alternative to FISH Testing (1834)
J Bodo, JJ Lin, JP Maciejewski, AE Schade, ED Hsi
Institute of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Diagnostics Research/Development, Eli Lilly and Company, Indianapolis, IN

Board Number 270
Progesterone Induces NF-kB Activation through PI3K/Akt-2 Signal Pathway Which Regulates Focal Adhesion Kinase (FAK) in MCF-7 Breast Cancer (1835)
F Candanedo-Gonzalez, R Espinosa-Neira, S Villegas-Comenfort, N Serna Marquez, P Cortes-Reynosa, E Perez Salazar
Oncology Hospital, National Medical Center Century XXI, IMSS, Mexico City, Mexico; CINVESTAV-IPN, Mexico City, Mexico

Board Number 271
VEGFR1: Target for Anti-Angiogenic Therapy? An Immunohistochemical Study Highlighting Heterogeneity of Tumor-Associated Endothelial Cells (1836)
N D’Haene, F Hulet, J Allard, C Mari, C Deceaestecker, J Salmon
Erasmus Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium; Center for Microscopy and Molecular Imaging, ULB, Gosselies, Belgium

Board Number 272
The RANK Pathway in Breast Cancer: Src Plays a Role! (1846)
R Li, T Nguyen, C Kragel, K Zhang, WE Grizzle, O Hameed, GP Siegal, S Wei
University of Alabama at Birmingham, Birmingham, AL
Expression of Cancer Testis (CT) Antigens in Thymus of the Fetus (1843)

AA Jungbluth, D Frosina, M Holz, S Gnijatic, GC Spagnoli, AM Mueller
Ludwig Institute for Cancer Research, New York, NY; University Hospital, Basel, Switzerland; University Hospital, Bonn, Germany

Galectin-3, STn and Tn: Expression Profile in Pancreatic Neoplasms and Gastrointestinal Stomal Tumors (1842)

K Jiang, C Cohen, SR Stowell, RD Cummings, MT Siddiqui
Emory University School of Medicine, Atlanta, GA

Succinate Dehydrogenase Deficiency Is Associated with Decreased 5-Hydroxymethylcytosine Production in Gastrointestinal Stomal Tumors: Implications for Mechanisms of Tumorigenesis (1848)

EF Mason, JL Hornick
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Enhancement of Cellular Tumorigenic Potential by Human Papilloma Virus and Epstein-Barr Virus Co-Infection (1857)

M Shi, R Jiang, O Ekshyyan, C-AO Nathan, L Fletcher, RS Scott
Louisiana State University Health Science Center, Shreveport, LA

A Subset of Kaposi Sarcoma Cases Harbors Clonal Immunoglobulin Heavy Chain Gene Rearrangement: A Novel Finding Which Raises the Question of Transdifferentiation (1839)

JT Geyer, G Ballon, K Nie, YL Wang, E Cesarman
Weill Cornell Medical College, New York, NY

High-Dimensional Mass Cytometry Analysis Reveals Differential STAT Activation in Cellular Subsets of Chronic Myelogenous Leukemia (1837)

J De, NP Shah, CT Ballentine, HT Maeker
Stanford University, Stanford, CA; University of California San Francisco, San Francisco, CA; MTFE Records, Oakland, CA

STAT3 and STAT5a Are Potential Therapeutic Targets in Castration-Resistant Prostate Cancer (1849)

SK Mohanty, K Yazig, B Cinar, MB Amin, D Lühringer, S Alkan
Cedars-Sinai Medical Center, Los Angeles, CA

ALK Protein Expression Correlates with ALK Rearrangement, but Not Increased ALK Copy Number in Lung Adenocarcinomas (1933)

B Ren, LA McMahon, Q Yang, N Wang, P Rothberg, Z Zhou, FL Li, H Xu
University of Rochester Medical Center, Rochester, NY

Comparative Study of FISH and Immunohistochemistry Assays for the Detection of ALK-Positive Non-Small-Cell Lung Cancers: Report of a Series of 878 Cases (1877)

F Cabiclic, D Chifireanu, F Dogay, R Corre, H Lena, M Le Calve, N Rioux-Leclercq, M-A Belaud-Rotureau
CHU Pontchaillou, Rennes, France; Faculty of Medicine, Rennes, France

EML4-ALK Fusion Gene-Positive Lung Cancer: Its Usefulness in Immunohistochemical Screening and Its Histological Variation (1920)

K Nagata, M Shimizu, S Ishiguro
Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; PCL Japan, Suginami-ku, Tokyo, Japan

ALK Gene Rearrangement Testing in Non-Small Cell Lung Carcinoma by ThinPrep-FISH (1914)

EC Minca, BP Portier, W Zhang, J Brainard, C Farver, Y Feng, PC Ma, V Arrossi, N Pennell, RR Tubbs
Cleveland Clinic Foundation, Cleveland, OH

EGFR, KRAS and ALK Molecular Tests Can Be Performed Using Existing Stained Histologic Slides, Including Small Biopsies: A Proof-of-Concept Study (1918)

S Mukhopadhyay, J Tull, S Zhang
State University of New York Upstate Medical University, Syracuse, NY

Pathway Interplay: Activation of EGFR, ERK, and AKT in Early-Stage Lung Adenocarcinomas (1900)

AE Kovach, V Morales-Oyarvide, DE Shvetz, S Tammireddy, V Klepeis, EJ Mark, Dias Santagata, AI Iafrate, M Minokudsoon
Massachusetts General Hospital (MGH), Boston, MA; MGH, Boston, MA

MET Copy Number by Dual Color Brightfield In Situ Hybridization and Fluorescence In Situ Hybridization Correlates with Met Protein Expression in Lung Adenocarcinomas (1942)

L Sholl, H Sun, A Ligon, M Butaney, PA Janne, S Rodig
Brigham and Women’s Hospital, Boston, MA; Dana Farber Cancer Institute, Boston, MA

Correlation between Morphologic Phenotype and Genotype of Lung Adenocarcinoma Based on a New IASLC/ATS/ERS Classification with Nuclear Grading (1917)

N Motoi, S Sato, Y Saito, H Ninomiya, K Takeuchi, Y Ishikawa
Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan

Cytologic-Histologic Correlation of Lung Adenocarcinoma Subtyping (1936)

EF Rodriguez, S Monaco, S Dacic
University of Pittsburgh, Pittsburgh, PA

Complex Acinar Pattern: A Distinct Morphologic Subtype and a Poor Prognostic Indicator in Primary Lung Adenocarcinoma (1951)

C Wang, HY Durra, Y Huang, V Manicha
Temple University Hospital, Philadelphia, PA

Clinicopathological Significance of Early-Stage Lung Adenocarcinoma with Micropapillary Component: Associations with Prognosis, EGFR and KRAS Gene Mutations (1959)

A Yoshizawa, S Sumiyoshi
Shinshu University Hospital, Matsumoto, Nagano, Japan; Kyoto University Hospital, Kyoto, Japan

Radiologic-Pathologic Correlation before Signout Significantly Reduces Overdiagnosis of Pulmonary Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma in Surgically Resected Lung Nodules (1885)

S Harari, J Ko, H Pass, D Naidich, J Suh
NYU Langone Medical Center, New York, NY
Board Number

292 Genomic Rearrangements in Lung Adenocarcinoma: Lineage Relationship between In Situ and Invasive Components (1919)
SJ Murphy, FR Harris, M-C Aubry, J Felipe Lima, SH Johnson, BW Eckloff, CT Seto, M Asiedu, T Petikert, P Yang, G Vasmatzis, DA Wigle
Mayo Clinic, Rochester, MN

293 Proteomic Approach Revealed Galectin-4 as a Lymph Node Metastasis Predictor in Lung Adenocarcinoma (1886)
T Hayashi, T Saito, K Takamochi, K Mitani, S Oh, K Suzuki, T Yao
Juntendo University, School of Medicine, Tokyo, Japan

294 Current American Joint Commission on Cancer (AJCC) Guidelines Upstage Patients with Synchronous Bilateral pM1a Pulmonary Adenocarcinomas (1950)
AE Walts, TK Leong, AM Marchevsky
Cedars-Sinai Medical Center, Los Angeles, CA

295 Wedge Resection and Staging Lymphadenectomy Can Downstage Primary Pulmonary Adenocarcinomas (1949)
AE Walts, AM Marchevsky
Cedars-Sinai Medical Center, Los Angeles, CA

296 Expression Profiles of the Regulatory Master p63 Gene in Pulmonary Adenocarcinoma Recapitulate the Normal and Developmental Lung (1925)
G Pelosi, F Perrone, E Tamborini, E De Paoli, A Fabbri, P Scanagatta, R-A Romano, S La Rosa, U Pastorino, M Papotti
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; State University of New York at Buffalo, Center for Excellence in Bioinformatics and Life Sciences, Buffalo, NY; Unsubria University at Varese, Varese, Italy; San Luigi Gonzaga Hospital and University of Turin, Turin, Italy

297 Analysis of Napsin A Expression in Mucinous Lung Tumors on Histological and Cytological Specimens (1887)
JJ Heymann, RS Hoda, T Scognamiglio
Weill Cornell Medical College, New York, NY

298 Pulmonary Sarcomatoid Carcinoma – Immunohistochemical Study of 35 Cases with Emphasis on the Utility of Napsin (1947)
SBSP Terra, MC Aubry, ES Yi, JM Boland
Mayo Clinic, Rochester, MN

299 Napsin A Expression in Neuroendocrine Tumors of the Lung (1896)
P Joubert, H Wang, MS Roh, MC Pietanza, I Sarkaria, WD Travis, N Rekhtman
Memorial Sloan-Kettering Cancer Center, New York, NY; College of Medicine, Dong-A University, Busan, Korea

300 Fatty Acid Hydrolase Is Preferentially Expressed in Pulmonary Carcinoid Tumors (1940)
K Shilio, J Ravi, M Nasser, D Cohen, W Zhao, M Villalona, J Fukuoka, J Jen, T Franks, W Travis, R Ganju
Ohio State University, Columbus, OH; Toyma University, Toyma, Japan; Mayo Clinic, Rochester, MN; JPC, Silver Spring, MD; Memorial Sloan-Kettering Cancer Center, New York, NY

Board Number

301 Increased Claudin 4 Expression Is Associated with Aggressiveness of Pulmonary Neuroendocrine Tumors (1905)
J Li, S Lu, S Mangray, B Aswad, R Monahan, L Noble, M Resnick, E Yakirevich
Alpert Medical School of Brown University, Providence, RI

Poster Session III
Tuesday, March 5, 2013
9:30 AM – 12:00 PM
CC Exhibit Hall A-D

Poster numbers to the left of the abstract title correspond to the board number where the poster will be displayed. The number in parentheses after the title is the abstract number in the Abstract Book. These posters will be on display this morning only.

BREAST

1 Analysis of Histopathologic Features Predictive for the Diagnosis of “Basal” like Breast Carcinoma (268)
MN Sable, TM Shet, AJ Patil, BG Ramnani, SB Desai
Tata Memorial Hospital, Mumbai, Maharashtra, India

2 Can Triple Negative Breast Tumors Be Further Subdivided by Immunohistochemical Analysis of Expression of Protein Panels? (111)
S Balci, C Irukkan, CL Shapiro, K Huebner, G Guler
Yildirim Beyazit University, Ankara, Turkey; James Cancer Hospital and Ohio State University Comprehensive Cancer Center, Columbus, OH; Ohio State University Comprehensive Cancer Center, Columbus, OH

3 How Luminal Are Triple Negative Breast Cancers? A Cytokeratin Co-Expression Study (244)
GM Oprea-Ilies, Y Liu, D Nickleach, LA Mclendon, SE Pambuccian
Emory University, Atlanta, GA; Loyola University, Maywood, IL; Winship Cancer Institute, Atlanta, GA

4 Role of Androgen Receptor (AR) as a Prognostic Factor in Primary Breast Cancer (BC) (240)
S Nofech-Mozes, C Parra-Herran, R Dent, C Villarreal, MA Quintayo, JMS Bartlett, J Starczynski, P Sun, S Narod, W Hanna
University of Toronto, Toronto, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada; Ontario Institute for Cancer Research, Toronto, Canada; Women’s College Hospital, Toronto, Canada

5 Immunohistochemical Expression of Androgen Receptor in Triple Negative Breast Cancer: Significant Association with Improved Disease Free Survival (290)
AA Thike, L Chong, PY Cheok, J Iqbal, PH Tan
Singapore General Hospital, Singapore, Singapore

6 The Basal-Like Molecular Subtype of Breast Carcinoma Shows Reduced Expression for Androgen Receptor When Compared to Other Subtypes (144)
PJJ DiMaggio, S Varma, TM D’Alfonso, Y-F Liu, Z Chen, RE Kaplan, SJ Shin
Weill Cornell Medical College, New York, NY
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>Expression of Androgen Receptor in Triple-Negative Breast Carcinomas and Inflammatory Breast Carcinomas (173)</td>
<td>Y Gong, W Wei, Y Wu, L Huo</td>
<td>University of Texas MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>8</td>
<td>Fumarate, an Oncometabolite Is Elevated in ER- Breast Cancers from African-American Women (152)</td>
<td>AK Esnukula, TJ Naab, LJ Ricks-Santi, WAI Frederick, RL DeWitty, Jr., Y Kanaan</td>
<td>Howard University Hospital, Washington, DC; Howard University College of Medicine, Washington, DC</td>
</tr>
<tr>
<td>10</td>
<td>Distinct ER Negative Breast Cancer Subtype-Specific Methylation Profiles (129)</td>
<td>DA Chitale, GW Divine, KM Chen, MJ Worsham</td>
<td>Henry Ford Hospital, Detroit, MI</td>
</tr>
<tr>
<td>12</td>
<td>Reduced Expression of TGF-Beta Receptor III Is a Specific Event in Triple Negative Breast Carcinomas (299)</td>
<td>N Virani, C Kleer</td>
<td>University of Michigan, Ann Arbor, MI</td>
</tr>
<tr>
<td>13</td>
<td>Diagnostic Utility of a 92-Gene Classifier in Triple-Negative Breast Carcinomas (121)</td>
<td>EF Brachtel, SE Kerr, J Anderson, Y Zhang, V Singh, MG Erlander, B Carey, WE Highsmith, CA Schnabel, SM Dry, PS Sullivan</td>
<td>Massachusetts General Hospital and Harvard Medical School, Boston, MA; Mayo Clinic, Rochester, MN; bioTheranostics, Inc., San Diego, CA; University of California Medical Center, Los Angeles, CA</td>
</tr>
<tr>
<td>14</td>
<td>Metabolomic Profiling Reveals Increased Arginine Metabolism in ER- Breast Cancers from African-American Women (151)</td>
<td>AK Esnukula, TJ Naab, LJ Ricks-Santi, WAI Frederick, RL DeWitty, Jr., Y Kanaan</td>
<td>Howard University Hospital, Washington, DC; Howard University College of Medicine, Washington, DC</td>
</tr>
<tr>
<td>15</td>
<td>HSET Expression in Triple Negative and Non-Triple Negative Breast Cancers (243)</td>
<td>GM Oprea Ilies, V Pannu, Y Liu, D Nickleach, SE Pambuccian, R Aneja</td>
<td>Emory University, Atlanta, GA; Georgia State University, Atlanta, GA; Winship Cancer Institute, Atlanta, GA; Loyola University Chicago, Maywood, IL</td>
</tr>
<tr>
<td>16</td>
<td>Clinopathologic and Immunophenotypic Characteristics of Triple Negative Invasive Lobular Carcinoma of the Breast (161)</td>
<td>L Galman, MA Akram, J Catalano, A Cordero, D Giri</td>
<td>Memorial Sloan-Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>17</td>
<td>MUC1 Is Expressed at High Frequency in Early-Stage Basal-Like Triple Negative Breast Cancer (166)</td>
<td>HL Gilmore, FW Abdul-Karim, A Sirou, J Miedler, P Fu, J Baar</td>
<td>University Hospitals Case Medical Center, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH</td>
</tr>
<tr>
<td>19</td>
<td>Microvessel Density as Determined by Computerized Image Analysis of CD105 Expression Correlates with Clinicopathological Features and Outcome in Triple-Negative Breast Cancer (139)</td>
<td>M De Brot, RM Rocha, FA Soares, H Golbi</td>
<td>University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; AC Camargo Hospital, Sao Paulo, Brazil</td>
</tr>
<tr>
<td>20</td>
<td>Breast Carcinomas with Low ER Expression Share Similar Clinicopathological Features with ER Negative Tumors (314)</td>
<td>Z Zhang, J Wang, P Tang</td>
<td>University of Rochester Medical Center, Rochester, NY; RTI Health Solution, Research Triangle Park, NC</td>
</tr>
<tr>
<td>21</td>
<td>Folate Receptor alpha Is Frequently Expressed in ER/PR Negative and Triple Negative Breast Cancers (287)</td>
<td>D Tacha, R Bremer</td>
<td>Biocare Medical, LLC, Concord, CA</td>
</tr>
<tr>
<td>22</td>
<td>Determining the Frequency of MAGI3-AKT3 Gene Rearrangements in Triple Negative Breast Cancer (296)</td>
<td>S Varma, JM Mosquera, TY MacDonald, MA Rubin, SJ Shin</td>
<td>Weil Cornell Medical College, New York, NY</td>
</tr>
<tr>
<td>23</td>
<td>Expression of Cancer Stem Cell Markers Aldh1 and Ezh2 Are Increased in Triple Negative Breast Cancers (185)</td>
<td>J Iqbal, KW Lau, AA Thike, SS Ahmed, PH Tan</td>
<td>Singapore General Hospital, Singapore, Singapore</td>
</tr>
<tr>
<td>24</td>
<td>Immunohistochemical Evaluation of TFF1 and TFF3 Expression in ER-Negative Breast Carcinomas (215)</td>
<td>H Liu, J Shi, J Prichard, F Lin</td>
<td>Geisinger Medical Center, Danville, PA</td>
</tr>
<tr>
<td>25</td>
<td>Intraoperative Margin Assessment Significantly Improves Quality of Care in Patients Undergoing Breast Conserving Surgery (192)</td>
<td>SG Karak, LP Middleton, M Yi, KK Hunt, AA Sahin</td>
<td>University of Texas MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>26</td>
<td>Frozen Section Evaluation of Breast Carcinoma Sentinel Lymph Nodes: A Retrospective Review of 1940 Cases (258)</td>
<td>JS Poling, P Argani, AM Cimino-Mathews</td>
<td>Johns Hopkins Hospital, Baltimore, MD</td>
</tr>
<tr>
<td>27</td>
<td>Sentinel Lymph Node Status among Patients with Pure Ductal Intraepithelial Neoplasia/Ductal Carcinoma In Situ Treated by Mastectomy (157)</td>
<td>C Flynn, DR Lannin, FA Tavassoli</td>
<td>Yale University School of Medicine, New Haven, CT; Yale New Haven Hospital, New Haven, CT</td>
</tr>
</tbody>
</table>
## Board Number

### 28

Tumor Budding Is Significantly Associated with Lymph Node Metastasis in Invasive Ductal Breast Cancer (293)
- **M Trippel, K Pfaltz, I Zlobec, C Tapia**
  - University of Bern, Bern, Switzerland
### 29

Relationship of Sentinel and Axillary Lymph Node Status with Locoregional Recurrence/Metastasis: A Seven-Year Clinical Follow-Up Study (256)
- **J Petersen, ME Vergara-Lluri, Y Omidvar, R Prati, SK Apple**
  - David Geffen School of Medicine at UCLA, Los Angeles, CA
### 30

Multicentric Comparative Study between One-Step Nucleic Acid Amplification (OSNA) Whole Node Assay and Standard Histology for Axillary Lymph Node Assessment (272)
- **L Sansano, B Viettes, M Sancho, C Garcia, I Amendoaiera, L Bernet, JM Perez, M Espinosa-Bravo, IT Rubio, S Ramon y Cajal, V Pég**
  - H. U. Vall d’Hebron, Barcelona, Spain; H. U. Virgen del Rocio, Sevilla, Spain; H. de Salamanca, Salamanca, Spain; H. de Sao Joao, Porto, Portugal; H. Lluis Alcanyis, Xativa, Valencia, Spain; H. U. Vall d’Hebron, Barcelona, Spain
### 31

Concordance of Fine Needle Aspiration, Sentinel Lymph Node, and Axillary Dissection in Assessing Nodal Metastasis in Breast Cancer Patients (250)
- **LN Parsons, B Behmaram, Z Basir**
  - Medical College of Wisconsin, Milwaukee, WI
### 32

Prognostic Significance of Fibroblast Growth Factor Receptor 2 (FGFR-2) Overexpression in Invasive Mammary Carcinoma (BRCA) (190)
- **BVS Kallukry, RN Al-Rohil, MJ Presta, GM Sheehan, CE Sheehan, AB Boguniewicz, JS Ross**
  - Georgetown University Hospital, Washington, DC; Albany Medical College, Albany, NY
### 33

Prognostic Significance of Fibroblast Growth Factor Receptor 3 (FGFR-3) Overexpression in Invasive Mammary Carcinoma (BRCA) (100)
- **RN Al-Rohil, MJ Presta, BVS Kallukry, GM Sheehan, CE Sheehan, AB Boguniewicz, JS Ross**
  - Albany Medical College, Albany, NY; Georgetown University Hospital, Washington, DC

---

### DERMATOPATHOLOGY

#### Board Number

### 34

Comparing BRAF Mutation Status in Corresponding Primary and Metastatic Cutaneous Melanomas: Implications on Optimized Targeted Therapy (495)
- **M Sarraf, R Habib, R Gerges, J Saab, A Loya, S Sheikh, M Satti, C Oberkanins, I Khalifeh**
  - American University of Beirut Medical Center, Beirut, Lebanon; ViennaLab Diagnostics GmbH, Vienna, Austria; Weill-Cornell Medical Center, New York, NY; Shaukat Khanum Memorial Cancer Center and Research Hospital, Lahore, Pakistan; Dhahran Health Center, SAMSO, Dhahran, Saudi Arabia; King Abdulaziz Medical City, Jeddah, Saudi Arabia
### 35

BRAF V600 Mutation Detection by Immunohistochemistry Shows Tumor Homogeneity between Primary and Metastatic Sites (455)
- **L Boursault, V Haddad, T Jouary, B Vergier, S Verdon, A de Mascarel, JP Merlio**
  - CHU et Université, Bordeaux, France, Metropolitan
Board Number
45 Spitz Nevi Frequently Show DNA Copy Number Abnormalities by FISH Using Probes for RREB1 (6p25), MYB (6q23), CEP6 (6 Centromere), and CCND1 (11q13) (461)
KJ Craddock, Z Hindi, C Shiau, A Al-Habeeb, D Ghazarian
University Health Network, Toronto, ON, Canada

46 Microphthalmia-Associated Transcription Factor (MITF) Promiscuity: Staining Patterns in Fibrohistiocytic Lesions (466)
N Farahani, D Frishberg, B Balzer, B Catherine, JM Wu
 Cedars-Sinai Medical Center, Los Angeles, CA

47 Rabbit Polyclonal Anti-SOX10 Is a Reliable IHC Marker for Melanoma and Its Mimics (514)
GG Yang, A Minasyan, J Gordon, M Lacey, K Lundquist
Cell Marque Incorporation, Rocklin, CA

48 Immunohistochemical Expression of Hormone Receptors in Melanoma of Pregnant Women, Non-Pregnant Women and Men: A Comparison Study (515)
JH Zhou, KB Kim, P Fox, JN Myers, VG Prieto
University of Texas MD Anderson Cancer Center, Houston, TX

49 Comparison of Stromal Expression of CD34 and Neoplastic Cell Expression of HMB-45 in Primary Melanomas and Melanocytic Nevii of Skin (492)
S Sabeti, M Khahavi, M Pourabdollah Toutkaboni, F Malekzad
Shahid Beheshti University of Medical Sciences, Loghman Hakim Hospital, Tehran, Islamic Republic of Iran; Shahid Beheshti University of Medical Sciences, NRITLD, Tehran, Islamic Republic of Iran; Shahid Beheshti University of Medical Sciences, Dermatology Research Center, Shohadaie Tajrish Hospital, Tehran, Islamic Republic of Iran

50 Incidence and Description of Nevus Cell Rests and Their Distinction from Isolated Tumor Cells in Sentinel Lymph Nodes Removed for Melanoma Staging (464)
LD Duncan, KL DeSouza, JM Lewis
University of Tennessee Medical Center, Knoxville, TN

51 Why Do Melanomas Ulcerate? A Re-Evaluation after Matching for Thickness (458)
E Castro-Echeverry, K Walker, RT Zreik, A Rao, MP Fernandez
Scott and White Memorial Hospital, Temple, TX

52 The Impact on Final Breslow Thickness and Sentinel Lymph Node Status with Initial Biopsies of Cutaneous Melanomas Transacted at the Base (452)
A Agarwal, CA Torres-Cabala, MT Tetzlaff, DL Stockman, V Chu, VG Prieto, JL Curry
Baylor College of Medicine, Houston, TX; University of Texas MD Anderson Cancer Center, Houston, TX

53 Metastatic Melanoma to the Parotid Gland: Different Clinical Outcomes Based upon the Presence of Known or Unknown Primary (478)
TJ Lawrence, SY Lai, RL Bassett, VG Prieto
University of Texas MD Anderson Cancer Center, Houston, TX

Board Number
54 Lethal Childhood Melanoma: A Clinicopathological Study of 12 Cases (489)
CN Prieto-Granada, C Lezcano, A Piris, R Scoyler, M Mihm
Baystate Medical Center, Springfield, MA; Brigham and Women’s Hospital, Boston, MA; Massachusetts General Hospital, Boston, MA; Sydney Medical School, Sydney, NSW, Australia

55 Reducing Block Sampling in Melanoma Re-Excision Specimens (467)
C Fives, CCBB Heffron
Cork University Hospital, Wilton, Cork, Ireland

56 Cytology of the Week Cases (COWs): Impact of a Longitudinal Educational Intervention on Cytopathology RISE Scores (529)
K White, E Khanafshar
University of California, San Francisco, CA

57 The Value of Tracking Forms in a Pathology Residency Program To Improve Resident Self-Reflection (526)
E Shaw, J Stepp, K Jones, A Rao
Scott & White Healthcare, Temple, TX

58 Mock Gynecologic Cytology Proficiency Testing as a Training Tool for AP Residents (525)
DJ Salmi, BD Toth, CS Kong
Stanford University, Stanford, CA

59 Team-Based Learning in Pathology Residency Training (517)
TC Brandler, J Laser, AK Williamson, J Louie, MJ Esposito
Hofstra-North Shore LIJ School of Medicine, Lake Success, NY

60 Intraoperative Consultation Rounds: A Pathologist Educational and Quality Assurance Initiative (516)
J Babwah, S Raphael, C Rowsewell
Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

61 Confidence, Knowledge, and Skills at the Beginning of Residency: A Survey of Pathology Residents (522)
CM Hsieh, NJ Nolan
George Washington University, Washington, DC

62 A Reusable iPad Application Framework for Anatomic Pathology Education (519)
TC Cornish, AD Tatsas, B Kim, C Sandone, BJ Norman, RH Hruban
Johns Hopkins University School of Medicine, Baltimore, MD

63 Cytoplasmic PTEN Protein Loss Distinguishes Intraductal Carcinoma of the Prostate from High Grade Prostatic Intraepithelial Neoplasia (958)
TL Lotan, B Gumuskaya, H Rahimi, JL Hicks, T伊wата, BD Robinson, JJ Epstein, AM De Marzo
Johns Hopkins Medical Institutions, Baltimore, MD

64 PTEN Protein Loss Is More Frequent in ERG-Positive Prostate Tumors (959)
TL Lotan, A Chaux, S Peskoe, J Hicks, EA Platz, GJ Netto, AM De Marzo
Johns Hopkins Medical Institutions, Baltimore, MD; Johns Hopkins School of Public Health, Baltimore, MD
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title and Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>65</td>
<td>Quadruple Immunostain for PTEN, ERG and Basal Cell Markers Distinguishes Intraductal Carcinoma of the Prostate from High Grade PIN on Needle Biopsy (960) TL Lotan, JS Han, JL Hicks, M Zhou, C Magi-Galluzzi, JI Epstein, AM De Marzo Johns Hopkins Medical Institutions, Baltimore, MD; Cleveland Clinic, Cleveland, OH</td>
</tr>
<tr>
<td>67</td>
<td>PTEN Abnormalities in Clinically Insignificant and Significant Prostate Cancer: An Analysis by Mate-Pair Next Generation and Sanger Sequencing (995) ER Parrilla Castellar, JC Cheville, BR Kipp, SJ Murphy, SB Terra, G Vasmazidis, RJ Karnes, WR Sakov Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>68</td>
<td>Association of ERG/PTEN Status with PSA Recurrence after Radical Prostatectomy (968) R Mehra, AM Chinnaiyan, LP Kanju, A Wu, RB Shah, N Palanisamy, R Lonigro, SA Tamlals University of Michigan, Ann Arbor, MI; Caris Pathology, Irving, TX</td>
</tr>
<tr>
<td>69</td>
<td>ERG Protein Expression and PTEN Loss Are Uncommon in Prostate Cancer of Chinese Population (1080) T Xing, X Pei, W Fang, H He Peking University, Health Science Center, Beijing, China</td>
</tr>
<tr>
<td>70</td>
<td>Assessment of ERG Expression in Latent Prostate Cancer (876) B Furusato, H Takahashi, M Okayasu, M Kido, T Kimura, S Egawa, M Iegami, H Hano Jikei University School of Medicine, Tokyo, Japan</td>
</tr>
<tr>
<td>71</td>
<td>A Simple Method To Obtain a High Percentage of Fresh Prostate Tissue from Radial Prostatectomy Specimens without Compromising the Evaluation of Tumor Grade, Stage and Margin Status (829) J-Y Chen, MKT Win, S-J Chang, L-Y Yang, M-P Tsai, Y-L Chen, C-M Liu, Y-F Cheng, A-Y Chuang Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan</td>
</tr>
<tr>
<td>72</td>
<td>Semaphorin 4F as a Critical Regulator of Neuro-Epithelial Interactions and a Biomarker of Aggressive Prostate Cancer (895) D He, Y Ding, D Florentin, M Ittmann, G Ayala University of Texas Health Sciences Center Medical School, Houston, TX; Baylor College of Medicine, Houston, TX</td>
</tr>
<tr>
<td>73</td>
<td>Length of Prostate Biopsy Core: Does It Impact the Detection of Cancer? (870) PO Fiset, A Aprikian, F Brimo McGill University, Montreal, QC, Canada</td>
</tr>
<tr>
<td>74</td>
<td>Novel Prostate Cancer Stem Cells (PCSC) Signaling Pathways: Implications of Toll-Like Receptors (TLRs) and Steroid Hormone Receptors (SHRs) (868) WJ Favaro, A Billis, U Ferreira School of Medicine, University of Campinas (Unicamp), Campinas, SP, Brazil</td>
</tr>
<tr>
<td>75</td>
<td>Early Overexpression of the Bombesin Receptor Type 2 in Prostatic Carcinogenesis (939) M Korner, B Waser, R Rehmann, JC Reubi Institute of Pathology of the University of Berne, Berne, Switzerland</td>
</tr>
<tr>
<td>76</td>
<td>Stratification of Seminal Vesicle Invasion as Prognostic Factors in Prostate Cancer (988) M Okayasu, H Takahashi, T Yamamoto, B Furusato, S Mizukami, S Egawa, H Hano Jikei University School of Medicine, Tokyo, Japan</td>
</tr>
<tr>
<td>77</td>
<td>Prostate Cancer within 0.01 cm of a Negative Surgical Margin of a pT2 Prostatectomy Specimen Predicts Recurrence (1053) LD True, JP Izzard, VL Funda, R Schmidt, WJ Ellis, PH Lange, DW Lin, B Dalkin, JL Wright University of Washington, Seattle, WA</td>
</tr>
<tr>
<td>78</td>
<td>Foamy Gland Carcinoma of the Prostate in Needle Biopsy: Incidence, Gleason Grade, and Comparative AMACR vs ERG Expression (1068) JI Warrick, PA Humphrey University of Michigan, Ann Arbor, MI; Washington University, Saint Louis, MO</td>
</tr>
<tr>
<td>79</td>
<td>Association of Fatty Acid Synthase Polymorphisms and Expression with Prostate Cancer Recurrence after Radical Prostatectomy (832) J Cheng, RD Payne Ondracek, KA Kasza, B Xu, JR Marshall Roswell Park Cancer Institute, Buffalo, NY</td>
</tr>
<tr>
<td>80</td>
<td>Korean Nomogram for Prediction of Biochemical Recurrence of Clinically Localized Prostate Cancer in Koreans with Emphasis on International Variation of Prostate Cancer (836) YM Cho, SJ Jung, N Cho, M-J Kim, MWW Kattan, C Yu, JY Ro University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea; Inje University Paik Hospital, Pusan, Republic of Korea; Yonsei University, Seoul, Republic of Korea; Cleveland Clinic, Cleveland, OH; Methodist Hospital and Weill Medical College of Cornell University, Houston, TX</td>
</tr>
<tr>
<td>81</td>
<td>Reporting Guidelines for Prostate Biopsies – A Survey of 266 European Pathologists (812) D Berney, F Algaba, P Camparo, E Comperat, D Griffiths, G Kristiansen, A Lopez-Beltran, R Montironi, M Varma, L Egevad St Bartholomew’s Hospital, London, United Kingdom; Fundacio Puigvert-University Autonomous, Barcelona, Spain; Centre de Pathologie Amiens Picardie, Paris, France; Hopital La Pitie-Salpetriere, Paris, France; University Hospital of Wales, Cardiff, United Kingdom; University of Bonn, Bonn, Germany; Cordoba University Medical School, Cordoba, United Kingdom; Polytechnic University of the Marche Region, Ancona, United Kingdom; Karolinska Institutet, Stockholm, Sweden</td>
</tr>
<tr>
<td>82</td>
<td>Architectural Heterogeneity and Cribriform Pattern Predict Adverse Clinical Outcome for Gleason Grade 4 Prostatic Adenocarcinoma (852) F Dong, Y Ping, C Wang, S Wu, Y Xiao, WS McDougal, RH Young, C-L Wu Massachusetts General Hospital, Boston, MA</td>
</tr>
</tbody>
</table>
BAP1 Loss Results in mTORC1 Activation in Clear Cell Renal Cell Carcinoma (925)
P Kapur, A Christie, S Pena-Llopis, V Margulis, Y Lotan, X-J Xie, J Brugarolas
University of Texas Southwestern Medical Center, Dallas, TX

Characterization of Fibromuscular Pseudocapsule of Renal Cell Carcinoma (1011)
LP Roquero, ON Kryvenko, NS Gupta, MW Lee
Henry Ford Health System, Detroit, MI; Johns Hopkins Hospital, Baltimore, MD

Detailed Histologic Evaluation of Renal Cell Carcinoma (RCC) Subtypes in 138 Metastatic Tumors with Emphasis on Homology with Primary Site (824)
EE Chang, DJ Luthringer, M de Peralta-Venturina, B Balzer, S Wang, JM Wu, MB Amin
Cedars-Sinai Medical Center, Los Angeles, CA

TFE3 Break-Apart FISH Has a Higher Sensitivity for Xp11.2 Translocation-Associated Renal Cell Carcinoma Than TFE3 or Cathepsin K Immunohistochemical Staining Alone: Expanding the Morphologic Spectrum (1007)
Q Rao, SR Williamson, S Zhang, JN Eble, DJ Grignon, M Wang, X-J Zhou, W Huang, P-H Tan, GT MacLennan, L Cheng
Indiana University School of Medicine, Indianapolis, IN; Nanjing Jinling Hospital, Nanjing University School of Medicine, Nanjing, China; Nanjing Medical University Affiliated Nanjing Hospital (Nanjing First Hospital), Nanjing, China; Singapore General Hospital, Singapore, Singapore; Case Western Reserve University, Cleveland, OH

Diagnostic and Prognostic Role of Immunohistochemical Expression of Napsin A in Renal Cell Carcinoma: A Study Including 233 Primary and Metastatic Cases (1081)
B Xu, S Abourbih, K Sircar, W Kassouf, A Aprikian, S Tanguay, F Brimo
McGill University Health Center, Montreal, QC, Canada; University of Texas MD Anderson Cancer Center, Houston, TX

HER2 Status and Association with Clinical Features and Outcome in Micropapillary Urothelial Carcinoma (1046)
WR Sakov, SA Schneider, RF Tarrell, JC Cheville
Mayo Clinic, Rochester, MN

The Role of Immunohistochemistry in the Diagnosis of Flat Urothelial Lesions: A Study Using CK20, CK5/6, P53, CD138, and HER2/Neu (920)
S Jung, C Wu, Z Islami, S Tanguay, A Aprikian, W Kassouf, F Brimo
McGill University Health Center, Montreal, QC, Canada; University of Texas MD Anderson Cancer Center, Houston, TX

Her2 Expression in Urothelial Carcinoma with Micropapillary Morphology: Preferential Overexpression by the Micropapillary Component (908)
H Huang, S Jadallah, Y-B Chen, A Gopalan, SW Fine, SK Tickoo, GV Iyer, G Dalbagni, D Solit, VE Reuter, HA Al-Ahmadi
Memorial Sloan-Kettering Cancer Center, New York, NY
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>p53, pRb, Cyclin D1 and HER2 Expression in a Heterogeneous Cystectomy Cohort (1033)</td>
<td>L Schultz, SJT Spagnul, SM Bezerra, GR Damm, TS Giulianielas, WH da Costa, GC Guimaraes, FA Soares, IW da Cunha</td>
<td>Antonio Prudente Foundation, São Paulo, Brazil; AC Camargo Hospital, São Paulo, Brazil</td>
</tr>
<tr>
<td>101</td>
<td>Comparison of Tyrosine Kinase Receptors HER2, EGFR and VEGFR Expression in Micropapillary Urothelial Carcinoma with Invasive Urothelial Carcinoma (952)</td>
<td>J Li, D Yang, L Noble, M Resnick, A Amin</td>
<td>Rhode Island Hospital/Warren Alpert Medical School of Brown University, Providence, RI</td>
</tr>
<tr>
<td>102</td>
<td>GATA3 Expression in Nested, Micropapillary, and Plasmacytoid Urothelial Carcinomas (1066)</td>
<td>J Warrick, N Palanisamy, J Siddiqui, R Mehra, A Wu, S Tomlins, LP Kunju</td>
<td>University of Michigan, Ann Arbor, MI</td>
</tr>
<tr>
<td>103</td>
<td>GATA3 Expression in Matched Paired Primary and Metastatic Urothelial Carcinomas (1089)</td>
<td>L Zhao, GP Paner, JB Taxy, T Antic, M Tretiakova</td>
<td>University of Chicago, Chicago, IL</td>
</tr>
<tr>
<td>104</td>
<td>GATA3 Is a Useful Marker for Signet Ring Adenocarcinoma of the Urinary Bladder (861)</td>
<td>CL Ellis, AG Chang, A Cimino-Mathews, P Argani, R Youssuf, P Kapur, EA Montgomery, JI Epstein</td>
<td>Johns Hopkins Hospital, Baltimore, MD; University of Texas Southwestern Medical Center, Dallas, TX</td>
</tr>
<tr>
<td>105</td>
<td>GATA3 Expression Alteration in High Grade and High Stage Urothelial Carcinoma (1059)</td>
<td>C Villa, B Zhu, C Luan, XJ Yang</td>
<td>Northwestern University, Chicago, IL</td>
</tr>
<tr>
<td>106</td>
<td>Expression of UDP-Glucuronosyltransferase 1A (UGT1A) in Bladder Cancer: Association with Prognosis and Regulation by Estrogen (912)</td>
<td>K Izumi, Y Li, H Ishiguro, Y Zheng, JL Yao, GJ Netto, M Miyamoto</td>
<td>University of Rochester, Rochester, NY; Johns Hopkins Medical Institutions, Baltimore, MD</td>
</tr>
<tr>
<td>107</td>
<td>Benign Testicular Teratomas in Postpubertal Patients: A Clinical, Histopathologic, and Molecular Genetic Analysis of 24 Cases (1086)</td>
<td>C Zhang, DM Berney, MS Hirsch, L Cheng, TM Ulbright</td>
<td>Indiana University School of Medicine, Indianapolis, IN; Queen Mary University of London, London, United Kingdom; Harvard Medical School, Boston, MA</td>
</tr>
<tr>
<td>108</td>
<td>Testicular Hemangioma: A Series of 8 Cases (942)</td>
<td>ON Kryvenko, JI Epstein</td>
<td>Johns Hopkins Hospital, Baltimore, MD</td>
</tr>
</tbody>
</table>

**Gynecologic & Obstetrics**

<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>109</td>
<td>MELF Pattern of Invasion: A Frequent Finding in Endometrial Carcinoma with DNA Mismatch Repair Abnormalities (1168)</td>
<td>YR Hussein, K Garg, R4 Soslow, D DeLair</td>
<td>Memorial Sloan-Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>110</td>
<td>Mismatch Repair Status in Recurrent Low Grade Endometrioid Adenocarcinomas (1198)</td>
<td>S Lu, R Buell-Gutbrod, MR Quddus, J Xiong, WD Lawrence, CJ Sung</td>
<td>Rhode Island Hospital, Providence, RI; Women and Infants Hospital, Providence, RI; Warren Alpert Medical School of Brown University, Providence, RI</td>
</tr>
<tr>
<td>111</td>
<td>Risk Factors in Patients with Low-Grade Endometrial Adenocarcinoma and Lung Recurrence Versus Recurrence at Other Sites. A Multi-Institutional Study (1226)</td>
<td>AA Roma, DA Barbuto, E Euscher, R Ali-Fehmi, B Djordjevic, JA Bennett, EE Frauenhoffer, SR Hong, I Kim, D Montiel, E Moschiano, A Malpica, EG Silva</td>
<td>Cleveland Clinic, Cleveland, OH; Cedar Sinai, Los Angeles, CA; MD Anderson, Houston, TX; Wayne State University, Detroit, MI; Ottawa Hospital, Ottawa, ON, Canada; Penn State University, Hershey, PA; Cheil General Hospital, Seoul, Korea; Instituto Nacional Cancerologia, Mexico, Mexico</td>
</tr>
<tr>
<td>112</td>
<td>Metabolomic Profile of Endometrioid Adenocarcinoma of the Endometrium (1150)</td>
<td>S Gatius, M Jove, A Yeramian, M Santacana, J Paillas, M Portero, R Pamplona, X Matias-Guiu</td>
<td>Hospital Universitari Arnuau de Vilanova, University of Lleida, IRB Lleida, Lleida, Spain</td>
</tr>
<tr>
<td>113</td>
<td>Low Stage Clear Cell Carcinoma of the Endometrium: A Review of Clinical Outcome and Survival (1105)</td>
<td>A Bakula, A Montgomery, A Brown, A Shafer, S Mandavalli</td>
<td>Hartford Hospital, Hartford, CT</td>
</tr>
<tr>
<td>114</td>
<td>Endometrial Clear Cell Carcinoma: Incidence and Clinicopathologic Features (1194)</td>
<td>GH Lewis, AK Folkins, CS Kong, RL Kempson, TA Longacre</td>
<td>Stanford University, Stanford, CA</td>
</tr>
<tr>
<td>115</td>
<td>Prognostic Factors in Clear Cell Carcinoma of the Endometrium: A Clinicopathologic Analysis of 50 Rigorously Classified Cases (1139)</td>
<td>O Fadare, W Zheng, MA Crispens, HW Jones III, D Khabele, K Gwin, SX Liang, K Mohammed, MM Desouki, V Parkash, JL Hecht</td>
<td>Vanderbilt University, Nashville, TN; University of Arizona, Tucson, AZ; University of Chicago, Chicago, IL; North Shore-LIJI, NHP, NY; UPMC, Pittsburgh, PA; Yale University, New Haven, CT; Harvard University, Boston, MA</td>
</tr>
<tr>
<td>116</td>
<td>The Clinicopathologic Significance of p53 and BAF250a (ARID1A) Expression in Clear Cell Carcinoma of the Endometrium (1138)</td>
<td>O Fadare, K Gwin, MM Desouki, MA Crispens, HW Jones III, D Khabele, K Mohammed, SX Liang, JL Hecht, V Parkash</td>
<td>University of Pittsburgh, Pittsburgh, PA; Upstate Medical University, New York, NY; The University of Chicago, Chicago, IL; North Shore-LIJI, NHP, NY; Arizona State University, Tucson, AZ; Harvard University, Boston, MA; Yale University, New Haven, NY</td>
</tr>
<tr>
<td>Board Number</td>
<td>Title</td>
<td>Authors</td>
<td>Institutions</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>117</td>
<td>Coordinate Patterns of ER, PR and WT1 Expression Are Useful in the Distinction of Ovarian from Endometrial Serous Carcinomas and Significantly Outperform Individual Markers (1137)</td>
<td>O Fadare, S James, MM Desouki, D Khabele</td>
<td>Vanderbilt University, Nashville, TN</td>
</tr>
<tr>
<td>118</td>
<td>Differential Vimentin Expression in Ovarian and Endometrial Endometrioid Adenocarcinomas: Diagnostic Utility in Distinguishing Double Primaries from Metastatic Tumors (1127)</td>
<td>MM Desouki, SJ Kallas, O Hameed, D Khabele, MA Crispens, O Fadare</td>
<td>Vanderbilt University, Nashville, TN</td>
</tr>
<tr>
<td>119</td>
<td>Clinical Significance of Lymphovascular Space Invasion in Uterine Serous Carcinoma (1106)</td>
<td>S Bandypadhyay, I Winer, I Mert, E Oliva, M Nucci, Z Al-Wahab, H Guan, H Arabi, B Alos, KK Van de Vijer, R Ali-Fehmi</td>
<td>Wayne State University, Detroit, MI; Massachusetts General Hospital, Boston, MA; Brigham and Women’s Hospital, Boston, MA; King Abdulaziz Medical City, Jiddah, Saudi Arabia</td>
</tr>
<tr>
<td>120</td>
<td>Trefoil Factor 3 (TFF3) Is an Independent Biomarker for Better Prognosis in Endometrial Endometrioid Adenocarcinoma but Not in Uterine Serous Carcinoma (1231)</td>
<td>DK Samrao, D Wang, P Mhavech-Fauceglia</td>
<td>LAC+USC, Los Angeles, CA; Roswell Park Cancer Institute, Buffalo, NY</td>
</tr>
<tr>
<td>121</td>
<td>Microsatellite Instability Influences Expression of Endometrial Carcinoma Biomarkers (1211)</td>
<td>E Okoye, A Bruegl, B Fellman, R Luthra, R Broaddus</td>
<td>MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>122</td>
<td>Quantitative Ki-67 Index as an Ancillary Tool in the Differential Diagnosis of Endometrial Lesions with Secretory Change (1153)</td>
<td>GT Gurda, AS Baras, I-M Shih, RJ Kurman</td>
<td>Johns Hopkins Hospital, Baltimore, MD</td>
</tr>
<tr>
<td>123</td>
<td>PAX8 Expression Is Useful To Distinguish Dedifferentiated Endometrioid Adenocarcinoma from Grade III Endometrioid Adenocarcinoma (1195)</td>
<td>Z Li, F Gao, W Hong, C Zhao</td>
<td>UPMC Magee-Womens Hospital, Pittsburgh, PA; Conemaugh Memorial Medical Center, Johnstown, PA</td>
</tr>
<tr>
<td>124</td>
<td>HER2 Testing in Endometrial Carcinoma: Four-Year Experience at a Large Tertiary Academic Center (1115)</td>
<td>N Buza, D English, AD Santin, P Hui</td>
<td>Yale University School of Medicine, New Haven, CT</td>
</tr>
<tr>
<td>125</td>
<td>Does Ovarian Hyperthecosis Contribute to the Genesis of Endometrial Polyps, Endometrial Hyperplasia, and Endometrioid Carcinoma in Postmenopausal Women? A Clinicopathologic Study of 238 Cases (1256)</td>
<td>C Zhang, CJ Sung, MR Quddus, RA Simon, WD Lawrence</td>
<td>Kent Memorial Hospital, Warwick, RI; Women &amp; Infants Hospital, Warren Alpert Medical School of Brown University, Providence, RI</td>
</tr>
<tr>
<td>126</td>
<td>Digital Image Analysis Shows Associations between Vitamin D Receptor, Age, and Tumor Type in Endometrial Carcinoma (1172)</td>
<td>AS Joehlin-Price, JA Stephens, DE Cohn, AA Suarez</td>
<td>Ohio State University Wexner Medical Center, Columbus, OH</td>
</tr>
<tr>
<td>127</td>
<td>Foam Cells on Endometrial Biopsies/Curettages – An Indication for Additional Sampling or Not? (1161)</td>
<td>M Holland, A Goyal</td>
<td>Cleveland Clinic Foundation, Cleveland, OH</td>
</tr>
<tr>
<td>128</td>
<td>Does Robotic Hysterectomy Increase the Incidence of Lymphovascular Space Invasion in Endometrial Cancer? (1100)</td>
<td>B Alos, D Shi, Z Al-Wahab, S Bandypadhyay, H Arabi, R Morris, N Salem, R Ali-Fehmi</td>
<td>Wayne State University, Detroit, MI; King Khaled National Guard Hospital, Jeddah, Saudi Arabia</td>
</tr>
<tr>
<td>129</td>
<td>Expression of Embryonic Markers in Endometrial Epitheliium: A Unique Topography with Implications for Tumorigenesis (1164)</td>
<td>BE Howitt, M Hersfs, G Ning, CP Crum</td>
<td>Brigham and Women’s Hospital, Boston, MA; University of Liege, Liege, Belgium; Jackson Laboratory, Farmington, CT</td>
</tr>
<tr>
<td>130</td>
<td>Diagnostic Clinical Application of Multi-Target Fluorescence In Situ Hybridization in Endometrial Biopsies: Prospective Study of 282 Cases (1111)</td>
<td>DG Bostwick, D Hossain, E Turbat-Herrera, P Schlosshauer</td>
<td>Bostwick Laboratories, Inc., Orlando, FL</td>
</tr>
<tr>
<td>131</td>
<td>Reproducibility and Cancer Risk Stratification of Endometrial Samplings Utilizing World Health Organization and Endometrial Intraepithelial Neoplasia Classifications (1241)</td>
<td>MM Tomic, NA Pele, JW Bishop, EC Huang</td>
<td>University of California, Davis Medical Center, Sacramento, CA</td>
</tr>
<tr>
<td>132</td>
<td>The Utility of Vaginal Pap Test in Patients with Endometrial Carcinoma Post Hysterectomy (1178)</td>
<td>A Karunamurthy, S Jain, C Zhao</td>
<td>University of Pittsburgh Medical Center, Pittsburgh, PA</td>
</tr>
<tr>
<td>133</td>
<td>Placental Pathology in IUGR Infants: An 8 Year Overview (1240)</td>
<td>J Thorne, P Downey, E Mooney</td>
<td>National Maternity Hospital, Dublin, Ireland</td>
</tr>
<tr>
<td>134</td>
<td>Morphologic Predictors of Early Complete Mole: A Comparison of Histology, p57 and Ploidy (1238)</td>
<td>SA Srivastava, DA Bell</td>
<td>Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>135</td>
<td>Differential Diagnosis between Early Complete and Partial Mole Using TSSC3 and P57 (Kip2) Antibodies: Correlation with DNA Ploidy (1146)</td>
<td>M Fukunaga</td>
<td>Jikei University Daisan Hospital, Komaeshi, Tokyo, Japan</td>
</tr>
<tr>
<td>136</td>
<td>Immunohistochemistry for the Imprint Gene Products TSSC3 To Facilitate Differential Diagnosis of Trophoblastic Diseases (1145)</td>
<td>M Fukunaga</td>
<td>Jikei University Daisan Hospital, Komaeshi, Tokyo, Japan</td>
</tr>
</tbody>
</table>
137  Development of the Fetal Uterus and Comparison to the Post-Menarchal Uterus  (1144)
C Flynn, RA Morotti, FA Tavassoli
Yale University School of Medicine, New Haven, CT

HEAD & NECK

138  EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma  (1312)
V Szablewski, J Solassol, L Crampette, M Larieux, A Tempier, V Costes
CHU Montpellier, Montpellier, France

139  Distinct MiRNA Expression Signature in Olfactory Neuroblastoma  (1278)
S Costinean, V Balatti, P Dama, L Cascione, CM Croce, PE Wakely
Ohio State University, Columbus, OH

140  Investigation of Beta-Catenin Gene and Protein in Ameloblastoma  (1279)
L De Faro Valverde, CB Schlaepfer-Sales, MEC Buim, FC Xavier, LMP Ramalho, JN Dos Santos, FA Soares, EAG Ramos, CA Gurgel
Federal University of Bahia, Salvador, Bahia, Brazil; Oswaldo Cruz Foundation-Gonçalo Moniz Research Center, Salvador, Bahia, Brazil; AC Camargo Hospital, São Paulo, Brazil

141  Absence of BRAF and NRAS Mutations in Chronic Lymphocytic Thyroiditis and Primary Thyroid Lymphomas  (1313)
B Thakral, J Nowak, M Eldibany
NorthShore University HealthSystem, Evanston, IL

142  Topographic Distribution of PTC by Mapping in Coronal Sections of Thyroidectomy Specimens  (1315)
K Williams, P Gulavita, B Purging, C Lai, B Olberg, KT Mai
Ottawa Hospital and the University of Ottawa, Ottawa, ON, Canada

143  The Variable Pathologic Presentations of Medullary & Micro-Medullary Thyroid Carcinoma: An Institutional Experience  (1305)
TD Samulski, V LiVolsi, K Montone, Z Baloch
Hospital of the University of Pennsylvania, Philadelphia, PA

144  Poorly Differentiated Oncocytic (Hurthle Cell) Follicular Carcinoma: An Institutional Experience  (1267)
S Bai, ZW Baloch, KT Montone, VA LiVolsi
Hospital of the University of Pennsylvania, Philadelphia, PA

145  GATA3 Immunexpression in Salivary Gland Neoplasms  (1307)
LE Schwartz, WH Westra, JA Bishop
Johns Hopkins Hospital, Baltimore, MD

146  Utility of Mammaglobin Immunostaining in the Diagnosis of Mammary Analogue Secretory Carcinoma of the Salivary Glands  (1270)
JA Bishop, R Yonescu, D Batista, WH Westra
Johns Hopkins Hospital, Baltimore, MD

147  Mammary Analogue Secretory Carcinoma (MASC) of the Salivary Gland: Revisiting Our Acinic Cell and Poorly Differentiated Carcinomas Using Immunohistochemistry and FISH Studies  (1299)
A Pinto, V Nose, Y-S Fan, C Gomez-Fernandez
University of Miami, Miami, FL

148  Analysis of PLAG1 & HMGA2 Rearrangement in Salivary Duct Carcinoma and an Examination of the Role of Precursor Lesions  (1266)
A Bahrami, B Perez-Ordonez, J Dalton, Z Yin, I Weinreb
St. Jude Children’s Research Hospital, Memphis, TN; University Health Network, Toronto, ON, Canada

149  Mucosal Microcystic Adnexal Carcinomas of the Head and Neck: A Report of 4 Cases  (1293)
AM Mills, ML Policarpio-Nicolás, SE Mills
University of Virginia, Charlottesville, VA; University of Texas Health Science Center at San Antonio, San Antonio, TX

150  Advantages of Three-Grade Histoprognostic Classification in Therapeutic Management of Primary Epithelial Parotid Carcinoma  (1311)
V Szablewski, M Wassef, MC Picot, R Garrel, V Costes
CHU de Montpellier, Montpellier, France; APHP, Paris, France

151  Salivary Adenoid Cystic Carcinoma: Something out of Notching?  (1268)
D Bell, L Miele, D Roberts, R Weber, E Hanna
MD Anderson Cancer Center, Houston, TX; UMMC, Jackson, MS

152  Comparison of p63 and p40 ($D\text{Np63 Isoform}$) as Basal and Myoepithelial Markers in Salivary Gland Tumors  (1258)
CE Aguilar, RR Seethala
University of Pittsburgh Medical Center, Pittsburgh, PA

153  Adenoid Cystic Carcinoma of Salivary Glands: Clinicopathologic Study with Emphasis on Myb Protein Expression  (1286)
N Katabi, A Ho, A Ho, I Ganly, R Ghossein
Memorial Sloan-Kettering Cancer Center, New York, NY

154  Positive SOX10 Expression in a Broad Range of Salivary Gland Tumors  (1295)
TL Ng, R West, S Kwok, G Berry, C Kong
Stanford University, Stanford, CA

155  Chronic Sclerosing Sialadenitis: A Morphologic Diagnosis with Clinicopathologic Correlation  (1274)
SA Brooks, MS Richardson
Medical University of South Carolina, Charleston, SC

156  IgG4-Related Disease Is a Rare Cause of Recurrent Mastoiditis and Can Be Mimicked by Severe Otitis Media  (1317)
NA Zane, S Kraft, W Faquin, JH Stone, V Deshpande
Massachusetts General Hospital, Boston, MA

157  Transcriptionally Active HPV Infection and Salivary Adenoid Cystic Carcinomas  (1283)
T Isayeva, D Xing, MS Brandwein-Gensler
University of Alabama at Birmingham, Birmingham, AL
158 Solitary Fibrous Tumor of Head and Neck; a Diverse Clinopathologic Spectrum (1287)
D Kleven, R Abdelsayed, S Sharma
Medical College of Georgia, Georgia Health Sciences University, Augusta, GA; College of Dental Medicine, Georgia Health Sciences University, Augusta, GA

HEMATOPATHOLOGY

159 PU-H71, a HSP90 Inhibitor, Antagonizesstroma-Induced Prosurvival Effects in CLL through Its Inhibition of the B-Cell Receptor Signaling Pathway (1382)
A Guo, S Chen, P Lu, Z Song, J Ma, RR Furman, M Coleman, G Chiosis, YL Wang
Weill Cornell Medical College, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY

160 Efficacy of FDG-PET Scan in Predicting the Histologic Grade of Follicular Lymphomas (1549)
G Zheng, X Wang, R Wahl, AS Duffield, KH Burns, CD Gocke, MJ Borowitz, M Vaicu-Ross
Johns Hopkins Hospital, Baltimore, MD

161 Positron Emission Tomography Reliably Distinguishes Aggressive but Not Low Grade Lymphomas from Reactive Lymph Nodes (1550)
G Zheng, M Vaicu-Ross, KH Burns, CD Gocke, MJ Borowitz, AS Duffield
Johns Hopkins Hospital, Baltimore, MD

162 Bruton Tyrosine Kinase Is Commonly Expressed in Mantle Cell Lymphoma and Its Attenuation by Ibrutinib Induces Apoptosis of Mantle Cell Lymphoma Cells (1358)
M Cinar, F Saee Hamedani, Z Ma, B Cinar; HM Amin, S Alkan Cedars-Sinai Medical Center, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX

163 BTK Inhibition and Response Prediction in Mantle Cell Lymphoma Cells (1437)
J Ma, A Guo, S Cheng, P Lu, P Martin, RR Furman, M Coleman, LY Wang
Weill Cornell Medical College, New York, NY

164 Array-Based Quantitative Nucleic Acid Protection Assay Can Reproducibly Identify Prognostic mRNA Biomarkers in Archival Mantle Cell Lymphoma Specimens (1538)
DT Yang, MJ Mauren, RF McClure, M Ming, B Link, TM Habermann, GR Shaw, JR Cerhan, BS Kahl, A Dogan
University of Wisconsin, Madison, WI; Mayo Clinic, Rochester, MN; University of Iowa, Iowa City, IA; Marshfield Clinic, Marshfield, WI

165 Detection of B-Cell Lymphoma in Bone Marrow Aspirates Using BIOMED-2 Immunoglobulin Primers (1335)
E Berget, L Helgeland, A Molven, O Vintervmyr
University of Bergen, Bergen, Norway; Haukeland University Hospital, Bergen, Norway

166 Expression of Phosphoprotein Associated with Glycosphingolipid Enriched Microdomains 1 Protein (PAG1) in B and T-Cell Lymphomas (1326)
MA Alderman, D Rolland, F Keyoumarsi, D Thomas, K Elenitoba-Johnson, M Lim, E Ivan
University of Michigan Health System, Ann Arbor, MI

167 Glycoproteome Analysis of T-Cell Lymphomas Identifies Selective Downregulation of CD48 Expression in Anaplastic Large Cell Lymphomas (ALCL) (1403)
E Ivan, Y Jeon, F Keyoumarsi, D Thomas, K Elenitoba-Johnson, M Lim
University of Michigan, Ann Arbor, MI; Seoul National University Hospital, Seoul, Korea

168 Constitutively Active STAT6 Represses BCL6 in Primary Mediastinal B-Cell Lymphoma (1426)
JK Lennerz, K Rommel, K Dorsch, E Kelsch, J Melzner, M Buck, K Leroy, S Bruderlein, P Moller, O Ritz
University of Ulm, Ulm, Germany; Institute for Research in Biomedicine, Bellinzona, Switzerland; University Paris East Creteil, Paris, France

169 Small Molecule PRIMA-1™ Induces Apoptosis in Waldenstrom Macroglobulinemia Cells and Exhibits a Synergistic Cytotoxic Response with Dexamethasone (1420)
K Kwan, MN Saha, S Koh, L Zhang, C Chen, H Chang
University Health Network, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada

170 Detecting Myelodysplastic Syndromes on Peripheral Blood Using a Machine Learning Approach To Analyze Multiparameter Hematology Analyzer Data (1399)
DG Hwang, DM Dorfman, DA Briggs, R Silverio, O Pozdnayakova
Virginia Mason Medical Center, Seattle, WA; Brigham and Women’s Hospital, Boston, MA; Dana Farber Cancer Institute, Boston, MA

171 The Clonal Fraction of MDS Cells in Standard Clinical Specimens: Implications for the Application of Array CGH Methods for Prognostic Studies (1518)
MK Sabik, N Wang, WR Burack
University of Rochester Medical Center, Rochester, NY

172 Dysregulated Myelomonocytic Signaling in Response to Colony Stimulating Factor Is Common in Myelodysplastic Syndrome (1371)
J Gao, S Swamianathan, Y-H Chen, L Peterson, C Goolsby
Northwestern University Feinberg School of Medicine, Chicago, IL

173 Additive Value of High-Throughput Sequencing of Myeloid-Associated Gene Mutations in Diagnosing Myeloproliferative Neoplasms (1528)
Y Wang, AK Ho, S Billouin-Fraser, Q Pan, D Jones
Quest Diagnostics Nichols Institute, Chantilly, VA

174 Correlation of JAK2 V617F Mutation Burden with Clinical and Hematologic Characteristics of Myeloproliferative Neoplasms (1342)
AF Brown, Y Wang, MM Abu-Ghusson, PA George, K Vadlamudi, WB Furmaga, H Fan
University of Texas Health and Science Center, San Antonio, TX

175 Dim CD33 Expression in Myelomonocytic Marrow Elements: A Novel Description of an Apparently Normal Variant (1492)
SK Rathke, AM Harrington, H Oltmann, SH Kroft
Medical College of Wisconsin, Milwaukee, WI
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>176</td>
<td>FISH Analysis of Blastic Plasmacytoid Dendritic Cell Neoplasm for 9p21.3 Deletion (1510)</td>
<td>R Setoodeh, H Shao, D Qin, L Mascinski, M Tahmasbi, M Naghashpour, L Zhang, K Liu</td>
<td>University of South Florida, Tampa, FL; Moffitt Cancer Center, Tampa, FL</td>
</tr>
<tr>
<td>177</td>
<td>B-Lymphoblastic Leukemia with t(14;19)(q32;p13.1) Involves the IGH@ and EPOR Genes and Is Associated with an Aggressive Clinical Course (1404)</td>
<td>JM Jaso, VW Lu, CC Yin, M Zhao, L Abruzzo, MJ You, LJ Medeiros, G Lu</td>
<td>University of Texas MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>178</td>
<td>Molecular Analysis of Myeloid Neoplasms with inv(3)(q21q26.2) Using Highly Multiplexed Sequencing (1468)</td>
<td>MO Nakashima, HJ Rogers, H Szpurna, T Moon, V Visconte, A Tabarroki, E Hasrouri, R Tiu, J Maciejewski, A Schade, JR Cook, FL Lachman, ED Hsi</td>
<td>Cleveland Clinic, Cleveland, OH; Eli Lilly and Co., Indianapolis, IN</td>
</tr>
<tr>
<td>179</td>
<td>Detection of BRAF V600E Mutations in Langerhans Cell Histiocytosis by Pyrosequencing (1541)</td>
<td>J Yuan, GC Caponetti, D Lytle, TC Greiner</td>
<td>University of Nebraska Medical Center, Omaha, NE</td>
</tr>
<tr>
<td>180</td>
<td>Estrogen Receptor Is Frequently Expressed by Follicular Dendritic Cell Sarcomas (1381)</td>
<td>KL Grogg, M Law, A Dogan</td>
<td>Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>181</td>
<td>Immunohistochemical Characterization of Vascular and Stromal Proliferations of Spleen (1475)</td>
<td>DP O’Malley, YS Kim, A Sohani, L Weiss, S Perkins, JS Burke, C Fisher, A Orazi</td>
<td>Clariant Inc./GE Healthcare, Aliso Viejo, CA; City of Hope National Medical Center, Duarte, CA; Massachusetts General Hospital, Boston, MA; University of Utah, Salt Lake City, UT; Alta Bates Medical Center, Berkeley, CA; Royal Marsden Hospital, London, England, United Kingdom; Weill-Cornell Medical College, New York, NY</td>
</tr>
<tr>
<td>182</td>
<td>Cutaneous Amyloidosis: Mass Spectrometry Based Proteomic Analysis Reveals Diverse Etiology Associated with Unique Histopathological Features (1338)</td>
<td>MC Bois, JD Theis, JA Vrana, CN Wieland, LA Erickson, KL Grogg, PJ Kurtin, A Dogan</td>
<td>Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>183</td>
<td>Data-Driven Iterative Refinement of Bone Marrow Ancillary Testing Guidelines Improves Test Utilization and Decreases Costs (1508)</td>
<td>AC Seegmiller, AS Kim, CA Mosse, MA Thompson, S Li, AC Shaver, MM Zutter</td>
<td>Vanderbilt University School of Medicine, Nashville, TN</td>
</tr>
<tr>
<td>184</td>
<td>Hematopathologic Discrepancy between Submitted and Review Diagnoses (1349)</td>
<td>K-C Chang, C Chang, S-W Huang, D Jones</td>
<td>National Cheng Kung University and Hospital, Tainan, Taiwan; Quest Diagnostics Nichols Institute, Chantilly, VA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>185</td>
<td>Automated nRBC Measurement Using the Sysmex XE-5000 Hematology Analyzer: Frequency and Clinical Significance of the nRBC Count (1398)</td>
<td>DH Hwang, DM Dorfman, DG Hwang, PA Senna, O Pozdnyakova</td>
<td>Brigham and Women’s Hospital, Boston, MA; Virginia Mason Medical Center, Seattle, WA</td>
</tr>
<tr>
<td>186</td>
<td>Determination of VH Family Usage in B Cell Lymphoma by BIOMED-2 IgH Clonality Assay (1419)</td>
<td>F Kuo, L Kuo</td>
<td>Brigham and Women’s Hospital, Boston, MA; Pomona College, Claremont, CA</td>
</tr>
<tr>
<td>187</td>
<td>Spectrum of Bone Marrow Morphologic Findings in Hepatitis C Patients with and without Prior Liver Transplantation (1339)</td>
<td>J Boone, W Cui</td>
<td>University of Kansas Medical Center, Kansas City, KS</td>
</tr>
<tr>
<td>188</td>
<td>Immunophenotypic Pictograms Facilitate Recall and Rapid Interpretation of Diagnostic Information Embedded in Multiparameter Immunophenotyping Assays for Leukemia and Lymphoma (1344)</td>
<td>A Bryan, G Pihan</td>
<td>Beth Israel Deaconess Medical Center, Boston, MA</td>
</tr>
</tbody>
</table>

**LIVER**

<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>189</td>
<td>Routine Liver Biopsy of the Background Liver Is Potentially Useful in Patients with Hepatocellular Carcinoma (1675)</td>
<td>L Fu, A-K Al-Omari, K Mitchell, T Taddei, J Pollak, D Jain</td>
<td>Yale New-Haven Hospital, New Haven, CT; Yale-New Haven Hospital, New Haven, CT</td>
</tr>
<tr>
<td>190</td>
<td>Morphologic and Immunohistochemical Features of Sarcomatoid Hepatocellular Carcinoma (1700)</td>
<td>T Nguyen, M Torbenson, T-T Wu, D Jain, M Yeh, N Shafizadeh, S Kakar</td>
<td>University of California San Francisco, San Francisco, CA; Johns Hopkins, Baltimore, MD; Mayo Clinic, Rochester, MN; Yale, New Haven, CT; University of Washington, Seattle, WA; Southern California Permanente Medical Group, Woodland Hills, CA</td>
</tr>
<tr>
<td>191</td>
<td>Mucinous Hepatocellular Carcinoma: A Previously Undescribed Variant of Hepatocellular Carcinoma (1705)</td>
<td>SN Salaria, MS Torberson</td>
<td>Johns Hopkins School of Medicine, Baltimore, MD</td>
</tr>
<tr>
<td>192</td>
<td>Histopathologic Features of Primary Hepatocellular Carcinomas Are Poor Predictors of Extrahepatic Metastasis (1669)</td>
<td>EF Clayton, LF Survey, MA Grilliot, MH Levine, EE Furth</td>
<td>Hospital of the University of Pennsylvania, Philadelphia, PA</td>
</tr>
<tr>
<td>193</td>
<td>Steatohepatitic Hepatocellular Carcinoma Did Not Increase in the Last Decade: Metabolic Syndrome May Not Be the Only Contributing Factor (1659)</td>
<td>J Alexander, M Torbenson, T-T Wu, MM Yeh</td>
<td>University of Washington, Seattle, WA; Johns Hopkins University, Baltimore, MD; Mayo Clinic, Rochester, MN</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>178</td>
<td>Automated nRBC Measurement Using the Sysmex XE-5000 Hematology Analyzer: Frequency and Clinical Significance of the nRBC Count (1398)</td>
<td>DH Hwang, DM Dorfman, DG Hwang, PA Senna, O Pozdnyakova</td>
<td>Brigham and Women’s Hospital, Boston, MA; Virginia Mason Medical Center, Seattle, WA</td>
</tr>
<tr>
<td>186</td>
<td>Determination of VH Family Usage in B Cell Lymphoma by BIOMED-2 IgH Clonality Assay (1419)</td>
<td>F Kuo, L Kuo</td>
<td>Brigham and Women’s Hospital, Boston, MA; Pomona College, Claremont, CA</td>
</tr>
<tr>
<td>187</td>
<td>Spectrum of Bone Marrow Morphologic Findings in Hepatitis C Patients with and without Prior Liver Transplantation (1339)</td>
<td>J Boone, W Cui</td>
<td>University of Kansas Medical Center, Kansas City, KS</td>
</tr>
<tr>
<td>188</td>
<td>Immunophenotypic Pictograms Facilitate Recall and Rapid Interpretation of Diagnostic Information Embedded in Multiparameter Immunophenotyping Assays for Leukemia and Lymphoma (1344)</td>
<td>A Bryan, G Pihan</td>
<td>Beth Israel Deaconess Medical Center, Boston, MA</td>
</tr>
</tbody>
</table>

**LIVER**

<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>189</td>
<td>Routine Liver Biopsy of the Background Liver Is Potentially Useful in Patients with Hepatocellular Carcinoma (1675)</td>
<td>L Fu, A-K Al-Omari, K Mitchell, T Taddei, J Pollak, D Jain</td>
<td>Yale New-Haven Hospital, New Haven, CT; Yale-New Haven Hospital, New Haven, CT</td>
</tr>
<tr>
<td>190</td>
<td>Morphologic and Immunohistochemical Features of Sarcomatoid Hepatocellular Carcinoma (1700)</td>
<td>T Nguyen, M Torbenson, T-T Wu, D Jain, M Yeh, N Shafizadeh, S Kakar</td>
<td>University of California San Francisco, San Francisco, CA; Johns Hopkins, Baltimore, MD; Mayo Clinic, Rochester, MN; Yale, New Haven, CT; University of Washington, Seattle, WA; Southern California Permanente Medical Group, Woodland Hills, CA</td>
</tr>
<tr>
<td>191</td>
<td>Mucinous Hepatocellular Carcinoma: A Previously Undescribed Variant of Hepatocellular Carcinoma (1705)</td>
<td>SN Salaria, MS Torberson</td>
<td>Johns Hopkins School of Medicine, Baltimore, MD</td>
</tr>
<tr>
<td>192</td>
<td>Histopathologic Features of Primary Hepatocellular Carcinomas Are Poor Predictors of Extrahepatic Metastasis (1669)</td>
<td>EF Clayton, LF Survey, MA Grilliot, MH Levine, EE Furth</td>
<td>Hospital of the University of Pennsylvania, Philadelphia, PA</td>
</tr>
<tr>
<td>193</td>
<td>Steatohepatitic Hepatocellular Carcinoma Did Not Increase in the Last Decade: Metabolic Syndrome May Not Be the Only Contributing Factor (1659)</td>
<td>J Alexander, M Torbenson, T-T Wu, MM Yeh</td>
<td>University of Washington, Seattle, WA; Johns Hopkins University, Baltimore, MD; Mayo Clinic, Rochester, MN</td>
</tr>
</tbody>
</table>
194 Endometrial Cysts within the Liver: A Rare Entity and Its Differential Diagnosis with Mucinous Cystic Neoplasms of the Liver (1686)
M Hsu, B Terris, T-T Wu, H-L Eng, W-T Huang, M Yeh
University of Washington, Seattle, WA; Descartes University, Paris, France; Mayo Clinic, Rochester, MN; Chang-Gung University, Kaohsiung, Taiwan

195 A Triple Stain of Reticulin, Glypican-3, and Glutamine Synthetase Is Useful for the Diagnosis of Liver Lesions (1715)
BJ Swanson, WL Marsh, Jr., WL Frankel
Ohio State University Wexner Medical Center, Columbus, OH

196 Focal Nodular Hyperplasia or Mass Effect? (1664)
BH Bryant, MP Upton, PE Swanson, MM Yeh, M Westerhoff
University of Washington, Seattle, WA

197 Hepatobiliary Aggressive B Cell Lymphomas: Histologic, Immunohistochemical and Genetic Evaluation of a Large Series (1657)
R Agrawal, KE Grimm, L Weiss, DP O’Malley
Clarinet Inc./GE Healthcare, Aliso Viejo, CA

198 GLUT1 Expression in Adult Hepatic Vascular Neoplasms (1678)
R Gill, C Sempoux, H Makhloof, S Thung, TT Amancio, V Alves, L Ferrell
UCSF, San Francisco, CA; Cliniques Universitaires Saint-Luc, Universite’ Catholique de Louvain, Brussels, Belgium; AFIP, Washington, DC; Mount Sinai Medical Center, New York, NY; University of São Paulo School of Medicine, São Paulo, Brazil

199 Tubulocystic Carcinoma of Bile Ducts: A Hitherto Unrecognized and Diagnostically Challenging Entity Often Mistaken as a Benign Lesion; Clinicopathologic Analysis of 6 Cases (1687)
K-T Jang, B Saka, K-T Jang, SY Kong, AB Farris, V Adsay
Emory University, Atlanta, GA; Memorial Sloan-Kettering Cancer Center, New York, NY; Pontificia University, Santiago, Chile; SMC, Seoul, Korea; U. Frontera, Temuco, Chile; Tokai University, Tokyo, Japan

200 Is 1 cm a Valid Cut-Off as the Cholecystectomy Indication for Gallbladder Polyps?: Clinicopathologic Analysis of 432 Cases (1673)
N Dursun, P Bagci, B Saka, O Basturk, C Vance, JC Roa, O Tapia, H Losada, J Sarmiento, T Tajiri, V Adsay
Emory University, Atlanta, GA; Memorial Sloan-Kettering Cancer Center, New York, NY; Pontificia University, Santiago, Chile

201 S100P as a Marker for Poor Survival and Advanced Stage in Gallbladder Carcinoma (1699)
AM Mathai, J Alexander, H-Y Huang, C-F Li, Y-M Jeng, K-M Fung, MM Yeh
University of Washington, Seattle, WA; Chang Gung University, Kaohsiung, Taiwan; Chi-Mei Medical Center, Tainan, Taiwan; National Taiwan University, Taipei, Taiwan; University of Oklahoma, Oklahoma City, OK

202 Adenomatous (Dysplastic) Transformation in Cholesterol Polyps (CPs) of the Gallbladder (GB) (1704)
B Saka, P Bagci, N Dursun, O Basturk, JC Roa, K-T Jang, O Tapia, H Losada, J Sarmiento, T Tajiri, V Adsay
Emory University, Atlanta, GA; Memorial Sloan-Kettering Cancer Center, New York, NY; Pontificia University, Santiago, Chile; SMC, Seoul, Korea; U. Frontera, Temuco, Chile; Tokai University, Tokyo, Japan

203 Cellular Phenotypes in Gallbladder Dysplasia: Diagnostic Significance and Clinical Associations in an Analysis of 318 Cases (1663)
P Bagci, B Saka, I Erbarut, N Dursun, O Basturk, JC Roa, OT Escalona, H Losada, K-T Jang, SY Kong, AB Farris, V Adsay
Emory University, Atlanta, GA; Memorial Sloan-Kettering Cancer Center, New York, NY; PU, Santiago, Chile; Frontera University, Temuco, Chile; SMC, Seoul, Korea

204 Expression of High Mobility Group AT-Hook 2 (HMGAA2) in Intrahepatic Cholangiocarcinomas: An Independent Prognostic Marker Associated with Poor Prognosis (1694)
C-T Lee, T-T Wu, C Lohse, L Zhang
National Cheng Kung University Hospital, Tainan, Taiwan; Mayo Clinic, Rochester, MN

**PANCREAS**

Tumor-Infiltrating Lymphocytes Do Not Affect Ki-67 Labeling Index in a Series of Pancreatic Neuroendocrine Tumors (PanNETs) (1801)
SC Wentz, C Shi, CM McCall, R Sharma, RH Hruban
Johns Hopkins Hospital, Baltimore, MD; Vanderbilt University Medical Center, Nashville, TN

High-Grade Neuroendocrine Carcinomas of the Pancreas: A Clinicopathologic Analysis of 60 Cases (1760)
Memorial Sloan-Kettering Cancer Center, New York, NY; Johns Hopkins University, Baltimore, MD; Emory University, Atlanta, GA; University of Pittsburgh, Pittsburgh, PA; Samsung MC, Seoul, Korea; Cleveland Clinic, Cleveland, OH; Mayo Clinic, Rochester, MN; Ohio State University, Columbus, OH; University of Michigan, Ann Arbor, MI; Brigham and Women’s Hospital, Boston, MD; Indiana University, Indianapolis, IN; Penn State Hershey MC, Hershey, PA

Nuclear Accumulation of β-Catenin in Well-Differentiated Pancreatic Neuroendocrine Tumors from Patients with Familial Adenomatous Polyposis (1763)
JC Dueber, C Shi
Vanderbilt University Medical Center, Nashville, TN

Estrogen-Induced Genes Are Expressed in Pancreatic Neuroendocrine Tumors (1781)
LT Ma, H Wang, A Rashid, RR Broaddus, JS Estrella
U.T. M.D. Anderson Cancer Center, Houston, TX

Comparison of PAX6 and PAX8 as Markers for Pancreatic Neuroendocrine Tumors (NETs) (1778)
J-P Lai, J Koo, F Chung, AB Mendez, M Kahn, R Mertens, D Dhall
Cedars-Sinai Medical Center, Los Angeles, CA
Histologic Changes in Non-Neoplastic Pancreas after Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma (1762)
University of Texas MD Anderson Cancer Center, Houston, TX

SOX9: A Novel Marker for Pancreatic Centroacinar Cell and Ductal Cell Differentiation (1793)
University of Texas, MD Anderson Cancer Center, Houston, TX

Trypsin Expression in Pancreatic Neuroendocrine Carcinomas: Potential Diagnostic Pitfall and Prognostic Marker (1768)
RP Graham, TC Smyrk, L Zhang
Mayo Clinic, Rochester, MN

Clinicopathologic Comparison of Ampullary Versus Pancreatic Carcinoma: Preinvasive Component, Size of Invasion, Stage, Resectability and Histologic Phenotype Are the Factors for the Significantly Favorable Outcome of Ampullary Carcinoma (1788)
B Saka, T Tajiri, N Ohike, P Bagci, A Krasinskas, GE Kim, SK Matihel, J Sarmiento, D Kooby, D Ozdemir, O Basturk, B El-Rayes, SY Kong, M Goodman, AB Farris, V Adsay
Emory University, Atlanta, GA; University of Pittsburgh, Pittsburgh, PA; UCSF, San Francisco, CA; Wayne State University, Detroit, MI

Depletion of Pancreatic Intranuclear Rodlets in Patients with Type 2 Diabetes (1764)
S El Hallani, P Milman, M Zhang, J Woulfe
Ottawa Hospital, Ottawa, ON, Canada

DNA Mismatch Repair Deficiency in Acinar Cell Carcinoma of the Pancreas: Frequency and Significance (1779)
W Liu, J Shia, EM O'Reilly, MA Lowery, PJ Allen, DS Klimstra Memorial Sloan-Kettering Cancer Center, New York, NY

Histopathologic Features That May Be Indicators of Prognosis in Ocular Sebaceous Carcinoma (1753)
JP Kapil, V Yin, D Kacerovska, D Kazakov, D Stockman, B Esmaeili, D Ivan
MD Anderson Cancer Center, Houston, TX; Charles University, Pilsen, Czech Republic

P16 and P53 Expression in Periocular Sebaceous Cell Carcinoma (1749)
WR Bell, K Singh, CG Eberhart
Johns Hopkins University School of Medicine, Baltimore, MD; Brown University, Providence, RI; Wilmer Eye Institute, Johns Hopkins Medical Institutions, Baltimore, MD

Identification of Ocular Sebaceous Neoplasia with Evaluation for Mismatch Repair Proteins (1757)
L Schoenfield, J Anthony, R Djoohan, I Lalak, M Levine, P Ng, J Perry, A Singh, T Plesev
Cleveland Clinic, Cleveland, OH
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>228</td>
<td>Genomic Landscape of Bladder Cancer Development from Incipient Field Effects to Invasive Disease (1817) T Majewski, J Bondaruk, W Choi, S Lee, W Chung, K Baggerly, C Dinney, HB Grossman, J-P Issa, D McConkey, S Scherer, B Czerniak UT MD Anderson Cancer Center, Houston, TX; Texas Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX; Temple University School of Medicine, Philadelphia, PA</td>
</tr>
<tr>
<td>229</td>
<td>Desktop Transcriptome Sequencing from Archival Tissue To Identify Clinically Relevant Translocations (1827) RT Sweeney, B Zhang, SX Zhu, S Varma, K Smith, SB Montgomery, M van de Rijn, J Zehnder, RB West Stanford School of Medicine, Stanford, CA</td>
</tr>
<tr>
<td>230</td>
<td>Methylation Patterns of Oligodendrogial Tumors (1818) B Melendez, P Mur, M Mollejo, C Fiano, JF Garcia, A Hernandez Lain, A Rodriguez de Lope, JA Rey Virgen de la Salud Hospital, Toledo, Spain; Xeral-Cies Hospital, Vigo, Spain; MD Anderson International, Madrid, Spain; 12 de Octubre Hospital, Madrid, Spain; Puerta de Hierro Hospital, Madrid, Spain; La Paz Hospital, Madrid, Spain</td>
</tr>
<tr>
<td>231</td>
<td>Mutation Profiling of Bladder Cancer Using Ion Torrent Sequencing (1832) EM Wojcik, AB Rosenfeld, ML Ziliox, ML Quek, GA Barkan, X Gai Loyola University, Maywood, IL</td>
</tr>
<tr>
<td>232</td>
<td>miRNA Profiling by Next Generation Sequencing and miRNA ISH in Ulcerative Colitis Neoplastic Progression (1831) NC Welker, J Lin, MP Bronner ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT; University of Indiana, Indianapolis, IN; University of Utah, Salt Lake City, UT</td>
</tr>
<tr>
<td>233</td>
<td>Customized Next Generation Sequencing Tail-End Data Analysis Pipeline for Clinical Cancer Genomics (1822) S Roy, MB Durso, A Wald, Y Nikiforov, M Nikiforova University of Pittsburgh, Pittsburgh, PA</td>
</tr>
<tr>
<td>234</td>
<td>Two New Stromal Signatures Stratify Breast Cancers with Different Prognosis (1809) X Guo, SX Zhu, K Montgomery, M van de Rijn, RB West Stanford University School of Medicine, Stanford, CA</td>
</tr>
<tr>
<td>235</td>
<td>Next Generation Sequencing in Clinical Environment for Cancer Therapy (1814) B Lee, Y-L Choi, HY Park, YH Ko Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, Korea</td>
</tr>
<tr>
<td>236</td>
<td>MEK Inhibition Induces Differential Mechanisms of Resistance in Thyroid and Melanoma BRAF\textsuperscript{V600E} Cell Lines (1806) ER Dorris, M Alhashemi, R Dunne, P Smyth, JJ O’Leary, O Sheils Trinity College Dublin, Dublin, Ireland</td>
</tr>
<tr>
<td>237</td>
<td>The Proportion of Contaminating Host Organ RNA within Clinical Biopsies of Metastatic Breast Cancer Is Minimal (1826) H Sun, C Hatzis, C Fu, R Avritscher, K Abrar, A Tam, S Curley, H Yao, J-N Vauthey, V Valero, D Booser, D Maru, S Hamilton, R Luthra, R Lau, RE Gould, L Pusztai, M Wallace, WF Symmans MD Anderson Cancer Center, Houston, TX; Nuvero Biosciences, Woburn, WA</td>
</tr>
<tr>
<td>238</td>
<td>Characterization of Cell Type Specific miRNA Profiles and Application to miRNA Profiles Derived From Tissues (1805) AS Baras, M McCall, T Cornish, M Halushka Johns Hopkins Hospital, Baltimore, MD; University of Rochester, Rochester, NY</td>
</tr>
<tr>
<td>239</td>
<td>Differential MicroRNA Expression in Colorectal Cancer Patients Presenting with Synchronous Hepatic Metastases (1808) CJ Ellermeier, K Cleveland, AS Brodsky, M Resnick Rhode Island Hospital/Warren Alpert Medical School of Brown University, Providence, RI</td>
</tr>
<tr>
<td>240</td>
<td>Analysis of Angiogenesis-Related Gene Expression Reveals a Profile with Prognostic Implications in Endometrioid Endometrial Carcinoma (1819) M Mendiola, A Redondo, J de Santiago, A Hernandez, E Perez- Fernandez, M Miguel-Martin, E Diaz, J Barriuso, V Heredia, L Yebenes, J Feliu, D Hardisson Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain; La Paz University Hospital, Madrid, Spain</td>
</tr>
<tr>
<td>241</td>
<td>Abstract Withdrawn</td>
</tr>
<tr>
<td>242</td>
<td>T-Cell Clonality Testing by Next Generation Sequencing: A Comparison of Benchtop Sequencing Platforms (1807) E Duncavage, J Schumacher, P Szankasi, T Kelley Washington University in St Louis, St. Louis, MO; ARUP Laboratories, Salt Lake City, UT; University of Utah, Salt Lake City, UT</td>
</tr>
<tr>
<td>244</td>
<td>Application of Image Analysis for Daily Monitoring of Positive Controls in Clinical Immunohistochemistry (1997) H Neufeld, R Berendt, D Pilaudzic, B Perez-Ordonez, B Ziola, B Gilks, J Garratt, C Cheung, J Krahn, S Carlsen, E Torlakovic University of Saskatchewan, Saskatoon, SK, Canada; University of Alberta, Edmonton, AB, Canada; McGill University, Montreal, QC, Canada; University of British Columbia, Vancouver, ON, Canada; Lions General Hospital, Vancouver, BC, Canada; University of Toronto, Toronto, ON, Canada</td>
</tr>
<tr>
<td>245</td>
<td>Previously Stained Slides for Use with Immunohistochemistry: A Single Institution Study for Consult Cases and Small Biopsies (2008) MD Rumery, DJ Davis, S Lucia University of Colorado, Aurora, CO</td>
</tr>
<tr>
<td>Board Number</td>
<td>Title</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>246</td>
<td>Proficiency Testing for Mismatch Repair Immunohistochemistry in Canada</td>
</tr>
<tr>
<td>247</td>
<td>Ranking of Individual Laboratory Performance in Immunohistochemistry</td>
</tr>
<tr>
<td>248</td>
<td>Photography Is an Underutilized Resource Crucial to Documentation of Cause of Death and Assurance of High Quality Postmortem Examinations</td>
</tr>
<tr>
<td>249</td>
<td>Validation of Remote Robotic Microscopy Using the iScan Coreo Au Platform</td>
</tr>
<tr>
<td>250</td>
<td>Validation of Two Whole Slide Imaging Scanners Based on the Draft Guidelines of the College of American Pathologists</td>
</tr>
<tr>
<td>251</td>
<td>Turnaround Time for Large or Complex Specimens in Surgical Pathology: A Q-Probes Study of 56 Institutions</td>
</tr>
<tr>
<td>252</td>
<td>Impact of Integrated Speech Recognition and Digital Dictation Software on Turnaround Times for Surgical Pathology Specimens</td>
</tr>
<tr>
<td>253</td>
<td>&quot;Dot the Form&quot; – An Easy Way To Improve Inpatient Biopsy Turnaround Time</td>
</tr>
<tr>
<td>254</td>
<td>Institution of 24 Hour Histology Processing and the Impact on Turn-around-Time</td>
</tr>
<tr>
<td>255</td>
<td>A Rapid Improvement Event Using Lean Concepts Can Substantially Improve Histology Laboratory Efficiency</td>
</tr>
<tr>
<td>256</td>
<td>&quot;Urgent&quot; Surgical Pathology Specimens; a Review and Comparison with Critical Values in Anatomical Pathology</td>
</tr>
<tr>
<td>257</td>
<td>Institutional Consultations for Continuation of Patient Care: An Audit of 4 Years Including 3193 Cases from a Single Institution</td>
</tr>
<tr>
<td>258</td>
<td>Lean Redesign of Operating Room Specimen Labeling Process</td>
</tr>
<tr>
<td>259</td>
<td>Surgical Pathology Report Defects: A Q-Probes Study of 73 Institutions</td>
</tr>
<tr>
<td>260</td>
<td>Impact of Streamlined Adverse Event Entry</td>
</tr>
<tr>
<td>261</td>
<td>Studying Amended Reports: Testing Effects of Time of Sign Out, Resident Involvement, and Specimen Type on Amendments</td>
</tr>
<tr>
<td>262</td>
<td>Assessment of Cognitive Bias as a Root Cause of Diagnostic Interpretation Error in Pathology Residents</td>
</tr>
<tr>
<td>263</td>
<td>Root Cause Analysis of Discordant and Deferred Frozen Section Diagnoses</td>
</tr>
</tbody>
</table>
Evaluation of ER, PR and Her2 in Breast Carcinoma Metastatic to Bone: A Comparison of Results between FNA Cell Blocks and Surgical Biopsies (1961)
G Aggarwal, J Magda, ME Arcila, O Lin, M Edelweiss Memorial Sloan-Kettering Cancer Center, New York, NY

Proposal for a New Classification of “Equivocal” Fibroepithelial Lesions (FELs) (2007)
E Resekrova, N Sneige University of Texas MD Anderson Cancer Center, Houston, TX

A Pragmatic Approach to Assay Selection: Comparison of In-House Validated Assays Versus CE-IVD Assays for the Analysis of High-Throughput Molecular Theranostic Assays (2000)
C O’Brien, E Logan, J Gibbons, O Shells, SE Langabeer, SP Finn St James’s Hospital, Dublin, Ireland; Trinity College, Dublin, Ireland
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Abstract Title</th>
<th>Authors</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><em>Isocitrate Dehydrogenase (IDH1/IDH2)</em> Mutation Types and Frequency in Periosteal Cartilaginous Tumors (27)</td>
<td><em>JM Carter, JS Voss, BR Kipp, DE Wenger, CY Inwards</em></td>
<td>Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>2</td>
<td><em>IDH1 and IDH2 Mutations in Chondrosarcoma – A Sequenom Mass Spectrometry Analysis of 53 Cases (19)</em></td>
<td><em>NP Agaram, K Nafa, B Laetitia, I Marc, SK Gary, HH John, HR Meera</em></td>
<td>Memorial Sloan-Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>3</td>
<td>Correlation of MDM2, p53 and MIB-1 Expression with Response to Neoadjuvant Chemotherapy in High-Grade Extremity Osteosarcomas and Clinical Outcome (72)</td>
<td><em>SN Shirke-Satpute, B Rekhi, SS Desai, A Puri, M Agarwal, NA Jambhekar</em></td>
<td>Tata Memorial Hospital, Mumbai, India</td>
</tr>
<tr>
<td>4</td>
<td><em>Rb1 and CDKNA2</em> Gene Deletions Do Not Predict Resistance to Neoadjuvant Chemotherapy in Patients with Osteosarcoma (22)</td>
<td><em>D Borys, RJ Canter, RA Schultz, J Gregg, JW Bishop, A Horvai</em></td>
<td>University of California Davis, Sacramento, CA; University of California Davis, Sacramento, CA; PerkinElmer, Spokane, WA; UCSF, San Francisco, CA</td>
</tr>
<tr>
<td>5</td>
<td>MicroRNA-199b-5p Is Involved in Notch Pathway of Osteosarcoma (88)</td>
<td><em>KY Won, YW Kim, H-S Kim, SK Lee, W-W Jung, Y-K Park</em></td>
<td>Kyung Hee University Hospital at Gangdong, Kyung Hee University, Seoul, Republic of Korea; College of Medicine, Kyung Hee University, Seoul, Republic of Korea; College of Health Science, Korea University, Seoul, Republic of Korea</td>
</tr>
<tr>
<td>6</td>
<td>Histomorphologic Features Predictive of Survival in Osteosarcoma (29)</td>
<td><em>MH Chui, A Griffin, M Wong, ME Blackstein, PC Ferguson, JS Wunder, RA Kandel, BC Dickson</em></td>
<td>Mount Sinai Hospital, Toronto, ON, Canada</td>
</tr>
<tr>
<td>7</td>
<td>Chondroid Chondoma: A Chondoma Subtype with Worse Prognosis (47)</td>
<td><em>DA Kerr, V Deshpande, P Kurzawa, GP Nielsen</em></td>
<td>Massachusetts General Hospital, Boston, MA; Greater Poland Cancer Centre, Poznan, Poland</td>
</tr>
<tr>
<td>8</td>
<td>Array Comparative Genomic Hybridization Analysis of a Conventional Chondoma and an Adjacent Benign Notochordal Tumor Shows No Direct Lineage Relationship (56)</td>
<td><em>YD Lee, V Nardi, LP Le, V Deshpande, FJ Hornicek, AJ Iafrate, GP Nielsen</em></td>
<td>Massachusetts General Hospital, Boston, MA</td>
</tr>
<tr>
<td>9</td>
<td>Expression of Mesenchymal Developmental Antigens in Chordoma (50)</td>
<td><em>S Koo, AG Montag</em></td>
<td>University of Chicago, Chicago, IL</td>
</tr>
<tr>
<td>11</td>
<td>Clinical and Biological Significance of Hepatoma-Derived Growth Factor in Ewing Sarcoma/PNET (92)</td>
<td><em>Y Yang, H Li, F Zhang, H Shi, A Han</em></td>
<td>First Affiliated Hospital and Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, China</td>
</tr>
<tr>
<td>12</td>
<td>C-MYC Protein Expression by Immunohistochemistry in CIC-DUX4 Rearranged Sarcomas Is Associated with Trisomy 8 (23)</td>
<td><em>D Buehler, K Choi, DG Thomas, DR Lucas, JB McHugh, A Inyang, BP Rubin, SD Billings, JR Goldblum, RM Patel</em></td>
<td>Cleveland Clinic, Cleveland, OH; University of Michigan, Ann Arbor, MI</td>
</tr>
<tr>
<td>13</td>
<td>Primary Myoepithelioma of the Orbit (71)</td>
<td><em>K Shah, Y Zhang, GP Nielsen, AE Rosenberg</em></td>
<td>University of Miami, Miller School of Medicine-Jackson Memorial Hospital, Miami, FL; Massachusetts General Hospital, Boston, MA</td>
</tr>
<tr>
<td>14</td>
<td>Primary Malignant Myoepithelial Tumor of Bone (94)</td>
<td><em>Y Zhang, GP Nielsen, K Raskin, N Cipriani, AE Rosenberg</em></td>
<td>University of Miami, Miller School of Medicine-Jackson Memorial Hospital, Miami, FL; Massachusetts General Hospital, Boston, MA</td>
</tr>
<tr>
<td>15</td>
<td>Metastatic Melanoma to Bone: A Clinicopathological Study of 236 Cases (77)</td>
<td><em>DL Stockman, AJ Lazar, W-L Wang</em></td>
<td>MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>16</td>
<td>Outpatient Core Needle Biopsy Versus Intraoperative Open Surgical Biopsy in the Diagnosis and Grading of Soft Tissue Neoplasms: Is One Method Better Than the Other? (44)</td>
<td><em>J Kaley, M Lindberg</em></td>
<td>University of Arkansas for Medical Sciences, Little Rock, AR</td>
</tr>
<tr>
<td>17</td>
<td>Prognostic Value of Subclassification of Pleomorphic Soft Tissue Sarcoma (STS): Myogenic Versus Non-Myogenic Differentiation (31)</td>
<td><em>NA Cipriani, P Kurzawa, J Mullen, V Deshpande, R Ahmad, GP Nielsen</em></td>
<td>Massachusetts General Hospital, Boston, MA; Greater Poland Cancer Centre, Poznan, Poland</td>
</tr>
<tr>
<td>18</td>
<td>Mitotic Count Is Sufficient To Predict Prognosis for Extremity Spindle Cell Soft Tissue Sarcomas (48)</td>
<td><em>HA Khoja, BC Dickson, JS Wunder, PC Ferguson, A Griffin, D Howarth, RA Kandel</em></td>
<td>Mount Sinai Hospital, Toronto, ON, Canada</td>
</tr>
</tbody>
</table>
19 Malignant Peripheral Nerve Sheath Tumor Development Is Associated with PTEN Loss and Activation of the PI3K/AKT/mTOR Pathway (83)
ME Vergara-Lluri, E Shurell, Y Li, H Wu, FC Eilber, SM Dry
David Geffen School of Medicine at UCLA, Los Angeles, CA

20 Utility of p16 in Distinguishing Lipomas and Well-Differentiated Liposarcomas Compared to Fluorescence In-Situ Hybridization (39)
RS Gonzalez, CM McClain, BK Chamberlain, CM Coffin, JM Cates
Vanderbilt University Medical Center, Nashville, TN

21 Endobronchial Lipoma – Clinicopathologic Analysis of 12 Cases Showing Benign Behavior and Lack of 12q13-15 Amplification, Despite Worrysome Morphological Features (21)
JM Boland, KJ Fritchie, MR Erickson-Johnson, AM Oliveira, TV Colby, AL Folpe
Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ

22 Dedifferentiated Liposarcoma Is the Most Frequent Liposarcoma Subtype. A Study from the French Sarcoma Group on the Subtype Frequencies in a Series of 1384 Liposarcomas with a Systematic Molecular Characterisation (63)
Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; Hôpital Cochin, Paris, France; Institut Paoli Calmette, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre Georges-François Leclerc, Dijon, France

23 Are Peripheral Pure Pleomorphic Sarcomas with MDM2 Amplification Dedifferentiated Liposarcomas? (54)
S Le Guellec, A Neuvile, F Chibon, D Ranchere-Vince, F Larousserie, P Terrier, J-M Coindre
Institut Claudius Regaud, Toulouse, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; CHU Cochin, Paris, France; Institut Gustave Roussy, Paris, for the French Sarcoma Group, France

24 MDM2 and CDK4 Coexpression Is Uncommon in Sarcomatoid Carcinomas (78)
A Sukeeda, A Yoshida, M Yoshida, K Tsuta, R Kushima, H Tsuda
National Cancer Center Hospital, Tokyo, Japan

25 Determining Tumor Heterogeneity and Response to Treatment Ex Vivo Using 3D Mammosphere Cultures Derived from Primary Breast Cancers and Metastases (167)
HL Gilmore, K Miskimen, A Difeo, LN Harris
Seidman Cancer Center, Cleveland, OH

26 Analysis of FOXP3 mRNA Expression in Subtypes of Breast Carcinoma and Breast Cancer Cell Lines (245)
F Ortiz-Martinez, A Perez-Balaguier, JM Sempera-Ortells, M Rodrigo, J Ponce, P Martinez-Prinado, E Lernara, S Sanchez-Puaya, F Aranda, G Pedro
University General Hospital, Alicante, Spain; University of Alicante, Alicante, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

27 A Subset of Gastrointestinal Stromal Tumors Previously Regarded as Wildtype GISTs Carries Sporadic Activating Mutations in the Extracellular Ligand Binding Domain of KIT (Exon 8, p.D419del) (69)
H-U Schilhaus, S Huss, S Merkelbach-Bruse, M Kleine, K Helen, R Buttner, E Wedelmann
Institute of Pathology, Cologne, Germany

28 Fascin-1 Overexpression and miR-133b Down-Regulation in the Progression of Gastrointestinal Stromal Tumor (91)
H Yamamoto, K Kohashi, A Fujita, Y Oda
Kyushu University, Fukuoka, Japan

29 Gastrointestinal Stromal Tumors (GISTs): Molecular Analysis of KIT/PDGFRα/BRAF Genes Refines Risk Assessment (Register Study) (67)
S Rossi, R Miceli, L Toffolatti, D Gasparotto, G Gallina, A Marzotto, E Scaramell, L Messneri, I Bearzi, G Mazzoleni, C Capella, G Arrigoni, A Sonzogni, A Sidoni, L Mariani, C Gnocchi, R Valentini, R Maestro, A Gronchi, PG Casali, AP Dei Tos
General Hospital, Treviso, Italy; Istituto Nazionale Tumori, Milan, Italy; CRO, Aviano, Italy; Firenze University School of Medicine, Firenze, Italy; University of Marche, Ancona, Italy; General Hospital, Bolzano, Italy; Macchi Fondation, Varese, Italy; San Raffaele Hospital, Milano, Italy; General Hospital, Bergamo, Italy; Medical School, Perugia, Italy; Novartis Farma, Origgio, Italy

Gastrointestinal Stromal Tumor Metastatic to Bone: Clinicopathological and Molecular Features of 29 Cases, Including 8 Previously Unreported Cases (51)
K Kosemehmetoglu, G Kaygusuz, K Fritchie, O Aydin, O Yapiyier, O Coskun, E Karatayli, G Guler, I Kuzu, S Dervisoglu
Hacettepe University, Ankara, Turkey; Ankara University, Ankara, Turkey; Mayo Clinic, Rochester, MN; Istanbul University Cerrahpasa School of Medicine, Istanbul, Turkey; Anadolu Medical Center, Kocaeli, Turkey; Yildirim Beyazit University Ankara Education and Research Hospital, Ankara, Turkey

Beta-Human Chorionic Gonadotropin Expression in Giant Cell Tumors (2064)
ME Lawless, MH Rendi
University of Washington, Seattle, WA

BREAST
34 Relationship between the Insulator Factors and the Methylation Status in Breast Neoplasia (241)
K Nomoto, J Imura, K Abe, Y Uchida, T Nakajima, S Miwa, S Hayashi, K Tsuneyama
Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan; Ibaraki Prefectural Central Hospital, Kasama, Ibaraki, Japan

35 Correlation of RANKL, IKKalpha/beta and Maspin Expression with FOXP3 Regulatory T-Cells in Immunophenotypes of Breast Carcinoma (252)
G Peiro, F Ortiz-Martinez, A Perez-Balaguer, P Martinez-Peinado, J Ponce, FL Aranda, E Lerma, J Sanchez-Paya, JM Sempere-Ortells
University General Hospital, Alicante, Spain; University of Alicante, Alicante, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

36 Equivocal HER2 FISH Results on Breast Core Biopsy with Ratio <2.0: Repeat HER2 Testing on Excision Specimens Impacts Patient Management (217)
C Livasy, B Calhoun, S Limentani
Levine Cancer Institute, Charlotte, NC

37 Variability in Her2neu Testing: Validation Study in Search of Economic Solution for India (246)
T Pai, T Sheh, A Patil, S Desai
Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India

38 HER2 Testing: Central Laboratory Assessment of HER2-Equivocal (2+ Staining) Samples Using IHC and Dual SISH (96)
GI Acosta Haah, IL Frahm, SI Sarancone, MC Horsburgh
Hospital de Oncologia Marie Curie, Caba, Buenos Aires, Argentina; Sanatorio Mater Dei, Caba, Buenos Aires, Argentina; Laboratorio Quantum Clinica de Diagnostico Medico, Rosario, Santa Fe, Argentina; Productos Roche SAQel, Tigre, Buenos Aires, Argentina

39 Delay to Formalin Fixation Negatively Affects on HER2 Test by Dual-Color Silver-Enhanced In Situ Hybridization (SISH) (195)
T Khoury, Q Liu, S Liu
Roswell Park Cancer Institute, Buffalo, NY

40 Image Analysis and Quantitative Real-Time PCR of Nuclear Antigens (ER, PgR, Ki-67) in Breast Cancer (283)
P Sinn, M Keller, V Elke, A Schneeweiss, R Wirtz
University of Heidelberg, Heidelberg, Germany; STRATIFYER Molecular Pathology GmbH, Köln, Germany; National Center of Tumor Diseases (NCT), Heidelberg, Germany

41 HER2 Amplification Status in Breast Cancer: The Effect of Adjusting for “Polysony 17” (159)
I Gagne, KJ Craddock, AM Mulligan
University Health Network, University of Toronto, Toronto, ON, Canada

42 Dual-Color In Situ Hybridization (Dual ISH) for Evaluation of HER2/Neu (HER2) Amplification in Breast Cancer (108)
K Astvatsaturyan, S Bose
Cedars-Sinai Medical Center, Los Angeles, CA

43 Her2/Neu (HER2) Intratumoral Genetic Heterogeneity in Breast Cancer and Its Concurrent Axillary Metastases (107)
K Astvatsaturyan, S Bose
Cedars-Sinai Medical Center, Los Angeles, CA

44 Concordance of HER2 Gene Status between Dual-Color Silver In Situ Hybridization (DSISH) and Fluorescence In Situ Hybridization (FISH) in Invasive Breast Carcinomas (IBCs) after Preoperative Chemotherapy (203)
Y Kwon, HS Kang, ES Lee, IH Park, GY Lee, SY Park, J Ro
National Cancer Center, Goyang, Republic of Korea

45 HER2 Testing of Multifocal Invasive Breast Carcinoma: How Many Blocks Are Enough? (115)
GC Bethune, MC Chang
Mount Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada

46 Negative HER-2 by Immunohistochemistry Correlates Strongly with Negative HER-2 Amplification by Fluorescence In Situ Hybridization in Triple Negative Breast Cancers (307)
R Xian, P Raghunath, Z Paul
Hospital of the University of Pennsylvania, Philadelphia, PA

47 Comparison of HER2 Testing by IHC/FISH and RT-PCR in Estrogen Receptor (ER) Negative or Borderline Patients (pts) with Early Stage Breast Cancer (ESBC) (282)
B Singh, N Zigaridis, S Butler, F Jamshidian, D Cherjavavaz, A Sing
New York University School of Medicine, New York, NY; Genomic Health, Inc., Redwood City, CA

48 Hormone Receptor and HER2/Neu Immunohistochemistry in Multifocal/Multicentric Breast Carcinoma (135)
S Covey, DD Baker, SM O’Connor
UNC School of Medicine, Chapel Hill, NC; Duke University, Durham, NC

49 Pattern of Tumour Cell Migration as a Prognostic Parameter for Lymph Node Metastasis in HER2-Enriched Breast Cancer (266)
I Roxanis, J Russell, B Lavery
Oxford University Hospitals NHS Trust and Oxford Biomedical Research Centre, Oxford, United Kingdom; Oxford Medical Genetics Laboratories, Oxford, United Kingdom; Oxford, United Kingdom

50 Correlation of Src Activation with Trastuzumab Response in Patients with HER2-Positive Breast Carcinoma (160)
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; University General Hospital, Alicante, Spain

51 BTG2 Loss Is Associated with Poor Prognosis in HER2+ Breast Cancer (180)
MM Hefti, N Knoblauch, AH Beck
Beth Israel Deaconess Medical Center, Boston, MA

52 The Utility of Phosphohistone H3 (PHH3) in Breast Cancer Grading (136)
X Cui, GP Stiegal, S Wei
University of Alabama at Birmingham, Birmingham, AL
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Board Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>53</td>
<td>63</td>
</tr>
<tr>
<td>Ki 67 in Breast Cancer: How Many Tumor Cells Do We Need To Count? (154)</td>
<td>Novel Mutations in Neuroendocrine Carcinoma of the Breast: Possible Therapeutic Targets (112)</td>
</tr>
<tr>
<td>HF Faragalla, L Feeley, A Bane, AM Mulligan</td>
<td>M Ballard, D Ang, C Beadling, A Warrick, A Schilling, R O’Gara, M Pukay, R West, C Corless, M Troxell</td>
</tr>
<tr>
<td>University Health Network, Toronto, ON, Canada; Cork University Hospital, Cork, Ireland; Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada</td>
<td>Oregon Health &amp; Science University, Portland, OR; Stanford University, Stanford, CA</td>
</tr>
<tr>
<td>Ki67 in Breast Cancer: The Effect of Different Length of Fixation on Ki 67 Index (155)</td>
<td>CYTOPATHOLOGY</td>
</tr>
<tr>
<td>HF Faragalla, L Feeley, A Bane, AM Mulligan</td>
<td></td>
</tr>
<tr>
<td>University Health Network, University of Toronto, Toronto, ON, Canada; Cork University Hospital, Cork, Ireland; Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada</td>
<td></td>
</tr>
<tr>
<td>The Satisfactory Reproducibility of the Ki-67 Index in Breast Carcinoma, and Its Poor Correlation with the Recurrence Score (225)</td>
<td></td>
</tr>
<tr>
<td>V Manucha, X Zhang, RM Thomas</td>
<td></td>
</tr>
<tr>
<td>Temple University Hospital, Philadelphia, PA</td>
<td></td>
</tr>
<tr>
<td>Automated and Visual Assessment of Ki-67 IHC in Breast Carcinoma: Comparison of 3 Antibody Clones (228)</td>
<td></td>
</tr>
<tr>
<td>EC Minca, SA Elizabeth, T Koji, F Heather, TR Raymond</td>
<td></td>
</tr>
<tr>
<td>Cleveland Clinic Foundation, Cleveland, OH; Ventana Medical Systems, Tucson, AZ; National Cancer Center Research Institute and Hospital, Tokyo, Japan</td>
<td></td>
</tr>
<tr>
<td>Comparison of Automated and Manual Assessment of Ki-67 Proliferative Activity in Invasive Breast Carcinomas (IBCs) (202)</td>
<td></td>
</tr>
<tr>
<td>Y Kwon, J Ro, ES Lee, HS Kang, SW Kim, KJ Kim, GK Lee</td>
<td></td>
</tr>
<tr>
<td>National Cancer Center, Goyang, Republic of Korea</td>
<td></td>
</tr>
<tr>
<td>Correlation of Ki-67 between Biopsy and Resection Specimens: Does “Hot-Spot” Counting Matter? (199)</td>
<td></td>
</tr>
<tr>
<td>Z Kos, DH Gravel, RJ Susan</td>
<td></td>
</tr>
<tr>
<td>Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada</td>
<td></td>
</tr>
<tr>
<td>GATA3 Expression and Relationship between Clinicopathological Parameters in Invasive Breast Carcinomas (125)</td>
<td></td>
</tr>
<tr>
<td>A Cakir, O Ekinci, I Isik Gomul, B Cetin, M Benekli, O Uluoglu</td>
<td></td>
</tr>
<tr>
<td>Corlu State Hospital, Tekirdag, Turkey; Gazi University School of Medicine, Ankara, Turkey</td>
<td></td>
</tr>
<tr>
<td>Significance of GATA3 Expression in Outcomes of Breast Cancer Patients Who Received Systemic Chemotherapy and/or Hormonal Therapy and Clinicopathological Features of GATA3 Positive Tumors (286)</td>
<td></td>
</tr>
<tr>
<td>M Surowiecka, C Blair, D Knapp, L Varghese, E Gulbahce</td>
<td></td>
</tr>
<tr>
<td>University of Minnesota, Minneapolis, MN; University of Alabama at Birmingham, Birmingham, AL; VAMC, Minneapolis, MN; Fairview Southdale Hospital, Edina, MN</td>
<td></td>
</tr>
<tr>
<td>GATA-3 Is Helpful in Differentiating Primary Mammary Neuroendocrine Carcinomas from Metastatic Neuroendocrine Tumors (130)</td>
<td></td>
</tr>
<tr>
<td>S Chopra, S Kim, S Bose, R Mertens, D Dhall</td>
<td></td>
</tr>
<tr>
<td>Cedars-Sinai Medical Center, Los Angeles, CA</td>
<td></td>
</tr>
<tr>
<td>Expression of Enhancer of Zeste Homolog 2 (EZH2) in Invasive Neuroendocrine Carcinoma of the Breast (174)</td>
<td></td>
</tr>
<tr>
<td>Y Gong, J Chen, J Wang, L Radvanyi, DG Rosen, Y Wu</td>
<td></td>
</tr>
<tr>
<td>University of Texas MD Anderson Cancer Center, Houston, TX</td>
<td></td>
</tr>
<tr>
<td>Massive Parallel Sequencing To Assess the Mutational Landscape of Fine Needle Aspirate Samples: A Pilot Study (354)</td>
<td></td>
</tr>
<tr>
<td>JL Costa, R Gerhard, ED Rossi, L Ciri, A Justino, JC Machado, F Schmitt</td>
<td></td>
</tr>
<tr>
<td>IPATIMUP – Instituto of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal; Catholic University of Sacred Heart, Rome, Italy; Medical Faculty of the University of Porto, Porto, Portugal</td>
<td></td>
</tr>
<tr>
<td>Fine Needle Aspiration Biopsy of Hodgkin Lymphoma: The UCSF Experience (347)</td>
<td></td>
</tr>
<tr>
<td>NT Can, A van Zante</td>
<td></td>
</tr>
<tr>
<td>University of Chicago, Chicago, IL; University of California, San Francisco, CA</td>
<td></td>
</tr>
<tr>
<td>Detection of KRAS and BRAF Hotspot Mutations on Cytology Smears in Metastatic Colorectal Carcinomas Using Pyrosequencing (397)</td>
<td></td>
</tr>
<tr>
<td>L Ma, L Ogden, J Dong, V Schnadig, M Eltorky, F Xu, G Huang, R Navigiri</td>
<td></td>
</tr>
<tr>
<td>University of Texas Medical Branch, Galveston, TX</td>
<td></td>
</tr>
<tr>
<td>Utilization of Cell-Transferred Cytologic Smears in Detection of EGFR and KRAS Mutations on Non-Small Cell Carcinoma of Lung and Comparison to Formalin-Fixed Tissue (360)</td>
<td></td>
</tr>
<tr>
<td>J Eaton, K Jones, L Cheng, M Randolph, H Cramer, H Wu</td>
<td></td>
</tr>
<tr>
<td>Indiana University, Indianapolis, IN</td>
<td></td>
</tr>
<tr>
<td>Correlation of Tumor Cell Percentage and Absolute Cell Count with EGFR and KRAS Analyses Using Cytological Specimens. A Retrospective Study of 118 Cases (371)</td>
<td></td>
</tr>
<tr>
<td>TJ Gniadek, D Munfas-McCray, P Illei, M-T Lin, M Thiess, E Gabrielson, F Askin, QK Li</td>
<td></td>
</tr>
<tr>
<td>Johns Hopkins University School of Medicine, Baltimore, MD</td>
<td></td>
</tr>
<tr>
<td>EGFR and KRas Mutation Analysis in Lung Adenocarcinoma: Adequacy of Cytology Samples (375)</td>
<td></td>
</tr>
<tr>
<td>JJ Heymann, J Saab, J Zachariah, RS Hoda</td>
<td></td>
</tr>
<tr>
<td>Weil Cornell Medical College, New York, NY</td>
<td></td>
</tr>
<tr>
<td>Comparing Automated with Manual HPV ISH, and P16 Immunohistochemistry in Assessing Metastatic Oropharyngeal Carcinoma (OPC) (361)</td>
<td></td>
</tr>
<tr>
<td>N Fatima, C Cohen, MT Siddiqui</td>
<td></td>
</tr>
<tr>
<td>Emory University Hospital, Atlanta, GA</td>
<td></td>
</tr>
<tr>
<td>The Sequential Application of Immunocytochemistry, BRAF-1 and N-RAS Mutation Analysis Identifies Malignant Follicular Thyroid Neoplasms on Liquid-Based Cytology (416)</td>
<td></td>
</tr>
<tr>
<td>ED Rossi, M Martini, P Straccia, S Capodimonti, CP Lombardi, A Pontecorvi, VG Vellone, GF Zannoni, LM Larocca, G Fadda</td>
<td></td>
</tr>
<tr>
<td>Catholic University, Rome, Italy</td>
<td></td>
</tr>
</tbody>
</table>
189

Board Number 72
MYB Translocation t(6;9) in Adenoid Cystic Carcinoma
Fine Needle Aspiration Biopsy Using Fluorescence In-Situ Hybridization (379)
JB Hudson, DH Robirds, BT Collins
Washington University in St Louis, Saint Louis, MO

Board Number 73
Role of Molecular Analysis on Classification of Pancreatic Cystic Lesions (PCLs) without Definitive Cytological Diagnoses (419)
Q Si, P Rodriguez-Urrego, AH Szporn, M Wu
Mount Sinai School of Medicine, New York, NY

Board Number 74
Aberrantly Elevated Galectin-3 and Carbohydrate Antigen Tn Expression in Fine Needle Aspiration Specimens of Pancreatic Ductal Adenocarcinoma but Not Neuroendocrine Tumors (420)
MT Siddiqui, K Jiang, SR Stowell, RD Cummings, C Cohen
Emory University School of Medicine, Atlanta, GA

Board Number 75
Utility of Islet-1, CD99, PAX8 and β-Catenin in Fine Needle Aspiration Workup of Non-Ductal Pancreatic Neoplasms (433)
C Velosa, J Nunez, JF Silverman
Allegheny General Hospital, Pittsburgh, PA

Board Number 76
Assessment of Diagnostic Yield of Traditional 22G FNA and Core Biopsy with the New 22G Echotip Procure Needle in Sampling of Solid Pancreatic Masses (384)
SK Jeffus, DS Strand, VM Shami, AY Wang, BG Sauer, EB Stelow
University of Virginia, Charlottesville, VA

Board Number 77
Diagnostic Error Assessment of EUS-FNA of Neuroendocrine Neoplasms of the Pancreas (377)
KK Hooper, S Li, F Mukhtar, J-E Eltoum
University of Alabama at Birmingham, Birmingham, AL

Board Number 78
Fine Needle Aspiration Diagnosis of Mucinous Cystic Neoplasms and Intraductal Papillary Mucinous Neoplasms of the Pancreas: Cytomorphology, CEA Level and K-ras Mutation Status (352)
X Chen, B Ustun, J Bernstein, H Ahsanian, D Chhieng, G Cai
Yale School of Medicine, New Haven, CT

Board Number 79
Metastatic Tumors to the Pancreas Diagnosed by Fine Needle Aspiration: A Multi-Institutional Analysis of 38 Cases (410)
MD Reid, HC Sullivan, E Henderson-Jackson, BA Centeno
Emory University School of Medicine, Atlanta, GA; H. Lee Moffitt Cancer Center, Tampa, FL

Board Number 80
Intraductal Tubulopapillary Neoplasm (ITPN) of Pancreas: Is Molecular Analysis of Cyst Fluid a Useful Adjunct in Distinguishing This Newly Recognized Tumor from Intraductal Papillary Mucinous Neoplasm (IPMN)? (373)
H Guo, S Nguyen, P delBrito, N Haddad, M Sidawy
Georgetown University Hospital, Washington, DC

Board Number 81
Endoscopic Ultrasound-Guided Fine-Needle Aspiration of the Pancreas: A Retrospective Study of 1,000 Cases (381)
AA Ibrahim, HM Cramer, IH Wu
Indiana University, Indianapolis, IN

Board Number 82
Dedifferentiated Liposarcoma and Pleomorphic Liposarcoma: A Comparative Study on FNA Cytomorphology and MDM2/CDK4 Expression (398)
A Marino-Enriquez, JL Hornick, ES Cibas, X Qian
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Board Number 83
Thymic Neoplasms: A Study of 59 Cases Diagnosed by Fine Needle Aspiration of the Anterior Mediastinum (409)
M Redelman, S Chen, H Cramer, R Emerson, X Wang
Indiana University School of Medicine, Indianapolis, IN

Board Number 84
An Institutional Quality Assurance Study To Identify Factors Influencing Rates of Thyroid Bethesda System Categories among Cytopathologists (442)
SE Wobker, LM Henderson, JS Cayless, SJ Maygarden
University of North Carolina Hospitals, Chapel Hill, NC

Board Number 85
Impact of Second Review of Thyroid FNA on the Implementation of Bethesda Classification: An Analysis of Cases on a Consult Service (365)
L Fu, D Chhieng, C Theoharis, K Schosfeld, AJ Adeniran
Yale School of Medicine, New Haven, CT

Board Number 86
Atypia in Follicular Neoplasm: Making a Case for Follicular Variant of Papillary Thyroid Carcinoma (431)
B Ustun, C Theoharis, D Chhieng, AJ Adeniran
Yale School of Medicine, New Haven, CT

Board Number 87
Use of HBME-1, p27 and Galectin-3 Triple Immunostaining in Cytology and Histology Specimens To Help Clarify Follicular Lesions of Undetermined Significance (FLUS) (448)
L Zhang, T Krausz, W Reeves, G Khan, RM DeMay
University of Chicago, Chicago, IL

Board Number 88
Cytopathologic and Molecular Diagnostic Clues to Poorly Differentiated Thyroid Carcinoma: A 10-Year Single Institution Experience (366)
L Fu, X Chen, B Ustun, JA Sosa, S Roman, E Holt, M Prasad, A Adeniran, D Chhieng, R Virk, C Theoharis
Yale-New Haven Hospital, New Haven, CT

Board Number 89
"Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance” in Bethesda System for Reporting Thyroid Cytology: Prediction of Malignant Risk in Subcategories with BRAF Mutation Results (380)
J Hyeon, S Ahn, YL Oh
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Board Number 90
Utility of Thyroglobulin Measurements in Fine Needle Aspiration Cytology of Lymph Nodes for the Detection of Metastatic Papillary Thyroid Carcinoma (395)
QKK Li, SL Nugent, J Straseski, D Cooper, S Riedel, FB Askin, L Sokoll
Johns Hopkins Medical Institutions, Baltimore, MD

Board Number 91
Histologic Correlation of Fine Needle Aspirations of 101 Hurthle Cell Lesions (445)
M Yee-Chang, R Pulinthanathu, A Simsir, W Sun
NYU Langone Medical Center, New York, NY
92 Atypia of Undetermined Significance in Thyroid Fine Needle Aspiration Biopsy Evaluated by Whole Slide Image Analysis with Risk Assessment of Malignancy (353)
   BT Collins, LE Collins
   Washington University in St Louis, St. Louis, MO

93 Fine-Needle Aspiration of Hurtle Cell Lesions: A 10-Year Retrospective Study of 147 Cases (400)
   SW McKee, HH Wu, X Wang, HM Cramer, S Chen
   Indiana University School of Medicine, Indianapolis, IN

94 Application of the Bethesda Thyroid System in the Pediatric Population (350)
   X Chen, H Honarpisheh, L Fu, C Theoharis, D Chhieng, D Kowalski
   Yale University, New Haven, CT

95 The Impact of Using the Bethesda System for Reporting Thyroid Cytology Diagnostic Criteria for the AUS/FLUS Category (391)
   B Lee, B Smola, X Jing
   University of Michigan Health System, Ann Arbor, MI

96 The Bethesda System for Reporting Thyroid Cytopathology: A Four-Year Single Academic Institution Experience (425)
   CGA Theoharis, DC Chhieng, D Kowalski, T Carling, R Udelsman, AJ Adeniran
   Yale University School of Medicine, New Haven, CT

97 Thyroid Bed Fine Needle Aspiration in Patients after Thyroidectomy – A Useful Follow-Up Tool with Proposed Diagnostic Categories (364)
   C Fox, M O’Neil, R Madan, OW Tawfik, P Thomas, F Fan
   University of Kansas Medical Center, Kansas City, KS

98 Atypia of Undetermined Significance (AUS) in Thyroid FNA. Malignancy Rate and Value of Substratification (438)
   H Wang, AS Ho, LGT Morris, O Lin
   Memorial Sloan-Kettering Cancer Center, New York, NY

99 Can Tall Cell Microcarcinoma Be Diagnosed on Fine Needle Aspiration Cytology? An Analysis of Clinicopathological Features, Preoperative Fine Needle Aspiration and Genetic Alteration (344)
   J Bernstein, ML Prasad, P Hui, C Theoharis, D Chhieng, AJ Adeniran
   Yale School of Medicine, New Haven, CT

100 Utility of Parathyroid Hormone Rinse Levels in Conjunction with Fine Needle Aspiration Cytology in the Evaluation of Indeterminate Parathyroid Neck Nodules (374)
    SL Hale, MW Riben, BC Handy, NP Caraway
    University of Texas MD Anderson Cancer Center, Houston, TX

101 Three Dimensional Cell Groups with Disordered Nuclei and Cellular Discohesion Are Associated with High Sensitivity and Specificity in the Cystoscopic Urine Diagnosis of Low Grade Urothelial Neoplasia (441)
    K Williams, P Williams, S Islam, C Marginean, H Sekhon, EC Belanger, KT Mai
    Ottawa Hospital and the University of Ottawa, Ottawa, ON, Canada

102 The Significance of Urothelial Cell Clusters in Voided Urine Specimens (392)
    BB Lee, X Jing, JC Pang, MH Roh
    University of Michigan Health System, Ann Arbor, MI

103 Urine Cytology in Pediatric Patients: A Clinicopathologic Correlation of 191 Cases (376)
    H Honarpisheh, D Chhieng, K Schofield, AJ Adeniran
    Yale School of Medicine, New Haven, CT

104 A Survey of Practice Patterns of Participants in the College of American Pathologists Interlaboratory Comparison Program in Nongynecologic Cytology (NGC) (403)
    AT Moriarty, R Nayar, M Auger; DFI Kurtzcy, N Thomas, R Laucirica, V Padmanaban, R Souers, MR Schwartz, M Fraig
    AmeriPath Indiana, Indianapolis, IN; Northwestern University Feinberg School of Medicine, Chicago, IL; McGill University Health Center, Montreal, Canada; University of Wisconsin, Wisconsin State Lab of Hygiene, Madison, WI; College of American Pathologists, Northfield, IL; Baylor College of Medicine, Houston, TX; Dartmouth-Hitchcock Medical Center, Lebanon, NH; Methodist Hospital, Houston, TX; University of Louisville, Louisville, KY

105 Liquid-Based Papanicolaou Tests in Endometrial Carcinoma Diagnosis (446)
    IZ Yildiz-Aktas, C Zhao
    UPMC, Pittsburgh, PA

106 DNA Qualitative and Quantitative Comparison of Alcohol Fixed Cytology Versus Formalin Fixed Tissue for PNA Clamp Real-Time PCR Detection of KRAS, EGFR and BRAF (413)
    F Rosenblum, K Tomaszewicz, M St. Cyr, A Fischer, EF Cosar, EM Kurian, L Hutchinson
    University of Massachusetts Medical Healthcare System, Worcester, MA

GASTROINTESTINAL

107 Epithelial-Mesenchymal Transition Phenotype Is Associated with Patient Survival in Small Intestinal Adenocarcinoma (740)
    HC Shin, A Kim, YK Bae, MJ Gu, ES Jung, Y-H Oh, H-I Bae, HJ Lee, S-M Hong
    Yeungnam University College of Medicine, Daegu, Republic of Korea; Catholic University of Korea College of Medicine, Seoul, Republic of Korea; Hanyang University College of Medicine, Seoul, Republic of Korea; Konyungpook National University School of Medicine, Daegu, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

108 Intralymphatic Tumor in Duodenal Biopsies: Clinicopathologic Features (741)
    S Shroff, MW Taggart, SC Abraham, A Rashid
    MD Anderson Cancer Center, Houston, TX

109 Clinicopathologic Features of Ampullary Adenocarcinoma of Indeterminate Histologic Type (Non-Intestinal, Non-Biliary) (764)
    L Vila Duckworth, A Alkhasavneh, N Desai, X Lu, A Sommerfeld, T George, T Zuluaga Toro
    University of Florida, Gainesville, FL
110 Immunohistochemical Study of Ampullary and Small Bowel Adenocarcinomas (633)
R Guo, A Rashid, M Overman, H Wang, J Abbruzzese, H Wang
UT MD Anderson Cancer Center, Houston, TX

111 Loss of SMAD4 Expression Is a Poor Prognostic Factor in Ampullary Adenocarcinoma (597)
A Alkhasawneh, L Vila Duckworth, N Desai, X Lu, A Sommerfeld, T George, T Zuluaga Toro
University of Florida, Gainesville, FL

112 The Pattern of CDX2 Expression in Ampullary Adenocarcinomas Predicts Biliary Versus Intestinal Phenotype: Prognostic Implications (765)
L Vila Duckworth, A Alkhasawneh, N Desai, A Sommerfeld, X Lu, T George, T Zuluaga Toro
University of Florida, Gainesville, FL

113 Duodenal Carcinomas of Non-Ampullary Origin Are Significantly More Aggressive Than Ampullary Carcinomas (728)
B Saka, P Bagci, A Krassinuskas, O Basturk, T Tajiri, N Ohike, GE Kim, S Balci, K-T Jang, S Bandypadhyay, D Kooby, SK Matthel, J Sarmiento, C Staley, D Ozdemir, SY Kong, AB Farris, V Adsay
Emory University, Atlanta, GA; UPMC, Pittsburgh, PA; Memorial Sloan-Kettering Cancer Center, New York, NY; TUHH, Tokyo, Japan; SU, Tokyo, Japan; UCSF, San Francisco, CA; SMC, Seoul, Korea; Wayne State University, Detroit, MI

114 Well Differentiated Neuroendocrine Tumors of the Duodenum: A Clinicopathologic Profile and Somatostatin Receptor 2 Expression (628)
MA Gilger, L Cassani, E Lindsey, F Revetta, E Liu, C Shi
Vanderbilt University School of Medicine, Nashville, TN

115 Loss of Cables Expression in Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Pancreas, and Lung (600)
T Arnaud, MS Pino, DC Chung, HL Sapp, D Rayson, V Deshpande, LR Zakerberg
Massachusetts General Hospital, Boston, MA; Queen Elizabeth II HSC, Halifax, NS, Canada

116 Methylguanine Methyltransferase (MGMT) Expression in Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas (755)
A Treece, L Council, J Posey III, S Harada
University of Alabama, Birmingham, AL

117 SATB2 Is a Highly Sensitive Marker for Hindgut Well-Differentiated Neuroendocrine Tumors (682)
Z Li, L Zhou, K Mei, L Jia, Q Kang, M Zhang, D Cao
Peking University Cancer Hospital, Beijing, China; Guangzhou Medical College, Guangzhou, China

118 Vascular Ectasia/Congestion as an Early Manifestation of Gastrointestinal Histopathology in Behcet’s Disease: A Study of 184 Biopsies from 24 Patients (595)
M Alimchandani, P Bagi, T Heller, CH Sibley, MM Quezado
National Institutes of Health, Bethesda, MD

119 Calretinin Immunohistochemistry Versus Acetylcholinesterase Histochemistry in Rectal Biopsies for the Diagnosis of Hirschsprung’s Disease (723)
M Rodrigues, PL Lourencao, SA Terra, EV Ortolani, BK Takegawa
Botucatu Medical School, University of São Paulo State, Unesp, Botucatu, Sao Paulo, Brazil

120 Where the Living Meets the Dead: Rinds of Bizarre Stromal Cells with Atypical Mitoses in Pseudosarcomatous Gastrointestinal (GI) Tract Lesions (693)
OG McDonald, EA Montgomery
Johns Hopkins Medical Institutions, Baltimore, MD

121 sLe4 on CD44v6 Is a Potential Biomarker of Severity in Inflammation-Associated Mucosal Disease (620)
MA Delgado, JC Brazil, NA Louis, CA Parkos, AB Farris
Emory University, Atlanta, GA

122 Digging Deeper into Problematic Polyps: Incidence of Diagnostic Change in Colorectal Polyp Specimens after Deeper Sectioning at Two Different Laboratories (697)
JA Nielsen, DJ Lager, M Lewin, J Weber, CA Roberts
ProPath, Dallas, TX; Texas Digestive Disease Consultants, Southlake, TX

123 Long Term Outcome Study of Patients with Both Inflammatory Bowel Disease and Microscopic Colitis during the Course of Illness (734)
S Schulte, T Khor, C Hagen, R Najarian, G Lauwers, R Odze, A Srivastava
Brigham and Women’s Hospital, Boston, MA; Massachusetts General Hospital, Boston, MA; Dartmouth-Hitchcock Medical Center, Dover, NH; Beth Israel Deaconess Medical Center, Boston, MA

124 Plexitis at Primary Ileoacaeal Resection Margins as Predictive Factor for Subsequent Recurrence in Crohn’s Disease (768)
LM Wang, CE Koh, A Szuts, S Olsonso-Goncalves, A Tzivinakis, H Misteli, R Guy, B George, NJ Mortensen
John Radcliffe Hospital Oxford University Hospital, Oxford, United Kingdom; Royal Prince Alfred Hospital, Sydney, Australia

125 Renvela Crystals in the Gastrointestinal (GI) Tract: A New Entity (602)
CA Arnold, BN Limkettai, T-C Liu, E Montgomery, K Nazar, MS Torbenson, MM Yearsley, D Lam-Himlin
Ohio State University, Columbus, OH; JHMI, Baltimore, MD; Washington University, St. Louis, MO; Mayo Clinic, Scottsdale, AZ

126 Abnormal Cyclin D1 and Chromosome 11 Centromere Detected by FISH in Non-Dysplastic Surveillance Biopsies Predicts Pouch Neoplasia (656)
W Jiang, M Bronner, B Shadrach, X Wu, B Shen, X Liu
Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA; University of Utah, Salt Lake City, UT; Cleveland Clinic, Cleveland, OH

127 Molecular, Histologic and Clinical Features of Persistent Intestinal Spirochetosis (752)
K Threlkeld, T Trainer, C Adamson, M Evans, R Wilcox
University of Vermont, Burlington, VT
Clinicopathological Characterization of 437 Hyperplastic and Sessile Serrated Polyps (611)
Z Chen, EA Krauss, L Zhang
Merck & Co., Rahway, NJ; University Medical Center of Princeton, Plainsboro, NJ; Robert Wood Johnson Medical School, New Brunswick, NJ

Molecular and Immunohistochemical Features of Mixed Conventional Adenomatous-Serrated Colonic Polyps (718)
GF Reis, S Kakar, JP Grenert
UCSF, San Francisco, CA

Morphologic and Immunohistochemical Characteristics of Colonic Serrated Polyps with Dysplasia (763)
K Viani, K Kim, A Srivastava, R Odze
Brigham and Women’s Hospital, Boston, MA; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Morphologic Reappraisal of Traditional Serrated Adenoma in 43 Cases (634)
S Hafezi-Bakhtiari, KP Batt, D Snover, E Torlakovic
University Health Network, University of Toronto, Toronto, ON, Canada; Hospital Pathology Associates, Minneapolis, MN; Fairview Southdale Hospital, Edina, MN

Gene Expression Profiling of Serrated Colorectal Polyps: Identification of Genes That Differentiate Hyperplastic Polyps (HPs) from Sessile Serrated Polyps (SSPs) (641)
Cleveland Clinic, Cleveland, OH

Sessile Serrated Adenoma (SSA) and Borderline Sessile Serrated Adenoma (BSSA) Differ from Hyperplastic Polyps (HP) and Normal Colorectal Mucosa by the Status of Endocrine Cells (695)
M Mohammadi, A Aziz, M Bzorek, S Holck
Hvidovre University Hospital, Hvidovre, Denmark; Hospital South, Naestved, Denmark

Dysplasia in Colonic Polyps: Discrimination through Digital Image Analysis (689)
DR Martin, AB Farris III
Emory University School of Medicine, Atlanta, GA

Adenoma Size and High Calcium Intake Are Independent Predictors of Cyclin D1 Overexpression: An Analysis of 339 Polyps (636)
CE Hagen, AS Andrew, Z Li, MA Greene, ME Goodrich, LF Butterly, JA Baron, AJ Dietrich, A Srivastava
Dartmouth-Hitchcock Medical Center, Lebanon, NH; Brigham and Women’s Hospital, Boston, MA

Interobserver Variability in Assessing High-Grade Dysplasia and Architecture in Colorectal Adenomas: A Multi-Centre Canadian Study (703)
A Osmond, H Li Chang, R Kirsch, D Divaris, V Falck, DF Liu, C Marginean, K Newell, J Parfitt, B Rudrick, H Sapp, J Walsh, S Smith, F Wasty, D Driman
Western University, London, Canada; University of Toronto, Toronto, Canada; Grand River Hospital, Kitchener, Canada; University of Calgary, Calgary, Canada; Woodstock General Hospital, Woodstock, Canada; University of Ottawa, Ottawa, Canada; Grey Bruce Health Services, Owen Sound, Canada; Dalhousie University, Halifax, Canada; Huron Perh Health Alliance, Stratford, Canada; St. Thomas Elgin General Hospital, St. Thomas, Canada

Inflammatory Bowel Disease (IBD)-Associated and Sporadic Colorectal Adenocarcinoma Is Immunophenotypically Different (776)
H Xie, W Jiang, B Shadrach, P Carver, X Liu
Cleveland Clinic, Cleveland, OH; Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA

Diagnostic Utility of p53 and Cytokeratin 7 Immunohistochemistry in Idiopathic Inflammatory Bowel Disease-Associated Neoplasia (775)
H Xie, S-Y Xiao, R Pai, K Lai, Y Wang, B Shen, X Liu
Cleveland Clinic, Cleveland, OH; University of Chicago, Chicago, IL

Staining Patterns of Anti-Apoptotic Protein Beclin-1 in Inflammatory Bowel Disease Associated Dysplasia and Carcinoma (644)
PJ Holmes, AV Gandhi, JP Palazzo
Thomas Jefferson University Hospital, Philadelphia, PA

Residual Tumor Burden in Rectal Cancer: A New Method of Assessing Pathologic Response to Neoadjuvant Therapy (590)
A Agarwal, G Chang, Y-C Hu, M Taggart, A Rashid, S Kopez, D Maru
Baylor College of Medicine, Houston, TX; University of Texas MD Anderson Cancer Center, Houston, TX

Discovery of New Histological Prognostic Factors in Rectal Adenocarcinocarcinoma Treated by Radiochemotherapy Followed by Total Mesorectum Excision (731)
A Sanner, J LeFevre, F Bretagniol, D Caazals-Hatem, Y Panis, P Bedossa, N Gueydi
Beaupre Hospital, Clichy, France, Metropolitan

Strong IMP3 Expression Is Associated with Reduced E-Cadherin Level and Decreased Survival in Rectal Adenocarcinoma Patients after Neoadjuvant Therapy (778)
X Yang, EF Cosar, L Hutchinson, Z Jiang, K Dresser, H Lee
UMass Memorial Medical Center, Worcester, MA; Albany Medical College, Albany, NY

The “Almost Normal” Liver Biopsy: A Differential for a Problematic Area of Liver Pathology (1716)
LD Wood, MS Torbenson
Johns Hopkins University, Baltimore, MD
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>144</td>
<td>Does Size Matter? – Assessing the Adequacy of Core Biopsies for Medical Liver Diseases</td>
<td>E Fryer, LM Wang, C Verrill, K Fleming</td>
<td>John Radcliffe Hospital, Oxford, United Kingdom</td>
</tr>
<tr>
<td>145</td>
<td>Association between Liver Biopsy Length and the Diagnosis of Non-Alcoholic Steatohepatitis</td>
<td>MR Peterson, CE Behling, NS Patel, AN Mackey, CS Hansen, R Loomba</td>
<td>UC San Diego Health System, San Diego, CA; Sharp Memorial Hospital, San Diego, CA</td>
</tr>
<tr>
<td>146</td>
<td>Idiopathic Post-Transplantation Hepatitis: Clinicopathologic Features</td>
<td>N Kramer, T-T Wu, CB Rosen, T Mounajjed</td>
<td>Auckland Hospital, Auckland, New Zealand; Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>147</td>
<td>Detecting C4d in Liver Allografts: Immunohistochemistry and Immunofluorescence Show Equivalent Staining</td>
<td>A Scherl, S Jakab, G Moeckel, K Mitchell, D Jain, S Emre, M Robert</td>
<td>Yale University School of Medicine, New Haven, CT</td>
</tr>
<tr>
<td>148</td>
<td>Immuno-Labeled Treg, T-Cells and Their Ratios Predict the Immunosuppression Therapy Effectiveness in Liver Allograft Recipients</td>
<td>A Abdul-Nabi, J Levitsky, H Li, W Zhang, S Rao, G-Y Yang</td>
<td>Northwestern University, Chicago, IL</td>
</tr>
<tr>
<td>149</td>
<td>The Pre-Senescence Features of Chronic Liver Allograft Rejection Can Be Recognized Prior to Full Development of Banff-Defined Criteria</td>
<td>S Hafezi-Bakhtiari, OA Adeyi</td>
<td>University Health Network, University of Toronto, Toronto, ON, Canada</td>
</tr>
<tr>
<td>150</td>
<td>Neonatal MSG Treatment in DIAR Mice Causes Macrovesicular Steatosis with Lobular Inflammation in the Liver</td>
<td>T Nishida, K Tsuneyama, K Nomoto, S Hayashi, S Miwa, T Nakajima, Y Nakamishi, Y Sasaki, S Nakamura, R Hokao, J Imura</td>
<td>University of Toyama, Toyama, Japan; Institute for Animal Reproduction, Kasumigaura, Ibaraki, Japan</td>
</tr>
<tr>
<td>151</td>
<td>Fatty Liver Contributes to Hepatocarcinogenesis in Cirrhotic Livers</td>
<td>J Alexander, M Torbenson, T-T Wu, MM Yeh</td>
<td>University of Washington, Seattle, WA; Johns Hopkins University, Baltimore, MD; Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>152</td>
<td>Infiltration of Inflammatory Cells Expressing Mitochondrial Proteins around Bile Ducts and Intraepithelial Layer May Be Involved in the Pathogenesis in Primary Biliary Cirrhosis</td>
<td>M Sasaki, Y Kakuda, M Kobayashi, M Miyakoshi, Y Sato, Y Nakamura</td>
<td>Kanazawa University Graduate School of Medicine, Kanazawa, Japan</td>
</tr>
<tr>
<td>153</td>
<td>Histopathologic Changes in Alcoholic Liver Disease Patients Treated with S-Adenosyl-L-Methionine: An In-Depth Look at Data from a Double-Blinded, Randomized, Placebo-Controlled Trial</td>
<td>MD Le, E Enbom, PK Traum, SW French, V Medici, CH Halsted</td>
<td>Harbor-UCLA Medical Center, Torrance, CA; University of California Davis, Sacramento, CA; University of California Davis, Davis, CA</td>
</tr>
<tr>
<td>154</td>
<td>IgG4 Reaction in Biliary Intraepithelial Neoplasia and Cholangiocarcinoma Arising from Sclerosing Cholangitis</td>
<td>K Harada, Y Sato, H Sato, H Ikeda, Y Nakamura</td>
<td>Kanazawa University Graduate School of Medicine, Kanazawa, Japan; Kanazawa University Hospital, Kanazawa, Japan</td>
</tr>
<tr>
<td>155</td>
<td>Energy Metabolic Change Induced by ERRa-PGC-1a Axis in Chronic Non-Suppurative Destructive Cholangitis of Primary Biliary Cirrhosis</td>
<td>K Harada, Y Sato, Y Kakuda, H Ikeda, Y Nakamura</td>
<td>Kanazawa University Graduate School of Medicine, Kanazawa, Japan; Kanazawa University Hospital, Kanazawa, Japan</td>
</tr>
<tr>
<td>156</td>
<td>Histological Features of Primary Biliary Cirrhosis Predict Biological Response to Therapy and Outcome</td>
<td>Y Kakuda, K Harada, Y Sato, M Sasaki, Y Nakamura</td>
<td>Kanazawa University Graduate School of Medicine, Kanazawa, Japan</td>
</tr>
<tr>
<td>157</td>
<td>Pathological Differences between IgG4-Related Sclerosing Cholangitis with and without Autoimmune Pancreatitis</td>
<td>K Harada, Y Nakamura</td>
<td>Kanazawa University Graduate School of Medicine, Kanazawa, Japan</td>
</tr>
<tr>
<td>158</td>
<td>Clinical Significance of Subacute Nonsuppurative Cholangitis: A Study of 25 Cases</td>
<td>L De La Cruz, BY Naini, HL Wang</td>
<td>University of California Los Angeles, Los Angeles, CA</td>
</tr>
<tr>
<td>159</td>
<td>IgM Positive Plasma Cells Can Distinguish Primary Biliary Cirrhosis from Autoimmune Hepatitis in Cirrhotic Livers</td>
<td>M Hsu, PE Swanson, M Yeh</td>
<td>University of Washington, Seattle, WA</td>
</tr>
</tbody>
</table>

**PANCREAS**

<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>160</td>
<td>A Comparison of the Morphology of Familial and Sporadic Pancreatic Cancers</td>
<td>AD Singhi, H Ishida, AP Klein, ZS Ali, Z Meriden, RH Hruban</td>
<td>Johns Hopkins University School of Medicine, Baltimore, MD</td>
</tr>
<tr>
<td>161</td>
<td>Molecular Comparison between Intraductal Tubulopapillary Neoplasms and Intraductal Tubular Adenomas of the Pancreas Indicates Their Distinctive Nature</td>
<td>H Yamaguchi, M Shinizu, Y Kuboki, T Furukawa</td>
<td>Saitama International Medical Center, Saitama Medical University, Hidaka, Japan; Tokyo Women’s Medical University, Tokyo, Japan</td>
</tr>
<tr>
<td>162</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Board Number</td>
<td>Title</td>
<td>Authors</td>
<td>Institution</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>162</td>
<td>MCT4 Expression in Pancreatic Cancer: Association with Prognosis, and Potential for Targeting Cancer Metabolism (1783)</td>
<td>J McFalls, ND Bubolz, E Knudsen, A Wikiewicz</td>
<td>Thomas Jefferson University Hospital, Philadelphia, PA; Jefferson Medical College, Philadelphia, PA; Thomas Jefferson University, Philadelphia, PA</td>
</tr>
<tr>
<td>163</td>
<td>Comparison of Chromosomal Abnormalities by Fluorescence In Situ Hybridization between Intraductal Papillary Mucinous Neoplasm and Pancreatic Ductal Adenocarcinoma (1785)</td>
<td>K Miyabe, H Inagaki, T Nakazawa, K Hayashi, J Naitoh, S Shimizu, H Kondo, M Yoshida, H Yamashita, S Unemura, Y Hori, H Ohara, T Joh</td>
<td>Nagoya City University, Nagoya, Japan</td>
</tr>
<tr>
<td>164</td>
<td>EGFR Expression in Pancreatic Adenocarcinoma: Relationship to Tumor Biology and Cell Adhesion Proteins (1769)</td>
<td>A Handra-Luca, P Hammel, P Ruszniewski, A Couvelard</td>
<td>APHP Hôpital Avicenne, Université Paris Nord Sorbonne, Cité, Bobigny, Ile de France, France; APHP Hôpital Bichat, Université Paris Nord Sorbonne, Cité, Paris, Ile de France, France; APHP Hôpital Beaujon, Université Paris Nord Sorbonne, Cité, Clichy, Ile de France, France</td>
</tr>
<tr>
<td>165</td>
<td>Cell Signaling Pathways from Pancreatic Intraepithelial Neoplasia (Pan-IN) to Invasive Adenocarcinoma (1789)</td>
<td>MT Salcedo, H Allende, T Macarulla, A Montero, V Peg, I Sansano, J Balsells, S Ramon y Cajal</td>
<td>Vall d’Hebron University Hospital, Barcelona, Spain</td>
</tr>
<tr>
<td>166</td>
<td>SPARC Expression in Pancreatic Adenocarcinoma: Development of a Robust, Predictive Immunohistochemical Assay and Scoring Method (1771)</td>
<td>PB Illei, E Conde, N Dominguez, C Plaza, P Redondo, A Suarez-Gauthier, C Heise, M Hidalgo, F Lopez-Rios</td>
<td>Johns Hopkins Medical Institutions, Baltimore, MD; Laboratorio de Dianas Terapéuticas, Madrid, Spain; Celgene Corporation, San Francisco, CA</td>
</tr>
<tr>
<td>167</td>
<td>MicroRNAs as Diagnostic Markers for Pancreatic Ductal Adenocarcinoma and Pancreatic Intraepithelial Neoplasm (1802)</td>
<td>Y Xu, AN Abou Tayoun, KM Abo, JM Pipas, SR Gordon, TB Gardner, RJ Barth, AA Surtawinata, GJ Tsongalis</td>
<td>Dartmouth-Hitchcock Medical Center, Lebanon, NH</td>
</tr>
<tr>
<td>168</td>
<td>Protein Expression of the SWI/SNF Chromatin Remodeling Subunits in Intraductal Papillary Mucinous Neoplasm (IPMN) and Pancreatic Ductal Adenocarcinoma (PDAC) (1796)</td>
<td>JF Solus, K Sahora, D Shvetz, C Fernandez-del-Castillo, MB Pitman, M Mino-Kenudson</td>
<td>Massachusetts General Hospital, Boston, MA</td>
</tr>
<tr>
<td>169</td>
<td>Differential Expression of Laminin β1 and β2 Isoforms in Pancreatic Adenocarcinoma (1784)</td>
<td>AB Mendez, SA Kim, M Guindi, M Kahn, S Chopra, AV Ljubimov, JY Ljubimova, D Dhall</td>
<td>Cedars-Sinai Medical Center, Los Angeles, CA</td>
</tr>
<tr>
<td>170</td>
<td>Activation of Src and STAT3 in Intraductal Papillary Mucinous Neoplasm of the Pancreas (IPMN) (1800)</td>
<td>JL Wang, D Shvetz, K Sahora, C Fernandez-del Castillo, M Pitman, M Mino-Kenudson</td>
<td>Massachusetts General Hospital and Harvard Medical School, Boston, MA</td>
</tr>
</tbody>
</table>

**GENITOURINARY**

<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution</th>
<th>City, State/Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>172</td>
<td>Weak Association of Prostatic Atrophy with High-Grade PIN and Low-Grade Cancer: Topographic Digital Study of 48 Whole-Mounted Prostatectomy Specimens (909)</td>
<td>KA Iczkowski, KC Torkko, RS Wilson, MS Lucia, DG Bostwick</td>
<td>University of Colorado Denver, Aurora, CO; Bostwick Laboratories, Inc., Glen Allen, VA</td>
<td></td>
</tr>
<tr>
<td>173</td>
<td>Stromal Epithelial Unit of the Prostate: A Potentially New Histological Finding in the Prostate with an Unknown Function (1051)</td>
<td>KJ Trautmann, JD Kronz</td>
<td>St. Alphonsus Medical Center-Nampa, Nampa, ID</td>
<td></td>
</tr>
<tr>
<td>174</td>
<td>The Association between Apoptosis and Androgen Receptor in Benign Prostatic Hyperplasia, Prostatic Intraepithelial Neoplasia and Prostate Carcinoma’ (818)</td>
<td>S Bircan, S Baspinar, KK Bozkurt, K Bozkurt, FN Kapucuoglu, A Kosar</td>
<td>Suleyman Demirel University School of Medicine, Isparta, Turkey</td>
<td></td>
</tr>
<tr>
<td>175</td>
<td>PTEN Losses by Fluorescence In Situ Hybridization (FISH) – but Not Immunohistochemistry – Correlate with Higher Gleason Grade: Prospective Study of 2261 Prostate Needle Biopsies in a Community Practice Setting (821)</td>
<td>DG Bostwick, H Singh, D Hossain</td>
<td>Bostwick Laboratories, Inc., Orlando, FL; Bostwick Laboratories, Inc., Glen Allen, VA</td>
<td></td>
</tr>
<tr>
<td>176</td>
<td>Prevalence of ERG Rearrangement, SPINK1 Overexpression and PTEN Deletion in Prostate Cancer of Korean Men (1085)</td>
<td>GS Yoon, K Park, T MacDonald, JY Choi, Z Chen, MA Rubin, JM Mosquera</td>
<td>Kyungpook National University, Daegu, Korea; Weill Medical College of Cornell University, New York, NY</td>
<td></td>
</tr>
<tr>
<td>177</td>
<td>Prostate Cancer Cells with TMPRSS2-ERG Gene Fusion or ERG Overexpression Are Not Selected in the Metastatic Process (871)</td>
<td>A Fleischmann, O Saramaki, T Visakorpi, I Zlovec, GN Thalmann</td>
<td>University of Bern, Bern, Switzerland; University of Tampere, Tampere, Finland</td>
<td></td>
</tr>
<tr>
<td>178</td>
<td>Added Value of ERG to PIN Cocktail for Evaluation of Atypical Small Acinar Proliferations (ASAP) of Prostate (1611)</td>
<td>EE Chang, DJ Luthringer, M de Peralta-Venturina, MB Amin</td>
<td>Cedars-Sinai Medical Center, Los Angeles, CA</td>
<td></td>
</tr>
</tbody>
</table>
179 Stromal Optic Anisotropy as a Prostate Prognosis Marker (1044)
S Sridharan, V Macias, K Tangella, A Kajdacy-Balla, G Popescu
University of Illinois at Urbana-Champaign, Urbana, IL; University of Illinois at Chicago, Chicago, IL; Christie Clinic, Urbana, IL

180 A Phase I Pilot Study of 99MTC-MIP-1404 Single Photon Emission Computed Tomography (SPECT)/CT Imaging in Men with Prostate Cancer Undergoing Radical Prostatectomy (884)
D Green, J Osborne, A Nikolopoulou, S Vallabhajosula, S Goldsmith, CS Friedman, S Goldenberg, BD Robinson, J Babich, D Scherr
Weill Cornell Medical College, New York, NY; Molecular Insight Pharmaceuticals, Inc., Cambridge, MA

181 Utility of Saturation Prostate Biopsy in Detection of Aggressive Prostate Cancer (1005)
LM Quintana, A Ward, E Genega, H Ye
Beth Israel Deaconess Medical Center, Boston, MA

182 Does Frozen Section Analysis of Surgical Margins during Laparoscopic Radical Prostatectomy Reduce the Risk of Biochemical Recurrence? (837)
B Choy, J Gordetsky, H Miyamoto
University of Rochester, Rochester, NY

183 The Value of the 2005 International Society of Urological Pathology (ISUP) Modified Gleason Grading System as Predictor of Biochemical Recurrence Following Radical Prostatectomy (816)
A Billis, L Meirelles, LLLL Freitas, LBE Costa, JFL Bonfitto, BL Ditiz, PH Poletto, LA Magna
School of Medicine, University of Campinas (Unicamp), Campinas, SP, Brazil

184 Differences in Prostate Cancer Grade, Stage, and Location in Radical Prostatectomy Specimens from United States and Japan (1047)
H Takahashi, JI Epstein, S Wakui, T Yamamoto, B Furusato, M Zhang
Jikei University School of Medicine, Tokyo, Japan; Johns Hopkins Hospital, Baltimore, MD

185 Long Term Follow-Up (F/U) in Patients with Initial PIN and Benign Prostate Biopsies (814)
Z Biljetina, J Zhang, A Yilmaz, K Trpkov
Calgary Laboratory Services and University of Calgary, Calgary, Canada

186 PARD3 Protein Overexpression Is Associated with Poor Survival of Patients with Clear-Cell Renal-Cell Carcinoma (856)
F Dugay, X LeGoff, F Chesnel, G Verhoest, F Jouan, C Henry, C Vigneau, N Riaux-Declercq, Y Arlot-Bonnemains, M-A Belaud-Rotureau
Faculty of Medicine, Rennes, France; CHU Pontchaillou, Rennes, France

187 BAP1 Loss Defines a Pathologically Aggressive Subgroup of Clear Cell Renal Cell Carcinoma (926)
P Kapur, A Christie, S Pena-Llopis, V Margulis, Y Lotan, X-J Xie, J Brugarolas
University of Texas Southwestern Medical Center, Dallas, TX

188 The Chromatin Remodeling Gene, ARID1A, Is a New Prognostic Marker in Clear Cell Renal Cell Carcinoma (1063)
SJ Wala, Z Lichner, A Scortilas, NMA White, AH Girgis, L Rotstein, KC Wiegand, A Latif, C Chow, D Huntsman, GM Yousef
Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Canada; University of Toronto, Toronto, Canada; University of Athens, Athens, Greece; British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada; Genetic Pathology Evaluation Centre, GPEC, Vancouver, Canada

189 Macrophage Inflammatory Protein-3α Is Downregulated in Clear Cell Renal Cell Carcinomas and Correlates with Stage and Grade (980)
E Munari, JS Poling, ND Gonzalez Roibon, SF Faraj, M Doucet, A Chaux, S Kominsky, KL Weher, GJ Netto
Johns Hopkins Hospital, Baltimore, MD; Universidad del Norte School of Medicine, Asuncion, Paraguay

190 Laminin β1 and β2 Expression in Vasculature of Clear Cell Renal Cell Carcinoma (825)
EE Chang, DJ Luthringer, M dePeralta-Venturina, N Babadorabad, AV Ljubimov, JJ Ljubimov, MB Amin, S Savola, L Barzon, G Masi, R Tardanico, JN Eble, M Chilosi, T Bohling, L Cheng, B Delahunt, S Gobbo, S Knuutila
University of Verona, Verona, Italy; Hartmann Institute and HUSLab, University of Helsinki, Helsinki, Finland; MRC-Holland, Amsterdam, Netherlands; University of Padua, Padua, Italy; Spedali Civili, Brescia, Italy; Indiana University School of Medicine, Indianapolis, IN; Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand

191 VHL Mutation, VHL Methylation, Chromosome 3p and Whole Genomic Status in Clear Cell Papillary Renal Cell Carcinoma (965)
University of Verona, Verona, Italy; Hartmann Institute and HUSLab, University of Helsinki, Helsinki, Finland; MRC-Holland, Amsterdam, Netherlands; University of Padua, Padua, Italy; Spedali Civili, Brescia, Italy; Indiana University School of Medicine, Indianapolis, IN; Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand

192 Frequency of Clear Cell Papillary Renal Cell Carcinoma in Cases of Low Grade Clear Cell Renal Cell Carcinoma: A 12 Year Retrospective Study from a Single Cancer Center (880)
S Gill, S Kandel, B Xu
State University of New York at Buffalo, Buffalo, NY; Roswell Park Cancer Institute, Buffalo, NY

193 Clear Cell Papillary Renal Cell Carcinoma (RCC) Is the 4th Most Common Histologic Type of RCC: A Study of 290 Consecutive Nephrectomies for RCC (1036)
S Shen, S Zheng, H Zhou, L Trioung, J Ro, A Ayala
Methodist Hospital, Houston, TX; Hainan Medical College, Haikou, Hainan, China

194 Clear Cell Tubulopapillary Renal Cell Carcinoma (CCTPRCC): A Further Distinction from Other Renal Epithelial Tumors (941)
B Krishnan, LD Trioung, SS Shen
Michael E. DeBakey VA Medical Center, Houston, TX; Baylor College of Medicine, Houston, TX; Methodist Hospital, Houston, TX
195 Histomorphological Features in Oncocytic Tumors That May Prevent Their Classification as Renal Oncocytoma (913)
S Jadallah, H Huang, Y-B Chen, A Gopalan, H Al-Ahmadie, S Fine, V Reuter, SK Tickoo
Memorial Sloan-Kettering Cancer Center, New York, NY

196 Comparison of p40 to p63 Expression in Micropapillary Urothelial Carcinoma (MPUC) and Conventional Urothelial Carcinoma (UC) (1094)
B Zhu, X Lin, SM Rohan, C Villa, E Gersbach, Y Wang, X Yang
Northwestern University, Chicago, IL

197 Overexpression of IGF1R Predicts Outcome in Invasive Urothelial Carcinoma of Urinary Bladder (883)
N Gonzalez-Roibon, J Kim, A Chaux, E Munari, SF Faraj, C Ellis, R Sharma, T Bivalacqua, M Schoemberg, GJ Netto
Johns Hopkins Hospital, Baltimore, MD; Norte University, Asuncion, Paraguay

198 Human Papillomavirus Is Not an Etiologic Agent of Urothelial Inverted Papillomas (792)
RE Alexander, A Lopez-Beltran, R Montironi, GT MacLennan, E Comperat, L Cheng
Indiana University School of Medicine, Indianapolis, IN; Cordoba University, Cordoba, Spain; Polytechnic University of the Marche Region, United Hospitals, Ancona, Italy; Case Western Reserve University, Cleveland, OH; Groupe Hospitalier Pitité-Salpêtrière, Paris, France

199 Long-Term Clinical Outcome of Urothelial Papilloma – Which Patients Need Follow-Up? (790)
S Al-Bashir, C Wang, A Yilmaz, T Bismar, K Trpkov
Calgary Laboratory Services and University of Calgary, Calgary, AB, Canada

200 Human Mismatch Repair Protein Expression in Bladder Cancer (934)
F Khani, E Xylinas, B Volkmer, L Kuth, DS Scherr, MA Rubin, JM Mosquera, RE Hautmann, R Kuefer, SF Shariat, BD Robinson
Weill Cornell Medical College, New York, NY; University of Ulm, Ulm, Germany

201 Recurrence and Progression Rates in Non-Invasive Papillary Urothelial Neoplasms of the Bladder: A Study of Tumors with Mixed Low and High Grades (1020)
RT Samdani, SG Sharma, RM Cox, HJ Spencer, N Golden
University of Arkansas for Medical Sciences, Little Rock, AR

202 Expression of EMT Markers in Sarcomatoid Urothelial Carcinoma of the Bladder (1022)
JM Sanfrancesco, S Gupta, A Shoskes, G Liever, D Hansel
Cleveland Clinic Foundation, Cleveland, OH

203 Oncofetal Proteins IMP3, Glypican-3 and TPBG Expression in Urothelial Carcinoma of the Bladder (935)
F Khani, E Xylinas, E Cha, B Volkmer, L Kuth, DS Scherr, MA Rubin, JM Mosquera, RE Hautmann, R Kuefer, SF Shariat, BD Robinson
Weill Cornell Medical College, New York, NY; University of Ulm, Ulm, Germany

204 IMP3, a Prognostic Biomarker for Disease Progression in Superficial Urothelial Carcinoma (843)
KM Cornejo, Z Jiang, C Owens
University of Massachusetts Medical School, Worcester, MA

205 Tubular Adenoma of the Urinary Tract: A Newly Described Entity (921)
C-S Kao, JI Epstein
Indiana University School of Medicine, Indianapolis, IN; Johns Hopkins Hospital, Baltimore, MD

206 PAX2 Expression in Malignant Germ Cell Tumors of the Testes: What Is the Significance of This Finding? (948)
MJ Lee, AP Vogt, AO Osunkoya
Emory University School of Medicine, Atlanta, GA

207 Intratubular Granulomatous Reactions within Seminiferous Tubules: A Spectrum of Diseases (927)
S Karram, C-S Kao, A Osunkoya, TM Ulbright, JI Epstein
Johns Hopkins Hospital, Baltimore, MD; Indiana University School of Medicine, Indianapolis, IN; Emory University School of Medicine, Atlanta, GA

208 Clinicopathological Analysis of Choriocarcinoma as Pure and Predominant Component of Testicular Germ Cell Tumor (798)
I Alvarado-Cabrero, N Hernandez-Toriz, GP Paner
Mexican Oncology Hospital, IMSS, Mexico City, Mexico; University of Chicago, Chicago, IL

209 Novel Detection of Testicular Carcinoma In Situ in AgarCytos of Testicular Sperm Extraction Specimens Using OCT3/4 and PLAP (900)
M Hessel, KW D’Hauwers, AF Hulsbergen, BD Braat, L Ramos, CA Hulsbergen-van de Kaa
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

210 Expression of CD30, oct3/4 and SOX-2 in Embryonal Carcinoma (EC) Component of Multi-Relapsed or Chemotherapy (CT) Refractory Germ-Cell Tumor (GCT) (841)
M Colecchia, N Nicola, S Andrea, P Biagio
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy

211 Revisiting the Atypical or So-Called “Anaplastic” Seminoma with Emphasis on Diffuse Atypia (797)
I Alvarado-Cabrero, N Hernandez-Toriz, GP Paner
Mexican Oncology Hospital, IMSS, Mexico City, Mexico; University of Chicago, Chicago, IL

212 Strong Association of Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression and Histologic Grade in Penile Squamous Cell Carcinomas (827)
A Chaux, E Munari, SF Faraj, N Gonzalez-Roibon, R Sharma, AL Cubilla, GJ Netto
Johns Hopkins Hospital, Baltimore, MD; Norte University, Asuncion, Paraguay; Instituto de Patologia e Investigacion, Asuncion, Paraguay
250 Lack of Expression of TUBB3 Is a Feature of Both BCL2-Positive and BCL2-Negative Follicular Lymphoma (1542)
A Zamo, F Erdini, C Marco
University of Verona, Verona, Italy

251 Intrafollicular Neoplasia/In Situ Follicular Lymphoma in Association with Different Types of Lymphoid Neoplasm, Is There a Biological Link? (1445)
A Martinez-Lopez, S Montes-Moreno, F Mazorra, A Batlle, F Jimenez-Burgos, Y Castro, C Barrionuevo, J Cruz-Cigudosa, A Bas-Vernal, MA Piris
Hospital Universitario Marqués de Valdecilla, Santander, Spain; Hospital Santa Barbara, Puertollano, Spain; Hospital Universitario Gregorio Marañón, Madrid, Spain; Instituto de Enfermedades Neoplásicas, Lima, Peru; Spanish National Cancer Research Centre, Madrid, Spain; Hospital Universitario Virgen de Arrixaca, Murcia, Spain

252 EZH2 Codon 641 Mutations in Chinese Follicular Lymphoma Patients (1384)
S Guo, JK Chan, K Fu, B Meng, J Iqbal, T McKeathan, RW Wang, TC Greiner, WC Chan
Xi Jing Hospital, the Fourth Military Medical University, Xi’an, Shaan Xi, China; Queen Elizabeth Hospital, Hong Kong, China; University of Nebraska Medical Center, Omaha, NE; Qi Lu Hospital, Shan Dong Medical University, Jinan, Shan Dong Province, China

253 A20 (TNFAIP3) Inactivation Is a Rare Event in Follicular Lymphoma (1487)
S Prakash, J Yan, K Nie, S Mathew, S Gogineni, Y Liu, DM Knowles, A Orazi, W Tam
Weill Cornell Medical College, New York, NY

254 Morphologic and Phenotypic Analysis of Cytogenetic Subsets of Follicular Lymphoma (1391)
PR Hosking, D Hoehn, VM Marty, A Bachir, G Bhagat
Columbia University Medical Center, New York, NY

255 MND82 but Not MUM1 Is a Useful Marker for Nodal Marginal Zone Lymphoma To Differentiate from Follicular Lymphoma (1354)
CK Chen, Z Mo, S Alkan
Cedars-Sinai Medical Center, Los Angeles, CA

256 CD10-Positive, Low Grade B-Cell Lymphomas with Marginal Zone-Like Features (1385)
JL Guthrie, J Polski
University of South Alabama, Mobile, AL

257 Differential CpG Methylation Profile of the ID4, GADD45G and DAPK Genes in Marginal Zone Lymphomas and Diffuse Large B Cell Lymphomas (1496)
KA Rizzo, Z Zhao, J Zhang, M Nassiri
Indiana University School of Medicine, Indianapolis, IN; University of South Carolina School of Medicine, Professional Pathology Services, Columbia, SC

258 Atypical Lymphoplasmacytoid Proliferation in the Thyroid: Critical Appraisal of the Conventional Morphologic Criteria for Extranodal Marginal Zone Lymphoma (1517)
P Sojitra, G Venkataraman, SS Smith, MM Velankar
Loyola University Medical Center, Maywood, IL

259 Splenic Marginal Zone Lymphoma: Comprehensive Analysis of Gene Expression and miRNA Profiling (1461)
M Mollejo, A Arribas, C Gomez-Ahud, M Sanchez-Beato, N Martinez, L Dilio, F Casado, MA Cruz, P Algarra, MA Piris
Hospital Virgen de la Salud, Toledo, Spain; NIMGenetics, Madrid, Spain; Fundación Investigación Biomédica, Hospital Universitario, Puerta de Hierro-Majadahonda, Madrid, Spain; Hospital Universitario Marqués de Valdecilla, Santander, Spain

260 Lymphoplasmacytoid Lymphoma (LPL) Frequently Show Mutations of the MYD88 Gene and Activation of B-Cell Differentiation Proteins APRIL, Blimp1 and BLNK. (1465)
F Nagl, C Sell, T Schuster, M Piris, F Fend, M Kremer
Staedtisches Klinikum Muenchen, Muenchen, Germany; Technical University of Munich, Muenchen, Germany; University Hospital Marqués de Valdecilla, Santander, Spain; University of Tuebingen, Tuebingen, Germany

261 Atypical Translocations in Mantle Cell Lymphoma: A Cytogenetic Diagnostic Dilemma (1452)
JR Menke, D Jevremovic, RP Ketterling, WR Sokol
UCSF, San Francisco, CA; Mayo Clinic, Rochester, MN

262 Characterization of Chronic Lymphocytic Leukemia with Mantle-Like Phenotype (1495)
P Reddy, D Bhawdoss, H Drum, T Kocher, J Taylor, M Gama, Y Xu
Genoptix Medical Laboratory, Carlsbad, CA

263 The Immunophenotype of Prolymphocytoid Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Revisited (1493)
SK Rathke, JC Chang, AM Harrington, H Olteanu, SH Kroft
Medical College of Wisconsin, Milwaukee, WI

264 CD1c Expression in B Cell Lymphoproliferative Disorders (1442)
E Martin, HI Meyerson
University Hospitals Case Medical Center, Cleveland, OH

265 A Subset of Rosai-Dorfman Disease Cases Exhibit Increased IgG4 Positive Plasma Cells, Another Red Herring? (1453)
MP Menon, MO Evbuomwan, J Rosai, ES Jaffe, S Pittaluga
Laboratory of Pathology, National Cancer Institute/National Institutes of Health, Bethesda, MD; Centro Consulenze Anatomia Patologica Oncologica, Milano, Italy

266 Automated Dual Color Kappa/Lambda mRNA In Situ Hybridization for Detection of Monoclonality Using Routine Light Microscopy in B-Cell Non-Hodgkin Lymphoma (1448)
S McGinn, W Day, A Pedata, C Morrison, T Grogan, L Rimsza
Genoptix Medical Laboratory, Carlsbad, CA

267 A Detailed Clinicopathologic Review of Castleman Disease Demonstrates That Atypical/Dysplastic Follicular Dendritic Cells Positive for SOX11, S-100, CXCL13, or D2-40 Are a Frequent Finding in Hyaline Vascular and Plasma Cell Variants (1478)
RS Ohgami, M Alcasid, RA Warnke, DA Arber
Stanford, Stanford, CA
200 Board Number

268 Follicular Dendritic Cell Sarcoma: An Underrecognized Disease Entity with Highly Heterogeneous Clinical, Pathologic, and Histogenetic Characteristics (1337)
OL Bohn, J Maragulia, O Lin, AD Zelenetz, J Teruya-Feldstein, ME Arcila
Memorial Sloan-Kettering Cancer Center, New York, NY

269 The Genetics of Interdigitating Dendritic Cell Tumors Shares Some Changes with Langerhans Cell Histiocytosis in Select Cases (1476)
DP O'Malley, L Zuckerberg, L Smith, TS Barry, S Guan, W Tam, A Orazzi, YS Kim, L Weiss
Clariant Inc./GE Healthcare, Aliso Viejo, CA; Massachusetts General Hospital, Boston, MA; University of Michigan, Ann Arbor, MI; Spectrum Pathology, Mission Viejo, CA; PathCentral, Irvine, CA; Weill-Cornell Medical Center, New York, NY; City of Hope National Medical Center, Duarte, CA

270 CD30 Expression in Non-Hodgkin B-Cell Lymphoma (1389)
M Hintzke, T Fenske, SH Kroft, H Olteanu, AM Harrington
Medical College of Wisconsin, Milwaukee, WI

271 Expression of the Anti-Oxidative Protein Paraoxonase 2 (PON2) in Malignant Lymphoma (1523)
AM Udager, D Rolland, F Keyoumarsi, DG Thomas, KSJ Elenitoba-Johnson, MS Lim, NG Bailey
University of Michigan, Ann Arbor, MI

272 Peripheral T-Cell Lymphomas of Follicular T-Helper (T<sub>FH</sub>) Cell Derivation with Hodgkin/Reed Sternberg Cells of B-Cell Lineage: Both EBV-Positive and EBV-Negative Variants Exist (1474)
A Nicolae, S Pittaluga, G Venkataraman, A Vijnovich-Baron, L Xi, M Raffeld, ES Jaffe
National Cancer Institute, Bethesda, MD; Loyola University Medical Center, Maywood, IL; Centro de Patología CEPACIT, Buenos Aires, Argentina

273 NK/T Cell Lymphomas: A Report of 72 Cases from India (1511)
T Shet, P Saryawanshi, M Sengar, H Menon, S Laskar
Tata Memorial Hospital, Mumbai, Maharashtra, India

274 Immunophenotypic Subsets of Peripheral T Cell Lymphomas (1449)
SM McGregor, MK Mirza, J Anastasi, JW Vardiman, E Hyjek, S Gerbxuani
University of Chicago Medicine, Chicago, IL

275 Flow-Cytometric Detection of Aberrant T-Cell Immunophenotype Accurately Predicts the Presence of Clonal TCR Gene Rearrangements (1482)
Paisoksantivatana, I Auer-Grzesiak, JM Luider, A Mansoor, M-T Shabani-Rad
University of Calgary, Calgary, AB, Canada

276 Crizotinib, a Novel Inhibitor of ALK, Induces Apoptosis and Down Regulation of pSTAT3 in ALK+ Anaplastic Large Cell Lymphoma (1502)
F Saei Hamedani, Z Mo, HM Amin, MA Cervania, S Alkan
Cedars-Sinai Medical Center, Los Angeles, CA; MD Anderson Cancer Center, Houston, TX

277 Immunophenotypic Analysis of T-Cell Large Granular Lymphocytic (T-LGL) Leukemia and Chronic Lymphoproliferative Disorder of NK Cells (CLPD-NK) (1490)
J Ragheb, L Peterson, Y-H Chen
Northwestern Memorial Hospital, Chicago, IL

278 Expression of Disialoganglioside GD2 in Neuroblastomas of Patients Treated with Immunotherapy (1869)
T Terzie, P Teira, S Cournoyer, M Peuchmaur, H Sartelet
Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada; Hopital Universitaire Robert-Debre, Paris, France

279 A Morphometric Study To Establish Subjective Index of Cerebellar Hypoplasia: A Special Emphasis on Cerebellar Hypoplasia in Trisomy 18 (1868)
Y Tanaka, M Tanaka, R Ijiri, K Kato, K Gomi, Y Itani, H Ishikawa, S Yamashita
Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan

280 Epithelioid Rhabdomyosarcomas: A Clinicopathologic and Molecular Study (1863)
R Alaggio, A Zin, A Rosolen, P Dall'Igna, G Bisogno, R Bertorelle
University of Padova, Padua, Italy; University Hospital Padova, Padua, Italy; Padua Hospital, University of Padua, Padua, Italy

281 Correlation of Prenatal Diagnosis and Pathology Findings Following Dilation and Evacuation for Fetal Anomalies (1865)
CA Boecking, EA Drey, WE Finkbeiner
UCSF, San Francisco, CA

282 Infections in a Children's Hospital Autopsy Population (1867)
J Springer, R Craver
Louisiana State University Health Science Center, New Orleans, LA

283 Honeycombing in Idiopathic Pulmonary Fibrosis: Pathology and Imaging Correlations (1957)
L Xu, S Kligerman, A Burke
University of Maryland Medical Center, Baltimore, MD

284 Focal Pulmonary Alveolar Proteinosis Is a Common Reaction and Progression Indicator in Idiopathic Pulmonary Fibrosis (1922)
S Nunomura, T Tanaka, K Otani, K Tabata, Y Konoh, K Kataoka, T Jokko, H Taniguchi, J Fukuoka
Toyama University Hospital, Toyama, Japan; Tosei General Hospital, Seto, Japan; Kinki Central Hospital, Itami, Japan

285 Acute Exacerbation of Non-Specific Interstitial Pneumonia Compared to That of Usual Interstitial Pneumonia (1915)
A Miyamoto, A Sharma, M Nishino, M Mino-Kenudson, EJ Mark
Toranomon Hospital, Tokyo, Japan; Massachusetts General Hospital, Boston, MA
286 Epithelial-Mesenchymal Transition (EMT) in Active Fibroblastic Foci in IPF/UIP (1911)
O Matsubara, K Miyai, Y Ishikawa, Y Nakatani, EJ Mark
National Defense Medical College, Tokorozawa, Saitama, Japan; Cancer Institute, Koto-ku, Tokyo, Japan; Chiba University, Chiba, Japan; Massachusetts General Hospital and Harvard Medical School, Boston, MA

287 Histopathologic Comparison of Biopsy with Subsequent Explant/Autopsy in Patients with Interstitial Lung Disease (1935)
AC Roden, RS Kuzo, DL Levin, T Moua, JH Ryu, ES Yi
Mayo Clinic, Rochester, MN

288 Down Regulation of Angiotensin II Receptor Type 1 (AGTR1) Contrast with Up Regulation of Type 2 (AGTR2) in Idiopathic Pulmonary Fibrosis (1924)
ER Parra, ADP Ruppert, MP Rangel, VL Capelozzi
University of São Paulo Medical School, São Paulo, Brazil

289 Elastic-Collagen Profile in Emphysematous Airspaces from Different Chronic Fibrosing Lung Disorders (1910)
LJ Marcal, L Antonangelo, ER Parra, FS Vargas, WR Teodoro, ECT Nascimento, VL Capelozzi
University of Sao Paulo Medical School, Sao Paulo, Brazil

290 Idiopathic Pleuropulmonary Fibroelastosis: Fact or Fancy? (1958)
X Yang, P Ahmadi Moghaddam, A Akalin, A Fraire
UMass Memorial Medical Center, Worcester, MA; Contribute Equally, UMASS Medical Center, Worcester, MA

291 Diffuse Alveolar Damage Is Not a Prominent Feature of Non-Lung-Transplant-Related Pleuroparenchymal Fibroelastosis (1946)
JJ Tanguay, E Ofek, S Keshavjee, TK Waddell, MM Gomes, DM Hwang
University Health Network, Toronto, ON, Canada; Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada

292 Multi-Institutional Review of Spontaneous Pneumothorax (SP) over an 11 Year Period (1873)
D Belchis, C Gocke, K Shekitha
Johns Hopkins University, Baltimore, MD; St. Agnes Hospital, Baltimore, MD

293 *EGFR* and *KRAS* Mutation Status in Patients with Non-Small Cell Lung Cancer and Additional Primary Colorectal or Gastric Cancer (1937)
MS Roh, PJ Choi, C Son
Dong-A University College of Medicine, Busan, Republic of Korea

294 Lung Carcinoma Masquerading as Desquamative Interstitial Pneumonia (DIP): Report of 7 Cases and Review of Literature (1931)
K Raparia, J Ketterer, ML Daturzo, Y-H Chang, TV Colby, KO Leslie
Northwestern University Feinberg School of Medicine, Chicago, IL; Italian Hospital of Buenos Aires, Buenos Aires, Argentina; Mayo Clinic, Scottsdale, AZ

295 Long Term Effects of EGFR Tyrosine Kinase Inhibitor Therapy on the Non-Neoplastic Lung (1939)
N Setia, PA Janne, LM Sholl
Brigham and Women's Hospital, Boston, MA; Dana Farber Cancer Institute, Boston, MA

296 Histologic Spectrum and Clinical Significance of Granulomatous Inflammation in Pulmonary Aspergillosis: A Study of 13 Cases with Comparison to Mycetomas and Invasive Aspergillosis (1871)
JF Back, S Mukhopadhyay
State University of New York Upstate Medical University, Syracuse, NY

297 Intraalveolar Fibrin Is Associated with Poor Outcomes in Cryptogenic Organizing Pneumonia (1921)
M Nishino, SK Mathai, WJ O'Donnell, RL Kradin
Massachusetts General Hospital, Boston, MA

298 The Pathology of Pulmonary Vein Radiofrequency Ablation (1901)
AE Kovach, GZ Cheng, CL Channick, R Channick, HA Gaisser, A Muniappan, RL Kradin
Massachusetts General Hospital (MGH), Boston, MA; MGH, Boston, MA

299 Biomarker Profile of Pulmonary Vasculature in Subjects with Portopulmonary Hypertension (1875)
N Boroumand, A Duarte, RT Meena, PJ Boor, AK Haque
University of Texas Medical Branch, Galveston, TX; Methodist Hospital, Houston, TX

300 Flow Cytometric Characterization of Peripheral Blood Fibrocytes in Lung Transplant Patients (1932)
AM Raza, Y Zu, PT Cagle, R Barrios, H Takei, Y Ge, A Ponce De Leon, A Ewton
Methodist Hospital, Houston, TX

301 Full-Field Optical Coherence Tomography (FFOCT): A Potential Alternative to Frozen Section Analysis (1892)
M Jain, N Narula, B Salamoon, N Altorki, S Mukherjee
Weill Medical College of Cornell University, New York, NY

302 Multiphoton Microscopy: A Potential “Optical Biopsy” Tool for Real-Time Evaluation of Lung Tumors without the Need for Exogenous Contrast Agents (1893)
M Jain, N Narula, A Aggarwal, N Altorki, S Mukherjee
Weill Medical College of Cornell University, New York, NY
### AUTOPSY

<table>
<thead>
<tr>
<th>Board Number</th>
<th>Poster Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>What Are We Missing? Repercussions of Declining Autopsy Rates (2)</td>
<td>MD Cain, CB Alexander, HM Hood, SD Reilly</td>
<td>University of Alabama at Birmingham, Birmingham, AL; Corizon, Brentwood, TN</td>
</tr>
<tr>
<td>2</td>
<td>Undiagnosed Fatal Malignant Tumor in Adult Autopsies: A 10 Year Retrospective Study (11)</td>
<td>S Parajuli, A Anesh, NJ Duker, MP Birkenbach, AL Mukherjee</td>
<td>Temple University Hospital, Philadelphia, PA</td>
</tr>
<tr>
<td>3</td>
<td>Intra-Uterine Fetal Demise: Autopsy and Clinical Findings amongst Different Age Groups in an Inner City Hospital (3)</td>
<td>M Deliu, MJ Mosunjac, MB Mosunjac</td>
<td>Emory University, Atlanta, GA</td>
</tr>
<tr>
<td>4</td>
<td>Postmortem Assessment of Polysplenia and Asplenia Syndromes: What Do Complex Congenital Anomalies Tell Us about Autopsy Quality? (13)</td>
<td>L Rooper, M Olson, K Flickinger, EC Burton</td>
<td>Johns Hopkins Hospital, Baltimore, MD</td>
</tr>
<tr>
<td>5</td>
<td>Causes of Death in Patients with Thrombotic Thrombocytopenic Purpura (TTP): A Single Institution 22-Year Autopsy Cohort (1)</td>
<td>AN Berg, MA Rollins-Raval, K Parker-Pitts, L Nichols, JS Raval</td>
<td>University of Pittsburgh Medical Center, Pittsburgh, PA</td>
</tr>
<tr>
<td>6</td>
<td>Causes of Death and Major Autopsy Findings in Liver Transplant Patients – A 35 Case Cohort Study (15)</td>
<td>B Shetuni, N Dimov, W Zhang, H Li, MS Rao, G-Y Yang</td>
<td>Northwestern University, Chicago, IL</td>
</tr>
<tr>
<td>7</td>
<td>Nonthrombotic Pulmonary Embolism: New Insights – A Large Autopsy Study (4)</td>
<td>MS Dettmer, N Willi, T Thiesler, P Ochsner, G Cathomas</td>
<td>Cantonal Hospital Liestal, Liestal, Switzerland</td>
</tr>
<tr>
<td>8</td>
<td>Hydrophilic Polymer Embolism: Incidence of a Recently Recognized Iatrogenic Disease in a Retrospective Autopsy- Based Study of 136 Patients (10)</td>
<td>RI Mehta, RI Mehta, JM Choi, RJ Castellani, AP Burke</td>
<td>University of Maryland Medical Center, Baltimore, MD; State University of New York Upstate Medical University, Syracuse, NY</td>
</tr>
<tr>
<td>9</td>
<td>Illicit Stimulant Abuse and Aortic Dissections in a Culturally Diverse Autopsy Population (9)</td>
<td>AP Martinez, M Aurelius, S Lathrop</td>
<td>University of New Mexico School of Medicine, Albuquerque, NM</td>
</tr>
<tr>
<td>10</td>
<td>Cardiovascular Pathology in Obstructive Sleep Apnea: A Retrospective Autopsy Study (17)</td>
<td>LM Warmke, MM Grimes</td>
<td>Virginia Commonwealth University Medical Center, Richmond, VA</td>
</tr>
<tr>
<td>11</td>
<td>Unique Autopsy and Biopsy Findings of Liver Small Cell Carcinoma – Early Identification of a Treatable Medical Emergency (8)</td>
<td>AA Lo, MS Siddiqui, H Li, W Zhang, MS Rao, Z-ME Chen, G-Y Yang</td>
<td>Northwestern University, Chicago, IL</td>
</tr>
<tr>
<td>12</td>
<td>A Rare Adult Autopsy Case of Von Gierke’s Disease with Significant Atherosclerosis (7)</td>
<td>K Konopka, L Kidd, G Krueger</td>
<td>University of Texas Health Science Center at Houston Medical School, Houston, TX; Methodist Hospital, Houston, TX</td>
</tr>
<tr>
<td>13</td>
<td>Sclerosing Papillary Hyperplasia without Myoepithelium: A Variant of Papillary Thyroid Carcinoma? (163)</td>
<td>RG Gamez, S Narendra, C Reynolds, DW Visscher</td>
<td>Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>14</td>
<td>Intracystic Papillary Carcinoma: A Closer Look into Its Relationship with In Situ and Invasive Carcinoma: Array Comparative Genomic Hybridization Study of 14 Cases (194)</td>
<td>T Khoury, Q Hu, S Liu, J Wang</td>
<td>Roswell Park Cancer Institute, Buffalo, NY</td>
</tr>
<tr>
<td>15</td>
<td>Significance of Myoepithelial Cell Layer around Ducts with Papillary Ductal Epithelial Neoplasia (DIN 1-3) (Papillary Ductal Carcinoma In-Situ, DCIS 1-3) (178)</td>
<td>M Harigopal, C Flynn, P Karan, M Orsaria, FA Tavassoli</td>
<td>Yale University School of Medicine, New Haven, CT</td>
</tr>
<tr>
<td>16</td>
<td>WT1 Immunohistochemistry as a Novel Marker for Breast Myoepithelial Cells (165)</td>
<td>M Ghofrani, O Saglam, E Tavassoli</td>
<td>PeaceHealth Laboratories, Vancouver, WA; Yale University, New Haven, CT</td>
</tr>
<tr>
<td>17</td>
<td>Immunohistochemical Profile of Breast Cancer with Respect to ER and HER2 Status (171)</td>
<td>NC Gloyeske, J Yu, E Elshaev, AH Woodard, DJ Dabbs, R Bhargava</td>
<td>Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA</td>
</tr>
<tr>
<td>18</td>
<td>Harmonization of Immunohistochemical Stains for Breast Cancer Biomarkers – An Athena Pathology Collaboration (110)</td>
<td>R Balassanian, JA Engelberg, JW Bishop, AD Borowsky, RD Cardiff, PM Carpenter, Y-T Chen, S Elson, F Hesteh, F Lin, NA Moatamed, B Perkovich, V Zhuang, SK Apple</td>
<td>University of California San Francisco, San Francisco, CA; University of California Davis, Davis, CA; University of California Irvine, Irvine, CA; University of California San Diego, San Diego, CA; University of California Los Angeles, Los Angeles, CA</td>
</tr>
</tbody>
</table>
Board Number | Title of the Presentation | Authors | Institution(s)
---|---|---|---
19 | Discordance in Estrogen Receptor, Progesterone Receptor and HER2 Status between Breast Primary Cancers and Respective Recurrences (124) | DA Budwit, SM O’Connor, CK Anders | University of North Carolina, Chapel Hill, NC
20 | Clinicopathologic Profile and Outcomes of Microinvasive Breast Cancer – An Analysis of 42 Cases (276) | LA Shatat, N Gloyeske, R Madan, O Tawfik, F Fan | University of Kansas, Kansas City, KS
21 | Endothelial Mesenchymal Transition Gene Signatures in Metastatic Early Stage Breast Cancer (315) | P Zhang, J He, R Zreik, A Rao | Scott and White Memorial Hospital, Temple, TX; Texas A&M University Health Science Center, Temple, TX
22 | Pathological Comparison of Breast Cancer Metastases with Primary Tumours in a Large Prospective Trial Testing Whole Genome Approach (205) | M Lacroix-Triki, I Treilleux, M-C Mathieu, D Loussouarn, G Mac Grogan, A Vincent-Salomon, F Penault-Llorca, T Filleron, T Dubois, T Bachelot, F Commo, M Campone, M Jimenez, F Andre | Institut Claudius Regaud, Toulouse, France; Centre L Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU, Nantes, France; Institut Bergonié, Bordeaux, France; Institut Curie, Paris, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre R Gauducheau, Saint Herblain, France; R&D UNICANCER, Paris, France
23 | Bcl-2 Downregulation Is Predictive of Complete Pathologic Response Following Neoadjuvant Chemotherapy in Breast Cancer (176) | S Goodman, T Stockl, S Lyle, D Kandil, K Edmiston, R Quinlan, A Khan | UMass Memorial Medical Center, Worcester, MA
24 | Modified Mandard Tumour Regression Grade Predicts Residual Cancer Burden Score in Neoadjuvant Treated Breast Cancer (267) | C Ryan, J White, F O’Connell, TJ Browne, L Feeley, MW Bennett | Cork University Hospital, Cork, NA, Ireland
25 | Stability and Prognostic Value of Slug, Sox9 and Sox10 Expression in Breast Cancers Treated with Neoadjuvant Chemotherapy (264) | C Riemenschneider, I Teleki, V Tischler, W Guo, Z Varga | Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; Semmelweis University, Budapest, Hungary; Albert Einstein College of Medicine, New York, NY
26 | Outcomes of Invasive Breast Cancer after Neoadjuvant Therapy and Its Association with Molecular Profiles (120) | J Boone, OW Tawfik, F Fan | University of Kansas Medical Center, Kansas City, KS
27 | Prediction of a Pathological Complete Response Defined as ypT0/is ypNx in the Setting of a Preoperative Systemic Therapy (EC-T4- Trastuzumab) of Invasive Breast Carcinoma by Evaluating bcl2 and TP53 on the Peratherapeutic Core Needle Biopsy Specimen (197) | D Klein, KC Siegmann-Luz, M Hahn, TN Fehm, UF Vogel | University Hospital, Eberhard-Karls-University, Tuebingen, Baden-Wuerttemberg, Germany
28 | Predicting OncoDx Recurrence Score with Immunohistochemical Markers Including Stromelysin (122) | SH Bradshaw, D Didutti, DH Gravel, EC Marginean, X Song, SJ Robertson | Ottawa Hospital, Ottawa, ON, Canada; Carleton University, Ottawa, ON, Canada
29 | Does Clinicopathologic Features Influence the Use of Adjuvant Chemotherapy in Early-Stage Breast Cancer Patients Who Have an Oncotype DX Intermediate Risk Score? (237) | MT Nguyen, Z Chen, T D’Alfonso, A Stessin, H Nagar, M Hayes, SJ Shin | Weill Cornell Medical Center, New York, NY; New York Presbyterian, Weill Cornell Medical Center, New York, NY
30 | How Much Is Oncotype DX Recurrence Score Impacting the Adjuvant Treatment Management of Node-Negative Early-Stage Breast Cancer Patients? (236) | MT Nguyen, Z Chen, T D’Alfonso, A Stessin, H Nagar, M Hayes, SJ Shin | Weill Cornell Medical Center, New York, NY; New York Presbyterian, Weill Cornell Medical Center, New York, NY
31 | ER and PR Immunohistochemistry and HER2 FISH vs. Oncotype DX®: Implications for Breast Cancer Treatment (249) | MM Park, JJ Ebel, DL Zynge | Ohio State University Medical Center, Columbus, OH
32 | Comparison of Oncotype DXTM Recurrence Score by Histologic Subtype of Breast Carcinoma (118) | PE Bomeisl, CL Thompson, LN Harris, HL Gilmore | University Hospitals Case Medical Center, Cleveland, OH; Seidman Cancer Center, Cleveland, OH
33 | Semi-Quantitative Immunohistochemical Scoring System Correlates with Oncotype DX® qRT-PCR Assay for Estrogen and Progesterone Receptors (123) | W Bshara, L Yan, S Liu, T Khoury | Roswell Park Cancer Institute, Buffalo, NY
34 | Correlation of Oncotype DX Recurrence Score with IRS1 and IRS2 Protein Expression and Cellular Localization in Breast Cancer (300) | V Walavalkar, D Kandil, S Lu, K Edmiston, L Shaw, A Khan | UMass Memorial Medical Center, Worcester, MA; Rhode Island Hospital, Providence, RI
35 | Utilizing the Oncotype DX Recurrence Score in the Adjuvant Treatment Management of Node-Positive, Early-Stage Breast Cancer Patients (238) | MT Nguyen, Z Chen, T D’Alfonso, A Stessin, H Nagar, M Hayes, SJ Shin | Weill Cornell Medical Center, New York, NY; New York Presbyterian, Weill Cornell Medical Center, New York, NY
43 Mucinous Carcinoma of the Breast: Clinicopathological Analysis with Emphasis on Biomarker Expression and Incidence of Metastasis and Recurrence (303)  
N Weil, OW Tawfik, F Fan  
University of Kansas Medical Center, Kansas City, KS

46 JAZF1/PHF1 Rearrangement in Primary Ossifying Sarcomas of the Heart: A Novel Gene Fusion (327)  
JK Schoolmeester, AL Folpe, WR Sukov, JC Hodge, JJ Maleszewski  
Mayo Clinic, Rochester, MN

47 Detection of Soluble Lectin-Like Oxidized Receptor (sLOX-1) as a Biomarker To Predict Sickle Cell Disease Vasculopathy (319)  
UC Davis Medical Center, Sacramento, CA

48 Preclinical Evaluation of Plaque Morphology and Development by Flat-Panel Computed Tomography (318)  
I Aboshady, LM Buja  
Texas Heart Institute, Houston, TX; University of Texas HSC, Houston, TX

49 The Activation of mTOR Pathway, a Marker of Endothelial Cell Involvement, Is Correlated with Antibody Mediated Rejection (328)  
M Tible, A Loupy, J-P Duong, P Bruneval  
PARCC, Paris, France; Hopital Europeen Georges Pompidou, Paris, France

50 The Biventricular Form of Arrhythmogenic Cardiomyopathy Is the Most frequent Morphologic Substrate of Juvenile Sudden Cardiac Death in Sports (322)  
M Mancini, CRT di Gioia, R Ierino, C Giordano, G d’Amati  
Istituto di Cardiologia, Roma, Italy

51 The Activation of mTOR Pathway, a Marker of Endothelial Cell Involvement, Is Correlated with Antibody Mediated Rejection (328)  
M Tible, A Loupy, J-P Duong, P Bruneval  
PARCC, Paris, France; Hopital Europeen Georges Pompidou, Paris, France

52 Hypersensitivity Myocarditis before Heart Transplantation Is Associated with Increased Acute Cellular Rejection after Transplantation (332)  
SK Yoshizawa, TS Kato, D Mancini, CC Marboe  
Columbia University Medical Center and the New York Presbyterian Hospital, New York, NY

53 Incidental Ascending Aortitis: The Histologic and Clinical Spectrum (331)  
L Xu, L Goicochea, F Tavora, A Burke  
University of Maryland Medical Center, Baltimore, MD; Messejana Heart and Lung Hospital, Fortaleza, CE, Brazil
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>54</td>
<td>Pediatric Marfan Syndrome Associated Aortic Disease: A Clinical-Morphologic Review (323)</td>
<td>DV Miller, LK Erickson, AT Yetman, SC Menon</td>
<td>University of Utah - Primary Children’s Medical Center, Salt Lake City, UT</td>
</tr>
<tr>
<td>55</td>
<td>Lymphoplasmacytic Response to Atheroma Mimicking Vasculitis (329)</td>
<td>AD Treacy, K Norita, PJ Ingram, MN Sheppard</td>
<td>National Heart and Lung Institute at the Royal Brompton Hospital, London, United Kingdom; Institute of Forensic Medicine, Belfast, United Kingdom</td>
</tr>
<tr>
<td>56</td>
<td>Correlations of Donor Specific Antibodies and Acute Rejection with T Cell Subtype Infiltrates in Endomyocardial Biopsies (320)</td>
<td>R Frank, M Kamoun, P Lal</td>
<td>Hospital of the University of Pennsylvania, Philadelphia, PA</td>
</tr>
<tr>
<td>57</td>
<td>Surgical Pathology of Ascending Aortic Aneurysms: Are There Clinical Correlates of Elastic Fragmentation of the Tunica Media? (324)</td>
<td>S Rizzo, M Martin, R Razzolini, G Gerosa, G Thiene, C Basso</td>
<td>University of Padua, Padua, Italy</td>
</tr>
<tr>
<td>58</td>
<td>Collagen Alterations in the Dissecting Aortic Aneurysm (DAA) Caused by N-(2-Aminoethyl) Ethanolamine (AEEA) in Rat (330)</td>
<td>Y Xu, G Vargas, PJ Boor</td>
<td>University of Texas Medical Branch, Galveston, TX</td>
</tr>
<tr>
<td>59</td>
<td>Primary Merkel Cell Carcinoma of Lymph Node: A Distinct Entity Has Lower Association with Merkel Cell Polyomavirus (MCPyV) Than Its Cutaneous Counterpart (486)</td>
<td>Z Pan, Y Chen, X Wu, V Trisal, S Wilczynski, Q Huang, P Chu, H Wu</td>
<td>University of Colorado Medical Center, Aurora, CO; City of Hope, Duarte, CA; Memorial Sloan-Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>60</td>
<td>Merkel Cell Polyomavirus Infection Associated with Akt/Mammalian Target of Rapamycin (4E-BP1) Signaling Pathway Activation in the Pathogenesis of Merkel Cell Carcinoma (472)</td>
<td>T Iwasaki, M Matsushima, D Nonaka, H Nakajima, S Kuvamoto, I Murakami, S San, O Yamamoto, K Hayashi</td>
<td>Tottori University, Yonago, Tottori, Japan; Christie Hospital, NHS Foundation Trust, Manchester, United Kingdom; Kochi University, Nankoku, Kouchi, Japan</td>
</tr>
<tr>
<td>61</td>
<td>Clinicopathological Characterization of MCPyV-Infected Merkel Cell Carcinomas in Japan and United Kingdom (481)</td>
<td>M Matsushima, T Iwasaki, D Nonaka, H Nakajima, S Kuvamoto, M Kato, I Murakami, S San, Y Kitamura, K Hayashi</td>
<td>Tottori University, Yonago, Tottori, Japan; Christie Hospital, NHS Foundation Trust, Manchester, United Kingdom; Kochi University, Nankoku, Kouchi, Japan</td>
</tr>
<tr>
<td>62</td>
<td>Primary Cutaneous Adenoid Cystic Carcinoma: Histological and Immunohistochemical Findings in a Series of 25 Cases (494)</td>
<td>A Santos-Briz, M Llamas, L Curto, T Mentzel, A Rutten, H Kutzner</td>
<td>Hospital Universitario de Salamanca, Salamanca, Spain; Hospital Universitario de la Princesa, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Dermatopathologische Gemeinschaftspraxis, Friedrichshafen, Germany</td>
</tr>
<tr>
<td>63</td>
<td>PTEN Status in Sporadic and Cowden Syndrome-Associated Trichilemmomas: Evaluation of Immunohistochemistry and Fluorescence In Situ Hybridization (505)</td>
<td>WR Sukov, W Shon, MM Wolz, CN Wieland, LE Gibson, MS Peters</td>
<td>Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>64</td>
<td>Differential Activation of the Mammalian Target of Rapamycin (mTOR) Pathway in Poromas and Porocarcinomas (465)</td>
<td>CT Elkins, OH Iwenofu, T Olenczi, SB Peters</td>
<td>Ohio State University Medical Center, Columbus, OH</td>
</tr>
<tr>
<td>65</td>
<td>Factor XIIIa Is a Highly Sensitive Nuclear Marker of Sebaceous Differentiation in Normal and Neoplastic Sebocytes (460)</td>
<td>LN Clark, HR Elwood, SC Shalin, BR Smoller, JM Gardner</td>
<td>University of Arkansas for Medical Sciences, Little Rock, AR</td>
</tr>
<tr>
<td>66</td>
<td>Metastatic Cutaneous Squamous Cell Carcinoma: Differential Gene Expression Profiling in Comparison to Primary Cutaneous Squamous Cell Carcinoma (503)</td>
<td>A Su, S Ra, X Li, S Binder</td>
<td>UCLA Medical Center, Los Angeles, CA; San Diego Pathologists Medical Group, San Diego, CA</td>
</tr>
<tr>
<td>67</td>
<td>Study of Cutaneous Metastases, Experience from Tertiary Cancer Center (475)</td>
<td>K Kantekure, D Sariya, S Lessin, H Wu</td>
<td>Fox Chase Cancer Center, Philadelphia, PA</td>
</tr>
<tr>
<td>68</td>
<td>Ossifying Fibromyxoid Tumor and Its Non-Ossifying Variant: A Diagnostic Challenge for Dermatopathologists (457)</td>
<td>D Buehler, N Atanaskova Mesinkovska, CM McClain, BP Rubin, J Goldblum, SD Billings</td>
<td>Cleveland Clinic, Cleveland, OH; Vanderbilt University, Nashville, TN</td>
</tr>
<tr>
<td>69</td>
<td>Do Cutaneous Leiomyomas Have Similar Morphological and Molecular Alterations to Uterine Tumors in the Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC)? (453)</td>
<td>LY Ballester, PP Aung, K Lara-Otero, WM Linehan, MJ Merino</td>
<td>NIH/NCI, Bethesda, MD</td>
</tr>
<tr>
<td>70</td>
<td>Evaluation of Fumarate Hydratase and Hypoxia-Associated Proteins in HLRCC Syndrome and Sporadic Cutaneous Leiomyomas (476)</td>
<td>JP Kapil, N Chakravarti, JL Curry, W-L Wang, VG Prieto, MT Tetlaff, C Torres-Cabala</td>
<td>MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>71</td>
<td>Immunohistochemical Re-Evaluation of Toker Cells in the Epidermis of the Nipple (498)</td>
<td>M Shimizu, M Nakamura, H Yamaguchi, K Nagata, M Yasuda</td>
<td>Saitama Medical University International Medical Center, Hidaka, Saitama, Japan</td>
</tr>
</tbody>
</table>
72 Cutaneous Mantle Cell Lymphoma: A Clinicopathologic Review (469)
AA Gru, LP Dehner, MY Hurley, L Brodell, M Anadkat, JL Frater
Washington University in St Louis, St. Louis, MO; Saint Louis University, St. Louis, MO

73 Hypopigmented Epitheliotropic T-Cell Dyscrasia as a Form of Prelymphomatous T-Cell Dyscrasia (511)
X Wang, YC Liu, CM Magro
Weill Medical College of Cornell University, New York, NY

74 Biclonality in Cutaneous Marginal Zone Lymphoma (487)
GG Panse, JM Henneberry
Baystate Medical Center, Springfield, MA

75 Marginal Zone Lymphoma of Eyelids: A Clinicopathological Entity. Histopathological and Molecular Analysis of 7 Cases (463)
A de Mascarel, M Parrens, M Beylot-Barry, O Fitoussi, F Baudner, S Marouan, S Rammeh, B de Barberyac, JP Merlio, B Vergier
University Hospital, Bordeaux, France, Metropolitan; Hospital of Bayonne, Bayonne, France, Metropolitan; University Hospital of Ibn Rochd, Casablanca, Morocco; Charles Nicolle Hospital, Tunis, Tunisia

76 T-Cell Subsets and Plasmacytoid Dendritic Cells in Rosacea and Cutaneous Lupus Erythematosus: A Comparative Immunophenotypic Analysis (456)
T Brown, Jr., K Choi, D Thomas, A Hristov, M Chan
University of Michigan Medical Center, Ann Arbor, MI

77 Nine Cases of Histiocytoid Sweet’s Syndrome (510)
X Wang, CM Magro
Weill Medical College of Cornell University, New York, NY

78 Skin Punch Biopsy Sectioning: Before or after Tissue Processing? (506)
N Sungu, S Orhun, S Marali, S Balci, A Kilicarslan, C Altunkaya, G Guler
Yildirim Beyazit University, Ankara, Turkey

79 Heparanase in Psoriasis: Its Role and Mode of Action (485)
T Neuman, I Lerner, E Zcharia, I Vlodavsky, M Elkin
Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rappaport Faculty of Medicine, Technion, Haifa, Israel

80 The Effects of Eculizumab on the Pathology of Degos Disease (509)
X Wang, CM Magro
Weill Medical College of Cornell University, New York, NY

GASTROINTESTINAL

81 Ueno Method Substaging pT1 Colorectal Adenocarcinoma by Depth & Width Measurement: An Interobserver Study (766)
LM Wang, EP Fryer, P Gill, C Hughes, A Szuts, R Perera, R Chetty
John Radcliffe Hospital Oxford University Hospital, Oxford, United Kingdom

82 Spectrum of Histopathological Changes Encountered in Stented Colorectal Carcinomas (CRC) (625)
E Fryer, LM Wang, R Guy, R Chetty
John Radcliffe Hospital, Oxford, United Kingdom

83 Retrospective Evaluation of Elastic Stain in the Assessment of Serosal Invasion of pT3N0Mx Colorectal Cancers (683)
WY Liang, CY Hsu, T Arnason, AT Hawkins, P Sylla, GY Lauwers
Veterans General Hospital-Taipei, Taipei, Taiwan; Massachusetts General Hospital, Boston, MA

84 Ileocecal Junction Carcinoma: Clinical-Pathologic Features (680)
L-H Lee, V Falck, X Gui
Calgary Laboratory Services and University of Calgary, Calgary, AB, Canada

85 A Bayesian Analysis of the Ratio, T1N1/T1N0, as a Marker of Relative Aggressive Potential in Colon Cancer (708)
A Patel, N Tabbara, AM Schwartz, DE Henson, K Butch
George Washington University Cancer Institute, Washington, DC; George Washington University, Washington, DC

86 Nuclear Immunoreactivity of β-Catenin Is Associated with Higher Expression of AMACR, Lower Rate of Nodal Metastasis, and Left-Side Location in Surgically Resected Deeply Invasive Colonic Cancer (677)
KK Lai, W Jiang, P Carver, A Liu, H Liu, B Zhang, H Xie, X Liu
Cleveland Clinic, Cleveland, OH; Thomas Jefferson University, Philadelphia, PA

87 Lymph Node Yield and MRI Correlation of Pathological Lymph Nodes after Neoadjuvant Chemoradiation in Rectal Cancer: The Importance of Lymph Node Size (727)
P Roy, A Chandra, M Kar, I Mallick, MK Roy, S Banerjee, D Midha, I Arun, SS Kurian
Tata Medical Center, Kolkata, West Bengal, India

88 MiRNA Profiling of Colorectal Carcinoma and Lymph Node Metastases (616)
S Costinean, V Balatti, P Dama, L Cascione, J Rock, CM Croce, WL Frankel
Ohio State University, Columbus, OH

89 Colon Cancer Nodal Staging Score: A Tool To Assess Adequacy of Nodal Harvesting in Pathology Practice (672)
A Kuchiba, P Lochhead, S Ogin
Dana-Farber Cancer Institute, Boston, MA; Brigham and Women’s Hospital, Boston, MA

90 Base Pair Changes in Assessing Microsatellite Instability and Correlation to Mismatch Repair Status by Immunohistochemistry (588)
K Affolter, A Wilson, W Samowitz, K Geiersbach
University of Utah, Salt Lake City, UT; ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT

91 Clinicopathologic Features of Microsatellite Instability-High (MSI-H) Colorectal Carcinomas in Patients >60 Years of Age (647)
H Hu, DJ Hartman, RE Brand, N Bahary, B Dudley, SI Chiosea, MN Nikiforova, RK Pai
University of Pittsburgh, Pittsburgh, PA
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>92</td>
<td>Microsatellite Instability-High (MSI-H) Left-Sided Colorectal Carcinoma Is Frequently Associated with Lynch Syndrome: Implications for Lynch Syndrome Screening and Detection (646)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>H Hu, DJ Hartman, RE Brand, N Bahary, B Dudley, SI Chiosea, MN Nikiforova, RK Pai</td>
<td>University of Pittsburgh, Pittsburgh, PA</td>
<td></td>
</tr>
<tr>
<td>93</td>
<td>An Unexpected Trend in the Prevalence of Microsatellite Instability in Colon Cancer (605)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BD Barrows, N Zarrin-Khameh, BL Masher</td>
<td>Baylor College of Medicine, Houston, TX</td>
<td></td>
</tr>
<tr>
<td>94</td>
<td>Clinical Outcomes and Microsatellite Instability Testing of Advanced Colorectal Adenomas in Patients under 45 (769)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>RF Watson, VM Kushner, J Goodwin, E Satar, RV Chokshi, NO Davidson, RA Azar, I Nalbantoglu</td>
<td>Washington University School of Medicine, St. Louis, MO</td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>Utilizing Image Analysis To Correlate Subsets of Tumor Infiltrating Lymphocytes with Prognosis in Colon Cancer Patients (667)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Y Kim, JM Bae, N-Y Cho, GH Kang</td>
<td>Seoul National University Hospital, Seoul, Korea; Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul, Korea</td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>Microsatellite Instability (MSI) and BRAF Mutation Tests Jointly Provide Useful Prognostic Information in 1861 Colorectal Cancers (688)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>P Lochhead, C Fuchs, S Ogino</td>
<td>Dana-Farber Cancer Institute, Boston, MA; Brigham and Women’s Hospital, Boston, MA</td>
<td></td>
</tr>
<tr>
<td>97</td>
<td>Should Histology Play a Role in Deciding Which Colorectal Carcinomas Should Be Tested for Lynch Syndrome? (637)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>STG Hammer, JK Greenson</td>
<td>University of Michigan Health System, Ann Arbor, MI</td>
<td></td>
</tr>
<tr>
<td>98</td>
<td>Clinical Experience with Mismatch Repair (MMR) Status and OncoType DX® Colon Cancer Recurrence Score® Assay in 917 Patients with Stage II Colon Cancer (603)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>H Bailey, J Anderson, V Tan, AC Tsiatis, FL Baehner, J Liu, M Lopatin, M Lee, C Millward</td>
<td>Genomic Health, Inc., Redwood City, CA; University of California, San Francisco, CA</td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>Microsatellite Instability and DNA Mismatch Repair Protein Deficiency in Chinese Patients with Sporadic Colorectal Cancer (649)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>D Huang, X Chen, B Yu, W Sheng, X Du</td>
<td>Fudan University Cancer Center, Shanghai, China</td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>Intrarectal Patch of Primary Squamous Cell Carcinoma (SCC): A Rare HPV-Related Variant (654)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>R Jain, I Lamzahi, S Jakate</td>
<td>Rush University Medical Center, Chicago, IL</td>
<td></td>
</tr>
<tr>
<td>101</td>
<td>High Proliferation Index Is Associated with Reduced Survival in Anorectal Melanomas – An Immunohistochemical and Molecular Study (643)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>D Hershkovitz, E Simon, E Sabo, J Sandbank, G Groisman, V Doviner, I Cohen, O Ben-Izhak</td>
<td>Rambam Health Care Campus, Haifa, Israel; Assaf Haroof Medical Center, Zerifin, Israel; Hillel Yaffe Medical Center, Hadera, Israel; Hadassah University Hospital, Jerusalem, Israel; Western Galilee Regional Hospital, Nahariya, Israel</td>
<td></td>
</tr>
<tr>
<td>102</td>
<td>CK17: An Adjunctive Marker of Invasion in Squamous Neoplastic Lesions of the Anus (714)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Primiani, RM Nazarian, K Linskey, LA Doyle, LM Duncan, R Odze, LR Zukerberg</td>
<td>Massachusetts General Hospital, Boston, MA; Brigham and Woman’s Hospital, Boston, MA</td>
<td></td>
</tr>
<tr>
<td>103</td>
<td>Anal Canal Syphilis: A Challenging Diagnosis for the Gastrointestinal Pathologist (631)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>P Gopal, RM Genta, R Shah</td>
<td>Miraca Life Sciences Research Institute, Irving, TX</td>
<td></td>
</tr>
<tr>
<td>104</td>
<td>Diagnostic Approach to Anal Condylomas Using p16, HPV L1 Capsid Protein and HPV Chromogenic In-Situ Hybridization (710)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>DT Patil, B Yang</td>
<td>Cleveland Clinic, Cleveland, OH</td>
<td></td>
</tr>
<tr>
<td>105</td>
<td>The Natural History of Anal Squamous Dysplasia – An 8 Year Follow Up Study (660)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S Kavast, MR Peterson</td>
<td>University of California, San Diego, CA</td>
<td></td>
</tr>
<tr>
<td>106</td>
<td>Histologic Correlation with the Clinical-Radiologic Acute Cholecystitis Syndrome (638)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>STG Hammer, KE Mautern, HD Appelman</td>
<td>University of Michigan Health System, Ann Arbor, MI</td>
<td></td>
</tr>
<tr>
<td>107</td>
<td>The Significance of Epithelial-Mesenchymal Transition (EMT) in Extratherapeutic Bile Duct Carcinoma: A Clinicopathologic Study of 122 Cases (699)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T Niita, T Mitsuhashi, Y Hatanaka, KC Hatanaka, S Hirano, Y Matsuno</td>
<td>Hokkaido University Hospital, Sapporo, Hokkaido, Japan; Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan</td>
<td></td>
</tr>
<tr>
<td>108</td>
<td>Expression Analysis of AKT/mTOR Signaling Pathway in Primary Tumors and Cell Lines Derived from Gallbladder Cancer (720)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>JC Roa, P Leal, P Garcia, O Tapia, H Weber</td>
<td>Pontificia Universidad Catolica, Santiago, Chile; Universidad de La Frontera, Temuco, Chile</td>
<td></td>
</tr>
<tr>
<td>109</td>
<td>Microsatellite Instability in Gallbladder Carcinoma (713)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Primiani, M Shahid, O Yilmaz, CR Ferrone, DR Borger, AJ Iafrate, AX Zhu, V Deshpande</td>
<td>Massachusetts General Hospital, Boston, MA</td>
<td></td>
</tr>
<tr>
<td>110</td>
<td>A Practical Diagnostic Panel for Distinguishing between Hepatocellular Lesions (742)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>F Siadat, P Williams, C Marginean</td>
<td>Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada</td>
<td></td>
</tr>
<tr>
<td>Number</td>
<td>Board</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>111</td>
<td>Frozen Diagnostic Features and Pitfalls of Needle Core Biopsies for Hepatocellular Mass Lesions (709)</td>
<td>Utility of KI-67 and Triple Stain Cocktail in Facilitating the Diagnosis of Intraductal Carcinoma of the Prostate (877)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N Patel, R Patel, J Wang  University of Cincinnati, Cincinnati, OH</td>
<td>E Gersbach, B Zhu, X Yang  Northwestern University, Chicago, IL</td>
<td></td>
</tr>
<tr>
<td>112</td>
<td>Peritoneal Malignant Mesothelioma (PMM), Papillary Serous Adenocarcinoma (PSA), and Reactive Mesothelial Hyperplasia (RHM) of the Peritoneum. An Immunohistochemical and Fluorescence In Situ Hybridization (FISH) Analysis (662)</td>
<td>ERG Immunohistochemical Staining Patterns as a Function of Prostate Cancer Distribution in Prostatic Evasive Anterior Tumours (962)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>T Kawai, S Hiroi, S Ogata, K Nakanishi, K Hiroshima, T Shinagawa, S Shimizu  National Defense Medical College, Tokorozawa, Saitama, Japan; Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Chiba, Japan; Kawasaki Municipal Ida Hospital, Kawasaki, Kanagawa, Japan; Showa General Hospital, Kodaira, Tokyo, Japan</td>
<td>O Mahamud, K Chadwick, NE Fleshner, AJ Evans  University Health Network, Toronto General Hospital, Toronto, ON, Canada; University Health Network, Princess Margaret Hospital, Toronto, ON, Canada</td>
<td></td>
</tr>
<tr>
<td>113</td>
<td>Mesenteric Lipodystrophy: A Frequently Underdiagnosed Entity (771)</td>
<td>c-MYC, HER2 and HER3 Expression in Localised Prostate Carcinoma Treated with Radical Radiotherapy: Modulation by Statins Use and Correlation with Clinical Progression (986)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>JM Wells, Z Yang  Penn State Milton S. Hershey Medical Center, Hershey, PA</td>
<td>A Navarro, J Castellvi, I Nunez, X Maldonado, J Morote, J Carles, M Aitzpurua, J Hernandez-Losa, S Ramon y Cajal, I De Torres  Hospital Universitari Vall d’Hebron, Barcelona, Spain</td>
<td></td>
</tr>
<tr>
<td>114</td>
<td>Inflammatory Reactions in Mesotheliomas: Diagnostic Pitfalls of Lymphohistiocytic Pattern, Lymphoid Reaction Mimicking Lymph Node Metastasis, and Fibrosclerosing Pattern Mimicking Sclerosing Mesenteritis (650)</td>
<td>miRNA Signatures of Indolent and Aggressive Prostate Cancer (875)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>T Huebner, JA Collins, A Burke  UMMC, Baltimore, MD</td>
<td>L Flynn, O Sheils, JJ O’Leary, SP Finn, W Watson, M Loda, L Mucci  University of Dublin, Trinity College, Dublin, Ireland; University College Dublin, Dublin, Ireland; Dana Farber Cancer Institute, Boston, MA; Harvard School of Public Health, Boston, MA</td>
<td></td>
</tr>
<tr>
<td>115</td>
<td>Significance of Signet-Ring Cells in Extracellular Mucin Pools Versus Tissue in High-Grade Mucinous Carcinoma Peritonei (743)</td>
<td>Quantification of Tumor in the Diagnostic Biopsy and Correlation with Prostatectomy Report (1032)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>J Sirintrapan, A Blackham, G Russell, J Stewart, P Shen, E Levine, K Geisinger, S Bergman, A Cmic  Wake Forest Baptist Health, Winston Salem, NC; UNC Chapel Hill, Chapel Hill, NC</td>
<td>L Schultz, CE Malaf, BF Pizzani, RC Silva, RH Falashi, MV Costa, MIO Schulz  Instituto de Anatomia Patológica, Piracicaba, SP, Brazil; Hospital dos Fornecedores de Cana, Piracicaba, SP, Brazil</td>
<td></td>
</tr>
<tr>
<td>116</td>
<td>Morphologic and Molecular Analysis of Appendiceal Serrated Lesions: Colonic Terminology May Not Be Applicable (642)</td>
<td>Do European Pathologists Follow ISUP 2005 Gleason Grading Guidelines? A Web Based Survey (813)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D Hernandez Gonzalez, X Liu, DT Patil, A Bennett, TP Plesec, JR Goldblum, S-F Kuan, E Downs-Kelly, B Shadrach, RK Pai, RK Pai  Cleveland Clinic, Cleveland, OH; University of Pittsburgh Medical Center, Pittsburgh, PA</td>
<td>DM Berney, F Algabe, P Camparo, E Comperat, D Griffiths, G Kristiansen, A Lopez-Beltran, R Montironi, M Varma, L Egevad  St Bartholomew’s Hospital, London, United Kingdom; Fundacion Puigvert-University Autonomous, Barcelona, Spain; Centre de Pathologie Amiens Picardie, Paris, France; Hospital La Pitié-Salpêtrière, Paris, France; University Hospital of Wales, Cardiff, United Kingdom; University of Bonn, Bonn, Germany; Cordoba University Medical School, Cordoba, Spain; Polytechnic University of the Marche Region, Ancona, Italy; Karolinska Institutet, Stockholm, Sweden</td>
<td></td>
</tr>
<tr>
<td>117</td>
<td>Histologic Variables and Patient Outcome in Prostate Biopsies with Atypical Small Acinar Proliferation Reclassified as Benign, ASAP or Cancer by Re-Review (929)</td>
<td>Immunohistochemical Expression of AIM1 in Normal Prostate and in Primary and Metastatic Prostate Carcinoma (888)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MG Keeney, JK Schoolmeister, RE Swapp, CM Lokse, BA Innan, TJ Sebo  Mayo Clinic, Rochester, MN</td>
<td>MC Haffner, S Vegnasubramanian, GJ Netto, A Chaux  Norte University, Asunción, Paraguay; Johns Hopkins University, Baltimore, MD</td>
<td></td>
</tr>
<tr>
<td>118</td>
<td>Significance of Prostatic Atypical Small Acinar Proliferation in Surgical Pathology Quality Assurance (1057)</td>
<td>Immunohistochemistry Is Rarely Used in the Evaluation of Prostate Needle Biopsy Material with Lesions &gt; 3 mm in Linear Extent (891)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>M Van Ness, O Lee, M Dall’Era, R Gandour-Edwards  UC Davis, Sacramento, CA</td>
<td>O Hameed, L Bloom, C Salih, PA Humphrey  Vanderbilt University, Nashville, TN; Washington University, St. Louis, MO</td>
<td></td>
</tr>
<tr>
<td>119</td>
<td>Significance of Increased Frequency of Her2/Neu Expression in Intraductal Carcinoma of the Prostate in Comparison to Conventional Prostatic Adenocarcinoma (1028)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
209

Board Number

128  Immunohistochemical Analysis of Speckle-Type POZ Protein (SPOP) in Prostate Cancer, High Grade Prostatic Intraepithelial Neoplasia and Benign Glands (1009)
A Razmaria, J Cohn, K White, D VanderGriend, GP Paner
University of Chicago, Chicago, IL

129  Is Race Predictive of Biochemical Recurrence Following Radical Prostatectomy? A Study in a Latin-American Country (817)
A Billis, L Meirelles, LLLL Freitas, AKS Uejo, H Covre, MVB Mota, LA Magna, LO Reis, U Ferreira
School of Medicine, University of Campinas (Unicamp), Campinas, SP, Brazil

130  Hormonotherapy in Prostate Cancer Influences Tumor Microvessel Density: New Perspectives for Prostate Cancer Treatment? (1025)
R Santi, E Comperat, L Masieri, S Serni, P Camparo, M Carini, G Nesi
University of Florence, Florence, Italy; Hopital La Pitié Salpetrière, Paris, France; Centre de Pathologie Amiens Picardie, Amiens, France

131  The Significance of Midline Crossing in Organ Confined pT2c Prostate Carcinoma (807)
A Bartakova, PH Sweet, AS Shabaik
UCSD, San Diego, CA; ULB, Brussels, Belgium

132  Decreased BRG1 Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma, a Potential Role for a Tumor Suppressor Gene Inactivation on Oncogenesis (979)
E Munari, A Chaux, SF Faraj, ND Gonzalez Roibon, R Sharma, GJ Netto
Johns Hopkins Hospital, Baltimore, MD; Universidad del Norte School of Medicine, Asuncion, Paraguay

133  B7H1 Expression and Association with Clinical Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients (937)
Johns Hopkins Pathology, Baltimore, MD; Johns Hopkins Hospital, Baltimore, MD; Facoltà di Medicina e Chirurgia Università del Piemonte Orientale Amedeo Avogadro, Novara, Italy; Johns Hopkins Hospital, Baltimore, MD

134  Nephrogenic Adenoma: A Report of 3 Unusual Cases Infiltrating into Perinephric Adipose Tissue (851)
M Diolombi, F Mercalli, JI Epstein
George Washington University Medical Center, Washington, DC; Facoltà di Medicina e Chirurgia Università del Piemonte Orientale Amedeo Avogadro, Novara, Italy; Johns Hopkins Hospital, Baltimore, MD

135  Multifocal/Bilateral Renal Tumors: New Insights in Histologic Types (940)
B Krishnan, LD Truong
Michael E. DeBakey VA Medical Center, Houston, TX; Baylor College of Medicine, Houston, TX

136  Multiphoton Microscopy in the Evaluation of Kidney Tumors (914)
M Jain, MM Shevchuk, BD Robinson, A Aggarwal, S Mukherjee, DS Scherr
Weill Medical College of Cornell University, New York, NY

137  Rhabdoid Differentiation in Renal Cell Carcinomas (RCCs): Clinicopathologic Analysis of 76 Cases (1004)
CG Przybycin, JK McKenney, M Mantoan-Padilha, JP Reynolds, C Magi-Galluzzi
Cleveland Clinic, Cleveland, OH

138  Is Papillary Renal Cell Carcinoma Derived from Proximal Convoluted Tubules? (1083)
XJ Yang, K Dykema, L Jia, E Gersbach, F Lin, S Shen, BT Teh
Northwestern University Feinberg School of Medicine, Chicago, IL; Van Andel Research Institute, Grand Rapids, MI; Geisinger Health System, Danville, PA; Methodist Hospital, Houston, TX

139  Renal Core Biopsies of Angiomyolipomas: Review of a Single Institution Eight Year Experience with an Emphasis on Angiomyolipomas with Epithelioid Features (1078)
AJ Wu, S Wolf, S Tomlins, R Mehra, LP Kunju
University of Michigan, Ann Arbor, MI

140  Comparative Gene Expression and miRNA Expression Patterns in Chromophobe Renal Cell Carcinoma (ChRCC) and Oncocytoma (OC) (800)
M Amin, AV Parwani, S Roy, S Bastacky, W LaFramboise, R Dhir
University of Pittsburgh Medical Center, Pittsburgh, PA

141  Hepatocyte Nuclear Factor 1 Beta and Galectin 3 Are Useful Biomarkers for Distinguishing Subtypes of Renal Epithelial Neoplasia (872)
TA Flood, BE Howitt, P Dal Cin, MS Hirsch
Brigham and Women’s Hospital, Boston, MA; Ottawa Hospital, Ottawa, ON, Canada

142  Accuracy of an Oligonucleotide-Based Fluorescence In Situ Hybridization (FISH) Urine Assay: Prospective Study of 389 Patients Monitored for Recurrence of Bladder Cancer (820)
DG Bostwick, D Hossain
Bostwick Laboratories, Inc., Orlando, FL

143  EGFR and ALK Mutational Events Are Not Present in Primary Adenocarcinoma of the Urinary Bladder (793)
RE Alexander, R Montironi, A Lopez-Beltran, M Wang, KM Post, JD Shen, AK Arnold, S Balbo, S Zhang, X Wang, SR Williamson, MO Koch, N Hahn, GT MacLennan, E Comperat, L Cheng
Indiana University School of Medicine, Indianapolis, IN; Polytechnic University of the Marche Region, Ancona, Italy; Cordoba University, Cordoba, Spain; Case Western Reserve University, Cleveland, OH; Groupe Hospitalier Pitié-Salpêtrière, Paris, France

144  micro-RNA Expression in Lethal and Non-Lethal Urothelial Cancers of the Bladder (1015)
D Rotzer, A Perren, A Fleischmann
University of Bern, Bern, Switzerland


Hospital La Pitié-Sampetriere, Université Paris VI, Paris, France; Karolinska University, Stockholm, Sweden; Faculty of Medicine, University of Cordoba, Cordoba, Spain; Fundacion Puigvert, Barcelona, Spain; Cedars-Sinai Medical Center, Los Angeles, CA; Johns Hopkins Hospital, Baltimore, MD; Uppsala University Hospital, Uppsala, Sweden; Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands; University Hospital Bonn, Bonn, Germany; Polytechnic University of the Marche Region, Ancona, Italy; Cordoba University, Cordoba, Spain

Clinicopathologic Characteristics and Overall Survival in Cystectomy Patients with Bladder Cancer Involving the Lower Gastrointestinal Tract (844) AM D’Souza, GS Phillips, KS Pohar, DL Zynzer

Ohio State University Medical Center, Columbus, OH

Immunooxpression of mTOR Pathway Members in Non-Invasive Papillary Urothelial Neoplasms of Bladder (805) S Arslanok, S Korkmaz, GJ Netto, DE Baydar

Hacettepe University Faculty of Medicine, Ankara, Turkey; Johns Hopkins University School of Medicine, Baltimore, MD

Significantly Decreased p63 and p40 Expression in Urothelial Carcinoma (UC) with Glandular Differentiation (GD) (1093) B Zhu, X Lin, SM Rohan, C Villa, E Gersbach, X Yang

Northwestern University Feinberg School of Medicine, Chicago, IL

Primary Paratesticular Rhabdomyosarcoma: A Clinicopathologic Study of 25 Cases (896) J Heitzman, P Rao

MD Anderson Cancer Center, Houston, TX

Somatic-Type Cancers in Patients with Testicular Germ Cell Tumors: Relationship to Yolk Sac Tumor and Utility of New Markers (840) CD Cole, TM Ulbright

Indiana University School of Medicine, Indianapolis, IN

The Utility of ERG Immunohistochemistry in Converting “Suspicious for” to “Definite” Lymphovascular Invasion in Non-Semimomatous Germ Cell Tumor of Testis (906) H Huang, S Jadallah, Y-B Chen, A Gopalan, HA Al-Ahmadie, SW Fine, VE Reuter, SK Tickoo

Memorial Sloan-Kettering Cancer Center, New York, NY

miRNA Expression in Lower and Upper Urothelial Carcinoma and the Potential Clinical Application (1070) S Wei, Y Yao, PK Gupta, Z Bing

Hospital of the University of Pennsylvania, Philadelphia, PA

Concomitant CIS Is a Risk Factor for the Occurrence of High Risk Bladder Cancer after Radical Nephroureterectomy (1054) T Tsuzuki, T Majima, N Sassa, S Ishida, R Hattori, M Gotoh, Nagoya Daini Red Cross Hospital, Nagoya, Japan; Nagoya University Hospital, Nagoya, Japan; Chukyo Hospital, Nagoya, Japan; Nagoya First Red Cross Hospital, Nagoya, Japan

Immunooxpression Status and Prognostic Significance of mTOR Pathway Members in Upper Tract Urothelial Carcinoma (864) SF Faraj, K Fujita, E Munari, A Chaux, ND Gonzalez Roibon, J Hicks, A Meeker, GJ Netto

Johns Hopkins University, Baltimore, MD; Universidad del Norte School of Medicine, Asuncion, Paraguay; Osaka General Medical Center, Osaka, Japan

Using Cytokeratin Expression Pattern To Evaluate Differentiation in Urothelial Carcinoma of the Upper Urinary Tract (897) J Heitzman, B Czerniak, CC Guo

UT MD Anderson Cancer Center, Houston, TX

Human Epidermal Growth Factor Receptor 2 Expression in Urothelial Carcinoma of the Renal Pelvis: Correlation with Clinicopathologic Parameters (859) L Eksani, AO Osunkoya

Emory University School of Medicine, Atlanta, GA

The Utility of SF-1 and Cathepsin K as Differentiating Immunohistochemical Markers in Adrenal Cortical Carcinoma and Epithelioid Angiomyolipoma (1021) TD Samulski, S Bai, AL Nunez, S Wei, L Wang, Z Bing

Hospital of the University of Pennsylvania, Philadelphia, PA; New York University, New York, NY; University of Alabama, Birmingham, AL
211

Spectrum of Vascular Lesions Involving the Adrenal Gland: A Clinicopathologic Study of 31 Cases (804)
MA Apushkin, MT Tretiakova, JB McHugh, DR Lucas, GP Paner, RM Patel
University of Chicago, Chicago, IL; University of Michigan, Ann Arbor, MI

GYNECOLOGIC & OBSTETRICS

Mutational Analysis of BRAF and KRAS in Atypical Proliferative (Borderline) Serous Tumors of the Ovary and Associated Peritoneal Implants from a Population-Based Cohort in Denmark (1102)
L Ardighieri, RJ Kurman, R Vang, I-M Shih
Johns Hopkins University School of Medicine, Baltimore, MD

BRAF Mutation-Associated Immunostaining Marker and Morphological Features in Peritoneal Implants and Atypical Proliferative (Borderline) Serous Tumors (APSTs) (1103)
L Ardighieri, RJ Kurman, K Maniar, I-M Shih
Johns Hopkins University School of Medicine, Baltimore, MD

Ovarian Borderline Tumors: Features Predictive of Progression (1252)
N Yoo, N Baza, JD Black, TJ Rutherford, FA Tavassoli
Yale New Haven Hospital, New Haven, CT

Additional Insights on Ovarian Low Grade Serous Carcinoma: A Study of Consecutive Cases with Primary Surgery Performed at a Single Institution (1210)
EO Kaye, E Euscher, A Malpica
MD Anderson Cancer Center, Houston, TX

Microinvasion in Ovarian Serous Tumor of Low Malignant Potential – Does It Matter? (1202)
RP Masand, A Malpica, P Ramalingam
Baylor College of Medicine, Houston, TX; MD Anderson Cancer Center, Houston, TX

PAX-8 and ER in Mucinous Tumors in the Ovary: Are They Useful in Distinguishing Primary from Metastasis? (1201)
RP Masand, A Malpica, P Ramalingam
Baylor College of Medicine, Houston, TX; UT MD Anderson Cancer Center, Houston, TX

Claudin-18 and MUC18C Immunohistochemistry Is Useful for Distinction between Primary Ovarian Mucinous Adenocarcinoma and Metastatic Colorectal Carcinoma Involving the Ovary (1155)
SA Halimi, D Maeda, M Fukayama
Graduate School of Medicine, University of Tokyo, Tokyo, Japan

Metastatic Adenocarcinoma from Pancreas Involving the Ovary; Histopathologic Analysis of 11 Cases (1215)
HS Park, CO Sung, K-R Kim
University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

Mucinous Ovarian Tumors in Childhood – An Institutional Experience (1140)
R Fan
Indiana University, Indianapolis, IN

Serous Tubal Intraepithelial Carcinoma: Unusual Variants Encountered in a 7 Year Experience (1248)
EJ Yang, CP Crum
Brigham and Women’s Hospital, Boston, MA

Evidence That High-Grade Serous Cancers and Their Precursors Arise from a PAX2-Negative Progenitor Cell in the Oviduct (1208)
G Ning, J Yuan, M Herfs, Y Yamamoto, JG Bijron, FD McKeon, WXian, CP Crum
Jackson Laboratory for Genetic Medicine, Farmington, CT; Institute of Medical Biology, Singapore, Singapore; University of Liege, Liege, Belgium; Genome Institute of Singapore, Singapore, Singapore; University of Utrecht, Utrech, Netherlands; Brigham and Women’s Hospital, Boston, MA

Early Genomic Instability in Tubo-Ovarian Preneoplastic Lesions (1119)
G Chene, A Tehtkov, E Pierre, JD Flauplat, N Radosevic-Robin, ACayre, P Penault-Llorca
Centre Jean Perrin and EA 4677 ERTICA University of Auvergne, Clermont-Ferrand, France; Estaing Hospital and EA 4677 ERTICA University of Auvergne, Clermont-Ferrand, France; Centre Jean Perrin and EA 4677 ERTICA University of Auvergne, Clermont-Ferrand, France

Laminin $\beta_1$ and $\beta_2$ Immunostaining in Ovarian Carcinoma (1186)
AR Laury, AE Walts
Cedars-Sinai Medical Center, Los Angeles, CA

miR-146b2 Enrichment in Developing and Progressing Ovarian Serous Tumor (1188)
S Lee, J Lee, S Kim, J Kim
Gacheon Gil Hospital, Incheon, Republic of Korea; Korea University Hospital, Seoul, Republic of Korea

Cellular Plasticity of Tubal and Ovarian Surface Epithelium: The Mixed Mesothelial-Mullerian Phenotype (1120)
MH Chui
Toronto General Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada

Precursor Lesions and Prognostic Factors in Primary Peritoneal Serous Carcinoma (1189)
SL Lee, G Nelson, Q Duan, AM Magliocco, MA Duggan
Foothills Medical Center, University of Calgary, Calgary, AB, Canada; Foothills Medical Center, Calgary, AB, Canada; University of Calgary, Calgary, AB, Canada; Lee Moffitt Cancer Center, Tampa, FL

Biomarker Based Ovarian Carcinoma Typing: A Retrospective Analysis of the OTTA Consortium (1191)
SL Lee, SE Kallegor, SJ Ramus, E Goode, M Duggan, DHuntsman, BC Gilks, K Martin
University of Calgary, Calgary, AB, Canada; University of British Columbia, Vancouver, BC, Canada; University of Southern California, Los Angeles, CA; Mayo Clinic, Rochester, MN
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>180</td>
<td>Differential Expression of SIRT1 and PGC1α in Ovarian Clear Cell Carcinomas vs Endometrial Carcinomas and Renal Clear Cell Carcinomas (1204)</td>
<td>MM Mishra, AS Joehlin-Price, JA Stephens, AA Suarez Ohio State University, Columbus, OH</td>
</tr>
<tr>
<td>181</td>
<td>BAF250a (ARID1A) Expression in Ovarian Clear Cell Adenocarcinoma with an Adenofibromatous Component (1209)</td>
<td>K Nishikimi, T Kiyokawa, S Tate, M Iwamoto, T Kisimoto, K Fugo, M Shozu Chiba University Graduate School of Medicine, Chiba, Japan</td>
</tr>
<tr>
<td>182</td>
<td>p53, WT1, and PAX8 Immunohistochemical Profiles in Ovarian Malignant Mesodermal Mixed Tumors (1239)</td>
<td>K Sy, M Cesari, S Nofech-Mozes, Z Ghorab, N Ismiil, V Dube, MA Khalifa, G Han Sunnybrook Health Sciences Centre, Toronto, Canada</td>
</tr>
<tr>
<td>183</td>
<td>Morphologic Features Suggestive of Endometriosis in Nondiagnostic Peritoneal Biopsies (1156)</td>
<td>BT Harrison, K Mittal New York University Langone Medical Center, New York, NY</td>
</tr>
<tr>
<td>184</td>
<td>Tumor Progression from Ovarian Endometriotic Cyst to Endocervical-Like ( Mullerian-Seromucinous) Tumors: Immunohistochemical Comparison of Endometriotic Cyst and the Neoplasm (1104)</td>
<td>A Ayhan, H Ogawa, T Seckin, E Kuhn, T-L Mao, N Singh, RJ Kurman, I-M Shih Johns Hopkins Medical Institutions, Baltimore, MD; Seirei Mikatahara General Hospital, Hamamatsu, Japan; National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan; North Shore LIJ-Lenox Hill Hospital, New York, NY; Barts and the London NHS Trust, London, United Kingdom</td>
</tr>
<tr>
<td>185</td>
<td>Well-Differentiated and Non-Invasive Diffuse Peritoneal Mesotheliomas Treated with HIPEC: Histologic Spectrum (1190)</td>
<td>M Lee, J Collins, A Burke UMMC, Baltimore, MD</td>
</tr>
<tr>
<td>187</td>
<td>Diagnostic and Prognostic Potential of HE4 in Ovarian Cancer (1185)</td>
<td>R Lange, S O'Toole, L Norris, M Petzold, A Harrison, R Varley, F Abbasuadeh, N Gleeson, J O'Leary Trinity College, Dublin, Ireland; St James’s Hospital, Dublin, Ireland; Dublin City University, Dublin, Ireland; Sahlgrenska Academy, University of Gothenburg, Germany</td>
</tr>
<tr>
<td>188</td>
<td>VCAM1 Expression Correlated with Tumorigenesis, Chemoresistance and Poor Prognosis in High Grade Serous Ovarian Cancer (1166)</td>
<td>J Huang, J Zhang, W Shan, I Mercado-Uribe, J Liu MD Anderson Cancer Center of Texas University, Houston, TX; Affiliated Hospital of Nantong University, Nantong, Jiangsu, China</td>
</tr>
<tr>
<td>189</td>
<td>Novel Hypoxia-Associated Markers of Chemoresistance in Ovarian Cancer (1203)</td>
<td>L McEvoy, S O'Toole, C Spillane, B Stordal, M Gallagher, C Martin, L Norris, N Gleeson, A McGoldrick, F Furlong, A McCann, O Sheils, J O'Leary Trinity College Dublin, Dublin, Ireland; University College Dublin, Dublin, Ireland</td>
</tr>
<tr>
<td>190</td>
<td>Secretion of Specific Toll-Like Receptor Signaling Proteins in the Response of Embryonal Carcinoma Cancer Stem Cells to Differentiation, Hypoxia and Chemotherapy (1147)</td>
<td>MF Gallagher, A Cooke, J O’Leary University of Dublin, Trinity College, Dublin, Ireland</td>
</tr>
<tr>
<td>192</td>
<td>A Quantitative Histomorphometric Classifier Identifies Aggressive Versus Indolent p16 Positive Oropharyngeal Squamous Cell Carcinoma (1291)</td>
<td>JS Lewis, Jr., S Ali, WL Thorstad, A Madabhushi Washington University, St. Louis, MO; Case Western Reserve University, Cleveland, OH</td>
</tr>
<tr>
<td>193</td>
<td>Lacking Caspid Protein Expression in p16 Positive Head and Neck Squamous Cell Carcinoma Using HPV-1 Immunohistochemistry (1261)</td>
<td>A Al-Ibraheemi, S Zhang UT Health, Houston, TX</td>
</tr>
<tr>
<td>194</td>
<td>Immunohistochemical Expression of p40 in Sarcomatoid Squamous Cell Carcinoma of the Head and Neck (1314)</td>
<td>KA West, DJ Buonocore, V Ghali, B Wang Beth Israel Medical Center, New York, NY</td>
</tr>
<tr>
<td>195</td>
<td>Comparison of p63 and p40 (DNP63) in the Diagnosis of Head and Neck Sarcomatoid Carcinoma (1269)</td>
<td>JA Bishop, EA Montgomery, WH Westra Johns Hopkins Hospital, Baltimore, MD</td>
</tr>
<tr>
<td>196</td>
<td>CD34 and α-SMA Distinguish Verrucous Hyperplasia from Verrucous Carcinoma (1296)</td>
<td>KM Paral, L Zhao, M Lingen, JB Taxy University of Chicago, Chicago, IL</td>
</tr>
<tr>
<td>197</td>
<td>Distinguishing between Dysplasia and Reactive Atypia in Laryngeal Mucosa: Utility of p53, Ki67, CD44 and p16 Immunohistochemistry (1284)</td>
<td>P Kamaleswaran, T Lum, LA Anderson, R Gupta University of Sydney, Sydney, Australia; Royal Prince Alfred Hospital, Sydney, Australia</td>
</tr>
</tbody>
</table>
206 Oral Mucosa and Soft Tissue Alterations Associated with Osteonecrosis of the Jaw (1282)
S Gill, N Hinchy, V Jayaprakash, M Sullivan, M Merzianu
State University of New York at Buffalo, Buffalo, NY; Roswell Park Cancer Institute, Buffalo, NY

207 P16 Overexpression in High-Grade Neuroendocrine Carcinomas of the Head and Neck Unrelated to HPV-Infection (1262)
L Alos, S Hakim, AB Large, N Guimera, W Quint, M Alberola, M-T Fernandez-Figuera, A Cardesa, J Ordi
Hospital Clinic, University of Barcelona, Barcelona, Spain; DDL Diagnostic Laboratory, Rijswijk, Netherlands; Hospital Valle Hebron, Barcelona, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Spain

208 Periostin Overexpression as a Poor Prognostic Factor in Patients with Nasopharyngeal Carcinoma (1289)
J Lan, H-Y Huang, H-C Tai, T-J Chen, C-F Li
Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan; Changhua Christian Hospital, Changhua, Taiwan; Chi-Mei Medical Center, Tainan, Taiwan; National Health Research Institutes, Tainan, Taiwan; Southern Taiwan University of Science and Technology, Tainan, Taiwan

209 Presence and Distribution of Plasmacytoid Dendritic Cells in Head and Neck Lymphoepithelial Carcinoma. Possible Role in the Pathogenesis and Potential Therapeutic Target (1276)
AM Cano-Valdez, C Guajardo-Lopez, K Ordonez-Pantoja, E Gonzalez-Conde, AG Puebla-Mora, A Mohar-Betancourt
Instituto Nacional de Cancerologia, Mexico City, Mexico; Centro Oncologico Tamaulipas, Ciudad Victoria, Mexico; Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico

210 TOP2A Overexpression as a Poor Prognostic Factor in Patients with Nasopharyngeal Carcinoma (1288)
J Lan, C-F Li, T-J Chen, H-C Tai, H-Y Huang
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Chi-Mei Medical Center, Tainan, Taiwan; Southern Taiwan University of Science and Technology, Tainan, Taiwan; National Health Research Institutes, Tainan, Taiwan; Changhua Christian Hospital, Changhua, Taiwan

211 Sonic Hedgehog Pathway (HHIP, PTCH1 and SHH) VEGF-A in Oral Squamous Cell Carcinomas: Association with Expression of VEGF-A and Microvessels (1306)
CB Schlaepfer-Sales, MEC Buim, RO Souza, LF Valverde, MCM Machado, JN Dos Santos, MG Reis, FJ Soares, EAG Ramos, CA Gurgel
Federal University of Bahia, Salvador, Bahia, Brazil; Oswaldo Cruz Foundation-Gonçalo Moniz Research Center, Salvador, Bahia, Brazil; AC Camargo Hospital, Sào Paulo, Brazil

212 SOX2 as a Potential Therapeutic Target in Squamous Cell Carcinoma of the Head and Neck (1272)
M Bode, A Schrock, PM Bareiss, F Goke, A Franzen, R Kirsten, A von Massenhoven, T van Bremen, F Bootz, G Kristiansen, C Lengerke, S Perner
Institution of Pathology, University Hospital of Bonn, Bonn, Germany; Institution of Otorhinolaryngology, University Hospital of Bonn, Bonn, Germany; Internal Medicine II, University Hospital of Tuebingen, Tuebingen, Germany
### HEMATOLOGY

- **Board Number**: 214

#### Primary Myelofibrosis with del(20q): Association with JAK2V617F Status (1408)
- **Authors**: S Kaul, G Lu, JM Gonzalez-Berjon, S Verstovsek, SA Pierce, T Muzzafar
- **Affiliation**: University of Texas MD Anderson Cancer Center, Houston, TX

#### Evaluation of Ancillary Test Utilization for Mast Cell Diseases (1388)
- **Authors**: R He, AJ Wood, D Chen, CA Hanson
- **Affiliation**: Mayo Clinic, Rochester, MN

#### The Clinical and Pathologic Features of Clonal Mast Cell Disorders That Fail To Meet the WHO Diagnostic Criteria for Systemic Mastocytosis (1533)
- **Authors**: AJ Wood, D Chen, R He, CA Hanson
- **Affiliation**: Mayo Clinic, Rochester, MN

#### Subtypes of Systemic Mastocytosis Exhibit Distinct Immunomorphologic Features in Bone Marrow Biopsies (1356)
- **Authors**: A Chiu, MB Czader, RC Ochs, D Wang, DC Park, JA Achim, D Frosina, A Goswami, T-F Julie, A Orazi
- **Affiliation**: Memorial Sloan-Kettering Cancer Center, New York, NY; Indiana University School of Medicine, Indianapolis, IN; Weill Cornell Medical College, New York, NY

#### Mast Cell Sarcoma: An Aggressive and Potentially Under-Diagnosed Neoplasm That May Be Responsive to Targeted Therapy (1501)
- **Authors**: RJH Ryan, C Akin, M Castells, MK Selig, GP Nielsen, JA Ferry, JL Hornick
- **Affiliation**: Massachusetts General Hospital, Boston, MA; Brigham and Women’s Hospital, Boston, MA

#### Occult Mastocytosis in AML with Inv(16) and Therapy-Related AML (1443)
- **Authors**: BA Martin, RC Johnson, JR Gottlib, DA Arber, TJ George
- **Affiliation**: Stanford University School of Medicine, Stanford, CA

#### Therapy-Related Extamedullary Hematopoiesis: An Unexpected Finding and Diagnostic Pitfalls (1531)
- **Authors**: DB Wimmer, E Salazar, AW Zieske, WL Chandler, MR Schwartz
- **Affiliation**: Methodist Hospital, Houston, TX

#### Myeloproliferative Neoplasms Occurring in Patients with a Cancer History (1545)
- **Authors**: L Zhang, W Xie, CY OK, LJ Medeiros, SA Wang
- **Affiliation**: UT MD Anderson, Houston, TX; Methodist Hospital, Houston, TX

#### Myeloid Neoplasms Following Solid Organ Transplantation: Clinicopathologic Studies of 11 Cases (1416)
- **Authors**: ST Kramer, DM Reddi, CM Lu, J Gong, C Rehder, E Wang
- **Affiliation**: Duke University Medical Center, Durham, NC; UCSF, San Francisco, CA; Thomas Jefferson University, Philadelphia, PA

#### Primary Myelodendritic Cell Neoplasms: A Description of 3 Cases (1429)
- **Authors**: AR Balog, HJ Meyerson
- **Affiliation**: University Hospitals Case Medical Center, Cleveland, OH

#### CD34 Expression Is Associated with an Adverse Outcome in Patients with NPM1-Positive Acute Myeloid Leukemia (1365)
- **Authors**: H Dang, M Chen, J Brandwein, H Chang
- **Affiliation**: University Health Network, Toronto, ON, Canada

#### Natural Killer Cell (NK) Subsets and NK-Like T-Cells (NKT) Vary in Acute Myeloid Leukemias (AML) and Myelodysplastic Syndromes (MDS) and May Correlate with Survival in AML (1322)
- **Authors**: N Aggarwal, SH Swerdlow, SP TenEyck, M Boyiadzis, RE Felgar
- **Affiliation**: University of Pittsburgh, School of Medicine, Pittsburgh, PA

#### Correlation of FLT3 Mutations with Expression of CD7 in Acute Myeloid Leukemia (1331)
- **Authors**: J Baqai, D Crisan
- **Affiliation**: William Beaumont Hospital, Royal Oak, MI

#### Genetic Subtypes of Acute Myeloid Leukemia Are Associated with Distinctive Features of the Bone Marrow Microenvironment (1411)
- **Authors**: VE Klepeis, LR Zakerberg, RP Hasserjian
- **Affiliation**: Massachusetts General Hospital, Boston, MA

#### Acute Megakaryoblastic Leukemia with Specific Translocation t(15;17): Clinical, Gross Genetic, and Chromosomal Analysis and Fluorescent In-Situ Hybridization in (APML) (1413)
- **Authors**: R Kolhe, A Rojiani, A Jillella, V Kota, L Waleczak, J Shaw, B DuPont
- **Affiliation**: Georgia Health Sciences University, Augusta, GA

#### Acute Megakaryoblastic Leukemia in Adults: A Clinicopathologic reappraisal of 50 Cases Using WHO Criteria (1377)
- **Authors**: JM Gonzalez-Berjon, G Lu, S Verstovsek, SA Pierce, CE Bueso Ramos, T Muzzafar
- **Affiliation**: University of Texas MD Anderson Cancer Center, Houston, TX

#### Myeloid Dendritic Cell Neoplasms: A Description of 3 Cases (1329)
- **Authors**: AR Balog, HJ Meyerson
- **Affiliation**: University Hospitals Case Medical Center, Cleveland, OH
234 Human Blastic Plasmacytoid Dendritic Cell Neoplasms. Characterization of a Series of 45 Cases with Clinical Correlation (1484)
A Parra Cubillos, A Martinez Lopez, W Salcedo Mercado, R Pajares, R Fuentes-Mateos, ME Castillo, R Franco, MA Piris, S Montes-Moreno, C Barriomueuo-Cornejo, S Casavilca-Zambrano, S Quintana-Treyuenque, C Samanez-Figari HUMV, Santander, Spain; CNIO, Madrid, Spain; FJD, Madrid, Spain; INEN, Lima, Peru; Instituto dei Tumori, Napoli, Italy; Medica INEN

235 Expansion of Non-Neoplastic Myeloblasts in Regenerative Bone Marrows Post Lymphoblastic Leukemia Therapy (1328)
O Asojo, N Karandikar, J Emmons, B Levenson, F Fuda UT Southwestern, Dallas, TX

236 Blood and Bone Marrow Myeloblasts Show Immunophenotypic Variation in Cases of Acute Lymphoblastic Leukemia (1348)
FJ Castro-Silva, NJ Karandikar, FS Fuda, BM Levenson UT Southwestern, Dallas, TX

237 Expression of MUM1 in B Lymphoblastic Leukemia/ Lymphoma, Burkitt Lymphoma, and T Lymphoblastic Leukemia/Lymphoma (1417)
EF Krasik, A Deucher, SJ McAlhany University of California San Francisco, San Francisco, CA

238 Increased Hematogones Mimic B Lymphoblastic Leukemia in Non-Transplant Bone Marrows of Patients Treated for Acquired Aplastic Anemia (1548)
X Zhao, DM Townsley, NS Young, I Maric NIH, Bethesda, MD

239 Detection of Minimal Residual Disease (MRD) in B Lymphoblastic Leukemia/Lymphoma, Burkitt Lymphoma, and T Lymphoblastic Leukemia/Lymphoma Using a 9 Parameter Kaluza Radar Plot (1436)
JM Luider, K Paisooksantivatana, A Mansoor, IA Auer-Grzesiak University of Calgary, Calgary, AB, Canada

240 Incorporation of Immunophenotyping in the Risk Stratification of Patients with Philadelphia Chromosome Negative B Cell Acute Lymphoblastic Leukemia (1352)
Y Chen, K Craddock, J Brandwein, H Chang University Health Network, Toronto, ON, Canada

241 Expression of CD1a, CD4 and Myeloid Antigens Correlate with Treatment Response and Survival in Adult T-Cell Acute Lymphoblastic Leukemia (1364)
Bl Dalal, A Al Magairi, S Pi, SY Lee, NS Khare, J Pal, A Bryant, S Lau, Y Abou Mourad Vancouver General Hospital, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada

242 Characterization of Anatomic Distribution of Acute Leukemia Relapse in the Pediatric Patients (1424)
K Lee, A McGranaham, T Winkler, X Liang Children, Aurora, CO; University of Colorado Denver School of Medicine, Aurora, CO

243 Incomplete Engraftment Is Not Equivalent to Residual Disease: A Two-Year Study of Hematological Malignancies (1422)
DR LaFrance, C Vencak-Jones, CA Mosse, A Seegmiller, AS Kim Vanderbilt University Medical Center, Nashville, TN

244 OCT-2 and BOB.1 Expression in Acute Leukemias (1506)
MT Schmidt, C Hayes, S Kitahara Cedars-Sinai Medical Center, Los Angeles, CA

245 Incomplete Engraftment Is Not Equivalent to Residual Disease: A Two-Year Study of Hematological Malignancies (1422)
DR LaFrance, C Vencak-Jones, CA Mosse, A Seegmiller, AS Kim Vanderbilt University Medical Center, Nashville, TN

246 Validation of a Real-Time PCR Assay for Detection of Pneumocystis jiroveci in Respiratory Specimens (1553)
KR Aroa, K Vadlamudi, LW Razai, JR Lindner, W Furgana, H Fan University of Texas Health Science Center, San Antonio, TX

247 Intracytoplasmic Granulocytic Morulae Counts on Confirmed Cases of Human Granulocytic Ehrlichiosis/Anaplasmosis in the Northeastern United States (1564)
JW Rand, A Tarasen, S Homan, E Tobin Albany Medical Center, Albany, NY

248 Identification of Burkholderia Cepacia Complex Isolates by MALDI-TOF MS from Burkholderia Cepacia Selective Agar (1556)
J Jedzkiewicz, M Fisher University of Utah, Salt Lake City, UT

249 Immunohistochemical and Genetic Evaluation of EBV-Positive Aggressive B Cell Lymphomas (1560)
DP O’Malley, KE Grimm, R Agrawal, LM Weiss Clariant Inc./GE Healthcare, Aliso Viejo, CA

250 New Archetypal Poxvirus Infection in an Immunosuppressed Man (1557)
N Lakis, D Blair, JL Abraham, Y Li, I Damon SUNY Upstate Medical University, Syracuse, NY; CDC, Atlanta, GA

251 Surgical Lung Biopsy in Immunosuppressed Pediatric Patients (1563)
JE Pogoriler, AN Husain University of Chicago Medical Center, Chicago, IL

252 Adenovirus Infection in Solid Organ Transplant Recipients (1558)
V Mehta, K Mudaliar, PC Chou, MM Picken Loyola University Medical Center, Chicago, IL; Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL

253 Identification of Fungi in Tissue: A Discrepancy between Histology/Cytology Versus Microbiology (1552)
M Agarunov, J Tetreault, L Calderin, J Aslunzadeh, M Fiel-Gan Hartford Hospital, Hartford, CT

254 Extra-Oral Plasmablastic Lymphomas as a Predominant Involvement Pattern in AIDS Patients of an Inner City Hospital (1566)
I Trgovic, C Duckworth, M Nguyen, C Gunthel, M Mosunjac Emory University, Atlanta, GA
255 Non-Classical MHC-1 Ia 1b HLA-E Expression Levels Are Maintained in HIV-1 Infected CD4 Positive T Cells (1567)
J Wicker, P Goepfert, S Sabbaj
University of Alabama at Birmingham, Birmingham, AL

256 Use of Locked Nucleic Acid Probes (LNA) Greatly Increases Sensitivity of Sanger Sequencing (SS): A Comparative Experience of Genotyping of KRAS Codons 12,13 (2043)
D A Chitale, L Whiteley, L Szymanski, M Cancovic
Henry Ford Hospital, Detroit, MI

257 Performance Evaluation Comparison of Three Commercially Available PCR-Based KRAS Mutation Testing Platforms (2035)
Indiana University School of Medicine, Indianapolis, IN

258 Comparative Analysis of Different Types of KRAS Mutation between Frozen and Paraffin Embedded Tissue Using the Pyrosequencing Method (2067)
Hospital A C Camargo, Sao Paulo, Brazil

259 KRAS/BRAF Mutations in Colorectal Carcinoma. A Comparative Study between Real-Time PCR, Sanger Sequencing and Chip-Hybridization PCR Based Technology (2056)
J Hernandez-Losada, R Somoza, R Mares, E Lindo, A Solsona, T Moline, S Landolfi, S Ramon y Cajal
Hospital University Vall d’Hebron, Barcelona, Spain; Vall d’Hebron Research Institute, Barcelona, Spain

260 Comparison of Three BRAF Mutation Tests in Formalin-Fixed Paraffin Embedded Clinical Samples (2037)
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; School of Medicine, Kyung Hee University, Seoul, Republic of Korea

261 Performance Studies of the New One-Day HER2 IQFISH PharmDx™ – European Multicentre Experience (2063)
M Lacroix-Triki, D Hardisson, MG Tibiletti, C Franchet, F Penault-Llorca, J Jacquemier, G Mac Grogan, L Arnould, T Garcia-Caballero, A Concha, G Viale, J Raschouf
Institut Claudius Regaud, Toulouse, France; University Hospital La Paz, Madrid, Spain; Ospedale di Circolo-Umberto I of Novara, Varese, Italy; Centre Jean Perrin, Clermont-Ferrand, France; Institut Pauli Calmettes, Marseille, France; Institut Bergomié, Bordeaux, France; Centre GE Leclerc, Dijon, France; University Hospital, Santiago de Compostela, Spain; University Hospital Virgen de las Nieves, Granada, Spain; Institute of Oncology and University of Milan, Milan, Italy; Targos Molecular Pathology gmbh, Kassel, Germany

262 Analytical Reproducibility of the Breast Cancer Intrinsic Subtyping Test and nCounter Analysis System Using Formalin-Fixed Paraffin-Embedded (FFPE) Breast Tumor Specimens (2075)
T Nielsen, S McDonald, S Kulkarni, J Storhoff, C Schaper, B Wallden, S Ferree, S Liu, V Huchtagowder, K Deschryver, V Holtschlag, G Barry, M Evenson, N Dowidar, M Maysuria, D Gao
British Columbia Cancer Agency, Vancouver, BC, Canada; Washington University School of Medicine, St. Louis, MO; NanoString Technologies, Seattle, WA; MyRAQA Inc., Redwood Shores, CA

263 Out of the Dark into the Light: Brightfield Dual In Situ Hybridization as a Modality for Assessing HER2 Gene Amplification in Invasive Urothelial Carcinoma (2044)
P Cotzia, A Bombonati, R O’Neill, D Jaller, R Draganova-Tacheva, C Solomides, S Peiper, P McCue, R Birbe
Thomas Jefferson University Hospital, Philadelphia, PA

264 Validation of Dual Color HER2/Chromosome 17 ISH (In-Situ Hybridization) – Comparison with Single Color CISH (Chromogenic In-Situ Hybridization) and Inter-Observer Reproducibility (2040)
M P Branscomb, J R Ross, D Horton, M S Rosco, T S Winokur, V V Reddy, S Wei, S Harada
University of Alabama at Birmingham, Birmingham, AL

265 Digital Imaging in Breast Cancer: An Ode to Microscopy (2048)
K D Drak Alsibai, S A Azoulay, O Languille-Mimoune, B Poullet, A Barres, C Adem
Institut de Pathologie de Paris, Paris, France

266 New Visualization Technique Enables Her2 Immunofluorescence Staining To Resemble Traditional Chromogenic DAB Stain (2065)
M Lazare, K Kenny, N Jun, A Kyshtoobayeva, D Hollman, D Henderson, A Corwin, T Ha, S Kaanumalle, C McCulloch, K Bloom
G E Global Research, Niskayuna, NY, Vanuatu; Clarient Diagnostics, a GE Healthcare Company, Aliso Viejo, CA

267 Novel Image Processing Technique Allows Immunofluorescence Signals To Resemble Traditional H&E Stain and Enable Multiple Biomarker Visualizations on a Single Slide (2066)
M Lazare, K Kenny, N Jun, A Kyshtoobayeva, D Hollman, D Henderson, A Corwin, T Ha, C Chow, K Bloom
G E Global Research, Niskayuna, NY; Clarient Diagnostics, a GE Healthcare Company, Aliso Viejo, CA

268 A Modified HER2 Image Analysis Algorithm with ASCO/CAP Criteria Has High Concordance with FISH (2071)
DM Minot, JS Voss, BR Kipp, A Dogan, RP Ketterling, AM Plagge, T Mounajjed, AC Clayton
Mayo Clinic, Rochester, MN

269 Image Analysis of Ki-67 IHC Stain for Breast Carcinoma – A Study Comparing Two Image Analysis Systems (2080)
A M Plagge, T Mounajjed, JS Voss, DM Minot, DJ Tuve, BR Kipp
Mayo Clinic, Rochester, MN
292 Comparison of LMP-1 Immunostaining Patterns with EBER-ISH Reactivity (2088)
J Thomas
Louisiana State University Health Science Center, Shreveport, LA

293 Useful Immunohistochemical Technique in Heavily Pigmented Malignant Melanoma (2083)
M Shimizu, Y Hosonuma, H Yamaguchi, K Nagata, M Yasuda
Saitama Medical University International Medical Center, Hidaka, Saitama, Japan

294 SLIM: Tool To Aid Pathologists in Separation of Prostate Cancer Gleason Grade 3 and 4 (2087)
University of Illinois at Urbana-Champaign, Urbana, IL; University of Illinois at Chicago, Chicago, IL; Christie Clinic, Urbana, IL

295 Colorimetric Detection of Prostate Cancer in Grid Regions Utilizing a Ratio of Racemase to High Molecular Weight Keratin (HMWK) and P63 (2041)
BM Brasseur, AD Johnson, JC Henrikson, JS Koopmeiners, KB Daniels, GJ Metzger, SC Schmechel
University of Minnesota, Minneapolis, MN

296 Unexpected PAX8 Reactivity in Metastatic High Grade Breast Cancer (2036)
KH Adamson, KH Allison, PE Swanson, SM Dintzis, MH Rendi
University of Washington, Seattle, WA

297 Lack of Reactivity with TdT in Small Cell Carcinoma (2077)
BR Oliai, CJ Buresh, RT Miller
ProPath Laboratory, Dallas, TX

298 Role of Magnification in Visual Evaluation of Manual and Automated HPV In-Situ Hybridization in Oropharyngeal Carcinoma Biopsy Samples (2084)
MT Siddiqui, C Cohen, N Fatima
Emory University Hospital, Atlanta, GA

299 Concordance Study Reveals a Higher Performance of OSNA over Morphologic Techniques To Detect Lymph Node Metastasis in Papillary Carcinoma of the Thyroid (2045)
S del Carmen, S Gattis, C Garcia-Macias, JA Baena-Fastegui, G Franch-Arcas, P Galindo, A Perez, J Pallares, D Cuevas, X Mattias-Gaita, E de Alava
Salamanca University Hospital-CIC-IBSAL, Salamanca, Spain; Arnau de Vilanova Hospital, Lleida, Spain

300 TTF-1 Associated Surfactant Deficiency: Role of Ultrastructural Evaluation (2099)
J Hicks, G Meriau, E Warthow, C Langston
Baylor College of Medicine & Texas Children’s Hospital, Houston, TX; Children’s Hospital Colorado, Aurora, CO

301 Odontogenic Myxoma: Review of Histopathologic, Immunocytochemical and Ultrastructural Features (2101)
J Hicks, R Laucrica, C Finch, J Bouquot
Baylor College of Medicine, Houston, TX; University of Texas Houston School of Dentistry, Houston, TX

302 COLVα2 a Biomarker of Vasculopathy in Scleroderma? (2103)
J Morais, P Martin, IC Camargo, ML Katayama, S Carrasco, C Goldeinstein-Schainber, ER Parras, F Barreence, AP Velosa, VL Capelozzi, WR Teodora
University of São Paulo Medical School, São Paulo, Brazil; Institute of Biomedical Sciences of the University of São Paulo, São Paulo, Brazil

303 Vesicular-Lamellated Bodies in a Case of Chromophobe Renal Cell Carcinoma: A Transitive Form between Mitochondria and Vesicle? (2102)
A Krausert, C Thomas, R Wieczorek, N Cassai
NYU School of Medicine, New York, NY; New York Harbor Healthcare System (NY VA), New York, NY

Poster Session VI
Wednesday, March 6, 2013
1:00 PM – 4:00 PM
CC Exhibit Hall A-D

Poster numbers to the left of the abstract title correspond to the board number where the poster will be displayed. The number in parentheses after the title is the abstract number in the Abstract Book. These posters will be on display this afternoon only.

BREAST

1 Clinicopathologic Evaluation of Apocrine Carcinoma of the Breast (175)
Y Gong, S Sioshansi, S Lu, D Kandil, A Khan
University of Massachusetts Medical School, Worcester, MA; Rhode Island Hospital, Providence, RI

2 Does Morphologic Apocrine Differentiation (AD) in Ductal or Lobular Breast Cancer Correlate with “Molecular Apocrine” Subset? (313)
D Zakhia, NS Gupta, DA Chitale
Henry Ford Hospital, Detroit, MI

3 Immunohistochemical Characterization of Cystic Hypersecretory Carcinoma (137)
TM D’Alfonso, Y-F Liu, SJ Shin
Weill Cornell Medical College, New York, NY

4 Metaplastic Breast Carcinoma: A Clinico-Pathological and Immunohistochemical Study (101)
FJ Altab, EAS Emam, GA Mokhtar, RY Bokhary, SM Al Amoudi, LA Baharih, HH Ali
King Abdullahz University, Jeddah, Western, Saudi Arabia

5 A New Rabbit Monoclonal E-Cadherin Antibody Shows Higher Sensitivity Than Mouse Monoclonal E-Cadherin [HECD-1] Antibody in Infiltrating Ductal Cell Carcinomas (181)
L Hoang, R Bremer, P Tang, DG Hicks, T Haas, D Tacha
Biocare Medical, LLC, Concord, CA; University of Rochester Medical Center, Rochester, NY; Mercy Health System, Janesville, WI
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>Aldehyde Dehydrogenase 1 (ALDH1) Expression in Non-Lobular Breast Carcinomas in African American Women (229)</td>
<td>TJ Naab, AK Esnaku, LJ Ricks-Santi, Y Kanaan, B Gold</td>
<td>Howard University Hospital, Washington, DC; Frederick National Laboratory for Cancer Research, Frederick, MD</td>
</tr>
<tr>
<td>7</td>
<td>ROR2 Expression in Breast Cancer (177)</td>
<td>X Guo, P Sweeney, S Varma, K Montgomery, RB West, M van de Rijn</td>
<td>Stanford University School of Medicine, Stanford, CA</td>
</tr>
<tr>
<td>8</td>
<td>Laminin β1 and Laminin β2 Expression in Invasive Breast Carcinoma (206)</td>
<td>J-P Lai, X Fan, J Ljubimova, A Ljubimov, S Bose</td>
<td>Cedars-Sinai Medical Center, Los Angeles, CA</td>
</tr>
<tr>
<td>9</td>
<td>Expression of Beclin-1 Protein in Breast Cancer (164)</td>
<td>AV Gandhi, PJ Holmes, JP Palazzo</td>
<td>Thomas Jefferson University Hospital, Philadelphia, PA</td>
</tr>
<tr>
<td>10</td>
<td>Differential Expression of miR-21, miR-205, miR-221, miR-222, and miR-150 in Molecular Subtypes of Breast Cancer (259)</td>
<td>A Poongothai, X Ling, P Sudipta, K Kalra, RK Pillai, MB Amin, S Bose</td>
<td>Biogenex Lab, Freemont, CA; Cedars-Sinai Medical Center, Los Angeles, CA</td>
</tr>
<tr>
<td>11</td>
<td>C/EBPβ Expression Is Predictor of Survival in Breast Cancer Patients (201)</td>
<td>E Kurzejamska, K Jistrom, P Religa</td>
<td>Karolinska Institutet, Stockholm, Sweden; Lund University, Lund, Sweden</td>
</tr>
<tr>
<td>12</td>
<td>Insulin Growth Factor Receptor-1 (IGF-1R) Overexpression Is Associated with Hormone Receptor Positive Ductal Carcinomas in African-American Women (150)</td>
<td>AK Esnaku, LJK Ricks-Santi, WAI Frederick, Y Kanaan, TJ Naab</td>
<td>Howard University Hospital, Washington, DC</td>
</tr>
<tr>
<td>13</td>
<td>Study of GLI1, GLI2 and GLI3 Transcripts Levels of Expression in Immunophenotypes of Breast Carcinoma and Breast Cancer Cell Lines (255)</td>
<td>A Perez-Balaguer, F Ortiz-Martinez, M Niveiro, FJ Aranda, E Lerma, G Peiro</td>
<td>University General Hospital, Alicante, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain</td>
</tr>
<tr>
<td>14</td>
<td>Toll-Like Receptor 3 Signaling in Breast Cancer (308)</td>
<td>M Yamashita, PE Bomeisl, GC Sen, HL Gilmore</td>
<td>University Hospitals Case Medical Center, Cleveland, OH; Case Western Reserve University, Cleveland, OH; Cleveland Clinic, Cleveland, OH</td>
</tr>
<tr>
<td>15</td>
<td>The Prognostic Value of STAT1 Overexpression and Clinicopathologic Features in Breast Cancer Patients Receiving Adjuvant Radiotherapy (127)</td>
<td>W-C Chen, C-L Wu, Y-H Lai, H-Y Chen, HHW Chen</td>
<td>National Cheng Kung University Medical College and Hospital, Tainan, Taiwan</td>
</tr>
<tr>
<td>16</td>
<td>BRST2, ER, e-Cadherin, CDX2, and NKX3.1 Utility in Distinguishing Diffuse Gastric from Lobular Carcinoma (210)</td>
<td>GH Lewis, R West, RK Pai, TA Longacre, KC Jensen</td>
<td>Stanford University, Stanford, CA; University of Pittsburgh, Pittsburgh, PA; VA Palo Alto HCS, Palo Alto, CA</td>
</tr>
<tr>
<td>17</td>
<td>Proliferation Markers PHH3, Ki67 and Mitotic Count All Show Significant Associations with Features of Aggressive Breast Carcinomas and Reduced Survival (198)</td>
<td>G Knutsvik, IM Stefansson, K Collett, LA Akslen</td>
<td>University of Bergen, Bergen, Norway; Haukeland University Hospital, Bergen, Norway</td>
</tr>
<tr>
<td>18</td>
<td>ARD1 Expression Correlates with Favorable Prognostic Variables in Invasive Mammary Carcinoma (MC) (239)</td>
<td>G Niu, BV'S Kallakury, AB Boguniewicz, CB Sheehan, CE Sheehan, JS Ross</td>
<td>Albany Medical College, Albany, NY; Georgetown University Hospital, Washington, DC</td>
</tr>
<tr>
<td>19</td>
<td>The Expression Level of PThoc1 Is Associated with Her2 Status and Tumor Size in Breast Cancer (213)</td>
<td>Y Li, J Yang, JA Almenara, HT Richard, JP Bergeron, DW Goodrich, MO Idowu</td>
<td>Virginia Commonwealth University Health System, Richmond, VA; Virginia Department of Health, Richmond, VA; Roswell Park Cancer Institute, Buffalo, NY</td>
</tr>
<tr>
<td>20</td>
<td>NKX3.1 Expression in Primary Breast Carcinoma (270)</td>
<td>MA Samols, A Subbawong, R Sharma, PB Illei, P Argani, AM Cimino-Mathews</td>
<td>Johns Hopkins Hospital, Baltimore, MD</td>
</tr>
<tr>
<td>21</td>
<td>Nogo-B and NgBR Are Strongly Associated with Luminal A Sub-Type Breast Cancer (302)</td>
<td>B Wang, B Zhao, J Huang, RQ Miao</td>
<td>China-Japan Friendship Hospital, Beijing, China; Medical College of Wisconsin, Milwaukee, WI</td>
</tr>
<tr>
<td>22</td>
<td>The Unique Role of ER-α36 in Maintaining a Close Relationship between ER-α66 and HER2 in Breast Cancer (183)</td>
<td>J Huang, CR Chitambar, B Behmaram, YC Cheng, Z Basir, A Walker</td>
<td>Medical College of Wisconsin, Milwaukee, WI</td>
</tr>
<tr>
<td>23</td>
<td>Classification of Recurrent MAST and NOTCH Mutations in Breast Carcinoma, a Study of Pre-Malignant Lesions Indicates Early Involvement (131)</td>
<td>MR Clay, F Sushama, WW Robert</td>
<td>Stanford Hospital and Clinics, Stanford, CA</td>
</tr>
<tr>
<td>24</td>
<td>Tumor Associated Inflammation Correlates with Poor Prognosis in Pregnancy Associated Breast Cancer (116)</td>
<td>LZ Blanco, Jr., A Mahajan, SA Khan, ME Sullivan, SM Rohan, KP Sziopikou</td>
<td>Northwestern University Feinberg School of Medicine, Chicago, IL</td>
</tr>
<tr>
<td>25</td>
<td>Synchronous Breast Cancers: Comparison of Racial Distribution in Pathologic Parameters of Aggressive Behavior (147)</td>
<td>C Duckworth, L Xu, G Birdsong, I Trgoveic, M Mosunjac</td>
<td>Emory University, Atlanta, GA</td>
</tr>
<tr>
<td>Board Number</td>
<td>Title</td>
<td>Authors</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Histopathologic Characteristics and Molecular Classification of Breast Cancer in Young Lebanese Women (312)</td>
<td>C Youssef, Massad, F Fedda, F Boulos American University of Beirut Medical Center, Beirut, Lebanon; University of Arkansas for Medical Sciences, Little Rock, AR</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>Male Breast Carcinoma: Clinicopathologic and Molecular Analysis of 89 Cases (188)</td>
<td>D Jaggiessarsingh, J Catalano, M Akram, E Brogi, M Murray Memorial Sloan-Kettering Cancer Center, New York, NY</td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>ER, PR, Her2, and Ki-67 Expression in Male and Female Breast Cancer (218)</td>
<td>MG Lockyer, E Martinez-Blanco, G Verstovsek, I Bedrosian, C Albarracin, D Rosen Baylor College of Medicine, Houston, TX; MD Anderson Cancer Center, Houston, TX</td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>Clinicopathologic Features of Male Paget Disease of Breast: 11 Cases from a Single Institute (146)</td>
<td>X Duan, A Gullett, N Sniege, D Rosen, E Resetkova, C Ersahin, Y Wu, I Bedrosian, CT Albarracin Loyola University Medical Center, Maywood, IL; MD Anderson Cancer Center, Houston, TX; University of Washington, Seattle, WA</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Multinucleation in Lobular Carcinoma In Situ: A Histologic Feature Specific for the Pleomorphic Variant (117)</td>
<td>LZ Blanco, Jr., A Mahajan, KP Sziopikou, B Susnik, ME Sullivan Northwestern University Feinberg School of Medicine, Chicago, IL; Abbott-Northwestern Hospital, Minneapolis, MN</td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>Carcinogenesis Pathways of Pleomorphic Lobular Carcinoma (207)</td>
<td>I Lamzabi, R Ghai, V Reddy, P Bitterman, R Singh, P Gattuso Rush University Medical Center, Chicago, IL</td>
<td></td>
</tr>
<tr>
<td>32</td>
<td>Changes in Breast Cancer Reports after Pathology Second Opinion (226)</td>
<td>V Marco Molina, T Muntal, J Cortes, B Gonzalez, I Rubio, F Garcia Hernandez Hospital Quiron Barcelona, Barcelona, Spain</td>
<td></td>
</tr>
<tr>
<td>33</td>
<td>Napsin A Expression in Anaplastic, Poorly Differentiated and Micropapillary Pattern Thyroid Carcinomas (541)</td>
<td>R Chernock, S El-Mofty, N Becker, J Lewis, Jr. Washington University School of Medicine, St Louis, MO</td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>MicroRNA Expression Profiles in Poorly Differenntiated Thyroid Carcinomas (545)</td>
<td>MS Dettmer, A Perren, P Komminoth, H Moch, YE Nikiforov, MN Nikiforov University of Pittsburgh Medical Center, Pittsburgh, PA; University of Bern, Bern, Switzerland; Trieml Elisabeth, Zurich, Switzerland; University Hospital Zurich, Zurich, Switzerland</td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>The Utility of Cyclin D1 in Distinguishing Encapsulated Follicular Variant of Papillary Thyroid Carcinoma from Follicular Adenoma (584)</td>
<td>DA Zakhia, W Advar, Z Zhang, O Alassi Henry Ford Health System, Detroit, MI</td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>Interobserver Variability in the Assessment of Extrathyroidal Extension in Papillary Thyroid Microcarcinoma (578)</td>
<td>R Virk, A Prasad, C Theoharis, M Prasad Yale School of Medicine, New Haven, CT; Hartford Hospital, Hartford, CT</td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>Micronuclei and Nuclear Buds: Highlighting Overlooked Indicators of Increased Chromosomal Damage in Thyroid Lesions with Emerin Immunohistochemistry (544)</td>
<td>I Coban, TD Kokenek Unal, A Erdogan Cakir, AS Oguz, M Alper Diskapi YB Training and Research Hospital, Ankara, Turkey; Corlu State Hospital, Corlu, Turkey</td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>BRAF V600E Mutation-Specific Monoclonal Antibody Is Predictive of BRAF Mutation Status Determined by Genotyping in Papillary Thyroid Carcinoma (531)</td>
<td>CA Adackapara, BE Howitt, LM Sholl, JF Krane, JL Hornick, JA Barletta Brigham and Women’s Hospital, Boston, MA</td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>Analysis of BRAFV600E Mutation Status in Papillary Thyroid Carcinoma with Single or Multiple Tumor Nodules (575)</td>
<td>JNM Tän, A de las Morenas, S Yang, H Xu Boston University Medical Center, Boston, MA</td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>BRAF Genetic Heterogeneity in Papillary Thyroid Carcinoma and Its Metastasis (538)</td>
<td>S Bose, A Pao, AE Walts Cedars-Sinai Medical Center, Los Angeles, CA</td>
<td></td>
</tr>
<tr>
<td>41</td>
<td>Hobnail Variant of Papillary Thyroid Carcinoma: Case Series with Fine-Needle Aspiration Cytology and Cell-Blocks (534)</td>
<td>S Asioli, F Pagni, F Maletta, D Pacchioni, A Sapino University of Turin, Turin, Italy; University Milan Bicocca, Milan, Italy</td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>BRAF Mutation Status Has a Limited Role in Predicting Long-Term Persistence in Papillary Thyroid Carcinoma (PTC) (580)</td>
<td>AE Walts, A Pao, S Bose Cedars-Sinai Medical Center, Los Angeles, CA</td>
<td></td>
</tr>
<tr>
<td>43</td>
<td>Interobserver Agreement in Interpreting Thyroid FNA with a Diagnosis of Atypia/Follicular Lesion of Undetermined Significance (FLUS/AUS) (576)</td>
<td>C Theoharis, M Wachtel, Z Baloch, M Bui, I Elliott, O Lin, A Simsr, E Stelow, A Adeniran, G Cai, M Harigopa, A Levi, B Ustun, M McKenzie, D Kowalski, D Chhieng Yale University, New Haven, CT; University of Virginia, Charlottesville, VA; University of Pennsylvania, Philadelphia, PA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Alabama, Birmingham, AL; Moffitt Cancer Center, Miami, FL; Texas Tech University, Lubbock, TX; New York University, New York, NY</td>
<td></td>
</tr>
<tr>
<td>44</td>
<td>Meta-Analysis of the Molecular-Expression Signatures Accuracy in Cytological Indeterminate Thyroid Nodules (546)</td>
<td>JA Diaz-Perez, A Reddy, D Amaro University of California, San Diego, La Jolla, CA; University of Santander, Bucaramanga, Santander, Colombia</td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>The Utility of Frozen Section in Surgical Management of Patients with Prior Indeterminate Thyroid FNA (563)</td>
<td>L Nelsen, M Lewis, B Birdsong, T Tadros, K Hanley Emory School of Medicine, Atlanta, GA</td>
<td></td>
</tr>
</tbody>
</table>
Pathologic and Molecular Characteristics of Papillary Thyroid Carcinoma in Pediatric Patients and Young Adults (550)
M Horne, S Perincheri, R Virk, P Hui, R Morotti, C Theoharis, M Prasad
Yale School of Medicine, New Haven, CT

Combination of HMGA2 and IMP3 Relative Quantitative RT-PCR Can Improve the Diagnostic Utility in Thyroid Neoplasms (553)
L Jin, RV Lloyd, KM Rumilla, J Zhang
Mayo Clinic, Rochester, MN; University of Wisconsin School of Medicine and Public Health, Madison, WI

TGFβ1 and Not TGFβ2 Is Upregulated in Hashimoto Thyroiditis-Related Papillary Thyroid Carcinoma (569)
M Petten, M Brace, M Bullock, J Wang, M Taylor, J Trites, R Hart
Dalhousie University, Halifax, NS, Canada

BRAFV600E Mutation in Papillary Thyroid Carcinomas (PTC) Associated with Hashimoto Thyroiditis (HASHI): A Clinicopathological Correlation (568)
S Perincheri, M Horne, R Virk, P Hui, M Prasad
Yale University, New Haven, CT

Whole Genome and Targeted Next Generation Sequencing in Thyroid Cancer (564)
Y Nikiforov, L Kelly, MB Durso, P Liu, J Luo, M Nikiforova
University of Pittsburgh, Pittsburgh, PA; Medical College of Wisconsin, Milwaukee, WI

Multifocal Fibrosing Thyroiditis and Its Association with Papillary Thyroid Carcinoma Using BRAF Pyrosequencing (548)
R Frank, ZW Baloch, C Gentile, CD Watt, VA LiVolsi
Hospital of the University of Pennsylvania, Philadelphia, PA

BRAF Mutation Testing in Atypia of Undetermined Significance and Suspicious for Malignant Categories of Thyroid Fine Needle Aspirations in Clinical Practice (536)
S Balci, N Dincer, A Kilicyazgan, G Guler
Hospital of the University of Pennsylvania, Philadelphia, PA

Adrenocortical Carcinomas: A Clinicopathological Analysis of 77 Cases (581)
A Weissferdt, A Phan, S Suster, CA Moran
University of Texas Health Science Center at Houston, Houston, TX; MD Anderson Cancer Center, Houston, TX; Medical College of Wisconsin, Milwaukee, WI

Adrenocortical Carcinomas: An Immunohistochemical Analysis of 40 Cases (582)
A Weissferdt, A Phan, S Suster, CA Moran
University of Texas Health Science Center at Houston, Houston, TX; MD Anderson Cancer Center, Houston, TX; Medical College of Wisconsin, Milwaukee, WI

Clear Cell Variant of Thyroid Carcinoma: A Clinicopathologic Study (542)
NA Cipriani, WC Faquin, PM Sadow
Massachusetts General Hospital, Boston, MA

A Review of Cystic Lesions of the Adrenal Gland: Our Experience over the Last 20 Years (571)
C Sebastiano, Z Zhao, F-M Deng, K Das
New York University Langone Medical Center, New York, NY; National Institute of Cancer, National Institutes of Health; University of Wisconsin, Madison, WI

Extra-Adrenal Pheochromocytoma/Paraganglioma – A Clinicopathological Study (561)
D Molina, SW Fine, HA Al-Ahmadi, Y-B Chen, A Gopalan, VE Reuter, SK Tickoo
Memorial Sloan-Kettering Cancer Center, New York, NY

A Study of Phox2b and Gata3 Expression in Tumors of Autonomic Nervous System Derivation (566)
D Nonaka, BY Wang, C-CJ Sun
Christie Hospital and the University of Manchester, Manchester, United Kingdom; Albert Einstein College of Medicine and Beth Israel Medical Center, New York, NY; University of Maryland School of Medicine and University of Maryland Medical Center, Baltimore, MD

SDHB Mutation in High-Altitude Paraganglioma/ Pheochromocytoma (537)
OL Bohn, SO Miranda-Symes, S Montilla-Fonseca, E Cortez-Gutierrez, S Sanchez-Sosa
Hospital Angeles, Puebla, Mexico; Hospital Juarez, Puebla, Mexico

Correlation of Immunostains for Protein Expression with Genetic Abnormality of SDHB in Paraganglioma/ Pheochromocytoma (557)
Y Liang, SS Abadin, W-L Wang, ND Perrier, AJ Lazar
University of Texas MD Anderson Cancer Center, Houston, TX

SDHB Negative Staining as an Indicator of Presence of SDHB, SDHC and SDHD Germ Line Mutations in Pheochromocytomas and Paragangliomas (540)
E Castelblanco, S Gatius, J Pallares, M Santacana, A de Cubas, A Cascon, M Robledo, X Matias-Guiu
Hospital Universitari Arnau de Vilanova, University of Lleida, IRB Lleida, Lleida, Catalonia, Spain; Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain

DNA Methylation Profiling Identifies Different Prognostic Clusters of Pancreatic Neuroendocrine Tumors (572)
M Stefanoli, D Furlan, N Sahnane, S La Rosa, C Romualdi, F Sessa, C Capella
University of Insubria, Varese, Italy; Ospedale di Circolo, Varese, Italy; University of Padova, Padova, Italy
<table>
<thead>
<tr>
<th>Page 222</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
</tr>
</thead>
</table>
| 64 | Correlation between immunohistochemical Expressions of Somatostatin Receptor (SSTR)2a & mTOR and Clinical Response by Octreotide & Everolimus in Metastatic Pancreatic Neuroendocrine Tumors (PNET) in the Liver: A First Report on the Predictive Role of SSTR and mTOR in the Large Series of Referred Cases (567)  
RY Osamura, M Matsuda, C Inomoto, H Kajiwara  
International University of Health and Welfare Mitaka Hospital, Mitaka, Tokyo, Japan; Tokai University School of Medicine, Isehara, Kanagawa, Japan |
| 65 | Spindle Cell Oncocytomas and Granular Cell Tumors of the Pituitary Are Variants of Pituicytoma (560)  
O Mete, MB Lopes, SL Asa  
University Health Network, Toronto, ON, Canada; University of Virginia Health System, Charlottesville, VA |
| 66 | Achaete-Scute Homolog-1 (ASH1) as a Marker of Poorly Differentiated Neuroendocrine Carcinomas of Different Sites: A Validation Study Using Immunohistochemistry and Quantitative RT-PCR on 335 Cases (554)  
S La Rosa, A Marando, G Gatti, I Rapa, M Volante, M Papotti, F Sessa, C Capella  
Ospedale di Circolo, Varese, Italy; University of Insubria, Varese, Italy; University of Turin, Turin, Italy |
| 67 | TROP2 Expression in Various Tumors – A Potential Diagnostic Marker for Papillary Thyroid Carcinoma (558)  
H Liu, J Shi, F Lin  
Geisinger Medical Center, Danville, PA |
| 68 | Application of Mitosis-Specific Antibody Phospho-Histone H3 in Neuroendocrine Tumors (565)  
D Nonaka  
Christie Hospital and the University of Manchester, Manchester, United Kingdom |
| 69 | Distinct Thyroid Pathology Findings from Patients with Li-Fraumeni Syndrome (573)  
V Sujoy, J Barletta, V Nose  
University of Miami, Miami, FL; Brigham and Women's Hospital, Boston, MA |
| 70 | Pathology of Prophylactic Thyroidectomies in Patients with Germline Mutations Affecting the Extracellular Cysteine-Rich and the Intracellular Tyrosine Kinase Domains of the RET Protein (530)  
R Abi-Raad, RK Virk, RA Morotti, SA Rivkees, CK Breuer, R Udelsman, JA Sosa, ML Prasad  
Yale University School of Medicine, New Haven, CT |
| 71 | Morphological and Stem Cell-Like Features Predictive of Stage in Medullary Thyroid Carcinoma (552)  
T Ionnidis, J Moorhead, A Blanes, SJ Diaz-Cano  
King's College Hospital, London, United Kingdom; University of Malaga School of Medicine, Malaga, Spain |

**GASTROINTESTINAL**

<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
</tr>
</thead>
</table>
| 72 | Uregulation of A20 Is Induced by Helicobacter pylori Infection in Gastric Epithelial Cells (759)  
T Uchida, LT Nguyen, M Moriyama  
Oita University, Yufu, Oita, Japan; 108 Hospital, Hanoi, Viet Nam |
| 73 | Ancillary Stains Do Not Improve Helicobacter pylori Detection in Patients with Mild Disease, Even If Campylobacter-Like Organism (CLO) Tests Are Positive (706)  
NC Panarelli, DS Ross, OE Bernheim, ZB Landzberg, AN Schuetze, SE Jenkins, BR Landzberg, RK Yantiss  
Weill Cornell Medical College, New York, NY |
| 74 | Helicobacter Carditis and Its Association with Symptoms, EGD Findings and Coexistent Helicobacter Gastritis, Helicobacter Duodenitis, Gastroesophageal Reflux and Barrett’s Esophagus (678)  
I Lamzabi, R Jain, S Jakate  
Rush University Medical Center, Chicago, IL |
| 75 | Proton Pump Inhibitor Use in Patients with Helicobacter Gastritis Increases the Risk for Corpus-Predominant Gastritis and Pernenterosal Lesions of the Proximal Stomach (674)  
KR Kumar, R Iqbal, E Coss, I Park, B Cryer, RM Genta  
Miraca Life Sciences Research Institute, Irving, TX; UT Southwestern Medical School, Dallas, TX; Dallas VAMC, Dallas, TX; Dallas VAMC, Dallas, TX |
| 76 | Collagenous Gastritis: A Morphologic and Immunohistochemical Study of 27 Cases (601)  
T Arnason, I Brown, B O’Brien, C Wilson, H Winter, GY Lauwers  
Massachusetts General Hospital, Boston, MA; Royal Brisbane and Women’s Hospital, Brisbane, Qld, Australia; Sullivan Nicolaides Pathology, Brisbane, Qld, Australia |
| 77 | Prevalence of Plasma Cells and Lymphoid Follicles in Sleeve Gastrectomy Specimens: Redefining Normal Stomach Histology (732)  
M Saroufim, G Shamseddine, B Safadi, F Boulos  
American University of Beirut Medical Center, Beirut, Lebanon |
| 78 | Inflammatory Fibroid Polyps of the Gastrointestinal Tract: Spectrum of Clinical, Morphological, and Immunohistochemistry Features (686)  
T-C Liu, M-T Lin, E A Montgomery, A Singh  
Washington University, St. Louis, MO; Johns Hopkins University, Baltimore, MD; University of Pittsburgh, Pittsburgh, PA |
| 79 | Morphology and Natural History of Familial Adenomatous Polyposis (FAP)-Associated Dysplastic Fundic Gland Polyps (FGPs) (684)  
WY Liang, T Arnason, E Alfaro, P Kelly, M Genevey, RD Odze, GY Lauwers  
Massachusetts General Hospital, Boston, MA; Brigham and Women’s Hospital, Boston, MA |
| 80 | Fundic Gland Polyps with Dysplasia: Prevalence and Risk Factors (753)  
D Torrence, M Balakrishnan, R Yantiss, S Lagarde, J Gibson, D Jain  
Yale School of Medicine, New Haven, CT; Weill Medical College of Cornell University, New York, NY; Yale New Haven Hospital, New Haven, CT |
| 81 | Correlation of Ki67 Labelling Index in FNA and Biopsy of GIST with Ki67 and Mitotic Rate in Resection Specimens (615)  
JA Collins, WS Twaddell  
University of Maryland Medical Center, Baltimore, MD |
82 Mitosis-Specific Marker PHH3 Immunostain Is a More Sensitive and Efficient Method To Evaluate the Mitotic Activity in Gastrointestinal Stromal Tumor (GIST) (785)
S Zhu, F Lin, ZE Chen
Geisinger Medical Center, Danville, PA

83 Plexiform Fibromyxoma of the Gastric Antrum: Clinicopathologic and Molecular Characterization of 5 Cases (756)
M Tripathi, H Li Chang, D Divaris, R Pace, E Szentgyorgyi, A Grin, B Dickson, A Pollett, C Streutker, R Riddell, R Kirsch
St. Michael’s Hospital, Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Grand River Hospital, Toronto, ON, Canada; Toronto General Hospital, University Health Network, Toronto, ON, Canada

84 Ki67 Proliferative Index: A Sensitive Indicator of Prognosis in Gastric Neuroendocrine Neoplasms (751)
H Tatii Dogan, A Kilicarslan, S Balci, O Basaran Aydogdu, G Guler
Yildirim Beyazit University, Ankara, Turkey

85 Benign Epithelial Downgrowth in Gastric Carcinoid Tumors: A Potential Diagnostic Pitfall (717)
M Ramineni, MW Taggart, SC Abraham
MD Anderson Cancer Center, Houston, TX

86 HER2 Status in Gastric and Gastroesophageal Junction Adenocarcinoma: A Clinicopathologic and Prognostic Analysis from Four Chinese Clinical Centers (739)
W Sheng, D Huang, X Zhou, S Ni, X Du
Fudan University Cancer Center, Shanghai, China

87 Etiology and Histomorphology of Esophageal Gastric Junction Intramucosal Adenocarcinoma (IMC): In Comparison to Esophageal IMC (786)
H Zhu, Z Li, H Xie, TW Rice, LA Rybicki, JR Goldblum, X Liu
Cleveland Clinic Foundation, Cleveland, OH; Second Military Medical University, Shanghai, China

88 HER2 Status in Biopsy vs. Resection Specimens of Gastric and Gastroesophageal Adenocarcinoma – Is Tumour Heterogeneity a Problem? (767)
T Wang, ET Hsieh, P Henry, W Hanna, CJ Streutker, A Grin
University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; St. Michael’s Hospital, Toronto, ON, Canada

89 Small (≤ 2 cm) Carcinomas in the Proximal Stomach Demonstrate Distinct Clinicopathologic Features from Those in the Distal and Corpus: A Proposal for Classification of Gastric Cancer by Location (648)
Q Huang, J Shi, Q Sun, H Yu, J Chen, H Wu, JK Gold, H Mashimo, C Yu, GY Lauwers
Nanjing Drum Tower Hospital, Nanjing, China; VA Boston Healthcare System, West Roxbury, MA; Massachusetts General Hospital, Boston, MA

90 Pathway-Dependent Roles of ARID1A Expression Loss in Gastric Cancer: Relationships with Epstein-Barr Virus Infection and Microsatellite Instability (585)
H Abe, D Maeda, T Hishima, Y Iwasaki, M Fukayama
Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan

91 ARID1A Expression and Association with Mismatch Repair Gene Status in Gastric Carcinomas (748)
K Sy, S Hafezi-Bakhtiari, SJ Catherine, CA Blaise
University of Toronto, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada; St. Michael’s Hospital, Toronto, ON, Canada

92 Molecular Subtypes of Gastric Cancer Are Associated in Part with Tumor Histology (744)
O Speck, W Tang, DR Morgan, MO Meyers, RL Dominguez, E Martinez, P-F Kuan, ML Galley
University of North Carolina Hospitals, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC; UNC Hospitals, Chapel Hill, NC; Western Regional Hospital, Santa Rosa de Copan, Honduras; Hospital Evangelico, Siguatepeque, Honduras; UNC, Chapel Hill, NC

93 Amplification of the Genes on Chromosome 19q13.3 Represents the Signature Molecular Event Predicting the Clinical Outcome of Gastric Adenocarcinoma (749)
D Tan, T Khor
MD Anderson Cancer Center, Houston, TX

94 Does Clear Cell Carcinoma of Stomach Exist? Clinicopathologic and Prognostic Significance of Clear Cell Changes in 762 Gastric Adenocarcinomas (664)
A Kim, J-Y Kim, N Shin, W-Y Park, DY Park
Pusan National University Hospital, Busan, Korea

95 Level of miR-125B and miR-451 and Deregulated Expression of PI3K/AKT/mTOR Pathway in Gastric Cancer (750)
O Tapia, I Riquelme, A Sandoval, P Letelier, P Leal, JC Roa
University of La Frontera, Temuco, Chile

96 “Crawling-Type” Adenocarcinoma of the Stomach: A Distinct Entity Preceding Poorly Differentiated Adenocarcinoma (661)
H Kawachi, N Okamoto, T Yoshida, K Kitagaki, M Sekine, M Kobayashi, K Kojima, T Kawano, Y Eishi
Tokyo Medical and Dental University/Clinica Las Condes, Santiago, Chile; Tokyo Medical and Dental University, Tokyo, Japan; Kudanzaka Hospital, Tokyo, Japan

97 Very Well Differentiated Gastric Cancer of Intestinal Metaplasia-Type: A Systemic Analysis (761)
T Ushiku, S Ban, T Arnason, T Hishima, M Fukayama, GY Lauwers
Massachusetts General Hospital, Boston, MA; University of Tokyo, Tokyo, Japan; Saiseikai Kawaguchi General Hospital, Saitama, Japan; Tokyo Metropolitan Komagome Hospital, Tokyo, Japan

98 Biomarkers in a Large Cohort of Gastric and GEJ Adenocarcinomas – Prevalence and Spectrum of Expression (724)
S Rost, D Dunlap, S Chan, S Sa, S Mocci, H Koeppen
Genentech, South San Francisco, CA
A Large Cohort of Consecutive Patients Confirmed Frequent HER2-Positivity in Gastric Carcinomas with Advanced Stages (593)
S Ahn, J Cho, CK Park, S Kim, K-M Kim
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

The Incidence of EBV and Her2 Positivity in Gastric Cancers (652)
C Irkkan, S Balci, G Guler Tezel, B Akinci, B Yalcin, G Guler
Yildirim Beyazit University, Ankara, Turkey; Hacettepe University, Ankara, Turkey

Correlation of Her2 Protein Expression and Gene Amplification between Endoscopic and Surgical Specimens of Gastric Cancer (653)
C Irkkan, S Balci, G Guler Tezel, B Akinci, B Yalcin, G Guler
Yildirim Beyazit University, Ankara, Turkey; Hacettepe University, Ankara, Turkey

Gastrointestinal Biopsy Findings of Autoimmune Enteropathy – A Review of 20 Cases (690)
R Masia, S Peyton, GY Lauwers, I Brown
Massachusetts General Hospital, Boston, MA; Pathology Queensland, Herston, Queensland, Australia

Gastrointestinal Pathology in Inflammatory Bowel Disease (614)
A Cockburn, R Genta
Miraca Life Sciences Research Institute, Irving, TX

Pathy/Focal Chronic Pouchitis Is Related to Crohn’s Disease (639)
X Hao, W Xin
University Hospitals Case Medical Center, Cleveland, OH; Case Western Reserve University, Cleveland, OH

Pseudooinvasion and Dysplasia in Peutz-Jeghers Hamartomatous Polyps (719)
MP Riley, Z Yang
Penn State Milton S. Hershey Medical Center, Hershey, PA

Brunner Gland Cysts: Morphologic and Endoscopic Features (675)
DJ Lager, JA Nielsen, M Lewin, CA Roberts
ProPath, Dallas, TX

Histology and Histopathology of Minor Papilla (Accessory Ampulla): An Analysis of 160 Cases with Emphasis on Features with Potential Impact on Daily Surgical Pathology Practice (705)
D Ozdemir, B Saka, P Bagci, N Dursun, I Erbarut, S Bandopadhyay, L Ducato, M Reid, AB Farris, O Basturk, V Adsay
Emory University, Atlanta, GA; Wayne State University, Detroit, MI; Memorial Sloan-Kettering Cancer Center, New York, NY

Disturbances of Intrahepatic Venous and Arterial Microcirculation in Idiopathic Portal Hypertension (1710)
Y Sato, K Harada, M Sasaki, Y Nakamura
Kanazawa University Graduate School of Medicine, Kanazawa, Japan

Hepatic Portal Fibrosis but Not Central Fibrosis Is Associated with Elevated Right Atrial Pressure in Patients with Right Heart Failure (1670)
D-F Dai, MM Yeh
University of Washington, Seattle, WA

Histology of Liver Injury Secondary to Chronic Passive Congestion in Heart Failure (1696)
C Louie, N Kambham, T Daugherty, J Higgins
Stanford Hospital and Clinics, Stanford, CA

Different Collagen Types Show Variable Increases from Early to Late Stages of Hepatitis-C Related Liver Fibrosis (1667)
W Chen, JB Rock, MM Yearsley, LD Ferrell, WL Frankel
Ohio State University Wexner Medical Center, Columbus, OH; University of California, San Francisco, CA

Aberrant von Willebrand Factor (vWF) Expression of Sinusoidal Endothelial Cells in Nodular Regenerative Hyperplasia and Obliterative Portal Venopathy (1720)
X Zhang, TD Schiano, SN Thung, SC Ward, MI Fiel
Yale University School of Medicine, New Haven, CT; Mount Sinai Medical Center, New York, NY

Hepatic Outflow Obstruction: Underappreciated Histologic Features on Biopsy (1677)
MA Gilger, MK Washington
Vanderbilt University School of Medicine, Nashville, TN

Liver Fibrosis Quantitation Via Image Analysis: Correlation with Pathologist Assessment and Clinical Parameters (1698)
J Mas-Moya, P Bagci, K-T Jang, MJ Lee, HD Kitajima, DR Martin, NV Adsay, AB Farris
Emory University, Atlanta, GA; University of Arizona, Tucson, AZ

Altered Hepatic Vascular and Lobular Organization near Centrizonal Scars in Chronic Venous Outflow Obstruction (1692)
G Krings, B Meydan, L Ferrell
UCSF, San Francisco, CA; Ondokuz Mayis, Samsun, Turkey

Immunohistochemical Examination of Arginase-1 Expression in Hepatoblastomas (1666)
JC Chang, DL Stockman, S Szabo
Medical College of Wisconsin, Milwaukee, WI; MD Anderson Cancer Center, Houston, TX; Children’s Hospital of Wisconsin, Milwaukee, WI

Reevaluation of the Diagnostic Utility of Villin and Mammaglobin in the Differential Diagnosis between Metastatic Breast Ductal Carcinoma and Intrahepatic Cholangiocarcinoma in the Liver (1718)
Z Yang
Penn State Milton S. Hershey Medical Center, Hershey, PA

Expression of Liver Fatty Acid Binding Protein (LFABP) in Hepatocellular Carcinomas (1668)
S-J Cho, LD Ferrell, RM Gill
University of California San Francisco, San Francisco, CA
International Consensus Study on the Terminology and Diagnosis of Tumoral Intraepithelial Neoplasms (“Adenomas” and “Intracystic Papillary Neoplasms” of WHO-2010) of the Gallbladder (1758)
Emory University, Atlanta, GA; SMC, Seoul, Korea; SU, Tokyo, Japan; INCMN, Mexico, Mexico; Johns Hopkins University, Baltimore, MD; Jichi Medical University, Tochigi, Japan; Tokyo Women’s Medical University, Tokyo, Japan; HU, Aomori, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; TUM, Munich, Germany; MGH, Boston, MA; NCCK, Kashiwa City, Japan; PU, Santiago, Chile; Saitama Medical University, Saitama, Japan; CH, Paris, France; UV, Verona, Italy; KCH, London, United Kingdom; TUHH, Tokyo, Japan

Pancreatic Serous Cystadenomas Fine Needle Aspirations: Improving Diagnostic Yield with Cell Blocks and Inhibin (1790)
M Salomao, H Remotti, J D Allendorf, J M Poneros, A Sethi, TA Gonda, A Saqi
Columbia University, New York, NY

Deregulated Mucin Carbohydrate Antigens Tn and Sialosyl-Tn: Potential Utility in Fine Needle Aspiration Specimens of Pancreas (1773)
K Jiang, C Cohen, SR Stowell, RD Cummings, MT Siddiqui
Emory University School of Medicine, Atlanta, GA

Evaluation of Immunohistochemical Study of Maspin for Pancreatic Tumors Should Be Made in Caution: Immunohistochemical Studies and Quantitative Analysis of mRNA Using Materials from Endoscopic Ultrasound Guided-Fine Needle Aspiration (1782)
K Marukawa, T Mitsuhashi, Y Matsu
Hokkaido University Hospital, Sapporo, Hokkaido, Japan

Pancreatic Ductal Adenocarcinomas with Multiple Large Cystic Structures: A Clinicopathologic and Immunohistochemical Study of Seven Cases (1786)
T Nitta, T Mitsuhashi, Y Hatanoaka, S Hirano, Y Matsu
Hokkaido University Hospital, Sapporo, Hokkaido, Japan; Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan

Neoplasms and Pseudotumors Associated with Low (Intrapancreatic) Union of Cystic Duct into Common Bile Duct: A Clinicopathologic Analysis of 15 Cases of a Hitherto Unrecognized Phenomenon (1767)
RS Gonzalez, B Saka, P Bagci, I Erbarut, SK Matihel, D Kooby, C Staley, B El-Rayes, J Sarmiento, R Everett, AB Farris, M Reid, V Adsay
Emory University, Atlanta, GA

Inconclusive Cytology and Non-Contributory Cyst Fluid Tumor Marker Analysis of Pancreatic Cystic Lesion: Is It the End of the Story? (1804)
M Zhang, M Carrozza, Y Huang
Temple University Hospital, Philadelphia, PA
144 Progressive Loss of Basal Cells: A Possible Precursor of Limited Adenocarcinoma of Prostate (985)

M Nadji
University of Miami/Jackson Memorial Hospital, Miami, FL

145 Immunohistochemical Evaluation of TMPRSS2-ERG Gene Fusion in Focal Prostatic Atrophy (1000)

ACS Plaza, I. Meirelles, LLLL Freitas, LBE Costa, JFL Bonfitto, BL Diniz, PH Poletto, A Bills
School of Medicine, University of Campinas (Unicamp), Campinas, SP, Brazil

146 Diagnostic Utility of Androgen Receptor Expression in Discriminating Poorly Differentiated Urothelial and Prostate Carcinoma (853)

MR Downes, N al Daoud, TH van der Kwast
University Health Network, Toronto, ON, Canada

147 The Expression Levels of Cytoplasmic and Membranous Jagged-1 Are Associated with Progression and Metastasis of Prostate Cancer (1092)

X Zhou, H Zhu, S Redfield, M Mollaee, Z He, J Lewin, L Miele
University of Mississippi Medical Center, Jackson, MS;
University of Mississippi Medical Center, Jackson, MS

148 Comparison of p40 (ΔNp63) and p63 Expression in Prostate Tissues as Markers of Benign Glands (1018)

V Salier, C Stephan, N Wernert, S Perner, G Kristiansen
University of Bonn, Bonn, Germany; Charite-Universitatsmedizin Berlin, Berlin, Germany

149 Univariate and Multivariate Analysis of Histological Features Associated with the Use of Immunohistochemistry for the Diagnosis of Prostatic Carcinoma in Needle Biopsy Material (890)

O Hameed, LI Bloom, C Salih, PA Humphrey
Vanderbilt University, Nashville, TN; Washington University, St. Louis, TN

150 Finasteride Treatment Has Significant Effect on Androgen Receptor Expression in Prostate Epithelium (919)

KA Johnson, W Ricke, W Huang
University of Wisconsin, Madison, WI

151 Targeting the Neural Microenvironment in Prostate Cancer: A Neoadjuvant Botox Clinical Trial (874)

D Floretin, Y Ding, D He, C Creighton, A Frolov, D Kadmon, M Ittmann, G Ayala
Baylor College of Medicine, Houston, TX; University of Miami/Jackson Memorial Hospital, Miami, FL

152 Clinical Follow-Up of Patients with Initial ASAP Biopsy Reclassified by a Urologic Pathologist as Benign, ASAP or Cancer: Does “Accurate” Interpretation Have Clinical Relevance? (928)

MG Keeney, JK Schoolmeester, RE Swapp, BA Inman, CM Lohse, TJ Sebo
Mayo Clinic, Rochester, MN

153 Pseudoangiomatous Stromal Hyperplasia (PASH) of Prostatic Stroma Is Immunohistochemically Similar to Mammary PASH (822)

NO Bullock, R Cartun, R Muller, A Ricci, Jr.
Hartford Hospital, Hartford, CT
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>154</td>
<td>Incidental Secondary Pathological Findings in Prostate Needle Biopsies and Radical Prostatectomy Specimens (1012)</td>
<td>FL Rosario-Quinones, PD Unger, G-Q Xiao</td>
<td>Mount Sinai Medical Center, New York, NY</td>
</tr>
<tr>
<td>155</td>
<td>Clinical Outcomes of Patients with pT2b and Small Size pT3a Renal Cell Carcinomas Are Similar (1090)</td>
<td>H Zhong, K Atwood, Y Huang, B Xu</td>
<td>Cancer Institute of New Jersey, Robert Wood Johnson Medical School, UMDNJ, New Brunswick, NJ; Roswell Park Cancer Institute, Buffalo, NY; State University of New York at Buffalo, Buffalo, NY</td>
</tr>
<tr>
<td>156</td>
<td>Fuhrman Grading in Renal Cell Carcinoma: Comparison between Core Needle Biopsies and Surgical Resections (810)</td>
<td>JA Bennett, LA Wilkinson, CS Abendroth, EE Frauenhoffer, B Han</td>
<td>Penn State Hershey Medical Center, Hershey, PA</td>
</tr>
<tr>
<td>157</td>
<td>GATA 3 Immunohistochemical Expression in Primary and Metastatic Renal Cell Carcinomas (981)</td>
<td>E Munari, N Gonzalez-Roibon, SF Faraj, A Chaux, ME Allaf, R Sharma, GJ Netto</td>
<td>Johns Hopkins Hospital, Baltimore, MD; Norte University, Asuncion, Paraguay</td>
</tr>
<tr>
<td>158</td>
<td>Revisiting Decreasing Sperm Density in USA: A Single Center Experience (1008)</td>
<td>M Rasul, N Rosa, S Rasul, P Kumar, H Islam, F Moy</td>
<td>Westchester Medical Center, Valhalla, NY; New York Medical College, Valhalla, NY</td>
</tr>
<tr>
<td>159</td>
<td>PAX Immunoreactivity Patterns in Anaplastic Wilms Tumors (863)</td>
<td>R Fan</td>
<td>Indiana University, Indianapolis, IN</td>
</tr>
<tr>
<td>160</td>
<td>Renal Cell Carcinoma: A Study of PMS2 and MSH6 Expression in Histologic Subtypes with Clinicopathologic Correlation (1049)</td>
<td>PS Taucht-Nishi, D Chen, M Morisada, J Fife, H Shinoda, D Shimizu</td>
<td>Queens Medical Center, Honolulu, HI; University of Hawaii, Honolulu, HI</td>
</tr>
<tr>
<td>161</td>
<td>The Impact of Routine Frozen Section Analysis during Cystectomy on Surgical Margins and Long-Term Outcomes (916)</td>
<td>J Jean-Gilles, Jr., JL Yao, PA di Sant’Agnesese, H Miyamoto</td>
<td>University of Rochester, Rochester, NY</td>
</tr>
<tr>
<td>162</td>
<td>SPINK1 Expression as a Diagnostic Marker in Flat Urothelial Carcinoma In-Situ Lacks Specificity and Sensitivity (967)</td>
<td>A McDaniel, N Palantisamy, A Wu, R Mehra, S Tomlins, LP Kunju</td>
<td>University of Michigan Health System, Ann Arbor, MI</td>
</tr>
<tr>
<td>163</td>
<td>Immunohistochemical Expression and Prognostic Value of ARID1A in Invasive Urothelial Carcinoma of Urinary Bladder (865)</td>
<td>SF Faraj, N Gonzalez-Roibon, A Chaux, E Munari, C Ellis, T Driscoll, MP Schoenberg, T Bivalacqua, I-M Shih, GJ Netto</td>
<td>Johns Hopkins Hospital, Baltimore, MD; Norte University, Asuncion, Paraguay</td>
</tr>
<tr>
<td>164</td>
<td>Distinguishing Primary Urinary Bladder Adenocarcinoma from Secondary Involvement by Colorectal Adenocarcinoma: Extended Immunohistochemical Profiles Emphasizing Novel Markers (1006)</td>
<td>Q Rao, SR Williamson, A Lopez-Beltran, R Montironi, W Huang, JN Eble, DJ Grignon, KO Koch, MT Idrrees, X-J Zhou, LA Baldridge, L Cheng</td>
<td>Indiana University School of Medicine, Indianapolis, IN; Nanjing University School of Medicine, Nanjing, China; Cordoba University, Cordoba, Spain; Polytechnic University of the Marche Region, United Hospitals, Ancona, Italy; Nanjing Medical University Affiliated Nanjing Hospital, Nanjing, China</td>
</tr>
<tr>
<td>165</td>
<td>SIX1 Expression Correlates with Tumor Grade of Urothelial Carcinoma (809)</td>
<td>RC Batiste, R Rong, L-P Wang, Z Bing</td>
<td>Hospital of the University of Pennsylvania, Philadelphia, PA</td>
</tr>
<tr>
<td>166</td>
<td>Immunohistochemical Expression of Maspin, p53 and Ki67 in Bladder Urothelial Tumors, and Their Relationship with Clinicopathological Parameters’ (1084)</td>
<td>G Yazvac, S Bircan</td>
<td>Suleyman Demirel University School of Medicine, Isparta, Turkey</td>
</tr>
<tr>
<td>167</td>
<td>Expression of PAX8 in Non-Invasive Urothelial Carcinoma of the Bladder (1023)</td>
<td>JM Sanfrancesco, C Maggi-Galluzzi, D Hansel</td>
<td>Cleveland Clinic Foundation, Cleveland, OH</td>
</tr>
<tr>
<td>168</td>
<td>Evaluation of ΔNp63 Expression in Urothelial Cell Carcinoma (1072)</td>
<td>KA West, DJ Buonocore, D Lucido, L Kiss, B Wang, V Ghali</td>
<td>Beth Israel Medical Center, New York, NY</td>
</tr>
<tr>
<td>169</td>
<td>Sarcomatoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic Study of 31 Cases (1024)</td>
<td>JM Sanfrancesco, D Hansel</td>
<td>Cleveland Clinic Foundation, Cleveland, OH</td>
</tr>
<tr>
<td>170</td>
<td>Fatty Acid Synthase Overexpression in Testicular Germ Cell Tumors: Potential Role in Progression of Non-Seminomatous Germ Cell Tumors (973)</td>
<td>K Miyai, K Iwaya, O Matsubara, JY Ro</td>
<td>National Defense Medical College, Tokorozawa, Saitama, Japan; Methodist Hospital, Houston, TX</td>
</tr>
<tr>
<td>171</td>
<td>Analysis of Arterial Vasculature Present in Vasectomy Specimens: Utility of Histologic Examination (997)</td>
<td>AP Patel, GJ Lowe, DL Zynger</td>
<td>Ohio State University Medical Center, Columbus, OH</td>
</tr>
<tr>
<td>172</td>
<td>The Effects of Chemotherapy on Spermatocytic Seminoma (811)</td>
<td>DM Berney, W Ansell, J Shamash</td>
<td>St Bartholomew’s Hospital, Queen Mary University of London, London, United Kingdom</td>
</tr>
<tr>
<td>173</td>
<td>Upper Urinary Tract Urothelial Carcinoma with Intratubular Spread (1026)</td>
<td>J Sarungham, M Choudhury, X Yang, M Zhong</td>
<td>New York Medical College, Valhalla, NY; Northwestern University Feinberg School of Medicine, Chicago, IL</td>
</tr>
<tr>
<td>Board Number</td>
<td>Title</td>
<td>Institution(s)</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>174</td>
<td>The Diagnostic Utility of S100P, PAX8, and P63 in the Differential Diagnosis of Urothelial Carcinoma of the Renal Pelvis and Collecting Duct Carcinoma (982)</td>
<td>J Munkberg, J McKenney, S Sharma, N Golden, R Cox University of Arkansas for Medical Sciences, Little Rock, AR; Cleveland Clinic, Cleveland, OH</td>
<td></td>
</tr>
<tr>
<td>175</td>
<td>SALL4 and PAX8 Expression in Carcinomas from Various Organs (956)</td>
<td>F Lin, J Shi, M Wilkerson, H Liu Geisinger Medical Center, Danville, PA</td>
<td></td>
</tr>
<tr>
<td>176</td>
<td>When Worlds Collide: A Series of Genitourinary Collision Tumors (801)</td>
<td>W Anani, S Roy, M Amin, U Rao, I Pantanowitz, A Parwani University of Pittsburgh Medical Center, Pittsburgh, PA</td>
<td></td>
</tr>
<tr>
<td>177</td>
<td>A New Rabbit Monoclonal Antibody Against PAX2 (953)</td>
<td>A Li, N Jiang, H Pan, A Nand, J Gardiner, Z Fang, T Chen Epitomics, Inc., Burlingame, CA</td>
<td></td>
</tr>
<tr>
<td>178</td>
<td>Genitourinary Malakoplakia: Clinicopathologic Features and Ultrastructural Findings of 15 Cases (815)</td>
<td>A Bills, I Meirelles, LLLL Freitas, AA Tavares, FF Carvalho, JPU Fontenele, LGF Cortes School of Medicine, University of Campinas (Unicamp), Campinas, SP, Brazil</td>
<td></td>
</tr>
<tr>
<td>179</td>
<td>Can Pathologists Reliably Categorize Visually Interpreted Immunohistochemical Stains at a Level More Precise Than Present, Equivocal, Absent? (1056)</td>
<td>F Vakar-Lopez, J Xia, R Etzioni, LD True University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA</td>
<td></td>
</tr>
<tr>
<td>180</td>
<td>Androgen Receptor Expression in Genitourinary Neoplasms (1074)</td>
<td>E Williams, J Higgins, J McKenney, A Sangoi, M Troxell Oregon Health &amp; Science University, Portland, OR, Stanford, Stanford, CA; Cleveland Clinic Foundation, Cleveland, OH; El Camino Hospital, Mountain View, CA</td>
<td></td>
</tr>
<tr>
<td>181</td>
<td>SF-1 Immunohistochemical Expression in Tumors (1073)</td>
<td>M Wilkerson, F Lin, J Shi Geisinger Medical Center, Danville, PA</td>
<td></td>
</tr>
</tbody>
</table>

**GYNECOLOGIC & OBSTETRICS**

<table>
<thead>
<tr>
<th>Board Number</th>
<th>Title</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>182</td>
<td>Low Grade Squamous Intraepithelial Lesion/Cannot Exclude High Grade Squamous Intraepithelial Lesion (LSIL-H): A Unique Cytologic Abnormality (1108)</td>
<td>S Barron, Z Li, RM Austin, C Zhao Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA</td>
</tr>
<tr>
<td>183</td>
<td>Clinopathological Characteristics of Ciliated Change of Endocervical Gland: A Mimic of “Endocervical Glandular Dysplasia” (1179)</td>
<td>F Kawakami, Y Mikami, Y Ebina, H Yamada, T Itoh Kobe University Hospital, Kobe, Hyogo, Japan; Kyoto University Hospital, Kyoto, Japan</td>
</tr>
<tr>
<td>185</td>
<td>Morphometric Analysis in the Distinction between Invasive and In Situ Endocervical Adenocarcinoma (1217)</td>
<td>C Parra-Herran, T Hope, S Nofech-Mozes, T Rashed, G Han, E Slodkowska, F-J Lu, N Ismiil, M Khalifa, G Clarke, M Yaffe, M Cesari Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Centre for Imaging Technology Commercialization, Toronto, ON, Canada</td>
</tr>
<tr>
<td>186</td>
<td>PAX8 in Conjunction with p16 and ER Aids in the Distinction between Mesonephric Proliferations and Adenocarcinomas of Cervix (1151)</td>
<td>A Goyal, B Yang Cleveland Clinic Foundation, Cleveland, OH</td>
</tr>
<tr>
<td>187</td>
<td>Positive Margin Status in Uterine Cervix Cone Specimens Is Associated with Persistent/Recurrent High-Grade Dysplasia (1236)</td>
<td>R Shaco-Levy, G Eger, J Dreher, D Benharroch, M Meirovitz Soroka University Medical Center, Beer-Sheva, Israel; Ben-Gurion University of the Negev, Beer-Sheva, Israel; Clalit Health Services, Tel-Aviv, Israel</td>
</tr>
<tr>
<td>188</td>
<td>Is Radical Hysterectomy Necessary in Early Cervical Cancer? (1235)</td>
<td>R Shaco-Levy, S Sade, J Dreher, M Meirovitz Soroka University Medical Center, Beer-Sheva, Israel; Ben-Gurion University of the Negev, Beer-Sheva, Israel; Clalit Health Services, Tel-Aviv, Israel</td>
</tr>
<tr>
<td>189</td>
<td>Neoadjuvant Radio-Chemotherapy for Uterine Cervix Carcinoma: A Regression Grading System as a New Prognostic Parameter (1253)</td>
<td>GF Zannoni, VG Vellone, C Brunelli, G Amadio, G Fadda, ED Rossi, G Scambia, V Masciullo Catholic University, Rome, Italy</td>
</tr>
<tr>
<td>190</td>
<td>Interaction of Platelets with Ovarian Carcinoma Cells Leads to Induction of an Epithelial-Mesenchymal-Transition (EMT)-Associated Gene Expression Profile in Carcinoma Cells (1122)</td>
<td>N Conlon, C Spillane, N Cooke, S O'Toole, C Martin, O Sheils, D Kenny, M Berndti, J O’Leary St James’s Hospital, Dublin, Ireland; Coombe Women and Infants University Hospital, Dublin, Ireland; University of Dublin, Trinity College, Dublin, Ireland; Dublin City University, Dublin, Ireland; Royal College of Surgeons Ireland, Dublin, Ireland</td>
</tr>
<tr>
<td>191</td>
<td>Upregulation of miR-141 Potentially Limits Expression of JAG1 in Epithelial Ovarian Neoplasia (1180)</td>
<td>L Keogh, P Smyth, J O’Leary, O Sheils, R Flavin St. James's Hospital and Trinity College Dublin, Dublin, Ireland</td>
</tr>
<tr>
<td>192</td>
<td>Mechanisms of Expression and Regulation of SOX2 and Its Targets in Two Embryonal Carcinoma Cell Lines (1242)</td>
<td>S Vencken, MF Gallagher, G Blackshields, C Martin, OM Sheils, JJ O’Leary University of Dublin, Trinity College, Dublin, Ireland</td>
</tr>
<tr>
<td>193</td>
<td>Isolation and Interrogation of Ovarian Cancer Stem Cells (1143)</td>
<td>B Ffrench, M Gallagher, A Cooke, B Storal, S O’Toole, C Martin, O Sheils, J O’Leary Trinity College Dublin, Dublin, Ireland</td>
</tr>
</tbody>
</table>
229

Board Number

194  Inhibition of Human Embryonal Carcinoma Cancer Stem Cells by Co-Culture with Their Differentiated Progeny (1148)
M Gallagher, B French, G Gasch, A Cooke, JJ O’Leary
University of Dublin, Trinity College, Dublin, Ireland

195  PAX8 in Smooth Muscle Tumors of Mullerian Versus Non-Mullerian Origin (1177)
AN Karnezis, AE Horvai, JT Rabban
University of California, San Francisco, CA

196  PTEN and P16 Expression Highlights Atypia and Malignant Transformation in Smooth Muscle Tumors of the Uterus (1174)
MW Jones, R Bhargava, DJ Dahbs, O Agnieszka, G Trucco
University of Pittsburgh, Pittsburgh, PA

197  Immunohistochemistry Helps To Discriminate between Symplastic Leiomyoma and Leiomyosarcoma of the Uterus (1141)
S Feller, I Zlobec, H Burger, SC Schaefer
University of Bern, Bern, Switzerland

198  The Use of Progesterone Receptor (PR) and p53 in Assessing Uterine Smooth Muscle Tumors of Uncertain Malignant Potential (STUMP) (1229)
J Ross, S Wei, K Zhang, M Conner
University of Alabama at Birmingham, Birmingham, AL

199  Prognostic Impact of Sarcomatous Component in Uterine Carcinosarcoma (1205)
M Moghadamfalahi, H Alatassi
University of Louisville Hospital, Louisville, KY

200  Ease of Application of Diagnostic Criteria for Premalignant Endometrial Lesions (1175)
J Kaley, A Melnyk, J Bornhorst, C Chen, C Quick
UAMS, Little Rock, AR

201  What Predicts Recurrence in Low-Stage Endometrioid Endometrial Carcinoma? A Clinicopathological Review of 159 Cases (1152)
S Gupta, S Srivastava, D Lim
National University Health System, Singapore, Singapore; Cancer Science Institute, Singapore, Singapore

202  MicroRNAs Expression Varies with Stromal Signatures in Myoinvasive Endometrioid Endometrial Carcinomas (1134)
I Espinosa, L Catasus, I Ferrer, E D’Angelo, A Mozos, E Serrano, J Prat
Hospital de la Santa Creu i Sant Pau, Institute of Biomedical Research (IIB Sant Pau), Autonomous University of Barcelona, Barcelona, Spain

203  Loss of ARID1A in Uterine Endometroid Carcinoma Is Associated with Microsatellite Instability (1200)
T-L Mao, K-K Tao, M-C Lin, L-H Tseng
National Taiwan University Hospital and Medical College, National Taiwan University, Taipei, Taiwan; National Taiwan University Hospital, Taipei, Taiwan

204  Primary Squamous Cell Carcinomas of Upper Genital Tract Show Immunonegativities for P16G64E and Absence of Human Papilloma Virus DNA (1251)
SH Yoo, E-M Son, CO Sung, K-R Kim
University of Ulsan College of Medicine, Seoul, Korea

Board Number

205  DPC4 Immunostaining in Mullerian Tumors with and without Mucinous Differentiation (1133)
E Elishaev, X Li, A Kanbour-Shakir, SE Taylor, RP Edwards, J Yu, AH Woodard, MW Jones, R Bhargava
Magee-Womens Hospital of UPMC, Pittsburgh, PA

206  Distinct GATA1 Point Mutations in Identical Twin Boys with Down Syndrome and Transient Abnormal Myelopoiesis from a Triplet Pregnancy (1250)
L Yin, MA Lovell, ML Wilson, Q Wei, X Liang
University of Colorado School of Medicine, Aurora, CO; Denver Health Medical Center, Denver, CO; Children’s Hospital Colorado, Aurora, CO

207  Clinical Significance of Positive P16/Ki-67 Dual-Stained Cytology in Negative Papanicolaou Cytology (1163)
S-R Hong, H-S Kim, TJ Kim, J-S Park
Cheil General Hospital, Kwandong University, Seoul, Korea; Cheil General Hospital and Women’s Healthcare Center, Kwandong University College of Medicine, Seoul, Korea; School of Medicine, Catholic University of Korea, Seoul, Korea

208  Collateral Sensitivity to Cisplatin in KB-8-5-11 Is Confluence Dependant (1187)
D Lawlor, C Spillane, J O’Leary, B Stordial
Trinity College Dublin, Dublin, Ireland

209  PSMA Is Highly Expressed in Gynecologic Tumor Neovasculature, but Lacks Expression in Normal Tissues (1221)
EC Pirog, G Wernicke, NH Bander
Weill Cornell Medical College, New York, NY

HEMATOPATHOLOGY

210  NK Cell Reference Ranges Established by Flow Cytometry in Reactive and Lymphomatous Lymph Nodes (1507)
J Schumann, AM Harrington, SH Kroft, H Olteanu
MCW, Milwaukee, WI

211  CD56 Expression as a Reactive Phenomenon in Myeloblasts, Monocytes, and Granulocytes after Chemotherapy for Lymphoblastic Leukemia (1543)
CM Zaremba, NJ Karandikan, FS Fuda, SA Monaghan, J Emmons
University of Texas Southwestern Medical Center, Dallas, TX

212  Comparison of Adequacy and Diagnostic Utility of FNA and Tissue Core Biopsy Samples Submitted for Flow Cytometric Analysis (1515)
GD Smith, JD Boyd, H Hong, R Juskevicius
East Carolina University, Greenville, NC

213  CD177 (NB1) Expression on Neutrophils; in Search of a Kappa/Lambda Ratio for Myeloid Clonality (1456)
H Meyerson, A Balog
University Hospitals Case Medical Center, Cleveland, OH

214  PAX5 Expression by Flow Cytometry. A Feasibility Study (1455)
M Merzianu, D Pan, R Furlage, PK Wallace
Roswell Park Cancer Institute, Buffalo, NY

D Mandelker, DM Dorfman, B Li, O Pozdnuyakova
Brigham and Women’s Hospital, Boston, MA
B-Cell and Plasma Cell Clones with Identical Light Chain Expression by 8-Color Flow Cytometry and DNA Content Analysis: A Predictor of Diagnosis? (1499)
FN Rosado, WG Morice, R He, MT Howard, ED McPhail
Mayo Clinic, Rochester, MN

JL Seningen, LN Dao, KK Reichard, FN Rosado, WG Morice II
Mayo Clinic, Rochester, MN

Characterization of Rare Clonal Abnormal Plasma Cells in Monoclonal Gammopathy of Undetermined Significance (MGUS) by Flow Cytometry: Diagnostic Utility and Optimization of Technique (1504)
D Salem, P Tembhare, R Braylan, CO Landgren, N Korde, A Zingone, R Costello, E Manasanch, M Kwok, M Roschewski, I Maric, K Calvo, C Yuan, M Stetler-Stevenson
CCRC, NCI, NIH, Bethesda, MD; Clinical Center, NIH, Bethesda, MD

Optimizing Manual Flow Cytometric Analysis for Lymphoma Using an Automated Computational Tool (1363)
FE Craig, R Brinkman, SP Ten Eyck, N Aghaeepour
University of Pittsburgh School of Medicine, Pittsburgh, PA; British Columbia Cancer Agency, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada

A Retrospective Study of Correlation of Morphological Patterns, MIPI Proliferation Index and Survival Analysis in 134 Cases of Plasmacytoma (1374)
K Ghodke, S Gujral
Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India

Plasma Cell Phenotyping and DNA Content Analysis by 8-Color Flow Cytometry: A Highly Sensitive Assay That Simultaneously Measures Clonality, Ploidy, and Proliferation (1463)
WG Morice II, MM Timm, D Jevremovic, RP Ketterling, S Kumar, KK Reichard
Mayo Clinic, Rochester, MN

Diagnostic and Prognostic Significance of CD200 Expression in Plasma Cell Myeloma (1433)
D Long, A Kim, S Li
Vanderbilt University School of Medicine, Nashville, TN

Plasma Cell Leukemia: Impact of Cytogenetic Profile on Prognosis (1464)
T Muzzafar, S Kaul, JM Gonzalez-Berjon, J Shah
University of Texas MD Anderson Cancer Center, Houston, TX

A Comparative Study of Multiple Myeloma with Two Independent Clones and Those with a Single Clone (1430)
G Li, AS Braverman, CA Axiotes
SUNY Downstate Medical Center, Brooklyn, NY; Kings County Hospital Center, Brooklyn, NY

CD20+ Plasma Cell Myeloma (PCM): Molecular Characterization by miRNA Profiling Leads to New Insights into Disease Biology and Clinico-Pathological Behavior (1415)
R Kolhe, A Rojiant, A Jillella, V Kota
Georgia Health Science University, Augusta, GA
Correlation of LPL and ADAM29 Gene Expression with Mutational Status of IGHV Genes in Chronic Lymphocytic Leukemia (1362)
AL Cota, D Crisan
William Beaumont Hospital, Royal Oak, MI

Aldehyde Dehydrogenase 1 (ALDH1) Is a Novel Marker for Tumor-Associated Macrophages and Dendritic Cells in Mature B-Cell Lymphomas (1427)
V Leventaki, K Kunkalla, Y Liu, C Qu, NK Agarwal, JL Medeiros, F Vega-Vazquez
UT MD Anderson Cancer Center, Houston, TX

TIM3 Is Underexpressed on Myeloblasts in Myelodysplastic Syndrome (MDS) (1372)
KJ Garner, SP Ten Eyck, FE Craig, CG Roth
University of Pittsburgh Medical Center, Pittsburgh, PA

Impaired B-Cell Development Can Predict Chronic Graft-Versus-Host Disease in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome (1447)
K Mast, MR Khawaja, A Tewari, M Nassiri, S Zhang, J Zhou, RP Nelson, M Czader
Indiana University School of Medicine, Indianapolis, IN

Inhibition of ATF5 Sensitizes Glioblastoma Cells to the Cytotoxic Effects of TNF-Related Apoptosis Inducing-Ligand (TRAIL) in a CHOP-DR5 Dependent Manner (1745)
MD Siegelin, JM Angelastro, LA Greene
Columbia University College of Physicians and Surgeons, New York, NY; University of California, Davis, CA

MicroRNA, MGMT Methylation and PTEN & P53 Mutations in Glioblastomas (1741)
IBMCC-USAL/CSIC, Salamanca, Spain; IECCSYL, Salamanca, Spain; IBSAL, Salamanca, Spain; Hospital Virgen Vega, Salamanca, Spain; Hospital Universitario, Salamanca, Spain

Insular Low Grade Gliomas (LGG): The Role of Molecular Markers and Extent of Surgical Resection (EOR) (1730)
G De Maglio, T Ias, M Skrap, S Pizzolito
University Hospital S.Maria della Misericordia, Udine, Italy

Utility of Olig2 and Notch-1 Immunostains in Glioblastomas in a Routine Histopathology Setting (1746)
OL Snir, AF Ziober, MD Feldman, Z Mourelatos
University of Pennsylvania, Philadelphia, PA

Lack of Human Cytomegalovirus in Gliomas. A Viral Load Analysis by Quantitative Real Time–PCR (1733)
Elche University Hospital, Elche, Alicante, Spain; Alicante University Hospital, Alicante, Spain; Castellon Provincial Hospital, Castellon, Spain

Analysis of IDH Mutation, 1p19q Deletion, and PTEN Loss in Low Grade Diffuse Gliomas (1742)
N Sabha, CB Knobbe, S Al Omar, A Von Deimling, T Mak, A Perry, G Zadeh, A Guha, SE Croul
Hospital for Sick Children, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; University of Heidelberg, Heidelberg, Germany; UCSF, San Francisco, CA

Histology and Immunohistochemical Profile of Diffuse Intrinsic Pontine Glioma (DIPG) (1726)
LY Ballester, Z Wang, S Sandilya, M Miettinen, PC Burger, C Eberhart, FJ Rodriguez, E Raabe, KE Warren, MM Quezado
NIH/NCI, Bethesda, MD; Johns Hopkins University, Baltimore, MD

1p/19q Co-Deletion and Polysomy in Oligodendroglial Tumors – A Single Institution Study (1728)
H Chen, C Stewart, R Marc, H Jason, W Lu, J Saresh, NH Khedouri, H Meera
Memorial Sloan-Kettering Cancer Center, New York, NY

The Expression of Progenitor Cell Markers in Primary Central Nervous System Lymphoma: Role of SOX2/OCT4 in Lymphomas with B-Cell Phenotype (1376)
G Gul Niflioglu, M Pekmezci, EF Krasik, T Tihan
Dokuz Eylul University, Izmir, Turkey; University of California San Francisco, San Francisco, CA

Ras-MAPK Pathway Mutation Analysis in Cerebellopontine Angle Tumors (1729)
MD Cykowski, RA Allen, K-M Fung, ED Stolzenberg, ST Dunn
University of Oklahoma Health Sciences Center, Oklahoma City, OK

Utility of Steroidalogenic Factor-1 in the Pathologic Evaluation of Clinically Non-Functioning Pituitary Adenomas (1739)
M Pekmezci, T Tihan
University of California San Francisco, San Francisco, CA

Factors Associated with Survival in Patients with Breast Cancer (BC) Brain Metastasis (BM) (1738)
R Li, K Zhang, GP Siegal, S Wei
University of Alabama at Birmingham, Birmingham, AL

The Utility of Immunohistochemical Markers for the Differential Diagnosis of Metastatic Melanoma in the Central Nervous System (1732)
M Gamsizkan, HA Simsek, T Tihan, I Yilmaz, A Griffin, O Onguru
GATA, Ankara, Turkey; Eskisehir Military Hospital, Eskisehir, Turkey; UCSF, San Francisco, CA; GATA Haydarpasa Education and Research Hospital, Istanbul, Turkey

Frontotemporal Lobar Degeneration (FTLD): Updated Pathology and Co-Existing Neuropathological Phenomena in a Cohort of 52 Patients (1724)
K Au, S Black, J Bilbao, M Maselis, J Keith
Sunnybrook Health Sciences Centre, Toronto, ON, Canada

Autopsy Bias Adjustment for Factors Associated with Cortical Beta-Amyloid Deposition (1731)
DB Fekedulegn, CM Burckel, JS Nelson
Biostatistics and Epidemiology Branch, Health Effects Laboratory Division, Morgantown, WV; Pacific Health Research Institute, Honolulu, HI
<table>
<thead>
<tr>
<th>Board Number</th>
<th>Pathologic Findings in Radiographic Nonlesional Pharmacoresistant Epilepsy (1744)</th>
</tr>
</thead>
<tbody>
<tr>
<td>254</td>
<td>AR Shih, RA Prayson, Cleveland Clinic, Cleveland, OH</td>
</tr>
<tr>
<td>255</td>
<td>α-Synuclein in the Mucosa of the Human Vermiform Appendix (1735)</td>
</tr>
<tr>
<td></td>
<td>MT Gray, DG Munoz, DA Gray, JM Woulfe, Ottawa Hospital Research Institute, Ottawa, ON, Canada; University of Ottawa, Ottawa, ON, Canada; University of Toronto, Toronto, ON, Canada</td>
</tr>
<tr>
<td>256</td>
<td>Amyotrophic Lateral Sclerosis (ALS) Admission Rates and Metals Detected in Private Drinking Water Wells in Texas (1747)</td>
</tr>
<tr>
<td></td>
<td>MS Wachtel, BB Miller, Texas Tech University Health Sciences Center, Lubbock, TX</td>
</tr>
</tbody>
</table>

**INFORMATICS**

<table>
<thead>
<tr>
<th>Board Number</th>
<th>Customizing Anatomical Pathology Laboratory Information System (AP-LIS) Tools To Augment Laboratory Workflow, Reporting, and Patient Safety (1574)</th>
</tr>
</thead>
<tbody>
<tr>
<td>257</td>
<td>IC Cucoranu, SA Yousem, A Piccoli, AV Parwani, L Pantanowitz, UPMC, Pittsburgh, PA</td>
</tr>
<tr>
<td>258</td>
<td>Synoptic Report Generators for Molecular and Ancillary Test Reporting in Anatomic Pathology Laboratory Information System (APLIS) (1568)</td>
</tr>
<tr>
<td></td>
<td>A Alkhasawneh, B Harris, H-J Dong, RW Allan, University of Florida, Gainesville, FL</td>
</tr>
<tr>
<td>259</td>
<td>Standardized Checklist/Synoptic Tool for Reporting of Uropathology Neoplasms: Implementation and Experience with 6885 Resected Specimens (1570)</td>
</tr>
<tr>
<td></td>
<td>W Anani, A Piccoli, L Pantanowitz, A Parwani, University of Pittsburgh Medical Center, Pittsburgh, PA</td>
</tr>
<tr>
<td>260</td>
<td>Deployment of an Orders Interface between SunQuest CoPathPlus (SQCP) and Dako’s Automated Immunoperoxidase Staining Platform (1581)</td>
</tr>
<tr>
<td></td>
<td>M Haghighi, M Czechowski, K Roszka, M Tuthill, Henry Ford Health System, Detroit, MI</td>
</tr>
<tr>
<td>261</td>
<td>Efficient Donor Tissue Assessment through Integrated WSI and LIS for a Regional Organ Donor Bank: An Untapped Application of Virtual Microscopy (1584)</td>
</tr>
<tr>
<td></td>
<td>S Jakate, D Cimbaluk, M Harmon, M Jendrisak, Rush University Medical Center, Chicago, IL; Gift of Hope, Itasca, IL</td>
</tr>
<tr>
<td>262</td>
<td>Whole Slide Imaging Performance (1579)</td>
</tr>
<tr>
<td></td>
<td>CS Friedman, L Rivera, V Brodsky, New York-Presbyterian Hospital/Weill Cornell Medical College, New York, NY</td>
</tr>
<tr>
<td>263</td>
<td>Virtual Slides in Surgical Pathology Practice - Keep Them or Toss Them? (1596)</td>
</tr>
<tr>
<td></td>
<td>CM van Slambrouck, DS McClintock, University of Chicago, Chicago, IL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Board Number</th>
<th>Digitized Whole Slides for Breast Pathology Interpretation: Pathologists Use and Perceptions (1592)</th>
</tr>
</thead>
<tbody>
<tr>
<td>264</td>
<td>T Onega, KH Allison, N Ostler, J Elmore, DL Weaver, University of Washington, Seattle, WA; Dartmouth School of Medicine, Hanover, NH; University of Vermont, Burlingame, VT</td>
</tr>
<tr>
<td>265</td>
<td>Automated Whole Slide Image Screening for Identification of Malignant Cytologic Criteria in Pancreactobiliary Brushings by Use of Spatially-Invariant Vector Quantization (SIVQ) (1582)</td>
</tr>
<tr>
<td></td>
<td>JA Hipp, JC Pang, UJ Balis, University of Michigan Ann Arbor, Ann Arbor, MI</td>
</tr>
<tr>
<td>266</td>
<td>Challenges in Establishing the WSI Based Digital Pathology Facility and Telepathology Network between Pakistan and USA (1598)</td>
</tr>
<tr>
<td></td>
<td>Y Yagi, I Qureshi, AZ Malik, DC Wilbur, Massachusetts General Hospital, Boston, MA; Holy Family Hospital, Rawalpindi, Pakistan</td>
</tr>
</tbody>
</table>

**Evaluation of Whole Slide Imaging Systems Prior to Establishing a Model Digital Pathology Network for the Air Force Medical Service: Methods and Selection Criteria (1595) |
|              | C Saylor, D Lesniak, L Pantanowitz, J Duboy, O Aridor, L Anthony, N Lancia, J Ho, AV Parwani, University of Pittsburgh Medical Center, Pittsburgh, PA; University of Pittsburgh School of Medicine, Pittsburgh, PA; 81st Medical Group Hospital, Keesler Air Force Base, Biloxi, MS |
| 268          | Telepathology for Frozen Section Analysis: A Validation of Remote Meeting Technologies (RMT)™ Software (1571) |
|              | S Barasch, Z Li, J Stewart III, University of Wisconsin, Madison, WI                         |
| 269          | Live Streaming Using Consumer Level Technology (1591) |
|              | N Nassiri, MB Czader, Indiana University School of Medicine, Indianapolis, IN                   |
| 270          | Evaluation of a Web-Based Telepathology Consultation Service Platform (1573) |
|              | IC Cucoranu, SA Yousem, G Romero Lauro, W Cable, J McHugh, AV Parwani, L Pantanowitz, UPMC, Pittsburgh, PA |

<table>
<thead>
<tr>
<th>Board Number</th>
<th>Design and Implementation of a Model Digital Pathology Network for Teleconsultation and Workload Distribution within the Air Force Medical Service (1594)</th>
</tr>
</thead>
<tbody>
<tr>
<td>271</td>
<td>AV Parwani, L Anthony, O Aridor, D Glinski, R Bond, N Lancia, JP Pelletier, DM Selby, E Green, K Rickard, C Saylor, J Ho, University of Pittsburgh School of Medicine, Pittsburgh, PA; University of Pittsburgh Medical Center, Pittsburgh, PA; 81st Medical Group Hospital, Biloxi, MS; Wilford Hall Ambulatory Surgical Center, San Antonio, TX; David Grant Medical Center, Fairfield, CA; Wright-Patterson Medical Center, Fairborn, OH</td>
</tr>
<tr>
<td>272</td>
<td>Diagnostic Challenges and Advantages of International Telepathology between Two Medical Institutions (1576)</td>
</tr>
<tr>
<td></td>
<td>C Di Loreto, JW Bishop, M Gambharoti, R Canter, D Borys, University of California Davis, Sacramento, CA; Rizzoli Orthopedic Institute, Bologna, Italy</td>
</tr>
</tbody>
</table>
273 Telecytology for On-Site Adequacy Evaluation Decreases the Nondiagnostic Rate in Endoscopic Ultrasound-Guided Fine-Needle Aspiration of Pancreatic Lesions (1580)
B Graber, A Roy, RD Szyjkowski, KK Khurana
SUNY Upstate Medical University, Syracuse, NY

274 Implementation of a Pathology Teaching Website with Integrated Whole Slide Imaging for Greater Compatibility with Tablets/Smartphones (1569)
M Amin, J McHugh, T Harper, J Duboy, L Pantanowitz, AV Parwani
University of Pittsburgh Medical Center, Pittsburgh, PA

275 Evaluation of Image Analysis for Interpretation of Her-2 Dual In Situ Hybridization (1577)
JL Fine, DJ Dabbs, K McManus, R Bhargava
University of Pittsburgh, Pittsburgh, PA

276 Utilizing Image Analysis in the Assessment of Decalcification Effects on Prognostic Breast Markers (1588)
S Maclary, S Kalaria, A Gertych, F Chung, B Knudsen, S Bose, B Balzer
Cedars-Sinai Medical Center, Los Angeles, CA

277 How Digital Image Analysis Applied to Immunohistochemistry Helps To Assess Biomarker Coexpression (1590)
X Moles Lopez, P Barbot, N D’Haene, C Maris, S Rorive, I Salmon, C Decaestecker
Université Libre de Bruxelles (ULB), Brussels, Belgium; Center for Microscopy and Molecular Imaging, ULB, Gosselies, Belgium; Erasme Hospital ULB, Brussels, Belgium

278 Morphometric Analysis in the Diagnosis of Ductal (DCIS) and Lobular Carcinoma In Situ (LCIS) (1593)
C Parra-Herran, T Hope, E Slodkowska, F-I Lu, T Rashed, M Katic, G Han, G Clarke, M Yaffe, S Nofech-Mozes
Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; Centre for Imaging Technology Commercialization, Toronto, ON, Canada

PULMONARY

279 Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Pleomorphic Malignant Mesothelioma (1948)
M Vivero, LR Chirieac, F Galeateau-Salle
Brigham and Women’s Hospital, Boston, MA; CHU Caen Cote De Nacre, Caen, France

280 Expression of IMP3 and Deletion of p16 Are Diagnostic and Prognostic Biomarkers in Mesothelial Proliferations (1899)
M Karanian, N Le Stang, F Galeateau Salle
CHU Caen Cote De Nacre, Caen, France

281 Combined Use of p16 FISH and Bap1 Immunohistochemistry Optimizes Diagnosis of Malignant Pleural Mesothelioma (1913)
SM McGregor, A Minor, C Fitzpatrick, AN Husain, E Hyjek, W Vigeswaran, T Krausz
University of Chicago Medicine, Chicago, IL

282 Diagnostic Utility of p16 FISH in Distinguishing between Biphasic Mesothelioma and Epithelioid Mesothelioma (1888)
K Hiroshima, D Wu, K Nabeshima, T Yusa, D Ozaki, Y Nakatani, T Nishikawa
Tokyo Women’s Medical University Yachiyo Medical Center, Yachiyo, Chiba, Japan; Fukuoka University, Fukuoka, Japan; Chiba Rosai Hospital, Ichihara, Chiba, Japan; Chiba University, Chiba, Japan; Tokyo Women’s Medical University, Tokyo, Japan

283 D2-40 as a Marker To Differentiate Malignant Mesothelioma from Non-Small Cell Carcinoma (1883)
J Felipe Lima, MC Aubry, AC Roden
Mayo Clinic, Rochester, MN

284 Claudin-4: An Effective Immunohistochemical (IHC) Marker Distinguishing Primary and Metastatic Lung Adenocarcinoma from Pleural Epithelioid Malignant Mesothelioma (1926)
AS Perry, GS Pinkus, JM Corson
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

285 Expression of Laminin β1 and β2 Chains in Malignant Mesothelioma (1908)
AE Lo, MN de Peralta-Venturina, AM Marchevsky
Cedars-Sinai Medical Center, Los Angeles, CA

286 Detection of Soluble Mesothelin in Serum and Pleural Effusion of Malignant Pleural Mesothelioma: A Contribution to Cytology (1882)
F Fedeli, P4 Canessa, P Ferro, E Battolla, P Dessanti, A Vigan, L Chiafferi, MC Franceschini, V Fontana, B Bacigalupo, MP Pistillo, S Roncella
ASL5, La Spezia, Italy; ASL5, Sarzana (SP), Italy; IRCCS A.O.U., San Martino-IST, Genova, Italy; AIL, La Spezia, Italy

287 Comparative Immunohistochemical Analysis of Pulmonary and Thymic Neuroendocrine Carcinomas Using Pax8 and TTF-1 (1953)
A Weissferdt, N Kalhor, CA Moran
University of Texas Health Science Center at Houston, Houston, TX; MD Anderson Cancer Center, Houston, TX

288 Glucose Transporter-1 Protein Expression in Thymic Epithelial Neoplasms: A Marker for Poor Prognosis (1879)
SY Chang, SM Jenkins, KK Edwards, M-C Aubry, ES Yi, SD Casstvi, Yi Garces, AC Roden
Mayo Clinic, Rochester, MN

289 MAML2 Rearrangements in Thymic Mucoepidermoid Carcinomas (1934)
AC Roden, M Erickson-Johnson, ES Yi, JJ Garcia
Mayo Clinic, Rochester, MN

290 MECT1-MAML2 Fusion Transcript Expression in Lung Mucoepidermoid Carcinoma (1897)
N Kalhor, J Fujimoto, J Rodriguez, LA Byers, MS Kies, WL Hofstetter, AK El-Naggar, D Bell
University of Texas MD Anderson Cancer Center, Houston, TX

291 Immunohistochemical Profile of Resected Large Cell Carcinoma of the Lung (1955)
J Xie, Y Liu, JF Silverman
Allegheny General Hospital, Pittsburgh, PA
292 p40 (ΔNP63) and Keratin 34βE12 Provide Greater Diagnostic Accuracy Than p63 in the Evaluation of Small Cell Lung Carcinoma in Small Biopsy Samples (1876)
KJ Butnor, JL Burchette
University of Vermont/Fletcher Allen Health Care, Burlington, VT; Duke University Medical Center, Durham, NC

293 Combining Inhibitor of DNA – Binding Proteins and Angiogenic Markers Expression Predict Long Term Survival of Patients with Non-Small Cell Lung Cancer (1870)
L Antonangelo, TS Tuma, FS Vargas, ER Parra, RM Terra, M Acencio, VL Capelozzi
University of São Paulo Medical School, São Paulo, Brazil

294 Co-Expression of Estrogen Receptor-α36 and Extra-Nuclear Estrogen Receptor-α66 Is Associated with Advanced Pathological and Clinical Stages in Non-Small Cell Lung Cancer (1889)
J Huang, AC Mackinnon, A Leuvano, N Rao
Medical College of Wisconsin, Milwaukee, WI

295 Protein Arginine Methyltransferase-5 Overexpression Is Frequently Observed in Non-Small Cell Lung Carcinomas (1941)
K Shilo, X Wu, S Sharma, M Welliver, W Duan, M Villalona, J Fukuoka, C Li, S Sif, R Baiocchi, G Otterson
Ohio State University, Columbus, OH; Toyama University, Toyama, Japan

296 Expression of microRNA miR-205 in Pulmonary Squamous Cell Carcinoma and Adenocarcinoma (1898)
K Kalra, L Xue, EE Chang, R Pillai, MB Amin, DJ Luthringer
Cedars-Sinai Medical Center, LA, CA; BioGenex Laboratories, Fremont, CA

297 Intratumoral Blood Vessels and Basement Membranes Show Laminin β1 Overexpression in Pulmonary Squamous Cell Carcinoma and Adenocarcinoma: A Potential Target for Nanomedicine Drugs (1907)
AE Lo, AM Marchevsky, MN de Peralta-Venturina
Cedars-Sinai Medical Center, Los Angeles, CA

298 Overexpression of the Tumor Stomal Marker Periostin Is Correlated with p53 Levels in Non-Small Cell Lung Cancer Detected by Immunohistochemistry Using Lung Cancer Tissue Microarray (TMAs) (1884)
TJ Gniadek, C Choi, Y Tian, H Zhang, E Gabrielson, F Askin, QK Li
Johns Hopkins University School of Medicine, Baltimore, MD

299 p53 Immunostaining Should Be Used in Conjunction with p16 in Differentiating Metastatic Cervical Squamous Cell Carcinoma Involving the Lung from Primary Lung Squamous Cell Carcinoma (1909)
D Maeda, T Inoue, S Morita, M Fukayama
Graduate School of Medicine, University of Tokyo, Tokyo, Japan

300 Pulmonary Metastatic Nodules of Endometrial Stromal Sarcoma: a Histopathologic Review of 10 Cases (1923)
JY Park, CO Sung, SY Song, JH Han, SJ Jung, K-R Kim
University of Ulsan College of Medicine, Seoul, Korea; Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea
2012-13 Abstract Review Board

Adebowale Adeniran
Mousa Al-Abbadi
Mahul B. Amin
Judith Aranson
Andrea V. Arrossi
Aaron Arrossi
Birzhan Bandarchi
Justine Barletta
Julietta Elena Barroeta
Sheldon I. Bastacky
Michael G. Bayerl
Andrew H. Beck
Andrew M. Bellizzi
Jagdish W. Butany
Helen P. Cathro
Hong Chang
Anthony Chang
Liang Cheng
Patricia Chevez-Barrios
Simon I. Chiosea
Dhananjay Arun Chitale
Deborah J. Chute
Blaise A. Clarke
David W. Cohen
Margaret H. Collins
Michelle Cox
Thomas J. Cummings
Bogdan A. Czerniak
Vikram Deshpande
Rajan Dewar
Erinn P. Downs-Kelly
Leona A. Doyle
Sarah M. Dry
Isam-Eldin A. Eltoum
Linda Ernst
Oluwole Fadare
Carol F. Farver
Laura S. Finn
Andrew L. Folpe
Jason C. Ford
Mostafa M. Fraig
Christine E. Fuller
William K. Funkhouser
Joanna Gibson
David J. Grignon
Katja Gwin
G. Kenneth Haines III
Omar Hameed
Krisztina Z. Hanley
Donna E. Hansel
Jonathan L. Hecht
Walter H. Henricks
Guillermo A. Herrera
Michelle S. Hirsch
Eric D. Hsi
Travis Hollmann
Ralph Hruban
Michael O. Idowu
Kedar Vishwas Inamdar
Bruce A. Jones
Jeffrey L. Jorgensen
Sanjay Kakar
Kamal K. Khurana
David S. Klimstra
Gordon K. Klintworth
Soheila Korourian
Diane P. Kowalski
Friederike Kreisel
L. Priya Kunju
Marc Ladanyi
Han Sung Lee
Marino E. Leon
Richard M. Levenson
Helen Liapis
Robert B. Lorsbach
Haresh Mani
Meg McLachlin
Dan A. Milner
Kisha Mitchell
Gilbert W. Moeckel
David H. Myerson
Vidhya Nair
Robert M. Najarian
Cynthia C. Nast
G. Petur Nielsen
Torsten O. Nielsen
I. Tolgay Ocal
Shuji Ogino
N. Paul Ohori
Juan P. Olano
Christopher Otis
Robert F. Padera
Rish K. Pai
Glandell P. Paner
Judy C. Pang
Liron Pantanowitz
Deepa T. Patil
Bruce R. Pawel
John D. Pfeifer
Maria M. Picken
Thomas P. Plesec
Suzanne Z. Powell
Richard A. Prayson
Charles M. Quick
Prabha B. Rajan
John D. Reith
Daniel G. Remick
David L. Rimm
Lisa M. Rimsza
Scott J. Rodig
Rene Rodriguez
J. Jordi Rowe
Brian P. Rubin
Jeffrey E. Saffitz
Melinda E. Sanders
Lynn Schoenfeld
Alireza Sepehr
Shree G. Sharma
Konstantin Shilo
Lynette M. Sholl
Momin T. Siddiqui
Amitabh Srivastava
Edward B. Stelow
Anat Stemmer-Rachamimov
Michael Barry Stokes
Carmela D. Tan
Michael T. Tetzlaff
Lester D. R. Thompson
Scott Tomlins
Kril Trpkov
Paul VanderLaan
Francisco Vega
Hannes Vogel
Helen H. Wang
Sa Wang
Robert B. West
Gayle L. Winters
Agnieszka Witkiewicz
Mamoun Younes
George M. Yousef
Dani S. Zander
Ming Zhou

Adebowale Adeniran
Mousa Al-Abbadi
Mahul B. Amin
Judith Aranson
Andrea V. Arrossi
Aaron Arrossi
Birzhan Bandarchi
Justine Barletta
Julietta Elena Barroeta
Sheldon I. Bastacky
Michael G. Bayerl
Andrew H. Beck
Andrew M. Bellizzi
Jagdish W. Butany
Helen P. Cathro
Hong Chang
Anthony Chang
Liang Cheng
Patricia Chevez-Barrios
Simon I. Chiosea
Dhananjay Arun Chitale
Deborah J. Chute
Blaise A. Clarke
David W. Cohen
Margaret H. Collins
Michelle Cox
Thomas J. Cummings
Bogdan A. Czerniak
Vikram Deshpande
Rajan Dewar
Erinn P. Downs-Kelly
Leona A. Doyle
Sarah M. Dry
Isam-Eldin A. Eltoum
Linda Ernst
Oluwole Fadare
Carol F. Farver
Laura S. Finn
Andrew L. Folpe
Jason C. Ford
Mostafa M. Fraig
Christine E. Fuller
William K. Funkhouser
Joanna Gibson
David J. Grignon
Katja Gwin
G. Kenneth Haines III
Omar Hameed
Krisztina Z. Hanley
Donna E. Hansel
Jonathan L. Hecht
Walter H. Henricks
Guillermo A. Herrera
Michelle S. Hirsch
Eric D. Hsi
Travis Hollmann
Ralph Hruban
Michael O. Idowu
Kedar Vishwas Inamdar
Bruce A. Jones
Jeffrey L. Jorgensen
Sanjay Kakar
Kamal K. Khurana
David S. Klimstra
Gordon K. Klintworth
Soheila Korourian
Diane P. Kowalski
Friederike Kreisel
L. Priya Kunju
Marc Ladanyi
Han Sung Lee
Marino E. Leon
Richard M. Levenson
Helen Liapis
Robert B. Lorsbach
Haresh Mani
Meg McLachlin
Dan A. Milner
Kisha Mitchell
Gilbert W. Moeckel
David H. Myerson
Vidhya Nair
Robert M. Najarian
Cynthia C. Nast
G. Petur Nielsen
Torsten O. Nielsen
I. Tolgay Ocal
Shuji Ogino
N. Paul Ohori
Juan P. Olano
Christopher Otis
Robert F. Padera
Rish K. Pai
Glandell P. Paner
Judy C. Pang
Liron Pantanowitz
Deepa T. Patil
Bruce R. Pawel
John D. Pfeifer
Maria M. Picken
Thomas P. Plesec
Suzanne Z. Powell
Richard A. Prayson
Charles M. Quick
Prabha B. Rajan
John D. Reith
Daniel G. Remick
David L. Rimm
Lisa M. Rimsza
Scott J. Rodig
Rene Rodriguez
J. Jordi Rowe
Brian P. Rubin
Jeffrey E. Saffitz
Melinda E. Sanders
Lynn Schoenfeld
Alireza Sepehr
Shree G. Sharma
Konstantin Shilo
Lynette M. Sholl
Momin T. Siddiqui
Amitabh Srivastava
Edward B. Stelow
Anat Stemmer-Rachamimov
Michael Barry Stokes
Carmela D. Tan
Michael T. Tetzlaff
Lester D. R. Thompson
Scott Tomlins
Kril Trpkov
Paul VanderLaan
Francisco Vega
Hannes Vogel
Helen H. Wang
Sa Wang
Robert B. West
Gayle L. Winters
Agnieszka Witkiewicz
Mamoun Younes
George M. Yousef
Dani S. Zander
Ming Zhou
## Disclosure Information

<table>
<thead>
<tr>
<th>Abstract</th>
<th>Name</th>
<th>Relevant Disclosure Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>28</td>
<td>Raymond Tubbs</td>
<td>Grant/Research Support from Ventana and Honoraria for speaking</td>
</tr>
<tr>
<td>42</td>
<td>Chia Soo</td>
<td>Scarless Laboratories, Inc.; Chia Soo is an inventor of perivascular stem cell-related patents filed from UCLA. Dr. Soo is co-founder of Scarless Laboratories Inc., which sublicenses perivascular stem cell-related patents from the UC Regents, which also hold equity in the company.</td>
</tr>
<tr>
<td>42</td>
<td>Bruno Peault</td>
<td>Scarless Laboratories, Inc.; Bruno Peault is an inventor of perivascular stem cell-related patents filed from UCLA.</td>
</tr>
<tr>
<td>42</td>
<td>Kang Ting</td>
<td>Scarless Laboratories, Inc.; Kang Ting are inventors of perivascular stem cell-related patents filed from UCLA. Kang Ting is co-founder of Scarless Laboratories Inc, which sublicenses perivascular stem cell-related patents from the UC Regents, which also hold equity in the company.</td>
</tr>
<tr>
<td>47</td>
<td>Vikram Deshpande</td>
<td>Grant/Research Support from Affymetrix</td>
</tr>
<tr>
<td>56</td>
<td>Vikram Deshpande</td>
<td>Grant/Research Support from Affymetrix</td>
</tr>
<tr>
<td>69</td>
<td>Eva Wardelmann</td>
<td>Grant/Research Support from Novartis Oncolog; Board membership, honoraria</td>
</tr>
<tr>
<td>69</td>
<td>Hans-Ulrich Schildhaus</td>
<td>Grant/Research Support from Novartis Oncology</td>
</tr>
<tr>
<td>69</td>
<td>Sebastian Huss</td>
<td>Novartis</td>
</tr>
<tr>
<td>79</td>
<td>Julia Gouffon</td>
<td>Employee of Affymetrix Inc.</td>
</tr>
<tr>
<td>96</td>
<td>Gabriela Acosta Haab</td>
<td>Consultant for Roche</td>
</tr>
<tr>
<td>96</td>
<td>Sandra Sarancone</td>
<td>Consultant for Roche</td>
</tr>
<tr>
<td>96</td>
<td>Isabel Frahm</td>
<td>Consultant for Roche</td>
</tr>
<tr>
<td>96</td>
<td>Maria Horsburgh</td>
<td>Employee of Roche</td>
</tr>
<tr>
<td>99</td>
<td>Kimberly Allison</td>
<td>Genentech Speakers Bureau member</td>
</tr>
<tr>
<td>99</td>
<td>Fredrick Waldman</td>
<td>Employee of Quest Diagnostics</td>
</tr>
<tr>
<td>99</td>
<td>Sandra Shin</td>
<td>Consultant for Signal Genetics, LLC</td>
</tr>
<tr>
<td>100</td>
<td>Jeffrey Ross</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>107</td>
<td>Shikha Bose</td>
<td>Grant/Research Support from Roche</td>
</tr>
<tr>
<td>108</td>
<td>Shikha Bose</td>
<td>Grant/Research Support from Roche</td>
</tr>
<tr>
<td>112</td>
<td>Christopher Corless</td>
<td>Consultant for and Grant/Research Support from Novartis, Pfizer, Bayer, Ion Torrent/Life Technologies</td>
</tr>
<tr>
<td>121</td>
<td>Yi Zhang</td>
<td>Employee of bioTheranostics, Inc., San Diego, CA</td>
</tr>
<tr>
<td>121</td>
<td>Mark Erlander</td>
<td>Employee of bioTheranostics, Inc., San Diego, CA</td>
</tr>
<tr>
<td>121</td>
<td>Jeff Anderson</td>
<td>Employee of bioTheranostics, Inc., San Diego, CA</td>
</tr>
<tr>
<td>121</td>
<td>Catherine Schnabel</td>
<td>Employee of bioTheranostics, Inc., San Diego, CA</td>
</tr>
<tr>
<td>121</td>
<td>Veena Singh</td>
<td>Employee of bioTheranostics, Inc., San Diego, CA</td>
</tr>
<tr>
<td>130</td>
<td>Shikha Bose</td>
<td>Grant/Research Support from Roche</td>
</tr>
<tr>
<td>134</td>
<td>Giovanni Pitari</td>
<td>I (Giovanni Pitari) own the patent rights of the technology that is discussed in the abstract.</td>
</tr>
<tr>
<td>134</td>
<td>Ruth Birbe</td>
<td>Grant/Research Support from Ventana Medical Systems, Inc</td>
</tr>
<tr>
<td>137</td>
<td>Sandra Shin</td>
<td>Consultant for Signal Genetics, LLC</td>
</tr>
<tr>
<td>138</td>
<td>Rachel Flinchum</td>
<td>Employee of Signal Genetics, LLC</td>
</tr>
<tr>
<td>138</td>
<td>Nathan Brown</td>
<td>Employee of Signal Genetics, LLC</td>
</tr>
<tr>
<td>138</td>
<td>Sandra Shin</td>
<td>Consultant for Signal Genetics, LLC</td>
</tr>
<tr>
<td>138</td>
<td>Linda Saint John</td>
<td>Employee of Signal Genetics, LLC</td>
</tr>
<tr>
<td>138</td>
<td>Ryan van Laar</td>
<td>Employee of Signal Genetics, LLC</td>
</tr>
<tr>
<td>143</td>
<td>Sandra Shin</td>
<td>Consultant for Signal Genetics, LLC</td>
</tr>
<tr>
<td>144</td>
<td>Sandra Shin</td>
<td>Consultant for Signal Genetics, LLC</td>
</tr>
<tr>
<td>169</td>
<td>Sandra Shin</td>
<td>Consultant for Signal Genetics, LLC</td>
</tr>
<tr>
<td>181</td>
<td>Ryan Bremer</td>
<td>Employee of Biocare Medical, LLC</td>
</tr>
<tr>
<td>181</td>
<td>Thomas Haas</td>
<td>Consultant for Biocare Medical, LLC</td>
</tr>
<tr>
<td>181</td>
<td>David Tacha</td>
<td>Employee of Biocare Medical, LLC</td>
</tr>
<tr>
<td>181</td>
<td>Laura Hoang</td>
<td>Employee of Biocare Medical, LLC</td>
</tr>
<tr>
<td>190</td>
<td>Jeffrey Ross</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>196</td>
<td>Kimberly Allison</td>
<td>Genentech - Speakers Bureau member</td>
</tr>
<tr>
<td>228</td>
<td>Sheppard Elizabeth</td>
<td>Employee of Ventana Medical Systems, Inc.</td>
</tr>
<tr>
<td>228</td>
<td>Tubbs Raymond</td>
<td>Consultant for Ventana Medical Systems, Inc.</td>
</tr>
<tr>
<td>228</td>
<td>Free Heather</td>
<td>Employee of Ventana Medical Systems, Inc.</td>
</tr>
<tr>
<td>231</td>
<td>Arul Chinnaiyan</td>
<td>Consultant for Ventana Medical Systems, Inc., Genprobe; The University of Michigan has been issued a patent on the detection of ETS gene fusions in prostate cancer, on which A.M.C. is a co-inventor. The University of Michigan licensed the diagnostic field of use to Gen-Probe Inc (San Diego, CA).</td>
</tr>
<tr>
<td>236</td>
<td>Sandra Shin</td>
<td>Consultant for Signal Genetics, LLC</td>
</tr>
<tr>
<td>237</td>
<td>Timothy D’Alfonso</td>
<td>Consultant for Signal Genetics, LLC</td>
</tr>
<tr>
<td>237</td>
<td>Sandra Shin</td>
<td>Consultant for Signal Genetics, LLC</td>
</tr>
<tr>
<td>Name</td>
<td>Relationship/Role</td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Timothy D’Alfonso</td>
<td>Consultant for Signal Genetics, LLC</td>
<td></td>
</tr>
<tr>
<td>Sandra Shin</td>
<td>Consultant for Signal Genetics, LLC</td>
<td></td>
</tr>
<tr>
<td>Jeffrey Ross</td>
<td>Employee of Foundation Medicine Inc.</td>
<td></td>
</tr>
<tr>
<td>Wedad Hanna</td>
<td>Consultant for Roche Canada</td>
<td></td>
</tr>
<tr>
<td>P Sudipta</td>
<td>Employee of Bio Genex</td>
<td></td>
</tr>
<tr>
<td>Krishan Kalra</td>
<td>Employee of Bio Genex</td>
<td></td>
</tr>
<tr>
<td>AR Poongothai</td>
<td>Employee of Bio Genex</td>
<td></td>
</tr>
<tr>
<td>Xu Ling</td>
<td>Employee of Bio Genex</td>
<td></td>
</tr>
<tr>
<td>Raymond Tubbs</td>
<td>Grant/Research Support from Ventana Medical Systems, Inc. and Honoraria for speaking</td>
<td></td>
</tr>
<tr>
<td>G Budd</td>
<td>Consultant for Ventana Medical Systems, Inc.</td>
<td></td>
</tr>
<tr>
<td>Larry Morrison</td>
<td>Employee of Ventana Medical Systems, Inc.</td>
<td></td>
</tr>
<tr>
<td>Jeffrey Ross</td>
<td>Employee of Foundation Medicine Inc.</td>
<td></td>
</tr>
<tr>
<td>Philip Stephens</td>
<td>Employee of Foundation Medicine Inc.</td>
<td></td>
</tr>
<tr>
<td>John Curran</td>
<td>Employee of Foundation Medicine Inc.</td>
<td></td>
</tr>
<tr>
<td>Jeffrey Ross</td>
<td>Employee of Foundation Medicine Inc.</td>
<td></td>
</tr>
<tr>
<td>Geoff Otto</td>
<td>Employee of Foundation Medicine Inc.</td>
<td></td>
</tr>
<tr>
<td>Gary Palmer</td>
<td>Employee of Foundation Medicine Inc.</td>
<td></td>
</tr>
<tr>
<td>Roman Yelensky</td>
<td>Employee of Foundation Medicine Inc.</td>
<td></td>
</tr>
<tr>
<td>Sean Downing</td>
<td>Employee of Foundation Medicine Inc.</td>
<td></td>
</tr>
<tr>
<td>Doron Lipson</td>
<td>Employee of Foundation Medicine Inc.</td>
<td></td>
</tr>
<tr>
<td>Siraj Ali</td>
<td>Employee of Foundation Medicine Inc.</td>
<td></td>
</tr>
<tr>
<td>Vincent Miller</td>
<td>Employee of Foundation Medicine Inc.</td>
<td></td>
</tr>
<tr>
<td>David Rimm</td>
<td>Consultant for and Shareholder of HistoRx Inc</td>
<td></td>
</tr>
<tr>
<td>James Fujimoto</td>
<td>Massachusetts Institute of Technology, Lightlabs Imaging, Carl Zeiss Meditec. I receive royalties from intellectual property owned by Massachusetts Institute of Technology and licensed to Lightlabs Imaging, Westford, MA, and Carl Zeiss Meditec, Dublin, CA</td>
<td></td>
</tr>
<tr>
<td>Diana Cherbavaz</td>
<td>Employee of Genomic Health, Inc.</td>
<td></td>
</tr>
<tr>
<td>Amy Sing</td>
<td>Employee of Genomic Health, Inc.</td>
<td></td>
</tr>
<tr>
<td>Baljit Singh</td>
<td>Consultant for and Grant/Research Support from Genomic Health, Inc</td>
<td></td>
</tr>
<tr>
<td>Farid Jamshidian</td>
<td>Employee of Genomic Health, Inc.</td>
<td></td>
</tr>
<tr>
<td>Steve Butler</td>
<td>Employee of Genomic Health, Inc.</td>
<td></td>
</tr>
<tr>
<td>Ralph Wirtz</td>
<td>Employee of STRATIFYER Molecular Pathology GmbH</td>
<td></td>
</tr>
<tr>
<td>Ryan Bremer</td>
<td>Employee of Biocare Medical, LLC</td>
<td></td>
</tr>
<tr>
<td>David Tacha</td>
<td>Employee of Biocare Medical, LLC</td>
<td></td>
</tr>
<tr>
<td>Helen Bailey</td>
<td>Employee of Genomic Health, Inc.</td>
<td></td>
</tr>
<tr>
<td>Vivian Tan</td>
<td>Employee of Genomic Health, Inc.; stockholder</td>
<td></td>
</tr>
<tr>
<td>Athanasios Tsiantis</td>
<td>Employee of Genomic Health, Inc.; stockholder</td>
<td></td>
</tr>
<tr>
<td>June Liu</td>
<td>Employee of Genomic Health, Inc.; stockholder</td>
<td></td>
</tr>
<tr>
<td>Steven Butler</td>
<td>Employee of Genomic Health, Inc.</td>
<td></td>
</tr>
<tr>
<td>Carl Millward</td>
<td>Employee of Genomic Health, Inc.; stockholder</td>
<td></td>
</tr>
<tr>
<td>Joe Anderson</td>
<td>Employee of Genomic Health, Inc.; stockholder</td>
<td></td>
</tr>
<tr>
<td>Frederick Baehner</td>
<td>Employee of Genomic Health, Inc.; stockholder</td>
<td></td>
</tr>
<tr>
<td>Linda Saint John</td>
<td>Employee of Signal Genetics, LLC</td>
<td></td>
</tr>
<tr>
<td>Sandra Shin</td>
<td>Consultant for Signal Genetics, LLC</td>
<td></td>
</tr>
<tr>
<td>Nathan Brown</td>
<td>Employee of Signal Genetics, LLC</td>
<td></td>
</tr>
<tr>
<td>Rachel Flinchum</td>
<td>Employee of Signal Genetics, LLC</td>
<td></td>
</tr>
<tr>
<td>Ryan van Laar</td>
<td>Employee of Signal Genetics, LLC</td>
<td></td>
</tr>
<tr>
<td>Sandra Shin</td>
<td>Consultant for Signal Genetics, LLC</td>
<td></td>
</tr>
<tr>
<td>David Chhieng</td>
<td>Consultant for BD Diagnostics</td>
<td></td>
</tr>
<tr>
<td>David Chhieng</td>
<td>Consultant for BD Diagnostics</td>
<td></td>
</tr>
<tr>
<td>David Chhieng</td>
<td>Consultant for BD Diagnostics</td>
<td></td>
</tr>
<tr>
<td>David Chhieng</td>
<td>Consultant for BD Diagnostics</td>
<td></td>
</tr>
<tr>
<td>David Chhieng</td>
<td>Consultant for BD Diagnostics</td>
<td></td>
</tr>
<tr>
<td>David Chhieng</td>
<td>Consultant for BD Diagnostics</td>
<td></td>
</tr>
<tr>
<td>David Chhieng</td>
<td>Consultant for BD Diagnostics</td>
<td></td>
</tr>
<tr>
<td>David Chhieng</td>
<td>Consultant for BD Diagnostics</td>
<td></td>
</tr>
<tr>
<td>David Chhieng</td>
<td>Consultant for BD Diagnostics</td>
<td></td>
</tr>
<tr>
<td>David Chhieng</td>
<td>Consultant for BD Diagnostics</td>
<td></td>
</tr>
<tr>
<td>David Chhieng</td>
<td>Consultant for BD Diagnostics</td>
<td></td>
</tr>
<tr>
<td>Edmund Cibas</td>
<td>Grant/Research Support from Veracyte</td>
<td></td>
</tr>
<tr>
<td>Andrew Fischer</td>
<td>Hologic Corporation; Dr. Andrew Fischer is an inventor of Cellient cell block technology, and he receives royalties for sales of Cellient products.</td>
<td></td>
</tr>
<tr>
<td>Massih Abawi</td>
<td>Employee of Quest Diagnostics</td>
<td></td>
</tr>
<tr>
<td>Marc Sanidad</td>
<td>Employee of Quest Diagnostics</td>
<td></td>
</tr>
</tbody>
</table>
238

417 Dan Jones Employee of Quest Diagnostics
417 JoAnn Kelly Employee of Quest Diagnostics
417 Yasmin Hijazi Employee of Quest Diagnostics
425 David Chhieng Consultant for BD Diagnostics
430 David Chhieng Consultant for BD Diagnostics
431 David Chhieng Consultant for BD Diagnostics
443 Andrew Fischer Hologic Corporation; Dr. Andrew Fischer is an inventor of Cellient cell block technology, and he receives royalties for sales of Cellient products.
444 Andrew Fischer Hologic Corporation; Dr. Andrew Fischer is an inventor of Cellient cell block technology, and he receives royalties for sales of Cellient products.
466 Bonnie Balzer Grant/Research Support from Roche
477 Xiao-Jun Ma Employee of Advanced Cell Diagnostics
477 Xingyong Wu Employee of Advanced Cell Diagnostics
477 Yuling Luo Employee of Advanced Cell Diagnostics
493 Angel Santos-Briz Consultant for Roche
494 Angel Santos-Briz Consultant for Roche
507 Doron Lipson Employee of Foundation Medicine Inc.
507 Kiel Iwanik Employee of Foundation Medicine Inc.
507 Jeffrey Ross Employee of Foundation Medicine Inc.
507 Vincent Miller Employee of Foundation Medicine Inc.
507 Gary Palmer Employee of Foundation Medicine Inc.
507 Philip Stephens Employee of Foundation Medicine Inc.
507 Amy Donahue Employee of Foundation Medicine Inc.
507 John Curran Employee of Foundation Medicine Inc.
507 Jamie Buell Employee of Foundation Medicine Inc.
507 Sean Downing Employee of Foundation Medicine Inc.
507 Roman Yelensky Employee of Foundation Medicine Inc.
507 Geoff Otto Employee of Foundation Medicine Inc.
527 Steve Rath Grant/Research Support from AHRQ
527 Stephen Raab Grant/Research Support from Agency for Healthcare Research and Quality
566 Vikram Deshpande Consultant for BD Diagnostics
569 Vivian Tan Employee of Genomic Health, Inc.; stockholder
569 Helen Bailey Employee of Genomic Health, Inc.
569 Athanasios Tsiatis Employee of Genomic Health, Inc.; stockholder
569 Mark Lee Employee of Genomic Health, Inc.; stockholder
569 Margarita Lopatin Employee of Genomic Health, Inc.; stockholder
569 Carl Millward Employee of Genomic Health, Inc.; stockholder
569 Joseph Anderson Employee of Genomic Health, Inc.; stockholder
569 Frederick Baehner Employee of Genomic Health, Inc.; stockholder
569 June Liu Employee of Genomic Health, Inc.; stockholder
619 Lindsay Freed RedPath Integrated Pathology, Inc.; Intern, financially supported by RedPath Integrated Pathology, Inc. via a contractor position.
619 Sydney Finkelstein Employee of RedPath Integrated Pathology, Inc.
619 Eric Ellsworth Employee of RedPath Integrated Pathology, Inc.
619 Sara Jackson Employee of RedPath Integrated Pathology, Inc.
621 Vikram Deshpande Grant/Research Support from Affymetrix
623 Jeffrey Ross Employee of Foundation Medicine Inc.
623 Vikram Deshpande Grant/Research Support from Affymetrix
713 Vikram Deshpande Grant/Research Support from Affymetrix
718 James Grenert Grant/Research Support from Pathwork Diagnostics
724 Susan Sa Employee of Genentech/Roche
724 Simonetta Mocci Employee of Genentech/Roche
724 Hartmut Koeppen Employee of Genentech/Roche
724 Deborah Dunlap Employee of Genentech/Roche
724 Sara Chan Employee of Genentech/Roche
737 Philip Stephens Employee of Foundation Medicine Inc.
737 Roman Yelensky Employee of Foundation Medicine Inc.
737 Alex Parker Employee of Foundation Medicine Inc.
737 Geoff Otto Employee of Foundation Medicine Inc.
737 Amy Donahue Employee of Foundation Medicine Inc.
737 Sohail Balasubramanian Employee of Foundation Medicine Inc.
737 Mirna Jarosz Employee of Foundation Medicine Inc.
<table>
<thead>
<tr>
<th>Name</th>
<th>Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maureen Cronin</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Jeffrey Ross</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Sean Downing</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Doron Lipner</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Gary Palmer</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Vikram Deshpande</td>
<td>Grant/Research Support from Affymetrix</td>
</tr>
<tr>
<td>Margaret Guillecy</td>
<td>Consultant for Roche, McKesson, Abbott and Generation Health</td>
</tr>
<tr>
<td>Vikram Deshpande</td>
<td>Grant/Research Support from Affymetrix</td>
</tr>
<tr>
<td>Miguel Rivera</td>
<td>Grant/Research Support from Affymetrix</td>
</tr>
<tr>
<td>David Ting</td>
<td>Grant/Research Support from Affymetrix</td>
</tr>
<tr>
<td>Eugene Hsieh</td>
<td>Consultant for and Grant/Research Support from Hoffman-La Roche</td>
</tr>
<tr>
<td>Wedad Hanna</td>
<td>Consultant for Roche Canada</td>
</tr>
<tr>
<td>Michael Berger</td>
<td>Grant/Research Support from Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Rohit Mehra</td>
<td>Genprobe; The University of Michigan has been issued a patent on the detection of ETS gene fusions in prostate cancer, on which R.M. is a coinventor. The University of Michigan licensed the diagnostic field of use to Gen-Probe Inc (San Diego, CA).</td>
</tr>
<tr>
<td>Michael Berger</td>
<td>Grant/Research Support from Foundation Medicine Inc.</td>
</tr>
<tr>
<td>David Bostwick</td>
<td>Employee of and Shareholder of Bostwick Laboratories, Inc; CELLAY, Inc - Shareholder</td>
</tr>
<tr>
<td>Deloar Hossain</td>
<td>Employee of Bostwick Laboratories</td>
</tr>
<tr>
<td>David Bostwick</td>
<td>Employee of and Shareholder of Bostwick Laboratories; CELLAY, Inc - Shareholder</td>
</tr>
<tr>
<td>Deloar Hossain</td>
<td>Employee of Bostwick Laboratories</td>
</tr>
<tr>
<td>Harpreet Singh</td>
<td>Employee of Bostwick Laboratories</td>
</tr>
<tr>
<td>Bonnie Balzer</td>
<td>Grant/Research Support from Roche</td>
</tr>
<tr>
<td>Michael Berger</td>
<td>Grant/Research Support from Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Michael Berger</td>
<td>Grant/Research Support from Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Marc-Antoine Belaud-Rotureau</td>
<td>Consultant for and Grant/Research Support from Abbott</td>
</tr>
<tr>
<td>Shin Egawa</td>
<td>Grant/Research Support from Takeda Pharmaceutical Company, Astellas, AstraZeneca and Takeda Pharmaceutical Company; Astellas; AstraZeneca</td>
</tr>
<tr>
<td>Anastasia Nikolopoulou</td>
<td>Grant/Research Support from Molecular Insight Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>Shankar Vallabhasoula</td>
<td>Grant/Research Support from Molecular Insight Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>Stanley Goldsmith</td>
<td>Grant/Research Support from Molecular Insight Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>Joseph Osbourne</td>
<td>Grant/Research Support from Molecular Insight Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>John Babich</td>
<td>Employee of Molecular Insight Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>Constantin Friedman</td>
<td>Grant/Research Support from Molecular Insight Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>Sagit Goldenberg</td>
<td>Molecular Insight Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>Brian Robinson</td>
<td>Grant/Research Support from Molecular Insight Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>David Green</td>
<td>Grant/Research Support from Molecular Insight Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>Douglas Scherr</td>
<td>Grant/Research Support from Molecular Insight Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>John Bomalaski</td>
<td>Employee of and Shareholder of Polaris Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Ryan Bremer</td>
<td>Employee of Biocare Medical, LLC</td>
</tr>
<tr>
<td>Thomas Haas</td>
<td>Consultant for Biocare Medical, LLC</td>
</tr>
<tr>
<td>Laura Hoang</td>
<td>Employee of Biocare Medical, LLC</td>
</tr>
<tr>
<td>Weimin Qi</td>
<td>Employee of Biocare Medical, LLC</td>
</tr>
<tr>
<td>Joseph Chu</td>
<td>Employee of Biocare Medical, LLC</td>
</tr>
<tr>
<td>David Tacha</td>
<td>Employee of Biocare Medical, LLC</td>
</tr>
<tr>
<td>Brian Robinson</td>
<td>Grant/Research Support from Molecular Insight Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>Douglas Scherr</td>
<td>Grant/Research Support from Molecular Insight Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>Brian Robinson</td>
<td>Grant/Research Support from Molecular Insight Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>Douglas Scherr</td>
<td>Grant/Research Support from Molecular Insight Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>Douglas Scherr</td>
<td>Grant/Research Support from Molecular Insight Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>Brian Robinson</td>
<td>Grant/Research Support from Molecular Insight Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>Zhihing Fang</td>
<td>Employee of Epitomics, Inc.</td>
</tr>
<tr>
<td>Hongyang Pan</td>
<td>Employee of Epitomics, Inc.</td>
</tr>
<tr>
<td>Nenghui Jiang</td>
<td>Employee of Epitomics, Inc.</td>
</tr>
<tr>
<td>Aihua Li</td>
<td>Employee of Epitomics, Inc.</td>
</tr>
<tr>
<td>Taiying Chen</td>
<td>Employee of Epitomics, Inc.</td>
</tr>
<tr>
<td>Asish Nand</td>
<td>Employee of Epitomics, Inc.</td>
</tr>
<tr>
<td>Juliet Gardiner</td>
<td>Employee of Epitomics, Inc.</td>
</tr>
<tr>
<td>Rohit Mehra</td>
<td>Genprobe; The University of Michigan has been issued a patent on the detection of ETS gene fusions in prostate cancer, on which R.M. is a coinventor. The University of Michigan licensed the diagnostic field of use to Gen-Probe Inc (San Diego, CA).</td>
</tr>
</tbody>
</table>
Nallasivam Palanisamy Consultant for Ventana Medical Systems, Inc.
Nallasivam Palanisamy Consultant for Ventana Medical Systems, Inc.
Arul Chinnaiyan Consultant for Ventana Medical Systems, Genprobe; The University of Michigan has been issued a patent on the detection of ETS gene fusions in prostate cancer, on which A.M.C. is a coinventor. The University of Michigan licensed the diagnostic field of use to Gen-Probe Inc (San Diego, CA).
Rohit Mehra Genprobe; The University of Michigan has been issued a patent on the detection of ETS gene fusions in prostate cancer, on which R.M. is a coinventor. The University of Michigan licensed the diagnostic field of use to Gen-Probe Inc (San Diego, CA).
Jeffrey Ross Employee of Foundation Medicine Inc.
Brian Robinson Grant/Research Support from Molecular Insight Pharmaceuticals, Inc
Roman Yelensky Employee of Foundation Medicine Inc.
Jeffrey Ross Employee of Foundation Medicine Inc.
Doron Lipson Employee of Foundation Medicine Inc.
Lazaro Garcia Employee of Foundation Medicine Inc.
John Curran Employee of Foundation Medicine Inc.
Sean Downing Employee of Foundation Medicine Inc.
Geoff Otto Employee of Foundation Medicine Inc.
Vincent Miller Employee of Foundation Medicine Inc.
Kristin Mahoney Employee of Foundation Medicine Inc.
Gary Palmer Employee of Foundation Medicine Inc.
Sohail Balasubramanian Employee of Foundation Medicine Inc.
Philip Stephens Employee of Foundation Medicine Inc.
Saskia Biskup Shareholder of CeGaT
Nicole Oberbeckmann Employee of CeGaT
Brian Robinson Grant/Research Support from Molecular Insight Pharmaceuticals, Inc
Scott Tomlins Consultant for Gen-Probe, Inc. and Ventana Medical Systems, Inc.; The University of Michigan has been issued a patent on the detection of ETS gene fusions in prostate cancer, on which Dr Tomlins is listed as a coinventor. The University of Michigan licensed the diagnostic field of use to Gen-Probe Inc (San Diego, CA).
Kathleen Cooney University of Michigan - Patent; The University of Michigan has filed a patent concerning genetic testing for the HOXB13 gene mutation, on which Dr. Cooney is listed as an co-inventor.
Nallasivam Palanisamy Consultant for Ventana Medical Systems
Arul Chinnaiyan Consultant for Ventana Medical Systems, Genprobe; The University of Michigan has been issued a patent on the detection of ETS gene fusions in prostate cancer, on which A.M.C. is a coinventor. The University of Michigan licensed the diagnostic field of use to Gen-Probe Inc (San Diego, CA).
Brian Robinson Grant/Research Support from Molecular Insight Pharmaceuticals, Inc
Nallasivam Palanisamy Consultant for Ventana Medical Systems
Rohit Mehra Genprobe; The University of Michigan has been issued a patent on the detection of ETS gene fusions in prostate cancer, on which R.M. is a coinventor. The University of Michigan licensed the diagnostic field of use to Gen-Probe Inc (San Diego, CA).
Nallasivam Palanisamy Consultant for Ventana Medical Systems, Inc.
Arul Chinnaiyan Consultant for Ventana Medical Systems, Genprobe; The University of Michigan has been issued a patent on the detection of ETS gene fusions in prostate cancer, on which A.M.C. is a coinventor. The University of Michigan licensed the diagnostic field of use to Gen-Probe Inc (San Diego, CA).
Rohit Mehra Genprobe; The University of Michigan has been issued a patent on the detection of ETS gene fusions in prostate cancer, on which R.M. is a coinventor. The University of Michigan licensed the diagnostic field of use to Gen-Probe Inc (San Diego, CA).
Rohit Mehra Genprobe; The University of Michigan has been issued a patent on the detection of ETS gene fusions in prostate cancer, on which R.M. is a coinventor. The University of Michigan licensed the diagnostic field of use to Gen-Probe Inc (San Diego, CA).
Xiao-Jun Ma Employee of Advanced Cell Diagnostics
David Bostwick Employee of and Shareholder of Bostwick Laboratories, Inc.; CELLAY, Inc - Shareholder
Delor Hossain Employee of Bostwick Laboratories
Peter Schlosshauer Employee of Bostwick Laboratories
Elba Turbat-Herrera Employee of Bostwick Laboratories
Christopher Crum Patent - The author is named on a patent application resulting from this work.
Christopher Crum Patent - The author is named on a patent application resulting from this work.
Christopher Crum Patent - The author is named on a patent application resulting from this work.
Christopher Crum Patent - The author is named on a patent application resulting from this work.
Christopher Crum Patent - The author is named on a patent application resulting from this work.
<p>| 1448 | Lisa Rimsza | Grant/Research Support from Ventana Medical Systems, Inc. |
| 1448 | Thomas Grogan | Employee of Ventana Medical Systems, Inc. |
| 1448 | Christopher Morrison | Employee of Ventana Medical Systems, Inc. |
| 1459 | Fai Chung | Grant/Research Support from Roche |
| 1466 | Eric Hsi | Consultant for Leica |
| 1467 | Eric Hsi | Consultant for Leica |
| 1468 | Felicitas Lacbawan | Consultant for Leica |
| 1468 | Eric Hsi | Consultant for Leica |
| 1470 | Sa Wang | Grant/Research Support from Seattle Genetics Inc |
| 1475 | Lawrence Weiss | Employee of Clarient Inc./GE Healthcare |
| 1476 | Lawrence Weiss | Employee of Clarient Inc./GE Healthcare |
| 1480 | Sa Wang | Grant/Research Support from Seattle Genetics Inc |
| 1481 | Eric Hsi | Consultant for Leica |
| 1485 | Edmund Cibas | Grant/Research Support from Veracyte |
| 1494 | Lisa Rimsza | Grant/Research Support from Ventana Medical Systems, Inc. |
| 1498 | Sa Wang | Grant/Research Support from Seattle Genetics Inc |
| 1498 | Eric Hsi | Consultant for Leica |
| 1500 | Jessica Altman | Astellas Pharm - Advisory Board member |
| 1528 | Yongbao Wang | Employee of Quest Diagnostics |
| 1528 | Qiulu Pan | Employee of Quest Diagnostics |
| 1528 | Shere Billouin-Fraser | Employee of Quest Diagnostics |
| 1528 | Dan Jones | Employee of Quest Diagnostics |
| 1528 | Albert Ho | Employee of Quest Diagnostics |
| 1544 | Sa Wang | Grant/Research Support from Seattle Genetics Inc |
| 1545 | Sa Wang | Grant/Research Support from Seattle Genetics Inc |
| 1560 | Kate Grimm | Employee of Clarient Inc./GE Healthcare |
| 1560 | Renuka Agrawal | Employee of Clarient Inc./GE Healthcare |
| 1560 | Lawrence Weiss | Employee of Clarient Inc./GE Healthcare |
| 1578 | Constantin Friedman | Grant/Research Support from Molecular Insight Pharmaceuticals, Inc |
| 1579 | Constantin Friedman | Grant/Research Support from Molecular Insight Pharmaceuticals, Inc |
| 1588 | Shawn Maclary | Grant/Research Support from Roche |
| 1588 | Shikha Bose | Grant/Research Support from Roche |
| 1588 | Sonia Kalari | Grant/Research Support from Roche |
| 1588 | Beatrice Knudsen | Grant/Research Support from Roche |
| 1588 | Fai Chung | Grant/Research Support from Roche |
| 1588 | Bonnie Balzer | Grant/Research Support from Roche |
| 1588 | Arkadiusz Gertych | Grant/Research Support from Roche |
| 1594 | Jonhan Ho | Grant/Research Support from Omnyx |
| 1595 | Jonhan Ho | Grant/Research Support from Omnyx |
| 1597 | Charles Law | Employee of Kitware Inc |
| 1607 | Robert Montgomery | Consultant for and Grant/Research Support from Astella, Alexion, Genzyme, Viropharma |
| 1607 | Andrea Zachary | One Lambda - Honoraria |
| 1607 | Serena Bagnasco | Consultant for Alexion |
| 1607 | Lorraine Racusen | Consultant for Viropharma; Alexion |
| 1608 | Robert Montgomery | Consultant for and Grant/Research Support from Astella, Alexion, Genzyme, Viropharma |
| 1608 | Serena Bagnasco | Consultant for Alexion |
| 1608 | Lorraine Racusen | Consultant for Viropharma, Alexion |
| 1621 | J Charles Jennette | Consultant for Genentech |
| 1624 | David Bostwick | Employee of and Shareholder of Bostwick Laboratories; CELLAY, Inc - Shareholder |
| 1624 | David Hull | Employee of Bostwick Laboratories |
| 1633 | Volker Nickeleit | Grant/Research Support from Astellas Pharmaceuticals |
| 1633 | Harsharan Singh | Grant/Research Support from Astellas Pharmaceuticals |
| 1636 | Behzad Najafian | Grant/Research Support from Genzyme, a Sanofi Company |
| 1636 | Michael Mauer | Consultant for and Grant/Research Support from Genzyme |
| 1657 | Kate Grimm | Employee of Clarient Inc/GE Healthcare |
| 1657 | Renuka Agrawal | Employee of Clarient Inc./GE Healthcare |
| 1657 | Lawrence Weiss | Employee of Clarient Inc./GE Healthcare |
| 1658 | Yuki Tanaka | Shareholder of Kyushu University |
| 1658 | Shimichi Aishima | Grant/Research Support from Kyushu University |
| 1658 | Yuichiro Kubo | Shareholder of Kyushu University |
| 1661 | Emily White | Employee of Foundation Medicine Inc. |
| 1661 | Sean Downing | Employee of Foundation Medicine Inc. |
| 1661 | Philip Stephens | Employee of Foundation Medicine Inc. |</p>
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sohail Balasubramanian</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Tina Richards</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Lazaro Garcia</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Roman Yelensky</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Vincent Miller</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Selmira Terzic</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>John Curran</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Jeffrey Ross</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Geoff Otto</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Doron Lipson</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Gary Palmer</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Kristin Mahoney</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Vera Banning</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Ping Zhou</td>
<td>Employee of Biocare Medical, LLC</td>
</tr>
<tr>
<td>David Tacha</td>
<td>Employee of Biocare Medical, LLC</td>
</tr>
<tr>
<td>Ryan Bremer</td>
<td>Employee of Biocare Medical, LLC</td>
</tr>
<tr>
<td>Bhuvnesh Sharma</td>
<td>Employee of Biocare Medical, LLC</td>
</tr>
<tr>
<td>Thomas Haas</td>
<td>Consultant for Biocare Medical, LLC</td>
</tr>
<tr>
<td>Angel Santos-Briz</td>
<td>Consultant for Roche</td>
</tr>
<tr>
<td>Raymond Tubbs</td>
<td>Grant/Research Support from Ventana; Honoraria for speaking</td>
</tr>
<tr>
<td>Roger Schultz</td>
<td>Employee of Signature Genomics</td>
</tr>
<tr>
<td>Blake Baliff</td>
<td>Employee of Signature Genomics</td>
</tr>
<tr>
<td>Vikram Deshpande</td>
<td>Grant/Research Support from Affymetrix</td>
</tr>
<tr>
<td>Dora Dias-Santagata</td>
<td>Consultant for BioReference Laboratories Inc</td>
</tr>
<tr>
<td>Manuel Hidalgo</td>
<td>Consultant for and Grant/Research Support from Celgene Corporation</td>
</tr>
<tr>
<td>Carla Heise</td>
<td>Employee of Celgene Corporation</td>
</tr>
<tr>
<td>Fernando Lopez-Rios</td>
<td>Grant/Research Support from Celgene Corporation</td>
</tr>
<tr>
<td>Vikram Deshpande</td>
<td>Grant/Research Support from Affymetrix</td>
</tr>
<tr>
<td>Meredith Halks-Miller</td>
<td>Employee of Pathwork Diagnostics</td>
</tr>
<tr>
<td>Michael Walker</td>
<td>Consultant for Pathwork Diagnostics</td>
</tr>
<tr>
<td>W David Henner</td>
<td>Employee of Pathwork Diagnostics</td>
</tr>
<tr>
<td>Lawrence Weiss</td>
<td>Grant/Research Support from Pathwork Diagnostics</td>
</tr>
<tr>
<td>Anand Kulkarni</td>
<td>Grant/Research Support from Pathwork Diagnostics</td>
</tr>
<tr>
<td>Federico Monzon</td>
<td>Consultant for Pathwork Diagnostics</td>
</tr>
<tr>
<td>William Rogers</td>
<td>Grant/Research Support from Pathwork Diagnostics</td>
</tr>
<tr>
<td>Glenda Anderson</td>
<td>Consultant for Pathwork Diagnostics</td>
</tr>
<tr>
<td>James Grenert</td>
<td>Grant/Research Support from Pathwork Diagnostics</td>
</tr>
<tr>
<td>Charles Handorf</td>
<td>Grant/Research Support from Pathwork Diagnostics</td>
</tr>
<tr>
<td>Raji Pillai</td>
<td>Employee of Pathwork Diagnostics</td>
</tr>
<tr>
<td>Oliver Kim</td>
<td>Grant/Research Support from Pathwork Diagnostics</td>
</tr>
<tr>
<td>Frederic Waldman</td>
<td>Employee of Quest Diagnostics</td>
</tr>
<tr>
<td>Sandra Shin</td>
<td>Consultant for Signal Genetics, LLC</td>
</tr>
<tr>
<td>Kimberly Allison</td>
<td>Genentech - Speakers Bureau member</td>
</tr>
<tr>
<td>David Eberhard</td>
<td>Employee of Flagship Biosciences</td>
</tr>
<tr>
<td>Christos Hatzis</td>
<td>Employee of Nuvera Biosciences</td>
</tr>
<tr>
<td>Eric Hsi</td>
<td>Consultant for Leica</td>
</tr>
<tr>
<td>Sydney Finkelstein</td>
<td>Employee of RedPath Integrated Pathology, Inc.</td>
</tr>
<tr>
<td>Belaud-Rotureau</td>
<td>Consultant for and Grant/Research Support from Abbott</td>
</tr>
<tr>
<td>Henry Tazelaar</td>
<td>Consultant for Intermune</td>
</tr>
<tr>
<td>Krishan Kalra</td>
<td>Employee of BioGenex</td>
</tr>
<tr>
<td>Ling Xue</td>
<td>Employee of BioGenex</td>
</tr>
<tr>
<td>Henry Tazelaar</td>
<td>Consultant for Intermune</td>
</tr>
<tr>
<td>Jeffrey Ross</td>
<td>Employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>Yuichi Ishikawa</td>
<td>Grant/Research Support from Sony</td>
</tr>
<tr>
<td>Raymond Tubbs</td>
<td>Grant/Research Support from Ventana Medical Systems, Inc.; Honoraria for speaking</td>
</tr>
<tr>
<td>David Rimm</td>
<td>Consultant for and Shareholder of HistoRx Inc</td>
</tr>
<tr>
<td>Margaret Gulley</td>
<td>Consultant for Roche, McKesson, Abbott and Generation Health</td>
</tr>
<tr>
<td>Stephen Raab</td>
<td>Grant/Research Support from Agency for Healthcare Research and Quality</td>
</tr>
<tr>
<td>Stephen Raab</td>
<td>Grant/Research Support from Agency for Healthcare Research and Quality</td>
</tr>
<tr>
<td>Eric Ellsworth</td>
<td>Employee of RedPath Integrated Pathology, Inc.</td>
</tr>
<tr>
<td>Sara Jackson</td>
<td>Employee of RedPath Integrated Pathology, Inc.</td>
</tr>
</tbody>
</table>
Brendan Corcoran  Employee of RedPath Integrated Pathology, Inc.
Sydney Finkelstein  Employee of RedPath Integrated Pathology, Inc.
Ruth Birbe  Grant/Research Support from Ventana Medical Systems, Inc
Torsten Nielsen  Bioclassifier, LLC; Dr. Nielsen discloses that he is a co-founder of Bioclassifier, LLC which licensed the PAM50 algorithm to NanoString Technologies.
Malini Maysuria  Employee of NanoString Technologies; Stock Options from NanoString
Sean Ferree  Employee of NanoString Technologies; Stock Options from NanoString
Naeem Dowidar  Employee of NanoString Technologies; Stock Options from NanoString
Carl Schaper  Consultant for NanoString Technologies
James Storhoff  Employee of NanoString Technologies; Stock Options from NanoString
Brett Wallden  Employee of NanoString Technologies; Stock Options from NanoString
Yuling Luo  Employee of Advanced Cell Diagnostics, Inc.
Hongwei Wang  Employee of Advanced Cell Diagnostics, Inc.
Xiao-Jun Ma  Employee of Advanced Cell Diagnostics, Inc.
Nikola Valkov  Employee of Bostwick Laboratories, Inc.
Rick Voyles  Bostwick Laboratories
Michael Kulikowski  Employee of Bostwick Laboratories
Deloar Hossain  Employee of Bostwick Laboratories
David Bostwick  Employee of and Shareholder of Bostwick Laboratories; CELLAY, Inc - Shareholder
Krishan Kahra  Employee of BioGenex
Ling Xue  Employee of BioGenex
Raymond Tubbs  Grant/Research Support from Ventana and Honoraria for speaking
THANK YOU FOR YOUR USCAP MEMBERSHIP PAYMENT.

We’re pleased that you have chosen to continue your commitment to North America’s leading pathology organization. As a member of the USCAP you have a wide array of benefits designed to keep you informed of the fast moving world of pathology. We’ve included a sampling of these benefits below; however for a full listing, please log onto our website: www.uscap.org

Membership status includes benefits like:

- **Learn:** members-only educational discounts
  - Online, at your convenience. Tailor your educational requirements to your schedule with our extensive list of online courses from world-class authorities.
  - Or in beautiful venues throughout North America. Obtain up to 400 CME credits (of which 350 can be SAM’s). Attend our accredited educational conferences, held quarterly, in stunning locales.

- **Simplify your MOC management**
  - Manage your MOC credits through your individual, online professional portfolio found on the USCAP website. Evaluate courses, print certificates and transmit your education credits—all in one place!

- **Connect with world-class pathology professionals**
  - Membership connects you to the “Who’s Who” of pathology through our membership directory. Or utilize MyPath™ —The USCAP’s premiere portal to the world of pathology—which includes the National Institute of Health’s PubMed biomedical information. Research. Bookmark. Collaborate.

- **Stay informed with USCAP’s leading journals**
  - Members receive their choice of USCAP’s leading journals, “Modern Pathology” or “Laboratory Investigation” with information designed to keep you in the vanguard of our profession.

- **Advance your career**
  - New opportunities await at our online Career Center.

- **Dual membership within the International Academy of Pathology**
  - Links you with colleagues through worldwide affiliated divisions.

Please don’t hesitate to contact our Membership Team at 706.733.7550, or at help@uscap.org, should you have any questions about your membership benefits. Thanks!
Something big is about to happen in cancer diagnostics.

In 2013, Dako launches new solutions for cancer diagnostics that will help move pathology forward on A Better Path™.

Visit us at booth no. 638 and find out what’s new.